<SEC-DOCUMENT>0000939767-23-000019.txt : 20230207
<SEC-HEADER>0000939767-23-000019.hdr.sgml : 20230207
<ACCEPTANCE-DATETIME>20230207162201
ACCESSION NUMBER:		0000939767-23-000019
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		95
CONFORMED PERIOD OF REPORT:	20221230
FILED AS OF DATE:		20230207
DATE AS OF CHANGE:		20230207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		23595378

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>exel-20221230.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:72618e96-9a19-4b18-ab04-d375d7716d96,g:fc8ea608-bee1-4b83-89de-139db7d65bef,d:a855702135904005a41d208deb24e60a--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:exel="http://www.exelixis.com/20221230" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20221230</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV80L2ZyYWc6YWRkZjY3N2E4MWJhNDFiY2I1Y2ExMDAyYjcwMjMxMmQvdGFibGU6N2NhMDU2YzBjNTBkNDliZGFjZmVmODBiYzY1ZjAzMjAvdGFibGVyYW5nZTo3Y2EwNTZjMGM1MGQ0OWJkYWNmZWY4MGJjNjVmMDMyMF8yLTEtMS0xLTkyMTUw_5610300f-162b-45d5-8814-2ef5b4ad3680">false</ix:nonNumeric><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV80L2ZyYWc6YWRkZjY3N2E4MWJhNDFiY2I1Y2ExMDAyYjcwMjMxMmQvdGFibGU6N2NhMDU2YzBjNTBkNDliZGFjZmVmODBiYzY1ZjAzMjAvdGFibGVyYW5nZTo3Y2EwNTZjMGM1MGQ0OWJkYWNmZWY4MGJjNjVmMDMyMF80LTEtMS0xLTkyMTUw_ddde23dc-65c1-4652-ae18-165675d43c5a">2022</ix:nonNumeric><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV80L2ZyYWc6YWRkZjY3N2E4MWJhNDFiY2I1Y2ExMDAyYjcwMjMxMmQvdGFibGU6N2NhMDU2YzBjNTBkNDliZGFjZmVmODBiYzY1ZjAzMjAvdGFibGVyYW5nZTo3Y2EwNTZjMGM1MGQ0OWJkYWNmZWY4MGJjNjVmMDMyMF81LTEtMS0xLTkyMTUw_662a7c46-655e-4294-8449-dd1e3193937e">FY</ix:nonNumeric><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV80L2ZyYWc6YWRkZjY3N2E4MWJhNDFiY2I1Y2ExMDAyYjcwMjMxMmQvdGFibGU6N2NhMDU2YzBjNTBkNDliZGFjZmVmODBiYzY1ZjAzMjAvdGFibGVyYW5nZTo3Y2EwNTZjMGM1MGQ0OWJkYWNmZWY4MGJjNjVmMDMyMF82LTEtMS0xLTkyMTUw_5eac582c-f8c5-4286-a7cf-04b49a8e2354">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMC0xLTEtOTIxNTA_96cbace8-4798-438d-bd6a-d3ce92ddad69">http://www.exelixis.com/20221230#OperatingLeaseRightOfUseAssetAndOtherAssets</ix:nonNumeric><ix:nonNumeric contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMC0xLTEtOTIxNTA_bf05f744-ae2c-4625-a413-f24a3f80b54d">http://www.exelixis.com/20221230#OperatingLeaseRightOfUseAssetAndOtherAssets</ix:nonNumeric><ix:nonNumeric contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMC0xLTEtOTIxNTA_3805e340-1810-45ae-9746-eaa8274e40f1">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMC0xLTEtOTIxNTA_4cf525be-b16c-489c-b6e4-ee90a9a764d7">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20221230.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife95f2dac98345e09e30688f417dfefd_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ia7a2db918d5e4f25a57dfd066511af97_I20230130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="icd975ad7811c4bdbb2315643b04037a2_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2e996a9f240456487cb91fc0c52e1a1_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d55e02ba3ae4c8999e690629fe6d584_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9ff1b0e91924c73b4c456c2235ab6cf_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47a0764d353e4fb3a7ec06de9aca7c16_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8380d5f4f944a18a412a44050718011_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i968c32c71952402cb10bdb7c8f5f4c8e_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad8294bfd197493791fd98694c5266f2_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i663037ccb1ec482e8ebc1bbf359c95b4_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee90ac3decac457ea10ccb1f57c3be9f_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i316600a670354ae9bed12cb08f90fbad_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d397c56f7c747a1b4c4ee65c9dca93f_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied0a8550944e400eb840fecf7a697f8a_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a3670052766460e8f6681bfb2fe46da_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7bb9a335486433c81f3f5733d3aaad8_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36ea7ff7478a47f29ac8ddc870f601a1_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0deb65d8e8541f4befd56d486e027aa_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac71ca2b42784a9596529526d80870fe_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b022f123e124eebacb65e193a7ca348_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30d6ea6119494ce99990ec9f421bf661_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b916a4ad0de4c3ea7891d04e8a0e888_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf9048c142784771b43942a372d1013d_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0958ab0a7b904c6abbc804e49a0e9544_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f9dad1068314e4a821e9fa7b5dfc712_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1d8b28295254e3c9d72be053782f1f6_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfd5463291344fadbad875183adfc559_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61bccae84739493aa433b75b3289741b_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ebcf341e8d14a8d8af6c5f7a8d997dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d4b232e8fca4e8d9de8920ba88d1665_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86a7ae9225ca4247aa92ff18efbb1e3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic180e4d772ed46dc825b7445c7893c6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d92019d1cca43aebdc002637f9a8e0a_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia138b200885a4b769244acdf9eeab22d_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd740e63081e4029889559bc739aee7d_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i564bbd54548d41f68982fea9945c6519_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6372aa2efa047d3814f185d55ca1da9_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ae29c61f4c04cdda5f6e25561c082eb_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7de5204d64db4e1094ecd5b8bfca36d1_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28cc46cb8b1541b3b1c30a1b510db95d_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43e43644871943ca80e12287cd11f468_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>exel:product</xbrli:measure></xbrli:unit><xbrli:unit id="country"><xbrli:measure>exel:country</xbrli:measure></xbrli:unit><xbrli:context id="i4e1b3f5f23e243f1b8637a1014a5195a_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>exel:segment</xbrli:measure></xbrli:unit><xbrli:context id="i4c2389c4c21e47d38ba918260c486bdd_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i89478d8e53974982878b9f548166f990_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dafc9c29ab84bcc889c1cf9052a086e_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib74e5ab8178d4970b8e0465f6fa0028c_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71aecadc693d426fb5b155f638d21467_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc1b4ef9e9b84a8ebf2dfd01a3004c70_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic649dcb8633a451880ff42451fc2f3ab_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47c31e24d2c0403d83cfc5c2eb92f86f_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae02cfb8959147e8a8be84c7f06c568f_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7fd8bc4b5b142a1a7297763d8461fc6_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if237b256b8c34d6f87bec83d450b03ab_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d8ad44c76d84c439d5d4844f913bf36_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b45a28b3ddd4011af15bed2146cd292_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied57fc239c1a4a7b97626aba030a42ad_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id94aae6775c049b5b2b45d949aafa52c_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaed8d85227d3483f90cb59be9e884d22_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide7ae702d2f94f168ad5eb6d613db43b_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9229604d9ad94d6fa4aaff91b181d1fa_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85155e2e92604cd8af2bbc12fed76b09_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb94516f996c436291373f1bb4adcaf9_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0831affdb6f74cd590e4619e798c6ede_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f5b33e3f9374a4080cdf99a2599aa23_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09e575bca46c4ee7b2977bb349efda52_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8451b3d5bb240c7a4b4e0fc57e84305_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cd9ed86ff6d4038bcad39e7fb9d9344_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdcd0d0a9429406cbdb4291bcd54d608_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i119efb5fb69c4904bcc940dbd2963d2b_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04453331d42244feaf8b6ea4c41db316_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d85564049e049b68f2010d3e0f72113_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i820e2862a6184ec388d2114fd98baf4a_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff9f443812b14ed79359b92769535720_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbbcd4f4e254417c814ceb83cd2b0472_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99b39711f74648d78882998f94841261_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3365323e5089466b94bbb9251d2fff94_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied54335b6e124ce78abd0708eb3c5f6a_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i262b07d55db34a90b4349cb8911e546e_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7239796cf414e5b9d7107ff0f6c6ba5_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72ae7ad08b2a48ae9bbf227c4be302ca_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id368c47c3f5d481db02eba2d8009c964_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19da7b7d320c44d5b7e1755d3f209f69_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d6fe72170844659b8059e439eb16e3c_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e7719032719481b9bb97d521869817b_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82d900845d714ced98be563122eec84e_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7e319ed079a4b688272f575c6d79fb7_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia505016291bc4b92966a63cb457f79cf_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fc646f54374425da47c013312f9a8e2_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7afa411719d4768beb18974c2d9df7d_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8173bdcf6bc42f08c968eda65dfc2a6_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c0ed898ca774d77b13b623d417de030_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabb415230cfe48b99b7d9b8d3f6efd7e_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb1d7000657e4ce4b150b18dd4413a53_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f2783aaa2794de7bb52b691c9662d08_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied38d86192994bb4b9a4d9a3b0c3fa39_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2acaaacb5c8468bb06c3310cf75f928_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf3671d9a5af4d39a8d091071f92b7ff_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33892ff3208246fab5f7275cef00bcf7_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i991465767e2240f6921b76dcc130c033_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60160fe976124e808a313207fe175c03_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fec469537054a23b86c5d87638062e6_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i966ed994207841c3950965f3ec961e93_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic667289b49764b95a7d7f096cb54a98b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1326a18371364e4d964deea38459c405_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11f3424e5d624831b1f13418acf4a9c2_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i793cb0fdacf74d2d8650c8f711d32ff7_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a6accba75744f11a98c8b6488700e99_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58f96bba653a49e1ae627198e6f38b55_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27f15e30b5a74aa49673c0f2c8433728_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic81d2dff655c411a851f03dcaae0e471_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70318e17c7ab4b68b6b925151523736a_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4f5961955974e53a8d6b5ad85acfe4d_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39c122c614074046abcfbcc446a1fa98_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibad41c5a867e42328f87a6be4ab95e02_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibce8519fb88b4643a598a9f10397b3fb_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fc4fe1515e740b5b2fedc80ab3c29d8_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="i850883eb6ca848ccbe6e3680f28bee20_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i125cc20cc74341a5b27b3efd37225cf0_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd9cf65a286f4e7da9b13796a041f58f_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib11873105d5440f2b04ad3921ee0e374_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4810c81a75b84f8b964fb340d02890c0_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie49ad1f5b50641398e4bd5e6a19ec508_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b1223169902474aafc57a25d19dcaff_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d5c30fce06545d9a3baacb0b0ab774e_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaedfc761d77477d83685f07ca670fc4_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i337a214cbd1b44929248114a2eb85662_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e5a7fdf85fc4fc7bfa8e4d51f47e59b_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f50051810c4c1faeb0643d2151e699_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i071e191539a447ab937022c70f4066ae_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3ca226cd81a48daacc85597ee8e0f61_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ae1f8be861d4b04aa760182f4297029_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d556ca23f9e45b4b9ed6c03f967c59b_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc4a5bca80f542428c9f79064ba8ff59_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a65d7d772494943b214d873b45da310_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice176fd5f4104315b8f2c270962294fa_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i206233ca66af4b1a9cf478e3d8d24963_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aa5c591d2414c088c15c92ff3156418_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbc3624e7a294295a982185658426bfe_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82f90a00897a46f1957e0414cc090bbe_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5276ec4d64fb4ba49c9c540fea11a982_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41fe2331cabe4050a30129ee051c2799_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bc9a78c8ba049f1946264d1c52f58e9_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d753c4338ff47ef84b0c40394bd5147_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c3596696fae4d9fb41163e7ddd3e386_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7048757da4c04483a7c963e440b237a5_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b2a018fee9e45548471c0835e50f5b6_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02a9e43c4eda4262b8e648fb4debd1eb_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:BioInventInternationalABBioInventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d84069f159b428fbda44b41dd831144_D20221101-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CybrexaTherapeuticsLLCCybrexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ec846e4aef84ad2ae39d1d13246bfc6_I20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CybrexaTherapeuticsLLCCybrexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd58ac0e41e340fc877768fad90c5f62_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CybrexaTherapeuticsLLCCybrexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3334291a8ef14e57a8f54daf44f344c8_D20221101-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:SairopaBVSairopaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6fd500061c74be88ef95fc875ef99af_I20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:SairopaBVSairopaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia026be7c5b9b41a3a54316d617e77f69_D20221101-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CatalentIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0f7c864ef914e8b9ebcaa0c64e1ece3_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id82fc91049724181b2a5e0f40253e48c_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i361ef59b0f2e4fddaf4c38b878d30ec0_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if09743b2bc6e41bdb6f96e1e3fef767b_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f1d4c0db61942b98ec8d831869eff8a_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b10b0b7dac44f40b1acc72e8f727bc8_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57b0ec642b2d416d99ecaed9d2670965_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic56eac004a664b27807f0d574730e620_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20c6ba758c364e9cbc586045aa0a9faa_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i191d7158380c4447a4808cab8812db7f_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b13e9beb6b943898d6cef7a1e02fc9e_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5acd41dc9f24b53b18e9a7c0319506c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf3d41d8f12c40e4baaa791aadb41393_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32b96a13da9e4c34a6911c04c05af3e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78d5da90485a4254a56630c577874e45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i972ae3af601c4166b2b7375fcce4b2f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97a943d0ee094645bee3a1a59e2108dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic81da6fcbafc408f85a016575fc626ad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>exel:investment</xbrli:measure></xbrli:unit><xbrli:unit id="bond"><xbrli:measure>exel:bond</xbrli:measure></xbrli:unit><xbrli:unit id="numberofsponsoredenterprise"><xbrli:measure>exel:numberOfSponsoredEnterprise</xbrli:measure></xbrli:unit><xbrli:context id="ieebb4571285b4760b2d6ffadd98aa2a3_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i678fac2def204c018d03c82ac9dbc312_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a347ff0104c4e37a0b5967300b9b308_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2525f5b5cbe34620878e5e9e6f0c1c1e_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cd2228030e9433ab02d7801959e3ef3_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40eb4f16efe747339fc781b4b8ab1d9d_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic099aa5b5a354fd0bc57f4dfc1f82f5f_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ff0318ea05d43dc8f548eb4b0abeaab_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iace46fa599fd439ea6f6a1a2dd79a719_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia52f875fc7ea48afad6c5d1f838e319a_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a1f30ef6bf04adebfc61920cd8a412a_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i199c2fdbc09541b98fa084e45047c999_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie569dd4e72ad4efea4960bffc82ca79e_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a4566d6932b48aa8902d306c989ff52_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia82be6e971604c2da30b378bdf9985c9_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3fc431dacf844f38ad9667dc0e877c2_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic96a10d99c47408289f5ad833d6120b8_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75ea1cc7d48743c88632a3cf80cbd319_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a1d047b86f24d2083f214d75c5134ef_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51fb172e52eb436f82f975928b0d6479_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia20e3dbd8a4d45d884a2d75792ca5567_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i471e33a44e454a859ed17e9d46754e8e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfd0873a4a96461ba27862f3c00db9c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f0f51588cc244e6bc024c642a236d9e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i726e2aeff8e4434ab43684910d66fa92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10af3e3a1cd64127a91cee9c3a18360c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aefb57539a84853a9275b9c5978a13c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ef8749612e74ad38eff74f7f8441bae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fd89a3bfdd74436bbebaf5f5a836492_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebe7e70eb57b4339a8a7e41055b873ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iada6509b74ef42d1ab3a02e9916aa003_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97e1a85481df47c6ba245c6579743863_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73559db97810456c9b104a736adc72f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35acff8b86c74ab6877bd2ff37df8915_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3b577aa781240a89ea986321d268054_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bc81f428a0846d484b97bfeeb05fb15_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b4bcecee8844c49bc7fe25f8b70e6b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i333e0adca8ad4c98adc9303eaa294dee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia12585f72d404b3b9451798d475c2669_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d2966ecc3e24e2cb9545a4f31ab7a68_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dfc0620ff1b4f0d83f4e9ed4f789075_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddcafb03f418408d86fae11b5091d968_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12667066e7cc4662b0936e2e393953fd_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="derivative_instrument"><xbrli:measure>exel:derivative_instrument</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i042731f45c434908a7097f420a97138c_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4218de4396fe4f889b222285008565ab_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf9ed26c4ba2489591ac9c39a8bf7ce1_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e4b169888c84090b5422b97549cd20c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08940ae14c044060b10d9ea3213210f3_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54d01b1ebd6a4b07bfe50d2f94bef6b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29abdea0de484029b656cfe3041033c3_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied09a4ba58274c3596cc89a3777f1174_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7215386183c44fd2aa5b09fe609d09a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb968a7ec21c46bda8be17bee6c569df_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89d86279d8cf4c6688a69b3db5f0650e_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i261b348dea0344bc94589101e7e53f5e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd4ba0df5aff4776bc4e4486814a14a1_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a48c86b35e6435ea5fd025596c4038e_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e43db2475c746e19470fa095df95b14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e7aa72456ac4985a26e7ee7471b2167_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44a51d0f954f47abb686f58842236e4b_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ebe5b3d3ea6429d897818f4d64c6c70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e2afee13177452697583dfe3fb2e778_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib510a5b7f321419fafd9bcd1b30bce22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5160dca23cbd4534bbd8f0c6583551eb_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14b02cd880bf4d00b829d7485dae8233_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee5871015bd64ea0a1cea69d5451681c_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ff342a670f4b08a73196e2c605fefd_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2297486cdd248d085cac7850abaaf71_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5491aa8fe4e24ba3ac8e4aaa781cce6a_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53d5d9f5ba5145de91b7ed6cafe85f4b_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i001bf94dda6a471d908297d31da5650a_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b2da2883e9244eb867ae85f79b46942_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i448f6fe1dd7842a5b8a72af4bafcacbe_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i265887804270466a84b8183ec8c715b9_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i078320950f3f4080b9cc748699315beb_D20220525-20220525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exel:AmendedAndRestated2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-25</xbrli:startDate><xbrli:endDate>2022-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3874dd04524f404cad068734350f1731_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exel:AmendedAndRestated2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fad33a89ad640298188cf7bb295b4ae_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exel:AmendedAndRestated2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a61f81952984a76817f7077b77e352c_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94edb7e6d39c450a954861e65f48c315_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4196c2fa72f4675a1c7dc4470ac938f_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d192ee0ba8049e2a30c45ffc397e321_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0d9106c860342c6a5490820d5ac452c_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ab3ba9b700146e8a378297f9a6ef6c5_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d394ecf14b74946a77659139d5f4878_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4d13e607a19484395fc6a707a9c2df9_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1665a438e56445b78cb7452df0643ba1_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c54a7d88c1f429ba5559d7d2282d65c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5de3dc69b844f86ba1ee22cce4ea5c9_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3d7d02ac4d34267a1d46e90f45bef37_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aae7ba847d34422b359963bd9dc87f5_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fb2e18c946f487ea024e74f846cd36a_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6d07a5ce0b943d9851f70f5a1bc4058_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1b5d625613f4f5d933afddd77da19b7_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8a52c2ef07a4489ad93e8b30e5e3368_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63901f6ae4fb4bcbb543c24cd2c4216a_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib652a5d9ce3a49709aea2941cebaac3b_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04f2cc9dcfa7426e99f081418b205d0e_D20221001-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id33e4bb7f86d4f63bb3483974950eb21_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">exel:A2021AwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i053c349bf2894f5c9e19fc0cf85fe118_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesClinicalTrialResultsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a76d7c8a8dc41cfa3f976f8a86b8ac3_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5603f2e0fff4c849973ffaeafa13517_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i425a3fc9ca83455daa4acf0026125185_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2fc11d4d2754631a3733ccac92d04e3_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4e6cc8bacaf4594895d5bbfc9c89791_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:StatusAxis">exel:NotProbableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f5be490ad62428386485550713032a7_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic95667d6b2e54d3fa5b025ecb0ffea4b_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71c697b2f65940fa81b21b627eb077fb_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56ed82a42994483c92b32ba299673685_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib28ac370d4ef4ca68b7bea32798fe004_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i124df26053054aa2bdf51a23778af8d1_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i4ca72b16cd354168a6373fa5107c1cb5_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46d4a2a715724209a705ccaf6ae07793_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>exel:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i787ca4c1857e40088e47d31bcee1d60b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia855702135904005a41d208deb24e60a_1"></div><div style="min-height:36pt;width:100%"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:199.50pt"><tr><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">FORM </span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6NTE0YjVjOTFmMTdjNDA5MGFmN2VmNDMyZmY0YzEzYzMvdGFibGVyYW5nZTo1MTRiNWM5MWYxN2M0MDkwYWY3ZWY0MzJmZjRjMTNjM18wLTEtMS0xLTkyMTUw_c419ca7d-8ab4-4ece-8044-c324d9f8b716">10-K</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTY3_851ec150-92ec-4456-8130-27df67121c3a">&#9746;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl81NDk3NTU4MTc5NTQ_a2895cf6-3d51-4ed0-a0b2-a8f3ac752678"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl81NDk3NTU4MTc5NTQ_a794da58-d11b-401e-b69f-895b33aef7e2">December&#160;30</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTcy_c0014a1f-773a-4047-8c8e-a7f88b8946c4">&#9744;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the transition period from               to                     </span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zODU_4ecf8373-c73a-4056-bb4e-dedfd9982eae">000-30235</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:204.00pt"><tr><td style="width:1.0pt"></td><td style="width:202.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:47pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="text-align:center"><img src="exel-20221230_g1.jpg" alt="exel-20221230_g1.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"/></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6ZWI0ZWU4YzFiZTYyNDRkMzlmZTQ0MmUxYWE5MTE5MzEvdGFibGVyYW5nZTplYjRlZThjMWJlNjI0NGQzOWZlNDQyZTFhYTkxMTkzMV8xLTAtMS0xLTkyMTUw_6697713e-4e51-4d60-9001-c83fec2f9f4c">EXELIXIS, INC.</ix:nonNumeric></span></td></tr><tr style="height:11pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6ZGUwMDMzYzIxY2ZiNDQ3OWJjZGIwYmQwYTY4NDY4NGQvdGFibGVyYW5nZTpkZTAwMzNjMjFjZmI0NDc5YmNkYjBiZDBhNjg0Njg0ZF8wLTAtMS0xLTkyMTUw_786653ca-5c1b-4324-9ab4-74e17c860288">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6ZGUwMDMzYzIxY2ZiNDQ3OWJjZGIwYmQwYTY4NDY4NGQvdGFibGVyYW5nZTpkZTAwMzNjMjFjZmI0NDc5YmNkYjBiZDBhNjg0Njg0ZF8wLTEtMS0xLTkyMTUw_fc0a92c2-3ba2-44a3-8b10-c04aaceda475">04-3257395</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTU_5b7a6974-d3d3-405d-acec-0fce47b76809">1851 Harbor Bay Parkway</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTk_c51bf921-7571-45b0-9b53-6761d4abd301">Alameda,</ix:nonNumeric> <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl80MDI_68fd953c-6e93-4231-8b08-7cb5fc44ec3d">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl80MDU_b693fbb2-86b5-47a7-a2d2-fdca12064168">94502</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl80MTA_6b0ebf6d-1994-424c-bf37-251e0180a201">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl80MTQ_0f10cfd9-3466-426d-9f5a-547cb7af8585">837-7000</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:38.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6YzBmNDcxNDY3MzZjNDhhNjhmYzBiYjU5ZmMzMDcxZDkvdGFibGVyYW5nZTpjMGY0NzE0NjczNmM0OGE2OGZjMGJiNTlmYzMwNzFkOV8xLTAtMS0xLTkyMTUw_723f8982-f5bf-4e32-91af-7d2878c6fa9f">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6YzBmNDcxNDY3MzZjNDhhNjhmYzBiYjU5ZmMzMDcxZDkvdGFibGVyYW5nZTpjMGY0NzE0NjczNmM0OGE2OGZjMGJiNTlmYzMwNzFkOV8xLTEtMS0xLTkyMTUw_382f1f77-7263-4999-8695-7fe5b2c3d9fc">EXEL</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6YzBmNDcxNDY3MzZjNDhhNjhmYzBiYjU5ZmMzMDcxZDkvdGFibGVyYW5nZTpjMGY0NzE0NjczNmM0OGE2OGZjMGJiNTlmYzMwNzFkOV8xLTItMS0xLTkyMTUw_bde82e10-9ff4-4b4a-aabb-711e3fc66edb">The Nasdaq Stock Market LLC</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">None</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;<ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTY4_1b2bdb6a-24fe-41bc-a78e-229692794403">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTY5_e6a2349b-ade3-4f87-8c7d-3eb80b4a9e18">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;<ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTcw_c9e0f615-4725-4ddd-a511-1f500d554a22">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTcz_e18865cc-07e8-4028-8a2b-19968a1b6427">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6M2EwMmE1YTRlYzliNDA4OTg4NDIzZTg3MjI4NDRiMjkvdGFibGVyYW5nZTozYTAyYTVhNGVjOWI0MDg5ODg0MjNlODcyMjg0NGIyOV8wLTAtMS0xLTkyMTUw_34c545a5-0f9d-4068-bb0b-5d92ee5b1a94">Large accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6M2EwMmE1YTRlYzliNDA4OTg4NDIzZTg3MjI4NDRiMjkvdGFibGVyYW5nZTozYTAyYTVhNGVjOWI0MDg5ODg0MjNlODcyMjg0NGIyOV8xLTQtMS0xLTkyMTUw_08116f63-d6ca-4a87-8e03-9a5db068c585">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6M2EwMmE1YTRlYzliNDA4OTg4NDIzZTg3MjI4NDRiMjkvdGFibGVyYW5nZTozYTAyYTVhNGVjOWI0MDg5ODg0MjNlODcyMjg0NGIyOV8yLTQtMS0xLTkyMTUw_7365cbe4-5c02-441b-9514-89b5b1fe9ab5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTc0_d613466c-0f81-4c1b-beb6-dc98bfc3abd3">&#9746;</ix:nonNumeric></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTc1_7910bf5f-466b-4849-9aad-05872a73e349">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter: $<ix:nonFraction unitRef="usd" contextRef="ife95f2dac98345e09e30688f417dfefd_I20220701" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8yOTk5_7bff524c-d59e-4123-8e40-8e5a9c94457b">6,831,299,691</ix:nonFraction>. Excludes shares of the registrant&#8217;s common stock held by persons who were directors and/or executive officers of the registrant at&#160;July&#160;1, 2022&#160;on the basis that such persons may be deemed to have been affiliates of the registrant at such date. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Number shares of the registrant&#8217;s common stock outstanding as of January&#160;30, 2023: <ix:nonFraction unitRef="shares" contextRef="ia7a2db918d5e4f25a57dfd066511af97_I20230130" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zODQ4MjkwNzEyMTIw_e951e337-3b34-420a-a796-ff29b29c7b6b">324,087,337</ix:nonFraction></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTcx_f2dbae03-fee2-4d8c-8705-8c5fca8a4ebf" escape="true">Certain portions of the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than April 29, 2023, in connection with the registrant&#8217;s 2023 Annual Meeting of Stockholders are incorporated herein by reference into Part III of this Annual Report on Form 10-K.</ix:nonNumeric></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div></div></div><div id="ia855702135904005a41d208deb24e60a_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_10">PART&#160;I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_16">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_19">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_22">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_25">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_28">57</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_31">PART&#160;II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_34">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_34">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_37">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_37">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_40">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_55">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_55">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_58">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_58">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_121">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_121">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_124">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_124">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_127">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_127">119</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_1302">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_1302">119</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_130">PART&#160;III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_133">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_133">119</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_136">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_136">119</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_139">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_139">120</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_142">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_142">120</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_145">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_145">120</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_148">PART IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_151">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_151">121</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_154">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_154">125</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_157">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_157">126</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ia855702135904005a41d208deb24e60a_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of the statements under the captions &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business&#8221; and elsewhere in this Annual Report on Form&#160;10-K are forward-looking statements. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed under the heading &#8220;Item&#160;1A. Risk&#160;Factors&#8221; as well as those discussed elsewhere in this Annual Report on Form 10-K. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">statements.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our securities involves a high degree of risk. Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, as well as other risks that we face, can be found under the heading &#8220;Item 1A. Risk Factors&#8221; below.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Our ability to grow our company is dependent upon the commercial success of CABOMETYX in its approved indications and the continued clinical development, regulatory approval, clinical acceptance and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Pricing for pharmaceutical products, both in the U.S. and in foreign countries, has come under increasing attention and scrutiny by federal, state and foreign national governments, legislative bodies and enforcement agencies. Initiatives arising from this scrutiny may result in changes that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">The timing of the entrance of generic competitors to CABOMETYX and legislative and regulatory action designed to reduce the barriers to the development, approval and adoption of generic drugs in the U.S. could limit the revenue we derive from our products, most notably CABOMETYX, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">We may be unable to expand our discovery and development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy data for those products sufficiently differentiated to compete in our highly competitive market environment.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">The regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities are lengthy, uncertain and subject to change, and may not result in regulatory approvals for additional cabozantinib indications or for our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our other product candidates, grow more quickly than the revenues we generate.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance and investments, which subjects us to a number of risks. For example, we rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and we are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S. In addition, our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">We are subject to healthcare laws, regulations and enforcement, as well as laws and regulations relating to privacy, data collection and processing of personal data; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Data breaches, cyber attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our prospects for growth.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BASIS OF PRESENTATION</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2022, which was a 52-week fiscal year, ended December&#160;30, 2022, fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended January&#160;1, 2021. For convenience, references in this report as of and for the fiscal years ended December&#160;30, 2022, and January&#160;1, 2021 are indicated as being as of and for the years ended December&#160;31, 2022 and 2020, respectively.</span></div><div id="ia855702135904005a41d208deb24e60a_13"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and combination regimens at the forefront of cancer care. Through the commitment of our drug discovery, development and commercialization resources, we have produced four marketed pharmaceutical products, including our flagship molecule, cabozantinib. We continue to evolve our product portfolio, leveraging our investments, expertise and strategic partnerships, to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales related to cabozantinib account for the majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 62 other countries as: CABOMETYX&#174; (cabozantinib) tablets approved both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab) for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA and European Commission (EC), for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo). See &#8220;&#8212;Collaborations and Business Development Activities&#8212;Other Collaborations.&#8221;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The year 2022 was our sixth year of annual profitability, which featured growth in net product revenues of approximately 30% year-over-year as a result of increased sales of our cabozantinib products in the U.S., supplemented by an approximately 16% year-over-year increase in royalties earned pursuant to collaboration agreements with our ex-U.S. partners. We plan to continue leveraging the resulting operating cash flows to support the ongoing investigation of cabozantinib in phase 3 trials for new indications and the advancement of a broad array of diverse biotherapeutics and small molecule programs for the treatment of cancer exploring multiple modalities and mechanisms of action. Of the clinical-stage assets that have emerged from our drug discovery and preclinical activities thus far, the furthest along are zanzalintinib (formerly XL092), a next-generation oral tyrosine kinase inhibitor (TKI) and XB002, an ADC that targets tissue factor (TF).  As we continue to bolster our pipeline, we pursue options to acquire other investigational drug candidates from third parties if those assets demonstrate evidence of clinical success. One example of this approach is CBX-12 (alphalex</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> exatecan), a clinical-stage peptide-drug conjugate (PDC) invented by Cybrexa Therapeutics (Cybrexa) that utilizes Cybrexa&#8217;s proprietary alphalex technology to enhance the delivery of exatecan, a highly potent, second-generation topoisomerase I inhibitor, to tumor cells.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exelixis Marketed Products: CABOMETYX and COMETRIQ</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As detailed below, CABOMETYX and COMETRIQ have been approved to treat patients with various forms of cancer by the FDA for the U.S. market, the EC for the European Union (EU) markets and the Japanese Ministry of Health, Labour and Welfare (MHLW), as well as by comparable regulatory authorities across other markets worldwide.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approval Date</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regimen</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Major Markets</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="15" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX&#174;<br/>(cabozantinib)</span></td><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Renal Cell Carcinoma (RCC) </span></td></tr><tr style="height:38pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patients with advanced RCC who have received prior anti-angiogenic therapy</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 25, 2016</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:38pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Advanced RCC in adults following prior VEGF-targeted therapy</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 9, 2016</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with advanced RCC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 19, 2017</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:38pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-line treatment of adults with intermediate- or poor-risk advanced RCC</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 17, 2018</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with curatively unresectable or metastatic RCC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 25, 2020</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-line treatment of patients with advanced RCC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 22, 2021</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combination with OPDIVO&#174; (nivolumab)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-line treatment for patients with advanced RCC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combination with OPDIVO</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with unresectable or metastatic RCC</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 25, 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combination with OPDIVO</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td></tr><tr style="height:14pt"><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hepatocellular Carcinoma (HCC)</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HCC in adults who have previously been treated with sorafenib</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2018</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with HCC who have been previously treated with sorafenib</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 14, 2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with unresectable HCC that has progressed after cancer chemotherapy</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 27, 2020</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td></tr><tr style="height:14pt"><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Differentiated Thyroid Cancer (DTC)</span></td></tr><tr style="height:93pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Adult and pediatric patients 12 years of age and older with locally advanced or metastatic DTC that has progressed following prior VEGF receptor-targeted therapy and who are RAI-refractory or ineligible</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 17, 2021</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Adult patients with locally advanced or metastatic DTC, refractory pr not eligible to RAI who have progressed during or after prior systemic therapy</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 3, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ&#174;<br/>(cabozantinib)</span></td><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medullary Thyroid Cancer (MTC)</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with progressive, metastatic MTC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 29, 2012</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:44pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adult patients with progressive, unresectable locally advanced or metastatic MTC</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 25, 2014</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, 2021 and 2020, we generated $1,401.2 million, $1,077.3 million and $741.6 million, respectively, in net product revenues from sales of CABOMETYX and COMETRIQ. Outside the U.S., we rely on collaboration partners for the commercialization of CABOMETYX and COMETRIQ; Ipsen Pharma SAS (Ipsen) is responsible for all territories outside of the U.S. and Japan, and Takeda Pharmaceutical Company Limited (Takeda) is responsible for the Japanese market. In 2022, 2021 and 2020, we earned $121.4 million, $105.1 million and $78.4&#160;million, respectively, of royalties on net sales of cabozantinib products outside of the U.S. For additional information on the terms of our collaboration agreements with Ipsen and Takeda, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Cabozantinib Commercial Collaborations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Renal Cell Carcinoma - CABOMETYX is a Leading TKI Treatment Option for Patients with Advanced RCC</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CABOMETYX has become a standard of care for the treatment of patients suffering from advanced RCC, and a growing number of these patients have been or will be treated with CABOMETYX. In 2022, approximately 32,200 patients with advanced kidney cancer required systemic therapy in the U.S., with over 20,000 patients receiving first-line treatment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since CABOMETYX was first approved, we have deployed our promotional and medical affairs teams to educate physicians about CABOMETYX. We believe that the product&#8217;s success is attributable to the strength of the clinical data reflected in its FDA-approved labeling for advanced RCC. The CABOMETYX label incorporates the results of the METEOR, CABOSUN and CheckMate-9ER clinical trials. In July 2015, we announced positive results of METEOR, a phase 3 pivotal trial comparing CABOMETYX to everolimus in patients with advanced RCC who have experienced disease progression following treatment with at least one prior VEGF receptor inhibitor. These results formed the basis for the FDA&#8217;s approval in April 2016, following which CABOMETYX became the first and only single-agent therapy approved in the U.S. for previously treated advanced RCC to demonstrate statistically significant and clinically meaningful improvements in three key efficacy parameters in a global pivotal trial: overall survival (OS); progression-free survival (PFS); and objective response rate (ORR). Subsequently, in October 2016, we announced positive results from CABOSUN, a randomized, open-label, active-controlled phase 2 trial conducted by the Alliance for Clinical Trials in Oncology, comparing cabozantinib with sunitinib in patients with previously untreated advanced RCC with intermediate- or poor-risk disease. These results formed the basis for the FDA&#8217;s approval in December 2017 of CABOMETYX for previously untreated patients with advanced RCC, and for this patient population, CABOMETYX is the only approved single-agent therapy to demonstrate improved PFS compared with sunitinib, a first-generation TKI that was the previous standard of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CABOMETYX has also demonstrated positive clinical results in combination with immune checkpoint inhibitors (ICIs), most notably in CheckMate-9ER, an open-label, randomized, multinational phase 3 pivotal trial evaluating OPDIVO, an ICI developed by BMS, in combination with CABOMETYX versus sunitinib in patients with previously untreated, advanced or metastatic RCC. Results from CheckMate-9ER demonstrated that the combination of CABOMETYX and OPDIVO doubled PFS and ORR and reduced the risk of disease progression or death by 40% compared with sunitinib, and formed the basis for the FDA&#8217;s approval of the combination in January 2021 as a first-line treatment of patients with advanced RCC. The National Comprehensive Cancer Network (NCCN),</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the nation&#8217;s foremost non-profit alliance of leading cancer centers,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has included the combination of CABOMETYX with OPDIVO in its Clinical Practice Guidelines for Kidney Cancer as a Category 1 option for the first-line treatment of patients with clear cell RCC. The NCCN also lists single-agent CABOMETYX as a category 1 preferred regimen in subsequent treatments for patients with clear cell RCC, and as a preferred systemic therapy regimen for non-clear cell RCC, supporting CABOMETYX&#8217;s position in the RCC treatment landscape.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, in markets outside the U.S., we continued to work closely with our collaboration partner Ipsen in support of its regulatory strategy and commercialization efforts for CABOMETYX as a treatment for advanced RCC, both as a single agent and in combination with OPDIVO, as well as in preparation for submission of applications for approvals of CABOMETYX in combination with other therapies, and similarly with our collaboration partner Takeda with respect to the Japanese market. As a result of the approvals of CABOMETYX and/or the combination of CABOMETYX with OPDIVO for RCC indications in 62 countries outside of the U.S., including the Member States of the EU, Japan, the U.K., Canada, Brazil, Taiwan, South Korea and Australia, CABOMETYX has continued to grow markedly outside the U.S. both in sales revenue and the number of RCC patients benefiting from its clinical effect. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hepatocellular Carcinoma - CABOMETYX Offers an Important Alternative for Patients with Previously Treated HCC</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liver cancer is a leading cause of cancer death worldwide, accounting for more than 800,000 deaths and 900,000 new cases each year. In the U.S., the incidence of liver cancer more than tripled over the past four decades. Although HCC is the most common form of liver cancer, making up about three-fourths of the more than 41,000 cases of liver cancer estimated to be diagnosed in the U.S. during 2023, this patient population has long been underserved. Prior to 2017, there </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was only one approved systemic therapy for the treatment of HCC. Since that time, multiple new therapies were approved in the U.S. for HCC, both for previously untreated patients and for patients previously treated with sorafenib. Given the introduction of new and demonstrably more effective therapies, including ICI combination therapies, we believe the second- and later-line market for HCC therapies has the potential to grow significantly in coming years, as these new treatment options are expected to improve longer-term outcomes, thereby resulting in a greater number of patients receiving multiple lines of therapy. With the approval of CABOMETYX in January 2019 for HCC patients previously treated with sorafenib, we expect to continue to play a key role in the treatment landscape for these patients.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s approval of CABOMETYX&#8217;s HCC indication was based on our phase 3 pivotal study, CELESTIAL. The CELESTIAL study met its primary endpoint, demonstrating that cabozantinib significantly improved OS, as compared to placebo. The NCCN has included CABOMETYX in its Clinical Practice Guidelines for Hepatobiliary Cancers as a Category 1 option for the treatment of patients with HCC (Child-Pugh Class A only) who have been previously treated with sorafenib, providing further support for CABOMETYX as an important treatment option for eligible HCC patients.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., the EC&#8217;s approval of CABOMETYX provided physicians in the EU with a second approved therapy for the second-line treatment of this aggressive and difficult-to-treat cancer, and approvals from Health Canada and the Japanese MHLW brought a much-needed therapy to HCC patients in those countries. In addition to the Member States of the EU, Japan, the U.K. and Canada, CABOMETYX is also approved for previously treated HCC indications in Brazil, Taiwan, South Korea, Australia and Hong Kong, among other countries.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Differentiated Thyroid Cancer - An Opportunity for CABOMETYX to Help an Underserved Patient Population </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 44,000 new cases of thyroid cancer will be diagnosed in the U.S. in 2023. Differentiated thyroid tumors, which make up about 90% of all thyroid cancers, are typically treated with surgery followed by ablation of the remaining thyroid with RAI. Approximately 5% to 15% of differentiated thyroid tumors are resistant to RAI treatment. With limited treatment options, these patients have a life expectancy of only three to six years from the time metastatic lesions are detected. New treatment options are therefore urgently needed.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced that COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib in patients with RAI-refractory DTC who have progressed after up to two prior VEGF receptor-targeted therapies, met its co-primary endpoint of demonstrating significant improvement in PFS as compared with placebo. These results formed the basis for the FDA&#8217;s approval in September 2021 of CABOMETYX f</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic DTC that has progressed following prior VEGF receptor-targeted therapy and who are RAI-refractory or ineligible. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced the commercial launch of CABOMETYX in this patient group upon the FDA&#8217;s approval, and we have seen a strong uptake in prescriptions for CABOMETYX in previously treated DTC during the months that followed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., our collaboration partner Ipsen </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received approval from the EC in May 2022 for CABOMETYX as a monotherapy for the treatment of adult patients with locally advanced or metastatic DTC, refractory or not eligible to RAI who have progressed during or after prior systemic therapy, which followed an approval from Health Canada in April 2022 to market CABOMETYX for a similar DTC indication.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medullary Thyroid Cancer - COMETRIQ, the First Commercial Approval of Cabozantinib</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates suggest that there will be approximately 950 MTC cases diagnosed in the U.S. in 2023, and COMETRIQ has served as an important treatment option for these patients since January 2013. The FDA&#8217;s approval of COMETRIQ for progressive, metastatic MTC was based on our phase 3 trial, EXAM. The EXAM trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful prolongation in PFS for cabozantinib, as compared to placebo. We are continuing to market COMETRIQ c</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">apsules for MTC patients at the labeled dose of 140 mg.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exelixis Development Programs</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have extensive expertise in the clinical development of oncology products, which we continue to leverage for the investigation of additional clinical uses of cabozantinib in combination with other therapies. Those activities comprise the cabozantinib development program described below. We also apply that expertise to advancing our company&#8217;s next generation of cancer treatments: innovative therapies that have the potential to help future cancer patients recover stronger and live longer. Accordingly, we have initiated clinical studies for our small molecule drug candidates, zanzalintinib and XL102, as well as for our first biotherapeutics product candidate, XB002, and these activities are described under &#8220;&#8212;Pipeline Development Programs - Advancing Exelixis&#8217; Future Cancer Therapy Candidates.&#8221;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cabozantinib and our pipeline development programs is provided below.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib Development Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cabozantinib inhibits the activity of tyrosine kinases, including MET, AXL, VEGF receptors and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance and maintenance of the tumor microenvironment. Objective tumor responses have been observed in patients treated with cabozantinib in multiple individual tumor types investigated in phase 1, 2 and 3 clinical trials to date, reflecting the medicine&#8217;s broad clinical potential. We are continuing to evaluate cabozantinib in combination with ICIs in late-stage clinical trials that we sponsor, along with our collaboration partners, across RCC and metastatic castration-resistant prostate cancer (mCRPC). Beyond clinical trials that we or our collaboration partners sponsor, independent investigators also conduct trials evaluating cabozantinib through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program (NCI-CTEP) or our investigator sponsored trial (IST) program. In addition to co-funding select trials with us, our collaboration partners Ipsen and Takeda have conducted trials in their respective territories through similar independently-sponsored programs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Combination Studies with BMS</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we entered into a clinical collaboration agreement with BMS for the purpose of conducting clinical studies combining cabozantinib with BMS&#8217; PD-1 ICI, nivolumab, both with or without BMS&#8217; CTLA-4 ICI, ipilimumab. Based on the data from CheckMate-9ER, the first clinical trial conducted under this collaboration, the FDA approved CABOMETYX in combination with OPDIVO on January 22, 2021 as a first-line treatment of patients with advanced RCC. We continue to evaluate these combinations in COSMIC-313, a phase 3 pivotal trial in previously untreated advanced RCC. Pursuant to our agreements with BMS, each party is responsible for supplying finished drug product for the applicable clinical trial, and responsibility for the payment of costs for each trial is determined on a trial-by-trial basis. For additional information on the terms of the BMS clinical trial collaboration agreement, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Cabozantinib Development Collaborations&#8212;BMS Collaboration</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COSMIC-313 - RCC. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we initiated COSMIC-313, a multicenter, randomized, double-blinded, controlled phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. Patients were randomized 1:1 to the experimental arm of the triplet combination of cabozantinib, nivolumab and ipilimumab or to the control arm of nivolumab and ipilimumab in combination with matched placebo. We announced top-line results from COSMIC-313 in July 2022, and in September 2022 we presented the data at the Presidential Symposium III at the 2022 European Society for Medical Oncology (ESMO) Congress. The trial met its primary endpoint, demonstrating significant improvement in blinded independent radiology committee (BIRC)-assessed PFS at the primary analysis for the triplet combination, reducing the risk of disease progression or death compared with the doublet combination of nivolumab and ipilimumab (hazard ratio: 0.73; 95% confidence interval [CI]: 0.57-0.94; P=0.01). Median PFS for the triplet combination was not reached (95% CI: 14.0-not estimable) versus 11.3 months for the doublet combination of nivolumab and ipilimumab (95% CI: 7.7-18.2). At a prespecified interim analysis for the secondary endpoint of OS, the triplet combination did not demonstrate a significant benefit, and therefore, the trial will continue to the next analysis of OS, expected in 2023. The safety profile observed in the trial was reflective of the known safety profiles for each single agent, as well as the combination regimens used in this study. Based on feedback from the FDA, we do not intend to submit a supplemental new drug application (sNDA) for the combination regimen based on the currently available data, and we plan to discuss a potential regulatory submission with the FDA when the results of the next OS analysis are available. We are sponsoring COSMIC-313, and BMS is providing nivolumab and ipilimumab for the study free of charge.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Combination Studies with Roche</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaborations with F. Hoffmann-La Roche Ltd. (Roche) for the purpose of evaluating the combination of cabozantinib and Roche&#8217;s anti-PD-L1 ICI, atezolizumab, diversifying our exploration of cabozantinib combinations with ICIs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COSMIC-021 - Locally Advanced or Metastatic Solid Tumors</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In February 2017, we entered into a master clinical supply agreement with Roche. As part of the clinical supply agreement, in June 2017, we initiated COSMIC-021, a large phase 1b dose escalation study that is evaluating the safety and tolerability of the cabozantinib and atezolizumab combination in patients with locally advanced or metastatic solid tumors. We are the trial sponsor of COSMIC-021, and Roche is providing atezolizumab free of charge. The study is divided into two parts: a dose-escalation phase, which was completed in 2018; and an expansion cohort phase, which is ongoing. Enrollment in the expansion phase of this study </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">includes 20 combination therapy tumor expansion cohorts in non-small cell lung cancer (NSCLC), mCRPC, RCC and various other tumor types. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CONTACT trials. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The encouraging efficacy and safety data that emerged from COSMIC-021 have been instrumental in guiding our clinical development strategy for cabozantinib in combination with ICIs. Informed by these data, we also entered into a joint clinical research agreement with Roche in December 2019, pursuant to which we are evaluating the cabozantinib and atezolizumab combination in two late-stage clinical trials: CONTACT-03, which focuses on patients with inoperable, locally advanced or metastatic RCC who have progressed during or following treatment with an ICI as the immediate preceding therapy; and CONTACT-02, which focuses on patients with mCRPC who have been previously treated with one novel hormonal therapy (NHT). A third trial, CONTACT-01, which focused on patients with metastatic NSCLC who have been previously treated with an ICI and platinum-containing chemotherapy, did not meet its primary endpoint of OS at final analysis. For additional information on the terms of the Roche joint clinical research agreement, see &#8220;&#8211;Collaborations and Business Development Activities&#8211;Cabozantinib Development Collaborations&#8211;Roche Collaboration.&#8221; </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> CONTACT-03 - RCC.</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Taking into account the rapidly evolving treatment landscape </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for RCC and based on positive early-stage results from COSMIC-021, in July 2020, we and Roche initiated CONTACT-03, a global, multicenter, randomized, open-label phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus cabozantinib alone in patients with inoperable, locally advanced or metastatic RCC who progressed during or following treatment with an ICI as the immediate preceding therapy. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients are randomized 1:1 to the experimental arm of cabozantinib in combination with atezolizumab or to the control arm of cabozantinib alone. The two primary efficacy endpoints for CONTACT-03 are PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1 as assessed by BIRC and OS, and secondary efficacy endpoints include PFS, ORR and duration of response (DOR) as assessed by the investigators. CONTACT-03 is sponsored by Roche and co-funded by us. In addition, both Ipsen and Takeda have the right to opt in and co-fund the trial and if doing so, they will have access to the results to support potential future regulatory submissions in their respective territories outside of the U.S. In January 2022, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we announced the completion of enrollment of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">523 patients at 168 sites globally. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on current event rates, we anticipate announcing results of the primary PFS analysis in the first half of 2023. We intend to use the data from CONTACT-03 to further study the therapeutic potential of cabozantinib in this patient population, both as a single agent and in combination with ICIs. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CONTACT-02 - mCRPC. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Cancer Society</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in 2023, approximately 288,000 new cases of prostate cancer will be diagnosed in the U.S., and 34,000 people will die from the disease. Prostate cancer that has spread beyond the prostate and does not respond to androgen-suppression therapies&#8212;a common treatment for prostate cancer&#8212;is known as mCRPC. Researchers estimate that in the U.S. in 2020, 43,000 men were diagnosed with mCRPC, which has a median survival of less than two years. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to this significant unmet need and based on positive early-stage results from Cohort 6 of COSMIC-021, in June 2020, we and Roche initiated CONTACT-02, a global, multicenter, randomized, open-label phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab in patients with mCRPC who have been previously treated with one NHT. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he trial aims to enroll approximately 580 patients at approximately 280 sites globally, and we expect to complete enrollment in the second half of 2023. Patients are being randomized 1:1 to the experimental arm of cabozantinib in combination with atezolizumab or to the control arm of a second NHT (either abiraterone and prednisone or enzalutamide). The two primary efficacy endpoints for CONTACT-02 are PFS per RECIST v. 1.1 as assessed by BIRC and OS, and secondary efficacy endpoints include ORR, prostate-specific antigen response rate and DOR. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONTACT-02 is sponsored by us and co-funded by Roche. In addition, both Ipsen and Takeda have opted into and are co-funding the trial, and both companies will have access to the results to support potential future regulatory submissions in their respective territories outside of the U.S. Based on current event rates, we anticipate announcing results of the primary PFS analysis in the second half of 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CONTACT-01 - NSCLC.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2020, we and Roche initiated CONTACT-01, a global, multicenter, randomized, open-label phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus docetaxel in patients with metastatic NSCLC who have been previously treated with an ICI and platinum-containing chemotherapy. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients were randomized 1:1 to the experimental arm of cabozantinib in combination with atezolizumab and the control arm of docetaxel. In December 2022, we announced that the trial did not meet its primary efficacy endpoint of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OS at final analysis. The safety profile of the combination of cabozantinib and atezolizumab was consistent with the known safety profiles for each single agent, and no new safety signals were identified. Detailed findings from CONTACT-01 will be submitted for presentation at a future medical meeting.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A complete listing of all ongoing cabozantinib trials can be found at </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.ClinicalTrials.gov</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Development Programs - Advancing Exelixis&#8217; Future Cancer Therapy Candidates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To continue growing our pipeline, we are investing heavily in the identification, exploration and advancement of new approaches to treating cancer. Several product candidates have progressed into clinical trials, including both small molecules and an assortment of multi-modal biotherapeutics that we have discovered or in-licensed and believe have the potential to treat a variety of cancers. The following table summarizes our current and planned clinical development activities outside of the cabozantinib franchise:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.982%"><tr><td style="width:1.0%"></td><td style="width:19.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CLINICAL DEVELOPMENT PROGRAM FOR PIPELINE</span></div></td></tr><tr><td colspan="3" style="background-color:#40aeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product Candidate</span></div></td><td colspan="3" style="background-color:#40aeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Mechanism of Action</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#40aeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Setting</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#40aeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Status Update</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zanzalintinib</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next-generation tyrosine kinase inhibitor (TKI) targeting MET/VEGFR/AXL/MER</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced or metastatic solid tumors</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Phase 1b trials evaluating zanzalintinib as a single-agent and in combination with immune checkpoint inhibitors (ICIs)</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">combination regimens ongoing </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">In combination with atezolizumab and with avelumab (STELLAR-001)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">In combination with nivolumab, with nivolumab and ipilimumab and with a fixed dose of nivolumab and relatlimab (STELLAR-002)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;</span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorectal cancer (CRC)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Phase 3 trial evaluating zanzalintinib in combination with atezolizumab ongoing (STELLAR-303)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-clear cell renal cell carcinoma (RCC)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Phase 3 trial evaluating zanzalintinib in combination with nivolumab ongoing (STELLAR-304)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XB002</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Next-generation tissue factor (TF)-targeting antibody-drug conjugate (ADC)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Advanced solid tumors</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1 trial evaluating single-agent and ICI combination regimens ongoing (JEWEL-101)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.02pt">In combination with nivolumab, with bevacizumab, and potentially with additional ICIs or other targeted therapies</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XL102</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Potent, selective, orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Advanced or metastatic solid tumors</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Phase 1 trial evaluating single-agent ongoing and combination regimens planned (QUARTZ-101)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.02pt">In combination with fulvestrant, with abiraterone and prednisone and potentially with other anti-cancer regimens</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CBX-12</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Peptide-drug conjugate (PDC) enhancing delivery of exatecan, a highly potent, second-generation topoisomerase I inhibitor, to tumor cells</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Advanced or metastatic refractory solid tumors</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Phase 1/2 evaluating CBX-12 as a single-agent ongoing (sponsored by Cybrexa)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zanzalintinib Development Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first compound discovered at Exelixis to enter the clinic following our re-initiation of drug discovery activities in 2017 was zanzalintinib, a next-generation oral TKI that targets VEGF receptors, MET, AXL, MER and other kinases implicated in cancer&#8217;s growth and spread. In designing zanzalintinib, we sought to build upon our experience with cabozantinib, retaining a similar target profile while improving key characteristics, including the pharmacokinetic half-life. We are evaluating zanzalintinib in a growing clinical development program across various tumor types.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">STELLAR-001 - Advanced Solid Tumors. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the FDA&#8217;s acceptance of our Investigational New Drug (IND) for zanzalintinib, in February 2019, we initiated STELLAR-001, a multicenter phase 1b clinical trial evaluating the pharmacokinetics, safety, tolerability and preliminary anti-tumor activity of zanzalintinib. STELLAR-001 is divided into dose-escalation and expansion phases. In October 2020, we presented data </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at the 32nd EORTC-NCI-AACR Symposium (the 2020 ENA Symposium) that suggest zanzalintinib has a desirable therapeutic profile. We believe it pairs the potential for significant anti-tumor activity with a much shorter clinical pharmacokinetic half-life than cabozantinib, and also presents the potential for synergistic effects in combination with ICIs. In consideration of these data, we amended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the phase 1 study protocol in October 2020 to include dose-escalation and expansion cohorts for zanzalintinib in combination with atezolizumab, and again in March 2021 to include dose-escalation and expansion cohorts for zanzalintinib in combination with avelumab, an ICI developed by Merck KGaA, Darmstadt, Germany (Merck KGaA) and Pfizer Inc. (Pfizer). We have established a </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recommended dose of 100 mg for both single-agent zanzalintinib and zanzalintinib in combination with atezolizumab, and we have begun enrolling expansion cohorts for patients with clear cell RCC, non-clear cell RCC, hormone-receptor positive breast cancer, mCRPC and colorectal cancer (CRC). The dose-escalation stage for zanzalintinib in combination with avelumab is ongoing, with expansion cohorts planned initially in urothelial carcinoma (UC). We presented data from STELLAR-001 during poster sessions at the most recent ESMO Congress in September 2022, which showed zanzalintinib has demonstrated preliminary, clinical activity similar to that observed with cabozantinib in phase 1 across a range of solid tumors and dose levels, with a manageable safety profile</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary efficacy endpoints for the expansion phase may include ORR per RECIST v. 1.1 and PFS per RECIST v. 1.1, in each case as assessed by the investigator.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">STELLAR-002 - Advanced Solid Tumors. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we initiated STELLAR-002, a multicenter phase 1 clinical trial evaluating the safety, tolerability and efficacy of zanzalintinib in combination with either nivolumab, nivolumab and ipilimumab, or a fixed dose of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nivolumab and relatlimab, a lymphocyte activation gene-3-blocking antibody developed by BMS (which replaced Nektar Therapeutics&#8217; bempegaldesleukin in the original trial protocol, which we announced in October 2022). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">STELLAR-002 is divided into dose-escalation and expansion phases. We have established a recommended dose of 100 mg for zanzalintinib in combination with nivolumab, and we have begun enrolling expansion cohorts for patients with clear cell RCC. The dose-escalation stage for zanzalintinib in the other combination regimens is ongoing and is continuing to enroll patients with advanced solid tumors. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the dose-escalation results, STELLAR-002 may enroll additional expansion cohorts for patients with clear cell and non-clear cell RCC, mCRPC, UC, HCC, NSCLC, CRC and squamous cell cancers of the head and neck (SCCHN). The primary efficacy endpoint of the expansion phase will be ORR, except for the cohort of patients with mCRPC, for which the primary efficacy endpoint will be duration of radiographic PFS. To better understand the individual contribution of the therapies, treatment arms in the expansion cohorts may include zanzalintinib as a single agent in addition to the ICI combination regimens.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">STELLAR-303 - CRC</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. CRC is the third most common cancer and the third-leading cause of cancer-related deaths in the U.S. According to the American Cancer Society, approximately 153,000 new cases will be diagnosed in the U.S. and around 52,000 people will die from the disease in 2023. Colorectal cancer is most frequently diagnosed among people aged 65-74 and is more common in men and those of African American descent. Nearly a quarter of colorectal cancer cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 15%. It has been estimated that approximately 43-45% of metastatic colorectal cancer cases exhibit a RAS mutation. In June 2022, we initiated STELLAR-303, a global, multicenter, randomized, open-label phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab versus regorafenib in patients with metastatic non-microsatellite instability-high or non-mismatch repair-deficient CRC who have progressed after, or are intolerant to, the current standard of care. The trial aims to enroll approximately 600 patients with documented RAS status at approximately 137 sites globally. Patients are being randomized 1:1 to the experimental arm of zanzalintinib in combination with atezolizumab or to the control arm of regorafenib. The primary objective of STELLAR-303 is to evaluate the efficacy of the combination in patients with RAS wild-type disease, and outcomes in patients with RAS-mutated disease will also be evaluated. The primary efficacy endpoint of STELLAR-303 is OS, and additional efficacy endpoints include PFS, ORR and DOR per RECIST v. 1.1, in each case as assessed by the investigator. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">STELLAR-304 - Non-Clear Cell RCC</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In December 2022, we initiated STELLAR-304, a global, multicenter, randomized, open-label phase 3 pivotal trial evaluating zanzalintinib in combination with nivolumab versus sunitinib in previously </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">untreated patients with advanced non-clear cell RCC. The trial aims to enroll approximately 291 patients at approximately 170 sites globally. Patients are being randomized 2:1 to the experimental arm of zanzalintinib in combination with nivolumab or to the control arm of sunitinib. The primary efficacy endpoints of STELLAR-304 are PFS and ORR per RECIST v 1.1., in each case as assessed by BIRC. The secondary efficacy endpoint is OS.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond STELLAR-303 and STELLAR-304, we intend to explore a series of early-stage and/or pivotal trials evaluating zanzalintinib in novel combination regimens across a broad array of future potential indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">XB002 Development Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XB002 (formerly ICON-2) is our lead TF-targeting ADC program, in-licensed from Iconic Therapeutics, Inc. (Iconic), now a wholly owned subsidiary of Endpoint Health, Inc. XB002 is an ADC composed of a human monoclonal antibody (mAb) against TF that is conjugated to a cytotoxic agent. TF is highly expressed on tumor cells and in the tumor microenvironment, and TF overexpression, while not oncogenic itself, facilitates angiogenesis, metastasis and other processes important to tumor development and progression. After binding to TF on tumor cells, XB002 is internalized, and the cytotoxic agent is released, resulting in targeted tumor cell death. XB002 is a rationally designed next-generation ADC that leverages proprietary linker-payload technology. Based on promising preclinical data</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we exercised our exclusive option to license XB002 in December 2020, resulting in our assuming responsibility for all subsequent clinical development of XB002. In December 2021, we amended our agreement with Iconic to acquire broad rights to use the anti-TF antibody used in XB002 for any application, including conjugated to other payloads, as well as rights within oncology to a number of other anti-TF antibodies developed by Iconic, including for use in ADCs and multispecific biotherapeutics. For additional information on our business development activities with Iconic, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Research Collaborations and In-licensing Arrangements&#8212;Iconic.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">JEWEL-101 - Advanced Solid Tumors</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2021, we initiated JEWEL-101, a multicenter phase 1, open-label clinical trial</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evaluating the</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of XB002 in patients with advanced solid tumors for which therapies are unavailable, ineffective or intolerable. The trial is divided into dose-escalation and cohort-expansion phases and aims to enroll approximately 450 patients with advanced solid tumors, with the primary objective of determining the maximum tolerated dose or recommended dose levels for intravenous infusion of XB002 as a single agent and in combination with either nivolumab or bevacizumab, a mAb developed by Roche. In October 2022, we announced promising initial dose-escalation results from JEWEL-101 during the Antibody-drug Conjugates Poster Session at the 34th EORTC-NCI-AACR Symposium (2022 ENA Symposium). The data demonstrated that XB002 was well-tolerated at multiple dose levels, and pharmacokinetic analyses showed that XB002 remains stable after infusion with low levels of free payload in circulation. The planned cohort-expansion phase, which we expect to initiate during 2023, is designed to further explore the selected dose of XB002, both as a single agent and in combination with either nivolumab or bevacizumab, in individual tumor cohorts, which may include forms of NSCLC, cervical cancer, ovarian cancer, UC, SCCHN, pancreatic cancer, esophageal cancer, mCRPC, triple negative breast cancer and hormone-receptor positive breast cancer, and will evaluate ORR per RECIST v. 1.1 as a primary endpoint as well as XB002&#8217;s safety, tolerability and pharmacokinetic profile. We also intend to initiate additional dose-escalation and expansion cohorts to evaluate the potential of XB002 in combination with additional ICIs and other targeted therapies across a wide range of tumor types, including indications other than those currently addressed by commercially available TF-targeted therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">XL102 Development Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XL102 (formerly AUR102) is the lead compound under our research collaboration with Aurigene Oncology, Ltd. (Aurigene). It is a potent, selective, irreversible and orally bioavailable covalent inhibitor of CDK7, which is an important regulator of the cellular transcriptional and cell cycle machinery. Based on encouraging</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> preclinical data for XL102, which we presented, along with Aurigene, at the 2020 ENA Symposium in October 2020, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we exercised our exclusive option to license XL102 in December 2020, resulting in our assuming responsibility for all subsequent clinical development of XL102. For additional information on our collaboration with Aurigene, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Research Collaborations and In-licensing Arrangements &#8212;Aurigene.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">QUARTZ-101 - Advanced Solid Tumors</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In January 2021, we initiated QUARTZ-101, a multicenter phase 1, open-label clinical trial evaluating the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of XL102, both as a single agent and in combination with other anti-cancer therapies, in patients with inoperable, locally advanced or metastatic solid tumors. The trial is divided into dose-escalation and cohort-expansion phases and aims to enroll approximately 298 patients with advanced solid tumors, with the primary objective of determining the maximum tolerated dose or recommended dose levels for daily oral administration of XL102 as a single agent, as well as in combination with </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fulvestrant for patients with hormone-receptor positive breast cancer and with abiraterone and prednisone for patients with mCRPC. Combinations with other agents may also be evaluated in the future. In December 2022, we announced initial dose-escalation results from QUARTZ-101 during the Poster Session at the 2022 San Antonio Breast Cancer Symposium. The data demonstrated that XL102 was well-tolerated at multiple dose levels, and a pharmacokinetic analysis showed rapid absorption of XL102 and an elimination half-life of 5-9 hours and supported adding investigation of twice-daily oral dosing. We are continuing to evaluate the efficacy of XL102 in additional patients during this initial dose-escalation phase. The subsequent cohort-expansion phase is designed to further explore the selected dose of XL102 as a single agent and in combination regimens in individual tumor cohorts, including ovarian cancer, triple-negative breast cancer, hormone-receptor positive breast cancer and mCRPC, and will evaluate ORR per RECIST v. 1.1 as assessed by the investigator, as well as XL102&#8217;s safety, tolerability and pharmacokinetic profile.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development of CBX-12</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we executed an exclusive collaboration agreement with Cybrexa providing us with the right to acquire CBX-12, a clinical-stage, first-in-class PDC that utilizes Cybrexa&#8217;s proprietary alphalex technology to enhance delivery of exatecan to tumor cells. CBX-12 is currently being evaluated in a phase 1 clinical trial to explore its </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmacokinetics, safety, tolerability and preliminary anti-tumor activity in patients with advanced or metastatic refractory solid tumors. The trial is divided into dose-escalation and cohort-expansion phases, with the primary objective of determining the recommended dose levels for intravenous infusion of CBX-12 as a single agent. Data from this trial reported in an oral presentation during a plenary session at the 2022 ENA Symposium demonstrated preliminary anti-tumor activity in a heavily pretreated patient population, including a complete response in a patient with ovarian cancer. The subsequent cohort-expansion phase is designed to further explore the selected dose of CBX-12 as a single agent in individual tumor cohorts, including forms of ovarian cancer, breast cancer, NSCLC and small cell lung cancer, and will evaluate ORR per RECIST v. 1.1 as assessed by the Investigator, as well as CBX-12&#8217;s safety, tolerability and pharmacokinetic profile. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on the Cybrexa option arrangement, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Research Collaborations and In-licensing Arrangements&#8212;Cybrexa.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">XL114 Development Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XL114 (formerly AUR104) is </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a novel anti-cancer compound that inhibits activation of the CARD11-BCL10-MALT1 (CBM) complex, a key component of signaling downstream of B- and T-cell receptors, which promotes B- and T-cell lymphoma survival and proliferation. At the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Association of Cancer Research</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Annual Meeting in April 2021, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurigene</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> presented preclinical data (Abstract 1266) demonstrating that XL114 exhibited potent anti-proliferative activity in a large panel of cancer cell lines ranging from hematological cancers to solid tumors with excellent selectivity over normal cells. We exercised our exclusive option to in-license XL114 in October 2021,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> resulting in our assuming responsibility for all subsequent clinical development, manufacturing and commercialization of XL114. For additional information on our collaboration with Aurigene, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Research Collaborations and In-licensing Arrangements&#8212;Aurigene.&#8221; </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we initiated a first-in-human, phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of XL114 as a monotherapy in patients with non-Hodgkin&#8217;s lymphoma (NHL). Based on initial findings in this phase 1 trial and the evolving treatment landscape for NHL, we have discontinued development of XL114 as of January 2023.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expansion of the Exelixis Pipeline</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasing our access to novel anti-cancer agents is essential to our pipeline strategy and overall business goals. We are working to expand our oncology product pipeline through drug discovery efforts, which encompass our diverse biotherapeutics and small molecule programs exploring multiple modalities and mechanisms of action. This approach provides a high degree of flexibility with respect to target selection and allows us to prioritize those targets that we believe have the greatest chance of yielding impactful therapeutics. As part of our strategy, our drug discovery activities have included research collaborations, in-licensing arrangements and other strategic transactions that increase our discovery bandwidth and allow us to access a wide range of technology platforms. In November 2022, we executed an option agreement with Sairopa, B.V. (Sairopa) to develop ADU-1805, a potentially best-in-class mAb that targets SIRP&#945;. For more information on the Sairopa option arrangement, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Research Collaborations and In-licensing Arrangements.&#8221; </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to discovering or in-licensing antibodies and other biotherapeutics or small molecule drug candidates aimed at specific targets, we are building our portfolio of potential cancer therapies through various business development arrangements with other companies that expand our capability to identify new targets using their proprietary technology platforms. One example is our exclusive option and license agreement with BioInvent International AB (BioInvent), described in more detail below, which is focused on the identification and development of novel antibodies for use in immuno-oncology therapeutics utilizing BioInvent&#8217;s proprietary n-CoDeR&#174; antibody library and patient-centric F.I.R.S.T</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also continued our efforts to increase our laboratory space during 2022, both by expanding our leased space at our Alameda headquarters and as part of our planned new Exelixis East facilities in the Greater Philadelphia area, which are intended to further enhance the capacity and capability of our biotherapeutics and small molecule discovery efforts. As of the date of this Annual Report on Form 10-K, we are currently advancing more than 10 discovery programs and expect to progress up to five new development candidates into preclinical development during 2023. In addition, we will continue to engage in business development initiatives with the goal of acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biotherapeutics Programs</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Much of our drug discovery activities focuses on discovering and advancing various biotherapeutics that have the potential to become anti-cancer therapies, such as bispecific antibodies, ADCs and other innovative treatments. ADCs in particular present a unique opportunity for new cancer treatments, given their capabilities to deliver anti-cancer payload drugs to targets with increased precision while minimizing impact on healthy tissues. This biotherapeutic approach has been validated by multiple regulatory approvals for the commercial sale of ADCs in the past several years. To facilitate the growth of these programs, we have established multiple research collaborations and in-licensing arrangements and entered into other strategic transactions that provide us with access to antibodies and binders, which are the starting point for use with additional technology platforms that we employ to generate next-generation ADCs or multispecific antibodies. In addition to the option deals with Cybrexa and Sairopa, some of our active research collaborations for biotherapeutics programs include collaborations with: </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Adagene Inc. (Adagene), which is focused on using Adagene&#8217;s SAFEbody</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology to develop novel masked ADCs or other innovative biotherapeutics with potential for improved therapeutic index;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">BioInvent, which is intended to expand our portfolio of antibody-based therapies and will utilize BioInvent&#8217;s proprietary n-CoDeR antibody library and patient-centric F.I.R.S.T screening platform, which together are designed to allow for parallel target and antibody discovery; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Catalent, Inc.&#8217;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc. (individually and collectively referred to as Catalent), which is focused on the discovery and development of multiple ADCs using Catalent&#8217;s proprietary SMARTag&#174; site-specific bioconjugation technology;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Invenra, Inc. (Invenra), which is focused on the discovery and development of novel binders and multispecific antibodies for the treatment of cancer; and </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">N</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BE-Therapeutics AG (NBE), which is focused on the discovery and development of multiple ADCs by leveraging NBE&#8217;s unique expertise and proprietary platforms in ADC discovery, including NBE&#8217;s SMAC-Technology&#8482; (a site-specific conjugation technology) and novel payloads.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have already made significant progress under these and other research collaborations and in-licensing arrangements and believe we will continue to do so in 2023 and future years. For example, based on promising preclinical data for XB002, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we exercised our exclusive option to license XB002 from Iconic in December 2020 and initiated the JEWEL-101 phase 1 clinical trial in June 2021.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For additional information on XB002, see &#8220;&#8212;Exelixis Development Programs&#8212;Pipeline Development Programs - Advancing Exelixis&#8217; Future Cancer Therapy Candidates&#8212;XB002 Development Program.&#8221; Also, as a direct result of these arrangements, we are advancing three biotherapeutics development candidates: XB010, XB014 and XB628. XB010, our first ADC advanced internally, targets the tumor antigen 5T4, incorporates an antibody sourced from Invenra and was constructed using Catalent&#8217;s SMARTag site-specific bioconjugation platform.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XB014 and XB628 are bispecific antibodies; XB014 combines a PD-L1 targeting arm with a CD47 targeting arm to block a macrophage checkpoint; and XB628 targets PD-L1 and natural killer cell receptor group 2A (NKG2A), identified as an emerging immune checkpoint that may mediate resistance to classical checkpoint inhibition. Both XB014 and XB628 were developed through our collaboration with Invenra. For additional information on these specific research collaborations and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in-licensing arrangements related to our biotherapeutics programs, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Research Collaborations and In-licensing Arrangements.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Small Molecule Programs</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its formation in 2000, our drug discovery group has advanced 25 compounds to the IND-stage, either independently or with collaboration partners, and today we deploy our drug discovery expertise to advance small molecule drug candidates toward and through preclinical development. These efforts are led by our experienced scientists, including some of the same scientists who led the efforts to discover cabozantinib, cobimetinib and esaxerenone, each of which are now commercially distributed drug products. We augment our small molecule discovery activities through research collaborations and in-licensing arrangements with other companies engaged in small molecule discovery, including:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">STORM Therapeutics LTD (STORM), which is focused on the discovery and development of inhibitors of novel RNA modifying enzymes, including ADAR1; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Aurigene, which is focused on the discovery and development of novel small molecules as therapies for cancer; and </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">StemSynergy Therapeutics, Inc. (StemSynergy), which is focused on the discovery and development of novel oncology compounds aimed to inhibit tumor growth by targeting Casein Kinase 1 alpha (CK1&#945;) and the Notch pathway.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on these research collaborations and in-licensing arrangements related to our small molecule programs, see &#8220;&#8212;Collaborations and Business Development Activities&#8212;Research Collaborations and In-licensing Arrangements.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amongst our small molecule programs, furthest along are zanzalintinib, which was discovered at Exelixis, and XL102 which was discovered at Aurigene. Zanzalintinib first entered the clinic in 2019, and we initiated the first two phase 3 pivotal studies evaluating zanzalintinib in 2022, and XL102 entered the clinic in 2021. For additional information on these clinical trial programs, see &#8220;&#8212;Exelixis Development Programs&#8212;Pipeline Development Programs - Advancing Exelixis&#8217; Future Cancer Therapy Candidates.&#8221; In addition, we continue to make progress on multiple, additional lead optimization programs for inhibitors of a variety of targets that we believe play significant roles in tumor growth, and we anticipate that some of these other programs could reach development candidate status in 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations and Business Development Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading biopharmaceutical companies for the commercialization and further development of the cabozantinib franchise. Additionally, we have made considerable progress under our existing research collaborations and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. We expect to enter into additional, external collaborative relationships around assets and technologies that complement our drug discovery and clinical development efforts. Under our commercial collaborations, we are entitled to receive milestones and royalties or, in the case of cobimetinib, royalties from sales outside the U.S. and a share of profits (or losses) from commercialization in the U.S. Under our research collaborations and in-licensing arrangements, we are obligated to pay milestones and royalties to our various partners. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib Commercial Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ipsen Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Under the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended on four occasions, including in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, Ipsen paid us aggregate upfront payments of $210.0 million in 2016. As of December&#160;31, 2022, we achieved aggregate milestone payments of $489.5 million related to regulatory and commercial </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progress by Ipsen since the inception of the collaboration agreement, including two regulatory milestone payments during 2022 totaling $27.0 million upon approval by the EC and Health Canada of CABOMETYX as monotherapy for the treatment of adult patients with locally advanced or metastatic DTC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also eligible to receive future development and regulatory milestone payments from Ipsen, totaling an aggregate of $19.5 million upon additional approvals of cabozantinib in future indications and/or jurisdictions, as well as contingent payments of up to $350.0 million and CAD$26.5 million associated with future sales milestones. We will further receive royalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan. We are entitled to receive a tiered royalty of 22% to 26% on annual net sales, with separate tiers for Canada; these 22% to 26% royalty tiers reset each calendar year. As of December&#160;31, 2022, we have earned royalties of $382.1 million on net sales of cabozantinib by Ipsen since the inception of the collaboration agreement. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on total net sales of any product containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Accordingly, and </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consistent with our historical agreement with GSK, we are required to pay a 3% royalty to Royalty Pharma on total net sales of any product incorporating cabozantinib, including net sales by Ipsen.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for 35% of such costs, provided Ipsen chooses to opt into such trials. In accordance with the collaboration agreement, Ipsen has opted into and is co-funding certain clinical trials, including: CheckMate-9ER, COSMIC-021, COSMIC-311, COSMIC-312, CONTACT-01 and CONTACT-02</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain responsible for manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. Relatedly, we entered into a supply agreement with Ipsen to supply finished and labeled drug product for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a pharmacovigilance agreement, which defines each partner&#8217;s responsibilities for safety reporting. The pharmacovigilance agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from territories outside of the U.S. and Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Ipsen.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (1) the expiration of patent claims related to cabozantinib, (2) the expiration of regulatory exclusivity covering cabozantinib or (3) ten years after the first commercial sale of cabozantinib, other than COMETRIQ. The supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the FDA or EMA orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended on three occasions to, among other things, modify the amount of reimbursements we receive for costs associated with our required pharmacovigilance activities and milestones we are eligible to receive, as well as modify certain cost sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02. Under the collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received an upfront payment of $50.0 million from Takeda in 2017. As of December&#160;31, 2022, we have also achieved regulatory and development milestones in the aggregate of $127.0 million related to regulatory and commercial progress by Takeda since the inception of the collaboration agreement. We are eligible to receive additional regulatory and development milestone payments, without limit, for additional potential future indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are further eligible to receive commercial milestones, including milestone payments earned for the first commercial sale of a product, of&#160;$119.0 million. We also receive royalties on the net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&#160;15%&#160;to&#160;24%&#160;on the initial $300.0 million of net sales, and following this initial $300.0 million of net sales, we are then entitled to receive a tiered royalty of 20%&#160;to&#160;30%&#160;on annual net sales thereafter; these 20% to 30% royalty tiers reset each calendar year. As of December&#160;31, 2022, we have earned royalties of $21.5 million on net sales of cabozantinib by Takeda since the inception of the collaboration agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with our historical agreement with GSK, we are required to pay a 3% royalty to Royalty Pharma on total net sales of any product incorporating cabozantinib, including net sales by Takeda. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for CONTACT-01 and CONTACT-02, Takeda is responsible for 20% of the costs associated with the cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and 100% of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. In accordance with the collaboration agreement, Takeda has opted into and is co-funding CheckMate-9ER, certain cohorts of COSMIC-021, CONTACT-01 and CONTACT-02.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, we are responsible for the manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. Relatedly, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a safety data exchange agreement, which defines each partner&#8217;s responsibility for safety reporting. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (1) two years after first generic entry with respect to such product in Japan or (2) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first six years of the collaboration will constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib Development Collaborations </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BMS Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#8217;s ICIs, nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab as a treatment option for RCC in the COSMIC-313 trial. For a description of the COSMIC-313 trial, see &#8220;&#8212;Exelixis Development Programs&#8212;Cabozantinib Development Program&#8212;Combination Studies with BMS.&#8221;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement with BMS, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts are governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial is conducted under a combination IND application, unless otherwise required by a regulatory authority. Each party is responsible for supplying finished drug product for the applicable clinical trial, and responsibility for the payment of costs for each such trial will be determined on a trial-by-trial basis. Following the FDA&#8217;s approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC, we and BMS commenced the commercial launch of the combination and have agreed to pursue commercialization and marketing efforts independently.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Roche Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#8217;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. Under this agreement with Roche, in June 2017, we initiated COSMIC-021 and in December 2018, we initiated COSMIC-312. We were the sponsor of both trials, and Roche provided atezolizumab free of charge. Building upon encouraging clinical activity observed in COSMIC-021, in December 2019 we entered into a joint clinical research agreement with Roche for the purpose of further evaluating the combination of cabozantinib with atezolizumab in patients with locally advanced or metastatic solid tumors, including in the CONTACT-01, CONTACT-02 and CONTACT-03 studies. If a party to the joint clinical research agreement proposes any additional combined therapy trials beyond these three ongoing phase 3 pivotal trials, the joint clinical research agreement provides that such proposing party must notify the other party and that if agreed to, any such additional combined therapy trial will become part of the collaboration, or if not agreed to, the proposing party may conduct such additional combined therapy trial independently, subject to specified restrictions set forth in the joint clinical research agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the joint clinical research agreement, each party granted to the other a non-exclusive, worldwide (excluding, in our case, territory already the subject of a license by us to Takeda), non-transferable, royalty-free license, with a right to sublicense (subject to limitations), to use the other party&#8217;s intellectual property and compounds solely as necessary for the party to perform its obligations under the joint clinical research agreement. The parties&#8217; efforts are governed through a joint steering committee established to guide and oversee the collaboration and the conduct of the combined therapy trials. Each party is responsible for providing clinical supply for all combined therapy trials, and the cost of the supply will be borne by such party. The clinical trial expenses for each combined therapy trial agreed to be conducted jointly under the joint clinical research agreement are shared equally between the parties, and the clinical trial expenses for each additional combined therapy trial not agreed to be conducted jointly under the joint clinical research agreement are borne by the proposing party, except that the cost of clinical supply for all combined therapy trials are borne by the party that owns the applicable product. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the joint clinical research agreement provides that it will remain in effect until the completion of all combined therapy trials under the collaboration, the delivery of all related trial data to both parties, and the completion of any then agreed-upon additional analyses. The joint clinical research agreement may be terminated for cause by&#160;either party based on any uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party will terminate upon completion of any ongoing activities under the joint clinical research agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zanzalintinib Clinical Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to diversify our exploration of the therapeutic potential of zanzalintinib, we have also entered into multiple collaboration and supply agreements to evaluate zanzalintinib in various combination trials, including with Roche&#8217;s atezolizumab, Merck KGaA and Pfizer&#8217;s avelumab, and BMS&#8217; nivolumab, ipilimumab and relatlimab.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These agreements facilitate the efficient exploration of the safety and efficacy of zanzalintinib in combinations with a variety of established cancer therapies as we continue to build a broad development program for zanzalintinib. For descriptions of our ongoing clinical trials evaluating zanzalintinib in combination with other therapies, see &#8220;&#8212;Exelixis Development Programs&#8212;Pipeline Development Programs - Advancing Exelixis&#8217; Future Cancer Therapy Candidates&#8212;Zanzalintinib Development Program.&#8221; </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Collaborations and In-licensing Arrangements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our pipeline expansion efforts, we have entered into several research collaborations and in-licensing arrangements, as well other strategic transactions that collectively serve to increase our discovery bandwidth and allow us to access a wide range of technology platforms. More recently, we have focused our business development activities on late preclinical and early-stage clinical assets that align with our oncology development expertise and have immediate potential as product candidates to treat cancer patients, including the following:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Cybrexa</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In November 2022, we entered into an agreement with Cybrexa that provides us the right to acquire CBX-12. Under the agreement, we made an upfront payment to Cybrexa in exchange for the right to acquire CBX-12 pending certain phase 1 results and to fund certain development and manufacturing expenses incurred by Cybrexa to advance CBX-12 according to an agreed development plan. Cybrexa may also be eligible to receive additional potential development, regulatory and commercial milestone payments, as well as a fee for the acquisition of CBX-12 upon evaluation of a pre-specified clinical data package to be delivered by Cybrexa. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Sairopa</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In November 2022, we entered into an exclusive option and license agreement and clinical development collaboration with Sairopa to develop ADU-1805. The collaboration is intended to expand our clinical pipeline with an IND filing for ADU-1805 anticipated in early 2023 to explore its applicability across multiple tumor types, as well as the potential to combine ADU-1805 with zanzalintinib and approved ICIs. Under the agreement, we made an upfront payment to Sairopa, including additional payments for near-term milestones, in exchange for an option to obtain an exclusive, worldwide license to develop and commercialize ADU-1805 and other anti-SIRP&#945; antibodies, and for certain expenses to be incurred by Sairopa in conducting prespecified phase 1 clinical studies of ADU-1805 during the option period. Sairopa is eligible to receive additional development milestone payments during the option period. Following the completion of the prespecified clinical studies, we have the right to exercise our option upon payment of an option exercise fee. Upon option exercise, Sairopa will be eligible to receive additional development and commercial milestone payments, as well as royalties on potential sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are continuing to make progress on our various research collaborations and in-licensing arrangements focused on our early-stage pipeline with the goal of advancing new biotherapeutics and small molecule development candidates towards the clinic, including the following: </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Catalent</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In September 2020, we entered into a collaboration and license agreement with Catalent to develop multiple ADCs using Catalent&#8217;s proprietary SMARTag site-specific bioconjugation technology. Under the September 2020 agreement, we made an upfront payment in exchange for an exclusive option to license up to four targets using Catalent&#8217;s ADC platform over a three-year period. In addition, in August 2022 we exercised our right to extend the target selection term to five years and nominate up to two additional targets for an additional payment. For each option we decide to exercise, we will be required to pay an exercise fee, and we would then assume responsibility for all subsequent clinical development, manufacturing and commercialization for that program. Catalent would then become eligible for potential development, regulatory and commercial milestone payments, as well as royalties on potential sales. We have also committed to contribute research funding to Catalent for discovery and preclinical development work. In November 2022, we entered into a separate license agreement with Catalent for three target programs with lead antibody and/or ADC candidates. The ADC candidates were developed using Catalent&#8217;s SMARTag technology, and each of the licensed antibodies has potential for development as an ADC or other biologic therapy using a variety of technologies to which we have access through our partnership network. Under the November 2022 agreement, we made an upfront payment in exchange for rights to the three biotherapeutics programs. We will fund the development work conducted by Catalent until development candidate selection is complete, after which we will assume responsibility for all subsequent preclinical, clinical and commercial activities. Catalent will be eligible for potential development and commercial milestone payments, as well as royalties on potential sales. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">BioInvent</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2022, we entered into an exclusive option and license agreement with BioInvent to identify and develop novel antibodies for use in immune-oncology therapeutics. The collaboration is intended to expand our portfolio of antibody-based therapies and will utilize BioInvent&#8217;s proprietary n-CoDeR antibody library and patient-centric F.I.R.S.T screening platform, which together are designed to allow for parallel target and antibody discovery. Under the agreement, we made an upfront payment in exchange for rights to select three targets identified using BioInvent&#8217;s proprietary F.I.R.S.T platform and n-CoDeR library. BioInvent is responsible for initial target and antibody discovery activities, and characterization of antibody mechanism of action. We may exercise an option to in-license any of the target programs upon identification of a development candidate directed to that target. Upon option exercise, we will pay an option exercise fee and will assume responsibility for all future </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development and commercialization activities for the development candidate, including potential ADC and bispecific antibody engineering activities. In addition, BioInvent will be eligible for potential development and commercial milestone payments, as well as royalties on potential sales.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">STORM. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we entered into an exclusive collaboration and license agreement with STORM to discover and advance novel drug candidates intended for the treatment of cancer. Our collaboration focuses initially on the RNA modifying enzyme ADAR1, building on early work by STORM applying its proprietary RNA epigenetic platform, as well as exploring an additional undisclosed target. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, we</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> made an upfront payment in exchange for exclusive licenses to these two discovery programs. STORM is responsible for discovery and generation of lead candidates for both target programs, and</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we will assume responsibility for IND-enabling studies and all subsequent clinical development, manufacturing and commercialization activities.</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">STORM is eligible for potential development, regulatory and commercial milestone payments, as well as royalties on potential sales. We have also committed to contribute research funding to STORM for discovery and preclinical development work for each program.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Adagene. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we entered into a collaboration and license agreement with Adagene to utilize Adagene&#8217;s SAFEbody technology platform to generate masked versions of mAbs from our growing preclinical </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pipeline for the development of ADCs or other innovative biotherapeutics against Exelixis-nominated targets. Under the agreement, we made an upfront payment in exchange for an exclusive, worldwide license to develop and commercialize any potential ADC products generated by Adagene with respect to an initial target, as well as a second target we may nominate during the collaboration term. For each target that we nominate, we would then assume responsibility for all subsequent clinical development, manufacturing and commercialization for that program.</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adagene is eligible for potential development, regulatory and commercial milestone payments, as well as royalties on potential sales.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">NBE. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a collaboration and license agreement with NBE to discover and develop multiple ADCs for oncology applications by leveraging NBE&#8217;s unique expertise and proprietary platforms in ADC discovery, including NBE&#8217;s SMAC-Technology and novel payloads. Under the agreement, we made an upfront payment in exchange for exclusive options to nominate four targets using NBE&#8217;s ADC platform over a two-year period. For each option we decide to exercise, we will be required to pay an exercise fee, and we would then assume responsibility for all subsequent clinical development, manufacturing and commercialization connected with any resulting program. NBE would then become eligible for potential development, regulatory and commercial milestone payments, as well as royalties on potential sales. We have also committed to contribute research funding to NBE for discovery and preclinical development work.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Aurigene. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we entered into an exclusive collaboration, option and license agreement with Aurigene to in-license as many as six oncology target programs to discover and develop small molecules as therapies for cancer, and in April 2021, we expanded the collaboration to include three additional early discovery programs for a total of nine programs. Under the agreement, we made upfront payments in exchange for exclusive options to license eight of the nine programs to date, and we will pay an additional upfront payment upon the nomination of the ninth program. Based on encouraging preclinical data for XL102, the lead Aurigene program targeting CDK7, we exercised our exclusive option to license XL102 in December 2020, resulting in our assuming responsibility for all subsequent clinical development, manufacturing and commercialization of XL102 and payment of an exercise fee to Aurigene, and we initiated the QUARTZ-101 phase 1 clinical trial evaluating XL102 in January 2021. For additional information on XL102, see &#8220;&#8212;Exelixis Development Programs&#8212;Pipeline Development Programs - Advancing Exelixis&#8217; Future Cancer Therapy Candidates&#8212;XL102 Development Program.&#8221; </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we exercised our exclusive option to in-license XL114, Aurigene&#8217;s novel CBM inhibitor, in October 2021,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> resulting in our assuming responsibility for all subsequent clinical development, manufacturing and commercialization of XL114 and payment of an option exercise fee to Aurigene</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Based on initial findings in this phase 1 trial and the evolving treatment landscape for NHL, we have discontinued development of XL114 as of January 2023. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on XL114, see &#8220;&#8212;Exelixis Development Programs&#8212;Pipeline Development Programs - Advancing Exelixis&#8217; Future Cancer Therapy Candidates&#8212;XL114 Development Program.&#8221; With respect to XL102, Aurigene is eligible for potential development, regulatory and commercial milestone payments, as well as royalties on potential sales. Beyond XL102, we are continuing to work with Aurigene to advance the other small molecule programs through preclinical development. For each additional option we decide to exercise, we will be required to pay an exercise fee, and we would then assume responsibility for all subsequent clinical development, manufacturing and commercialization for that program. Aurigene would then become eligible for potential development, regulatory and commercial milestone payments, as well as royalties on potential sales. We are also responsible for research funding for the discovery and preclinical development </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">work on these programs. Under the agreement, Aurigene retains limited development and commercial rights for India and Russia.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Iconic. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into an exclusive option and license agreement with Iconic to advance an innovative next-generation ADC program for cancer, leveraging Iconic&#8217;s expertise in targeting TF in solid tumors. Under the original May 2019 agreement, we gained an exclusive option to license XB002, Iconic&#8217;s lead TF ADC program, in exchange for an upfront payment to Iconic and a commitment for preclinical development funding. Based on encouraging preclinical data, we exercised our exclusive option to license XB002 in December 2020, resulting in our assuming responsibility for all subsequent clinical development, manufacturing and commercialization for XB002 and payment of an option exercise fee to Iconic. Following the FDA&#8217;s acceptance of our IND for XB002 in April 2021, we initiated a phase 1 clinical trial of XB002 in June 2021 designed to evaluate its pharmacokinetics, safety, tolerability and preliminary efficacy as a monotherapy in patients with advanced solid tumors. For additional information on XLB002, see &#8220;&#8212;Exelixis Development Programs&#8212;Pipeline Development Programs - Advancing Exelixis&#8217; Future Cancer Therapy Candidates&#8212;XB002 Development Program.&#8221; In January 2022, we announced an amendment to our agreement with Iconic, which we entered into in December 2021, to acquire broad rights to use the anti-TF antibody used in XB002 for any application, including conjugated to other payloads, as well as rights within oncology to a number of other anti-TF antibodies developed by Iconic, including for use in ADCs and multispecific biotherapeutics. Under the amended agreement, we made a final payment to Iconic and will not owe Iconic any further payments, but we will continue to be responsible for milestone payments and royalties owed to other companies pursuant to prior agreements between Iconic and those companies.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Invenra. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we entered into a collaboration and license agreement with Invenra to discover and develop multispecific antibodies for the treatment of cancer. Invenra is responsible for antibody lead discovery and generation while we will lead IND-enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities. The collaboration agreement provides that we will receive an exclusive, worldwide license to one preclinical, multispecific antibody asset, and that we will pursue multiple additional discovery projects across three different programs during the term of the collaboration. In October 2019, we expanded our collaboration to include the development of novel binders against six additional targets, which we can use to generate multispecific antibodies based on Invenra&#8217;s B-Body</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology platform, or with other platforms and formats at our option. We amended the agreement again in March 2020 and January 2021 to enable the use of target binders in non-Invenra platform-based modalities, such as ADC platforms, and to enable the development of biparatopic antibodies, respectively. Then in August 2021, we further expanded our collaboration to include an additional 20 targets</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biotherapeutics</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> discovery and development, for which we agreed to pay Invenra exclusivity payments and research program funding over a three-year period. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration, Invenra is eligible for project initiation fees and potential development, regulatory and commercial milestone payments, as well as tiered royalties on net sales of any approved products. We also have the right to exercise options with respect to certain of Invenra&#8217;s other research programs in exchange for an option exercise payment, and Invenra is eligible for milestone payments and royalties for any products that arise from these optioned research programs.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">StemSynergy. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, we entered into an exclusive collaboration and license agreement with StemSynergy for the discovery and development of novel oncology compounds targeting CK1&#945;, a component of the Wnt signaling pathway implicated in key oncogenic processes, including in colorectal cancers. One such compound, EXEL-4329, reached development candidate status in 2021. In May 2021, we amended the agreement to provide for an additional research platform to explore inhibitors of the Notch pathway, a major developmental pathway that regulates cancer stem cells in Notch-driven cancers, such as certain types of T-cell lymphomas and esophageal adenocarcinomas. Under the agreement, we paid StemSynergy upfront payments in each of 2018 and 2021, and StemSynergy is eligible for additional research and development funding on an as needed basis. StemSynergy is also eligible for potential development, regulatory and commercial milestone payments, as well as royalties on potential sales. We will be solely responsible for the commercialization of products that arise from the collaboration.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the commercialization of our first product, COMETRIQ, our primary business strategy was focused on the development and out-license of compounds to pharmaceutical and biotechnology companies under collaboration agreements that allowed us to retain economic participation in compounds and support additional development of our proprietary products.&#160;Our collaboration agreements with Genentech and Daiichi Sankyo are representative of this historical </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">strategy. Under our collaboration agreement with Genentech we out-licensed the further development and commercialization of COTELLIC, and under our collaboration agreement with Daiichi Sankyo we granted Daiichi Sankyo an exclusive, worldwide license to certain intellectual property, including MINNEBRO. We have since evolved and are now a fully integrated biopharmaceutical company focused on driving the expansion and depth of our product offerings through the continued development of the cabozantinib franchise and drug discovery efforts. While these historical collaboration agreements have the potential to provide future revenue, and while we have received some collaboration revenues from these arrangements, we do not expect to receive significant revenues from these historical collaboration agreements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Product Supply</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing or distribution facilities for chemistry, manufacturing and control (CMC) development activities, preclinical, clinical or commercial production and distribution for our current products and new product candidates. Instead, we rely on various third-party contract manufacturing organizations to conduct these operations on our behalf. As our operations continue to grow in these areas, we continue to expand our supply chain through additional third-party contract manufacturers, distributors and suppliers. Specifically with respect to CABOMETYX, we entered into agreements with secondary contract manufacturing organizations to produce additional commercial supplies of CABOMETYX tablets and cabozantinib drug substance, which bolsters our commercial supply chain and serves to mitigate the risk of supply chain interruptions or other failures. For our portfolio of biotherapeutics and small molecules, we continue to expand our network through well-established and reputable global third-party contract manufacturers for our CMC development and manufacturing that have good regulatory standing, suitable manufacturing capacities and capabilities. We anticipate that this network will meet our future commercial manufacturing and supply needs for our product candidates currently in development, should such programs advance to regulatory approval and subsequent commercialization. These third parties must comply with applicable regulatory requirements, including the FDA&#8217;s Current Good Manufacturing Practice (GMP), the EC&#8217;s Guidelines on Good Distribution Practice (GDP), as well as other stringent regulatory requirements enforced by the FDA or foreign regulatory agencies, as applicable, and are subject to routine inspections by such regulatory agencies. In addition, through our third-party contract manufacturers and data service providers, we continue to provide serialized commercial products as required to comply with the Drug Supply Chain Security Act (DSCSA) and its foreign equivalents where applicable.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor and evaluate the performance of our third-party contract manufacturers on an ongoing basis for compliance with these requirements and to affirm their continuing capabilities to meet both our commercial and clinical needs. We also have contracted with a third-party logistics provider, with multiple distribution locations, to provide shipping and warehousing services for our commercial supply of both CABOMETYX and COMETRIQ in the U.S. We employ highly skilled personnel with both technical and manufacturing experience to diligently manage the activities at our third-party contract manufacturers and other supply chain partners, and our quality department audits them on a periodic basis.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We source raw materials that are used to manufacture our drug substance from multiple third-party suppliers in Asia, Europe and North America. We stock sufficient quantities of these materials and provide them to our third-party drug substance contract manufacturers so they can manufacture adequate drug substance quantities per our requirements, for both clinical and commercial purposes. We then store drug substance at third-party facilities and provide appropriate amounts to our third-party drug product contract manufacturers, who then manufacture, package and label our specified quantities of finished goods for COMETRIQ and CABOMETYX, respectively. In addition, we rely on our third-party contract manufacturers to source materials such as excipients, components and reagents, which are required to manufacture our drug substance and finished drug product.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to having expanded our commercial supply chain to include secondary contract manufacturing organizations, we have established and continue to maintain substantial safety stock inventories for our drug substance and drug products, and we store these quantities in multiple locations. The quantities that we store are based on our business needs and take into account scenarios for market demand, production lead times, potential supply interruptions and shelf life for our drug substance and drug products. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our response to the COVID-19 pandemic has included more frequent engagement with our vendors to maintain the consistency and effectiveness of our third-party contract manufacturers and other supply chain partners, however we have not experienced significant production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic or the ongoing Russo-Ukrainian War</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe that our current manufacturing network has the appropriate capacity to produce sufficient commercial quantities of CABOMETYX to support the currently approved RCC, HCC and DTC indications, and also potential additional indications if trials evaluating CABOMETYX in those indications prove to be successful and gain regulatory approval in the future. Our manufacturing footprint also enables us to fulfill our supply obligations for our products and product candidates to our collaboration partners for global commercial and development purposes.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing and Sales</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a fully integrated commercial team consisting of sales, marketing, market access, and commercial operations functions. Our sales team promotes CABOMETYX and COMETRIQ in the U.S. We market our products in the U.S. and concentrate our efforts on oncologists, oncology nurses, pharmacists and other healthcare professionals. In addition to using customary in-person pharmaceutical company practices, we also utilize digital marketing technologies to expand our engagement opportunities with customers.&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial products, CABOMETYX and COMETRIQ, are sold initially through wholesale distribution and specialty pharmacy channels and then, if applicable, resold to hospitals and other organizations that provide CABOMETYX and COMETRIQ to end-user patients. To facilitate our commercial activities in the U.S., we also employ various third parties, such as advertising agencies, market research firms and vendors providing other sales-support related services as needed, including digital marketing and other non-personal promotion. We believe that our commercial team and distribution practices are sufficient to facilitate our marketing efforts in reaching our target audience and our delivery of our products to patients in a timely and compliant fashion.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on Ipsen and Takeda for ongoing and further commercialization and distribution of CABOMETYX in territories outside of the U.S., as well as for access and distribution activities for the approved products under named patient use programs or similar programs with the effect of introducing earlier patient access to CABOMETYX, and we also rely on Ipsen for these same activities with respect to the commercialization and distribution of COMETRIQ outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help ensure that all eligible patients in the U.S. have appropriate access to CABOMETYX and COMETRIQ, we have established a comprehensive reimbursement and patient support program called Exelixis Access Services (EASE). Through EASE, we provide co-pay assistance to qualified, commercially insured patients to help minimize out-of-pocket costs and provide free drug to uninsured or under-insured patients who meet certain clinical and financial criteria. In addition, EASE provides comprehensive reimbursement support services, such as prior authorization support, benefits investigation and, if needed, appeals support. Beyond financial assistance, patients who participate in EASE also receive treatment coordination through a dedicated case manager, as well as clinical outreach and support from a network of oncology nurses or other healthcare professionals who help many of these patients better understand how to take their medication and mitigate side effects.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental, Health and Safety</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development processes involve the controlled use of certain hazardous materials and chemicals. In the U.S., at the federal, state and local levels, and in other foreign countries, we are subject to environmental, health and workplace safety laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous materials. While we have incurred, and will continue to incur, expenditures to maintain compliance with these laws and regulations, we do not expect the cost of complying with these laws and regulations to be material.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laboratory Safety Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the focus of our business in discovering and developing drug products, many of our employees work in our on-site laboratory facilities. All laboratory staff are trained on chemical hygiene, the use of personal protective equipment, and certain other relevant laboratory safety topics, such as working with blood-borne pathogens, and current staff are retrained regularly. We also extend these trainings to facilities staff and others who support our work in the labs. In an effort to maintain a safe environment for all staff, we regularly perform thorough safety inspections of our laboratories, and continuously update our procedures based on the observations made during these inspections. Additionally, we conduct periodic industrial hygiene monitoring to ensure lab staff working with certain known hazardous chemicals do not exceed regulated exposure limits, regularly test and certify fume hoods, biosafety cabinets and other individual pieces of equipment on which employees rely, and adhere to the standards set by the Environmental Protection Agency, the Occupational Safety and Health Administration, Cal-OSHA and Bay Area Air Quality Management District, among other governing bodies, to ensure compliance with laws and regulations and to maintain a safe work environment.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate, among other things, research and development activities and the testing, marketing approval, manufacture, quality control, safety, effectiveness, labeling, storage, distribution, post-marketing safety reporting, export, import, record keeping, advertising and promotion of our products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before product candidates may be marketed in the U.S. generally involves the following:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">nonclinical laboratory and animal tests, some of which must be conducted in accordance with Good Laboratory Practices (GLP);</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">submission of an IND, which contains results of nonclinical studies (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, laboratory evaluations of the chemistry, formulation, stability and toxicity of the product candidate), together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, and must become effective before human clinical trials may begin;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">approval by an independent institutional review board or ethics committee at each clinical trial site before each trial may be initiated;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">adequate and well-controlled human clinical trials conducted in accordance with the protocol, IND and Good Clinical Practice (GCP) to establish the safety and efficacy of the investigational drug candidate for its proposed intended use;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">for drug products, submission of a New Drug Application (NDA) to the FDA for commercial marketing, or generally of an sNDA, for approval of a new indication if the product is already approved for another indication;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">for biotherapeutic products, submission of a Biologics License Application (BLA) to the FDA for commercial marketing, or generally a supplemental Biologics License Application (sBLA) for approval of a new indication if the product is already approved for another indication;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">pre-approval inspection of manufacturing facilities and selected clinical investigators, clinical trial sites and/or Exelixis as the clinical trial sponsor for their compliance with GMP and GCP, respectively;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">payment of user fees for FDA review of an NDA or BLA unless a fee waiver applies;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">agreement with the FDA on the final labeling for the product and design and implementation of any required Risk Evaluation and Mitigation Strategy;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">if the FDA convenes an advisory committee, satisfactory completion of the advisory committee review; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">FDA approval of the NDA or sNDA, or BLA or sBLA.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Phase 1 studies</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which involve the initial introduction of a new drug product candidate into humans, are initially conducted in a limited number of subjects to test the product candidate for safety, tolerability, absorption, metabolism, distribution and excretion in healthy humans or patients. In rare cases, a Phase 1 study that is designed to assess effectiveness may serve as the basis for FDA marketing approval of a drug or for a label expansion. For instance, at FDA&#8217;s discretion, a product may receive approval based on a Phase 1b study if effectiveness results from the study are extremely compelling, approval of the drug would address a significant unmet patient need, and the drug is being approved through the accelerated approval pathway.&#160;As discussed below, Accelerated Approval generally requires at least one post-approval study to confirm clinical benefit.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Phase 2 studies</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are conducted with groups of patients afflicted with a specified disease in order to provide enough data to evaluate the preliminary efficacy, optimal dosage, and common short-term side effect and risks associated with the drug. Multiple phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive phase 3 clinical trials. Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Phase 3 studies</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are conducted to gather the additional information about effectiveness and safety across a higher number of patients and evaluate the overall benefit-risk relationship of the product candidate following </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earlier phase evaluations, which will have provided preliminary evidence suggesting an effective dosage range and acceptable safety profile for the product candidate. Phase 3 trials are also intended to provide an adequate basis for physician labeling of the product if it is approved.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may require, or companies may pursue, additional clinical trials after a product is approved. These so-called post-marketing or &#8220;phase 4&#8221; studies may be deemed a condition to be satisfied after a drug receives approval. Failure to satisfy such post-marketing commitments can result in FDA enforcement action, up to and including withdrawal of NDA approval. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Review and Approval</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For approval of a new drug or changes to the labeling of an approved drug, including new indications, the results of product development, preclinical studies and clinical trials are submitted to the FDA as part of an NDA, or as part of an sNDA. The submission of an NDA requires payment of a substantial user fee to the FDA. The FDA may convene an advisory committee to provide clinical insight on NDA review questions, although the FDA is not required to follow the recommendations of an advisory committee. The FDA may initially issue a Refuse to File letter for an incomplete NDA or sNDA, or it may deny approval of an NDA or sNDA by way of a Complete Response letter if the applicable regulatory criteria are not satisfied, or alternatively require additional clinical and/or nonclinical data and/or an additional phase 3 pivotal clinical trial. Once issued, the FDA may withdraw product approval if ongoing regulatory standards are not met or if safety problems occur after the product reaches the market. Satisfaction of FDA development and approval requirements or similar requirements of state, local and foreign regulatory agencies typically takes several years, and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease. In particular, the FDA has developed and implemented, and continues to develop and implement, various guidance, programs and initiatives specific to oncology products that can affect product development and the data necessary for approval. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including obtaining prior FDA approval of certain changes to the approved NDA, record-keeping requirements, and reporting of adverse experiences with, and interruptions in the manufacture of, the drug. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies. Thus, we and our third-party contract manufacturing organizations are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMP, which impose certain manufacturing requirements (including procedural and documentation requirements) upon us and our third-party contract manufacturing organizations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Orphan Drug Act of 1983, as amended, provides incentives for the development of drugs and biotherapeutic products for rare diseases or conditions that affect fewer than 200,000 people in the U.S. (or for which there is no reasonable expectation that the cost of developing and making available the drug in the U.S. for such disease or condition will be recovered from sales of the drug in the U.S.). Certain of the incentives turn on the drug first being designated as an orphan drug. To be eligible for designation as an orphan drug (Orphan Drug Designation), the drug must have the potential to treat such rare disease or condition as described above. In addition, the FDA must not have previously approved a drug considered the &#8220;same drug,&#8221; as defined in the FDA&#8217;s orphan drug regulations, for the same orphan-designated indication or the sponsor of the subsequent drug must provide a plausible hypothesis of clinical superiority over the previously approved same drug. Upon receipt of Orphan Drug Designation, the sponsor is eligible for tax credits of up to 25% for qualified clinical trial expenses and waiver of the Prescription Drug User Fee Act application fee. In addition, upon marketing approval, an orphan-designated drug could be eligible for seven years of market exclusivity if no drug considered the same drug was previously approved for the same orphan condition (or if the subsequent drug is demonstrated to be clinically superior to any such previously approved same drug). Such orphan drug exclusivity, if awarded, would only block the approval of any drug considered the same drug for the same orphan indication. Moreover, a subsequent same drug could break an approved drug&#8217;s orphan exclusivity through a demonstration of clinical superiority over the previously approved drug.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expedited FDA Approval Pathways</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has various programs that are intended to expedite or simplify the process for developing and reviewing promising drugs, or to provide for the approval of a drug on the basis of a surrogate endpoint. Generally, drugs that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. Examples of such programs included Fast Track designation, breakthrough therapy designation, priority review and accelerated approval, and the eligibility criteria of and benefits for each program vary: </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Fast Track is a process designed to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening diseases or conditions that demonstrate the potential to fill unmet medical needs, by providing, among other things, eligibility for accelerated approval if relevant criteria are met, and rolling review, which allows submission of individually completed sections of an NDA or for FDA review before the entire submission is completed. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Breakthrough therapy designation is a process designed to expedite the development and review of drugs that are intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review, and rolling review.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Priority review is designed to shorten the review period for drugs that treat serious conditions and that, if approved, would offer significant advances in safety or effectiveness or would provide a treatment where no adequate therapy exists. Under priority review, the FDA aims to take action on the application within six months as compared to a standard review time of 10 months. Sponsors may also obtain a priority review voucher upon approval of an NDA for certain qualifying diseases and conditions that can be applied to a subsequent NDA submission</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Accelerated approval provides for an earlier approval for a new drug that is intended to treat a serious or life-threatening disease or condition and that provides a meaningful advantage over available therapies and demonstrates an effect on a surrogate endpoint, or an intermediate clinical endpoint, which is considered reasonably likely to predict clinical benefit. As a condition of approval, the FDA requires that a sponsor of a product candidate receiving accelerated approval perform post-marketing clinical trials or provide data on established clinical endpoints from the same trial to confirm the clinical benefit as predicted by the surrogate marker trial. The FDA may require such trials to be underway prior to approval, or within a specific period thereafter, and will specify the conditions for such trials. Further, sponsors must provide reports on post-marketing trial progress no later than 180 days after approval and every 180 days thereafter until such trials are completed. The failure to conduct required post-marketing trials with due diligence and or to submit the required reports are prohibited acts, and these failures by sponsor in administering such trials, or the failure of such trials to confirm the clinically meaningful outcome, may result in withdrawal of the approval of the drug or the indication approved under accelerated approval. The FDA can also withdraw an accelerated approval on an expedited basis provided it follows certain procedures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, with respect to oncology products, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the FDA may review applications under the Real-Time Oncology Review (RTOR) program established by the FDA&#8217;s Oncology Center of Excellence. The RTOR program, which allows an applicant to pre-submit components of the application to allow the FDA to review clinical data before the complete filing is submitted, aims to explore a more efficient review process to ensure that safe and effective treatments are available to patients as early as possible, while maintaining and improving review quality. Drugs considered for review under the RTOR program must be likely to demonstrate substantial improvements over available therapy, which may include drugs previously granted breakthrough therapy designation for the same or other indications, and must have straight-forward study designs and endpoints that can be easily interpreted.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Abbreviated FDA Approval Pathways and Generic Products</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Drug Price Competition and Patent Term Restoration Act of 1984 (The Hatch-Waxman Act) established two abbreviated approval pathways for drug products in which potential competitors may rely upon the FDA&#8217;s prior approval of the same or similar drug product.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Abbreviated New Drug Application (ANDA). An ANDA may be approved by the FDA if the applicant demonstrates that the proposed generic product is the same as the approved drug, which is referred to as the Reference Listed Drug (RLD).&#160;Generally, an ANDA must contain data and information showing that the proposed generic product and RLD (1)&#160;have the same active ingredient, in the same strength and dosage form, to be delivered via the same route of administration, (2)&#160;are intended for the same uses, and (3)&#160;are bioequivalent.&#160;This is instead of independently demonstrating the proposed product&#8217;s safety and effectiveness through clinical development. Conducting bioequivalence testing is generally less time consuming and costly than conducting a full set of clinical trials in humans. In this regard, the FDA has published draft guidance containing product-specific </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bioequivalence recommendations for drug products containing cabozantinib, the active pharmaceutical ingredient in CABOMETYX and COMETRIQ, as it does for many FDA-approved drug products.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">505(b)(2)&#160;NDAs.&#160;A 505(b)(2) NDA is an application for which one or more of the investigations relied upon by the applicant for approval were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. Under Section 505(b)(2) NDA of the Federal Food, Drug, and Cosmetic Act (FDCA), an applicant may rely, in part, on the FDA&#8217;s previous approval of a similar product, or published literature, in support of its application. If the 505(b)(2) NDA applicant establishes that reliance on the FDA&#8217;s prior findings of safety and efficacy for an approved product is scientifically appropriate, it may eliminate the need to conduct certain preclinical or clinical studies. The FDA may require additional studies or measurements, including comparability studies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike a full NDA for which the sponsor has conducted or obtained a right of reference to all the data essential to approval, the filing of an ANDA or a 505(b)(2) NDA may be delayed due to patent or exclusivity protections covering an approved product. The Hatch-Waxman Act provides (a) up to five years of exclusivity for the first approval of a new chemical entity (NCE) exclusivity and (b) three years of exclusivity for approval of an NDA or sNDA for a product that is not an NCE but rather where the application contains new clinical studies conducted or sponsored by the sponsor and considered essential to the approval of the NDA or sNDA (three-year &#8220;changes&#8221; exclusivity). NCE exclusivity runs from the time of approval of the NDA and bars FDA from accepting for review of any ANDA or 505(b)(2) NDA for a drug containing the same active moiety for five years (or for four years if the application contains a Paragraph IV certification that a reference product patent is invalid or not infringed by the ANDA/505(b)(2) NDA product). The three-year &#8220;changes&#8221; exclusivity generally bars the FDA from approving any ANDA or 505(b)(2) NDA application that relies on the information supporting the approval of the drug or the change to the drug for which the information was submitted and the exclusivity granted.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both Congress and the FDA are considering, and have enacted, various legislative and regulatory proposals focused on drug competition, including legislation focused on drug patenting and provision of drug to generic applicants for testing. For example, the Ensuring Innovation Act, enacted in April 2021, amended the FDA&#8217;s statutory authority for granting NCE exclusivity to reflect the agency&#8217;s existing regulations and longstanding interpretation that award NCE exclusivity based on a drug&#8217;s active moiety, as opposed to its active ingredient, which is intended to limit the applicability of NCE exclusivity, thereby potentially facilitating generic competition. In addition, the Further Consolidated Appropriations Act, 2020, which incorporated the framework from the Creating and Restoring Equal Access To Equivalent Samples (CREATES) legislation, allowed ANDA, 505(b)(2) NDA or biosimilar developers to obtain access to branded drug and biotherapeutic product samples. Further, Section 3222 of the Consolidated Appropriations Act, 2023, enacted on December 29, 2022 (the 2023 Appropriations Act), requires the FDA to make therapeutic equivalence determinations for 505(b)(2) NDAs at the time of approval, or up to 180 days thereafter, if requested by the applicant. Additionally, Section 3224 of the 2023 Appropriations Act allows the FDA to approve an ANDA even if there are differences between the generic drug&#8217;s proposed labeling and that of the listed drug due to the FDA approving a change to the listed drug&#8217;s label (excluding warnings) within 90 days of when the ANDA is otherwise eligible for approval, provided that the ANDA applicant agrees to submit revised labeling for the generic drug within 60 days of approval. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book Listing.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;An NDA sponsor must identify to the FDA patents that claim the drug substance or drug product or approved method of using the drug. When the drug is approved, those patents are among the information about the product that is listed in the FDA publication, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is referred to as the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any applicant who files an ANDA or a 505(b)(2) NDA must certify, for each patent listed in the Orange Book for the RLD that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA, (2) such patent has expired, (3) the listed patent will expire on a particular date and approval is sought after patent expiration, or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. An ANDA or 505(b)(2) NDA applicant may also submit a statement that it intends to carve-out from the labeling of its product an RLD&#8217;s use that is protected by exclusivity or a method of use patent. The fourth certification described above is known as a Paragraph IV certification. A notice of the Paragraph IV certification must be provided to each owner of the patent that is the subject of the certification and to the reference NDA holder. The reference NDA holder and patent owners may initiate a patent infringement lawsuit in response to the Paragraph IV notice. Filing such a lawsuit within 45 days of the receipt of the Paragraph IV certification notice prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA or 505(b)(2) NDA applicant. The ANDA or 505(b)(2) NDA also will not receive final approval until any applicable non-patent exclusivity listed in the Orange Book for the RLD has expired.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Approval Outside of the United States </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the U.S., we are subject to regulations of other countries governing clinical trials and the manufacturing, commercial sales and distribution of our products outside of the U.S. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the U.S. before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the EU, before we may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The way clinical trials are conducted in the EU has undergone a major change with the application of Regulation (EU) 536/2014, repealing the existing Directive 2001/20/EC. This new regulation harmonizes the assessment and supervision processes for clinical trials throughout the EU, via an EU portal and database, which the EMA will maintain in collaboration with the Member States and the EC. Following the EC&#8217;s confirmation of full functionality of the Clinical Trials Information System (CTIS) through an independent audit, which was published in the Official Journal of the European Union in August 2021, Regulation (EU) 536/2014 became applicable concurrent with the CTIS &#8220;go-live&#8221; date on January 31, 2022. While existing clinical trials could continue to be conducted under the rules of Directive 2001/20/EC until January 31, 2025, any clinical trial initiated on or after January 31, 2023 must comply with the rules of the new regulation. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under EU regulatory systems, a company may submit a marketing authorization application (MAA) either under centralized or decentralized procedure. Under the centralized procedure, MAAs are submitted to the EMA for scientific review by the Committee for Medicinal Products for Human Use (CHMP) so that an opinion is issued on product approvability. The opinion is considered by the EC which is responsible for granting the centralized marketing authorization in the form of a binding EC decision. If the application is approved, the EC grants a single marketing authorization that is valid for all EU Member States as well as Iceland, Liechtenstein and Norway, collectively the European Economic Area. The decentralized and mutual recognition procedures, as well as national authorization procedure are available for products for which the centralized procedure is not compulsory. The mutual recognition procedure provides for the EU Member States selected by the applicant to mutually recognize a national marketing authorization that has already been granted by the competent authority of another Member State, referred to as the Reference Member State (RMS). The decentralized procedure is used when the product in question has yet to be granted a marketing authorization in any Member State. Under this procedure the applicant can select the Member State that will act as the RMS. In both the mutual recognition and decentralized procedures, the RMS reviews the application and submits its assessment of the application to the Member States where marketing authorizations are being sought, referred to as Concerned Member States. Within 90 days of receiving the application and assessment report, each Concerned Member State must decide whether to recognize the RMS assessment or reject it on the basis of potential serious risk to public health. If the disputed points cannot be resolved, the matter is eventually referred to the Coordination Group on Mutual Recognition and Decentralised Procedures in the first instance to reach an agreement and failing to reach such an agreement, a referral to the EMA and the CHMP for arbitration that will result in an opinion to form the basis of a decision to be issued by the EC binding on all Member States. If the application is successful during the decentralized or mutual recognition procedure, national marketing authorizations will be granted by the competent authorities in each of the Member States chosen by the applicant.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditional marketing authorizations may be granted in the centralized procedure for a limited number of medicinal products for human use referenced in EU law applicable to conditional marketing authorizations where the clinical dataset is not comprehensive, if (1) the risk-benefit balance of the product is positive, (2) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3) unmet medical needs will be fulfilled and (4) the benefit to public health of the immediate availability on the market of the medicinal product outweighs the risk inherent in the fact that additional data are still required.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the U.S., we may apply for designation of a product as an orphan drug for the treatment of a specific indication in the EU before the application for marketing authorization is made. In the EU, orphan designation is available for products in development which are either: (a) intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in the EU; or (b) intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition affecting a larger number of persons but when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the medicinal product. Additionally, the sponsor of an application for designation of a product as an orphan drug in the EU must establish that there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition or even if such treatment exists, the product will be of significant benefit to those affected by that condition.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drugs in the EU enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant for a similar medicinal product can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product. The period of market exclusivity may be reduced to six years if at the end of the fifth year it is established that the criteria for orphan designation are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare and Privacy Regulation </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, also govern our business. If we fail to comply with those laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected. The laws that may affect our ability to operate include, but are not limited to: the federal Anti-Kickback Statute (AKS), which prohibits, among other things, soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce or reward for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as Medicare and Medicaid; the FDCA and its implementing regulations, which prohibit, among other things, the introduction or delivery for introduction into interstate commerce of any drug that is adulterated or misbranded; and federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent. Additionally, we are subject to state law equivalents of each of the above federal laws, which may be broader in scope and apply regardless of whether the payer is a governmental healthcare program, and many of which differ from each other in significant ways and may not have the same effect, further complicate compliance efforts.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use and disclosure of personal information. For example, the California Consumer Privacy Act of 2018, as amended (CCPA), went into operation in January 2020 and broadly defines personal information, affords California residents expanded privacy rights and protections and provides for civil penalties for violations and a private right of action related to certain data security breaches. These protections were expanded by the California Privacy Rights Act (CPRA), which became effective in most key respects in January 2023 and will be enforceable in most key respects beginning on July 1, 2023. Privacy laws in other states may also impact our operations, including both comprehensive and sector specific legislation, and Congress is considering additional federal privacy legislation. In addition, most healthcare professionals and facilities who may prescribe our products and from whom we may obtain patient health information, are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology and Clinical Health Act (HIPAA). Although we are not considered to be a covered entity or business associate under HIPAA with respect to our clinical and commercial activities, we could be subject to penalties if we use or disclose individually identifiable health information in a manner not authorized or permitted by HIPAA. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including laws in all 50 states requiring security breach notification in some circumstances. The CCPA, as amended by the CPRA, HIPAA and these other laws could create liability for us or increase our cost of doing business. International laws, such as the EU General Data Protection Regulation 2016/679 (GDPR), could also apply to our operations. Failure to provide adequate privacy protections and maintain compliance with applicable privacy laws could jeopardize business transactions across borders and result in significant penalties.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Patient Protection and Affordable Care Act of 2010, as amended (PPACA) created a federal requirement under the federal Open Payments program, that requires certain manufacturers to track and report to the Centers for Medicare &amp; Medicaid Services (CMS) annually certain payments and other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as ownership interests held by such physicians and their immediate family during the previous calendar year.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our products are covered in the U.S. by the Medicaid program, we have various obligations, including government price reporting and rebate requirements, which generally require us to pay substantial rebates or offer our drugs at substantial discounts to certain purchasers (including &#8220;covered entities&#8221; purchasing under the 340B Drug Discount Program (the 340B Program)). CMS continues to issue guidance and rulemaking governing our participation in the Medicaid Drug Rebate Program, and we cannot predict how future guidance or rules would affect our profitability (including due the potential for increases in our overall Medicaid rebate liability and the obligation to charge greatly reduced prices to covered entities. We are also required to discount our products to authorized users of the Federal Supply Schedule of the General Services Administration, under which additional laws and requirements apply. These programs require submission of pricing </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">data and calculation of discounts and rebates pursuant to complex statutory formulas and regulatory guidance, as well as the entry into government procurement contracts governed by the Federal Acquisition Regulations, and the guidance governing such calculations is not always clear. Compliance with such requirements can require significant investment in personnel, systems and resources. Failure to properly calculate prices, or to offer required discounts or rebates could subject us to substantial penalties.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our approved products and any future products of ours will depend, in part, on the extent to which their costs will be covered by third-party payers, such as government health programs, commercial insurance and managed healthcare organizations. Each third-party payer may have its own policy regarding what products it will cover, the conditions under which it will cover such products, and how much it will pay for such products. Third-party payers may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. Moreover, a third-party payer&#8217;s decision to provide coverage for a drug product does not guarantee what reimbursement rate, if any, will be approved. Patients may be less likely to use our products if coverage is not provided and reimbursement may not cover a significant portion of the cost of our products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and other potentially significant markets for our products, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products and therapies, which may result in lower average selling prices. In some cases, for example, third-party payers try to encourage the use of less expensive generic products through their prescription benefits coverage and reimbursement and co-pay policies. Further, the increased emphasis on managed healthcare in the U.S. and on country-specific and national pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing coverage and/or reimbursement controls and measures, could have a material adverse impact on our net product revenues and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and some foreign countries are considering proposals or have enacted legislative and regulatory changes to the healthcare system that could affect our ability to sell our products profitably. Among policy makers and payers in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been increasing legislative and enforcement interest in the U.S. with respect to drug pricing practices. In particular, there have been several recent U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as executive orders, designed to, among other things: reduce or limit the prices of drugs and make them more affordable for patients (including, for example, by tying drug prices to the prices of drugs in other countries); reform the structure and financing of Medicare Part D pharmaceutical benefits; implement additional data collection and transparency reporting regarding drug pricing, rebates, fees and other remuneration provided by drug manufacturers; enable the government to negotiate prices under Medicare; revise rules associated with the calculation of average manufacturer price and best price under Medicaid; eliminate the AKS discount safe harbor protection for manufacturer rebate arrangements with Medicare Part D plan sponsors; create new AKS safe harbors applicable to certain point-of-sale discounts to patients and fixed fee administrative fee payment arrangements with pharmacy benefit managers; and revise the rebate methodology under the Medicaid Drug Rebate Program. For instance, in August 2022, President Biden signed the Inflation Reduction Act, which among other things: allows for CMS to impose price controls for certain single-source drugs and biotherapeutics reimbursed under Medicare Part B and Part D; subjects drug manufacturers to civil monetary penalties and a potential excise tax for offering a price that is not equal to or less than the government-imposed &#8220;maximum fair price&#8221; under the law; imposes additional rebates for price increases that exceed inflation; and redesigns the funding and benefit structure of the Medicare Part D program, potentially increasing manufacturer liability while capping annual out-of-pocket drug expenses for Medicare beneficiaries. These provisions have started taking effect incrementally beginning in 2022 and may be subject to various legal challenges. As of the date of this Annual Report on Form 10-K, CMS has commenced public rulemaking and issued guidance addressing certain aspects of the Inflation Reduction Act, and overtime the Inflation Reduction Act could reduce the revenues we are able to collect from sales of our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products and increase our government discount and rebate liabilities; however, the degree of impact that the Inflation Reduction Act will ultimately have upon our business remains unclear. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biotherapeutic product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including the National Medicaid Pooling Initiative. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. pharmaceutical industry has already been significantly impacted by major legislative initiatives and related political contests. For instance, efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA, some of which have been successful, create considerable uncertainties for all businesses involved in healthcare, including our own. In addition, there have been, and may in the future be, initiatives at both the federal and state-level that could significantly modify the terms and scope of government-provided health insurance coverage, ranging from establishing a single-payer, national health insurance system to more limited &#8220;buy-in&#8221; options to existing public health insurance programs, each of which could have a significant impact on the healthcare industry. Although such attempts to reform the U.S. healthcare system have not significantly impacted our business to date, it is possible that additional legislative, executive and judicial activities in the future could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these developments and trends, third-party payers are increasingly attempting to contain healthcare costs by limiting coverage and the level of reimbursement of new drugs. These entities could refuse, limit or condition coverage for our products, such as by using tiered reimbursement or pressing for new forms of contracting, or alternatively for patients who rely on our co-pay assistance program, implement co-pay accumulators or maximizers that exempt such co-pay assistance from deductibles (or otherwise modify benefit designs in a manner that takes into account the availability of co-pay assistance), which has increased and could further increase the costs of our co-pay assistance program or cause patients to abandon CABOMETYX or COMETRIQ therapy due to higher out-of-pocket costs. Due to general uncertainty in the current regulatory and healthcare policy environment, and specifically regarding positions that the Biden Administration may take with respect to these issues, we are unable to predict the impact of any legislative, regulatory, third-party payer or policy actions, including potential cost containment and healthcare reform measures. In addition, it is also possible that CMS could issue new rulemaking or guidance that would affect the amount of rebates owed under the Medicaid Drug Rebate Program. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in some foreign countries, the proposed pricing for a drug must be approved before its cost may be funded within the respective national healthcare system. The requirements governing drug pricing vary widely from country to country. For example, EU Member States may restrict the range of medicinal products for which their national healthcare systems provide reimbursement and may control the prices of medicinal products for human use. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profits the medicinal product generates for the company placing it on the market. Pricing and reimbursement negotiations with governmental authorities or payers in EU Member States can take six to 12 months or longer after the initial marketing authorization is granted for a product, or after the marketing authorization for a new indication is granted. To obtain reimbursement and/or pricing approval in some countries, drug manufacturers and collaboration partners may also be required to conduct a study or otherwise provide data that seeks to establish the cost effectiveness of a new drug compared with other available established therapies. Other cost-control initiatives are similarly focused on affordability and accessibility, such as the Regulation on Health Technology Assessment (HTA Regulation) adopted in December 2021 and entering into application in 2025, as well as other upcoming legislative and policy changes aimed at increasing cooperation between EU Member States, and once enacted these initiatives may further impact the price and reimbursement status of many medicinal products. There can be no assurance that any country that has price controls, reimbursement limitations or other requirements for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products on cost-effectiveness grounds. Historically, products launched in EU Member States and other non-U.S. jurisdictions do not follow the price structures of the U.S., and they generally tend to be priced significantly lower.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many companies focused on the development of small molecules, antibodies and other treatments for cancer. Our competitors and potential competitors include major pharmaceutical and biotechnology companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing research activities similar to ours. Many of the organizations competing with us have greater capital resources, larger research and development staff and facilities, deeper regulatory expertise and more extensive product manufacturing and commercial capabilities than we do, which may afford them a competitive advantage.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition for Cabozantinib</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our ability to successfully compete will depend on, among other things:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">efficacy, safety and reliability of cabozantinib, both alone and in combination with other therapies;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">timing and scope of regulatory approval;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the speed at which we develop cabozantinib for the treatment of additional tumor types beyond its approved indications;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our ability to complete clinical development and obtain regulatory approvals for cabozantinib, both alone and in combination with other therapies;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our ability to manufacture and sell commercial quantities of cabozantinib product to the market;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our ability to successfully commercialize cabozantinib, both as a single agent and as part of any combination therapy regimen, and secure coverage and adequate reimbursement in approved indications;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">product acceptance by physicians and other health care providers;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the level of our collaboration partners&#8217; investments in the resources necessary to successfully commercialize cabozantinib, or any combination therapy regimen that includes cabozantinib, in&#160;territories where they are approved;&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">skills of our employees and our ability to recruit and retain skilled employees;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">protection of our intellectual property, including our ability to enforce our intellectual property rights against potential generic competition; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the availability of substantial capital resources to fund development and commercialization activities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the quality and breadth of activity observed with cabozantinib, the skill of our employees and our ability to recruit and retain skilled employees, our patent portfolio and our capabilities for research and drug development are competitive strengths. However, many large pharmaceutical and biotechnology companies have significantly larger intellectual property estates than we do, more substantial capital resources than we have, and greater capabilities and experience than we do in preclinical and clinical development, sales, marketing, manufacturing and regulatory affairs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the specific indications for which CABOMETYX is currently or may be approved, based on the results from clinical trials currently evaluating cabozantinib, are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. While we have had success in adapting our development strategy for the cabozantinib franchise to address the competitive landscape, including through evaluation of therapies that combine ICIs with other targeted agents, it is uncertain whether current and future clinical trials, including those evaluating cabozantinib in combination with an ICI in HCC, NSCLC and mCRPC, will lead to regulatory approvals, or whether physicians will prescribe regimens containing cabozantinib instead of competing product combinations in approved indications. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the principal competition for cabozantinib in the indications for which it is approved or for which it has been or is currently being evaluated in potentially label-enabling trials, both as a single agent and in combination with other therapies. The information below does not include all competitor products, but rather those approved products that have or we believe may capture significant market share within their respective indications, or with respect to therapies still in development, those that are likely to overlap with patient populations that are or may be treated with cabozantinib or a combination therapy regimen that includes cabozantinib.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition in Approved Cabozantinib Indications</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CABOMETYX - RCC:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe the principal competition for CABOMETYX in advanced RCC includes: the combination of Merck &amp; Co.&#8217;s pembrolizumab and Pfizer&#8217;s axitinib; the combination of BMS&#8217;s ipilimumab and nivolumab; and the combination of Merck &amp; Co.&#8217;s pembrolizumab and Eisai&#8217;s lenvatinib. Additionally, there are a variety of therapies being developed for advanced RCC, including: the combination of Peloton Therapeutics&#8217; (a wholly owned subsidiary of Merck &amp; Co.) belzutifan (also known as MK-6482) and Eisai&#8217;s lenvatinib; the combination of Merck &amp; Co.&#8217;s pembrolizumab, Eisai&#8217;s lenvatinib and Peloton Therapeutics&#8217; belzutifan; the combination of Merck &amp; Co.&#8217;s pembrolizumab and quavonlimab and Eisai&#8217;s lenvatinib; and Peloton Therapeutics&#8217; belzutifan.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The competitive landscape for RCC is evolving rapidly, especially given the entrance and increased adoption of ICI and ICI-TKI combination therapies into the RCC treatment landscape, particularly in the first-line setting. This has led to changing trends in prescribing and sequencing of certain drugs and combinations across different lines of therapy. It is difficult to predict how these changes will affect sales of CABOMETYX during 2023 and going forward.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CABOMETYX - HCC: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the principal competition for CABOMETYX in previously treated HCC includes: Bayer&#8217;s regorafenib; and Eisai&#8217;s lenvatinib. Additionally, there are a variety of therapies being developed for previously treated HCC, including the combination of Roche&#8217;s atezolizumab and either Eisai&#8217;s lenvatinib or Bayer&#8217;s sorafenib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competitive landscape for HCC has significantly changed with the increased adoption of ICI combination therapies in the first-line setting, which may lead to an increase in prescribing and sequencing of TKIs in subsequent lines of therapy. It is difficult to predict how these changes will affect sales of CABOMETYX during 2023 and going forward.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CABOMETYX - DTC: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the principal competition for CABOMETYX in its previously treated DTC indication includes two treatments that are also approved for previously untreated DTC: Bayer&#8217;s sorafenib; and Eisai&#8217;s lenvatinib. In addition, we believe there is also competition for CABOMETYX from therapies approved to treat patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are RAI-refractory (if RAI is appropriate), including: Blueprint Medicine&#8217;s and Roche&#8217;s pralsetinib; and Loxo Oncology&#8217;s (a wholly owned subsidiary of Eli Lilly) selpercatinib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the approvals of RET inhibitors to treat certain DTC patients, there has been little change in the competitive landscape for RAI-refractory DTC treatments during recent years. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COMETRIQ - MTC:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe that the principal competing anti-cancer therapy to COMETRIQ in progressive, metastatic MTC is Genzyme&#8217;s vandetanib, which has been approved by the FDA and the EC for the treatment of symptomatic or progressive MTC in patients with unresectable, locally advanced, or metastatic disease, as well as other therapies that have been recently approved to treat patients with advanced or metastatic RET-mutant MTC who require systemic therapy, including: Blueprint Medicines&#8217; and Roche&#8217;s pralsetinib; and Loxo Oncology&#8217;s selpercatinib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the recent approvals of RET inhibitors to treat certain MTC patients, there has been little change in the treatment landscape for progressive, metastatic MTC during recent years, and due to the limited number of ongoing late-stage clinical trials in this indication, we do not expect many additional competitors to emerge in 2023. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition in Potential Cabozantinib Indications</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cabozantinib in combination with ICI &#8211; mCRPC:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CONTACT-02 is a phase 3 pivotal trial evaluating the combination of cabozantinib and atezolizumab in patients with mCRPC who have been previously treated with one NHT. Should the combination of cabozantinib and atezolizumab be approved for the treatment of these mCRPC patients, we believe its principal competition may include: Janssen Biotech&#8217;s (a wholly owned subsidiary of Johnson &amp; Johnson) abiraterone; Astellas Pharma&#8217;s and Pfizer&#8217;s enzalutamide; Sanofi&#8217;s docetaxel; the combination of Merck &amp; Co.&#8217;s pembrolizumab and Astellas Pharma&#8217;s and Pfizer&#8217;s enzalutamide; the combination of BMS&#8217; nivolumab and Sanofi&#8217;s docetaxel; Veru Pharma&#8217;s sabizabulin; and generic versions of abiraterone and docetaxel. In addition, we believe there may be competition for the combination of cabozantinib and atezolizumab in mCRPC from approved therapies or therapies in late-stage development focused on the subset of mCRPC patients who are prostate-specific membrane antigen positive, including: </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis&#8217; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">177</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lu-PSMA-617;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> POINT Biopharma&#8217;s </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">177</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lu-PNT2002; Telix International&#8217;s </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">177</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lu-DOTA-rosopatamab; and Curium US LLC&#8217;s </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">177</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lu-PSMA-I&amp;T.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition for Zanzalintinib</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zanzalintinib in combination with ICI - CRC: STELLAR-303 is a phase 3 pivotal trial evaluating the combination of zanzalintinib and atezolizumab in patients with metastatic non-microsatellite instability-high or non-mismatch repair-deficient CRC who have progressed after, or are intolerant to, the current standard of care. Should the combination of zanzalintinib and atezolizumab be approved for the treatment of these CRC patients, we believe its principal competition may include: Bayer&#8217;s regorafenib; the combination of Ipsen&#8217;s irinotecan and either Eli Lilly&#8217;s cetuximab or Merck &amp; Co.&#8217;s pembrolizumab; the combination of Eisai&#8217;s lenvatinib and Merck &amp; Co.&#8217;s pembrolizumab; the combination of Merck &amp; Co.&#8217;s pembrolizumab and favezelimab; and the combination of Taiho Oncoloy&#8217;s trifluridine/tipiracil and Roche&#8217;s bevacizumab.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zanzalintinib in combination with ICI - RCC: STELLAR-304 is a phase 3 pivotal trial evaluating zanzalintinib in combination with nivolumab in previously untreated patients with advanced non-clear cell RCC. Should the combination of zanzalintinib and nivolumab be approved for the treatment of these RCC patients, we believe its principal competition may include similar therapies that compete with cabozantinib or combination regimens containing cabozantinib in their various approved RCC indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition for Cobimetinib and Esaxerenone</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is competition for both cobimetinib and esaxerenone in the specific indications and territories where they are approved, and there are regular new entrants and developments in all aspects of these markets. However, given the relatively lesser degree of adoption of these therapies within the broader markets in which they compete and their minimal contribution to our total revenues as out-licensed products, we do not believe changes in the competitive landscape in these indications will have a material impact on our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively seek patent protection in the U.S., EU and selected other foreign jurisdictions to cover our drug candidates and related technologies. Patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country. We have numerous patents and pending patent applications that relate to methods of screening drug targets, compounds that modulate drug targets, as well as methods of making and using such compounds.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While many patent applications have been filed relating to the drug candidates that we have developed, the majority of these are not yet issued or allowed. To our knowledge, we own all global patents necessary for the continued sale and development of cabozantinib and cobimetinib, and we either own or have in-licensed all global patents for our other drug candidates, as further described below.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cabozantinib is covered by more than 15 issued patents in the U.S., building from U.S. Patent No.&#160;7,579,473, for the composition of matter of cabozantinib and pharmaceutical compositions thereof. This composition of matter patent would expire in September 2024, but we have been granted a patent term extension to extend the term to August 2026. The following table describes the US patents that cover our marketed cabozantinib products, and which are listed in the Orange Book. Except as otherwise noted, the stated expiration dates include any patent term extensions already granted. In addition to the composition of matter patent referenced above, the table includes patents directed to, among other things, particular salts, polymorphs, formulations, or use of the compound in the treatment of specified diseases or conditions. We continue to pursue additional patents and patent term extensions in the U.S. and other territories covering various aspects of our cabozantinib products that may, if issued, extend exclusivity beyond the expiration of the patents listed in the table.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:12.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent No.</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">General Subject Matter</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Expiration</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="10" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,579,473</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,497,284</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,877,776</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salt and polymorphic forms of cabozantinib </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,724,342</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulations of cabozantinib</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr style="height:15pt"><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,034,873&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,039,757</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td></tr><tr style="height:15pt"><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,091,439&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crystalline salt forms of cabozantinib</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,091,440&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical composition </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,098,015&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,298,349&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical composition</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="7" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,579,473</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,877,776</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salt and polymorphic forms of cabozantinib</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,717,720</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulations of cabozantinib</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td></tr><tr style="height:15pt"><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,091,439&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crystalline salt forms of cabozantinib</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,091,440&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical composition</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,098,015&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,298,349&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical composition</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Given the importance of our intellectual property portfolio to our business operations, we vigorously enforce our rights and defend against challenges that have arisen or may arise with respect to patents and patent applications required for the commercialization of medicines containing cabozantinib. For example, in September 2019, we received a Paragraph IV notice letter regarding an ANDA submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets, which MSN then amended with additional Paragraph IV certifications in May 2020, January 2022 and June 2022. In response, we have filed a total of four patent infringement lawsuits against MSN in the United States District Court for the District of Delaware (the Delaware District Court): the first two lawsuits filed in October 2019 and May 2020 were later consolidated into a single case (referred to as MSN I) and adjudicated at a bench trial in May 2022; and the third and fourth lawsuits filed in February 2022 and July 2022, respectively, were also consolidated into a single case (referred to as MSN II) and will be adjudicated at another bench trial scheduled for October 2023. In January 2023, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the Delaware District Court issued a ruling in the MSN I case, rejecting MSN&#8217;s invalidity challenge to U.S. Patent No. 7,759,473, which expires in 2026, but also ruled that MSN&#8217;s proposed ANDA product does not infringe U.S. Patent No. 8,877,776, which expires in 2030. This ruling in MSN I does not address the parties&#8217; claims in the MSN II lawsuit.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> In addition, in May 2021, we received Paragraph IV certification notice letters regarding an ANDA submitted to the FDA by Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva), requesting approval to market a generic version of CABOMETYX tablets, which Teva then amended with additional Paragraph IV certifications in July 2022. In response, we have filed two patent infringement lawsuits against Teva in the Delaware District Court in June 2021 and September 2022, which were consolidated into a single case, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">all proceedings in our litigation against Teva were stayed pursuant to an order of the Delaware District Court in October 2022. Most recently, o</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n February 6, 2023, we received a Paragraph IV certification notice letter regarding an ANDA submitted to the FDA by Cipla Limited (Cipla) requesting approval to market a generic version of CABOMETYX tablets. We cannot predict the ultimate outcome of these ANDA submissions and/or any related lawsuits or provide assurance that these lawsuits will prevent the introduction of a generic version of CABOMETYX for any particular length of time, or at all. For a more detailed discussion of these litigation matters, see &#8220;Legal Proceedings&#8221; in Part I, Item 3 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, cabozantinib is protected by issued patents covering the composition of matter and methods of use. The issued patent would expire in September 2024, but we have applied for and either have obtained, or expect to obtain Supplementary Protection Certificates in the EU to extend the term to 2029. In addition to the composition of matter patent, the table below includes certain later-expiring patents directed to the commercial product, including, particular salts, polymorphs, formulations, or use of the compound in the treatment of specified diseases or conditions. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.767%"><tr><td style="width:1.0%"></td><td style="width:12.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent No.</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">General Subject Matter</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Expiration</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX </span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2213661</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter and methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2387563</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salt and polymorphic forms of cabozantinib and methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ </span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2213661</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter and methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2387563</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salt and polymorphic forms of cabozantinib and methods of treatment</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Similarly, in Japan, cabozantinib is protected by issued patents covering the composition of matter, and salts thereof, as well as pharmaceutical compositions and related methods of use, and Takeda has applied for patent term extension in Japan to extend the term to 2029. Foreign counterparts of the issued U.S. and European composition of matter patents have been issued in Australia and Canada and are anticipated to expire in 2024. We have other filed patent applications and issued patents in the U.S. and other selected countries covering certain synthetic methods, salts, polymorphs, formulations, prodrugs, metabolites and combinations of cabozantinib that, if issued, are anticipated to expire as late as 2037. Outside the U.S. and Japan, cabozantinib is licensed to Ipsen, and in Japan, cabozantinib is licensed to Takeda, each in accordance with the respective collaboration agreements. A discussion of risks and uncertainties that may affect our patent position and other proprietary rights is set forth in &#8220;Risk Factors,&#8221; contained in Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zanzalintinib and Other Drug Candidates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have issued patents and pending patent applications, and will continue to file new patent applications, in the U.S., the EU and other selected countries covering our other drug candidates in clinical and/or preclinical development, including zanzalintinib, XB002 and XL102. Zanzalintinib in particular is covered by U.S. Patent No. 11,542,259, and we have pending patent applications in the U.S. and other selected countries covering the composition of matter, certain synthetic methods, salts, polymorphs, formulations and combinations of zanzalintinib that, if issued, are anticipated to expire between 2039 and 2043, excluding any potential patent term adjustments and/or extensions. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained licenses from various parties that give us rights to technologies that we deem to be necessary or desirable for our research and development. These licenses (both exclusive and non-exclusive) may require us to pay royalties as well as upfront and milestone payments.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We require our scientific personnel to maintain laboratory notebooks and other research records in accordance with our policies, which are designed to strengthen and support our intellectual property protection. In addition to our patented intellectual property, we also rely on trade secrets and other proprietary information, especially when we do not believe that&#160;patent</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protection is appropriate or can be obtained. We also require all of our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who receive proprietary information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all proprietary information developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Furthermore, our agreements with employees and, in most circumstances, our agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors expressly provide that all inventions, concepts, developments, copyrights, trademarks or other intellectual property developed by an employee during the employment period, or developed by a service provider during the service period or utilizing our proprietary drugs or information, shall be our exclusive property. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Employees and Commitment to Diversity, Equity and Inclusion</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had 1,223 employees, representing a 28% increase in our employee workforce as compared to December 31, 2021. Of these employees, 600 are members of our research and development teams and 623 are members of our commercial, general and administrative teams. Of these employees, 215 hold Ph.D. degrees, 23 hold M.D. (or foreign equivalent) degrees, 32 hold PharmD degrees and 111 hold other professional degrees such as a J.D. or M.B.A. None of our employees are represented by a labor union, and we consider our employee relations to be good.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the past five years, our employee turnover has remained consistently below average for the U.S. life sciences industry generally. Given our expanding operations and need to further grow our headcount to support our business, we continually assess employee turnover, recruitment initiatives, compensation and benefits programs, safety in </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performing critical laboratory work, diversity and other matters relevant to human capital management, and we review results with our Board of Directors on a periodic basis.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an equal opportunity employer and maintain policies that prohibit unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital and veteran status. We are proud to employ a diverse workforce that, as of December&#160;31, 2022, was 59% non-white and 52% women. In addition, as of December&#160;31, 2022, 54% of our positions that manage other employees directly were held by non-whites and 44% were held by women, and women made up 33% of our senior leadership team. We strive to build and nurture a culture where all employees feel empowered to be their authentic selves. We respect and appreciate each employee&#8217;s unique perspective and experiences, and value their contributions to our mission. It is important that we celebrate, encourage and support similarities and differences to drive innovation for the benefit of our employees, patients and community.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Culture, Compensation and Benefits</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Exelixis, we value being exceptional in what we do and how we lead, excelling for patients by going the extra mile to care for them and exceeding together as a business and contributor to the scientific community. We strive to live these values every day across the company, integrating them into everything from our interview, hiring and onboarding processes, to our performance evaluation, rewards and promotion programs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide generous compensation packages designed to attract and retain high-quality employees, and all of our employees are eligible for cash bonuses and grants of long-term incentive awards. We regularly evaluate our compensation programs with an independent compensation consultant and utilize industry benchmarking in an effort to ensure they are competitive with the biotechnology and biopharmaceutical companies against which we compete for talent, as well as fair and equitable across our workforce with respect to gender, race and other personal characteristics. We utilize a third-party firm to conduct an annual pay equity analysis; for 2022, the fourth year in a row, this analysis demonstrated no gender or ethnicity-based disparities. In addition, we are proud to provide a variety of programs and services to help employees meet and balance their needs at work, at home and in life, including an attractive mix of healthcare, insurance and other benefit plans. We deliver a benefits program that is designed to keep our employees and their families mentally, physically and emotionally healthy, which includes not only medical, dental and vision benefits, but also dependent care, mental health and other wellness benefits. For a discussion of workplace safety measures we have taken, see &#8220;&#8212;Environmental, Health and Safety.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond compensation and benefits, we also value career development for all employees, and we offer a tuition reimbursement program, as well as professional development courses ranging from technical training, competency-based workshops and leadership development programs facilitated by external partners who are experts in their respective fields. Direct managers also take an active role in identifying individualized development plans to assist their employees in realizing their full potential and creating opportunities for promotions and added responsibilities that enhance the engagement and retention of our workforce.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in Delaware in November 1994 as Exelixis Pharmaceuticals, Inc. and changed our name to Exelixis, Inc. in February 2000. Our principal executive offices are located at 1851 Harbor Bay Parkway, Alameda, California 94502. Our telephone number is (650) 837-7000. We maintain a site on the worldwide web at www.exelixis.com; however, information found on our website is not incorporated by reference into this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available free of charge on or through our website our Securities and Exchange Commission (SEC) filings, including our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains a site on the worldwide web that contains reports, proxy and information statements and other information regarding our filings at www.sec.gov.</span></div><div id="ia855702135904005a41d208deb24e60a_16"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to the risks discussed elsewhere in this report, the following are important factors that make an investment in our securities speculative or risky, and that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occur, our business and the value of your investment in our company could be harmed.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Products</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow our company is dependent upon the commercial success of CABOMETYX in its approved indications and the continued clinical development, regulatory approval, clinical acceptance and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that for the foreseeable future, our ability to maintain or meaningfully increase cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. In this regard, part of our strategy is to pursue additional indications for CABOMETYX and increase the number of cancer patients who could potentially benefit from this medicine. However, we cannot be certain that the clinical trials we and our collaboration partners are conducting will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if the required regulatory approvals to market CABOMETYX for additional indications are achieved, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. If revenue from CABOMETYX decreases or remains flat, or if we are unable to expand the number of labeled indications for which CABOMETYX is approved, or if we or our collaboration partners fail to achieve anticipated product royalties and collaboration milestones, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow revenues from sales of CABOMETYX depends upon the degree of market acceptance among physicians, patients, healthcare payers, and the medical community.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase or maintain revenues from sales of CABOMETYX for its approved indications is, and if approved for additional indications will be, highly dependent upon the extent of market acceptance of CABOMETYX among physicians, patients, foreign and U.S. government healthcare payers such as Medicare and Medicaid, commercial healthcare plans and the medical community. Market acceptance for CABOMETYX could be impacted by numerous factors, including the effectiveness and safety profile, or the perceived effectiveness and safety profile, of CABOMETYX compared to competing products, the strength of CABOMETYX sales and marketing efforts and changes in pricing and reimbursement for CABOMETYX. If CABOMETYX does not continue to be prescribed broadly for the treatment of patients in its approved indications, our product revenues could flatten or decrease, which could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our competitors may develop products and technologies that impair the relative value of our marketed products and any current and future product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is competitive and characterized by constant technological change and diverse offerings of products, particularly in the area of oncology therapies. Many of our competitors have greater capital resources, larger research and development staff and facilities, deeper regulatory expertise and more extensive product manufacturing and commercial capabilities than we do, which may afford them a competitive advantage. Further, our competitors may be more effective at in-licensing and developing new commercial products that could render our products, and those of our collaboration partners, obsolete and noncompetitive. We face, and will continue to face, intense competition from biopharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing scientific and clinical research activities similar to ours.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the specific indications for which CABOMETYX is currently or may be approved, based on the results from clinical trials currently evaluating cabozantinib, are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. Even if our current and future clinical trials, including those evaluating cabozantinib in combination with an ICI in mCRPC or evaluating zanzalintinib in combination with an ICI in CRC and RCC, produce positive results sufficient to obtain marketing approval by the FDA and other global regulatory authorities, it is uncertain whether physicians will choose to prescribe regimens containing our products instead of competing products and product combinations in approved indications.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain or increase our sales, marketing, market access and product distribution capabilities for our products, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with maintaining and continuously improving our commercial organization, including our potential inability to successfully recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are competing for talent with numerous commercial- and precommercial-stage, oncology-focused biopharmaceutical companies seeking to build out and maintain their commercial organizations, as well as larger biopharmaceutical organizations that have extensive, well-funded and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. Also, to the extent that the commercial opportunities for CABOMETYX grow over time, we may not properly scale the size and experience of our commercialization teams to market and sell CABOMETYX successfully in an expanded number of indications. If we are unable to maintain or scale our commercial function appropriately, we may not be able to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize our products successfully is highly dependent on the extent to which health insurance coverage and reimbursement is, and will be, available from third-party payers, including foreign and U.S. governmental payers, such as Medicare and Medicaid, and private health insurers. Third-party payers continue to scrutinize and manage access to pharmaceutical products and services and may limit reimbursement for newly approved products and indications. Patients are generally not capable of paying for CABOMETYX or COMETRIQ themselves and rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. Accordingly, market acceptance of CABOMETYX and COMETRIQ is dependent on the extent to which coverage and reimbursement is available from third-party payers. These entities could refuse, limit or condition coverage for our products, such as by using tiered reimbursement or pressing for new forms of contracting, or alternatively for patients who rely on our co-pay assistance program, implement co-pay accumulators or maximizers that exempt such co-pay assistance from patient deductibles (or otherwise modify benefit designs in a manner that takes into account the availability of co-pay assistance), which has increased and could further increase the costs of our co-pay assistance program or cause patients to abandon CABOMETYX or COMETRIQ therapy due to higher out-of-pocket costs. If third-party payers do not provide or increase limitations on coverage or reimbursement for CABOMETYX or COMETRIQ, our revenues and results of operations may suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford CABOMETYX or COMETRIQ.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current healthcare laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. healthcare system may affect our ability to commercialize our marketed products profitably.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state governments in the U.S. are considering legislative and regulatory proposals to change the U.S. healthcare system in ways that could affect our ability to continue to commercialize CABOMETYX and COMETRIQ profitably. Similarly, among policy makers and payers, there is significant interest in promoting such changes with the stated goals of containing healthcare costs and expanding patient access. The life sciences industry and specifically the market for the sale, insurance coverage and distribution of pharmaceuticals has been a particular focus of these efforts and would likely be significantly affected by any major legislative or regulatory initiatives. In addition, there have been, and may in the future be, initiatives at both the federal and state level that could significantly modify the terms and scope of government-provided health insurance coverage, ranging from changes to some or all of the provisions of the PPACA to establishing a single-payer, national health insurance system to more limited &#8220;buy-in&#8221; options to existing public health insurance programs, any of which could have a significant impact on the healthcare industry. Although such attempts to reform the U.S. healthcare system have not significantly impacted our business to date, it is possible that additional legislative, executive and judicial activities in the future could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because we participate in the 340B Program to sell a portion of our marketed products, changes in the administration of the program could have a material adverse impact on our revenues. Some manufacturers are currently involved in ongoing litigation regarding the legality of contract pharmacy arrangements under the 340B Program, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which may affect the way in which manufacturers are required to extend discounts to covered entities through contract pharmacies. Effective July 2022, we implemented a 340B Program Integrity Initiative, pursuant to which we request all hospital covered entities (i.e., hospitals that participate in the 340B Program) to provide claims-level data for CABOMETYX and COMETRIQ dispensed by contract pharmacies. A covered entity that elects not to provide this limited claims data and that does not have an in-house pharmacy may designate a single contract pharmacy location within our authorized specialty pharmacy network. We believe this initiative will provide much-needed transparency and promote compliance with program requirements, and at the same time, should not restrict patient access to our medicines. HHS has notified us that it is reviewing our policy, and we have responded to HHS&#8217; request for information. Since 2021, numerous manufacturers that previously implemented similar contract pharmacy integrity programs have received enforcement letters from HHS stating that those manufacturers&#8217; actions restricted contract pharmacy transactions in violation of the 340B Program statute, which may subject them to repayment of overcharges and civil monetary penalties. As mentioned above, certain of these manufacturers are now in litigation with the government over the legality of these programs, and depending on the outcome of such litigation, we may be required to modify or suspend our 340B Program Integrity Initiative. Further, it is possible that HHS could seek to implement administrative proceedings to recover overcharges and/or impose civil monetary penalties against us regarding our 340B Program Integrity Initiative. If such proceedings were implemented against us, a negative ruling could have a material adverse effect on our business, financial condition and results of operations. Due to general uncertainty with respect to this litigation and in the current regulatory and healthcare policy environment, and specifically regarding positions that the Biden Administration may take with respect to these issues, we are unable to predict the impact of any legislative, regulatory, third-party payer or policy actions, including potential cost containment and healthcare reform measures. If enacted, we and any third parties we might engage may be unable to adapt to any changes implemented as a result of such measures, and we could face difficulties in maintaining or increasing profitability or otherwise experience a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing for pharmaceutical products in the U.S. has come under increasing attention and scrutiny by federal and state governments, legislative bodies and enforcement agencies. Initiatives arising from this scrutiny may result in changes that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There continue to be U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as executive orders, designed to, among other things: reduce or limit the prices of drugs and make them more affordable for patients (including, for example, by tying drug prices to the prices of drugs in other countries); reform the structure and financing of Medicare Part D pharmaceutical benefits; implement additional data collection and transparency reporting regarding drug pricing, rebates, fees and other remuneration provided by drug manufacturers; enable the government to negotiate prices under Medicare; revise rules associated with the calculation of average manufacturer price and best price under Medicaid; eliminate the AKS discount safe harbor protection for manufacturer rebate arrangements with Medicare Part D plan sponsors; create new AKS safe harbors applicable to certain point-of-sale discounts to patients and fixed fee administrative fee payment arrangements with pharmacy benefit managers; and revise the rebate methodology under the Medicaid Drug Rebate Program. For instance in August 2022, President Biden signed the Inflation Reduction Act, which among other things: allows for CMS to impose price controls for certain single-source drugs and biotherapeutics reimbursed under Medicare Part B and Part D; subjects drug manufacturers to civil monetary penalties and a potential excise tax for offering a price that is not equal to or less than the government-imposed &#8220;maximum fair price&#8221; under the law; imposes Medicare rebates for price increases that exceed inflation; and redesigns the funding and benefit structure of the Medicare Part D program, potentially increasing manufacturer liability while capping annual out-of-pocket drug expenses for Medicare beneficiaries. These provisions have started taking effect incrementally in late 2022 and may be subject to various legal challenges. As of the date of this Annual Report on Form 10-K, CMS has commenced public rulemaking and issued guidance addressing certain aspects of the Inflation Reduction Act, and overtime the Inflation Reduction Act could reduce the revenues we are able to collect from sales of our products and increase our government discount and rebate liabilities; however, the degree of impact that the Inflation Reduction Act will ultimately have upon our business remains unclear. In addition, we cannot know the final form or timing of any other legislative, regulatory and/or administrative measures, and some of these pending and enacted legislative proposals or executive rulemaking, if implemented without successful legal challenges, would likely have a significant and far-reaching impact on the biopharmaceutical industry and therefore also likely have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biotherapeutic product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including the National Medicaid Pooling Initiative. In particular, the obligation to provide notices of price increases to purchasers under laws such as California&#8217;s SB-17 may influence customer ordering patterns for CABOMETYX and COMETRIQ, which in turn may increase the volatility of our revenues as a reflection of changes in inventory volumes. Furthermore, adoption of these drug pricing transparency regulations, and our associated compliance obligations, may increase our general and administrative costs and/or diminish our revenues. Implementation of these federal and/or state cost-containment measures or other healthcare reforms may limit our ability to generate product revenue or commercialize our products, and in the case of drug pricing transparency regulations, may result in fluctuations in our results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lengthy regulatory pricing and reimbursement procedures and cost control initiatives imposed by governments outside the U.S. could delay the marketing of and/or result in downward pressure on the price of our approved products, resulting in a decrease in revenue.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., including major markets in the EU and Japan, the pricing and reimbursement of prescription pharmaceuticals is generally subject to significant governmental control. In these countries, pricing and reimbursement negotiations with governmental authorities or payers can take six to 12 months or longer after the initial marketing authorization is granted for a product, or after the marketing authorization for a new indication is granted. This can substantially delay broad availability of the product. To obtain reimbursement and/or pricing approval in some countries, our collaboration partners Ipsen and Takeda may also be required to conduct a study or otherwise provide data that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies. The conduct of such a study could also result in delays in the commercialization of CABOMETYX. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, cost-control initiatives, increasingly based on affordability and accessibility, as well as post-marketing assessments of the added value of CABOMETYX and COMETRIQ as compared to existing treatments, could influence the prices paid for and net revenues we realize from CABOMETYX and COMETRIQ, or the indications for which we are able to obtain reimbursement, which would result in lower license revenues to us. Recent legislative changes and ongoing policy changes in the EU are aimed at increasing cooperation between the EU Member States. Such initiatives, particularly the HTA Regulation adopted in December 2021, may further impact the price and reimbursement status of CABOMETYX and COMETRIQ when it enters into application 2025.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The timing of the entrance of generic competitors to CABOMETYX and legislative and regulatory action designed to reduce barriers to the development, approval and adoption of generic drugs in the U.S. could limit the revenue we derive from our products, most notably CABOMETYX, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDCA, the FDA can approve an ANDA for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. The FDA can also approve an NDA under section 505(b)(2) of the FDCA that relies in part on the agency&#8217;s findings of safety and/or effectiveness for a previously approved drug, where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use. Both the ANDA and 505(b)(2) NDA processes are discussed above in &#8220;Item 1. Business&#8212;Government Regulation&#8212;FDA Review and Approval&#8212;Abbreviated FDA Approval Pathways and Generic Products&#8221; in this Annual Report on Form 10-K. In either case, if an ANDA or 505(b)(2) NDA applicant submits an application referencing one of our marketed products prior to the expiry of one or more our Orange Book-listed patents for the applicable product, we may litigate with the potential generic competitor to protect our patent rights, which would result in substantial costs, divert the attention of management, and could have an adverse impact on our stock price. For example, MSN, Teva and Cipla have separately submitted ANDAs to the FDA requesting approval to market their respective generic versions of CABOMETYX tablets, and we have subsequently filed patent enforcement lawsuits against both companies. For a more detailed discussion of these litigation matters, see &#8220;Legal Proceedings&#8221; in Part I, Item 3 of this Annual Report on Form 10-K. It is possible that MSN, Teva, Cipla or other companies, following FDA approval of an ANDA or 505(b)(2) NDA, could introduce generic or otherwise competitor versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and we expect that generic cabozantinib products would be offered at a significantly lower price compared to our marketed cabozantinib products. Regardless of the regulatory approach, the introduction of a generic version of cabozantinib would likely decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. There are also equivalent procedures in the EU permitting authorization of generic versions and biosimilars of medicinal products authorized in the EU once related data and market exclusivity periods have expired.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government has also taken numerous legislative and regulatory actions to expedite the development and approval of generic drugs and biosimilars. Both Congress and the FDA are considering, and have enacted, various legislative and regulatory proposals focused on drug competition, including legislation focused on drug patenting and provision of drug to generic applicants for testing. For example, the Ensuring Innovation Act, enacted in April 2021, amended the FDA&#8217;s statutory authority for granting NCE exclusivity to reflect the agency&#8217;s existing regulations and longstanding interpretation that award NCE exclusivity based on a drug&#8217;s active moiety, as opposed to its active ingredient, which is intended to limit the applicability of NCE exclusivity, thereby potentially facilitating generic competition. In addition, the Further Consolidated Appropriations Act, 2020, which incorporated the framework from the CREATES legislation, allowed ANDA, 505(b)(2) NDA or biosimilar developers to obtain access to branded drug and biotherapeutic product samples. Further, Section 3222 of the of the 2023 Appropriations Act requires the FDA to make therapeutic equivalence determinations for 505(b)(2) NDAs at the time of approval, or up to 180 days thereafter, if requested by the applicant. Additionally, Section 3224 of the 2023 Appropriations Act allows the FDA to approve an ANDA even if there are differences between the generic drug&#8217;s proposed labeling and that of the listed drug due to the FDA approving a change to the listed drug&#8217;s label (excluding warnings) within 90 days of when the ANDA is otherwise eligible for approval, provided that the ANDA applicant agrees to submit revised labeling for the generic drug within 60 days of approval. While the full impact of these provisions is unclear at this time, its provisions do have the potential to facilitate the development and future approval and market success of generic versions of our products, introducing generic competition that could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Growth of Our Product Portfolio and Research and Development</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to expand our discovery and development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is focused on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. In this regard, we have invested in substantial technical, financial and human resources toward drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. Notwithstanding this investment, many programs that initially show promise will ultimately fail to yield product candidates for multiple reasons. For example, product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apart from our drug discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates and technologies. However, the in-licensing and acquisition of product candidates and technologies is a highly competitive area, and many other companies are pursuing the same or similar product candidates and technologies to those that we may consider attractive. In particular, larger companies with more capital resources and more extensive clinical development and commercialization capabilities may have a competitive advantage over us. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We may also be unable to in-license or acquire additional product candidates and technologies on acceptable terms that would allow us to realize an appropriate return on our investment. Even if we succeed in our efforts to obtain rights to suitable product candidates and technologies, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products and technologies will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target company, or retain key personnel of the acquired business. Furthermore, we could assume unknown or contingent liabilities or otherwise incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our financial condition and results of operations. If our drug discovery efforts, including research collaborations, in-licensing arrangements and other business development activities, do not result in suitable product candidates, our business and prospects for growth could suffer.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy data for those products sufficiently differentiated to compete in our highly competitive market environment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are inherently risky and may reveal that cabozantinib, despite its approval for certain indications, or a new product candidate, is ineffective or has an unacceptable safety profile with respect to an intended use. Such results may significantly decrease the likelihood of regulatory approval of a product candidate or of an approved product for a new indication. Moreover, the results of preliminary studies do not necessarily predict clinical or commercial success, and late-stage or other potentially label-enabling clinical trials may fail to confirm the results observed in early-stage trials or preliminary studies. Although we have established timelines for manufacturing and clinical development of cabozantinib and our other product candidates based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those timelines.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events, during or as a result of clinical investigations, that could delay or prevent commercialization of cabozantinib in new indications or of zanzalintinib or other new product candidates. These events may include:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">lack of acceptable efficacy or a tolerable safety profile;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">negative or inconclusive clinical trial results that require us to conduct further testing or to abandon projects;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">discovery or commercialization by our competitors of other compounds or therapies that show significantly improved safety or efficacy compared to cabozantinib or our other product candidates;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our inability to identify and maintain a sufficient number of clinical trial sites; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">lower-than-anticipated patient registration or enrollment in our clinical testing; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">additional complexities posed by clinical trials evaluating cabozantinib, zanzalintinib or our other product candidates in combination with other therapies, including extended timelines to provide for collaboration on clinical development planning, the failure by our collaboration partners to provide us with an adequate and timely supply of product that complies with the applicable quality and regulatory requirements for a combination trial</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">reduced staffing or shortages in laboratory supplies and other resources necessary to complete the trials; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">failure of our third-party contract research organizations or investigators to satisfy their contractual obligations, including deviating from any trial protocols; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">withholding of authorization from regulators or institutional review boards to commence or conduct clinical trials or delays, variations, suspensions or terminations of clinical research for various reasons, including noncompliance with regulatory requirements or a determination by these regulators and institutional review boards that participating patients are being exposed to unacceptable health risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing Russo-Ukrainian War has had a modest impact on our clinical development operations, particularly with respect to patient recruitment, potentially delaying our ability to complete enrollment in a timely manner. In addition, this conflict has had and may continue to have an adverse impact on the ability of clinical sites and their patients to adhere to trial protocols for in-office clinical visits and other procedures, our ability to supply clinical sites with cabozantinib or other study drugs and to pay clinical sites and investigators for work performed, as well as our ability to collect data and conduct site monitoring visits, all of which could undermine the data quality for patients enrolled at these clinical sites. The need to shift enrollment of patients away from these clinical sites or close certain sites entirely, or to replace patients in affected territories should investigators be unable to continue treating and monitoring them, could further impact our anticipated timelines for completing the trials and achieving clinical endpoints, as well as increase our clinical development expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are further delays in or termination of the clinical testing of cabozantinib, zanzalintinib or our other product candidates due to any of the events described above or otherwise, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. Furthermore, we rely on our collaboration partners to fund a significant portion of our cabozantinib clinical development programs. Should one or all of our collaboration partners decline to support future planned clinical trials, we will be entirely responsible for financing the further development of the cabozantinib franchise or our other product candidates and, as a result, we may be unable to execute our current business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to pursue the further development of the cabozantinib franchise, zanzalintinib or our other product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions in accordance with our stated timelines or at all. Our planned clinical trials may not begin on time, or at all, may not be completed on schedule, or at all, may not be sufficient for registration of our product candidates or otherwise may not result in an approvable product. The duration and the cost of clinical trials vary significantly as a result of factors relating to a particular clinical trial, including, among others: the characteristics of the product candidate under investigation; the number of patients who ultimately participate in the clinical trial; the duration of patient follow-up; the number of clinical sites included in the trial; and the length of time required to enroll eligible patients. Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, uncertain and subject to change, and may not result in regulatory approvals for additional cabozantinib indications or for our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities associated with the research, development and commercialization of the cabozantinib franchise, zanzalintinib and our other product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the U.S., as well as by comparable regulatory authorities in other territories. The processes of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive and often takes many years, if approval is obtained at all, and they can vary substantially based upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or sNDA can be submitted to the FDA, or a marketing authorization application to the EMA or any application or submission to comparable regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or sNDA or decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, we may encounter delays or rejections based upon changes in policy, which could cause delays in the approval or rejection of an application for cabozantinib or for zanzalintinib or our other product candidates. For example, the FDA launched Project Optimus in 2021 as an initiative to reform the dose optimization and dose selection paradigm in oncology drug development, which was driven by the FDA&#8217;s concerns that the current paradigm for dose selection may result in doses and schedules of molecularly targeted therapies that are inadequately characterized before initiating pivotal trials. Through collaboration with the biopharmaceutical industry, academia and other stakeholders, the FDA&#8217;s goal for this initiative is to advance an oncology dose-finding and dose optimization paradigm that emphasizes dose selections that maximize efficacy as well as safety and tolerability. In support of this initiative, the FDA may request sponsors of oncology product candidates to conduct dose optimization studies pre- or post-approval, and the FDA also continues to develop and finalize guidance documents and implement initiatives regarding the development and clinical research of oncology product candidates. Recently, in part due to questions raised by the process underlying the approval of an Alzheimer&#8217;s disease drug,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government authorities and other stakeholders have been scrutinizing the accelerated approval pathway, with some stakeholders advocating for reforms. Even prior to this, the FDA has held Oncologic Drugs Advisory Committee meetings to discuss accelerated approvals for which confirmatory trials have not verified clinical benefit. Such scrutiny, among other factors, has resulted in voluntary withdrawals of certain products and indications approved on an accelerated basis. Spurred by the Alzheimer&#8217;s drug controversy, the HHS Office of Inspector General has also initiated an assessment of how the FDA implements the accelerated approval pathway. In addition, Section 3210 of the 2023 Appropriations Act revised the accelerated approval pathway. Although this legislation did not change the standard for accelerated approval, it, among other things: requires the FDA to specify the conditions for required post-marketing trials; permits the FDA to require such trials to be underway prior to approval, or within a specific period after approval; requires sponsors to provide reports on post-marketing trial progress no later than 180 days after approval and every 180 days thereafter until such trials are completed; makes the failure to conduct required post-marketing trials with due diligence and the failure to submit the required reports prohibited acts; and details procedures the FDA must follow to withdraw an accelerated approval on an expedited basis. While it is not clear at this time how these legislative and regulatory initiatives will affect our plans to pursue accelerated approval for one or more of our product candidates, these developments may have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more new indications or approves one of our other product candidates, including zanzalintinib, for use, such approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, and/or production of the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product and could impose requirements for post-marketing studies, including additional research and clinical trials, all of which may result in significant expense and limit our and our collaboration partners&#8217; ability to commercialize cabozantinib, zanzalintinib or our other product candidates in any new indications. Failure to complete post-marketing requirements of the FDA in connection with a specific approval in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or ultimately restrict the commercialization of cabozantinib, zanzalintinib or another product candidate in the approved indication. Regulatory agencies could also impose various administrative, civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval. Further, current or any future laws or executive orders governing FDA or foreign regulatory approval processes that may be enacted or executed could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Financial Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our other product candidates, grow more quickly than the revenues we generate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we reported net income of $182.3 million and $231.1 million for the fiscal years ended December&#160;31, 2022 and 2021, respectively, we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to predict the extent of future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; our achievement of development, regulatory and commercial milestones, if any, under our collaboration agreements; the amount of royalties from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements; other collaboration revenues; and the level of our expenses, including those associated with our extensive drug discovery, clinical development and business development activities, both for the cabozantinib franchise and our other product candidates, as well as our general business expansion plans. Our expected future expenses in particular may also be increased by inflationary pressures, which could increase the costs of outside services, labor, raw materials and finished drug product. We expect to continue to spend substantial amounts to fund the continued development of the cabozantinib franchise for additional indications and of our other product candidates, as well as the commercialization of our approved products. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including research collaborations, in-licensing arrangements and other strategic transactions that align with our oncology drug development, regulatory and commercial expertise, which efforts could involve substantial costs. To offset these costs in the future, we will need to generate substantial revenues. If these costs exceed our current expectations, or we fail to achieve anticipated revenue targets, the market value of our common stock may decline.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and we are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon the regulatory, commercial, medical affairs, market access and other expertise and resources of our collaboration partners, Ipsen and Takeda, for commercialization of CABOMETYX in their respective territories outside of the U.S. We cannot control the amount and timing of resources that our collaboration partners dedicate to the commercialization of CABOMETYX, or to its marketing and distribution, and our ability to generate revenues from the commercialization of CABOMETYX by our collaboration partners depends on their ability to obtain and maintain regulatory approvals for, achieve market acceptance of, and to otherwise effectively market, CABOMETYX in its approved indications in their respective territories. If our collaboration partners are unable or unwilling to invest the resources necessary to commercialize CABOMETYX successfully in the EU, Japan and other international territories where it has been approved, this could reduce the amount of revenue we are due to receive under these collaboration agreements, thus resulting in harm to our business and operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance and investments, which subjects us to a number of risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established clinical and commercial collaborations with leading biopharmaceutical companies for the development and commercialization of our products, and our dependence on these collaboration partners subjects us to a number of risks, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our collaboration partners&#8217; decision to terminate our collaboration, or their failure to comply with the terms of our collaboration agreements and related ancillary agreements, either intentionally or as a result of negligence or other insufficient performance;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our inability to control the amount and timing of resources that our collaboration partners devote to the development or commercialization of our products;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the possibility that our collaboration partners may stop or delay clinical trials, fail to supply us on a timely basis with product required for a combination trial, or deliver product that fails to meet appropriate quality and regulatory standards;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">disputes that may arise between us and our collaboration partners that result in the delay or termination of the development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the possibility that our collaboration partners may experience financial difficulties that prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our collaboration partners&#8217; inability to obtain regulatory approvals in a timely manner, or at all; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our collaboration partners&#8217; failure to comply with legal and regulatory requirements relevant to the authorization, marketing, distribution and supply of our marketed products in the territories outside the U.S. where they are approved; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our collaboration partners&#8217; failure to properly maintain or defend our intellectual property rights or their use of our intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential litigation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not receive collaboration revenues or otherwise realize anticipated benefits from such collaborations, and our product development efforts and prospects for growth could be delayed or disrupted, all of which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To expand our early-stage product pipeline, we have augmented our drug discovery activities with multiple research collaborations and in-licensing arrangements with other companies. Our dependence on our relationships with these research and in-licensing partners subjects us to numerous risks, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our research and in-licensing partners&#8217; decision to terminate our relationship, or their failure to comply with the terms of our agreements, either intentionally or as a result of negligent performance;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">disputes that may arise between us and our research and in-licensing partners that result in the delay or termination of research activities with respect to any in-licensed assets or supporting technology platforms;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the possibility that our research and in-licensing partners may experience financial difficulties that prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the possibility that our research and in-licensing partners may be acquired and that any acquiring entity may not honor our partners&#8217; research commitments or otherwise fail to continue fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our research and in-licensing partners&#8217; failure to properly maintain or defend their intellectual property rights or their use of third-party intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our license to develop these assets or utilize technology platforms;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">laws, regulations or practices imposed by countries outside the U.S. that could impact or inhibit scientific research or the development of healthcare products by foreign competitors or otherwise disadvantage healthcare products made by foreign competitors, as well as general political or economic instability in those countries, any of which could complicate, interfere with or impede our relationships with our ex-U.S. research, development and in-licensing partners; and</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our research and in-licensing partners&#8217; failure to comply with applicable healthcare laws, as well as established guidelines, laws and regulations related to GMP and GLP.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not be able to expand our product pipeline or otherwise realize a return on the resources we will have invested to develop these early-stage assets, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third parties upon which we rely to perform clinical trials for cabozantinib in new indications or for new product candidates do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to conduct clinical trials for cabozantinib or for new potential product candidates independently, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government, third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, or if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical trial or data security protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or commercialize cabozantinib beyond currently approved indications or obtain regulatory approval for zanzalintinib or our other product candidates. In addition, due to the complexity of our research initiatives, we may be unable to engage with third-party contract research organizations that have the necessary experience and sophistication to help advance our drug discovery efforts, which would impede our ability to identify, develop and commercialize our potential product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We lack our own manufacturing and distribution capabilities necessary for us to produce materials required for certain preclinical activities and to produce and distribute our products for clinical development or for commercial sale, and our reliance on third parties for these services subjects us to various risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing or distribution facilities for CMC development activities, preclinical, clinical or commercial production and distribution for our current products and new product candidates. Instead, we rely on various third-party contract manufacturing organizations to conduct these operations on our behalf. As our operations continue to grow in these areas, we continue to expand our supply chain through additional third-party contract manufacturers, distributors and suppliers. To establish and manage our supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to fulfill compliance with applicable regulatory requirements. Although we maintain significant resources to directly and effectively oversee the activities and relationships with the companies in our supply chain, we do not have direct control over their operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party contract manufacturers may not be able to produce or deliver material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our preclinical, clinical development and commercial needs and applicable regulatory requirements. Although we have not yet experienced significant production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic or the ongoing Russo-Ukrainian War, our third-party contract manufacturers, distributors and suppliers could experience operational delays due to lack of capacity or resources, facility closures and other hardships as a result of these types of global events, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our preclinical, clinical or commercial products. If our third-party contract manufacturers, distributors and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our manufacturing, distribution and supply arrangements, we may not have adequate remedies for any breach. Furthermore, their failure to supply us could impair or preclude meeting commercial or clinical product supply requirements for us or our partners, which could delay product development and future commercialization efforts and have a material adverse impact on our business, financial condition and results of operations. In addition, through our third-party contract manufacturers and data service providers, we continue to provide serialized commercial products as required to comply with the DSCSA and its foreign equivalents where applicable. If our third-party contract manufacturers or data service providers fail to support our efforts to continue to comply with DSCSA and its foreign equivalents, as well as any future electronic pedigree requirements, we may face legal penalties or be restricted from selling our products.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party scientific advisors and contractors we rely on to assist with our drug discovery efforts do not perform as expected, the expansion of our product pipeline may be delayed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work with scientific advisors at academic and other institutions, as well as third-party contractors in various locations throughout the world, that assist us in our research and development efforts, including in drug discovery and preclinical development strategy. These third parties are not our employees and may have other commitments or contractual obligations that limit their availability to us. Although these third-party scientific advisors and contractors generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. There has also been increased scrutiny surrounding the disclosures of payments made to medical researchers from companies in the pharmaceutical industry, and it is possible that the academic and other institutions that employ these medical researchers may prevent us from engaging them as scientific advisors and contractors or otherwise limit our access to these experts, or that the scientific advisors themselves may now be more reluctant to work with industry partners. Even if these scientific advisors and contractors with whom we have engaged intend to meet their contractual obligations, their ability to perform services may be impacted by increased demand for such services from other companies or by other external factors, such as reduced capacity to perform services. If we experience additional delays in the receipt of services, lose work performed by these scientific advisors and contractors or are unable to engage them in the first place, our discovery and development efforts with respect to the matters on which they were working or would work in the future may be significantly delayed or otherwise adversely affected.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Healthcare Regulatory and Other Legal Compliance Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to healthcare laws, regulations and enforcement; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal and state healthcare laws and regulations, which laws and regulations are enforced by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the risk and impact of improper business conduct or inaccurate reporting, we could be subject to enforcement of the following, including, without limitation:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the federal AKS;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the FDCA and its implementing regulations;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">federal civil and criminal false claims laws, including the civil False Claims Act, and the Civil Monetary Penalties Law;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">HIPAA and its implementing regulations, as amended; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">state law equivalents of each of the above federal laws;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the Open Payments program of the PPACA;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">state and local laws and regulations that require drug manufacturers to file reports relating to marketing activities, payments and other remuneration and items of value provided to healthcare professionals and entities; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">state and federal pharmaceutical price and price reporting laws and regulations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be subject to the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, medical professionals employed by national healthcare programs) and its foreign equivalents, as well as federal and state consumer protection and unfair competition laws.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These federal and state healthcare laws and regulations govern drug marketing practices, including off-label promotion, and also impact our current and future business arrangements with third parties, including various healthcare entities. If our operations are found, or even alleged, to be in violation of the laws described above or other governmental regulations that apply to us, we, or our officers or employees, may be subject to significant penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, imprisonment, reputational harm, additional reporting requirements and oversight through a Corporate Integrity Agreement or other monitoring agreement, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Furthermore, responding to any such allegation or investigation </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and/or defending against any such enforcement actions can be time-consuming and would require significant financial and personnel resources. Therefore, if any state or the federal government initiates an enforcement action against us, our business may be impaired, and even if we are ultimately successful in our defense, litigating these actions could result in substantial costs and divert the attention of management.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer patient assistance programs and donations to patient assistance foundations created by charitable organizations could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help patients afford our products, we have a patient assistance program and also occasionally make donations to independent charitable foundations that help financially needy patients. These types of programs designed to assist patients with affording pharmaceuticals have become the subject of Congressional interest and enhanced government scrutiny. The HHS Office of Inspector General established guidelines permitting pharmaceutical manufacturers to make donations to charitable organizations that provide co-pay assistance to Medicare patients, provided that manufacturers meet certain specified compliance requirements. In the event we make such donations but are found not to have complied with these guidelines and other laws or regulations respecting the operation of these programs, we could be subject to significant damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. Moreover, in December 2020, the CMS finalized changes to Medicaid Drug Rebate Program pricing calculations regarding the provision of co-payment assistance to patients that may be impacted by private insurer accumulator programs. The portion of this rule dealing with manufacturer co-payment assistance (and related support programs) was challenged and vacated by a federal court in May 2022 (and CMS did not appeal). However, it is possible that CMS could issue new rulemaking or guidance that would affect the amount of rebates owed under the Medicaid program or otherwise limit our ability to support our patient co-pay assistance program. We also rely on a third-party hub provider and exercise oversight to monitor patient assistance program activities. Hub providers are generally hired by manufacturers to assist patients with insurance coverage, financial assistance and treatment support after the patients receive a prescription from their healthcare professional. For manufacturers of specialty pharmaceuticals (including our marketed products), the ability to have a single point of contact for their therapies helps ensure efficient medication distribution to patients. Accordingly, our hub activities are also subject to scrutiny and may create risk for us if not conducted appropriately. A variety of entities, including independent charitable foundations and pharmaceutical manufacturers, but not including our company, have received subpoenas from the U.S. Department of Justice (DOJ) and other enforcement authorities seeking information related to their patient assistance programs and support, and certain of these entities have entered into costly civil settlement agreements with DOJ and other enforcement authorities that include requirements to maintain complex corporate integrity agreements that impose significant reporting and other requirements. Should we or our hub providers receive a subpoena or other process, regardless of whether we are ultimately found to have complied with the regulations governing patient assistance programs, this type of government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to laws and regulations relating to privacy, data protection and the collection and processing of personal data. Failure to maintain compliance with these regulations could create additional liabilities for us.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legislative and regulatory landscape for privacy and data protection continues to evolve in the U.S. and other jurisdictions around the world. For example, the CPRA went into operation in 2020 and affords California residents expanded privacy rights and protections, including civil penalties for violations and statutory damages under a private right of action for data security breaches. These protections were expanded by the CPRA, which became effective in January 2023 and will be enforceable in most key respects beginning on July 1, 2023. Privacy laws in other states may also impact our operations, including both comprehensive and sector-specific legislation, and Congress is also considering additional federal privacy legislation. In addition, most healthcare professionals and facilities are subject to privacy and security requirements under HIPAA with respect to our clinical and commercial activities. Although we are not considered to be a covered entity or business associate under HIPAA, we could be subject to penalties if we use or disclose individually identifiable health information in a manner not authorized or permitted by HIPAA. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. For example, in the EU, the GDPR regulates the processing of personal data of individuals within the EU, even if, under certain circumstances, that processing occurs outside the EU, and also places restrictions on transfers of such data to countries outside of the EU, including the U.S. Should we fail to provide adequate privacy or data security protections or maintain compliance with these laws and regulations, including the CCPA, as amended by the CPRA, as well as the GDPR, we could be subject to sanctions or other penalties, litigation, an increase in our cost of doing business and questions concerning the validity of our data processing activities, including clinical trials.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Information Technology and Intellectual Property</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data breaches, cyber-attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and our third-party service providers, such as contract research organizations, collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our collaboration partners. We have also outsourced significant elements of our information technology infrastructure to third parties and, as a result, such third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation, and while we have enhanced and are continuing to enhance our cybersecurity efforts commensurate with the growth and complexity of our business, our systems and those of third-party service providers may be vulnerable to a cyber-attack. In addition, we are heavily dependent on the functioning of our information technology infrastructure to carry out our business processes, such as external and internal communications or access to clinical data and other key business information. Accordingly, both inadvertent disruptions to this infrastructure and cyber-attacks could cause us to incur significant remediation or litigation costs, result in product development delays, disrupt critical business operations, expend key information technology resources and divert the attention of management. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the aggregate impact of cyber-attacks on our operations and financial condition has not been material to date, we and our third-party service providers have frequently been the target of threats of this nature and expect them to continue. Any future data breach and/or unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose our sensitive business information or sensitive business information of our collaboration partners, which may lead to significant liability for us. A data security breach could also lead to public exposure of personal information of our clinical trial patients, employees or others and result in harm to our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents including the GDPR, subject us to investigations and mandatory corrective action, or otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant financial exposure. Furthermore, the costs of maintaining or upgrading our cybersecurity systems (including the recruitment and retention of experienced information technology professionals, who are in high demand) at the level necessary to keep up with our expanding operations and prevent against potential attacks are increasing, and despite our best efforts, our network security and data recovery measures and those of our third-party service providers may still not be adequate to protect against such security breaches and disruptions, which could cause material harm to our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem lawful and appropriate. However, these applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties, and we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. Third parties may also attempt to invalidate or design around our patents, or assert that they are invalid or otherwise unenforceable, and seek to introduce generic versions of cabozantinib. For example, we received Paragraph IV certification notice letters from MSN, Teva and Cipla concerning the respective ANDAs that each had filed with the FDA seeking approval to market their respective generic versions of CABOMETYX tablets. Should MSN, Teva, Cipla or any other third parties receive FDA approval of an ANDA or a 505(b)(2) NDA with respect to cabozantinib, it is possible that such </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company or companies could introduce generic versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and the resulting generic competition could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. They may also be negatively impacted by the decisions of foreign courts, which could limit the protection contemplated by the original regulatory approval and our ability to thwart the development of competing products that might otherwise have been determined to infringe our intellectual property rights. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in the EU, have compulsory licensing laws based on related EU rules, under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Initiatives seeking compulsory licensing of life-saving drugs are also becoming increasingly prevalent in developing countries either through direct legislation or international initiatives. Governments in those developing countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products or product candidates, thereby reducing our product sales. Moreover, the Russian Federation has and may further limit protections on patents originating from &#8220;unfriendly countries&#8221; (including the U.S.) in response to sanctions relating to the ongoing Russo-Ukrainian War, and in general, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We also rely on trade secret protection for some of our confidential and proprietary information, and we are taking security measures to protect our proprietary information and trade secrets, particularly in light of recent instances of data loss and misappropriation of intellectual property in the biopharmaceutical industry. However, these measures may not provide adequate protection, and while we seek to protect our proprietary information by entering into confidentiality agreements with employees, partners and consultants, as well as maintain cybersecurity protocols within our information technology infrastructure, we cannot provide assurance that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to accomplish or could require substantial time and expense. In addition, we may be subject to claims that our employees or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that they used or sought to use patent inventions belonging to their former employers. Furthermore, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents or otherwise employs their proprietary technology without authorization. Regardless of their merit, such claims could require us to incur substantial costs and divert the attention of management and key technical personnel in defending ourselves against any such claims or enforcing our own patents. In the event of any third party&#8217;s successful claim of patent infringement or misappropriation of trade secrets, we may lose valuable intellectual property rights or personnel, which could impede or prevent the achievement of our product development goals, or we may be required to pay damages and obtain one or more licenses from these third parties, subjecting us to substantial </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">royalty payment obligations. We may not be able to obtain these licenses on commercially reasonable terms, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations, Managing Our Growth and Employee Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the COVID-19 pandemic has had a modest impact on our business operations, in particular with respect to our clinical trial, drug discovery and commercial activities. We anticipate that a further prolonged, or more severe, global public health crisis could limit our ability to identify and work with clinical investigators at clinical trial sites globally to enroll, initiate and maintain treatment per protocol of patients for our ongoing clinical trials. Disruptions to medical and administrative operations at clinical trial sites, including staffing and materials shortages and the implementation of crisis management initiatives, have and may continue to reduce personnel and other resources necessary to conduct our clinical trials, which could further delay some of our clinical trial plans or may require certain trials to be temporarily suspended. We are also reliant on laboratory materials manufactured and distributed from areas that continue to be impacted by both the COVID-19 pandemic and other natural disasters, for which supply has become limited. If we are unable to obtain the requisite materials to conduct our planned drug discovery activities, we may be required to redirect the focus of, or even suspend, such activities. Should the COVID-19 pandemic be further prolonged or grow in severity, we may ultimately be unable to achieve our drug discovery and preclinical development objectives within the previously disclosed timelines, which could have a material adverse impact on our prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to manage our growth, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations, in particular as we continue to grow our pipeline of product candidates. This growth places significant demands on our management and resources, and our current and planned personnel and operating practices may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, facilities, operational and financial systems, and procedures and controls, as well as expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We continue to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. If we are unable to manage our growth effectively, or we are unsuccessful in recruiting qualified management personnel, there could be a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. Also, we may not have sufficient personnel to execute our business plans. Retaining and, where necessary, recruiting qualified clinical, commercial, scientific and pharmaceutical operations personnel will be critical to support activities related to advancing the development programs for the cabozantinib franchise and our other product candidates, successfully executing upon our commercialization plan for the cabozantinib franchise and our proprietary research and development efforts. Competition is intense for experienced clinical, commercial, scientific and pharmaceutical operations personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Environmental and Product Liability</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development processes involve the controlled use of hazardous materials, including chemicals and biological materials, and our operations can produce hazardous waste products. We cannot eliminate the risk of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accidental contamination or discharge, or any resultant injury from these materials, and we may face liability under applicable laws for any injury or contamination that results from our use or the use by our collaboration partners or other third parties of these materials. Such liability may exceed our insurance coverage and our total assets, and in addition, we may be required to indemnify our collaboration partners against all damages and other liabilities arising out of our development activities or products produced in connection with our collaborations with them. Moreover, our continued compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be held liable if any product we or our collaboration partners develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop in the future. We maintain limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib. However, our insurance may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been and may in the future be highly volatile.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been highly volatile, and it may remain highly volatile or fluctuate substantially due to factors such as the following, many of which we cannot control:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the announcement of FDA or other regulatory approval or non-approval, or delays in the FDA or other regulatory review process with respect to cabozantinib, zanzalintinib or our other product candidates, our collaboration partners&#8217; product candidates being developed in combination with either cabozantinib, zanzalintinib or our other product candidates, or our competitors&#8217; product candidates;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the commercial performance of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products, including royalties paid under our collaboration and license agreements;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">adverse or inconclusive results or announcements related to our or our collaboration partners&#8217; clinical trials or delays in those clinical trials;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the timing of achievement of our clinical, regulatory, partnering, commercial and other milestones for the cabozantinib franchise, zanzalintinib or any of our other product candidates or programs;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our ability to make future investments in the expansion of our pipeline through drug discovery, including future research collaborations, in-licensing arrangements and other strategic transactions;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our ability to obtain the materials and services, including an adequate product supply for any approved drug product, from our third-party vendors or do so at acceptable prices;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib, zanzalintinib and our other product candidates;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">actions taken by regulatory agencies, both in the U.S. and abroad, with respect to cabozantinib or our clinical trials for cabozantinib, zanzalintinib or our other product candidates; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">unanticipated regulatory actions taken by the FDA as a result of changing FDA standards and practices concerning the review of product candidates, including approvals at earlier stages of clinical development or with lesser developed data sets and expedited reviews;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the announcement of new products or clinical trial data by our competitors;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the announcement of regulatory applications, such as MSN&#8217;s, Teva&#8217;s and Cipla&#8217;s respective ANDAs, seeking approval of generic versions of our marketed products;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">quarterly variations in our or our competitors&#8217; results of operations;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">changes in our relationships with our collaboration partners, including the termination or modification of our agreements, or other events or conflicts that may affect our collaboration partners&#8217; timing and willingness to develop, or if approved, commercialize our products and product candidates out-licensed to them;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the announcement of an in-licensed product candidate or strategic acquisition;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">litigation, including intellectual property infringement and product liability lawsuits, involving us;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">changes in earnings estimates or recommendations by securities analysts, or financial guidance from our management team, and any failure to achieve the operating results projected by securities analysts or by our management team;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the entry into new financing arrangements;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">developments in the biopharmaceutical industry;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">additions and departures of key personnel or board members;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the disposition of any of our technologies or compounds; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">general market, macroeconomic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other factors could have material adverse impact on the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. Likewise, as a result of significant changes in U.S. or global political and macroeconomic conditions, including historically high inflation, as well as policies governing foreign trade and healthcare spending and delivery, or the ongoing Russo-Ukrainian War, the financial markets could continue to experience significant volatility that could also continue to negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been initiated. A securities class action suit against us could result in substantial costs and divert the attention of management, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">a prohibition on actions by our stockholders by written consent;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">advance notice requirements for director nominations and stockholder proposals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div id="ia855702135904005a41d208deb24e60a_19"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.<br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="ia855702135904005a41d208deb24e60a_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties<br/><br/>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters is located in Alameda, California, where we lease approximately 610,000 square feet of office and laboratory space under multiple leases. Approximately 100,000 square feet of leased laboratory space in Alameda is under construction and anticipated to be available for operations in 2025. Also in 2022, we established a presence for Exelixis East in the Greater Philadelphia area and signed intermediate-term office and laboratory space. We believe these leased facilities are sufficient to accommodate our current and near-term needs.</span></div><div id="ia855702135904005a41d208deb24e60a_25"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MSN I ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an ANDA submitted to the FDA by MSN, requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the May 5, 2020 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. The two lawsuits comprising the MSN I litigation, numbered Civil Action Nos. 19-02017 and 20-00633, were consolidated in April 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our MSN I complaints, we sought, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties narrowed their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the trial addressed two issues: (1) infringement of claim 1 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A bench trial for MSN I occurred in May 2022, and on January 19, 2023, the Delaware District Court issued a ruling rejecting MSN&#8217;s invalidity challenge to U.S. Patent No. 7,759,473. The Delaware District Court also ruled that MSN&#8217;s proposed ANDA product does not infringe U.S. Patent No. 8,877,776 and entered judgment that the effective date of any final FDA approval of MSN&#8217;s ANDA shall not be a date earlier than August 14, 2026, the expiration date of U.S. Patent No. 7,759,473. This ruling in MSN I does not impact our separate and ongoing MSN II lawsuit. At this time, we are evaluating the next course of action, but we intend to vigorously defend our intellectual property rights, including through potential appeal.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MSN II ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. In particular, the January 11, 2022 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment). On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 are invalid and not infringed. On June 7, 2022, we received notice from MSN that it had further amended its ANDA to assert an additional Paragraph IV certification. As currently amended, MSN&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. 11,298,349 (pharmaceutical composition). On July 18, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 11,298,349 arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. On August 9, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 11,298,349 are invalid and not infringed and amended its challenges to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 to allege that these patents are not enforceable based on equitable grounds. The two lawsuits comprising the MSN II litigation, numbered Civil Action Nos. 22-00228 and 22-00945, were consolidated in October 2022 and involve Exelixis patents that are different from those asserted in the MSN I litigation described above.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 would also infringe certain claims of each patent, if those claims are not found to be invalid. In our MSN II complaints, we are seeking, among other remedies, equitable relief enjoining MSN from infringing the asserted patents, as well as an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patents No. 11,091,439, 11,091,440, 11,098,015 and 11,298,349, the latest of which expires on February 10, 2032. A bench trial for MSN II has been scheduled for October 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Teva ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. On July 29, 2022, we received notice from Teva that it had amended its ANDA to assert an additional Paragraph IV certification. As amended, Teva&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. 11,298,349 (pharmaceutical composition). On September 2, 2022, we filed a complaint in the Delaware District Court for patent infringement against Teva, asserting infringement of U.S. Patent No. 11,298,349 arising from Teva&#8217;s amended ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873, 10,039,757 and 11,298,349, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva from infringing these patents. On September 30, 2022, the parties filed a stipulation to consolidate the two lawsuits, numbered Civil Action Nos. 21-00871 and 22-01168, and to stay all proceedings, which was granted by the Delaware District Court on October 3, 2022. Following a similar order granted by the Delaware District Court on February 9, 2022 to stay all proceedings with respect to Civil Action No. 21-00871, this case remained administratively closed, and Civil Action No. 22-01168 was administratively closed on October 3, 2022.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 6, 2023, we received a notice letter regarding an ANDA submitted to the FDA by Cipla, including a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,039,757 (methods of treatment), 11,098,015 (methods of treatment), 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,298,349 (pharmaceutical composition).</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cipla&#8217;s ANDA requests approval to market a generic version of CABOMETYX tablets prior to the expiration of the aforementioned patents. We have not yet responded to this Paragraph IV certification notice letter but are evaluating it and will vigorously defend our cabozantinib intellectual property estate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><div id="ia855702135904005a41d208deb24e60a_28"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ia855702135904005a41d208deb24e60a_31"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ia855702135904005a41d208deb24e60a_34"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has traded on the Nasdaq Global Select Market under the symbol &#8220;EXEL&#8221; since April 11, 2000.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;30, 2023, there were 339 holders of record of our common stock. The number of record holders is based upon the actual number of holders registered on our books at such date and does not include holders of shares in &#8220;street names&#8221; or persons, partnerships, associations, corporations or other entities identified in security position listings maintained by depository trust companies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have not paid dividends on our common stock. We currently intend to retain all future earnings, if any, for use in our business and currently do not plan to pay any cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our Board of Directors.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no unregistered sales of equity securities by us during the year ended December&#160;31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Repurchases of Equity Securities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no repurchases&#160;of our common stock during the year ended December&#160;31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This performance graph shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of ours under the Securities Act of 1933, as amended.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares, for the five-year period ended December&#160;31, 2022, the cumulative total return for our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index. The graph assumes that $100 was invested on December&#160;31, 2017 in each of our common stock, the Nasdaq Composite Total Return Index and the Nasdaq Biotechnology Total Return Index and assumes reinvestment of any dividends. The stock price performance on the following graph is not necessarily indicative of future stock price performance.</span></div><div style="margin-top:9pt;text-indent:18pt"><img src="exel-20221230_g2.jpg" alt="exel-20221230_g2.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Composite Total Return</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Biotechnology Total Return</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132</span></td></tr></table></div><div id="ia855702135904005a41d208deb24e60a_37"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Reserved</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="ia855702135904005a41d208deb24e60a_40"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of the statements under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; are forward-looking statements. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Item&#160;1A. Risk&#160;Factors&#8221; as well as those discussed elsewhere in this Annual Report on Form 10-K. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an oncology company innovating next-generation medicines and combination regimens at the forefront of cancer care. Through the commitment of our drug discovery, development and commercialization resources, we have produced four marketed pharmaceutical products, including our flagship molecule, cabozantinib. We continue to evolve our product portfolio, leveraging our investments, expertise and strategic partnerships, to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, ADCs and other biotherapeutics. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales related to cabozantinib account for the majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the FDA and in 62 other countries as: CABOMETYX tablets, both alone and in combination with BMS&#8217; OPDIVO for advanced RCC, for previously treated HCC and, currently by the FDA and EC, for previously treated, RAI-refractory DTC and COMETRIQ capsules approved for progressive, metastatic MTC. For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC, an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech; and MINNEBRO, an oral, non-steroidal, selective blocker of MR, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue leveraging our operating cash flows to support the ongoing investigation of cabozantinib in phase 3 trials for new indications and the advancement of a broad array of diverse biotherapeutics and small molecule programs for the treatment of cancer exploring multiple modalities and mechanisms of action. Of the clinical-state assets that have emerged from our drug discovery and preclinical activities thus far, the furthest along are zanzalintinib, a next-generation oral TKI, and XB002, an ADC that targets TF. We are also focused on conserving cash and managing risks of clinical failure by securing options to acquire other investigational drug candidates from third parties if those assets demonstrate evidence of clinical success. One example of this approach is CBX-12, a clinical-stage PDC invented by Cybrexa that utilizes Cybrexa&#8217;s proprietary alphalex technology to enhance the delivery of exatecan, a highly potent, second-generation topoisomerase I inhibitor, to tumor cells.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib Franchise</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA first approved CABOMETYX as a monotherapy for previously treated patients with advanced RCC in April 2016, and then for previously untreated patients with advanced RCC in December 2017. In January 2021, the CABOMETYX label was expanded to include first-line advanced RCC in combination with OPDIVO, which was the first CABOMETYX regimen approved for treatment in combination with an ICI. In addition to RCC, in January 2019, the FDA approved CABOMETYX for the treatment of patients with HCC previously treated with sorafenib, and then in September 2021, the FDA approved CABOMETYX for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic DTC that has progressed following prior VEGF receptor-targeted therapy and who are RAI-refractory or ineligible.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To develop and commercialize CABOMETYX and COMETRIQ outside the U.S., we have entered into license agreements with Ipsen and Takeda. We granted to Ipsen the rights to develop and commercialize cabozantinib outside of the U.S. and Japan, and to Takeda we granted the rights to develop and commercialize cabozantinib in Japan. Both Ipsen and Takeda also contribute financially and operationally to the further global development and commercialization of the cabozantinib franchise in other potential indications, and we work closely with them on these activities. Utilizing its </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory expertise and established international oncology marketing network, Ipsen has continued to execute on its commercialization plans for CABOMETYX, having received regulatory approvals and launched in multiple territories outside of the U.S., including in the EU, the United Kingdom and Canada, as a treatment for advanced RCC and for HCC in adults who have previously been treated with sorafenib. In addition, in March 2021, Ipsen and BMS received regulatory approval from the EC for CABOMETYX in combination with OPDIVO as a first-line treatment for patients with advanced RCC, followed by additional regulatory approvals for the combination in other territories beyond the EU. Most recently, in May 2022, we announced that Ipsen received regulatory approval from the EC for CABOMETYX as a monotherapy for the treatment of adult patients with locally advanced or metastatic, RAI-refractory or ineligible DTC and who have progressed during or after prior systemic therapy, which followed an approval from Health Canada in April 2022 for a similar DTC indication. With respect to the Japanese market, Takeda received Manufacturing and Marketing Approvals in 2020 from the Japanese MHLW of CABOMETYX as a treatment of patients with curatively unresectable or metastatic RCC and as a treatment of patients with unresectable HCC who progressed after cancer chemotherapy. In August 2021, Takeda and Ono Pharmaceutical Co., Ltd., BMS&#8217; development and commercialization partner in Japan, received Manufacturing and Marketing Approval from the MHLW of CABOMETYX in combination with OPDIVO as a treatment for unresectable or metastatic RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our regulatory and commercialization efforts in the U.S. and the support provided to our collaboration partners for rest-of-world regulatory and commercialization activities, we are also pursuing other indications for cabozantinib that have the potential to increase the number of cancer patients who could potentially benefit from this medicine. We are continuing to evaluate cabozantinib in combination with ICIs in late-stage clinical trials that we sponsor, along with our collaboration partners, across RCC and mCRPC. Beyond clinical trials that we or our collaboration partners sponsor, independent investigators also conduct trials evaluating cabozantinib through our CRADA with NCI-CTEP or our IST program. Over time, the data we have obtained from these investigator-sponsored clinical trials have helped advance our development program for the cabozantinib franchise by informing subsequent label-enabling trials, including COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib in previously treated patients with RAI-refractory DTC, from which positive results served as the basis for the FDA&#8217;s and EC&#8217;s approvals of CABOMETYX for DTC. Moreover, these data sets may also prove valuable by informing our development plans for zanzalintinib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building on preclinical and clinical observations that cabozantinib in combination with ICIs may promote a more immune-permissive tumor environment, we initiated numerous pivotal studies to further explore these combination regimens. The first of these studies to deliver results was CheckMate-9ER, a phase 3 pivotal trial evaluating the combination of CABOMETYX and OPDIVO compared to sunitinib in previously untreated, advanced or metastatic RCC, and positive results from CheckMate-9ER served as the basis for the FDA&#8217;s, EC&#8217;s and MHLW&#8217;s approvals of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC in January 2021, March 2021 and August 2021, respectively. We are also collaborating with BMS on COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. We announced top-line results from COSMIC-313 in July 2022, and in September 2022 we presented the data at the Presidential Symposium III at the 2022 ESMO Congress. The trial met its primary endpoint, demonstrating significant improvement in BIRC-assessed PFS at the primary analysis for the triplet combination. At a prespecified interim analysis for the secondary endpoint of OS, the triplet combination did not demonstrate a significant benefit, and therefore, the trial will continue to the next analysis of OS, expected in 2023. The safety profile observed in the trial was reflective of the known safety profiles for each single agent, as well as the combination regimens used in this study. Based on feedback from the FDA, we do not intend to submit an sNDA for the combination regimen based on the currently available data, and we plan to discuss a potential regulatory submission with the FDA when the results of the next OS analysis are available.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To diversify our exploration of combinations with ICIs, we also initiated multiple trials evaluating cabozantinib in combination with Roche&#8217;s ICI, atezolizumab, beginning in 2017 with COSMIC-021, a broad phase 1b study evaluating the safety and tolerability of the cabozantinib and atezolizumab combination with atezolizumab in patients with a wide variety of locally advanced or metastatic solid tumors. The encouraging efficacy and safety data that emerged from COSMIC-021 have been instrumental in guiding our clinical development strategy for cabozantinib in combination with ICIs. We are currently evaluating the cabozantinib and atezolizumab combination in two late-stage trials: CONTACT-03, in which focuses on patients with inoperable, locally advanced or metastatic RCC who have progressed following treatment with an ICI as the immediate proceeding therapy; and CONTACT-02, which focuses on patients with mCRPC who have been previously treated with one NHT. A third trial, CONTACT-01, which focused on patients with metastatic NSCLC who have been previously treated with an ICI and platinum-containing chemotherapy, did not meet its primary endpoint of OS at final analysis. CONTACT-03 is sponsored by Roche and co-funded by us, and we anticipate announcing results of the primary PFS analysis </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from CONTACT-03 in the first half of 2023. CONTACT-02 is sponsored by us and co-funded by Roche, and we anticipate completing enrollment and announcing results of the primary PFS analysis in the second half of 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our cabozantinib clinical trials, see &#8220;Business&#8212;Exelixis Development Programs&#8212;Cabozantinib Development Program&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zanzalintinib</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first compound to enter the clinic following our re-initiation of drug discovery activities in 2017 was zanzalintinib, a next-generation oral TKI that targets VEGF receptors, MET, AXL, MER and other kinases implicated in cancer&#8217;s growth and spread. In designing zanzalintinib, we sought to build upon our experience with cabozantinib, retaining a similar target profile while improving key characteristics, including the pharmacokinetic half-life. To date, we have initiated two large phase 1b clinical trials studying zanzalintinib: STELLAR-001 and STELLAR-002. STELLAR-001 is a phase 1b clinical trial evaluating zanzalintinib, both as a monotherapy and in combination with either atezolizumab or Merck KGaA&#8217;s and Pfizer&#8217;s avelumab. We have established a recommended dose of 100 mg for both single-agent zanzalintinib and zanzalintinib in combination with atezolizumab, and we have begun enrolling expansion cohorts for patients with clear cell RCC, non-clear cell RCC, hormone-receptor positive breast cancer, mCRPC and CRC. The dose-escalation stage for zanzalintinib in combination with avelumab is ongoing, with expansion cohorts planned initially in UC. We presented data from STELLAR-001 during poster sessions at the 2022 ESMO Congress in September 2022, which showed zanzalintinib has demonstrated preliminary, clinical activity similar to that observed with cabozantinib in phase 1 across a range of solid tumors and dose levels, with a manageable safety profile. STELLAR-002 is a phase 1b clinical trial evaluating zanzalintinib in combination with either nivolumab, nivolumab and ipilimumab, or a fixed dose of nivolumab and BMS&#8217; relatlimab. We have established a recommended dose of 100 mg for zanzalintinib in combination with nivolumab, and we have begun enrolling patients in expansion cohorts for patients with clear cell RCC. The dose-escalation stage for zanzalintinib in the other combination regimens is ongoing and is continuing to enroll patients with advanced solid tumors in dose-escalation cohorts. Depending on the dose-escalation results, STELLAR-002 may enroll expansion cohorts for patients with clear cell and non-clear cell RCC, mCRPC, UC, HCC, NSCLC, CRC and SCCHN. To better understand the individual contribution of the therapies, treatment arms in the expansion cohorts may include zanzalintinib as a single agent in addition to the ICI combination regimens. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also initiated two phase 3 pivotal trials evaluating zanzalintinib in combination with ICIs in 2022. The first trial, STELLAR-303, was initiated in June 2022 and is evaluating zanzalintinib in combination with atezolizumab versus regorafenib in patients with metastatic non-microsatellite instability-high or non-mismatch repair-deficient CRC who have progressed after, or are intolerant to, the current standard of care. The trial aims to enroll approximately 600 patients worldwide with documented RAS status at approximately 137 sites globally. The primary objective of STELLAR-303 is to evaluate the efficacy of the combination in patients with RAS wild-type disease, and outcomes in patients with RAS-mutated disease will also be evaluated. The primary efficacy endpoint of STELLAR-303 is OS, and additional efficacy endpoints include PFS, ORR and DOR per RECIST v. 1.1, in each case as assessed by the investigator. The second trial, STELLAR-304, was initiated in December 2022 and is evaluating zanzalintinib in combination with nivolumab versus sunitinib in previously untreated patients with advanced non-clear cell RCC. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he trial aims to enroll approximately 291 patients at approximately 170 sites globally. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary efficacy endpoints of STELLAR-304 are PFS and ORR per RECIST v 1.1, in each case as assessed by </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BIRC</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The secondary efficacy endpoint is OS. Beyond STELLAR-303 and STELLAR-304, we intend to explore a series of early-stage and pivotal trials evaluating zanzalintinib in novel combination regimens across a broad array of future potential indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our zanzalintinib clinical trials, see &#8220;Business&#8212;Exelixis Development Programs&#8212;Pipeline Development Programs &#8211; Advancing Exelixis&#8217; Future Cancer Therapy Candidates&#8212;Zanzalintinib Development Program&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biotherapeutics</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Much of our drug discovery activities focuses on discovering and advancing various biotherapeutics that have the potential to become anti-cancer therapies, such as bispecific antibodies, ADCs and other innovative treatments. ADCs in particular present a unique opportunity for new cancer treatments, given their capabilities to deliver anti-cancer payload drugs to targets with increased precision while minimizing impact on healthy tissues. This biotherapeutic approach has been validated by multiple regulatory approvals for the commercial sale of ADCs in the past several years. Furthest along amongst our biotherapeutics programs is XB002, our lead TF-targeting ADC program, in-licensed from Iconic. We are evaluating XB002, both as a single agent and in combination with either nivolumab or Roche&#8217;s bevacizumab, in JEWEL-101, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a phase 1 study in patients with advanced solid tumors for which therapies are unavailable, ineffective or intolerable. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we announced promising initial dose-escalation results from JEWEL-101 during the Antibody-drug Conjugates Poster Session at the 2022 ENA Symposium. The data demonstrated that XB002 was well-tolerated at multiple dose levels, and a pharmacokinetic analysis confirmed that XB002 was stable with low levels of free payload. The planned cohort-expansion phase, which we expect to initiate during 2023, is designed to further explore the selected dose of XB002, both as a single agent and in combination with either nivolumab or bevacizumab, in individual tumor cohorts, which may include forms of NSCLC, cervical cancer, ovarian cancer, UC, SCCHN, pancreatic cancer, esophageal cancer, mCRPC, triple negative breast cancer and hormone-receptor positive breast cancer, and we also intend to initiate additional dose-escalation and expansion cohorts to evaluate the potential of XB002 in combination with additional ICIs and other targeted therapies across a wide range of tumor types, including indications other than those currently addressed by commercially available TF-targeted therapies. For additional information on JEWEL-101 and our development plans for XB002, see &#8220;Business&#8212;Exelixis Development Programs&#8212;Pipeline Development Programs &#8211; Advancing Exelixis&#8217; Future Cancer Therapy Candidates&#8212;XB002 Development Program&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most recently, in November 2022, we executed two option deals that highlight our strategic efforts to access clinical- or near-clinical-stage assets: an exclusive collaboration agreement with Cybrexa providing us with the right to acquire CBX-12; and an exclusive clinical development and option agreement with Sairopa to develop ADU-1805, a potentially best-in-class mAb that targets SIRP&#945;. For more information on these arrangements, see &#8220;Business&#8212;Collaborations and Business Development Activities&#8212;Research Collaborations and In-licensing Arrangements&#8221; in Part I, Item 1 of this Annual Report on Form 10-K. CBX-12 is currently being evaluated in a phase 1 clinical trial to explore its </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmacokinetics, safety, tolerability and preliminary anti-tumor activity in patients with advanced or metastatic refractory solid tumors. For more information on the current development of CBX-12, see &#8220;Business&#8212;Exelixis Development Programs&#8212;Pipeline Development Programs &#8211; Advancing Exelixis&#8217; Future Cancer Therapy Candidates&#8212;Development of CBX-12&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To facilitate the growth of our various biotherapeutics programs, we have established multiple research collaborations and in-licensing arrangements and entered into other strategic transactions that provide us with access to antibodies, binders, payloads and conjugation technologies, which are the components employed to generate next-generation ADCs or multispecific antibodies. In addition to the option deals with Cybrexa and Sairopa, some of our active research collaborations for biotherapeutics programs include collaborations with: </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Adagene, which is focused on using Adagene&#8217;s SAFEbody technology to develop novel masked ADCs or other innovative biotherapeutics with potential for improved therapeutic index;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">BioInvent, which is intended to expand our portfolio of antibody-based therapies and will utilize BioInvent&#8217;s proprietary n-CoDeR antibody library and patient-centric F.I.R.S.T screening platform, which together are designed to allow for parallel target and antibody discovery;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Catalent, which is focused on the discovery and development of multiple ADCs using Catalent&#8217;s proprietary SMARTag site-specific bioconjugation technology;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Invenra, which is focused on the discovery and development of novel binders and multispecific antibodies for the treatment of cancer; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">NBE, which is focused on the discovery and development of multiple ADCs by leveraging NBE&#8217;s unique expertise and proprietary platforms in ADC discovery, including NBE&#8217;s SMAC-Technology and novel payloads.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have already made significant progress under these and other research collaborations and in-licensing arrangements and believe we will continue to do so in 2023 and in future years. For example, as a direct result of these arrangements, we are advancing three biotherapeutics development candidates: XB010, XB014 and ZB628. XB010, our first ADC advanced internally, targets the tumor antigen 5T4 and incorporates antibodies sourced from Invenra and was constructed using Catalent&#8217;s SMARTag site-specific bioconjugation platform. XB014 and XB628 are bispecific antibodies: XB014 combines a PD-L1 targeting arm with a CD47 targeting arm to block a macrophage checkpoint; and XB628 targets PD-L1 and NKG2A, identified as an emerging immune checkpoint that may mediate resistance to classical checkpoint inhibition. Both XB014 and XB628 were developed through our collaboration with Invenra.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on these specific research collaborations and in-licensing arrangements related to our biotherapeutics programs, see &#8220;Business&#8212;Collaborations and Business Development Activities&#8212;Research Collaborations and In-licensing Arrangements&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Small Molecules</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its formation in 2000, our drug discovery group has advanced 25 compounds to the IND stage, either independently or with collaboration partners, and today we deploy our drug discovery expertise to advance small molecule drug candidates toward and through preclinical development. These efforts are led by our experienced scientists, including some of the same scientists who led the efforts to discover cabozantinib, cobimetinib and esaxerenone, each of which are now commercially distributed drug products. For example, zanzalintinib, which was discovered at Exelixis, has now entered into phase 3 clinical trials. We augment our small molecule discovery activities through research collaborations and in-licensing arrangements with other companies engaged in small molecule discovery, including: </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">STORM, which is focused on the discovery and development of inhibitors of novel RNA modifying enzymes, including ADAR1;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Aurigene, which is focused on the discovery and development of novel small molecules as therapies for cancer; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">StemSynergy, which is focused on the discovery and development of novel oncology compounds aimed to inhibit tumor growth by targeting CK1&#945; and the Notch pathway.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on these research collaborations and in-licensing arrangements related to our small molecule programs, see &#8220;Business&#8212;Collaborations and Business Development Activities&#8212;Research Collaborations and In-licensing Arrangements&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most advanced compounds to emerge from these arrangements is XL102, our lead program targeting CDK7, in-licensed from Aurigene.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are evaluating XL102, both as a single agent and in combination with other anti-cancer therapies, in QUARTZ-101, a phase 1 study in patients with inoperable, locally advanced or metastatic solid tumors. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we announced initial dose-escalation results from QUARTZ-101 during the Poster Session at the 2022 San Antonio Breast Cancer Symposium. The data demonstrated that XL102 was well-tolerated at multiple dose levels and a pharmacokinetic analysis supported adding investigation of twice-daily oral dosing. We are continuing to evaluate the efficacy of XL102 in additional patients during this initial dose-escalation phase. The subsequent cohort-expansion phase is designed to further explore the selected dose of XL102 as a single agent and in combination regimens in individual tumor cohorts, including ovarian cancer, triple-negative breast cancer, hormone-receptor positive breast cancer and mCRPC. For additional information on QUARTZ-101 and our development plans for XL102, see &#8220;Business&#8212;Exelixis Development Programs&#8212;Pipeline Development Programs &#8211; Advancing Exelixis&#8217; Future Cancer Therapy Candidates&#8212;XL102 Development Program&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report on Form 10-K, we are currently advancing more than 10 discovery programs and expect to progress up to five new development candidates into preclinical development during 2023. In addition, we will continue to engage in business development initiatives with the goal of acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Business Updates and Financial Highlights</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we continued to execute on our business objectives, generating significant revenues from operations and enabling us to continue to seek to maximize the clinical and commercial potential of our products and expand our product pipeline. Significant business updates and financial highlights for 2022 and subsequent to year-end include:</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Updates</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In January 2022, we appointed Vicki L. Goodman, M.D., as Executive Vice President, Product Development &amp; Medical Affairs, and Chief Medical Officer. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In January 2022, we announced the completion of enrollment for CONTACT-03. Based on current event rates, we anticipate announcing results of the primary PFS analysis in the first half of 2023.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In January 2022, we announced an amendment to our exclusive option and license agreement with Iconic to acquire broad rights to use the anti-TF antibody incorporated into XB002 for any application, including conjugated to other payloads, as well as rights within oncology to a number of other anti-TF antibodies developed by Iconic, including for use in ADCs and multispecific biotherapeutics.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In January 2022, cabozantinib in combination with ICIs in patients with forms of previously treated CRC was the subject of multiple data presentations at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In February 2022, cabozantinib in patients with forms of RCC and other genitourinary cancers was the subject of multiple data presentations at the 2022 ASCO Genitourinary Cancers Symposium.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In February 2022, we filed a patent lawsuit in the Delaware District Court against MSN asserting infringement of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 arising from MSN&#8217;s further amendment of its ANDA. This lawsuit, along with a subsequent lawsuit we filed against MSN in July 2022 asserting infringement of U.S. Patent No. 11,298,349, comprise MSN II, a new case against MSN involving Exelixis patents that are different from those asserted previously in the consolidated MSN I patent lawsuits that we filed in 2019 and 2020 and were adjudicated at a bench trial in May 2022. A bench trial for MSN II has been scheduled for October 2023. For a more detailed discussion of the MSN II litigation matter, see &#8220;Legal Proceedings&#8221; in Part I, Item 3 of this Annual Report on Form 10-K.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In March 2022, we announced results from the final OS analysis of COSMIC-312 trial, which showed neither improvement nor detriment in OS for cabozantinib in combination with atezolizumab versus sorafenib in patients with previously untreated advanced HCC. Based on this outcome for OS and the rapidly evolving treatment landscape for previously untreated HCC, we do not intend to submit an sNDA to the FDA for the combination regimen. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In April 2022, we announced the initiation of a phase 1 clinical trial evaluating XL114 as a monotherapy in patients with NHL. Based on initial findings in this phase 1 trial and the evolving treatment landscape for NHL, we have discontinued development of XL114 as of January 2023.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In May 2022, we announced that Ipsen received regulatory approvals from the EC and Health Canada for CABOMETYX as a monotherapy for patients with previously treated, RAI-refractory DTC.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In June 2022, cabozantinib in patients with forms of NSCLC, UC, RCC, SCCHN and DTC was the subject of multiple data presentations at the 2022 ASCO Annual Meeting.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In June 2022, we announced an exclusive option and license agreement with BioInvent to identify and develop novel antibodies for use in immuno-oncology therapeutics utilizing BioInvent&#8217;s n-CoDeR antibody library and patient-centric F.I.R.S.T screening platform. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In June 2022, we announced the initiation of STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab in patients with metastatic non-microsatellite instability-high or non-mismatch repair-deficient CRC who have progressed after or are intolerant to the current standard of care. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In July 2022, we announced an exclusive license agreement with Ryvu to develop novel targeted therapies utilizing Ryvu&#8217;s STING technology. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In July 2022, we announced results from the phase 3 COSMIC-313 trial, in which the triplet combination of cabozantinib, nivolumab and ipilimumab met its primary endpoint, demonstrating significant improvement in PFS versus the doublet combination of nivolumab and ipilimumab at the primary analysis. At a prespecified interim analysis for the secondary endpoint of OS, the triplet combination did not demonstrate a significant benefit, and therefore the trial will continue to the next analysis of OS, expected in 2023.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In September 2022, we filed a patent lawsuit in the Delaware District Court against Teva, asserting infringement of U.S. Patent No. 11,298,349 arising from Teva&#8217;s amendment of its ANDA, originally filed with the FDA in May 2021. This lawsuit, our second case against Teva, has been consolidated with the prior patent lawsuit we filed in June 2021 and involves an Exelixis patent that is different from those asserted previously in June 2021. All proceedings were stayed pursuant to an order of the Delaware District Court in October 2022. For a more detailed discussion of the Teva litigation matter, see &#8220;Legal Proceedings&#8221; in Part I, Item 3 of this Annual Report on Form 10-K.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In September 2022, clinical data from COSMIC-313 were presented as part of Presidential Symposium III at the 2022 ESMO Congress. In addition, cabozantinib in patients with in RCC, DTC and advanced adrenocortical carcinoma was the subject of multiple data presentations, and we also presented phase 1b data from STELLAR-001, in which zanzalintinib demonstrated preliminary clinical activity similar to that observed with cabozantinib in phase 1 across a range of solid tumors with an acceptable safety profile.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In October 2022, we announced an expansion of our clinical trial collaboration and supply agreement with BMS to include the use of the fixed-dose combination of nivolumab and relatlimab in STELLAR-002, our ongoing phase 1b clinical trial evaluating zanzalintinib in combination with multiple ICIs in advanced solid tumors. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In October 2022, we announced promising initial dose-escalation results from JEWEL-101, the ongoing phase 1 trial evaluating XB002 in patients with advanced solid tumors, during the Antibody-drug Conjugates Poster </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Session at the 2022 ENA Symposium. The data demonstrated that XB002 was well-tolerated at multiple dose levels, and a pharmacokinetic analysis confirmed that XB002 was stable with low levels of free payload.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In November 2022, we announced an agreement with Cybrexa that provides us the right to acquire CBX-12, a clinical-stage PDC that utilizes Cybrexa&#8217;s proprietary alphalex technology to enhance delivery of exatecan to tumor cells.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In November 2022, we announced an exclusive option and license agreement and clinical development collaboration with Sairopa to develop ADU-1805, a mAb that targets SIRP&#945;.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In November 2022, we announced a new license agreement with Catalent for three target programs with lead antibody and/or ADC candidates.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In December 2022, we announced initial dose-escalation results from QUARTZ-101, our phase 1 trial evaluating XL102 in patients with advanced solid tumors, during the Poster Session at the 2022 San Antonio Breast Cancer Symposium. The data demonstrated that XL102 was well tolerated at multiple dose levels.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In December 2022, we announced results from the phase 3 CONTACT-01 trial evaluating cabozantinib in combination with atezolizumab in patients with previously treated NSCLC, in which the combination did not meet its primary endpoint of OS at final analysis.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In December 2022, we announced the initiation of STELLAR-304, a global phase 3 pivotal trial evaluating zanzalintinib in combination with nivolumab in previously untreated patients with advanced non-clear cell RCC. The primary endpoints are PFS and ORR per RECIST v. 1.1, and the secondary endpoint is OS.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In December 2022, we appointed Dana T. Aftab, Ph.D., as Executive Vice President, Discovery and Translational Research, and Chief Scientific Officer.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In January 2023, the Delaware District Court issued a ruling in the MSN I trial, rejecting MSN&#8217;s challenge to U.S. Patent No. 7,759,473, which expires August 14, 2026. The Delaware District Court also ruled that MSN&#8217;s proposed ANDA product does not infringe U.S. Patent No. 8,877,776, which expires October 8, 2030, and entered judgment that the effective date of any final FDA approval of MSN&#8217;s ANDA shall not be a date earlier than August 14, 2026, the expiration date of U.S. Patent No. 7,759,473. This ruling in MSN I does not address the parties&#8217; claims in the MSN II lawsuit. For a more detailed discussion of the MSN I litigation matter, see &#8220;Legal Proceedings&#8221; in Part I, Item 3 of this Annual Report on Form 10-K. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In February 2023, we received a notice letter regarding an ANDA submitted to the FDA by Cipla, including a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,039,757 (methods of treatment), 11,098,015 (methods of treatment), 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,298,349 (pharmaceutical composition).</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cipla&#8217;s ANDA requests approval to market a generic version of CABOMETYX tablets prior to the expiration of the aforementioned patents. We have not yet responded to this Paragraph IV certification notice letter but are evaluating it and will vigorously defend our cabozantinib intellectual property estate.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In February 2023, cabozantinib in patients with forms of RCC will be the subject of multiple data presentations at the 2023 ASCO Genitourinary Cancers Symposium.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Net product revenues for 2022 were $1,401.2 million, as compared to $1,077.3 million for 2021.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Total revenues for 2022 were $1,611.1 million, as compared to $1,435.0 million for 2021.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Research and development expenses for 2022 were $891.8 million, as compared to $693.7 million for 2021.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Selling, general and administrative expenses for 2022 were $459.9 million, as compared to $401.7 million for 2021.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Provision for income taxes for 2022 was $52.1 million, as compared to $63.1 million for 2021.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Net income for 2022 was $182.3 million, or $0.57 per share, basic, and $0.56 per share, diluted, as compared to $231.1 million, or $0.73 per share, basic, and $0.72 per share, diluted, for 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Results of Operations&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the detailed components and analysis of the amounts above.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outlook, Challenges and Risks</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to face numerous challenges and risks that may impact our ability to execute on our business objectives. In particular, for the foreseeable future, we expect our ability to generate sufficient cash flow to fund our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. However, we cannot be certain that the clinical trials we and our collaboration partners are conducting will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if the required regulatory approvals to market CABOMETYX for additional indications are achieved, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. In addition, CABOMETYX will only continue to be commercially successful if private third-party and government payers continue to provide coverage and reimbursement. As is the case for all innovative pharmaceutical therapies, obtaining and maintaining coverage and reimbursement for CABOMETYX is becoming increasingly difficult, both within the U.S. and in foreign markets. In addition, healthcare policymakers in the U.S. are increasingly expressing concern over healthcare costs, and corresponding legislative and policy initiatives and activities have been launched aimed at increasing the healthcare cost burdens borne by pharmaceutical manufacturers, as well as expanding access to, and restricting the prices and growth in prices of, pharmaceuticals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Achievement of our business objectives will also depend on our ability to maintain a competitive position in the shifting landscape of therapeutic strategies for the treatment of cancer, which we may not be able to do. On an ongoing basis, we assess the constantly evolving landscape of other approved and investigational cancer therapies that could be competitive, or complementary in combination, with our products, and then we adapt our development strategies for the cabozantinib franchise and our pipeline product candidates accordingly, such as by modifying our clinical trials to include evaluation of our therapies with ICIs and other targeted agents. Even if our current and future clinical trials, including those evaluating cabozantinib in combination with an ICI in mCRPC or evaluating zanzalintinib in combination with an ICI in CRC and RCC, produce positive results sufficient to obtain marketing approval by the FDA and other global regulatory authorities, it is uncertain whether physicians will choose to prescribe regimens containing our products instead of competing products and product combinations in approved indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, we may eventually face competition from potential manufacturers of generic versions of our marketed products, including the proposed generic versions of CABOMETYX tablets that are the subject of ANDAs submitted to the FDA by MSN, Teva and Cipla. The approval of any of these ANDAs and subsequent launch of any generic version of CABOMETYX could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, our research and development objectives may be impeded by the challenges of scaling our organization to meet the demands of expanded drug development, unanticipated delays in clinical testing and the inherent risks and uncertainties associated with drug discovery operations, especially on the global level. In connection with efforts to expand our product pipeline, we may be unsuccessful in discovering new drug candidates or identifying appropriate candidates for in-licensing or acquisition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these challenges and risks are specific to our business, others are common to companies in the biopharmaceutical industry with development and commercial operations, and an additional category are macroeconomic, affecting all companies. For a more detailed discussion of challenges and risks we face, see &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div id="ia855702135904005a41d208deb24e60a_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2022, which was a 52-week fiscal year, ended December&#160;30, 2022, fiscal year 2021, which was a 52-week fiscal year, ended December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended January&#160;1, 2021. For convenience, references in this report as of and for the fiscal years ended December&#160;30, 2022, and January&#160;1, 2021 are indicated as being as of and for the years ended December&#160;31, 2022 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This discussion and analysis generally addresses 2022 and 2021 items and year-over-year comparisons between 2022 and 2021. Discussions of 2020 items and year-over-year comparisons between 2021 and 2020 that are not included in this Annual Report on Form 10-K can be found in &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the SEC on February&#160;18, 2022.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by category were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.292%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.046%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611,062&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross product revenues, discounts and allowances, and net product revenues were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,951,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(549,926)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375,657)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401,243&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375,909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401,243&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net product revenues for the year ended December&#160;31, 2022, as compared to 2021, was primarily related to a 26% increase in the number of CABOMETYX units sold as a result of the FDA&#8217;s approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC, in part due to the longer duration of therapy for this combination and an increase in related market share, and to a lesser extent a 4% increase in the average net selling price of CABOMETYX.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our net product revenues will increase in fiscal year 2023, as compared to fiscal year 2022, primarily due to an increase in market share that occurred in fiscal year 2022, reflecting the continued evolution of the metastatic RCC, HCC and DTC treatment landscapes, as well as an increase in selling price. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize product revenues net of discounts and allowances that are described in &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; to our &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of this Annual Report on Form 10-K. Discounts and allowances as a percentage of gross revenues have increased over time as the number of patients participating in government programs has increased and as the discounts given and rebates paid to government payers have also increased. The increase in discounts and allowances for the year ended December&#160;31, 2022, as compared to 2021, was generally attributed to an increase in units sold and an increase in the utilization and the dollar amount of chargebacks related to the government&#8217;s 340B Program, which mandates drug manufacturers offer discount drug pricing for certain eligible covered entities that meet 340B Program requirements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our discounts and allowances as a percentage of gross revenues may increase during fiscal year 2023 for similar reasons noted above.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues include: (a) the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable, in the related period, that a milestone would be achieved and a significant reversal of revenues would not occur in future periods; (b) royalty revenues; and (c) the profit on the U.S. commercialization of COTELLIC from Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaborations and Business Development Activities&#8212;Cabozantinib Commercial Collaborations&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in the &#8220;Notes to Consolidated Financial Statements" contained in Part II, Item 8 of this Annual Report on Form 10-K for a discussion on the allocation of transaction price which impacts the proportion of milestone revenues allocated to license revenues and collaboration services revenues.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues, which are allocated between license revenues and collaboration services revenues, were $28.9 million for the year ended December&#160;31, 2022, as compared to $133.8 million for 2021. Milestone revenues by fiscal year included the following:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">For the year ended December&#160;31, 2022, $25.8&#160;million in revenues was recognized in connection with two regulatory milestones totaling $27.0&#160;million upon the approval by the EC and Health Canada, of cabozantinib as a monotherapy for the treatment of adult patients with locally advanced or metastatic DTC, refractory or not eligible to RAI who have progressed during or after prior systemic therapy. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">For the year ended December&#160;31, 2021, milestone revenues included: (1) $100.0 million related to a commercial sales milestone from Ipsen upon their achievement of $400.0&#160;million of net sales of cabozantinib in the related Ipsen license territory over four consecutive quarters; (2) $11.9&#160;million related to a $12.5&#160;million regulatory milestone Ipsen achieved upon submission of a variation application to the EMA for CABOMETYX as a treatment for patients with previously treated, RAI-refractory DTC; and (3) $18.9&#160;million in connection with a $20.0&#160;million milestone achieved following Takeda&#8217;s first commercial sale in Japan of CABOMETYX in combination with OPDIVO for the treatment of patients with curatively unresectable or metastatic RCC. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to uncertainties surrounding the timing and achievement of development, regulatory and commercial milestones, it is difficult to predict the timing of future milestones revenues; consequently, milestones may vary significantly from period to period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenues increased primarily as a result of an increase in Ipsen&#8217;s net sales of cabozantinib outside of the U.S. and Japan. Ipsen royalty revenues were $110.1 million for the year ended December&#160;31, 2022, as compared to $97.2&#160;million for 2021. Ipsen&#8217;s net sales of cabozantinib have continued to grow since their first commercial sale of the product in the fourth quarter of 2016, as a result of continued increased global demand of CABOMETYX, as monotherapy for the treatment of adult patients with advanced RCC following prior VEGF-targeted therapy and CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC. Royalty revenues for the year ended December&#160;31, 2022 also included $11.3 million, as compared to $7.9 million for 2021, related to Takeda&#8217;s net sales of CABOMETYX, which have continued to grow since their first commercial sale of product in Japan in 2020. Additionally, Takeda royalty revenues have increased for similar reasons noted above. As of December&#160;31, 2022, CABOMETYX is approved and commercially available in 62 countries outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of profits on the U.S. commercialization of COTELLIC under our collaboration agreement with Genentech was $7.7 million for the year ended December&#160;31, 2022, as compared to $8.1 million for 2021. We also earned royalty revenues on ex-U.S. net sales of COTELLIC by Genentech of $4.8 million for the year ended December&#160;31, 2022, as compared to $4.1 million for 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our license revenues may decrease in fiscal year 2023, as compared to fiscal year 2022, as a result of the anticipated achievement of fewer milestones in 2023, partially offset by an increase in royalty revenues related to an increase in product sales by Ipsen and Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Services Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, and product supply revenues, which are net of product supply costs and the royalties we pay to Royalty Pharma on sales by Ipsen and Takeda of products containing cabozantinib. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development cost reimbursements were $60.3&#160;million for the year ended December&#160;31, 2022, as compared to $116.8&#160;million for 2021. The decrease in development cost reimbursements was primarily due to Ipsen&#8217;s decision to opt in and co-fund COSMIC-311 development costs in the second quarter of 2021, which included a cumulative catch up for Ipsen&#8217;s share of global development costs incurred since the beginning of the study. To a lesser extent, the decrease was attributable to decreases in spending on the COSMIC-312, COSMIC-021 and COSMIC-311 studies, which was partially offset by an increase in spending on the CONTACT-02 study.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues were reduced by $16.2 million and $14.3 million for the years ended December&#160;31, 2022 and 2021, respectively, with respect to the 3% royalty we are required to pay on the net sales by Ipsen and Takeda of any product incorporating cabozantinib. As royalty generating sales of cabozantinib by Ipsen and Takeda have increased as described above, our royalty payments have also increased.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our collaboration services revenues may decrease in fiscal year 2023, as compared to fiscal year 2022, primarily as a result of a decrease in development cost reimbursement revenues on certain studies with our collaborators Ipsen and Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of goods sold and our gross margins were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists of a 3% royalty payable on U.S. net sales of any product incorporating cabozantinib, as well as the cost of inventory sold, indirect labor costs, write-downs related to expiring, excess and obsolete inventory, and other third-party logistics costs. The increase in cost of goods sold for the year ended December&#160;31, 2022, as compared to 2021, was primarily the result of increases in royalty payments as a result of increased U.S. CABOMETYX sales, which was partially offset by a decrease in certain period costs. We project our gross margin in fiscal year 2023 will remain consistent with fiscal year 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not track fully burdened research and development expenses on a project-by-project basis. We group our research and development expenses into three categories: (1) development; (2) drug discovery; and (3) other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds are being or may be studied in clinical trials. Our drug discovery group utilizes a variety of technologies, including in-licensed technologies, to enable the rapid discovery, optimization and extensive characterization of lead compounds and biotherapeutics such that we are able to select development candidates with the best potential for further evaluation and advancement into clinical development.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses by category were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses and other collaboration costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting and outside services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other development costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521,622&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,493&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other collaboration costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other drug discovery</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total drug discovery</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,713&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891,813&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693,716&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License and other collaboration costs presented in total development includes upfront license fees and development milestone payments associated with programs currently in clinical development stage while license and other collaboration costs presented in total drug discovery primarily includes upfront license fees, development milestone payments, and research funding commitments and other payments associated with our in-licensing collaboration programs in preclinical development stage.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Primarily includes personnel expenses, consulting and outside services and laboratory supplies, if not separately presented.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the allocation of general corporate costs to research and development services, and development cost reimbursements in connection with our collaboration arrangement with Roche executed in December 2019.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The increase in research and development expenses for the year ended December&#160;31, 2022, as compared to 2021, was primarily related to increases in license and other collaboration costs, personnel expenses, consulting and outside services costs, clinical trial costs and other research and development costs. Drug discovery-related license and other collaboration costs increased primarily due to increases in upfront license fees, including, in connection with our recent agreements with Sairopa and Catalent in the fourth quarter of 2022, and other increases in program initiation fees, development milestones, and research funding commitments related to collaboration agreements. Development-related license and other collaboration costs increased primarily due to our recent agreement with Cybrexa in the fourth quarter of 2022 for the right to acquire CBX-12, partially offset by the reversal of a development milestone in 2022, which was recorded in 2021. The milestone was reversed as the compound has not progressed as expected and therefore we are no longer able to predict when the milestone will occur. Personnel expenses increased primarily due to an increase in headcount to support our expanding discovery and development organizations. Consulting and outside services expenses increased primarily as a result of the continued growth in our discovery and research and development activities. Clinical trial costs, which include services performed by third-party contract research organizations and other vendors who support our clinical trials, increased primarily due to higher costs associated with various studies evaluating zanzalintinib and XB002, as well as the CONTACT-02 cabozantinib study, which were partially offset by decreases in costs associated with the COSMIC-312, COSMIC-313, and COSMIC-021 cabozantinib studies. Other research and development costs increased primarily related to technology costs, including our investments in digital transformation initiatives to support productivity and efficiency in our organization, and an increase in rent expenses, which were partially offset by development cost reimbursements in connection with our collaboration arrangement with Roche.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to reviewing the three categories of research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. These factors include enrollment in clinical trials for our drug candidates, preliminary data and final results from clinical trials, the potential market indications and overall clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to focus our development efforts on cabozantinib to maximize the therapeutic and commercial potential of this compound and, as a result, we project that a substantial portion of our research and development expenses will relate to the continuing late-stage clinical development program of cabozantinib. Notable ongoing company-sponsored studies resulting from this program include: COSMIC-313, for which BMS is providing nivolumab and ipilimumab free of charge; and CONTACT-02 for which Roche is sharing the development costs and providing atezolizumab free of charge.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are expanding our oncology product pipeline through drug discovery efforts, which encompass both biotherapeutics and small molecule programs with multiple modalities and mechanisms of action, with the goal of identifying new product candidates to advance into clinical trials. We also continue to engage in business development initiatives aimed at acquiring and in-licensing promising oncology platforms and assets, with the goal of utilizing our established preclinical and clinical development infrastructure to further characterize and develop such platforms and assets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our research and development expenses may increase in fiscal year 2023, as compared to fiscal year 2022, primarily driven by an increase in personnel expenses to support our expanding discovery and development organization and an increase in clinical trial costs, including our ongoing clinical evaluation of cabozantinib in late-stage trials, the initiation of new clinical trials and expansion of ongoing clinical trials evaluating other product candidates in our pipeline, including STELLAR-303 and STELLAR-304 and planned initiation of multiple additional phase 3 pivotal trials evaluating zanzalintinib, and also our current early-stage trials evaluating zanzalintinib, XB002 and XL102, as well as anticipated business development activities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A discussion of the risks and uncertainties with respect to our research and development activities, and the consequences to our business, financial position, and growth prospects can be found in &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of this Annual Report on Form&#160;10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459,856&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,715&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Excludes stock-based compensation allocated to selling, general and administrative expenses. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel expenses, stock-based compensation, marketing costs and certain other administrative costs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in selling, general and administrative expenses for the year ended December&#160;31, 2022, as compared to 2021, was primarily related to increases in personnel expenses, technology costs, rent expenses and marketing costs. Personnel expenses increased primarily due to an increase in administrative headcount to support our commercial and research and development organizations. The increase in technology costs includes our investments in digital transformation initiatives to support productivity and efficiency in our organization. Rent expenses increased primarily related to the commencement of new leases in 2022. Marketing costs increased primarily due to increased spending to expand our brand recognition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our selling, general and administrative expenses may increase in fiscal year 2023, as compared to fiscal year 2022, in support of our continued commercial investment in CABOMETYX and the growth in the broader organization.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Operating Income</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income was as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,488&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in non-operating income for the year ended December&#160;31, 2022, as compared to 2021, was primarily the result of an increase in interest income due to higher interest rates and higher investment balances.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes and the effective tax rates were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The decrease in provision for income taxes for the year ended December&#160;31, 2022, as compared to 2021, was primarily due to the decrease in pre-tax income. The effective tax rate for the year ended December&#160;31, 2022 differed from the U.S. federal statutory rate of 21% primarily due to the change in valuation allowance and a non-deductible warrant purchase, offset by the generation of federal tax credits. The effective tax rate for the year ended December&#160;31, 2021 differed from the U.S. federal statutory ra</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">te of 21% primarily due to non-deductible executive compensation, partially offset by excess tax benefits related to the exercise of certain stock options during the period and the generation of federal tax credits.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> We project that our effective tax rate will be between 20% and 22% in fiscal year 2023.</span></div><div id="ia855702135904005a41d208deb24e60a_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $2.1 billion in cash, cash equivalents, restricted cash equivalents and investments, as compared to $1.9 billion as of December&#160;31, 2021. We anticipate that the aggregate of our current cash and cash equivalents, short-term investments available for operations, net product revenues and collaboration revenues will enable us to maintain our operations for at least 12 months and thereafter for the foreseeable future.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary cash requirements for operating activities, which we project will increase in fiscal year 2023 as compared to fiscal year 2022, are for: employee related expenditures; costs related to our development programs and discovery programs; income tax payments; cash payments for inventory; royalty payments on our net product sales; and our leased facilities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act, signed into law on December 22, 2017, modified the tax treatment of research and development expenditures beginning in fiscal year 2022. Research and development expenditures are no longer currently deductible but instead must be amortized ratably over five years for domestic expenditures or 15 years for foreign expenditures. As a result, we generated a larger federal income tax liability in fiscal year 2022, which required larger estimated federal tax payments. We will realize a reduction of our federal income tax liability in future years as the capitalized research and development expenditures are amortized for tax purposes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of operating cash are: cash collections from customers related to net product sales, which we project will increase in fiscal year 2023, as compared to fiscal year 2022; cash collections related to royalties earned from our commercial collaboration arrangements with Ipsen, Takeda and others and cash collections upon achievement of certain development, regulatory and commercial milestones; and cash collections for cost reimbursements under certain of our development programs. The timing of cash generated from commercial collaborations and cash payments required for in-licensing collaborations relative to upfront license fee payments, research funding commitments, cost reimbursements, exercise of options payments and other contingent payments such as development milestone payments may vary from period to period.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have cash requirements related to capital expenditures to support the planned growth of our business including investments in laboratory facilities and equipment. We project that we may continue to spend significant amounts of cash to fund the development and commercialization of cabozantinib and the development of other product candidates in our pipeline, including zanzalintinib. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including additional research collaborations, in-licensing arrangements and other strategic transactions that align with our oncology drug development, and regulatory and commercial expertise. Financing these activities could materially impact our liquidity and capital resources and may require us to incur debt or raise additional funds through the issuance of equity. Furthermore, even though we believe we have sufficient funds for our current and future operating plans, we may choose to incur debt or raise additional funds through the issuance of equity based on market conditions or strategic considerations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Letters of Credit</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of $1.5 million and $16.7&#160;million as of December&#160;31, 2022 and 2021, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standby letter of credit entered in January 2021, as a guarantee of our obligation to fund our portion of the tenant improvements related to our Alameda build-to-suit lease was extinguished and the related collateral was returned in the third quarter of 2022, following the substantial completion of the building and the commencement of the lease.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt;text-indent:36pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294,403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash equivalents and investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Working capital</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in working capital as of December&#160;31, 2022, as compared to December&#160;31, 2021, was primarily due to the unfavorable impacts to our net current assets resulting from purchases of long-term investments and estimated tax payments made that are classified as long-term assets and liabilities in our Consolidated Balance Sheets. In the future, our working capital may be impacted by one of these factors or other factors, the amounts and timing of which are variable.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalent and investments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents primarily consist of cash deposits held at major banks, commercial paper, money market funds and other securities with original maturities 90 days or less. Restricted cash equivalents relate to our letters of credit agreements and are invested in short-term certificates of deposit as of December&#160;31, 2022 and marketable securities as of December&#160;31, 2021. For additional information regarding our cash, cash equivalents, restricted cash equivalents and investments, see &#8220;Note 4. Cash and Investments,&#8221; in our &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K. The increase in cash, cash equivalents, restricted cash equivalent and investments at December&#160;31, 2022, as compared to December&#160;31, 2021, was primarily due to cash inflows generated by our operations, including collections of amounts due from customers, and collection of a $100.0&#160;million milestone payment from Ipsen, partially offset by operating cash payments for employee related expenditures, cash payments to support our development and discovery programs, cash payments for capital expenditures, lease payments and tax payments.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow activities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(524,414)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,884)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,801)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities is derived by adjusting our net income for non-cash operating items such as deferred taxes, stock-based compensation, depreciation, non-cash lease expense, and changes in operating assets and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Consolidated Statements of Income.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities decreased for the year ended December&#160;31, 2022, as compared to 2021, primarily due to an increase in cash paid for certain operating expenses primarily employee related expenses, collaboration related research and development payments and tax payments, partially offset by an increase in cash received on sales of our products and from our commercial collaboration arrangements, including the collection of a $100.0&#160;million milestone payment from Ipsen.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in cash flows from investing activities primarily relates to the timing of marketable securities investment activity, acquisition of acquired in-process research and development technology and capital expenditures. Our capital expenditures primarily consist of investments to expand our operations and acquire assets that further support our research and development activities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities increased for the year ended December&#160;31, 2022, as compared to 2021, primarily due to a decrease in cash proceeds from maturities and sales of investments, an increase in purchases of investments, and an increase in purchases of in-process research and development technology related to certain of our in-licensing collaboration arrangements, which were partially offset by a decrease in capital expenditures. Capital expenditures primarily consisted of investments in leasehold improvements and equipment related to an expansion of laboratory facilities at our corporate campus and technology infrastructure investments to support our digital transformation initiatives.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in cash flows from financing activities primarily relate to proceeds from employee stock programs and taxes paid related to net share settlement of equity awards.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash was provided by financing activities for the year ended December&#160;31, 2022, as compared to net cash used in financing activities in the prior year ended December&#160;31, 2021. The increase in cash provided by financing activities was primarily due to lower withholding taxes remitted to the government related to net share settlements of equity awards partially offset by a decrease in proceeds received from the issuance of common stock under our equity incentive and stock purchase plans.</span></div><div id="ia855702135904005a41d208deb24e60a_49"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we anticipate the aggregate of our cash, cash equivalents and short-term investments and cash generated from operations to be sufficient to fund our contractual obligations, as well as cash requirements to support our ongoing operations and capital expenditures. Our contractual obligations as of December&#160;31, 2022 primarily consist of:</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating leases:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have certain lease agreements related to our corporate campus facilities and other short term leases, under which we are obligated to make minimum lease payments. As of December&#160;31, 2022, we had $19.6 million of minimum lease payments due in one year and $310.4 million due over the remaining lease term. The amounts presented herein include the estimated lease commitment payments at the estimated commencement of the lease.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase obligations:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Purchase obligations include firm purchase commitments related to manufacturing of inventory, software services and other facilities and equipment. As of December&#160;31, 2022, we had $55.0 million total purchase obligations due within one year and $11.0 million due after one year.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent payments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have committed to make certain contingent payments for potential future milestones, research funding commitments and royalties to certain collaboration partners, including contingent exercise fee payments if we decide to exercise certain of our options to in-license or acquire in-process research and development technology as part of our agreements with those parties. We do not expect these contingent payments to have a significant impact on our liquidity in the near term. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes 3 and 11 of &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K include additional information regarding our contractual obligations and contingencies.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we did not have any material off-balance-sheet arrangements, as defined by applicable SEC regulations.</span></div><div id="ia855702135904005a41d208deb24e60a_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions; and the amounts of deferred tax assets and liabilities including the related valuation allowance. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies relating to revenue recognition, inventory, clinical trial accruals, stock-based compensation and income taxes reflect the more significant estimates and assumptions used in the preparation of our Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete description of our significant accounting policies, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Revenues and Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenues when our customers obtain control of promised goods or services, in an amount that reflects the consideration to which we are entitled to in exchange for those goods or services. We calculate gross product revenues based on the price that we charge to the specialty pharmacies and distributors in the U.S. We estimate our domestic net product revenues by deducting from our gross product revenues: (a)&#160;trade allowances, such as discounts for prompt payment; (b)&#160;estimated government rebates and chargebacks; (c) certain other fees paid to specialty pharmacies, distributors and commercial payors; and (d) returns.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initially record estimates for these deductions at the time we recognize the related gross product revenue. We base our estimates for the expected utilization on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates as well as third-party market research data. We update our estimates every quarter to reflect actual claims and other current information. Actual rebates and chargebacks claimed for prior periods have varied from our estimates by less than 1% of the amount deducted from gross product revenues for the years ended December&#160;31, 2022 and 2021. Our current estimates may differ significantly from actual results.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements with third parties, under which we license certain rights to our intellectual property, and account for the arrangements as either license revenue or collaboration services revenue when the counterparty is a customer. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; product supply services; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. We use key assumptions to determine the standalone selling price, which may include forecast revenues and costs, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. At the end of each subsequent reporting period, we re-evaluate the probability of earning of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. For arrangements that may include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sale occurs or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Development milestone adjustments are recorded on a cumulative catch-up basis, which would affect collaboration services revenues in the period of adjustment. In addition, in recording revenues for our research and development services performance obligations, we use projected development cost estimates to determine the amount of revenue to record as we satisfy this performance obligation. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trial and Collaboration Accruals</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We execute all of our clinical trials with support from contract research organizations and other vendors and we accrue costs for clinical trial activities performed by these third parties based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, the activities performed for each patient, the number of active clinical sites and the duration for which the patients will be enrolled in the trial. Certain of our in-licensing collaboration arrangements include contingent payments in the form of development, regulatory and commercial milestones. We recognize expense for contingent payments when they are deemed probable of achievement which requires judgment as to the probability and timing of the achievement of the underlying milestones. To the extent actual results, or updated probability estimates, differ from current estimates, such amounts are recorded as an adjustment in the period estimates are revised. We monitor patient enrollment levels and assess the related research and development activities progress, including the probability of achieving milestones payments associated to the respective terms and conditions of our in-licensing and collaboration arrangements to the extent possible through internal reviews and estimates of the operational progress of our discovery and early-stage clinical development programs, correspondence with contract research organizations and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us, which may allow us to make a more accurate estimate in future periods. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense requires us to estimate the fair value of stock options, performance-based restricted stock units (PSUs) and PSUs subject to market conditions, and the estimated the number of shares subject to PSUs that will ultimately vest. To determine the fair value, we use models that require a number of complex and subjective assumptions including our stock price volatility, employee exercise patterns and risk-free interest rates. The value of a stock option is derived from its potential for appreciation. The more volatile the stock, the more valuable the option becomes because of the greater possibility of significant changes in stock price. Because there is a market for options on our common stock, we consider implied volatility as well as our historical volatility when developing an estimate of expected volatility. The expected option term also has a significant effect on the value of the option. The longer the term, the more time the option holder has to allow the stock price to increase without a cash investment and thus, the more valuable the option. Further, lengthier option terms provide more opportunity to take advantage of market highs. However, empirical data show that employees typically do not wait until the end of the contractual term of a nontransferable option to exercise. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we are required to estimate the expected term of the option for input to an option-pricing model. Monte Carlo simulation models are used to determine grant date fair value of awards with market conditions. The assumptions used in calculating the fair value of stock options and PSUs represent management&#8217;s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize stock-based compensation for PSUs over the requisite service period only for awards which we estimate will ultimately vest, which requires judgment as to the probability and timing of the achievement of the underlying performance goals. Significant factors we consider in making those judgments include forecasts of our product revenues and those of our collaboration partners, estimates regarding the operational progress of late-stage clinical development programs and discovery pipeline expansion performance targets. To the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised and as such, can materially affect our stock-based compensation expense in the current period and in the future.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compute our income tax provision or benefit under the asset and liability method. Significant estimates are required in determining our income tax provision or benefit. We base some of these estimates on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that we deem a reversal of any portion of our valuation allowance against our deferred tax assets to be appropriate, we recognize a tax benefit against our income tax provision in the period of such reversal. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the Consolidated Financial Statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We have elected to record interest and penalties in the accompanying Consolidated Statements of Income as a component of income taxes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div id="ia855702135904005a41d208deb24e60a_55"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to cash flow and earnings fluctuations as a result of certain market risks. These market risks primarily relate to credit risk, changes in interest rates and foreign exchange rates. Our investment portfolio is used to preserve our capital until it is required to fund operations, including our research and development activities. None of these market risk-sensitive instruments are held for trading purposes. We do not have derivative financial instruments in our investment portfolio.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest our cash in a variety of financial instruments, principally securities issued by the U.S. government and its agencies, investment-grade corporate bonds and commercial paper, and money market funds. These investments are denominated in U.S. Dollars. All of our interest-bearing securities are subject to interest rate risk and could decline in value if interest rates fluctuate. Substantially all of our investment portfolio consists of marketable securities with active secondary or resale markets to help ensure portfolio liquidity, and we have implemented guidelines limiting the term-to-maturity of our investment instruments. Due to the conservative and short-term nature of these instruments, we do not believe that we have a material exposure to interest rate risk. If market interest rates were to increase or decrease by one percentage point, the fair value of our investment portfolio would increase or decrease by an immaterial amount.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Exchange Rate Risk </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in the exchange rates of the U.S. dollar and foreign currencies may have the effect of increasing or decreasing our revenues and expenses. Royalty revenues and sales-based milestones we receive from our collaboration agreements with Ipsen, Takeda and Genentech are a percentage of the net sales made by those collaboration partners from sales made in countries outside the U.S. and are denominated in currencies in which the product is sold, which is predominantly the Euro or Japanese Yen. Research and development expenses include clinical trial services performed by third-party contract research organizations and other vendors located outside the U.S. that may bill us in currencies where their services are provided, which is predominantly the Euro. If the U.S. dollar strengthens against a foreign currency, then our royalty revenues will decrease for the same number of units sold in that foreign currency and the date we achieve certain sales-based milestones may also be delayed. Similarly, if the U.S. dollar weakens against a foreign currency, then our research and development expenses would increase. However, we believe that we are not subject to material risks arising from changes in foreign exchange rates and that a hypothetical 10% increase or decrease in foreign exchange rates would not have a material adverse impact on our financial condition, results of operations or cash flows.</span></div><div id="ia855702135904005a41d208deb24e60a_58"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_61">Report of Independent Registered Public Accounting Firm (PCAOB ID:</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV81OC9mcmFnOjM3MTNjMTE3MWE4ODRiM2NhYzBkYzJjNjg2ZWYzNTMzL3RhYmxlOjY5ZGNjMmNmMDU3YjQ5MmE5NGNiN2M3NTY0MDRjZjQ2L3RhYmxlcmFuZ2U6NjlkY2MyY2YwNTdiNDkyYTk0Y2I3Yzc1NjQwNGNmNDZfMS0wLTEtMS05MjE1MC90ZXh0cmVnaW9uOjEwNzA5MTkwNmEwNDQ2ZGFhNGYyMWJkOWVhNjM4YWZkXzcx_45146d0d-8f1b-4210-a2a1-a00f36f45f72">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_61">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_64">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_64">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_67">Consolidated Statements of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_67">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_70">Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_70">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_73">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_73">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_76">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_76">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_79">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_79">85</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="ia855702135904005a41d208deb24e60a_61"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Exelixis, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Exelixis, Inc. (the Company) as of December 30, 2022 and December 31, 2021, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 30, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8220;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 30, 2022 and December 31, 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 30, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 30, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 7, 2023 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Critical Audit Matter</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revenue recognition - product sales and accounts receivable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 30, 2022, the Company&#8217;s gross product revenues were $1,951.2 million. As discussed in Note 1 of the financial statements, the Company sells its products principally to specialty distributors and specialty pharmacy providers, or collectively, Customers. These Customers subsequently resell the products to health care providers and patients. Revenues from product sales are recognized when control is transferred to the Customer.</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the Company&#8217;s product sales was challenging, specifically related to the effort required to audit Customer sales activity to assess whether incentives resulted in orders in excess of demand and whether any such transactions meet the criteria for revenue recognition. This involved judgmentally assessing factors including market demand, Customer ordering patterns, Customer inventory levels, contractual terms and incentives offered.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#24282d;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls designed to monitor and review inventory levels in the channel. This includes testing relevant controls over the information systems that are important to the initiation, recording and billing of revenue transactions as well as controls over the completeness and accuracy of the data used.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span><br/></span></div><div><span style="color:#212529;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures over the Company&#8217;s product sales included, among others, examination of inventory channel reports for unusual trends or transactions as well as performing analytical procedures to detect and investigate anomalies within the data. Procedures included those to detect sales of short-dated product near year end as well as testing the completeness and accuracy of the underlying data. We tested credit memos issued during the year and after year-end. We also examined the terms and conditions of any new or amended contracts with Customers and its impact on the Company&#8217;s returns reserve. We also confirmed the terms and conditions of contracts directly with a selection of Customers, including whether there are side agreements and terms not formally included in the contract that may impact the Company&#8217;s returns reserve. In addition, we obtained written representations from members of the commercial function and the market access group regarding changes to Customer incentives and the completeness of the terms and conditions reported to the legal and accounting departments.</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82MS9mcmFnOjgwOWI2ZWIyNWVhMjRmOTQ4ZTE0MzA0YTg2N2I4YjcwL3RleHRyZWdpb246ODA5YjZlYjI1ZWEyNGY5NDhlMTQzMDRhODY3YjhiNzBfMzU2MQ_a8ab26c4-186a-4e62-98da-c559eb6fcdd5">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2002.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82MS9mcmFnOjgwOWI2ZWIyNWVhMjRmOTQ4ZTE0MzA0YTg2N2I4YjcwL3RleHRyZWdpb246ODA5YjZlYjI1ZWEyNGY5NDhlMTQzMDRhODY3YjhiNzBfMzU2Mg_40169825-1fbd-4710-9cc8-4bd65aa29a5d">San Mateo, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 7, 2023</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="ia855702135904005a41d208deb24e60a_64"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfNi0xLTEtMS05MjE1MA_de489bba-66b9-441a-9ac4-10e8e59e4648">501,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfNi0zLTEtMS05MjE1MA_587c4d7e-fbd2-487a-b944-985da759a51c">647,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfNy0xLTEtMS05MjE1MA_414e0bec-6970-49a8-839e-6c60141fe4a7">807,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfNy0zLTEtMS05MjE1MA_f07f5e71-5d14-4299-986b-71d8558cd237">819,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfOC0xLTEtMS05MjE1MA_92bb8135-0d4f-4e68-ae7c-732077e10871">214,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfOC0zLTEtMS05MjE1MA_efc2c9aa-47a2-4323-a1a6-b6bf04d1df46">282,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfOS0xLTEtMS05MjE1MA_f98e598e-e22c-4f55-9341-3311a9da546b">33,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfOS0zLTEtMS05MjE1MA_985f0e37-2daf-4329-b4f8-0d5607cc08e1">27,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTEtMS0xLTEtOTIxNTA_6f11fd40-776c-4e64-b455-b5c04f32e946">62,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTEtMy0xLTEtOTIxNTA_dd4e0162-fbc8-4d46-9792-c75399baf522">57,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTItMS0xLTEtOTIxNTA_97f3572f-8b31-4862-b343-21fb32c0d99c">1,618,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTItMy0xLTEtOTIxNTA_0906981f-29b5-40af-8772-f973c1928fa1">1,834,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTMtMS0xLTEtOTIxNTA_24023728-9c70-45ca-90bc-6f205e80cfc8">756,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTMtMy0xLTEtOTIxNTA_3541aedf-6417-4fa7-9fca-62e8d3f97ee8">371,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTQtMS0xLTEtOTIxNTA_bcae3203-d68a-445f-92b4-dd5ee954221b">110,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTQtMy0xLTEtOTIxNTA_88a43b02-74a0-4865-b9ba-e78c0826010f">104,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTUtMS0xLTEtOTIxNTA_c6abb1d1-479f-4b81-b66f-3087c591e08d">231,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTUtMy0xLTEtOTIxNTA_caf971cb-6be6-48fc-aef0-c7d1abcff172">111,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTYtMS0xLTEtOTIxNTA_2bd12415-1f37-4b89-baa9-9fde6b54424b">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTYtMy0xLTEtOTIxNTA_ede15ed7-6d4c-495d-9c93-8b466bfca208">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="exel:OperatingLeaseRightOfUseAssetAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTctMS0xLTEtOTIxNTA_9b2b7cea-2601-4dcc-b6e4-274094c7e36a">290,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="exel:OperatingLeaseRightOfUseAssetAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTctMy0xLTEtOTIxNTA_6f896e11-4e83-4f31-945a-3eeaded7ba1a">131,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTgtMS0xLTEtOTIxNTA_19eb547c-f2d5-44a7-a2fd-cae9423dd5c9">3,071,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTgtMy0xLTEtOTIxNTA_3cf415a9-95e9-4aae-8168-6f0c1f2667d7">2,616,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjEtMS0xLTEtOTIxNTA_3a8021a7-76e0-490c-8f80-65c2f819b5fb">32,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjEtMy0xLTEtOTIxNTA_fe6394c6-5666-439d-a062-2a1b0b6d673e">24,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjItMS0xLTEtOTIxNTA_7ae3b00e-d6cc-4869-aeae-825017957ddc">77,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjItMy0xLTEtOTIxNTA_532b7f49-873e-4213-9374-3ffc3159b683">61,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="exel:AccruedClinicalLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjMtMS0xLTEtOTIxNTA_9f180c66-68d5-4380-8860-271ed1f13ce2">65,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="exel:AccruedClinicalLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjMtMy0xLTEtOTIxNTA_13b1638a-424f-4ad3-8afc-c168c7f7eaa3">77,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates and fees due to customers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjQtMS0xLTEtOTIxNTA_09d9a23b-f420-403d-b833-71722f6d2112">50,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjQtMy0xLTEtOTIxNTA_4117aab4-4195-4be1-9f7f-21e297ef7db2">33,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued collaboration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="exel:AccruedCollaborationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjUtMS0xLTEtOTIxNTA_364054fe-d858-4b18-b2fc-bceb9f7659b7">20,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="exel:AccruedCollaborationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjUtMy0xLTEtOTIxNTA_69936fa3-29c3-4785-8659-70ae6481fde7">86,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjctMS0xLTEtOTIxNTA_5d474c39-6a1c-498a-a463-45eac2eb611f">78,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjctMy0xLTEtOTIxNTA_110c9a0e-52a7-4463-a74b-1b07f0d7b306">53,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjgtMS0xLTEtOTIxNTA_a1beae50-a9f8-42ee-a5b2-6fc024866e39">324,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjgtMy0xLTEtOTIxNTA_5aa1fdf7-d25d-47c7-95d1-38d7e30ab698">337,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjktMS0xLTEtOTIxNTA_9c2f20ec-646a-451a-8b95-cebeb37fe2ae">6,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjktMy0xLTEtOTIxNTA_e8bc5746-ac60-4cc3-a90a-a0027aa1a533">8,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzAtMS0xLTEtOTIxNTA_a09b7e62-12c4-49e3-87b5-3edad068aace">190,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzAtMy0xLTEtOTIxNTA_99043ca9-b284-4903-b857-f6a3fb638a61">51,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzEtMS0xLTEtOTIxNTA_3d4de216-e93a-468d-8def-72fdd1058159">61,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzEtMy0xLTEtOTIxNTA_87656948-d905-453a-870d-7b401cc0dd44">8,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzItMS0xLTEtOTIxNTA_96b50435-52c6-4c84-a546-81b6648f4aab">583,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzItMy0xLTEtOTIxNTA_2464e006-b891-44dc-baa7-5d3fe1e296fb">405,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzMtMS0xLTEtOTIxNTA_61757a1a-b661-4257-a1c7-3a9413e73b2b"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzMtMy0xLTEtOTIxNTA_579e277c-ed1f-4380-be13-2b006f66af2c"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzUtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjo1ZTcxMGZkMzFkYjc0OWJmYTFjYmEyNjFlZjk3NzAyMV8yMQ_1fdf5b4f-e5d9-4fd3-a0ca-73912c3da27f"><ix:nonFraction unitRef="usdPerShare" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzUtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjo1ZTcxMGZkMzFkYjc0OWJmYTFjYmEyNjFlZjk3NzAyMV8yMQ_53c48b67-11af-4f59-b2ae-960536f815bf">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzUtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjo1ZTcxMGZkMzFkYjc0OWJmYTFjYmEyNjFlZjk3NzAyMV8zNQ_1679e573-670e-4ddd-8a11-e1b4c3f18c25"><ix:nonFraction unitRef="shares" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzUtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjo1ZTcxMGZkMzFkYjc0OWJmYTFjYmEyNjFlZjk3NzAyMV8zNQ_ffdeb3bd-bdfb-478b-bc25-db784857f4a0">10,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzUtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjo1ZTcxMGZkMzFkYjc0OWJmYTFjYmEyNjFlZjk3NzAyMV82MA_3fc1072f-2837-4019-9c42-6347c865d5a2"><ix:nonFraction unitRef="shares" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzUtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjo1ZTcxMGZkMzFkYjc0OWJmYTFjYmEyNjFlZjk3NzAyMV82MA_b9d93b62-caaf-4f24-9580-a7a0870f1101">no</ix:nonFraction></ix:nonFraction> shares issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzUtMS0xLTEtOTIxNTA_ce0cec22-91c1-437f-a50c-2d808bb35ca1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzUtMy0xLTEtOTIxNTA_f7beb331-ed16-4b49-9d62-e5c804c299dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjoxMjA0ODIwZTUwZjI0MGJkYTc4ZmQzNzYxNjQ1NzVjYl8xOQ_7a147536-e9c1-4ab4-98f6-cfcbf033c335"><ix:nonFraction unitRef="usdPerShare" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjoxMjA0ODIwZTUwZjI0MGJkYTc4ZmQzNzYxNjQ1NzVjYl8xOQ_8b8261b1-0504-454e-a807-8dae2fb19925">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjoxMjA0ODIwZTUwZjI0MGJkYTc4ZmQzNzYxNjQ1NzVjYl8zMw_557e462a-f1fe-4980-a8a4-38622065a267"><ix:nonFraction unitRef="shares" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjoxMjA0ODIwZTUwZjI0MGJkYTc4ZmQzNzYxNjQ1NzVjYl8zMw_88582294-ca17-4f56-badb-5192a94b84a7">400,000</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjoxMjA0ODIwZTUwZjI0MGJkYTc4ZmQzNzYxNjQ1NzVjYl83OQ_13431a48-e0d1-4ba6-8ebd-b2fdba9be592"><ix:nonFraction unitRef="shares" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjoxMjA0ODIwZTUwZjI0MGJkYTc4ZmQzNzYxNjQ1NzVjYl83OQ_6d7eea78-4d79-4617-8905-a3efdeaad379">323,951</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjoxMjA0ODIwZTUwZjI0MGJkYTc4ZmQzNzYxNjQ1NzVjYl84Ng_2c0c3361-cb5c-40ae-965d-47398c39c8f3"><ix:nonFraction unitRef="shares" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjoxMjA0ODIwZTUwZjI0MGJkYTc4ZmQzNzYxNjQ1NzVjYl84Ng_aaca37e0-c730-488a-bb15-ef147cf9607f">318,842</ix:nonFraction></ix:nonFraction> at December&#160;31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMS0xLTEtOTIxNTA_f701c861-da34-41be-9acf-cc9623ac5501">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMy0xLTEtOTIxNTA_18e2fb6f-6883-4951-bbae-a3b7f87851d3">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzctMS0xLTEtOTIxNTA_b11db80e-e234-4904-8a8a-2ee567ab88f5">2,536,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzctMy0xLTEtOTIxNTA_4ced9110-bbe8-4407-b410-eec75382cac8">2,427,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzgtMS0xLTEtOTIxNTA_e17ed8a7-7684-40e4-aa94-1d921165801c">14,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzgtMy0xLTEtOTIxNTA_245eab50-9ce8-4151-8667-59ea0e3347d9">758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzktMS0xLTEtOTIxNTA_1a97d5b8-3c66-4a42-a4a9-578c984f866d">34,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzktMy0xLTEtOTIxNTA_d57eaf6e-5ae7-43f3-b29f-58d1be163ac0">216,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfNDAtMS0xLTEtOTIxNTA_c64bb8d5-a608-4535-aa21-5551c7f79a67">2,488,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfNDAtMy0xLTEtOTIxNTA_4612842b-4505-4d40-93bf-1c68e39ed7be">2,210,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfNDEtMS0xLTEtOTIxNTA_48fa3f64-f240-4672-ab4a-eb36fa091184">3,071,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfNDEtMy0xLTEtOTIxNTA_c37ba9a7-8447-41de-8af3-a0118982e987">2,616,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="ia855702135904005a41d208deb24e60a_67"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd975ad7811c4bdbb2315643b04037a2_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMy01LTEtMS05MjE1MA_b0fff0b2-6827-4b0e-a5b7-0ecb1ca80275">1,401,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e996a9f240456487cb91fc0c52e1a1_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMy03LTEtMS05MjE1MA_51483abd-0522-4fa1-82ee-8e3bf9f43240">1,077,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d55e02ba3ae4c8999e690629fe6d584_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMy05LTEtMS05MjE1MA_3f3b1cf2-381d-4490-a129-7e72684a1a66">741,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9ff1b0e91924c73b4c456c2235ab6cf_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNC01LTEtMS05MjE1MA_2a9e8891-458f-45bb-8bb1-09d17532eb16">162,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47a0764d353e4fb3a7ec06de9aca7c16_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNC03LTEtMS05MjE1MA_73cc83fd-670e-4d24-8fde-02acdacabe91">249,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8380d5f4f944a18a412a44050718011_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNC05LTEtMS05MjE1MA_4c068302-0f03-47f8-944b-fe681764d452">167,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i968c32c71952402cb10bdb7c8f5f4c8e_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNS01LTEtMS05MjE1MA_8df2e5ed-4152-448c-9a0c-08ea4cee77b0">47,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad8294bfd197493791fd98694c5266f2_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNS03LTEtMS05MjE1MA_e4ebda26-4825-41b0-96b8-a07ae06fc91c">107,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i663037ccb1ec482e8ebc1bbf359c95b4_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNS05LTEtMS05MjE1MA_edfab126-5009-4903-86c0-ef2cd261cdf5">78,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNi01LTEtMS05MjE1MA_00302604-80ee-421e-9ab4-3356b1761424">1,611,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNi03LTEtMS05MjE1MA_5e8ff85e-d223-448b-b5a1-49ebd1cab5bc">1,434,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNi05LTEtMS05MjE1MA_c7169fdc-ce48-4ba6-a673-d9a7e5b11ce4">987,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfOC01LTEtMS05MjE1MA_c96461ec-7ade-49ac-b960-0c4d3ba694c0">57,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfOC03LTEtMS05MjE1MA_6cb9e5b3-fe45-4ad4-ae39-213dc9ee3468">52,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfOC05LTEtMS05MjE1MA_84ec8947-6d3c-4817-bf37-5d343430e5e9">36,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfOS01LTEtMS05MjE1MA_22f310bd-84b0-4f86-a73e-5365b4d6a97e">891,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfOS03LTEtMS05MjE1MA_73eb8c6d-2970-47fd-95fb-5b0bf5144902">693,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfOS05LTEtMS05MjE1MA_60d51bb4-25a2-4e3f-8955-bcd6b5978db5">547,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTAtNS0xLTEtOTIxNTA_103f5945-e9d7-4bda-93bf-6801202764c7">459,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTAtNy0xLTEtOTIxNTA_24dbd1df-ff34-4a59-b80d-beb37682195d">401,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTAtOS0xLTEtOTIxNTA_864ced3d-9f7c-4b5d-9324-76dcabe5fedf">293,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTEtNS0xLTEtOTIxNTA_81151702-8f69-4c86-9a6d-067b639dd070">1,409,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTEtNy0xLTEtOTIxNTA_213cf0b1-b9a1-4eb1-a099-cdd427a8ce7b">1,148,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTEtOS0xLTEtOTIxNTA_7d295a45-fc6b-4e49-8e59-85b8065fc0f7">877,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTItNS0xLTEtOTIxNTA_e6b1998d-4930-4642-bba1-b3cb17b28116">201,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTItNy0xLTEtOTIxNTA_b6737a80-6634-4349-a428-90f926237d9c">286,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTItOS0xLTEtOTIxNTA_e7fe72e5-a083-446e-b4af-914ebc6b73ca">110,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTMtNS0xLTEtOTIxNTA_48b00b52-03da-4f5f-91bb-f28a7fb3fef0">33,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTMtNy0xLTEtOTIxNTA_5c929fc0-2bc0-4bf2-8ded-e867c4fc7f8a">7,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTMtOS0xLTEtOTIxNTA_6055e91d-8e87-40ee-a092-c14b14ba5328">19,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTQtNS0xLTEtOTIxNTA_d775cae3-6909-4a2f-b05f-d4d9cf1de443">197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTQtNy0xLTEtOTIxNTA_7d2a01d1-b541-49f4-a02e-cd9d6f485e3b">184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTQtOS0xLTEtOTIxNTA_ac531f2a-f46a-4ae1-a7f7-e22a568bc7b4">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTUtNS0xLTEtOTIxNTA_a0b1284c-1675-419f-8131-53f4989cfbe1">234,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTUtNy0xLTEtOTIxNTA_d16daec4-3705-4b17-9765-cc128972d0fc">294,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTUtOS0xLTEtOTIxNTA_69c3febe-15ea-4525-a990-2b251b9d63cc">130,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTYtNS0xLTEtOTIxNTA_28eb00ab-4bc1-44b7-9cf9-0de28e11991c">52,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTYtNy0xLTEtOTIxNTA_077f1940-d71b-43fc-8d46-5ac600651824">63,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTYtOS0xLTEtOTIxNTA_5c003af4-6ff3-4b02-88f1-fce3701e6475">19,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTctNS0xLTEtOTIxNTA_3b15d400-bb92-4d7a-a032-e180ba3a0d41">182,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTctNy0xLTEtOTIxNTA_eeb404a6-c5bd-42c9-9d01-e55e48a8fa12">231,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTctOS0xLTEtOTIxNTA_5db11cc8-9908-4324-abe8-1a5234e2031d">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTktNS0xLTEtOTIxNTA_e7576046-de8c-4e4b-8f1a-a2a5e8fbf66c">0.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTktNy0xLTEtOTIxNTA_71c71f80-68d4-443f-91bf-679335779fe1">0.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTktOS0xLTEtOTIxNTA_c9a9ab81-b73b-438b-a8cd-3436aef265cf">0.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjAtNS0xLTEtOTIxNTA_49356d69-ed32-4c36-8acb-b820d315faf2">0.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjAtNy0xLTEtOTIxNTA_e7e357d4-2b70-412a-af6d-d75deaa70b8f">0.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjAtOS0xLTEtOTIxNTA_ad90da54-0329-4889-98f6-3a65995bf613">0.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjItNS0xLTEtOTIxNTA_0e1dd32b-3a4a-4496-a5b4-d980f96a2213">321,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjItNy0xLTEtOTIxNTA_6a626d3b-14f8-4338-ab54-35df5b40ddbe">314,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjItOS0xLTEtOTIxNTA_f8910795-c30a-4ec4-ae9d-81d50eb9a1e4">308,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjMtNS0xLTEtOTIxNTA_809c5718-643a-4215-aa20-ff06e0828545">324,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjMtNy0xLTEtOTIxNTA_f92a657a-84e5-4482-85d8-1408afe7dacb">322,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjMtOS0xLTEtOTIxNTA_220c5542-0292-43aa-adfa-1c5cab6bf597">318,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div id="ia855702135904005a41d208deb24e60a_70"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfMi01LTEtMS05MjE1MA_3b15d400-bb92-4d7a-a032-e180ba3a0d41">182,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfMi03LTEtMS05MjE1MA_eeb404a6-c5bd-42c9-9d01-e55e48a8fa12">231,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfMi05LTEtMS05MjE1MA_5db11cc8-9908-4324-abe8-1a5234e2031d">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNC0wLTEtMS05MjE1MC90ZXh0cmVnaW9uOjIxYjAxNmZiYTkxMDQwZGE5NTc4NWZmNDAyZjZlMDhjXzk1_b46b9e4e-47b9-4558-9875-f41855c7f04d">3,886</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNC0wLTEtMS05MjE1MC90ZXh0cmVnaW9uOjIxYjAxNmZiYTkxMDQwZGE5NTc4NWZmNDAyZjZlMDhjXzk5_9accd112-d7d7-4f76-aece-f5cb96f70173">1,481</ix:nonFraction>, and $(<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNC0wLTEtMS05MjE1MC90ZXh0cmVnaW9uOjIxYjAxNmZiYTkxMDQwZGE5NTc4NWZmNDAyZjZlMDhjXzEwNw_cb9b710d-b349-4fb0-9b43-192177c1a8f2">394</ix:nonFraction>), respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNC01LTEtMS05MjE1MA_44cf54a0-a827-4acc-9638-36a4bc31f5e3">13,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNC03LTEtMS05MjE1MA_d6532486-69ce-4eed-acd0-87437df0cf08">5,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNC05LTEtMS05MjE1MA_781983b1-b93b-47d0-bd43-3580e60405c4">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNi01LTEtMS05MjE1MA_6189d028-8e32-4173-8349-25c2c46393cc">168,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNi03LTEtMS05MjE1MA_88b6d368-3b29-461a-8e67-464cdf4895e7">225,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNi05LTEtMS05MjE1MA_1808cf58-2382-46b4-bf50-1a0806ca9569">113,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="ia855702135904005a41d208deb24e60a_73"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.678%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee90ac3decac457ea10ccb1f57c3be9f_I20200103" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMjgtMS0xLTEtOTIxNTA_457e02b0-eba4-4843-b532-4c47b2b273a3">304,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee90ac3decac457ea10ccb1f57c3be9f_I20200103" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMjgtMy0xLTEtOTIxNTA_d78bcb52-4fe4-4618-97c8-9ba371e968ab">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i316600a670354ae9bed12cb08f90fbad_I20200103" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMjgtNS0xLTEtOTIxNTA_a4895d74-359e-420b-9d6a-150659a65eaa">2,241,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d397c56f7c747a1b4c4ee65c9dca93f_I20200103" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMjgtNy0xLTEtOTIxNTA_11ff366c-959b-4386-a853-67361224bbd3">3,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied0a8550944e400eb840fecf7a697f8a_I20200103" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMjgtOS0xLTEtOTIxNTA_ae6648fd-e78b-4342-b635-b517a5b1eaf6">559,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a3670052766460e8f6681bfb2fe46da_I20200103" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMjgtMTEtMS0xLTkyMTUw_57b13d95-e052-4879-99ac-8620e9fb916c">1,685,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7bb9a335486433c81f3f5733d3aaad8_D20200104-20210101" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMjktOS0xLTEtOTIxNTA_5fbf0abf-02bc-4ddb-b0b7-38d842aff8b4">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMjktMTEtMS0xLTkyMTUw_ea6d64d9-e7ef-4ffc-a872-10a9f4c3e901">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36ea7ff7478a47f29ac8ddc870f601a1_D20200104-20210101" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzAtNy0xLTEtOTIxNTA_2102e4c2-2b43-430e-8b7a-3200f8c2e870">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzAtMTEtMS0xLTkyMTUw_145bfbe4-955b-46e5-8ab0-3dbedf1cf243">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic0deb65d8e8541f4befd56d486e027aa_D20200104-20210101" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzEtMS0xLTEtOTIxNTA_c105ce1f-a9f8-4e86-8e8e-760495556341">6,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0deb65d8e8541f4befd56d486e027aa_D20200104-20210101" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzEtMy0xLTEtOTIxNTA_3c83c030-6b74-4572-9ed6-dda9bbf0d0a3">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac71ca2b42784a9596529526d80870fe_D20200104-20210101" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzEtNS0xLTEtOTIxNTA_b1a78749-7f3c-4b60-a0d3-023599b04c0e">24,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzEtMTEtMS0xLTkyMTUw_88c05cf0-3d82-4c3e-87bd-8c8f2eadae05">24,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac71ca2b42784a9596529526d80870fe_D20200104-20210101" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzItNS0xLTEtOTIxNTA_e9c198be-08dc-4c60-9b85-57987982440c">50,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzItMTEtMS0xLTkyMTUw_7d6e8e7a-e2b3-4e60-833b-04e1f1425bad">50,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac71ca2b42784a9596529526d80870fe_D20200104-20210101" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzMtNS0xLTEtOTIxNTA_6688f41e-85eb-4bec-bf0f-9333295e4923">105,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzMtMTEtMS0xLTkyMTUw_04c902c3-3250-498e-923b-70893eab1db3">105,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b022f123e124eebacb65e193a7ca348_I20210101" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzQtMS0xLTEtOTIxNTA_388d1ac0-85e2-4276-a25b-983179597a14">311,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b022f123e124eebacb65e193a7ca348_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzQtMy0xLTEtOTIxNTA_f8ec19bf-4dc2-4740-bea1-5eaab70fc900">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30d6ea6119494ce99990ec9f421bf661_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzQtNS0xLTEtOTIxNTA_5957fdbc-e778-4aba-9bc5-111b9dff8fc4">2,321,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b916a4ad0de4c3ea7891d04e8a0e888_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzQtNy0xLTEtOTIxNTA_cbab74b9-9afa-45ee-8eb9-fef2b96890fb">4,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf9048c142784771b43942a372d1013d_I20210101" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzQtOS0xLTEtOTIxNTA_6b95c66a-eadc-4a92-91f6-324ea50ef3ba">447,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0958ab0a7b904c6abbc804e49a0e9544_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzQtMTEtMS0xLTkyMTUw_69a89f1d-6759-4d72-bf4c-96baf1c82376">1,879,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f9dad1068314e4a821e9fa7b5dfc712_D20210102-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzUtOS0xLTEtOTMyMzE_be7cd87e-34c8-4e4b-8d13-0a1b43d71bd4">231,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzUtMTEtMS0xLTkyMTUw_7ec89d08-16e7-4f22-b8ff-d8e245b7126f">231,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1d8b28295254e3c9d72be053782f1f6_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzYtNy0xLTEtOTMyMzE_d0dae71e-ff97-4069-9d8d-d077083250ad">5,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzYtMTEtMS0xLTkyMTUw_6b180bc3-1221-4c53-b693-78fef33beb2f">5,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idfd5463291344fadbad875183adfc559_D20210102-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzctMS0xLTEtOTMyMzE_371e26f3-af34-4420-a093-5175add95be5">7,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd5463291344fadbad875183adfc559_D20210102-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzctMy0xLTEtOTMyMzE_86e7079e-4124-45a5-a8a8-a49c7ac91106">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61bccae84739493aa433b75b3289741b_D20210102-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzctNS0xLTEtOTMyMzE_3946013b-38f1-4d27-bf8d-b01c2fa952d8">24,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzctMTEtMS0xLTkyMTUw_07133055-7422-48bc-ba0a-00cab6b2ef45">24,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61bccae84739493aa433b75b3289741b_D20210102-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzgtNS0xLTEtOTMyMzE_37cef9bd-52f6-43e2-a100-11c61ecd58e7">39,142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzgtMTEtMS0xLTkyMTUw_3a921ddf-71cc-42d5-812c-307c6154d385">39,142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61bccae84739493aa433b75b3289741b_D20210102-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzktNS0xLTEtOTMyMzE_dd3ae9c5-1945-43f8-a08c-e77dd3272e90">120,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzktMTEtMS0xLTkyMTUw_bbf359dd-cbf2-476c-8c76-18203e847ba5">120,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ebcf341e8d14a8d8af6c5f7a8d997dd_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDAtMS0xLTEtOTIxNTA_d3750c15-e1e5-4fa3-b10f-e1ce21544120">318,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ebcf341e8d14a8d8af6c5f7a8d997dd_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDAtMy0xLTEtOTIxNTA_089ddf7f-b2c3-4e03-9dc5-1e96c352207d">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d4b232e8fca4e8d9de8920ba88d1665_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDAtNS0xLTEtOTIxNTA_f55c5471-5c16-4ae1-b50f-e5af032836b1">2,427,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86a7ae9225ca4247aa92ff18efbb1e3f_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDAtNy0xLTEtOTIxNTA_8f382b8c-8734-4b3d-adf2-61a2dff9d292">758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic180e4d772ed46dc825b7445c7893c6a_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDAtOS0xLTEtOTIxNTA_79c76d95-cae0-4302-b203-1339707a5cb2">216,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDAtMTEtMS0xLTkyMTUw_5065f869-a55f-4a7e-b900-8d8f09fff997">2,210,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d92019d1cca43aebdc002637f9a8e0a_D20220101-20221230" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDEtOS0xLTEtOTMyMzI_c3400c0f-fbeb-4247-ad5b-2c18bca5bcf4">182,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDEtMTEtMS0xLTkzMjMy_b57e3928-39dc-4b08-a5da-6eb3bed10cdf">182,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia138b200885a4b769244acdf9eeab22d_D20220101-20221230" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDItNy0xLTEtOTMyMzI_00be67b3-e1e9-44a8-b4a4-fe0d691f48fe">13,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDItMTEtMS0xLTkzMjMy_3c1f1407-6df7-49ff-8212-4bce51f74bc7">13,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd740e63081e4029889559bc739aee7d_D20220101-20221230" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDMtMS0xLTEtOTMyMzI_d53e3c37-7bf2-4fa7-8e3b-e4ef5bb65498">5,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd740e63081e4029889559bc739aee7d_D20220101-20221230" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDMtMy0xLTEtOTMyMzI_fc5fde2f-9898-4e31-bf9a-e855b10b8836">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564bbd54548d41f68982fea9945c6519_D20220101-20221230" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDMtNS0xLTEtOTMyMzI_6f19ccbd-4482-4e0b-afa8-088a5f934501">23,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDMtMTEtMS0xLTkzMjMy_45b2b61a-afb7-4f1f-b56a-15f1870100c3">23,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i564bbd54548d41f68982fea9945c6519_D20220101-20221230" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDQtNS0xLTEtOTMyMzI_053de087-5c82-44c8-a77a-83a084c47f35">23,344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDQtMTEtMS0xLTkzMjMy_bb7d6cb6-0d68-4a73-8063-a76c396954c6">23,344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564bbd54548d41f68982fea9945c6519_D20220101-20221230" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDUtNS0xLTEtOTMyMzI_2a884296-8160-4eb6-89fa-0c03dfeb6f2a">108,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDUtMTEtMS0xLTkzMjMy_13a206b0-e244-44c7-83c2-af7bb90148d9">108,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6372aa2efa047d3814f185d55ca1da9_I20221230" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDYtMS0xLTEtOTMyMzI_cf9132ed-7b09-4688-acd9-6e6430357f62">323,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6372aa2efa047d3814f185d55ca1da9_I20221230" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDYtMy0xLTEtOTMyMzI_2b4ea112-4cec-4caa-bbdb-3699dbb5922f">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ae29c61f4c04cdda5f6e25561c082eb_I20221230" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDYtNS0xLTEtOTMyMzI_1f29d4c8-203e-4858-888f-a02ae284c3c3">2,536,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7de5204d64db4e1094ecd5b8bfca36d1_I20221230" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDYtNy0xLTEtOTMyMzI_d67dd596-089c-48a6-9567-9010410db8bd">14,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28cc46cb8b1541b3b1c30a1b510db95d_I20221230" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDYtOS0xLTEtOTMyMzI_519ddf36-30dd-4efb-81ed-a6837d777bd7">34,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDYtMTEtMS0xLTkzMjMy_d904ebd5-1f14-4b98-bbcd-145051d1ebd5">2,488,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="ia855702135904005a41d208deb24e60a_76"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMi0xLTEtMS05MjE1MA_3b15d400-bb92-4d7a-a032-e180ba3a0d41">182,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMi0zLTEtMS05MjE1MA_eeb404a6-c5bd-42c9-9d01-e55e48a8fa12">231,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMi01LTEtMS05MjE1MA_5db11cc8-9908-4324-abe8-1a5234e2031d">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNC0xLTEtMS05NTc0MA_70466358-dc2b-40df-a85b-2c9966c5a8cc">20,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNC0zLTEtMS05MzQ4NA_c59a44eb-64f5-4090-add1-7e671f19f296">13,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNC01LTEtMS05MzUwNQ_76337c8c-5687-4510-93ed-c451369336f7">9,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNS0xLTEtMS05NTc0MA_2768f6c7-812e-4796-a1d6-3b04594e72e3">107,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNS0zLTEtMS05MzQ4NA_f793861e-f2fd-4f96-92a1-a9afb6d65c5a">119,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNS01LTEtMS05MzUwNQ_d06d0f6c-d35e-4e5a-b1be-806b68faaa5f">105,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="exel:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNi0xLTEtMS05NTc0MA_4565403c-2d7e-4647-8e12-62ccd1235a82">18,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="exel:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNi0zLTEtMS05MzQ4NA_b77b3de0-898a-4c57-a7b0-22ec9afe2ddb">5,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="exel:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNi01LTEtMS05MzUwNQ_47712ab0-cbdf-4f7a-b8dc-dbab5caa0c73">4,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNy0xLTEtMS05NTc0MA_5d271120-d61f-44e7-a913-0b0e23c485e3">60,358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNy0zLTEtMS05MzQ4NA_3cad82ce-3ebb-461b-8d3d-131fc564b6d8">46,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNy01LTEtMS05MzUxMg_432199aa-ebd5-4fac-b5a2-1046f7fb0961">15,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfOC0xLTEtMS0xMDUzNjY_02722db2-07b2-441a-888d-977a890cb19c">107,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfOC0zLTEtMS0xMDUzODM_cafe59a7-098e-4e4f-8ca0-f3eae845b6b1">14,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfOC01LTEtMS0xMDUzNzU_037578d8-fa92-4a08-b93a-6fe8c289bd11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfOC0xLTEtMS05NTc0MA_565a0176-0a92-460f-ba84-6d01ac97a3e1">525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfOC0zLTEtMS05MzQ4NA_cb56958f-333e-46d7-b4b3-c8f1ac8d05a3">9,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfOC01LTEtMS05MzUxOQ_a237350d-85a0-4596-8e7f-bcced950d870">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTAtMS0xLTEtOTU3NDA_c6761d38-d661-4e0b-8725-7d72ac83ce07">66,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTAtMy0xLTEtOTM0ODQ_9795d0cb-d342-4d29-b058-f6bf9fec8c94">122,324</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTAtNS0xLTEtOTM1NzI_ae15e468-d2f9-40b0-8128-19168f93caa3">42,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTEtMS0xLTEtOTU3NDA_997bb69b-14b1-4e52-9aec-9b40489ef4d9">11,683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTEtMy0xLTEtOTM0ODQ_8995dcf4-9ec2-4f57-8971-688f60aaeb19">13,209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTEtNS0xLTEtOTM1Nzk_5cc3877c-acb7-49fe-ae74-36c362acfc1e">21,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTMtMS0xLTEtOTU3NDA_07461712-99b6-4a11-a911-184ba8a5746f">28,259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTMtMy0xLTEtOTM0ODQ_f10d5d1e-791d-4917-b756-8da2bddd5edc">39,875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTMtNS0xLTEtOTM1ODY_65cc3fe7-a8a6-4647-876a-ceb567b60d2e">25,831</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTUtMS0xLTEtOTU3NDA_08d35676-8ae1-45b7-b060-90300f8047c7">2,483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTUtMy0xLTEtOTM1NjI_3627f58c-4407-4f5d-9d81-271c0b1b5bed">11,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTUtNS0xLTEtOTM1OTM_b02fb219-d5e7-432b-bc1e-0ba4a45bbf23">1,051</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued collaboration liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTYtMS0xLTEtOTU3NDA_6204e2ff-4a9b-4c9d-afd0-eb95488052c4">63,065</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTYtMy0xLTEtOTM1NjU_882eeda8-ee69-4aca-8a95-e85e152e083c">70,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTYtNS0xLTEtOTM2MDA_91e1c2ab-93dc-4304-8077-89211d36ddbe">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTctMS0xLTEtOTU3NDA_c65d3c61-940a-4f79-9233-396848e027e0">25,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTctMy0xLTEtOTM1Njg_a23acf97-c208-40db-8c65-a924863e6e0d">55,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTctNS0xLTEtOTM2MDc_5eba23f4-d3bf-4af4-a0e5-c73ef3044696">50,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTgtMS0xLTEtOTU3NDA_73c837c8-dcf4-4f5b-87c1-9992dd863d51">362,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTgtMy0xLTEtOTU3NDI_78444ae4-e87b-4304-a0a8-3fb5582d2acd">400,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTgtNS0xLTEtOTU3NDI_73555474-0540-4d14-a54b-f7871bbb8968">208,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjAtMS0xLTEtOTU3NDA_ea06d475-ff1c-48b8-a333-e288ebf31c2d">27,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjAtMy0xLTEtOTM2MTU_5938e3ca-8bcd-44a9-8ed6-c8c749834f33">54,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjAtNS0xLTEtOTM2MjQ_bff8a087-6fd5-4f47-934a-adc3708c240e">30,345</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjItMS0xLTEtMTA1Mzk2_1c9acb44-73ba-4aa5-ba8d-6a0e5d5f5be8">110,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjItMy0xLTEtMTA1NDAz_6f492c4d-29cf-473e-84b9-2cdaf40b5dc7">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjItNS0xLTEtMTA1NDEw_d5fab7f5-2289-4120-99c0-022aa3dfa11f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjItMS0xLTEtOTU3NDA_f31ee549-9456-4431-8d67-1919ce2beeff">1,450,716</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjItMy0xLTEtOTM2MTg_7d286817-6411-4f28-a9b8-111a6910daf6">1,357,168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjItNS0xLTEtOTM2MzE_400177cd-de4a-47f3-99c6-6e0a4d846591">1,070,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjMtMS0xLTEtOTU3NDA_0aded83a-1ac9-49ca-8613-57ffc9acbe05">1,064,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjMtMy0xLTEtOTM2MjE_6e209f09-3feb-43dc-a233-a4d9c2b7e96c">1,378,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjMtNS0xLTEtOTM2Mzg_2ac24ad6-0a38-423c-81a2-916a96ee2ce5">969,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjQtMS0xLTEtOTU3NDA_43c9f127-dde5-403b-8ad6-0cfca8c03de8">524,414</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjQtMy0xLTEtOTU3NDI_1226e2c5-012f-4d48-bd53-4a5e34d5fa16">42,884</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjQtNS0xLTEtOTU3NDI_c66ade58-8887-4ca1-a542-9edd73c3e709">131,215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjYtMS0xLTEtOTU3NDA_d9202fd1-2264-48d9-9e42-a42a3d72c061">23,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjYtMy0xLTEtOTM2NDk_53f36ade-b2c8-41ba-b136-d7f59a3e686b">24,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjYtNS0xLTEtOTM2NjI_4b601ef4-bb5f-4277-8975-6d4a3c618d7a">24,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjctMS0xLTEtOTU3NDA_08c0275d-6456-4bbf-9f02-342f904104d4">23,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjctMy0xLTEtOTM2NTI_57eab6b4-dd78-4d82-aa71-03cde67aae6a">39,108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjctNS0xLTEtOTM2Njk_3aeb1030-fe7d-4ce3-8b3d-14d9caa8f5fb">50,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjktMS0xLTEtOTU3NDA_792f500d-9f63-474d-9ce7-01c1abdf1e47">586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjktMy0xLTEtOTU3NDI_d3130da5-3d22-48c8-9a33-5a046ae7726e">14,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjktNS0xLTEtOTU3NDI_d09c81e9-781e-4169-acc1-30ca9df8a426">25,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzAtMS0xLTEtOTU3NDA_cc6c3efc-79dd-4e39-8bd1-2deb4baeb6b2">161,214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzAtMy0xLTEtOTU3NDI_6be97d53-7054-458b-93f8-5f3af27e71d6">343,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzAtNS0xLTEtOTU3NDI_2451fbe1-f472-4657-bc64-07c6b7818b31">52,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzEtMS0xLTEtOTU3NDA_fbf30839-1845-4431-9c65-f8c1959f78bc">663,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0958ab0a7b904c6abbc804e49a0e9544_I20210101" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzEtMy0xLTEtOTM2ODY_8c33c07c-26cc-466d-8795-b2bc514def21">320,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a3670052766460e8f6681bfb2fe46da_I20200103" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzEtNS0xLTEtOTM2OTM_99fd184c-76c7-434d-b936-82d337a2040b">268,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzItMS0xLTEtOTU3NDA_f8ef050a-f48f-4a00-95df-1f6d91aac77e">502,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzItMy0xLTEtOTU3NDI_a61249aa-a7b7-481a-9e53-202b803919e0">663,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0958ab0a7b904c6abbc804e49a0e9544_I20210101" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzItNS0xLTEtOTU3NDI_24e4e23e-250c-48ad-8e62-79bb70762c47">320,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzUtMS0xLTEtOTU3NDA_8f373c48-cb7b-49fa-bb35-623134160f5a">127,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzUtMy0xLTEtOTM3MDI_4bb5b815-bdf0-4076-947a-29c276891e7b">12,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzUtNS0xLTEtOTM3MDk_f5cc2a8d-9ca4-417f-b714-5ab1d7121c0a">4,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzctMS0xLTEtOTU3NDA_61e2e2c8-ccdd-49b5-9c66-20b99113a3c9">155,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzctMy0xLTEtOTM3MTY_d0b05fc7-c152-4708-8eba-8b436d0baadc">4,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzctNS0xLTEtOTM3MTk_7399ea75-f177-4b93-ae2e-38065a027b9a">4,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable for unsettled investment sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="exel:AccountsReceivableForUnsettledInvestmentSales" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNDItMS0xLTEtOTU3NDA_b189d2dc-ee4f-4827-b39b-c906e292d33d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="exel:AccountsReceivableForUnsettledInvestmentSales" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNDItMy0xLTEtOTM3NDE_f09a5a83-1094-4dcd-9831-656aac7e68fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="exel:AccountsReceivableForUnsettledInvestmentSales" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNDItNS0xLTEtOTM3MzE_d87a9b6f-2fa7-4e69-a5d5-3e3b821801f4">6,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="ia855702135904005a41d208deb24e60a_79"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="ia855702135904005a41d208deb24e60a_82"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4MzU_6860de19-6c3f-4a99-969f-4f5470d44f31" continuedAt="i902cb3a695d44c5ba3f0a6be64fea77f" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i902cb3a695d44c5ba3f0a6be64fea77f" continuedAt="i3e134cfe55b94c1ca5c91a28055d0160"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and combination regimens at the forefront of cancer care. Through the commitment of our drug discovery, development and commercialization resources, we have produced <ix:nonFraction unitRef="product" contextRef="i43e43644871943ca80e12287cd11f468_D20220101-20221230" decimals="INF" name="exel:NumberofProductsinCommercialMarket" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzg0ODI5MDc1NTg5MQ_da7350fd-976b-45d0-957c-27043562e465">four</ix:nonFraction> marketed pharmaceutical products, including our flagship molecule, cabozantinib. We continue to evolve our product portfolio, leveraging our investments, expertise and strategic partnerships, to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sales related to cabozantinib account for the majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in <ix:nonFraction unitRef="country" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="INF" name="exel:NumberOfCountriesWithDrugApprovalExcludingTheUS" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzg0ODI5MDc1NTg5Mw_b85d7e05-a696-4a32-8529-4cbff195e7fa">62</ix:nonFraction> other countries as: CABOMETYX&#174; (cabozantinib) tablets approved both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab) for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA and European Commission (EC), for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The other <ix:nonFraction unitRef="product" contextRef="i4e1b3f5f23e243f1b8637a1014a5195a_D20220101-20221230" decimals="INF" name="exel:NumberofProductsinCommercialMarket" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzg0ODI5MDc1NTg5MA_c731372e-470a-4044-9227-8fb0e790e19f">two</ix:nonFraction> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo). See &#8220;&#8212;Collaborations and Business Development Activities&#8212;Other Collaborations.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue leveraging our operating cash flows to support the ongoing investigation of cabozantinib in phase 3 trials for new indications and the advancement of a broad array of diverse biotherapeutics and small molecule programs for the treatment of cancer exploring multiple modalities and mechanisms of action. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4NDA_7087a072-d005-44f6-b472-a343fe9010df" escape="true">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2022, which was a 52-week fiscal year, ended December&#160;30, 2022, fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended January&#160;1, 2021. For convenience, references in this report as of and for the fiscal years ended December&#160;30, 2022 and January&#160;1, 2021 are indicated as being as of and for the years ended December&#160;31, 2022 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:FiscalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY5MDM_d627d00d-0479-43e4-a3d1-9803c5a66296" escape="true">We have made reclassifications to our prior years&#8217; Consolidated Financial Statements to conform to the current year&#8217;s presentation. These reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities, total operating, investing or financing cash flows or total stockholders&#8217; equity.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4MjE_2b4fcfce-69ef-4b3e-9707-e1295c256c34" escape="true">We operate in <ix:nonFraction unitRef="segment" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzczNw_e245af80-8a58-4b4e-823f-254b293a377f">one</ix:nonFraction> business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="i3e134cfe55b94c1ca5c91a28055d0160" continuedAt="i5a4d6f26b7344aadab19de48f8404304"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4MDQ_5e2a098e-3c37-420a-a3e9-9866a80ce89a" escape="true">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4MDc_0557fe3f-6479-403d-8f83-6c1570fe5271" continuedAt="if134536e334a460d914161824540f587" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements adopted by us since our filing of the Annual Report on Form 10-K for the year ended December 31, 2021, which could have a significant effect on our Consolidated Financial Statements.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4MDk_cb433c98-cab5-4677-9d92-be3f5cca20e3" escape="true">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4Mzg_1e82b142-4c98-481b-ab3c-2573d735720b" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include realized gains and losses on the sale of investments in other income, net in the accompanying Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. The classification of restricted cash equivalents as short-term or long-term is dependent upon the longer of the remaining term to maturity of the investment or the remaining term of the related restriction.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment Impairment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarterly, we assess each of our investments in available-for-sale debt securities whose fair value is below its cost basis to determine if the investment&#8217;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded as a reduction of other comprehensive income (loss), net of applicable taxes. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to exclude accrued interest from both the fair value and the amortized cost basis of the available-for-sale debt securities for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY3OTk_389dbd8f-34aa-4b92-8e2b-7114c80a0021" escape="true">We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="i5a4d6f26b7344aadab19de48f8404304" continuedAt="i654856df99c040999a3931c62f99c4e1"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4Nzk_32f4a571-9379-4646-b8bd-b4590224cfe3" escape="true">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income, net in the accompanying Consolidated Statements of Income.</ix:nonNumeric> Net foreign currency gains or losses were immaterial for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY3Njc_ba16cbde-2721-41fe-91b3-ebe4bde186a9" escape="true">Trade receivables, net, contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current economic conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers. We write off trade receivables and related allowances for credit losses when it becomes probable we will not collect the amount receivable. Write-offs for the years ended December&#160;31, 2022 and December&#160;31, 2021 were immaterial.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY5MDU_11e951f2-528b-40c3-a004-c7e58d28c3e8" escape="true">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration services revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4ODA_18304e74-2867-4add-90a6-fc6a4d9bb8f3" escape="true">We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to <ix:nonNumeric contextRef="i4c2389c4c21e47d38ba918260c486bdd_D20220101-20221230" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMTI3MTM_4e639b38-5da2-4c42-84be-2dfb101c7ec8">15</ix:nonNumeric> years and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize any material impairment charges in any of the periods presented.</ix:nonNumeric> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY5MDc_e9abb3c4-3938-4469-a049-8de73d020412" escape="true">We recorded goodwill amounts as the excess of purchase price over identifiable net assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in <ix:nonFraction unitRef="segment" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMTQzMDE_e245af80-8a58-4b4e-823f-254b293a377f">one</ix:nonFraction> business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level.</ix:nonNumeric> We did <ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMTQ0NTg_234c4fd8-fbec-4184-b898-789ab907cc81"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMTQ0NTg_a4f2177a-f4ac-43a9-b0bb-6000bbc6b09f"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMTQ0NTg_cdb4c217-d5df-4eff-af1a-0ebe1008b0e6">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t recognize any impairment charges in any of the periods presented.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY5MDg_5a2d3001-8823-4b5c-bbb5-7829b5ee8b1e" continuedAt="if77887dd930e4e07a2404fd738f43895" escape="true">The carrying value of our long-lived assets, which includes property and equipment, right-of-use assets and leasehold improvements, is reviewed for impairment whenever events or changes in circumstances indicate that the </ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="i654856df99c040999a3931c62f99c4e1" continuedAt="ibc58dd16d95a47efbea8aa46a3f498d7"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if77887dd930e4e07a2404fd738f43895">carrying value of the asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</ix:continuation></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY3Nzg_136d0e7a-710c-442b-ab74-2589554d1def" continuedAt="i1eb18b51b5e14eecb7f8180b30462eb6" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenues under the guidance of ASU Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 606). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established primarily from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discounts for Prompt Payment:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Customers in the U.S. receive a discount of <ix:nonFraction unitRef="number" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="2" name="exel:SalesRevenuePercentDiscountForPromptPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMTk0NjA_a80e26f3-6fdc-47c0-b353-3193bca35567">2</ix:nonFraction>% for prompt payment. We expect our Customers will earn <ix:nonFraction unitRef="number" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="INF" name="exel:SalesRevenueDiscountExpectedtobeEarnedPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMTk1MTc_0332ddd2-6cfd-4459-acf0-039a9b285686">100</ix:nonFraction>% of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="ibc58dd16d95a47efbea8aa46a3f498d7" continuedAt="i2102f20075d14d2499d17584c6074ccc"><ix:continuation id="i1eb18b51b5e14eecb7f8180b30462eb6" continuedAt="i432879a46c3b46bdbbb83f5c0ca78fab"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our Customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2020, the</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund <ix:nonFraction unitRef="number" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="2" name="exel:MedicarePartDFundingMandate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMjA5NjQ_6a2c78cc-79a2-4012-8751-3284b4481dd2">70</ix:nonFraction>% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to Customer, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Customer Credits: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Up-front License Fees: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="i2102f20075d14d2499d17584c6074ccc" continuedAt="i28665836a9cd44dc851f1ac1c244dd63"><ix:continuation id="i432879a46c3b46bdbbb83f5c0ca78fab" continuedAt="ic96b412336af43a581edccc26d73cc1c"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory and Development Milestone Payments: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development Cost Reimbursements:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation, which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Arrangements: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Sales-based Milestone Payments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists primarily of a <ix:nonFraction unitRef="number" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMjg5NjI_5a648cd1-55ae-4694-a849-c97b484311de">3</ix:nonFraction>% royalty we are required to pay on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. </span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic96b412336af43a581edccc26d73cc1c">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs.</ix:continuation> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY3OTA_94d5f0e9-31bb-4a84-8f87-ce4d6dc33299" continuedAt="i2fbc8e2931c142b697b9ba5c6c1f50ca" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees and option exercise fees, funded research and milestone payments incurred or probable to be incurred for our in-licensing arrangements with our collaboration partners for research programs in development and prior to regulatory approval; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial projects have been executed with support from third-party CROs, who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="i28665836a9cd44dc851f1ac1c244dd63" continuedAt="i22689378bc884887b51f138e6b806275"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2fbc8e2931c142b697b9ba5c6c1f50ca">accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.</ix:continuation></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY3NzE_c9d7c9b3-0b85-46dd-90eb-ac0ffbdeff0b" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected not to apply the recognition requirements of </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2016-02</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842) for short-term leases.</span></ix:nonNumeric></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expenses were $<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfNTQ5NzU1ODUyMjE3_d20a79bb-f401-4374-b456-928d139c36e7">41.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfNTQ5NzU1ODUyMTgy_f1b53c7b-822f-4a87-a98a-7b6b0881162e">31.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfNTQ5NzU1ODUzMDMw_0714596f-640d-4aab-b088-c701594051c0">25.1</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY3OTE_4920632c-3f18-4e03-8e12-a455cd8c6b2f" escape="true">We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in selling, general and administrative expenses.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4NzA_b398e148-f9a8-4daa-82e6-cb99f5190a75" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;units (RSUs), performance-based restricted&#160;stock&#160;units (PSUs), service-based&#160;stock&#160;options and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock&#160;Compensation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of RSUs and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for certain PSUs and RSUs with market vesting conditions and a Black-Scholes Merton option pricing model for stock options. Both pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatility when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense related to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis. Compensation expense related to RSUs with market vesting conditions is recognized regardless of the outcome of the market conditions.</span></ix:nonNumeric></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzg0ODI5MDc0NDkxOA_1f14daa2-7d5e-47f2-a99a-92ba81e2d1a2" escape="true">We continually assess our ownership, contractual and other interests in entities that are not wholly-owned whether we are the primary beneficiary of a variable interest entity (VIE) and therefore we must consolidate the entity. We apply a qualitative approach that determines whether we have both (1) the power to direct the activities that most significantly impact the economic performance of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We perform this assessment, as changes to existing relationships or future transactions may result in consolidation or deconsolidation of a VIE.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY3Nzk_8ce65512-f7a8-4fb9-a9b9-5a199b1f14eb" continuedAt="i1eef90633bb642ccb8e4387b8f320a7f" escape="true">Our provision for income taxes is computed under the asset and liability method. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or </ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="i22689378bc884887b51f138e6b806275"><ix:continuation id="i1eef90633bb642ccb8e4387b8f320a7f"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our provision for income taxes in the period of such reversal. Based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 31, 2022 and forecasts of future operating results, we do not have a valuation allowance against our deferred tax assets as described in &#8220;Note 9. Provision For Income Taxes&#8221;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div></ix:continuation><ix:continuation id="if134536e334a460d914161824540f587"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2021, which could have a significant effect on our Consolidated Financial Statements.</span></div></ix:continuation></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="ia855702135904005a41d208deb24e60a_85"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTA4MA_712680d0-f829-4078-9e2b-e4dc5dcced04" continuedAt="ia4f2821eef3e4b6b834c6594c3a043b9" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="ia4f2821eef3e4b6b834c6594c3a043b9" continuedAt="i077f7e709fbd486db3f740292d8e6502"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTA3Mw_6b78a879-f14d-4100-b1a7-aa7ae621fad7" continuedAt="i6a5ac00566c34610abbef3e019d7ca89" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89478d8e53974982878b9f548166f990_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMy01LTEtMS05MjE1MA_25dddde8-94f0-4949-8e14-6d0b96724f0d">1,951,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dafc9c29ab84bcc889c1cf9052a086e_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMy03LTEtMS05MjE1MA_90d22212-9f93-4066-b70e-ded4bd6b12e0">1,452,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib74e5ab8178d4970b8e0465f6fa0028c_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMy05LTEtMS05MjE1MA_5c637e5a-338c-428f-b3cb-f9349cffd18b">962,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71aecadc693d426fb5b155f638d21467_D20220101-20221230" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNC01LTEtMS05MjE1MA_5296a389-5ffc-41de-a270-793845c230b4">549,926</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc1b4ef9e9b84a8ebf2dfd01a3004c70_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNC03LTEtMS05MjE1MA_f2c7cf72-b8c2-454d-b5d7-2baf2d713dbc">375,657</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic649dcb8633a451880ff42451fc2f3ab_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNC05LTEtMS05MjE1MA_b42cf5cf-c146-4337-8057-55dcd30fa59d">221,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd975ad7811c4bdbb2315643b04037a2_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNS01LTEtMS05MjE1MA_b0fff0b2-6827-4b0e-a5b7-0ecb1ca80275">1,401,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e996a9f240456487cb91fc0c52e1a1_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNS03LTEtMS05MjE1MA_51483abd-0522-4fa1-82ee-8e3bf9f43240">1,077,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d55e02ba3ae4c8999e690629fe6d584_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNS05LTEtMS05MjE1MA_3f3b1cf2-381d-4490-a129-7e72684a1a66">741,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9ff1b0e91924c73b4c456c2235ab6cf_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNy01LTEtMS05MjE1MA_2a9e8891-458f-45bb-8bb1-09d17532eb16">162,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47a0764d353e4fb3a7ec06de9aca7c16_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNy03LTEtMS05MjE1MA_73cc83fd-670e-4d24-8fde-02acdacabe91">249,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8380d5f4f944a18a412a44050718011_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNy05LTEtMS05MjE1MA_4c068302-0f03-47f8-944b-fe681764d452">167,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i968c32c71952402cb10bdb7c8f5f4c8e_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfOC01LTEtMS05MjE1MA_8df2e5ed-4152-448c-9a0c-08ea4cee77b0">47,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad8294bfd197493791fd98694c5266f2_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfOC03LTEtMS05MjE1MA_e4ebda26-4825-41b0-96b8-a07ae06fc91c">107,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i663037ccb1ec482e8ebc1bbf359c95b4_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfOC05LTEtMS05MjE1MA_edfab126-5009-4903-86c0-ef2cd261cdf5">78,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c31e24d2c0403d83cfc5c2eb92f86f_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMTAtNS0xLTEtOTIxNTA_732f8a13-dd7e-404d-9249-8472f27a33b7">209,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae02cfb8959147e8a8be84c7f06c568f_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMTAtNy0xLTEtOTIxNTA_9422d73c-7b47-4dca-96dc-a8479096467d">357,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7fd8bc4b5b142a1a7297763d8461fc6_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMTAtOS0xLTEtOTIxNTA_5ad1917b-d7c7-4b2c-9dfe-bd686d608452">245,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMTEtNS0xLTEtOTIxNTA_00302604-80ee-421e-9ab4-3356b1761424">1,611,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMTEtNy0xLTEtOTIxNTA_5e8ff85e-d223-448b-b5a1-49ebd1cab5bc">1,434,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMTEtOS0xLTEtOTIxNTA_cfe11d31-5beb-4c0e-97b6-43104ef463d2">987,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with Topic 606. License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with Topic 808. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="i077f7e709fbd486db3f740292d8e6502" continuedAt="ib78dbe8dc72a4c5384b507917828b67f"><ix:continuation id="i6a5ac00566c34610abbef3e019d7ca89"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if237b256b8c34d6f87bec83d450b03ab_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfMi01LTEtMS05MzgwMw_065c7e33-0abf-4e25-bcf8-df59e2108064">1,375,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d8ad44c76d84c439d5d4844f913bf36_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfMi03LTEtMS05Mzc5Mw_d5d2e0e3-b75c-4027-a9fe-7032b25b1444">1,054,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b45a28b3ddd4011af15bed2146cd292_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfMi05LTEtMS05Mzc5Ng_dac37657-6568-4c58-a3bf-0475b738be0f">718,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied57fc239c1a4a7b97626aba030a42ad_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfMy01LTEtMS05MzgwMw_0d60b125-1a50-4169-88e2-7c7918038a9c">25,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id94aae6775c049b5b2b45d949aafa52c_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfMy03LTEtMS05Mzc5Mw_5c5b8b97-9ef2-4ddd-b9a0-3b1aa9c196aa">23,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed8d85227d3483f90cb59be9e884d22_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfMy05LTEtMS05Mzc5Ng_58b3320a-9658-4fbe-801f-1f6d3932dc81">22,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd975ad7811c4bdbb2315643b04037a2_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfNC01LTEtMS05MjE1MA_2048157e-2d43-4e5b-90da-4ec65f97ab52">1,401,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e996a9f240456487cb91fc0c52e1a1_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfNC03LTEtMS05MjE1MA_d8f60c08-0a85-444f-a9e2-9ee2d8fc6c52">1,077,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d55e02ba3ae4c8999e690629fe6d584_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfNC05LTEtMS05MjE1MA_f43b2873-4c75-49ac-b74a-34990eead811">741,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTA4NA_11eb27a7-ef80-4244-9085-a8919160bc12" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide7ae702d2f94f168ad5eb6d613db43b_D20220101-20221230" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi0xLTEtMS0xMDMxNzk_e7828dbc-8b66-4d26-83f3-79de6655e52d">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9229604d9ad94d6fa4aaff91b181d1fa_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi0zLTEtMS0xMDMxNzk_1a5b5932-78f7-4f6b-abc4-8337528b7a73">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i85155e2e92604cd8af2bbc12fed76b09_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi01LTEtMS0xMDMxNzk_25365a41-75a9-411e-81ff-ed89f7db407d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb94516f996c436291373f1bb4adcaf9_D20220101-20221230" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi0xLTEtMS05NzU0Ng_b2b60014-59ec-4693-b1a4-0aa538f4ca90">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0831affdb6f74cd590e4619e798c6ede_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi0zLTEtMS05NzU0Ng_b6edfaf4-4f44-471a-bc6a-25dc6584583b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4f5b33e3f9374a4080cdf99a2599aa23_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi01LTEtMS05NzU0Ng_857c4153-c22c-4144-ad98-df8cdd4a1335">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i09e575bca46c4ee7b2977bb349efda52_D20220101-20221230" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMy0xLTEtMS05NzU1Ng_ea7f7cf9-2393-4f88-98a5-1e0fd65eee2d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8451b3d5bb240c7a4b4e0fc57e84305_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMy0zLTEtMS05NzU1Ng_d4f359f5-5c72-4648-a8d0-c07673637628">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9cd9ed86ff6d4038bcad39e7fb9d9344_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMy01LTEtMS05NzU1Ng_8dc38be0-a204-4309-bee0-cea3a320d1f9">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibdcd0d0a9429406cbdb4291bcd54d608_D20220101-20221230" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi0xLTEtMS05Mzg3MQ_edd85bde-054c-47de-b01a-f1ee7732b2c3">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i119efb5fb69c4904bcc940dbd2963d2b_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi0zLTEtMS05MzgwNg_b305b16c-2597-4c6f-871f-b8ba65d9248a">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i04453331d42244feaf8b6ea4c41db316_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi01LTEtMS05MzgwOQ_a6dc3589-c8c6-4d1d-a776-5cc7c2a15c2f">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo Health, Incorporated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d85564049e049b68f2010d3e0f72113_D20220101-20221230" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfNi0xLTEtMS05Mzg4OQ_12acaa39-de95-4713-82cd-078728c14ef7">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i820e2862a6184ec388d2114fd98baf4a_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfNi0zLTEtMS05Mzg4Ng_3f3bf6da-12d3-45f8-afa6-7f8b9442be22">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff9f443812b14ed79359b92769535720_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfNi01LTEtMS05Mzg3OQ_7fdecb01-a3b3-4778-a5cc-28f0b934cb2b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifbbcd4f4e254417c814ceb83cd2b0472_D20220101-20221230" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfNi0xLTEtMS05Mzg3NA_66487d2f-f619-49d8-80ff-adb5606695d3">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i99b39711f74648d78882998f94841261_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfNi0zLTEtMS05Mzg1Mg_3d290d88-f5c9-4d9b-827b-94f698152b1e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3365323e5089466b94bbb9251d2fff94_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfNi01LTEtMS05Mzg1NQ_ca092ecc-6ca5-45a0-a3a5-7d0e13d5332c">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ied54335b6e124ce78abd0708eb3c5f6a_D20220101-20221230" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfMy0xLTEtMS05NzU4Nw_172f6497-3289-4e34-b57e-8b85ac0f0566">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i262b07d55db34a90b4349cb8911e546e_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfMy0zLTEtMS05NzU4Nw_a6ed92cd-7865-4f14-a678-6dd7d1857697">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic7239796cf414e5b9d7107ff0f6c6ba5_D20220101-20221230" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfMy0xLTEtMS05Mzk3Ng_aaafcbb2-0242-4be6-a62f-e9daa1738819">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72ae7ad08b2a48ae9bbf227c4be302ca_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfMy0zLTEtMS05Mzk2MQ_f71af2b1-ffa1-4719-9f0f-a69c971ed519">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id368c47c3f5d481db02eba2d8009c964_D20220101-20221230" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfNC0xLTEtMS05Mzk4NQ_8beeb1ee-f5df-4c8c-b8ab-abc0fae0252a">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i19da7b7d320c44d5b7e1755d3f209f69_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfNC0zLTEtMS05Mzk1OA_2d1decdc-3b57-471c-b434-eec5ca3b89a7">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d6fe72170844659b8059e439eb16e3c_D20220101-20221230" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfNy0xLTEtMS05Mzk4Mg_3814248d-2bec-4e93-ba71-6c6312654345">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e7719032719481b9bb97d521869817b_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfNy0zLTEtMS05Mzk1NQ_183a574a-ff70-40c5-9c74-ef0c61c35d31">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i82d900845d714ced98be563122eec84e_D20220101-20221230" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfOC0xLTEtMS0xMDk4OTE_22b6c31f-e0dc-4660-bb39-e18d66b33f1a">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic7e319ed079a4b688272f575c6d79fb7_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfOC0zLTEtMS0xMDk4ODg_b7cef721-d4c2-499f-a7df-ec714c3ed505">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTA3OA_a43ec7d8-982c-4487-939d-862b90794b59" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia505016291bc4b92966a63cb457f79cf_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfMi01LTEtMS05NDAwMQ_4d7293bf-7df5-403c-be72-06bc011994bb">1,413,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fc646f54374425da47c013312f9a8e2_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfMi03LTEtMS05Mzk5MQ_ba383408-4fd5-421e-b95c-2cdd648639e9">1,089,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7afa411719d4768beb18974c2d9df7d_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfMi05LTEtMS05Mzk5NA_d7240b5e-7d55-4d99-a92f-728d8f9708aa">752,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8173bdcf6bc42f08c968eda65dfc2a6_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfMy01LTEtMS05NDAwMQ_276588bf-b336-47d7-85e8-952f0651f411">168,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0ed898ca774d77b13b623d417de030_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfMy03LTEtMS05Mzk5MQ_c00e350f-6791-4346-8e28-6827bf1b82ed">302,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabb415230cfe48b99b7d9b8d3f6efd7e_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfMy05LTEtMS05Mzk5NA_f1c390da-b0d7-4154-8e85-d3ef4033bd04">151,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb1d7000657e4ce4b150b18dd4413a53_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfNC01LTEtMS05NDAwMQ_54a75e95-807a-4608-94f0-30c352d1f750">28,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2783aaa2794de7bb52b691c9662d08_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfNC03LTEtMS05Mzk5MQ_fb48080e-9212-4c21-8b1a-f2c4d0366a21">43,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied38d86192994bb4b9a4d9a3b0c3fa39_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfNC05LTEtMS05Mzk5NA_b575804d-9542-48ff-9b29-b9ce2de02bc6">83,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfNS01LTEtMS05MjE1MA_8ec888e9-fadd-4aa2-be52-4a78c9452151">1,611,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfNS03LTEtMS05MjE1MA_9f746fad-8c41-4c60-bc5f-e348827a9c7f">1,434,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfNS05LTEtMS05MjE1MA_4bdac1c5-b2a9-47ae-af95-76fbfb64ba25">987,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="ib78dbe8dc72a4c5384b507917828b67f" continuedAt="i4ba8b76b3fd94b3ca9789c8d5eb56441"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTA2OQ_06f97281-7032-4f6a-a37c-046ab9be0092" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2acaaacb5c8468bb06c3310cf75f928_I20210101" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMS0xLTEtMS05MjE1MA_8384881e-94ee-485d-9aa3-39af3f3e555c">9,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf3671d9a5af4d39a8d091071f92b7ff_I20210101" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMS0zLTEtMS05MjE1MA_0b10db07-173f-4d8f-951b-460baf108b05">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33892ff3208246fab5f7275cef00bcf7_I20210101" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMS01LTEtMS05MjE1MA_a765354b-7efd-4789-a2cc-d2923023826a">17,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0958ab0a7b904c6abbc804e49a0e9544_I20210101" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMS03LTEtMS05MjE1MA_343b6f08-4448-4d54-8450-d4db072a8385">30,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i991465767e2240f6921b76dcc130c033_D20210102-20211231" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMy0xLTEtMS05MjE1MA_8fa966bf-1518-4386-be68-fa27ee664d20">243,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60160fe976124e808a313207fe175c03_D20210102-20211231" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMy0zLTEtMS05MjE1MA_c2bc6562-7e02-48c2-a284-2fdadf7df280">30,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fec469537054a23b86c5d87638062e6_D20210102-20211231" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMy01LTEtMS05MjE1MA_7afbec70-ddbe-4ce8-b233-b1911def945c">100,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMy03LTEtMS05MjE1MA_d0cf0c98-ed63-47e2-abc6-0ad622d3946f">374,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i991465767e2240f6921b76dcc130c033_D20210102-20211231" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNC0xLTEtMS05MjE1MA_54ad165e-7d68-447b-b330-a5e71296e9a0">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60160fe976124e808a313207fe175c03_D20210102-20211231" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNC0zLTEtMS05MjE1MA_349c1d0a-881d-4f55-8d85-c73bd709a4a3">111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fec469537054a23b86c5d87638062e6_D20210102-20211231" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNC01LTEtMS05MjE1MA_137e2c1f-bad2-4d5f-8c04-988f11edd66d">1,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNC03LTEtMS05MjE1MA_b69faf14-d2f6-4add-bd2d-56a7155b67fc">1,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i991465767e2240f6921b76dcc130c033_D20210102-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNS0xLTEtMS05MjE1MA_0d665d7f-25ae-4d4e-bdb0-83e0eec102fa">238,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60160fe976124e808a313207fe175c03_D20210102-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNS0zLTEtMS05MjE1MA_d3d1bd42-a1ed-433b-9608-3353e91c48b5">25,021</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fec469537054a23b86c5d87638062e6_D20210102-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNS01LTEtMS05MjE1MA_5ed709b9-77f5-4e37-9df4-251879e61f25">94,564</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNS03LTEtMS05MjE1MA_33da7d7a-0dc9-4853-8f47-fcbe504951a1">357,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966ed994207841c3950965f3ec961e93_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNi0xLTEtMS05MjE1MA_4aff04a5-da96-485c-8981-796fc905f65d">14,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic667289b49764b95a7d7f096cb54a98b_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNi0zLTEtMS05MjE1MA_5231acbe-b2c1-4a66-9f15-5ce3f5aa1077">8,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1326a18371364e4d964deea38459c405_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNi01LTEtMS05MjE1MA_aac7fb1e-d500-4bc3-bdef-4979f710811f">24,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNi03LTEtMS05MjE1MA_2ef2bae4-a6bc-4e02-ac12-a5665400df1b">48,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f3424e5d624831b1f13418acf4a9c2_D20220101-20221230" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfOC0xLTEtMS05MjE1MA_2b416d1b-ea0a-4a3b-99c5-8004f5581de4">355,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i793cb0fdacf74d2d8650c8f711d32ff7_D20220101-20221230" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfOC0zLTEtMS05MjE1MA_794c7e2d-cdbb-4ec6-8d4c-3612821f992c">50,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a6accba75744f11a98c8b6488700e99_D20220101-20221230" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfOC01LTEtMS05MjE1MA_325a5916-ab3d-4d06-85e1-35e91fc14955">143,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfOC03LTEtMS05MjE1MA_bd1b33a5-33ab-415c-bca5-8cd911289af3">549,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f3424e5d624831b1f13418acf4a9c2_D20220101-20221230" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfOS0xLTEtMS05MjE1MA_43e18f2d-4ab3-49fb-9b55-ae06abdf1474">611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i793cb0fdacf74d2d8650c8f711d32ff7_D20220101-20221230" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfOS0zLTEtMS05MjE1MA_3d24fda0-0fde-4707-945c-116a6da6eb3f">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a6accba75744f11a98c8b6488700e99_D20220101-20221230" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfOS01LTEtMS05MjE1MA_689aaf1a-ac80-49b6-a545-66f883c544f9">209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfOS03LTEtMS05MjE1MA_ff3e28d5-9f9f-4407-8cd0-f87ee1c97942">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f3424e5d624831b1f13418acf4a9c2_D20220101-20221230" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMTAtMS0xLTEtOTIxNTA_a7e081f1-3909-48b6-925c-185ef20fe696">344,220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i793cb0fdacf74d2d8650c8f711d32ff7_D20220101-20221230" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMTAtMy0xLTEtOTIxNTA_295c7f42-ff27-4014-8a07-048126ffc646">44,094</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a6accba75744f11a98c8b6488700e99_D20220101-20221230" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMTAtNS0xLTEtOTIxNTA_229fcf6c-42a2-4475-85fa-bef3c912b7cb">132,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMTAtNy0xLTEtOTIxNTA_c97e1351-779e-4923-b504-bd704b5d75b3">521,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f96bba653a49e1ae627198e6f38b55_I20221230" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMTEtMS0xLTEtOTIxNTA_98d4e019-e4f7-41fd-a48b-ee0bf5717944">26,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27f15e30b5a74aa49673c0f2c8433728_I20221230" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMTEtMy0xLTEtOTIxNTA_13628f41-56de-4597-8b73-add77ebb56ce">14,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic81d2dff655c411a851f03dcaae0e471_I20221230" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMTEtNS0xLTEtOTIxNTA_6f9b1ea9-4fcb-4c5d-94af-3e1752e58ce2">35,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMTEtNy0xLTEtOTIxNTA_ac1db428-af3a-43f9-acfb-9e365ff58594">77,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. As of December&#160;31, 2022 and 2021, respectively, contract assets are primarily related to contract assets from Ipsen Pharma SAS (Ipsen) and c</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ontract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTA3Ng_8e3c01b6-fef4-44e9-a1ff-2270141e1efa" continuedAt="i04a3152778d64073b9a873633a763580" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjU1Y2YwYzI5MDU1YTQ2YTFhYWI5YThhNzU4MGMwYjIwL3RhYmxlcmFuZ2U6NTVjZjBjMjkwNTVhNDZhMWFhYjlhOGE3NTgwYzBiMjBfMi0xLTEtMS05MjE1MA_b323861b-2559-44e1-862f-812de1425e74">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjU1Y2YwYzI5MDU1YTQ2YTFhYWI5YThhNzU4MGMwYjIwL3RhYmxlcmFuZ2U6NTVjZjBjMjkwNTVhNDZhMWFhYjlhOGE3NTgwYzBiMjBfMi0zLTEtMS05MjE1MA_c9340da9-61a2-44ab-a8cd-f646f3e6e678">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjU1Y2YwYzI5MDU1YTQ2YTFhYWI5YThhNzU4MGMwYjIwL3RhYmxlcmFuZ2U6NTVjZjBjMjkwNTVhNDZhMWFhYjlhOGE3NTgwYzBiMjBfNS0xLTEtMS05MjE1MA_fb395738-6461-465a-a8f5-5ed899d4ca6f">7,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjU1Y2YwYzI5MDU1YTQ2YTFhYWI5YThhNzU4MGMwYjIwL3RhYmxlcmFuZ2U6NTVjZjBjMjkwNTVhNDZhMWFhYjlhOGE3NTgwYzBiMjBfNS0zLTEtMS05MjE1MA_e35ebc2c-63a7-4eed-9b1b-5632e337675f">7,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjU1Y2YwYzI5MDU1YTQ2YTFhYWI5YThhNzU4MGMwYjIwL3RhYmxlcmFuZ2U6NTVjZjBjMjkwNTVhNDZhMWFhYjlhOGE3NTgwYzBiMjBfNi0xLTEtMS05MjE1MA_9d0e498c-4b30-498c-b589-045684418efd">6,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjU1Y2YwYzI5MDU1YTQ2YTFhYWI5YThhNzU4MGMwYjIwL3RhYmxlcmFuZ2U6NTVjZjBjMjkwNTVhNDZhMWFhYjlhOGE3NTgwYzBiMjBfNi0zLTEtMS05MjE1MA_6ba2f695-52bf-4c13-a99b-30df71f64fbf">8,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjU1Y2YwYzI5MDU1YTQ2YTFhYWI5YThhNzU4MGMwYjIwL3RhYmxlcmFuZ2U6NTVjZjBjMjkwNTVhNDZhMWFhYjlhOGE3NTgwYzBiMjBfNy0xLTEtMS05MjE1MA_41c20800-ef66-4d64-a552-4fda5e0c1b7c">14,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjU1Y2YwYzI5MDU1YTQ2YTFhYWI5YThhNzU4MGMwYjIwL3RhYmxlcmFuZ2U6NTVjZjBjMjkwNTVhNDZhMWFhYjlhOGE3NTgwYzBiMjBfNy0zLTEtMS05MjE1MA_7c25059b-3a82-4536-9f03-f03d259d4a5f">16,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Presented in other long-term assets in the accompanying Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Presented in other current liabilities in the accompanying Consolidated Balance Sheets.</span></div></ix:nonNumeric><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"><ix:continuation id="i04a3152778d64073b9a873633a763580" continuedAt="i218994badfd140f5804597c4278add78">(3)</ix:continuation></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i218994badfd140f5804597c4278add78">&#160;&#160;&#160;&#160;Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets.</ix:continuation> </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div><span><br/></span></div><ix:continuation id="i4ba8b76b3fd94b3ca9789c8d5eb56441"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-5" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTQ5NzU1ODE5MDEx_aa6158e9-ab24-4835-995a-2971ab089204">8.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-5" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTQ5NzU1ODE4OTg2_fdbc87f3-f9a9-45d1-82a6-4814e2772a51">8.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-5" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTQ5NzU1ODE4OTkw_2c146725-9498-49e1-bd50-973a2d770efc">9.2</ix:nonFraction>&#160;million, respectively, in revenues that were included in the beginning deferred revenues balance for those years. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2022, 2021 and 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTQ5NzU1ODE5MDQw_b59dd265-ab43-408b-a841-37cae4fa10db">161.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTQ5NzU1ODE5MDM2_e3ce159c-a9d4-4e25-8af2-9c77edaea2c6">148.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTQ5NzU1ODE5MDMy_a622c8e1-83ad-4dda-9580-ba3daf8dfd50">169.7</ix:nonFraction>&#160;million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to milestone and royalty payments allocated to our license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNDY2Mw_e34cfb0a-9bc7-4ff2-a5f0-0a7a4c10f6e4">73.0</ix:nonFraction> million of the combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements&#8212; Cabozantinib Collaborations &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information about the expected timing to satisfy these performance obligations.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="ia855702135904005a41d208deb24e60a_88"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMzI0OTQ_1390e47e-2565-47b3-88fe-dea2577ded95" continuedAt="i7da0d2d93d414e53a1cf4e65c494918a" escape="true">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</ix:nonNumeric></span></div><ix:continuation id="i7da0d2d93d414e53a1cf4e65c494918a" continuedAt="iec6cf0d126984f7fba689471358aa160"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading biopharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have made considerable progress under our existing research collaboration and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading biopharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, to receive payments for product supply services, development cost reimbursements, and/or profit-sharing payments. See &#8220;Note 2. Revenues&#8221; for additional information on revenues recognized under our collaboration agreements during the years ended December&#160;31, 2022, 2021 and 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Commercial Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, we entered into a collaboration and license agreement with Ipsen, which was subsequently amended, for the commercialization and further development of cabozantinib. Under the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, Ipsen opted into and is now co-funding the development costs for COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with RAI-refractory DTC who have progressed after up to two VEGF receptor-targeted therapies. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ipsen </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s obligated to reimburse us for their share of COSMIC-311 global development costs, as well as an additional payment calculated as a percentage of such costs, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">triggered by the timing of the exercise of its option. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the decision to opt in and co-fund the development costs for COSMIC-311 represented a contract modification for additional distinct services at their standalone selling price and therefore was treated as a separate contract under Topic 606. Accordingly, collaboration services revenues for the year ended December&#160;31, 2021, includes a cumulative catch-up of $<ix:nonFraction unitRef="usd" contextRef="i70318e17c7ab4b68b6b925151523736a_D20210102-20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODU1MzQ4_faa055a7-2901-4cc7-a359-4f6cfca318b6">43.2</ix:nonFraction> million for Ipsen&#8217;s share of global development costs incurred since the beginning of the study and through the opt-in date.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (1) the expiration of patent claims related to cabozantinib, (2) the expiration of regulatory exclusivity covering cabozantinib or (3) <ix:nonNumeric contextRef="id4f5961955974e53a8d6b5ad85acfe4d_D20220101-20221230" name="exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMzI5Ng_385b4163-e5b1-43fa-b4e9-f58391d44662">ten years</ix:nonNumeric> after the first commercial sale of cabozantinib, other than COMETRIQ. A related supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="iec6cf0d126984f7fba689471358aa160" continuedAt="ib18980b7d5a4457dab6a1121aad4fe27"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the FDA or European Medicines Agency orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration under the Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, we received aggregate upfront payments of $<ix:nonFraction unitRef="usd" contextRef="i39c122c614074046abcfbcc446a1fa98_D20160101-20161231" decimals="-5" name="exel:UpfrontPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTA2MA_386064b9-2a74-4a42-b1ed-da0ff33a8dfe">210.0</ix:nonFraction> million from Ipsen in 2016. As of December&#160;31, 2022, we have achieved aggregate milestones of $<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-5" name="exel:MilestonePaymentsEarnedToDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODQ2NDAy_0651efb8-a988-4913-a9f3-e36cd86adef7">489.5</ix:nonFraction>&#160;million related to regulatory, development and sales-based threshold by Ipsen since the inception of the collaboration agreement, including $<ix:nonFraction unitRef="usd" contextRef="id4f5961955974e53a8d6b5ad85acfe4d_D20220101-20221230" decimals="-5" name="exel:MilestonePaymentsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODQ2NDI4_dfcfef91-c408-48ab-a9d9-f7b7eb64c4e1">27.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ibad41c5a867e42328f87a6be4ab95e02_D20210102-20211231" decimals="-5" name="exel:MilestonePaymentsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTI2OQ_cdc96c2a-efe8-4a83-800d-156e7e2e3268">112.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ibce8519fb88b4643a598a9f10397b3fb_D20200104-20210101" decimals="-5" name="exel:MilestonePaymentsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTI3Mw_270edb49-3189-414e-9ef1-b4fcfdc90dd9">20.0</ix:nonFraction> million in milestones achieved during the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we are eligible to receive additional regulatory and development milestone payments from Ipsen totaling an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i9fc4fe1515e740b5b2fedc80ab3c29d8_I20221230" decimals="-5" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ4OA_c79fda68-8f4e-43b7-a111-e9091a805a6f">19.5</ix:nonFraction> million, as well as sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to $<ix:nonFraction unitRef="usd" contextRef="i9fc4fe1515e740b5b2fedc80ab3c29d8_I20221230" decimals="-5" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTYxNg_57dff7a9-59c9-41c7-bc50-2b9794c0f6f5">350.0</ix:nonFraction> million and CAD$<ix:nonFraction unitRef="cad" contextRef="i9fc4fe1515e740b5b2fedc80ab3c29d8_I20221230" decimals="-5" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODU1NDE2_b39b6ab7-451e-48db-9107-371f3e2644b3">26.5</ix:nonFraction> million. We excluded these milestones from the transaction price as of December&#160;31, 2022 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will adjust the constraint applied to the variable consideration at each reporting period as uncertain events are resolved or other changes in circumstances occur. See </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;&#8212;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, below, for additional information related to the revenue recognition for this collaboration.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receive royalty revenues on the net sales of cabozantinib by Ipsen outside of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he U.S. and Japan. During the year ended December&#160;31, 2022 and going forward, we are entitled to receive a tiered royalty of <ix:nonFraction unitRef="number" contextRef="i850883eb6ca848ccbe6e3680f28bee20_D20220101-20221230" decimals="INF" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNjYzMw_a909a68c-8e4a-4e2f-9a2d-9613f67c4515">22</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i125cc20cc74341a5b27b3efd37225cf0_D20220101-20221230" decimals="INF" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNjYzOQ_cf48603d-7b13-4b51-a813-8d208bc6c3e2">26</ix:nonFraction>% on annual net sales, with separate tiers for Canada; these royalty tiers reset each calendar year.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to pay a <ix:nonFraction unitRef="number" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNzAzMA_5a648cd1-55ae-4694-a849-c97b484311de">3</ix:nonFraction>% royalty on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for <ix:nonFraction unitRef="number" contextRef="id4f5961955974e53a8d6b5ad85acfe4d_D20220101-20221230" decimals="2" name="exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNzQwOA_1da0493f-c681-4c5e-af86-81a760826778">35</ix:nonFraction>% of such costs, provided Ipsen chooses to opt into such trials. Ipsen has opted into and is co-funding certain clinical trials, including: CheckMate-9ER, COSMIC-021, COSMIC-311, COSMIC-312, CONTACT-01 and CONTACT-02.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain responsible for manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. Relatedly, we entered into a supply agreement with Ipsen to supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. The product is supplied at our cost, as defined in the agreement. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from territories outside of U.S. and Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Japan.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="ib18980b7d5a4457dab6a1121aad4fe27" continuedAt="i27d3a089fa91466a9a5cbf48d19fc50f"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from the Collaboration </span></div><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMzI1MDA_2f51d752-e9d0-4ab8-9fcd-d9ee00006f54" continuedAt="i14bcc173fef84e02a2869e826c2ddeea" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9cf65a286f4e7da9b13796a041f58f_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfMi01LTEtMS05MjE1MA_8eb0eb64-25cc-4ce7-9771-eb64ec250430">133,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib11873105d5440f2b04ad3921ee0e374_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfMi03LTEtMS05MjE1MA_94c0e7c3-a6ab-4fd6-900f-a5fd4644c03b">207,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4810c81a75b84f8b964fb340d02890c0_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfMi05LTEtMS05MjE1MA_32fdf79f-35f4-4603-9c1c-467499d18e9f">93,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49ad1f5b50641398e4bd5e6a19ec508_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfMy01LTEtMS05MjE1MA_33c3d9ac-bd66-4c2b-a664-82ddd9516165">34,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70318e17c7ab4b68b6b925151523736a_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfMy03LTEtMS05MjE1MA_87636b4b-a00b-4fa9-87f5-eeefc4e12ffb">94,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b1223169902474aafc57a25d19dcaff_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfMy05LTEtMS05MjE1MA_5988de9e-01fc-49c3-be87-c9679908644b">58,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4f5961955974e53a8d6b5ad85acfe4d_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfNC01LTEtMS05MjE1MA_9d64ed07-5cae-4620-8394-013544f88eb9">168,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibad41c5a867e42328f87a6be4ab95e02_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfNC03LTEtMS05MjE1MA_cf3cf0f8-e750-4501-ab63-04e2939b04d5">302,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce8519fb88b4643a598a9f10397b3fb_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfNC05LTEtMS05MjE1MA_82c710ce-b563-44a6-8cf1-08891f7169b2">151,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, we recognized $<ix:nonFraction unitRef="usd" contextRef="i9fc4fe1515e740b5b2fedc80ab3c29d8_I20221230" decimals="-5" name="exel:RevenueFromContractWithCustomerCommercialSalesMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODU1NzU3_ce189c7d-db5a-4689-bf06-b3e301c84f57">25.8</ix:nonFraction>&#160;million in revenues in connection with two regulatory milestones totaling $<ix:nonFraction unitRef="usd" contextRef="i9fc4fe1515e740b5b2fedc80ab3c29d8_I20221230" decimals="-5" name="exel:RevenueFromContractWithCustomerRegulatoryMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODU1ODMw_c07ccded-e91d-4a3e-ab1f-54c36f67b2a6">27.0</ix:nonFraction>&#160;million upon approval by the EC and Health Canada, of cabozantinib a monotherapy for the treatment of adult patients with locally advanced or metastatic DTC, refractory or not eligible to RAI who have progressed during or after prior systemic therapy.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i9fc4fe1515e740b5b2fedc80ab3c29d8_I20221230" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODU1NTcy_1029cc79-a75d-4180-a883-5cd529a55b41">35.4</ix:nonFraction> million of the transaction price was allocated to our research and development services performance obligation that has not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended effective March 2018, May 2019 and September 2020, to, among other things, modify the amount of reimbursements we receive, for costs associated with our required pharmacovigilance activities and milestones we are eligible to receive, as well as modify certain cost-sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda is responsible for a portion of the costs associated with the cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and <ix:nonFraction unitRef="number" contextRef="i1d5c30fce06545d9a3baacb0b0ab774e_D20220101-20221230" decimals="INF" name="exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTA1MTQ_84e67f75-23f6-42ed-9ce6-a1dfc1636194">100</ix:nonFraction>% of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Takeda has opted into and is co-funding CheckMate-9ER, certain cohorts of COSMIC-021, CONTACT-01 and CONTACT-02. Under the collaboration agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (1) <ix:nonNumeric contextRef="i1d5c30fce06545d9a3baacb0b0ab774e_D20220101-20221230" name="exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTEyODY_51484e6a-42da-4e42-92d6-4d1428d3259a">two years</ix:nonNumeric> after first generic entry with respect to such product in Japan or (2) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration under the Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ifaedfc761d77477d83685f07ca670fc4_D20170101-20171231" decimals="-5" name="exel:UpfrontPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTI2NzA_3b72bf1c-4e7c-4b45-bccb-fef18179ec0a">50.0</ix:nonFraction> million from Takeda in 2017. As of December&#160;31, 2022, we have also achieved regulatory and development milestones in the aggregate of $<ix:nonFraction unitRef="usd" contextRef="i337a214cbd1b44929248114a2eb85662_I20221230" decimals="-5" name="exel:MilestonePaymentsEarnedToDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODQ2NTAy_df4109e1-0474-45a6-af9b-be25e4b46612">127.0</ix:nonFraction>&#160;million since the inception of the collaboration agreement, including $<ix:nonFraction unitRef="usd" contextRef="i5e5a7fdf85fc4fc7bfa8e4d51f47e59b_D20220101-20221230" decimals="-5" name="exel:MilestonePaymentsEarned" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTY0OTI2NzUwMzk5OA_e1714451-4256-4e98-b821-0b9025082032">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="id1f50051810c4c1faeb0643d2151e699_D20210102-20211231" decimals="-5" name="exel:MilestonePaymentsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTI4NDk_594b7049-0ee5-4fba-901b-b816ebaefc31">35.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i071e191539a447ab937022c70f4066ae_D20200104-20210101" decimals="-5" name="exel:MilestonePaymentsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTI4NTM_e531de5a-1787-4d82-bbd1-4ea72fab013b">66.0</ix:nonFraction> million in milestones achieved during the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, as amended in 2020, we are eligible to receive additional regulatory and development milestone payments, without contractual limit, for additional potential future indications. We are further eligible to receive commercial milestones, including milestone payments earned for the first commercial sale of a product, </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="i27d3a089fa91466a9a5cbf48d19fc50f" continuedAt="i4e196932db954d7ca3a3413d7e3cf86c"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $<ix:nonFraction unitRef="usd" contextRef="i337a214cbd1b44929248114a2eb85662_I20221230" decimals="-5" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTMyOTU_a173aff2-e0a1-448f-8a48-b57673c748d5">119.0</ix:nonFraction> million. We excluded these milestones from the transaction price as of December&#160;31, 2022 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will adjust the constraint applied to the variable consideration at each reporting period as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also receive royalty revenues on the net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of <ix:nonFraction unitRef="number" contextRef="ia3ca226cd81a48daacc85597ee8e0f61_D20220101-20221230" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTM5MDM_b83e4408-f0fd-4757-a857-d60612f537c9">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i2ae1f8be861d4b04aa760182f4297029_D20220101-20221230" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTM5MDk_d371b582-bbd4-43d6-b493-46d6750f252b">24</ix:nonFraction>% on the initial $<ix:nonFraction unitRef="usd" contextRef="i4d556ca23f9e45b4b9ed6c03f967c59b_D20220101-20221230" decimals="-5" name="exel:RoyaltyTier" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTM5Mjc_cea65172-33c9-4c42-8739-6a09dbc587be">300.0</ix:nonFraction>&#160;million of net sales, and following this initial $<ix:nonFraction unitRef="usd" contextRef="i4d556ca23f9e45b4b9ed6c03f967c59b_D20220101-20221230" decimals="-5" name="exel:RoyaltyTier" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTM5NzE_62c8ffc4-d218-4835-877c-66555dea9220">300.0</ix:nonFraction>&#160;million of net sales, we are then entitled to receive a tiered royalty of <ix:nonFraction unitRef="number" contextRef="idc4a5bca80f542428c9f79064ba8ff59_D20220101-20221230" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTQwNDA_2668deec-e143-4a1f-abfa-bbab627c542a">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i3a65d7d772494943b214d873b45da310_D20220101-20221230" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTQwNDY_fe5ca1e6-a583-4668-b44b-ca38a02556e9">30</ix:nonFraction>% on annual net sales thereafter; these <ix:nonFraction unitRef="number" contextRef="idc4a5bca80f542428c9f79064ba8ff59_D20220101-20221230" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTQwODc_6fb8802e-4719-4670-85a3-1bdb09130425">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i3a65d7d772494943b214d873b45da310_D20220101-20221230" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTQwOTM_c341196b-7538-42de-befa-963302692fb2">30</ix:nonFraction>% royalty tiers reset each calendar year. Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to pay a <ix:nonFraction unitRef="number" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTQ0MjU_5a648cd1-55ae-4694-a849-c97b484311de">3</ix:nonFraction>% royalty on all net sales of any product incorporating cabozantinib, including net sales by Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, we are responsible for the manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. Relatedly, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a safety data exchange agreement, which defines each partner&#8217;s responsibility for safety reporting. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from the Collaboration</span></div><ix:continuation id="i14bcc173fef84e02a2869e826c2ddeea"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt;text-indent:36pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt;text-indent:36pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice176fd5f4104315b8f2c270962294fa_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfMi01LTEtMS05MjE1MA_022467ab-12bf-4c5f-b3bd-8587ca39e21c">11,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206233ca66af4b1a9cf478e3d8d24963_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfMi03LTEtMS05MjE1MA_630314f8-930f-4623-8065-9bb9c6969d52">26,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aa5c591d2414c088c15c92ff3156418_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfMi05LTEtMS05MjE1MA_0f5fb563-295d-4411-b47c-68b5a326cd1e">61,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbc3624e7a294295a982185658426bfe_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfMy01LTEtMS05MjE1MA_5ef8f237-78d4-472f-9ec4-1df38dccdaca">12,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82f90a00897a46f1957e0414cc090bbe_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfMy03LTEtMS05MjE1MA_ae0bd595-9a32-4d99-bf49-94c777c8223e">13,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5276ec4d64fb4ba49c9c540fea11a982_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfMy05LTEtMS05MjE1MA_9db99342-4a8c-400f-bb8e-565d86afb738">20,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e5a7fdf85fc4fc7bfa8e4d51f47e59b_D20220101-20221230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfNC01LTEtMS05MjE1MA_6240280b-4eda-4c0a-9dcf-628ba7683f52">24,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f50051810c4c1faeb0643d2151e699_D20210102-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfNC03LTEtMS05MjE1MA_a5ae9790-7541-4c25-88e6-953887d5033f">39,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071e191539a447ab937022c70f4066ae_D20200104-20210101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfNC05LTEtMS05MjE1MA_36b2cac9-6cbe-48db-bb93-b397ab95fafd">81,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i337a214cbd1b44929248114a2eb85662_I20221230" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTU5MTE_a9056b80-819c-4be3-aa16-09709ab72a89">37.6</ix:nonFraction>&#160;million of the transaction price was allocated to our research and development services performance obligations that have not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is one remaining performance obligation for the Ipsen collaboration agreement: the research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements). As part of the original contract, we also had a performance obligation associated with exclusive license for the commercialization and further development of cabozantinib, which was transferred in 2016. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are two remaining performance obligations for the Takeda collaboration agreement: (1) the research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements) and (2) the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. As part of the original contract, we had a performance obligation associated with the exclusive license for the commercialization and further development of cabozantinib, which was transferred in 2017.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have allocated the transaction price for each of these collaborations to the originally identified performance obligations based on our best estimate of their relative standalone selling price. For the licenses, the estimate of the relative standalone selling price was determined using a discounted cash flow valuation utilizing forecasted revenues and </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="i4e196932db954d7ca3a3413d7e3cf86c" continuedAt="i0a9052d03a094955af8470c35e26f4c4"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs. For research and development services the estimate of the relative standalone selling price was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The portion of the transaction price allocated to our license performance obligation is recorded immediately as our license represents functional intellectual property that was transferred at a point in time. The portion of the transaction price allocated to our research and development services performance obligation is being recognized as revenue using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union for the Ipsen collaboration and Japan for the Takeda collaboration, both of which are early 2030. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust the constraint applied to the variable consideration for the collaboration agreements in each reporting period as uncertain events are resolved or other changes in circumstances occur and we allocate those changes in the transaction price between our performance obligations. During the years ended December&#160;31, 2022, 2021 and 2020, the transaction price of the Ipsen and Takeda collaboration agreements increased as a result of the achievement of various milestones, and the reimbursements of research and development services related to committed and opt-in studies. We further updated the transaction price based upon the actual research and development services performed during the period and changes in our estimated reimbursements for our future research and development services. The portion of the increase in transaction price that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license was recognized during the period and the portion allocated to research and development services will be recognized in future periods as those services are delivered through early 2030. As of December&#160;31, 2022, variable consideration related to the remaining unearned regulatory and development milestones for both agreements remained constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Development Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BMS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#8217;s immune checkpoint inhibitors (ICIs), nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab as a treatment option for RCC in the COSMIC-313 trial. Under the collaboration agreement with BMS, we may also evaluate these combinations in other phase 3 pivotal trials in various other tumor types. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement with BMS, as amended, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts are governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial is conducted under a combination Investigational New Drug application, unless otherwise required by a regulatory authority. Each party is responsible for supplying finished drug product for the applicable clinical trial, and responsibility for the payment of costs for each such trial will be determined on a trial-by-trial basis. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">F. Hoffmann-La Roche Ltd. (Roche) Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#8217;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. Under this agreement with Roche, in June 2017, we initiated COSMIC-021, a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors, and in December 2018, we initiated COSMIC-312, a multicenter, randomized, controlled phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC. We are the sponsor of both trials, and Roche is providing atezolizumab free of charge.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a joint clinical research agreement with Roche for the purpose of further evaluating the combination of cabozantinib with atezolizumab in patients with locally advanced or metastatic solid tumors, </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="i0a9052d03a094955af8470c35e26f4c4" continuedAt="i69ae85071cce4bea81d26543c9f1d209"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including in the phase 3 pivotal clinical trials in advanced non-small cell lung cancer (CONTACT-01), metastatic castration-resistant prostate cancer (CONTACT-02) and RCC (CONTACT-03). If a party to the joint clinical research agreement proposes any additional combined therapy trials beyond these phase 3 pivotal trials, the joint clinical research agreement provides that such proposing party must notify the other party and that if agreed to, any such additional combined therapy trial will become part of the collaboration, or if not agreed to, the proposing party may conduct such additional combined therapy trial independently, subject to specified restrictions set forth in the joint clinical research agreement.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, a supplement to the joint clinical research agreement was signed amongst us, Roche and Takeda due to Takeda opting into fund the combined therapy trial of CONTACT-01 sponsored by Roche. Chugai was added as an affiliate of Roche.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All parties including Chugai conduct combined therapy trials in Japan upon the terms of the joint clinical research agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the joint clinical research agreement, each party granted to the other a non-exclusive, worldwide (excluding, in our case, territory already the subject of a license by us to Takeda), non-transferable, royalty-free license, with a right to sublicense (subject to limitations), to use the other party&#8217;s intellectual property and compounds solely as necessary for the party to perform its obligations under the joint clinical research agreement. The parties&#8217; efforts will be governed through a joint steering committee established to guide and oversee the collaboration and the conduct of the combined therapy trials. Each party will be responsible for providing clinical supply of their drug for all combined therapy trials, and the cost of the supply will be borne by such party. The clinical trial expenses for each combined therapy trial agreed to be conducted jointly under the joint clinical research agreement will be shared equally between the parties, and the clinical trial expenses for each additional combined therapy trial not agreed to be conducted jointly under the joint clinical research agreement will be borne by the proposing party, except that the cost of clinical supply for all combined therapy trials will be borne by the party that owns the applicable product. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the contract is within the scope of Topic 808 as it involves joint operating activities where both parties have active participation in the arrangement and are exposed to significant risks and rewards. Payments between us and Roche under this arrangement are not subject to other accounting literature. Payments due to Roche for our share of clinical trial costs incurred by Roche will be recorded as research and development expense and payments due from Roche for their share of clinical trial costs incurred by us will be recorded as a reduction of research and development expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the joint clinical research agreement provides that it will remain in effect until the completion of all combined therapy trials under the collaboration, the delivery of all related trial data to both parties, and the completion of any then agreed-upon additional analyses. The joint clinical research agreement may be terminated for cause by&#160;either party based on any uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party will terminate upon completion of any ongoing activities under the joint clinical research agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK and Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GlaxoSmithKline (GSK), that required us to pay a <ix:nonFraction unitRef="number" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMjY4MTE_5a648cd1-55ae-4694-a849-c97b484311de">3</ix:nonFraction>% royalty to GSK on the total worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. Effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on total net sales of any product containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalty fees earned by GSK and Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalty fees earned by GSK and Royalty Pharma were $<ix:nonFraction unitRef="usd" contextRef="i41fe2331cabe4050a30129ee051c2799_D20220101-20221230" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMjc1NjY_93295342-037a-41c2-a484-17f24ad81631">58.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8bc9a78c8ba049f1946264d1c52f58e9_D20210102-20211231" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMjc1NzA_48aacdf8-ecc3-4032-a0c5-99044ea56818">46.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8d753c4338ff47ef84b0c40394bd5147_D20200104-20210101" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMjc1Nzc_6dccfb19-5426-41dd-b07b-51bb0b0bbcf7">32.7</ix:nonFraction> million during the years ended December&#160;31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have out-licensed to Genentech under a worldwide collaboration agreement, the development and commercialization of cobimetinib, under the brand name COTELLIC. The terms of the collaboration agreement require that we share in the profits and losses received or incurred in connection with the commercialization of COTELLIC in the U.S. In </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="i69ae85071cce4bea81d26543c9f1d209" continuedAt="i824499adf4a542e1a885a2197e95d3d9"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition to our profit share in the U.S., we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="i2c3596696fae4d9fb41163e7ddd3e386_D20220101-20221230" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMjgyMTI_803c866e-c884-4d85-96a3-915cc7152601">12.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7048757da4c04483a7c963e440b237a5_D20210102-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMjgyMTY_35714d28-afd7-49ee-9676-fd581b4220c9">12.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i8b2a018fee9e45548471c0835e50f5b6_D20200104-20210101" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMjgyMjQ_ff12de1b-0ba8-41d5-8a3c-137ada810499">11.3</ix:nonFraction> million, in revenues from profits and losses on U.S commercialization and royalties on ex-U.S. sales under the collaboration agreement with Genentech and are included within license revenues on our Consolidated Statements of Income.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into collaborative arrangements with other pharmaceutical or biotechnology companies to develop and commercialize drug candidates or intellectual property. Our research collaborations and in-licensing arrangements are intended to enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Our research collaborations, in-licensing arrangements and other strategic transactions include upfront payments, development, regulatory, commercial milestone payments and royalty payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations provide us exclusive options that give us the right to license programs or acquire the intellectual property developed under the research collaborations for further discovery and development. When we decide to exercise the options, we are required to pay an exercise fee and then assume the responsibilities for all subsequent clinical development, manufacturing and commercialization. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we entered into an exclusive option and license agreement with BioInvent International AB (BioInvent), upon which we paid an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i02a9e43c4eda4262b8e648fb4debd1eb_D20220601-20220630" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODY1OTI5_34e003d6-6c34-4c6a-a938-803ac4b3289c">25.0</ix:nonFraction>&#160;million. If we decide to exercise the option, we will pay BioInvent an option exercise fee, and BioInvent would be eligible for additional payments from us for future development and commercial milestones, as well as royalties on future net sales of products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we entered into an agreement with Cybrexa Therapeutics, LLC (Cybrexa), which provides us the right to acquire CBX-12 (alphalex&#8482; exatecan), a clinical-stage peptide-drug conjugate that utilizes Cybrexa&#8217;s proprietary alphalex technology to enhance delivery of exatecan to tumor cells. Under the terms of the agreement, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i1d84069f159b428fbda44b41dd831144_D20221101-20221130" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODU5NzMw_794f4173-d1dd-4223-96ff-9fc0aeff9733">60.0</ix:nonFraction>&#160;million for a warrant entitling us to the right to acquire the Cybrexa affiliate that controls CBX-12 and related assets, and to fund certain development and manufacturing expenses incurred by Cybrexa to advance CBX-12 during the warrant period. Cybrexa will continue the development of CBX-12 according to an agreed development plan, including phase 1 studies, and may be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i5ec846e4aef84ad2ae39d1d13246bfc6_I20221130" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODYwMTI1_0ecd9f2a-3259-457f-a4eb-ed68de8c4a4b">65.0</ix:nonFraction>&#160;million in additional development milestone payments, during the warrant period. We may exercise the warrant for up to $<ix:nonFraction unitRef="usd" contextRef="i1d84069f159b428fbda44b41dd831144_D20221101-20221130" decimals="-5" name="exel:CollaborativeArrangementMaximumAmountOfWarrantExercise" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODYwMjQw_991cbff4-4d9a-4ea1-904c-230bf79bd3c2">300.0</ix:nonFraction>&#160;million based upon our evaluation of a pre-specified clinical data package to be delivered by Cybrexa. Following exercise of the warrant, Cybrexa would be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i1d84069f159b428fbda44b41dd831144_D20221101-20221130" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODYwNDE3_919fb5e5-f44e-40c6-832b-3f47ee7295f3">277.5</ix:nonFraction>&#160;million in additional payments upon achievement of further regulatory and commercial milestones.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined our arrangement with Cybrexa constitutes a variable interest in the Cybrexa affiliate that controls CBX-12 and related assets, and that the Cybrexa affiliate is a VIE; however, we are not the primary beneficiary of the Cybrexa affiliate as we do not control the activities that are most significant to the Cybrexa affiliate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accounted for our arrangement with Cybrexa as an acquisition of in-process research and development technology that does not have an alternative future use, and accordingly, recognized the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ifd58ac0e41e340fc877768fad90c5f62_D20220101-20221230" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMzg0ODI5MDc1NzgzMg_2bb8b665-f7d1-44ba-aaee-7a9277f35fb8">60.0</ix:nonFraction>&#160;million in research and development expenses during the year-ended December 31, 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we entered into an exclusive option and license agreement with Sairopa, B.V. (Sairopa). Under the terms of the agreement, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i3334291a8ef14e57a8f54daf44f344c8_D20221101-20221130" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODYwNzIx_7252bdad-e03c-4af7-b8d1-9081e47f9622">40.0</ix:nonFraction>&#160;million for an option to obtain an exclusive, worldwide license to develop and commercialize ADU-1805 and other anti-SIRP&#945; antibodies. Sairopa is eligible to receive additional development milestone payments during the option period totaling up to $<ix:nonFraction unitRef="usd" contextRef="id6fd500061c74be88ef95fc875ef99af_I20221130" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODYxMDY4_5ebb09ef-7464-4925-abdb-342213fa40f4">97.5</ix:nonFraction>&#160;million. Following the completion of the clinical studies, we may exercise the option for $<ix:nonFraction unitRef="usd" contextRef="i3334291a8ef14e57a8f54daf44f344c8_D20221101-20221130" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsExerciseAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODYxMTU0_935a577e-1a96-43e2-9481-ecff4ca1fd8b">225.0</ix:nonFraction>&#160;million based upon our evaluation of a pre-specified clinical data package to be delivered by Sairopa. Following the exercise of the option, Sairopa would be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i3334291a8ef14e57a8f54daf44f344c8_D20221101-20221130" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODYxMzM0_66fe142e-e6c4-41c2-90ee-3826aff5a6ce">465.0</ix:nonFraction>&#160;million in additional payments upon achievement of further development and commercial milestones, as well as royalties on future net sales of products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we entered into a new license agreement with Catalent, Inc.&#8217;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc., (individually and collectively referred to as Catalent). Under the terms of the agreement, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ia026be7c5b9b41a3a54316d617e77f69_D20221101-20221130" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODY4MTc4_10932ea2-6fd9-44e1-bdf3-3655f94bbc53">30.0</ix:nonFraction>&#160;million in exchange for rights to three biologics programs. We will also contribute research funding to Catalent for discovery and preclinical </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="i824499adf4a542e1a885a2197e95d3d9"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development work. Catalent would be eligible to receive potential future development, regulatory and commercial milestone payments, as well as royalties on future net sales of products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="ia0f7c864ef914e8b9ebcaa0c64e1ece3_D20220101-20221230" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODY2Mjk5_7e6f7b08-6e76-4c75-a6f8-db365f061161">203.9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="id82fc91049724181b2a5e0f40253e48c_D20210102-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODY2MzA1_ff9488ad-fa37-4f36-b0ac-cf36a0f22a48">176.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i361ef59b0f2e4fddaf4c38b878d30ec0_D20200104-20210101" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODY2MzEz_062eede4-af94-46c0-8574-3a5ceb717376">96.4</ix:nonFraction>&#160;million, respectively, relating to upfront license payments, research and development funding, development milestones, option fees and other fees within research and development expenses on the Consolidated Statements of Income. During the year ended December&#160;31, 2022, we reversed $<ix:nonFraction unitRef="usd" contextRef="ia0f7c864ef914e8b9ebcaa0c64e1ece3_D20220101-20221230" decimals="-5" sign="-" name="exel:IncreaseDecreaseInResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODc3MDky_c6543642-0415-46cc-9703-d1488f59b0f2">12.5</ix:nonFraction>&#160;million of previously recorded research and development expenses associated with a development milestone. The impact of the change in estimate on our basic and diluted earnings per share for the fiscal year ended December&#160;31, 2022 was an increase of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia0f7c864ef914e8b9ebcaa0c64e1ece3_D20220101-20221230" decimals="2" name="exel:IncreaseInBasicEarningsPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODc3MTA3_08487562-7cde-41bb-8324-6b4c9d8177f2"><ix:nonFraction unitRef="usdPerShare" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="2" name="exel:IncreaseInDilutedEarningsPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODc3MTA3_5be26ea7-4d7c-4a69-b94d-f3affbcdf0a1">0.04</ix:nonFraction></ix:nonFraction> per share. The milestone was reversed as the compound has not progressed as expected and therefore we are no longer able to predict when the milestone will occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, in conjunction with these collaborative in-licensing arrangements we are subject to potential future development milestones of up to $<ix:nonFraction unitRef="usd" contextRef="if09743b2bc6e41bdb6f96e1e3fef767b_I20221230" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODc0NTM2_5b1c84ee-b519-4038-a7b1-f2a6eb90723e">652.0</ix:nonFraction>&#160;million, regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="if09743b2bc6e41bdb6f96e1e3fef767b_I20221230" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODc0NTcx_12b75fe4-a02b-4435-9fa5-0a136c4aceff">634.3</ix:nonFraction>&#160;million and commercial milestones of up to $<ix:nonFraction unitRef="usd" contextRef="if09743b2bc6e41bdb6f96e1e3fef767b_I20221230" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODc0NjEw_ec7208af-9489-465c-b179-e0e7c3b241bb">3,153.0</ix:nonFraction>&#160;million, each in the aggregate per product or target, as well as royalties on future net sales of products.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="ia855702135904005a41d208deb24e60a_91"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMjcyMA_ddd95f06-07ae-4baa-bba7-1a82ba9831d6" continuedAt="i12ffe27d6cf64b14a0476fd075c41c00" escape="true">CASH AND INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="i12ffe27d6cf64b14a0476fd075c41c00" continuedAt="ib46c5d68e2c04c0c84203c9da2d3648b"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents</span></div><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMjY5NA_a4f4951d-783e-4697-82b1-9b2d77067571" escape="true"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMjY5NQ_04624f9a-ad98-4190-a6aa-c1291b1a203b" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmFkZjlmNjE4MzU4OTRhNmM4OTUzOTZlYmM5NDU1Y2IwL3RhYmxlcmFuZ2U6YWRmOWY2MTgzNTg5NGE2Yzg5NTM5NmViYzk0NTVjYjBfMi0xLTEtMS05MjE1MA_de489bba-66b9-441a-9ac4-10e8e59e4648">501,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmFkZjlmNjE4MzU4OTRhNmM4OTUzOTZlYmM5NDU1Y2IwL3RhYmxlcmFuZ2U6YWRmOWY2MTgzNTg5NGE2Yzg5NTM5NmViYzk0NTVjYjBfMi0zLTEtMS05MjE1MA_587c4d7e-fbd2-487a-b944-985da759a51c">647,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmFkZjlmNjE4MzU4OTRhNmM4OTUzOTZlYmM5NDU1Y2IwL3RhYmxlcmFuZ2U6YWRmOWY2MTgzNTg5NGE2Yzg5NTM5NmViYzk0NTVjYjBfNC0xLTEtMS05MjE1MA_c2fce49a-63ed-40c3-8e60-9155a7cb94cc">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmFkZjlmNjE4MzU4OTRhNmM4OTUzOTZlYmM5NDU1Y2IwL3RhYmxlcmFuZ2U6YWRmOWY2MTgzNTg5NGE2Yzg5NTM5NmViYzk0NTVjYjBfNC0zLTEtMS05MjE1MA_2e23683a-d2e3-4ba6-94fa-f65e66db14a3">16,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmFkZjlmNjE4MzU4OTRhNmM4OTUzOTZlYmM5NDU1Y2IwL3RhYmxlcmFuZ2U6YWRmOWY2MTgzNTg5NGE2Yzg5NTM5NmViYzk0NTVjYjBfNS0xLTEtMS05MjE1MA_b5637d6f-5d0a-4816-8247-5b30705b1fd9">502,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmFkZjlmNjE4MzU4OTRhNmM4OTUzOTZlYmM5NDU1Y2IwL3RhYmxlcmFuZ2U6YWRmOWY2MTgzNTg5NGE2Yzg5NTM5NmViYzk0NTVjYjBfNS0zLTEtMS05MjE1MA_0ba83212-68d6-42bd-aa1e-daf80d50faed">663,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit agreements and are invested in short-term certificates of deposit with original maturity of 90 days or less as of December 31, 2022 and money market fund securities as of December 31, 2021. The restricted cash equivalents are classified as other long-term assets. The standby letter of credit entered into in January 2021, as a guarantee of our obligation to fund our portion of the tenant improvements related to our Alameda build-to-suit lease was extinguished and the related collateral was returned in the third quarter of 2022, following the substantial completion of the building and the commencement of the lease. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="ib46c5d68e2c04c0c84203c9da2d3648b" continuedAt="i347dab8843234502829fbd06c655854b"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMjcxOA_7c63f789-3fed-4370-be15-d09d3b6de9ce" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f1d4c0db61942b98ec8d831869eff8a_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMy0xLTEtMS05MjE1MA_f4d613af-b9fe-4abb-ae8f-d76d9df06002">722,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f1d4c0db61942b98ec8d831869eff8a_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMy0zLTEtMS05MjE1MA_58f2e6ed-648a-4112-978d-8dbdcf43279d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f1d4c0db61942b98ec8d831869eff8a_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMy01LTEtMS05MjE1MA_430d8a73-2f3b-4a0a-9f79-5852af77574c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f1d4c0db61942b98ec8d831869eff8a_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMy03LTEtMS05MjE1MA_1cc40f7d-baed-48c4-940f-e4a2c8366e3e">722,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b10b0b7dac44f40b1acc72e8f727bc8_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNC0xLTEtMS05MjE1MA_29ac01a0-2e4e-4ca6-a0d4-368042659948">810,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b10b0b7dac44f40b1acc72e8f727bc8_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNC0zLTEtMS05MjE1MA_e74a2f5c-b5dc-4f27-8196-9f2e69a138af">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b10b0b7dac44f40b1acc72e8f727bc8_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNC01LTEtMS05MjE1MA_75c4d943-9b8e-4308-abc6-c0922e4bd617">13,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b10b0b7dac44f40b1acc72e8f727bc8_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNC03LTEtMS05MjE1MA_8639a94e-e2cc-4e6c-9b22-af542ba934c8">797,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b0ec642b2d416d99ecaed9d2670965_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNS0xLTEtMS05MjE1MA_145a0565-2846-47e5-bb9e-ae22f9663712">338,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b0ec642b2d416d99ecaed9d2670965_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNS0zLTEtMS05MjE1MA_30775ee0-d36c-485b-a998-85afa1562734">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57b0ec642b2d416d99ecaed9d2670965_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNS01LTEtMS05MjE1MA_7d0ab2e1-176a-4e12-bf15-d0693055b00f">5,679</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b0ec642b2d416d99ecaed9d2670965_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNS03LTEtMS05MjE1MA_0a58a070-a7f9-4ba6-9ed8-77a533d9f4d6">332,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56eac004a664b27807f0d574730e620_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNi0xLTEtMS05MjE1MA_5751340f-a624-4791-82b0-3ba623c570ee">16,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56eac004a664b27807f0d574730e620_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNi0zLTEtMS05MjE1MA_e80f40f4-af03-4243-935d-dcb6c07a17b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic56eac004a664b27807f0d574730e620_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNi01LTEtMS05MjE1MA_2d434522-beaa-4292-b3d1-36a149458d7d">223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56eac004a664b27807f0d574730e620_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNi03LTEtMS05MjE1MA_49eeda93-1aab-4b22-9ac3-38db902bd680">16,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNy0xLTEtMS05MjE1MA_8341a45b-e077-423a-9d7c-285ed38ec992">1,887,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNy0zLTEtMS05MjE1MA_1d61c439-ea80-4a84-a615-9c5af3def8b0">589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNy01LTEtMS05MjE1MA_c3eac080-9aba-4f44-915b-dfa8550137da">19,034</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNy03LTEtMS05MjE1MA_55c4fe68-f9aa-4032-bf96-15a436eedf57">1,868,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c6ba758c364e9cbc586045aa0a9faa_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfOC0xLTEtMS05MjE1MA_047174e6-80ef-4bf6-91dd-d92a8a957e34">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c6ba758c364e9cbc586045aa0a9faa_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfOC0zLTEtMS05MjE1MA_25ee9acc-1bf7-460e-ac9d-4e8663674fcc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c6ba758c364e9cbc586045aa0a9faa_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfOC01LTEtMS05MjE1MA_fcb89d40-a6ff-4cbe-9a64-b35745f07003">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c6ba758c364e9cbc586045aa0a9faa_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfOC03LTEtMS05MjE1MA_82286207-b186-4b97-af8e-fa4196b540f2">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i191d7158380c4447a4808cab8812db7f_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfOS0xLTEtMS05MjE1MA_243c3739-a0c9-4417-b181-16241476031b">94,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i191d7158380c4447a4808cab8812db7f_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfOS0zLTEtMS05MjE1MA_331af498-fd86-45b5-abfc-0a383f165426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i191d7158380c4447a4808cab8812db7f_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfOS01LTEtMS05MjE1MA_4578e31a-6dae-4483-beb6-4a461448c99f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i191d7158380c4447a4808cab8812db7f_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfOS03LTEtMS05MjE1MA_211aafc4-513c-4529-8dcc-b05862df325c">94,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b13e9beb6b943898d6cef7a1e02fc9e_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMTAtMS0xLTEtOTIxNTA_ad5cf0bc-9152-4e22-ac7d-b7284bd35525">103,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b13e9beb6b943898d6cef7a1e02fc9e_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMTAtMy0xLTEtOTIxNTA_0892d922-ca70-45c5-8cdf-bbd76297d53f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b13e9beb6b943898d6cef7a1e02fc9e_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMTAtNS0xLTEtOTIxNTA_58accac9-9cde-4918-8a12-729e4c3f5322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b13e9beb6b943898d6cef7a1e02fc9e_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMTAtNy0xLTEtOTIxNTA_b55331f3-992d-4bd3-be42-8c853e3e8905">103,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMTEtMS0xLTEtOTIxNTA_6b0ed635-198e-4800-98a9-7351b7b0a9b3">2,085,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMTEtMy0xLTEtOTIxNTA_3e9885d9-dc2e-4b2e-85db-dd99661ceefe">589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMTEtNS0xLTEtOTIxNTA_0c68445e-2eb7-41ad-b86e-93d60a81410b">19,034</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMTEtNy0xLTEtOTIxNTA_89a209b8-74a0-4354-bed1-dea4d53e94bc">2,066,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5acd41dc9f24b53b18e9a7c0319506c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMy0xLTEtMS05MjE1MA_2afb4190-ce0d-4ae6-a469-13b357c755cf">945,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5acd41dc9f24b53b18e9a7c0319506c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMy0zLTEtMS05MjE1MA_f5e02a54-76b8-4edf-90b0-e703240dd23f">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5acd41dc9f24b53b18e9a7c0319506c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMy01LTEtMS05MjE1MA_b4bb10c8-3f82-41b2-bd31-d9fadfbf4e8e">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5acd41dc9f24b53b18e9a7c0319506c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMy03LTEtMS05MjE1MA_bb0826ef-a77a-4851-9976-ef8df7d2ac0c">945,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf3d41d8f12c40e4baaa791aadb41393_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNC0xLTEtMS05MjE1MA_43b2923c-213c-45b4-8044-c80838313a95">541,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf3d41d8f12c40e4baaa791aadb41393_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNC0zLTEtMS05MjE1MA_2a80f24c-336e-48b1-a313-9c9c555be6ad">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf3d41d8f12c40e4baaa791aadb41393_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNC01LTEtMS05MjE1MA_ad4ddc63-fa96-4467-b331-165355b4ec2b">1,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf3d41d8f12c40e4baaa791aadb41393_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNC03LTEtMS05MjE1MA_d2c5337e-02fd-4433-8659-320e2abc6079">540,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32b96a13da9e4c34a6911c04c05af3e5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNS0xLTEtMS05MjE1MA_ed444065-c83b-4e1a-b3ce-ca2030438855">33,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32b96a13da9e4c34a6911c04c05af3e5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNS0zLTEtMS05MjE1MA_1ebfa874-b90f-45bd-aecf-366f1b4711b3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32b96a13da9e4c34a6911c04c05af3e5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNS01LTEtMS05MjE1MA_7937eeb9-6661-408d-9a01-cb96c935a75b">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32b96a13da9e4c34a6911c04c05af3e5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNS03LTEtMS05MjE1MA_00e0bd09-53cf-47ac-a714-007a34510475">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d5da90485a4254a56630c577874e45_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNi0xLTEtMS05MjE1MA_3818a5b9-d45e-43ed-ad94-6d02fd8774ab">12,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d5da90485a4254a56630c577874e45_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNi0zLTEtMS05MjE1MA_a19c2022-8b44-435d-ba3d-b129280423d9">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78d5da90485a4254a56630c577874e45_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNi01LTEtMS05MjE1MA_c83dca79-91c8-4606-9dc5-152928a2a31b">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d5da90485a4254a56630c577874e45_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNi03LTEtMS05MjE1MA_f6c30655-3a43-4436-83cb-07d4ca6eb844">12,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNy0xLTEtMS05MjE1MA_d2d90b01-c613-4b8c-856f-b13fb6526e3c">1,534,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNy0zLTEtMS05MjE1MA_00a5c6f5-56d3-4dd6-89f6-0731baaa3452">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNy01LTEtMS05MjE1MA_87bd1e73-8a6b-49bb-bad5-1a2218c44782">1,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNy03LTEtMS05MjE1MA_f9e2dc93-e32a-40a3-9076-45de1393bd75">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972ae3af601c4166b2b7375fcce4b2f9_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfOC0xLTEtMS05MjE1MA_50580b40-477d-47fe-b166-8e4d3cc7dcc8">135,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972ae3af601c4166b2b7375fcce4b2f9_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfOC0zLTEtMS05MjE1MA_3c5a14d1-fa5a-44f7-8437-34173102816c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972ae3af601c4166b2b7375fcce4b2f9_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfOC01LTEtMS05MjE1MA_a1fb9087-318b-4d73-8f0c-a48dec7d4936">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972ae3af601c4166b2b7375fcce4b2f9_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfOC03LTEtMS05MjE1MA_cbf668e3-5099-444b-8251-bd2278ef04e8">135,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a943d0ee094645bee3a1a59e2108dc_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfOS0xLTEtMS05MjE1MA_ed092222-77fd-4c6a-b665-51120f05caa1">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a943d0ee094645bee3a1a59e2108dc_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfOS0zLTEtMS05MjE1MA_307cb6b7-92c2-4211-86cc-56656c412ce5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a943d0ee094645bee3a1a59e2108dc_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfOS01LTEtMS05MjE1MA_1630baa4-6955-44d5-a555-513c98a7fe80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a943d0ee094645bee3a1a59e2108dc_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfOS03LTEtMS05MjE1MA_2a93f34d-95a6-424b-91f5-7c28442e4fb5">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic81da6fcbafc408f85a016575fc626ad_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMTAtMS0xLTEtOTIxNTA_6706da3a-8f4c-4281-8f9a-8db9a401b631">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic81da6fcbafc408f85a016575fc626ad_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMTAtMy0xLTEtOTIxNTA_7768c73e-f12c-4e67-b6d5-2ef8c9ee12ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic81da6fcbafc408f85a016575fc626ad_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMTAtNS0xLTEtOTIxNTA_e7a45be0-016b-46b2-8774-d8dfa4e7dbc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic81da6fcbafc408f85a016575fc626ad_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMTAtNy0xLTEtOTIxNTA_71676153-41d4-43cf-bc99-a31a2945ccd8">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMTEtMS0xLTEtOTIxNTA_1b5fcf3b-4224-4fe3-a43f-98c046121def">1,855,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMTEtMy0xLTEtOTIxNTA_4d8e8cde-6c0c-43ee-b9d5-94b59e4a8de2">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMTEtNS0xLTEtOTIxNTA_e3743e8f-447c-4c41-93f6-d4a1fb2fb803">1,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMTEtNy0xLTEtOTIxNTA_c91e4afd-2667-4409-bc3c-cda49ce804fb">1,854,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMTIzNQ_eda69a76-31ec-4557-9635-acc45cfc792b">7.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMTI0Mg_13b6d333-6da6-47cc-a68c-0f0890c86a9c">2.9</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively, and is included in prepaid and other current assets in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the years ended December&#160;31, 2022, 2021 and 2020.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="i347dab8843234502829fbd06c655854b"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMjcyNA_fa9eaa10-4995-4ee9-acab-31d7245782b3" continuedAt="i108f1a3b1711498bb94cd1f202b4d521" escape="true">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i108f1a3b1711498bb94cd1f202b4d521"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b10b0b7dac44f40b1acc72e8f727bc8_I20221230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjllMTc2YmNjYzdiZDRkOTE4YmE2YmIyNmE1NDJhNThmL3RhYmxlcmFuZ2U6OWUxNzZiY2NjN2JkNGQ5MThiYTZiYjI2YTU0MmE1OGZfMi0xLTEtMS05MjE1MA_950317d6-055b-4bfa-bf13-7ff9b0aa487a">706,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b10b0b7dac44f40b1acc72e8f727bc8_I20221230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjllMTc2YmNjYzdiZDRkOTE4YmE2YmIyNmE1NDJhNThmL3RhYmxlcmFuZ2U6OWUxNzZiY2NjN2JkNGQ5MThiYTZiYjI2YTU0MmE1OGZfMi0zLTEtMS05MjE1MA_6bb9c2a5-4d97-401f-9b21-8d8c36ec441e">13,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b0ec642b2d416d99ecaed9d2670965_I20221230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjllMTc2YmNjYzdiZDRkOTE4YmE2YmIyNmE1NDJhNThmL3RhYmxlcmFuZ2U6OWUxNzZiY2NjN2JkNGQ5MThiYTZiYjI2YTU0MmE1OGZfMy0xLTEtMS0xMDYzNjM_177a2e41-4201-4dad-9a97-5961eb3b9032">308,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57b0ec642b2d416d99ecaed9d2670965_I20221230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjllMTc2YmNjYzdiZDRkOTE4YmE2YmIyNmE1NDJhNThmL3RhYmxlcmFuZ2U6OWUxNzZiY2NjN2JkNGQ5MThiYTZiYjI2YTU0MmE1OGZfMy0zLTEtMS0xMDYzNjM_b3254282-4af2-4566-bc9e-7cabcba42883">5,679</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56eac004a664b27807f0d574730e620_I20221230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjllMTc2YmNjYzdiZDRkOTE4YmE2YmIyNmE1NDJhNThmL3RhYmxlcmFuZ2U6OWUxNzZiY2NjN2JkNGQ5MThiYTZiYjI2YTU0MmE1OGZfNS0xLTEtMS05MjE1MA_ac90a56a-3bd7-48bf-8130-85558742cfe4">15,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic56eac004a664b27807f0d574730e620_I20221230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjllMTc2YmNjYzdiZDRkOTE4YmE2YmIyNmE1NDJhNThmL3RhYmxlcmFuZ2U6OWUxNzZiY2NjN2JkNGQ5MThiYTZiYjI2YTU0MmE1OGZfNS0zLTEtMS05MjE1MA_1465ec79-d334-45f4-8e45-31f4b7f13274">223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjllMTc2YmNjYzdiZDRkOTE4YmE2YmIyNmE1NDJhNThmL3RhYmxlcmFuZ2U6OWUxNzZiY2NjN2JkNGQ5MThiYTZiYjI2YTU0MmE1OGZfNi0xLTEtMS05MjE1MA_8ae91f9c-c7c2-4f3a-92a6-26b784163625">1,030,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjllMTc2YmNjYzdiZDRkOTE4YmE2YmIyNmE1NDJhNThmL3RhYmxlcmFuZ2U6OWUxNzZiY2NjN2JkNGQ5MThiYTZiYjI2YTU0MmE1OGZfNi0zLTEtMS05MjE1MA_68e679be-d8d8-451c-ae71-946c39070131">19,034</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf3d41d8f12c40e4baaa791aadb41393_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfMy0xLTEtMS05MjE1MA_6a1ad48d-2e0e-4a83-ae97-1ca2b6b9e27d">385,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf3d41d8f12c40e4baaa791aadb41393_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfMy0zLTEtMS05MjE1MA_7599c6f3-93ea-40ff-8642-e84e2995a016">1,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5acd41dc9f24b53b18e9a7c0319506c_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfNC0xLTEtMS05MjE1MA_d58c9ad7-5fba-4ade-a79a-89de1f0b9e02">43,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5acd41dc9f24b53b18e9a7c0319506c_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfNC0zLTEtMS05MjE1MA_de02e308-570f-4488-9a86-852c05de6394">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32b96a13da9e4c34a6911c04c05af3e5_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfNS0xLTEtMS05MjE1MA_9dd9fa00-cc6d-4de8-9dd2-41be223e5b59">18,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32b96a13da9e4c34a6911c04c05af3e5_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfNS0zLTEtMS05MjE1MA_c9dbc710-37c3-4b41-a6d8-936a7f90f30a">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d5da90485a4254a56630c577874e45_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfNi0xLTEtMS05MjE1MA_67b9ba16-7421-4203-83ee-57775525487f">7,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78d5da90485a4254a56630c577874e45_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfNi0zLTEtMS05MjE1MA_896f798b-930a-42e3-8cc3-654b4a362b74">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfNy0xLTEtMS05MjE1MA_a0eacc5b-e84a-4fd1-9590-70fb05bbe36e">454,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfNy0zLTEtMS05MjE1MA_524eaaba-abe8-4f13-89d4-538c573cae5a">1,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="investment" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMTk1OQ_1ef845a1-c966-4ad0-ba3f-e0ad07357015">285</ix:nonFraction> and <ix:nonFraction unitRef="investment" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMTk2Ng_3fd94db6-f875-4a5a-8908-793c4424984c">133</ix:nonFraction> debt securities available-for-sale in an unrealized loss position as of December&#160;31, 2022 and 2021, respectively. All securities presented above have been in an unrealized loss position for less than twelve months except for <ix:nonFraction unitRef="bond" contextRef="i1b10b0b7dac44f40b1acc72e8f727bc8_I20221230" decimals="INF" name="exel:NumberOfBondSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfNTQ5NzU1ODE3ODg3_fad596fa-b6d3-40da-8f9c-17870eec5f9a">76</ix:nonFraction> corporate bond securities, <ix:nonFraction unitRef="bond" contextRef="ic56eac004a664b27807f0d574730e620_I20221230" decimals="INF" name="exel:NumberOfBondSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfNTQ5NzU1ODE3ODk1_8bca7657-d416-43fe-bb5e-3a0f7b2cc274">4</ix:nonFraction> municipal bond securities and <ix:nonFraction unitRef="numberofsponsoredenterprise" contextRef="i57b0ec642b2d416d99ecaed9d2670965_I20221230" decimals="INF" name="exel:NumberOfSponsoredEnterprises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfNTQ5NzU1ODE3OTY4_b0e0f9bc-f809-42f8-8203-19604a770664">1</ix:nonFraction> U.S. Treasury and government-sponsored enterprises security with an aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfNTQ5NzU1ODE3OTg2_23703ec1-4d37-454d-b5ec-12e6194e6594">237.6</ix:nonFraction>&#160;million and an aggregate $<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfNTQ5NzU1ODE3OTk1_523a143c-7e24-429c-881b-3d984fcbe1d2">6.1</ix:nonFraction>&#160;million unrealized losses as of December&#160;31, 2022. During the years ended December&#160;31, 2022 and 2021, we did <ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMjA3OQ_975b6538-a8ec-48a9-92e5-3cb6f436c3bd"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMjA3OQ_98e4cac8-e79a-4162-92a5-9ba3521eb737">not</ix:nonFraction></ix:nonFraction> record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis. </span></div><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMjcwOQ_1066a96a-985d-4717-ad77-fd55bf6990ab" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmRiNDZkODIxNmY2NTRkZWVhMDQzNGQ0NjI4NmU2ZmY1L3RhYmxlcmFuZ2U6ZGI0NmQ4MjE2ZjY1NGRlZWEwNDM0ZDQ2Mjg2ZTZmZjVfMi0xLTEtMS05MjE1MA_45a41a10-6255-4395-add5-20f13f2d76d1">1,114,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmRiNDZkODIxNmY2NTRkZWVhMDQzNGQ0NjI4NmU2ZmY1L3RhYmxlcmFuZ2U6ZGI0NmQ4MjE2ZjY1NGRlZWEwNDM0ZDQ2Mjg2ZTZmZjVfMi0zLTEtMS05MjE1MA_2a2a366e-4cc7-468e-9ce9-b8e24c564c78">1,168,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmRiNDZkODIxNmY2NTRkZWVhMDQzNGQ0NjI4NmU2ZmY1L3RhYmxlcmFuZ2U6ZGI0NmQ4MjE2ZjY1NGRlZWEwNDM0ZDQ2Mjg2ZTZmZjVfMy0xLTEtMS05MjE1MA_316bb038-3e26-4219-b653-75f4a6ca8660">753,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmRiNDZkODIxNmY2NTRkZWVhMDQzNGQ0NjI4NmU2ZmY1L3RhYmxlcmFuZ2U6ZGI0NmQ4MjE2ZjY1NGRlZWEwNDM0ZDQ2Mjg2ZTZmZjVfMy0zLTEtMS05MjE1MA_4013c05e-c819-411c-9cbb-f7dbed3891c8">365,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmRiNDZkODIxNmY2NTRkZWVhMDQzNGQ0NjI4NmU2ZmY1L3RhYmxlcmFuZ2U6ZGI0NmQ4MjE2ZjY1NGRlZWEwNDM0ZDQ2Mjg2ZTZmZjVfNC0xLTEtMS05MjE1MA_d514adde-924a-4b50-977a-d87576740fe8">1,868,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmRiNDZkODIxNmY2NTRkZWVhMDQzNGQ0NjI4NmU2ZmY1L3RhYmxlcmFuZ2U6ZGI0NmQ4MjE2ZjY1NGRlZWEwNDM0ZDQ2Mjg2ZTZmZjVfNC0zLTEtMS05MjE1MA_88567324-6d9e-410b-9e85-4852ea5bdf6f">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-indent:36pt"><span><br/></span></div><div id="ia855702135904005a41d208deb24e60a_94"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RleHRyZWdpb246OTlhOGUwYTIwODZiNGYyODhhOGY2NzFlODIyMjUyMjRfMTU1Mg_077efc74-f8fd-47fe-bf47-cb17356aa876" continuedAt="ib70b21da82544352a102bf2a15a1ee94" escape="true">FAIR VALUE MEASUREMENTS </ix:nonNumeric></span></div><ix:continuation id="ib70b21da82544352a102bf2a15a1ee94" continuedAt="i4eef2362d5714fd4af162b12c13db69d"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="i4eef2362d5714fd4af162b12c13db69d"><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.</span></div><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RleHRyZWdpb246OTlhOGUwYTIwODZiNGYyODhhOGY2NzFlODIyMjUyMjRfMTU0OQ_d9bfbd37-3e02-481a-8e11-8f933b3055ee" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieebb4571285b4760b2d6ffadd98aa2a3_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfMi0xLTEtMS05MjE1MA_db904178-4835-4bd6-b6e3-490d710e6dc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678fac2def204c018d03c82ac9dbc312_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfMi0zLTEtMS05MjE1MA_3ea8eb08-cdf9-43c1-bd05-b0ee61559c91">722,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a347ff0104c4e37a0b5967300b9b308_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfMi01LTEtMS05MjE1MA_a0582d97-7311-4bff-8123-740b8045646e">722,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2525f5b5cbe34620878e5e9e6f0c1c1e_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfMy0xLTEtMS05MjE1MA_b33f685d-6c7b-45a4-a3a6-759ae54652b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd2228030e9433ab02d7801959e3ef3_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfMy0zLTEtMS05MjE1MA_d1c7256a-4841-4bb7-b763-e45eb367638e">797,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40eb4f16efe747339fc781b4b8ab1d9d_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfMy01LTEtMS05MjE1MA_66dafdc9-1a46-4c04-8883-e48ac860a92e">797,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic099aa5b5a354fd0bc57f4dfc1f82f5f_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNC0xLTEtMS05MjE1MA_c1d58d12-3ac2-4f8e-aa00-59173551e755">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff0318ea05d43dc8f548eb4b0abeaab_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNC0zLTEtMS05MjE1MA_47b89e58-09a9-4312-bdbb-41341c1fda7c">332,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace46fa599fd439ea6f6a1a2dd79a719_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNC01LTEtMS05MjE1MA_365387d6-86b7-403c-8ad9-5f65575094d0">332,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia52f875fc7ea48afad6c5d1f838e319a_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNS0xLTEtMS05MjE1MA_9dceb5fe-c023-4005-8705-abc64e9268f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a1f30ef6bf04adebfc61920cd8a412a_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNS0zLTEtMS05MjE1MA_e265cfd2-8c39-4d77-8312-7b3bb35461b2">16,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i199c2fdbc09541b98fa084e45047c999_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNS01LTEtMS05MjE1MA_b5c85253-151e-40b9-8c71-6a4674a84e75">16,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie569dd4e72ad4efea4960bffc82ca79e_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNi0xLTEtMS05MjE1MA_7f599c16-dbee-4206-b6c3-ddd47de97bd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4566d6932b48aa8902d306c989ff52_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNi0zLTEtMS05MjE1MA_9de1b682-d98d-47d5-a521-5bef6d12e23a">1,868,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82be6e971604c2da30b378bdf9985c9_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNi01LTEtMS05MjE1MA_12ed3945-8497-4c80-8a1a-8c307d472bce">1,868,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3fc431dacf844f38ad9667dc0e877c2_I20221230" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNy0xLTEtMS05MjE1MA_4548993b-1f82-46a6-ae31-bdcf41f38236">94,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96a10d99c47408289f5ad833d6120b8_I20221230" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNy0zLTEtMS05MjE1MA_a24f984c-4f0c-4e25-adca-d97aff14e7bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75ea1cc7d48743c88632a3cf80cbd319_I20221230" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNy01LTEtMS05MjE1MA_df5ebaf3-b870-497a-b311-0b2b2ca45941">94,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a1d047b86f24d2083f214d75c5134ef_I20221230" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfOC0xLTEtMS05MjE1MA_7a465a42-fbda-4c0d-bcb7-7107efeebee7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51fb172e52eb436f82f975928b0d6479_I20221230" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfOC0zLTEtMS05MjE1MA_a373f09f-d692-435f-af3c-5cf70130042d">103,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia20e3dbd8a4d45d884a2d75792ca5567_I20221230" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfOC01LTEtMS05MjE1MA_3b9f6906-bfa6-44a7-98c1-a578cc9da5da">103,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie569dd4e72ad4efea4960bffc82ca79e_I20221230" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfOS0xLTEtMS05MjE1MA_b02cbb2a-37e0-46ac-9824-35d26123f4b9">94,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4566d6932b48aa8902d306c989ff52_I20221230" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfOS0zLTEtMS05MjE1MA_fcb4919a-91c9-4bb4-a920-a58480af7336">1,972,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82be6e971604c2da30b378bdf9985c9_I20221230" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfOS01LTEtMS05MjE1MA_dcafdeee-fb0b-4706-b4fb-1723b7da7518">2,066,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i471e33a44e454a859ed17e9d46754e8e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfMi0xLTEtMS05MjE1MA_bf4f56cc-5e3a-440a-9914-0bcf1565df34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfd0873a4a96461ba27862f3c00db9c8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfMi0zLTEtMS05MjE1MA_b6b8ae25-81d5-4899-9cfe-82a9257b4f0e">945,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0f51588cc244e6bc024c642a236d9e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfMi01LTEtMS05MjE1MA_629bc414-b59a-4cfb-835d-18794ad09de2">945,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i726e2aeff8e4434ab43684910d66fa92_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfMy0xLTEtMS05MjE1MA_0d156e9f-19e2-460c-9fc5-89e6ee00fc2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10af3e3a1cd64127a91cee9c3a18360c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfMy0zLTEtMS05MjE1MA_80d6d19e-0ee3-4225-9344-ff186c46f8e8">540,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aefb57539a84853a9275b9c5978a13c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfMy01LTEtMS05MjE1MA_a094adbe-1013-4a31-8c4a-170a27aeb90c">540,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ef8749612e74ad38eff74f7f8441bae_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNC0xLTEtMS05MjE1MA_87d2704d-81ec-434f-943b-1f6431c0976a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd89a3bfdd74436bbebaf5f5a836492_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNC0zLTEtMS05MjE1MA_52918966-7713-4a9e-bc6f-a002b635fa19">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebe7e70eb57b4339a8a7e41055b873ab_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNC01LTEtMS05MjE1MA_873e6efb-3c6e-4f55-9c21-2bf508b23ce8">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada6509b74ef42d1ab3a02e9916aa003_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNS0xLTEtMS05MjE1MA_8423543a-29f4-4ce9-8d5a-fec1a6809660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e1a85481df47c6ba245c6579743863_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNS0zLTEtMS05MjE1MA_da45bd50-ac4a-42ca-89ca-ffd2193c9eb0">12,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73559db97810456c9b104a736adc72f6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNS01LTEtMS05MjE1MA_71625a24-742d-4f3f-a013-eba09b1964f6">12,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35acff8b86c74ab6877bd2ff37df8915_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNi0xLTEtMS05MjE1MA_a86d3665-506f-4ae7-8ddd-9d3aff6a9961">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b577aa781240a89ea986321d268054_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNi0zLTEtMS05MjE1MA_bac7e9fb-8d5f-4340-8829-4380294e9461">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bc81f428a0846d484b97bfeeb05fb15_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNi01LTEtMS05MjE1MA_58548466-9009-48e3-994b-666f3e08e529">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b4bcecee8844c49bc7fe25f8b70e6b5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNy0xLTEtMS05MjE1MA_0a2f90ef-5d93-4ab3-ac0e-c4d13957d685">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i333e0adca8ad4c98adc9303eaa294dee_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNy0zLTEtMS05MjE1MA_ce3412ab-6802-4131-a0cb-bda0589948a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia12585f72d404b3b9451798d475c2669_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNy01LTEtMS05MjE1MA_4d3714eb-a45a-4bdc-82ce-415f2d142d80">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d2966ecc3e24e2cb9545a4f31ab7a68_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfOC0xLTEtMS05MjE1MA_471d155a-36c5-426f-9173-83f6d89c71aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dfc0620ff1b4f0d83f4e9ed4f789075_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfOC0zLTEtMS05MjE1MA_d1364f0a-1505-4328-bbaa-bab2092a99f3">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddcafb03f418408d86fae11b5091d968_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfOC01LTEtMS05MjE1MA_f6bfb835-8906-4a13-b46a-85f384ace19a">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35acff8b86c74ab6877bd2ff37df8915_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfOS0xLTEtMS05MjE1MA_3277b793-69ec-4005-9c62-c16301ff1040">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b577aa781240a89ea986321d268054_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfOS0zLTEtMS05MjE1MA_03e27575-d7ba-40fb-a4f9-082b0088d4cc">1,652,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bc81f428a0846d484b97bfeeb05fb15_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfOS01LTEtMS05MjE1MA_3b04e5dd-b4c0-428c-af31-381f714db695">1,719,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Foreign Currency Contracts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we initiated an operational hedging program and entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchange rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had <ix:nonFraction unitRef="derivative_instrument" contextRef="i12667066e7cc4662b0936e2e393953fd_I20221230" decimals="INF" name="us-gaap:DerivativeNumberOfInstrumentsHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RleHRyZWdpb246OTlhOGUwYTIwODZiNGYyODhhOGY2NzFlODIyMjUyMjRfNTQ5NzU1ODE3MzI2_e44b9386-1332-473a-ada2-1f265e3ff960">one</ix:nonFraction> forward contract outstanding to sell &#8364;<ix:nonFraction unitRef="eur" contextRef="i12667066e7cc4662b0936e2e393953fd_I20221230" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RleHRyZWdpb246OTlhOGUwYTIwODZiNGYyODhhOGY2NzFlODIyMjUyMjRfNTQ5NzU1ODE3MzY5_0f2776d3-8eb2-49f4-bf0c-7b96e06c1d79">3.6</ix:nonFraction>&#160;million. The forward contract with a maturity of <ix:nonNumeric contextRef="i042731f45c434908a7097f420a97138c_D20220101-20221230" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RleHRyZWdpb246OTlhOGUwYTIwODZiNGYyODhhOGY2NzFlODIyMjUyMjRfMzg0ODI5MDcwMTMxMA_bb4e8a35-0f7d-4247-9f58-984b692c0287">three months</ix:nonNumeric> is recorded at fair value and is included in prepaid expenses and other current assets in the Consolidated Balance Sheets. The unrealized loss on the forward contract is not material as of December&#160;31, 2022. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the years ended December&#160;31, 2022 and 2021 we recognized $<ix:nonFraction unitRef="usd" contextRef="i042731f45c434908a7097f420a97138c_D20220101-20221230" decimals="-5" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RleHRyZWdpb246OTlhOGUwYTIwODZiNGYyODhhOGY2NzFlODIyMjUyMjRfNTQ5NzU1ODE4Mjc5_8b3cbb48-75e6-4e56-b745-5db01bfb9d23">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4218de4396fe4f889b222285008565ab_D20210102-20211231" decimals="-5" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RleHRyZWdpb246OTlhOGUwYTIwODZiNGYyODhhOGY2NzFlODIyMjUyMjRfNTQ5NzU1ODE4MTM4_b24dee34-f583-426e-9320-354dadc0dfdf">0.8</ix:nonFraction> million of net gains on the maturity of forward contracts, which were included in other income (expense), net on our Consolidated Statements of Income.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="ia855702135904005a41d208deb24e60a_97"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RleHRyZWdpb246NDM3YjA1Y2E5ODZmNDNlZWJlZjA5Mzg4OTcyNjZiNDBfODI_8ef94b62-be67-4560-b757-85d773b6e6dc" continuedAt="icdecd2de844c486b967ecb30b63624ce" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="icdecd2de844c486b967ecb30b63624ce"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RleHRyZWdpb246NDM3YjA1Y2E5ODZmNDNlZWJlZjA5Mzg4OTcyNjZiNDBfNzg_5999db61-dd30-4a2c-9962-810405e6b310" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfMi0xLTEtMS05MjE1MA_c309b81f-da77-4921-b38a-021803ba868c">8,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfMi0zLTEtMS05MjE1MA_37d7ac0a-9f3d-48d8-a983-92dbcdd143dc">8,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfMy0xLTEtMS05MjE1MA_0cb509d3-bb7e-4802-a0f1-2eb703b4c250">43,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfMy0zLTEtMS05MjE1MA_f6e6b20f-3606-4f69-b2d3-c34cfd458d5b">27,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfNC0xLTEtMS05MjE1MA_29b1fc3d-c2c5-4ae4-a7b1-f239495c2c86">10,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfNC0zLTEtMS05MjE1MA_b9a22864-9eed-4fcb-af21-a18669e69da5">12,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfNS0xLTEtMS05MjE1MA_00701169-3e96-4267-b069-68c3dc8470e7">62,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfNS0zLTEtMS05MjE1MA_881f7a5a-a099-4d8b-96a7-9dad54edc2c2">49,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9ed26c4ba2489591ac9c39a8bf7ce1_I20221230" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfOC0xLTEtMS05MjE1MA_7e4e5b03-fac9-419e-b087-f1e30ebc4373">33,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e4b169888c84090b5422b97549cd20c_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfOC0zLTEtMS05NTgwMg_c803b2f2-3d14-4418-8c33-098bec006944">27,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08940ae14c044060b10d9ea3213210f3_I20221230" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfOS0xLTEtMS05MjE1MA_4cf5975c-672f-4412-8df7-1c9dd3a66392">28,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54d01b1ebd6a4b07bfe50d2f94bef6b4_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfOS0zLTEtMS05NTgwMg_b801253c-5bc9-43b6-b00d-b55e3af3c8ad">22,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfMTAtMS0xLTEtOTIxNTA_4df37e5f-870e-40db-a230-19b47a206335">62,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfMTAtMy0xLTEtOTIxNTA_a5353bbe-3628-443f-bec3-8596f17b7aae">49,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="ia855702135904005a41d208deb24e60a_100"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90ZXh0cmVnaW9uOjU0ZjUwMjRkN2Y3ZjQ1ZjI4YWUyYmZhMmRlYWE2ZjI1XzIwMA_26db53c4-ba7c-4a5f-be02-e7185012994d" continuedAt="ie57c1ba3a2ba43bb9f7ae06b1da528b8" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="ie57c1ba3a2ba43bb9f7ae06b1da528b8"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90ZXh0cmVnaW9uOjU0ZjUwMjRkN2Y3ZjQ1ZjI4YWUyYmZhMmRlYWE2ZjI1XzIwMg_ed2bc7f3-01ae-4c9e-aeba-23de548d02c9" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">up to <ix:nonNumeric contextRef="i29abdea0de484029b656cfe3041033c3_D20220101-20221230" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzItMS0xLTEtOTIxNTAvdGV4dHJlZ2lvbjo5Nzg0OTQxMGJlZTA0NTYyODZmMTEwYjJiNTM0ZTU0Nl8xMA_71088f02-2586-426f-ba79-ee27b246d25f">15</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied09a4ba58274c3596cc89a3777f1174_I20221230" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzItMy0xLTEtOTIxNTA_0be30cc8-5c82-4889-a8e9-6c537db423df">83,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7215386183c44fd2aa5b09fe609d09a0_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzItNS0xLTEtOTIxNTA_462d1e71-3376-4c83-8a5f-38179de31ec6">73,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">up to <ix:nonNumeric contextRef="idb968a7ec21c46bda8be17bee6c569df_D20220101-20221230" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzMtMS0xLTEtOTIxNTAvdGV4dHJlZ2lvbjpkOTZkYjU5ZDJiODU0MzQ3YWRiYzkyMTUzNDU3MGFlZl8xNjQ5MjY3NDQxNjg4_c6cb34ad-85d4-4252-a1f9-0c004512f6ce">3</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89d86279d8cf4c6688a69b3db5f0650e_I20221230" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzMtMy0xLTEtOTIxNTA_a084d218-eaf7-461d-90e5-97a874f397db">19,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i261b348dea0344bc94589101e7e53f5e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzMtNS0xLTEtOTIxNTA_4fed44ae-59f3-46d1-a56d-7e2a1bd6d67a">14,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icd4ba0df5aff4776bc4e4486814a14a1_D20220101-20221230" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzUtMS0xLTEtOTIxNTA_d438460a-ca72-410e-9f25-7b38d51d3578">7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a48c86b35e6435ea5fd025596c4038e_I20221230" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzUtMy0xLTEtOTIxNTA_c61d0bce-6f34-421d-80dd-600d33a8f43e">24,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e43db2475c746e19470fa095df95b14_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzUtNS0xLTEtOTIxNTA_e4176aca-7665-4bc9-a2bb-ad347c1e9c23">15,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e7aa72456ac4985a26e7ee7471b2167_D20220101-20221230" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzYtMS0xLTEtOTIxNTA_54e93b1c-2cd5-45b4-ae0d-ce3ad3535932">5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44a51d0f954f47abb686f58842236e4b_I20221230" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzYtMy0xLTEtOTIxNTA_c1b71be5-1c23-4a9c-9695-bf213697823e">39,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebe5b3d3ea6429d897818f4d64c6c70_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzYtNS0xLTEtOTIxNTA_0993faa2-2dc8-45f2-af22-1435af95d319">23,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e2afee13177452697583dfe3fb2e778_I20221230" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzctMy0xLTEtOTIxNTA_a1a61270-500e-43f5-a4a0-655298b4a9ef">4,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib510a5b7f321419fafd9bcd1b30bce22_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzctNS0xLTEtOTIxNTA_03a315b0-40ed-4b39-86b9-ef1f43e6a056">16,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzgtMy0xLTEtOTIxNTA_9ce55344-f915-4a98-b6e4-59927a611d23">171,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzgtNS0xLTEtOTIxNTA_b71fcad1-395d-4596-b15e-d6b2997e625d">144,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzktMy0xLTEtOTIxNTA_45472229-f628-4721-a104-88e4a2b69ada">60,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzktNS0xLTEtOTIxNTA_dd949083-9706-4ddf-ae12-c1ad003c30c2">40,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzEwLTMtMS0xLTkyMTUw_da7eed05-071d-4eea-8db7-82cbe70728fa">110,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzEwLTUtMS0xLTkyMTUw_637b63a0-37ab-4aaa-93d8-81206ed2bb53">104,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90ZXh0cmVnaW9uOjU0ZjUwMjRkN2Y3ZjQ1ZjI4YWUyYmZhMmRlYWE2ZjI1XzEyOQ_8c22a4f5-e1ec-4646-9676-d02157ebba98">20.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90ZXh0cmVnaW9uOjU0ZjUwMjRkN2Y3ZjQ1ZjI4YWUyYmZhMmRlYWE2ZjI1XzEzMw_4f6bca01-8cc9-4c24-b14f-d05e9ed30e3b">13.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90ZXh0cmVnaW9uOjU0ZjUwMjRkN2Y3ZjQ1ZjI4YWUyYmZhMmRlYWE2ZjI1XzE0MA_28154005-27b2-4b1e-b369-b6a1151dcd5f">9.1</ix:nonFraction> million during the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><div id="ia855702135904005a41d208deb24e60a_106"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkzMzQ_15808538-8f81-4278-8350-7784d19cd130" continuedAt="i4fbea4fa5ae74189959cc8e0e8c4bfc3" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="i4fbea4fa5ae74189959cc8e0e8c4bfc3" continuedAt="idf74fa12d5164f62be943b83bb289132"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans and ESPP</span></div><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkyOTk_df3319b6-f2f0-48c6-9612-415e1c3dbc32" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5160dca23cbd4534bbd8f0c6583551eb_D20220101-20221230" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzItMS0xLTEtOTIxNTA_68253b34-65f7-4ff6-b766-bbaf5f28b01d">45,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b02cd880bf4d00b829d7485dae8233_D20210102-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzItMy0xLTEtOTIxNTA_b5531be6-e398-4c49-8847-dbacb636c83b">46,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5871015bd64ea0a1cea69d5451681c_D20200104-20210101" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzItNS0xLTEtOTIxNTA_6a22da82-6364-45a1-a9ac-e699b77ffb3f">37,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37ff342a670f4b08a73196e2c605fefd_D20220101-20221230" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzMtMS0xLTEtOTIxNTA_b2ccb865-289c-4d1d-8c73-ff4a545e3646">62,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2297486cdd248d085cac7850abaaf71_D20210102-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzMtMy0xLTEtOTIxNTA_8e903f67-2ca9-4fb6-a8a2-6d9866580968">73,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5491aa8fe4e24ba3ac8e4aaa781cce6a_D20200104-20210101" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzMtNS0xLTEtOTIxNTA_96720bd9-20f6-4f2e-ad78-552b9732801e">67,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzQtMS0xLTEtOTIxNTA_1251b7c2-c215-43bb-a97c-c3673a232d4f">107,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzQtMy0xLTEtOTIxNTA_5a210a51-aeab-4da8-9283-d504bcd1bbe1">119,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzQtNS0xLTEtOTIxNTA_4308a136-4c49-4bc4-9683-9315220f28f9">105,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzItMS0xLTEtOTIxNTA_933d53be-1ede-4637-8202-26c1cf58a1d9">12,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzItMy0xLTEtOTIxNTA_f12c2f21-877b-46b5-9bdd-12a29bf6f9bc">19,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzItNS0xLTEtOTIxNTA_c3d7f287-82e6-4eea-918f-324569c6ea15">19,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzMtMS0xLTEtOTIxNTA_c74b8100-5c1e-4c2e-a58e-0260153829fc">69,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d5d9f5ba5145de91b7ed6cafe85f4b_D20210102-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzMtMy0xLTEtOTIxNTA_87ca9b87-7cf0-4b79-8b3e-fd2c6fd42ea7">53,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001bf94dda6a471d908297d31da5650a_D20200104-20210101" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzMtNS0xLTEtOTIxNTA_815b8af7-6722-4852-8d73-ce5a28c536b9">35,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzQtMS0xLTEtOTIxNTA_77bdb5c6-8f91-4d72-93f9-b8dc5bb6a7ce">21,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2da2883e9244eb867ae85f79b46942_D20210102-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzQtMy0xLTEtOTIxNTA_bc706b8d-9d6e-418d-9f36-eced58a3c0ea">43,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i448f6fe1dd7842a5b8a72af4bafcacbe_D20200104-20210101" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzQtNS0xLTEtOTIxNTA_b91059b8-70e3-4ada-8303-584273ad5a4d">47,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzUtMS0xLTEtOTIxNTA_4fdd822c-047b-422a-a9d8-4acaf7ee3587">3,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i265887804270466a84b8183ec8c715b9_D20210102-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzUtMy0xLTEtOTIxNTA_6cf198dc-f691-4027-965a-6208b6b42169">3,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzUtNS0xLTEtOTIxNTA_b5bb50b4-e4f6-48f5-8ced-f450644d6493">2,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzYtMS0xLTEtOTIxNTA_2b2e75e2-e67d-4cd4-bc48-25d76abc940a">107,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzYtMy0xLTEtOTIxNTA_b49dc969-ed5f-4671-bb3b-8af9522ad090">119,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzYtNS0xLTEtOTIxNTA_c54633a8-382e-4fec-86b6-2cba2e644588">105,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several equity incentive plans under which we granted stock options and RSUs, including PSUs, to employees and directors. On May 25, 2022, at the 2022 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The amendment and restatement increased the share reserve under the 2017 Plan by <ix:nonFraction unitRef="shares" contextRef="i078320950f3f4080b9cc748699315beb_D20220525-20220525" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTQyODY_676fa826-5f48-48dc-bd02-74fb732965be">28,500,000</ix:nonFraction> shares. As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i3874dd04524f404cad068734350f1731_I20221230" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTg4NDM_98ed262f-5f5a-4cce-a8ec-452004633476">31,971,047</ix:nonFraction> shares were available for grant under the 2017 Plan. The share reserve is reduced by <ix:nonFraction unitRef="shares" contextRef="i4fad33a89ad640298188cf7bb295b4ae_D20220101-20221230" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTQyOTg_b600d181-69f2-4278-ba5b-cdc281cf264a">1</ix:nonFraction> share for each share issued pursuant to a stock option and <ix:nonFraction unitRef="shares" contextRef="i4fad33a89ad640298188cf7bb295b4ae_D20220101-20221230" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTQzMDQ_d8f06f56-611e-42f3-a74a-4cf21edc05be">2</ix:nonFraction> shares for full value awards, including RSUs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors delegated responsibility for administration of our equity incentive plans to the Compensation Committee of our Board of Directors, including the authority to determine the term, exercise price and vesting requirements of each grant. Stock options granted to our employees and directors generally have a <ix:nonNumeric contextRef="i3a61f81952984a76817f7077b77e352c_D20220101-20221230" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkzMjY_926bcf1e-d2d0-4e11-88f7-4d90bc746c70">four-year</ix:nonNumeric> vesting term and a <ix:nonNumeric contextRef="i94edb7e6d39c450a954861e65f48c315_D20220101-20221230" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkzMzE_c20cd563-1f0d-4bfe-9c9f-ca25ecd0a281">one-year</ix:nonNumeric> vesting term, respectively, an exercise price equal to the fair market value on the date of grant, and a <ix:nonNumeric contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkzMzI_93350e35-6d04-4d1f-8849-4ff00d5a0da2">seven-year</ix:nonNumeric> life from the date of grant. RSUs granted to our employees and directors generally have a <ix:nonNumeric contextRef="ie4196c2fa72f4675a1c7dc4470ac938f_D20220101-20221230" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkzMTI_a4ecfc68-bc84-4bcb-8547-0c4cbd50cae0">four-year</ix:nonNumeric> vesting term and a <ix:nonNumeric contextRef="i1d192ee0ba8049e2a30c45ffc397e321_D20220101-20221230" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkyODc_16c5340d-fd53-463b-846d-9f2f3888d8e1">one-year</ix:nonNumeric> vesting term, respectively. PSUs granted pursuant to our equity incentive plans vest upon specified service conditions and the achievement of a performance target or market condition. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Change in Control and Severance Benefit Plan for certain executive officers. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&#8217;s employment is terminated without cause during a period commencing <ix:nonNumeric contextRef="if0d9106c860342c6a5490820d5ac452c_D20220101-20221230" name="exel:ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzIwNzY_e16d914c-d907-4be0-aacc-96fa86aa2908">one month</ix:nonNumeric> before and ending <ix:nonNumeric contextRef="i4c2389c4c21e47d38ba918260c486bdd_D20220101-20221230" name="exel:ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzIwOTc_200ea3e9-4ffc-45f6-8950-cf46bac792c3">thirteen months</ix:nonNumeric> following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all their outstanding equity awards accelerated and the exercise period for their stock options extended to no more than one year.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of <ix:nonFraction unitRef="number" contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI1NDU_ad4ac048-b169-4d30-91c7-c77b3aea63e2">85</ix:nonFraction>% of the closing price at the beginning of the offering period or <ix:nonFraction unitRef="number" contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI2MTI_04751227-d54f-4555-8240-ed17d7eac2af">85</ix:nonFraction>% of the closing price at the end of each <ix:nonNumeric contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230" name="exel:SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkzMTk_155d69a1-7e08-477a-8557-db3f551133ee">six-month</ix:nonNumeric> purchase period. As of December&#160;31, 2022, we had </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8ab3ba9b700146e8a378297f9a6ef6c5_I20221230" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI2OTg_6c98756d-10a2-47af-86a8-1bb52e5d6dc5">2,561,567</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares available for issuance under our ESPP. Pursuant to the ESPP, we issued <ix:nonFraction unitRef="shares" contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI3Nzk_9aa1ffe6-7783-43c9-bfff-e348a112173d">606,787</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i265887804270466a84b8183ec8c715b9_D20210102-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI3ODM_89109f41-2a9e-4885-8ab9-981e85367768">536,226</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI3OTA_547b038b-4667-44f9-beb2-86c80e87de91">534,419</ix:nonFraction> shares of common stock at an average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8ab3ba9b700146e8a378297f9a6ef6c5_I20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI4NDk_a05eadb2-b30e-4970-bb4c-a6cd1b0828ee">16.63</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2d394ecf14b74946a77659139d5f4878_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI4NTM_9e3560f9-4314-4236-918f-9f22ba6a2ba3">17.76</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia4d13e607a19484395fc6a707a9c2df9_I20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI4NjA_7e5a7313-0180-4e5a-b585-78b974f2df5a">14.55</ix:nonFraction> during the years ended December&#160;31, 2022, 2021 and 2020, respectively. Cash received </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from purchases under the ESPP for the years ended December 31, 2022, 2021 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $<ix:nonFraction unitRef="usd" contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230" decimals="-5" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzMwMTA_74d2a4df-a759-443b-921e-bee9ce1f9d93">10.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i265887804270466a84b8183ec8c715b9_D20210102-20211231" decimals="-5" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzMwMTQ_e4aa8fb3-0144-449a-ba32-43d13c838f95">9.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101" decimals="-5" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzMwMjE_fb6b0812-166f-4813-afb1-e8c9025c6cba">7.8</ix:nonFraction> million, respectively. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="idf74fa12d5164f62be943b83bb289132" continuedAt="i89d293a8c7254c40a3e383748bffb744"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used a Black-Scholes Merton option pricing model to value stock options and ESPP purchases. <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkyODk_1b730c02-d7c3-41cc-8db3-ce5a6b34acfd" continuedAt="i447bf2b9313a4b91a9481b1ca81dd23a" escape="true">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="i447bf2b9313a4b91a9481b1ca81dd23a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyYThhYzZiMjczYzE0ZWIwOTMwMjAzYjVjMzNlNDljYi90YWJsZXJhbmdlOjJhOGFjNmIyNzNjMTRlYjA5MzAyMDNiNWMzM2U0OWNiXzItMS0xLTEtOTIxNTA_827921e1-08ae-4104-8c16-2241c1b7b088">8.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyYThhYzZiMjczYzE0ZWIwOTMwMjAzYjVjMzNlNDljYi90YWJsZXJhbmdlOjJhOGFjNmIyNzNjMTRlYjA5MzAyMDNiNWMzM2U0OWNiXzItMy0xLTEtOTIxNTA_943dab6d-27e4-438d-b7a4-e4e0fa99089f">9.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyYThhYzZiMjczYzE0ZWIwOTMwMjAzYjVjMzNlNDljYi90YWJsZXJhbmdlOjJhOGFjNmIyNzNjMTRlYjA5MzAyMDNiNWMzM2U0OWNiXzItNS0xLTEtOTIxNTA_6ac8b975-88cb-4945-90ca-3b82bdbefe75">9.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyYThhYzZiMjczYzE0ZWIwOTMwMjAzYjVjMzNlNDljYi90YWJsZXJhbmdlOjJhOGFjNmIyNzNjMTRlYjA5MzAyMDNiNWMzM2U0OWNiXzMtMS0xLTEtOTIxNTA_3308dd1a-c331-41d5-b148-f1f17b2f6e1f">5.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i265887804270466a84b8183ec8c715b9_D20210102-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyYThhYzZiMjczYzE0ZWIwOTMwMjAzYjVjMzNlNDljYi90YWJsZXJhbmdlOjJhOGFjNmIyNzNjMTRlYjA5MzAyMDNiNWMzM2U0OWNiXzMtMy0xLTEtOTIxNTA_cc3da367-37fa-4c53-8de4-e6d18d50c0b5">6.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyYThhYzZiMjczYzE0ZWIwOTMwMjAzYjVjMzNlNDljYi90YWJsZXJhbmdlOjJhOGFjNmIyNzNjMTRlYjA5MzAyMDNiNWMzM2U0OWNiXzMtNS0xLTEtOTIxNTA_b9c370a6-a5a7-44df-b9c4-860f0d8550a1">6.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkyNzM_df01e2f2-6d5a-4448-9d29-2312ee49b5c3" escape="true"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkyOTA_cd92b29d-bc69-48b0-aca4-6d0e0e4b0dfb" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzMtMS0xLTEtOTIxNTA_a45c838f-9821-4fb0-aa25-c93a8cbcfaae">2.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzMtMy0xLTEtOTIxNTA_5c12dc30-7dfe-4cf9-98a7-e3f3378ed9d1">0.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzMtNS0xLTEtOTIxNTA_d8437c24-bea4-4f64-bd98-4dab60e5ffbd">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzQtMS0xLTEtOTIxNTA_b6d0f837-de04-4b75-bca0-2ac4b5b3fd06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzQtMy0xLTEtOTIxNTA_e19d1a3b-2e31-455b-8872-abf6d882e967">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzQtNS0xLTEtOTIxNTA_bddb7e16-a4a8-488a-a72d-a62a7b0728cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzUtMS0xLTEtOTIxNTA_7f4abb93-6711-4e40-90d1-069de5bf6f97">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzUtMy0xLTEtOTIxNTA_fed02b98-9ee0-4b5b-8e84-4b8630a0ff04">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzUtNS0xLTEtOTIxNTA_7c7dd5f1-d05a-4f33-904e-9f4282596e5f">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzYtMS0xLTEtOTIxNTA_0cc5ae32-a7fb-4933-aaf3-71031b26207b">4.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzYtMy0xLTEtOTIxNTA_230823d8-710e-4689-aae9-40a7df02ba34">4.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzYtNS0xLTEtOTIxNTA_7c98f494-5682-4f5a-8c18-e7099b49ca74">4.4</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzgtMS0xLTEtOTIxNTA_f521ae06-a2d6-4507-9059-d9c2f02a8be4">1.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i265887804270466a84b8183ec8c715b9_D20210102-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzgtMy0xLTEtOTIxNTA_9b49a30e-3b9e-4138-9277-e2ad9a9380d6">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzgtNS0xLTEtOTIxNTA_af793066-2b8c-4b69-950d-f655e7676379">0.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzktMS0xLTEtOTIxNTA_6950066a-5915-42c5-905f-cc678cde47c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i265887804270466a84b8183ec8c715b9_D20210102-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzktMy0xLTEtOTIxNTA_28a27305-8ad7-40d9-a983-1a08336c2206">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzktNS0xLTEtOTIxNTA_1e9dcc47-a0fd-46dc-b819-a49da5fd8fac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzEwLTEtMS0xLTkyMTUw_6d0d39e2-e271-4f20-909f-4dbfdafce8a6">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i265887804270466a84b8183ec8c715b9_D20210102-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzEwLTMtMS0xLTkyMTUw_6732a39c-8f93-4191-a09e-cedafc045efb">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzEwLTUtMS0xLTkyMTUw_8ebf2fae-48eb-4d05-9f89-955d5cbad100">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzExLTEtMS0xLTkyMTUw_e1a51c53-809c-4976-b579-0e41594f240f">6</ix:nonNumeric> months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i265887804270466a84b8183ec8c715b9_D20210102-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzExLTMtMS0xLTkyMTUw_6a8647a2-ce64-416c-8eef-1bce69584351">6</ix:nonNumeric> months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzExLTUtMS0xLTkyMTUw_0bf9617c-f33e-4d12-b0c7-31412e71d52c">6</ix:nonNumeric> months</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We considered both implied and historical volatility in developing our estimate of expected volatility. The assumption for the expected life of stock options is based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#8217; current expectations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs, including PSUs, was based on the closing price of the underlying common stock on the date of grant. </span></div><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkzMTM_5db6ddee-0b1a-4127-ac35-7cd82496d80b" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for stock options during the year ended December&#160;31, 2022 was as follows (in thousands</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzEtMS0xLTEtOTIxNTA_29078ab3-00b2-42cb-8ccd-e906e326564b">13,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzEtMy0xLTEtOTIxNTA_4467597b-8e93-4384-b6f6-580e90afaa11">16.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzItMS0xLTEtOTIxNTA_c8c9148b-f1a0-48d3-ad0c-4d36678674f4">589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzItMy0xLTEtOTIxNTA_bb339330-8080-4fd4-ae50-91999e60508b">19.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzMtMS0xLTEtOTIxNTA_bf956b36-d557-4a78-9e07-97af34747a5e">2,743</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzMtMy0xLTEtOTIxNTA_2fbc3448-e978-42d1-b2ef-cb15f71a1ae2">5.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzQtMS0xLTEtOTIxNTA_7733e8b0-e5e4-44a8-8d1a-7bd25ceecc4a">635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzQtMy0xLTEtOTIxNTA_93d44f94-bfd0-40db-9073-8c3f864d482f">21.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzUtMS0xLTEtOTIxNTA_32fd5cf4-3fd2-4f13-99cf-766a9669b48c">10,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzUtMy0xLTEtOTIxNTA_01cd21f2-615a-4ad3-96bb-154134687b9e">19.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzUtNS0xLTEtOTIxNTA_bfea4b42-49ee-402f-ad12-5a774acff8f4">3.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzUtNy0xLTEtOTIxNTA_22adee39-bc49-4316-802b-40ecf5e4ee00">9,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options exercisable at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzYtMS0xLTEtOTIxNTA_7d44b518-3134-4c1b-9d66-1a72ca982a9a">8,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzYtMy0xLTEtOTIxNTA_71163992-5bd9-448c-bf3f-716d7ada1f49">19.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzYtNS0xLTEtOTIxNTA_b363e9c7-b177-4e23-b43c-8ab1a624aa2d">2.4</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzYtNy0xLTEtOTIxNTA_01fad71c-50c0-4617-822e-8550dea57450">9,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i1665a438e56445b78cb7452df0643ba1_I20221230" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQwNTU_bc347059-dd1b-44b0-b144-8602a55a7181">16.6</ix:nonFraction> million of unrecognized compensation expense related to our unvested stock options. The compensation expense for the unvested stock options will be recognized over a weighted-average period of <ix:nonNumeric contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQyNDM_c5f92ede-7d29-4e54-b0f0-7be122bde76d">2.2</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="i89d293a8c7254c40a3e383748bffb744" continuedAt="i6893dd803da44bd0afb281c594060d66"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal year 2022 and the exercise prices, multiplied by the number of in-the-money stock options) that would have been received by the stock option holders had all stock option holders exercised their stock options on December&#160;31, 2022. The total intrinsic value of stock options exercised during the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQ3MTc_e182095c-9ced-4685-8902-826e7dd99c77">36.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQ3MjE_d83ac057-c957-4905-ac4c-89d45da9664e">76.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQ3Mjg_b35574f3-1b0e-43ba-b155-655c433436fb">106.5</ix:nonFraction> million, respectively. Cash received from stock option exercises during the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQ4Mjk_100acd27-84aa-4104-8814-33b2460eb855">13.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQ4MzM_2585be27-a213-4eb8-9215-d6b175a26a53">14.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQ4NDA_1b355483-095e-4a16-8cff-bd4fc38ae726">26.9</ix:nonFraction> million, respectively.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkyNzU_9efa44e1-faea-4874-80f5-efd171c7f10d" continuedAt="i06c71934ad6f413c84ec9153a35fd4a6" escape="true">Activity for RSUs during the year ended December&#160;31, 2022 was as follows (in thousands, except per share amounts):</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="i06c71934ad6f413c84ec9153a35fd4a6" continuedAt="i4a1a9602478543689e33e95abc1638f5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c54a7d88c1f429ba5559d7d2282d65c_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzEtMS0xLTEtOTIxNTA_7a629dfa-6b0e-4bbf-b7b7-bebf7241af03">6,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4c54a7d88c1f429ba5559d7d2282d65c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzEtMy0xLTEtOTIxNTA_ae84bbff-f82b-419a-89f7-a09811f311e8">21.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzItMS0xLTEtOTIxNTA_e2682de6-7446-4f35-89cf-e4324d2e2065">7,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzItMy0xLTEtOTIxNTA_8ff497c4-0dd5-4c58-b827-badb1fae5c49">21.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230" decimals="-3" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzMtMS0xLTEtOTIxNTA_cd05ecbf-6405-454d-8514-a92b821c79eb">2,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230" decimals="2" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzMtMy0xLTEtOTIxNTA_384a1273-4cfd-440d-8073-92225105a6cd">21.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzQtMS0xLTEtOTIxNTA_9dcab0dc-8860-458e-a5f6-a0c17fc1ebea">1,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzQtMy0xLTEtOTIxNTA_f5e17ae1-e7af-4bbe-9e42-bda05cc220b0">21.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5de3dc69b844f86ba1ee22cce4ea5c9_I20221230" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzUtMS0xLTEtOTIxNTA_b9de6bea-b5ac-47aa-a153-fefe5d4056ce">11,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib5de3dc69b844f86ba1ee22cce4ea5c9_I20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzUtMy0xLTEtOTIxNTA_d2c559b5-958f-4826-9886-49bcee3cecc0">21.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzUtNS0xLTEtOTIxNTA_76e7de3a-22c6-4409-bc4f-49fc9a743faf">1.8</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5de3dc69b844f86ba1ee22cce4ea5c9_I20221230" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzUtNy0xLTEtOTIxNTA_0d5586ec-7097-4496-8502-d2c2278ab2a1">181,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="ib5de3dc69b844f86ba1ee22cce4ea5c9_I20221230" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQ5NzU_0865aa33-ed1b-4fe2-8b74-65f017b57879">183.6</ix:nonFraction> million of unrecognized compensation expense related to our unvested RSUs which will be recognized over a weighted-average period of <ix:nonNumeric contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzUxMDM_09d924d9-a5ea-4176-9697-d609ac340bde">2.9</ix:nonNumeric> years.</span></div><ix:continuation id="i4a1a9602478543689e33e95abc1638f5"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for PSUs, during the year ended December&#160;31, 2022 was as follows (in thousands</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3d7d02ac4d34267a1d46e90f45bef37_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzEtMS0xLTEtOTIxNTA_cfff2090-4174-4547-a505-2bccfb0d5aca">6,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3d7d02ac4d34267a1d46e90f45bef37_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzEtMy0xLTEtOTIxNTA_e407d5fd-be97-4b0d-85f3-2631f9708148">23.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzItMS0xLTEtOTIxNTA_3d5ade14-0fe7-451b-a365-1fac59120489">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzItMy0xLTEtOTIxNTA_e1af4161-6590-4349-8887-4f7acebb13af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230" decimals="-3" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzMtMS0xLTEtOTIxNTA_4ee846d7-4897-4206-990d-21320e63e662">942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230" decimals="2" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzMtMy0xLTEtOTIxNTA_e4c47f62-9b9d-4d3f-941d-d345d0d8f3f9">21.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzQtMS0xLTEtOTIxNTA_dcd4f1fa-c94a-466b-a630-1ae39f3f5b7f">404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzQtMy0xLTEtOTIxNTA_34fe6ef6-02b7-4e84-b080-8940086e32b7">24.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9aae7ba847d34422b359963bd9dc87f5_I20221230" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzUtMS0xLTEtOTIxNTA_c51b3bde-0446-4c5a-86a9-cbf2bb259d12">4,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9aae7ba847d34422b359963bd9dc87f5_I20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzUtMy0xLTEtOTIxNTA_5d16cef7-9d92-4fe9-a325-61545a01d9aa">23.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzUtNS0xLTEtOTIxNTA_1601b9b7-561c-4a49-b4ef-2263bc5e1ce5">2.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aae7ba847d34422b359963bd9dc87f5_I20221230" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzUtNy0xLTEtOTIxNTA_9b76a3e6-1bdf-4c88-93fe-31c1672aa920">79,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, in connection with our long-term incentive compensation program, we awarded to certain employees an aggregate of <ix:nonFraction unitRef="shares" contextRef="i2fb2e18c946f487ea024e74f846cd36a_D20220301-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgyOTAyOA_45d5431c-1969-439f-8332-177a964bf6e9">1,003,482</ix:nonFraction> (the 2022 target amount) RSUs that are subject to a total shareholder return (TSR) market condition (the 2022 TSR-based RSUs). The TSR market condition for the 2022 TSR-based RSUs is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 1, 2022 through January 3, 2025. Depending on the results relative to the TSR market condition, the holders of the 2022 TSR-based RSUs may earn up to <ix:nonFraction unitRef="number" contextRef="i2fb2e18c946f487ea024e74f846cd36a_D20220301-20220331" decimals="2" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTQzMTI_a3b0af26-76bd-439c-a05d-b49fcbac8ef5">175</ix:nonFraction>% of the 2022 target amount of shares. <ix:nonFraction unitRef="number" contextRef="ia6d07a5ce0b943d9851f70f5a1bc4058_D20220301-20220331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTQzMDc_e55c3e1a-705a-48e5-abaf-b538e6ef30b4">50</ix:nonFraction>% of the shares earned pursuant to the 2022 TSR-based RSU awards will vest at the end of the performance period, and the remainder will vest approximately <ix:nonNumeric contextRef="ia6d07a5ce0b943d9851f70f5a1bc4058_D20220301-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTQzMTc_6d5590bc-3aa8-4c2b-8817-7436a470b36a">one year</ix:nonNumeric> later, subject to employee&#8217;s continuous service. These TSR-based RSUs will be forfeited if the market condition at or above a threshold level is not achieved at the end of the performance period on January 3, 2025.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="i6893dd803da44bd0afb281c594060d66" continuedAt="i65032007781e44c7b4d8257115b6255e"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkzMzk_fdb84ae0-25ee-4704-8ccf-cc20d6711822" continuedAt="i7cf559e9a3a446dbb217b64db3a61a3b" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia1b5d625613f4f5d933afddd77da19b7_D20220101-20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgyOTAzOQ_1c217b5b-c1db-49fe-8fa6-089ba120d356">33.17</ix:nonFraction> per share for the 2022 TSR-based RSUs:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of Exelixis common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8a52c2ef07a4489ad93e8b30e5e3368_I20221230" decimals="2" name="us-gaap:SharePrice" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTplNDQwMTg3ZmQyNmI0ODRlOGIxNWNiZDBiYjg1ZmM0ZC90YWJsZXJhbmdlOmU0NDAxODdmZDI2YjQ4NGU4YjE1Y2JkMGJiODVmYzRkXzAtMS0xLTEtOTIxNTA_b1e4e346-834f-4f4b-9f20-c9c60ee4134f">20.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1b5d625613f4f5d933afddd77da19b7_D20220101-20221230" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTplNDQwMTg3ZmQyNmI0ODRlOGIxNWNiZDBiYjg1ZmM0ZC90YWJsZXJhbmdlOmU0NDAxODdmZDI2YjQ4NGU4YjE1Y2JkMGJiODVmYzRkXzEtMS0xLTEtOTIxNTA_1b16fb64-bd36-4fc9-8906-b0ea6726da76">46.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1b5d625613f4f5d933afddd77da19b7_D20220101-20221230" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTplNDQwMTg3ZmQyNmI0ODRlOGIxNWNiZDBiYjg1ZmM0ZC90YWJsZXJhbmdlOmU0NDAxODdmZDI2YjQ4NGU4YjE1Y2JkMGJiODVmYzRkXzItMS0xLTEtOTIxNTA_021ea156-b1be-449a-9c26-fd3f170f89b2">1.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1b5d625613f4f5d933afddd77da19b7_D20220101-20221230" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTplNDQwMTg3ZmQyNmI0ODRlOGIxNWNiZDBiYjg1ZmM0ZC90YWJsZXJhbmdlOmU0NDAxODdmZDI2YjQ4NGU4YjE1Y2JkMGJiODVmYzRkXzMtMS0xLTEtOTIxNTA_f11477cd-601c-4b7e-9b6a-dde2f4f63840">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Monte Carlo simulation model also assumed correlations of returns of the stock prices of Exelixis common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, in connection with our long-term incentive compensation program, we awarded certain employees <ix:nonFraction unitRef="shares" contextRef="i63901f6ae4fb4bcbb543c24cd2c4216a_D20210301-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgzNDUwMg_13e18e47-7740-4867-ac9e-841623304ef1">1,027,650</ix:nonFraction> (the 2021 target amount) PSUs, subject to a performance and a market condition (the 2021 PSUs). Pursuant to the terms of 2021 PSUs, the holders of the awards may earn up to <ix:nonFraction unitRef="number" contextRef="i63901f6ae4fb4bcbb543c24cd2c4216a_D20210301-20210331" decimals="INF" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgzNDM3NA_0d1461b3-8711-4d50-a484-9c6e2f487d87">200</ix:nonFraction>% of the 2021 target amount, or up to <ix:nonFraction unitRef="shares" contextRef="i63901f6ae4fb4bcbb543c24cd2c4216a_D20210301-20210331" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgzNDM4MA_16109201-ec6e-4c0f-b834-adc494eaebed">2,055,300</ix:nonFraction> total shares, depending on the level of achievement of the performance condition related to certain net product revenues and a TSR market condition. The TSR market condition for the 2021 PSUs is based on our relative TSR percentile rank compared to companies in the Nasdaq Biotechnology Index during the performance period, which is January 2, 2021 through December 29, 2023. <ix:nonFraction unitRef="number" contextRef="ib652a5d9ce3a49709aea2941cebaac3b_D20210301-20210331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgzNTQwMw_bc31e3ae-1bdc-4d16-9b9a-abece591f645">50</ix:nonFraction>% percent of the shares earned subject to the performance and market conditions will vest at the end of the performance period and the remainder will vest approximately <ix:nonNumeric contextRef="i63901f6ae4fb4bcbb543c24cd2c4216a_D20210301-20210331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTgzNDk_2b859f2d-6f21-4f3e-b6d3-e329c7059015">one year</ix:nonNumeric> later subject to an employee&#8217;s continuous service. The 2021 PSUs will be forfeited if the performance condition at or above a threshold level is not achieved by December 29, 2023. The performance condition for target achievement of net product revenues relative to the 2021 PSUs was deemed probable of achievement in the fourth quarter of 2022 representing <ix:nonFraction unitRef="number" contextRef="i04f2cc9dcfa7426e99f081418b205d0e_D20221001-20221230" decimals="2" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgzNTY0Mw_f38ab5fd-6988-4d90-b2a9-a32931d4816f">100</ix:nonFraction>% of the 2021 PSUs target amount.</span></div><ix:continuation id="i7cf559e9a3a446dbb217b64db3a61a3b"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Monte Carlo simulation model was used to determine the grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="id33e4bb7f86d4f63bb3483974950eb21_D20220101-20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTgzNjU_a7e2a741-2b53-4978-be63-c412cd8f7b74">24.54</ix:nonFraction> for the 2021 PSUs based on the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of Exelixis common stock on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9aae7ba847d34422b359963bd9dc87f5_I20221230" decimals="2" name="us-gaap:SharePrice" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTplOGY2MGY4NmMzZWY0N2RiYTAwNWY2NWEyZWEwNmMyMi90YWJsZXJhbmdlOmU4ZjYwZjg2YzNlZjQ3ZGJhMDA1ZjY1YTJlYTA2YzIyXzAtMS0xLTEtOTg5NDM_b4086417-8313-4065-9615-5f8b9f70c730">21.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTplOGY2MGY4NmMzZWY0N2RiYTAwNWY2NWEyZWEwNmMyMi90YWJsZXJhbmdlOmU4ZjYwZjg2YzNlZjQ3ZGJhMDA1ZjY1YTJlYTA2YzIyXzEtMS0xLTEtOTg5NDM_dc7dd842-3819-4a76-8964-e1d4e7dd5b36">49.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTplOGY2MGY4NmMzZWY0N2RiYTAwNWY2NWEyZWEwNmMyMi90YWJsZXJhbmdlOmU4ZjYwZjg2YzNlZjQ3ZGJhMDA1ZjY1YTJlYTA2YzIyXzItMS0xLTEtOTg5NDM_b7cd1348-f94f-4d5e-a406-b80b9bd7d708">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTplOGY2MGY4NmMzZWY0N2RiYTAwNWY2NWEyZWEwNmMyMi90YWJsZXJhbmdlOmU4ZjYwZjg2YzNlZjQ3ZGJhMDA1ZjY1YTJlYTA2YzIyXzMtMS0xLTEtOTg5NDM_e94fb44e-092d-45d2-995b-dd6d5d77e854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the year ended December&#160;31, 2020, in connection with our long-term incentive compensation program, we awarded <ix:nonFraction unitRef="shares" contextRef="i053c349bf2894f5c9e19fc0cf85fe118_D20200104-20210101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgyNDg5OQ_01dec882-87eb-4120-b75a-99f5881d00b2">2,327,840</ix:nonFraction> PSUs (the 2020 target amount) that will vest upon the achievement of performance targets related to (i) clinical trial positive top-line results and (ii) product approvals by the FDA (the 2020 PSUs). Pursuant to the terms of the 2020 PSUs, employees may earn up to <ix:nonFraction unitRef="number" contextRef="i448f6fe1dd7842a5b8a72af4bafcacbe_D20200104-20210101" decimals="2" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgzNDQxNw_c5f1d91e-111c-41d3-b963-e63a80cfb0bd">200</ix:nonFraction>% of the 2020 target amount, or <ix:nonFraction unitRef="shares" contextRef="i448f6fe1dd7842a5b8a72af4bafcacbe_D20200104-20210101" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgyNTE5Mw_8adedd9a-82ad-43bf-8e8b-f90416e87963">4,655,680</ix:nonFraction> total shares, depending on the volume and timing of achievement of the performance targets. The 2020 PSUs will be forfeited if the performance targets are not met by December 31, 2024. The performance condition for threshold achievement of a product approval by the FDA relative to the 2020 PSUs occurred in the third quarter of 2021, representing <ix:nonFraction unitRef="number" contextRef="i4a76d7c8a8dc41cfa3f976f8a86b8ac3_D20210703-20211001" decimals="2" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgzNDY2OQ_0c9bef78-d9a6-46b1-a768-71d99eca322c">25</ix:nonFraction>% of the 2020 target amount. The performance condition for threshold achievement of positive top-line results by the FDA relative to the 2020 PSUs occurred in the third quarter of 2022, representing <ix:nonFraction unitRef="number" contextRef="ic5603f2e0fff4c849973ffaeafa13517_D20220702-20220930" decimals="2" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgzNDg5NA_dcb8a2fd-f939-4235-9493-203921255e71">25</ix:nonFraction>% of the 2020 target amount.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognition for PSUs commences when it is determined that attainment of the performance target is probable. Of the outstanding PSUs as of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i425a3fc9ca83455daa4acf0026125185_I20221230" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5Xzg0MDc_94360f42-5cd3-4256-abb2-7f0e1d026d64">869,502</ix:nonFraction> relate to awards for which we achieved the performance target. As of December&#160;31, 2022, the remaining unrecognized compensation expense for the PSUs achieved or deemed probable of achievement related to the PSUs was $<ix:nonFraction unitRef="usd" contextRef="if2fc11d4d2754631a3733ccac92d04e3_I20221230" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5Xzg2MTE_5e03bdf4-dfdf-490a-a5f3-fb3a3b11d295">11.0</ix:nonFraction> million, which will be recognized over a weighted-average period of <ix:nonNumeric contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5Xzg2NzQ_ecf20f5f-3c8b-4778-8e70-a579185213f2">2.3</ix:nonNumeric> years. The total unrecognized compensation expense for the PSUs for which we have not yet determined that attainment of the performance target is probable was $<ix:nonFraction unitRef="usd" contextRef="ic4e6cc8bacaf4594895d5bbfc9c89791_I20221230" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5Xzg4MzA_9005121b-bbb8-48e9-bac5-3631172a29e0">79.5</ix:nonFraction> million as of December&#160;31, 2022.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exelixis, Inc. 401(k) Plan (the 401(k) Plan)</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i65032007781e44c7b4d8257115b6255e">We sponsor the 401(k) Plan under which we make matching cash contributions to our employees&#8217; 401(k) accounts. We recorded compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkxNTA_9be71737-6697-482f-8fe8-b2cc36a599c4">11.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkxNTQ_da89d1ea-7037-4ed6-865f-d40c2ed787ac">9.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkxNjE_76e14ca2-a44b-4d0d-8994-4e8f566ebfea">6.7</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively, for matching contributions</ix:continuation>.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="ia855702135904005a41d208deb24e60a_109"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzQzOTI_9d4d35df-f6e1-48df-9024-1df43e59f7fb" continuedAt="iabe984b65b874e1692316c0ddc6db26e" escape="true">PROVISION FOR INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="iabe984b65b874e1692316c0ddc6db26e" continuedAt="ide397e7efc9f439d83a6af6952c7e389"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzQ0MDE_ec4b14f7-b90c-40fd-8add-72aae6417dee" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income before income taxes is derived solely from within the U.S. Our provision for income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzMtMS0xLTEtOTIxNTA_15f7d6f7-3cc3-4b15-a9ee-452a6d9bc6c6">100,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzMtMy0xLTEtOTIxNTA_c443d1d1-5cb6-4ae1-b931-eecafc06e638">11,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzMtNS0xLTEtOTIxNTA_ddf49ce2-1809-479f-9954-078b7562fcf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzQtMS0xLTEtOTIxNTA_3cf60b75-7b23-4e90-8d9d-7ad0b65f59d3">11,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzQtMy0xLTEtOTIxNTA_4913e6db-5988-4ead-a7d2-9f05b9da5882">5,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzQtNS0xLTEtOTIxNTA_6bb24f7c-099b-473a-8d50-18c94cbfaf71">3,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzUtMS0xLTEtOTIxNTA_ab9b8cde-062d-48a0-9b9f-89f5938133ee">112,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzUtMy0xLTEtOTIxNTA_97c1b44d-78d3-4cfe-8bc7-fe0db1887182">16,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzUtNS0xLTEtOTIxNTA_d105d108-98f6-40cd-988a-84c8eaf9ed83">3,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzctMS0xLTEtOTIxNTA_b7931b67-8287-4ae1-982e-200924c9ea9d">54,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzctMy0xLTEtOTIxNTA_04ff1b1e-6107-41ec-88dd-de83d41ee95d">46,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzctNS0xLTEtOTIxNTA_ae68dff6-0be2-4a6a-9a95-e2371483478c">14,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzgtMS0xLTEtOTIxNTA_151c5cbd-5fe3-4f96-850b-6e68d324a899">6,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzgtMy0xLTEtOTIxNTA_72d20819-bc1a-4043-86a3-f6ca2642f38d">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzgtNS0xLTEtOTIxNTA_c3837dbe-1735-4e88-ac9a-c9b6f3aa2846">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzktMS0xLTEtOTIxNTA_0e553243-0d5c-4879-84b6-b231ec0705c0">60,358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzktMy0xLTEtOTIxNTA_f3c7c99b-fff4-4b42-9ae5-1c5a39f46307">46,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzktNS0xLTEtOTIxNTA_20deb44e-a8da-4a55-8e9b-a67dca795db7">15,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzEwLTEtMS0xLTkyMTUw_6ee7a608-fe49-4a41-a5f7-ddd11bc95b4d">52,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzEwLTMtMS0xLTkyMTUw_7a7cdbc0-f9c6-4562-ab63-e74de5b9129d">63,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzEwLTUtMS0xLTkyMTUw_bd458919-9955-4097-81b2-ae218f29bb8c">19,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the years ended December&#160;31, 2022, 2021, and 2020 primarily relates to the utilization of federal tax attributes and state taxes in jurisdictions outside of California, for which we do not have net operating loss carryforwards due to a limited operating history.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our historical net operating losses were sufficient to fully offset any federal taxable income for the year ended December 31, 2020 but were not sufficient to fully offset federal taxable income for the years ended December&#160;31, 2022 and 2021.</span></div><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzQ0MDg_a1f04820-d756-4f16-befb-938344d9b8fc" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the U.S. federal income tax provision at the statutory federal income tax rate of 21% for each of the years ended December 31, 2022, 2021 and 2020, respectively, to our provision for income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal income tax provision at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzItMS0xLTEtOTIxNTA_6b62c0e3-1870-4474-9c4d-2ea5e61009dd">49,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzItMy0xLTEtOTIxNTA_be1ed11d-0ce0-4244-9297-2c260a3f6cc3">61,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzItNS0xLTEtOTIxNTA_d64d84fb-fc17-436e-b10b-5b5cc5f8eb6c">27,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax (benefit) expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzMtMS0xLTEtOTIxNTA_595c7f08-1f7c-4685-88f4-6d45ba75bd73">2,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzMtMy0xLTEtOTIxNTA_2d5add15-9d02-487c-8115-f02be1b4b3f5">1,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzMtNS0xLTEtOTIxNTA_26c16e7d-f550-4205-ba91-dd04c20b3535">2,232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzQtMS0xLTEtOTIxNTA_fbf4a009-83d2-4366-8539-bab5be2a906d">7,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzQtMy0xLTEtOTIxNTA_840658dc-7a38-46e3-bae7-26b8679109e5">2,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzQtNS0xLTEtOTIxNTA_08177094-52ef-4d20-b4ea-ef83319402a8">5,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzUtMS0xLTEtOTIxNTA_c5908a60-a6a6-4347-9f69-ccad55b01a97">14,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzUtMy0xLTEtOTIxNTA_493971b4-27db-474e-a006-75003351cabe">6,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzUtNS0xLTEtOTIxNTA_4c502d2f-86b9-4b15-805d-59eb5fccd02a">11,356</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzYtMS0xLTEtOTIxNTA_4d9421ff-71e3-4846-afcb-2101d24f037c">2,864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzYtMy0xLTEtOTIxNTA_bd4f6492-62f3-4619-b9c4-98abb26f5530">11,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzYtNS0xLTEtOTIxNTA_b28f4c36-d3c0-407a-8e1f-74247dc61bb3">20,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzctMS0xLTEtOTIxNTA_3fa8b1d2-3a29-4d99-9952-e57d07d0a688">4,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzctMy0xLTEtOTIxNTA_aafecd9e-7710-48d1-8a99-aeec1b9721c2">11,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzctNS0xLTEtOTIxNTA_06532ee4-8ec8-4ccc-996d-65329e352d21">18,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzgtMS0xLTEtOTIxNTA_506e54ff-0abc-475d-b44c-3be5fdf99cf0">3,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzgtMy0xLTEtOTIxNTA_ced2edc7-1f59-485e-8acf-27ba2bba43a5">2,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzgtNS0xLTEtOTIxNTA_eefb6fd2-6412-4396-930a-98762aa34338">2,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible warrant purchase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="exel:EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzktMS0xLTEtMTA0MDc2_5670c89a-e5c0-49bd-8190-f26f4b3b3e03">6,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="exel:EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzktMy0xLTEtMTA0MDg0_6431a6b1-7b02-458d-b647-5a8b3d783232">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="exel:EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzktNS0xLTEtMTA0MDkx_1d095352-8d49-4ccd-bbfd-2d9163dbab0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzktMS0xLTEtOTIxNTA_7cbf0d6e-c83c-453a-bb04-d1a87de44b02">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzktMy0xLTEtOTIxNTA_b77acc8c-af05-43db-99bc-fe6ac05a968d">1,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzktNS0xLTEtOTIxNTA_f2764606-8b1e-41e7-98dc-b0d919f857f5">562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzEwLTEtMS0xLTkyMTUw_9aecbbc1-26ea-46da-ac0d-8d5efe5c9a12">52,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzEwLTMtMS0xLTkyMTUw_cd96ce77-c4ec-44fe-a58b-e0e6974bfd89">63,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzEwLTUtMS0xLTkyMTUw_5f00e6cf-6570-4554-aa8b-4555e3ff5b1c">19,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="ide397e7efc9f439d83a6af6952c7e389" continuedAt="ic201008d94264d8dba04406b6bdc45b2"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzQ0MjI_4cf2b4c9-6c32-47a1-bc89-be7599573b86" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzMtMS0xLTEtOTIxNTA_e1c4b9b9-25db-450b-8707-edf628c20852">33,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzMtMy0xLTEtOTIxNTA_be22dafc-673b-48af-8d24-8f1248204a1f">17,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzQtMS0xLTEtOTIxNTA_70acec62-c6d7-448b-8cbb-6a56498855fb">40,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzQtMy0xLTEtOTIxNTA_894d6e73-55d5-4c41-a499-77e3cc1a7206">101,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzUtMS0xLTEtOTIxNTA_30dad60f-8d1c-4259-b30e-04012dd5bd9a">176,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzUtMy0xLTEtOTIxNTA_0ca915f5-4664-492f-bd91-2f76c7844cae">7,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzYtMS0xLTEtOTIxNTA_56e204e0-abae-4bb7-8e8f-06ba6175a27a">27,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzYtMy0xLTEtOTIxNTA_720284b2-51d4-4251-a736-b3c4b78ad31d">23,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="exel:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzctMS0xLTEtOTIxNTA_9e808780-0647-4a02-9c72-1966b6b9581d">46,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="exel:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzctMy0xLTEtOTIxNTA_650a1ce1-039b-4f11-8a7e-07715e45210b">12,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves not currently deductible</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzgtMS0xLTEtOTIxNTA_20769311-0941-4e93-a5e3-d9394df9f44d">22,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzgtMy0xLTEtOTIxNTA_4e9b4c6f-a34f-4485-b535-d57d1c18ae35">19,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzktMS0xLTEtOTIxNTA_cb0b167b-897f-4612-b2bc-5b59d2788330">7,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzktMy0xLTEtOTIxNTA_93bd88c2-f31e-4389-9caf-eaa028e50c8f">8,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzEwLTEtMS0xLTkyMTUw_f1ab5972-c15a-4b80-bb57-cfc546ead1fd">6,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzEwLTMtMS0xLTkyMTUw_c65a6b66-28e2-45bb-a021-5c10346df169">1,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzExLTEtMS0xLTkyMTUw_97056809-ba2e-4003-958b-aa950f713014">361,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzExLTMtMS0xLTkyMTUw_6960dab7-3402-49d2-829d-36b5a0ee8d49">191,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzEyLTEtMS0xLTkyMTUw_458e7dc1-b319-46d3-ad2a-d66517aad227">77,230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzEyLTMtMS0xLTkyMTUw_a7b4d8e8-a298-4011-a509-50aec3876050">70,068</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzEzLTEtMS0xLTkyMTUw_a4a963de-24c6-43df-a82b-b467a6b462b5">283,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzEzLTMtMS0xLTkyMTUw_1dc96e0b-d212-4caf-8b31-08bf7b80fc4b">121,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzE1LTEtMS0xLTkyMTUw_23a8e536-0db4-4101-bd8b-ffce25ea6e4a">52,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzE1LTMtMS0xLTkyMTUw_9cd0fc24-17b8-455f-be05-24cf140d5a87">9,907</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzE4LTEtMS0xLTkyMTUw_6b7b4a6f-bb9f-47b0-8b30-c5603039aa84">231,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzE4LTMtMS0xLTkyMTUw_ff9b717f-c9a6-4a6b-84cd-3e81829be14d">111,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 740: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December&#160;31, 2022, based on the evaluation and weighting of both positive and negative evidence, including our achievement of a cumulative three-year income position as of December&#160;31, 2022 and forecasts of future operating results, as well as considering the utilization of net operating losses and tax credits prior to their expiration, management has continued to determine that there is sufficient positive evidence to conclude that it is more likely than not the deferred tax assets are realizable. As of December&#160;31, 2022 and 2021, we continue to carry a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzIzMDU_8ce57a3c-5126-4199-a56a-e379323f1a95">77.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzIzMTI_64d262d1-aa81-47f4-a936-b912c6f07352">70.1</ix:nonFraction> million, respectively, against our California state deferred tax assets. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzI0MTA_ecfc79fc-2a59-418d-bf87-7acd888463b6">7.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzI0MTc_93a69d6f-811f-4226-b945-47ba2fe4f3d6">2.9</ix:nonFraction> million during the years ended December 31, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had state net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i7f5be490ad62428386485550713032a7_I20221230" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzI1MjI_6fba7154-5d48-48d8-9454-09345a32260d">414</ix:nonFraction>&#160;million, which expire in the years 2023 through 2036, California research and development tax credits of approximately $<ix:nonFraction unitRef="usd" contextRef="ic95667d6b2e54d3fa5b025ecb0ffea4b_I20221230" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzEwOTk1MTE2MzI1NTE_58b3504b-317d-48d6-9e92-979704467d3e">52</ix:nonFraction>&#160;million, which do not expire, and California Competes Tax Credits of approximately $<ix:nonFraction unitRef="usd" contextRef="ic95667d6b2e54d3fa5b025ecb0ffea4b_I20221230" decimals="-5" name="exel:TaxCreditCarryforwardAmountWithExpirationPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzEwOTk1MTE2MzI3Mzk_38b70ef8-7041-4367-81d6-3a3d448c76a2">1</ix:nonFraction>&#160;million, which begin to expire in 2028.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. We completed a Section 382 analysis through December&#160;31, 2022, and concluded that an ownership change, as defined under Section 382, had not occurred.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="ic201008d94264d8dba04406b6bdc45b2"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzQ0MTM_e7261226-a299-495a-926b-9df5329b5fd4" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our unrecognized tax benefits (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzItMS0xLTEtOTIxNTA_80a3be9f-7700-48f8-8d64-4c164feec3b7">83,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0958ab0a7b904c6abbc804e49a0e9544_I20210101" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzItMy0xLTEtOTIxNTA_ed3028ab-7605-4e16-b434-c3e9ac5c7a2e">80,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a3670052766460e8f6681bfb2fe46da_I20200103" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzItNS0xLTEtOTIxNTA_8fe3cd6d-9fdd-4587-a757-4cc24637e1c1">79,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to prior year provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzMtMS0xLTEtOTIxNTA_249331cc-5a71-4af6-91b5-417f49c32c41">715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzMtMy0xLTEtOTIxNTA_23862f30-1724-410d-bf7c-188417da89a0">728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzMtNS0xLTEtOTIxNTA_3daa16d5-d396-494f-8f0d-4f1b1cb206e3">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to current year provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzQtMS0xLTEtOTIxNTA_f1b43e2c-3a98-4557-a6cd-f8bbac1bd829">4,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzQtMy0xLTEtOTIxNTA_9f5c0794-b367-4d98-abe1-3beb1990d9d7">2,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzQtNS0xLTEtOTIxNTA_92ca1845-80cc-4c21-9633-b31976267f4d">3,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on the lapse of the applicable statutes of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzUtMS0xLTEtOTIxNTA_4d27f37c-d578-4ef0-8f86-5e14cb4096a2">721</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzUtMy0xLTEtOTIxNTA_f9f70a8a-0010-4bdd-901b-f6976b64e1f0">301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzUtNS0xLTEtOTIxNTA_edbb08f3-c448-4dfc-b21f-6ad3d51bc4f5">2,033</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzYtMS0xLTEtOTIxNTA_2a0fbbe3-c1b9-4b10-9ded-eab1a631e34e">87,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzYtMy0xLTEtOTIxNTA_6b9e6664-8c0d-4dc4-8ad6-7b627c4a60f8">83,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0958ab0a7b904c6abbc804e49a0e9544_I20210101" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzYtNS0xLTEtOTIxNTA_2a95d8dc-186c-4a91-8fe5-1e779dcb2e2c">80,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify unrecognized tax benefits as a reduction of deferred tax assets or as other long-term liabilities in the accompanying consolidated balance sheets. We do not anticipate that the amount of unrecognized tax benefits existing as of December&#160;31, 2022 will significantly change over the next 12 months. As of December&#160;31, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzM2MjI_e54f1ffe-ed8d-4143-befd-1394d9d9f75e">87.7</ix:nonFraction> million in unrecognized tax benefits, of which $<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzM2NjQ_ed81d23d-c59c-447c-80e2-7c1149fcf9ea">55.4</ix:nonFraction> million would reduce our income tax provision and effective tax rate, if recognized. Interest and penalties were nominal or zero for all periods presented. We have elected to record interest and penalties in the accompanying Consolidated Statements of Income as a component of income taxes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 2001 through 2022 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="ia855702135904005a41d208deb24e60a_112"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90ZXh0cmVnaW9uOmZlYzNiZTliODFlMjQ5OGU5YzJiMmZkZThhYTFiYWFjXzgwMQ_5073bb17-812a-40d3-a5c3-61887da2aae9" continuedAt="id52a8c42c53b4fb3b39652f75bf6614c" escape="true">NET INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="id52a8c42c53b4fb3b39652f75bf6614c"><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90ZXh0cmVnaW9uOmZlYzNiZTliODFlMjQ5OGU5YzJiMmZkZThhYTFiYWFjXzgyMA_3fbb9e1d-da9a-4ce2-9d8e-fd9154301ba1" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzMtNS0xLTEtOTIxNTA_380a7cc8-4a10-4538-9e88-0473245114c5">182,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzMtNy0xLTEtOTIxNTA_0bf48d82-682a-442b-9271-3412a2b0049c">231,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzMtOS0xLTEtOTIxNTA_929e5dcb-449a-4b9d-8c0e-b85add7e1f46">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzUtNS0xLTEtOTIxNTA_0e1dd32b-3a4a-4496-a5b4-d980f96a2213">321,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzUtNy0xLTEtOTIxNTA_6a626d3b-14f8-4338-ab54-35df5b40ddbe">314,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzUtOS0xLTEtOTIxNTA_f8910795-c30a-4ec4-ae9d-81d50eb9a1e4">308,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzYtNS0xLTEtOTIxNTA_3fe9610a-0502-4655-9af1-bb5babc27824">3,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzYtNy0xLTEtOTIxNTA_71b7dd3d-d868-4877-91e2-0016e49387cb">7,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzYtOS0xLTEtOTIxNTA_c42a45b6-971f-4128-83f3-0aaa3f8d7b83">9,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzctNS0xLTEtOTIxNTA_32fce9ca-3716-41ce-9e11-cafeae60845e">324,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzctNy0xLTEtOTIxNTA_e3974c29-3bab-4e43-9920-8ea9712d419d">322,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzctOS0xLTEtOTIxNTA_c8d05297-45e0-4dcd-b474-3837a6b68681">318,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzktNS0xLTEtOTIxNTA_e7576046-de8c-4e4b-8f1a-a2a5e8fbf66c">0.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzktNy0xLTEtOTIxNTA_71c71f80-68d4-443f-91bf-679335779fe1">0.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzktOS0xLTEtOTIxNTA_c9a9ab81-b73b-438b-a8cd-3436aef265cf">0.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzEwLTUtMS0xLTkyMTUw_49356d69-ed32-4c36-8acb-b820d315faf2">0.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzEwLTctMS0xLTkyMTUw_e7e357d4-2b70-412a-af6d-d75deaa70b8f">0.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzEwLTktMS0xLTkyMTUw_ad90da54-0329-4889-98f6-3a65995bf613">0.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options, unvested RSUs, unvested RSUs with market conditions, PSUs and ESPP contributions. Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. See &#8220;Note 8. Employee Benefit Plans&#8221; for a further description of our equity awards. <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90ZXh0cmVnaW9uOmZlYzNiZTliODFlMjQ5OGU5YzJiMmZkZThhYTFiYWFjXzgyNQ_6aababa7-655e-44a9-9b4e-ff29860c9671" continuedAt="i6330ef7387f44dcea07a83ce3df0551d" escape="true">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="i6330ef7387f44dcea07a83ce3df0551d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i71c697b2f65940fa81b21b627eb077fb_D20220101-20221230" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTpjMmRkNjJlNjU4ZmU0MmEwYTEwOGU3MDllNmY2ODhjZi90YWJsZXJhbmdlOmMyZGQ2MmU2NThmZTQyYTBhMTA4ZTcwOWU2ZjY4OGNmXzItNS0xLTEtOTIxNTA_30ac76d1-023f-4ea6-8b68-2136d094e7c8">17,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56ed82a42994483c92b32ba299673685_D20210102-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTpjMmRkNjJlNjU4ZmU0MmEwYTEwOGU3MDllNmY2ODhjZi90YWJsZXJhbmdlOmMyZGQ2MmU2NThmZTQyYTBhMTA4ZTcwOWU2ZjY4OGNmXzItNy0xLTEtOTIxNTA_bfc49e54-a0df-47d6-a9ef-340e5a9ccde2">14,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib28ac370d4ef4ca68b7bea32798fe004_D20200104-20210101" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTpjMmRkNjJlNjU4ZmU0MmEwYTEwOGU3MDllNmY2ODhjZi90YWJsZXJhbmdlOmMyZGQ2MmU2NThmZTQyYTBhMTA4ZTcwOWU2ZjY4OGNmXzItOS0xLTEtOTIxNTA_93d7a46a-98f3-4fe8-bbe6-27c5246ac05c">10,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><div id="ia855702135904005a41d208deb24e60a_115"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzEzMjY4_6eaf3868-8852-4c2f-8d34-0ab34968bfc8" continuedAt="i7641ca4187614d45b7a5d1d6dcb6d2ce" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i7641ca4187614d45b7a5d1d6dcb6d2ce" continuedAt="ie795cda754a849ffa7b7fbccbf28f04c"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have noncancellable operating leases of corporate headquarters, office and laboratory space in California and Pennsylvania totaling <ix:nonFraction unitRef="sqft" contextRef="i124df26053054aa2bdf51a23778af8d1_I20221230" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzU0OTc1NTgzNTkyNQ_5d41cfab-8171-467e-a721-1badbc17579b">673,978</ix:nonFraction> square feet with lease terms ending in 2024 through 2037. Certain of our leases include options to renew the lease or to early terminate the lease. As of December&#160;31, 2022, it is not probable we will exercise our options to renew these leases, nor is it probable that we will not exercise our option to terminate certain of our leases before the end of the lease term. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we have lease agreements for laboratory spaces located in Pennsylvania totaling <ix:nonFraction unitRef="sqft" contextRef="i4ca72b16cd354168a6373fa5107c1cb5_I20221230" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzU0OTc1NTgzMzY5Mw_0aff4959-e524-454c-99f7-e3dbc2869804">28,228</ix:nonFraction> square feet for which the leases of the premises have not commenced. We expect these leases to commence upon substantial completion of leasehold improvements by the lessor and upon receiving access to those premises.</span></div><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="exel:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzEzMjc2_217eb6ce-f6d1-4cdd-b062-57be858db131" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMC0xLTEtOTIxNTA_96cbace8-4798-438d-bd6a-d3ce92ddad69"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMC0xLTEtOTIxNTA_bf05f744-ae2c-4625-a413-f24a3f80b54d">Right-of-use assets included in other long-term assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMS0xLTEtOTIxNTA_317d47c1-86da-4f69-b383-cc80f1ed4fd9">234,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMy0xLTEtOTIxNTA_b0c7b7d5-085e-4673-b4ab-ef30f250b17d">45,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMC0xLTEtOTIxNTA_3805e340-1810-45ae-9746-eaa8274e40f1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMC0xLTEtOTIxNTA_4cf525be-b16c-489c-b6e4-ee90a9a764d7">Current portion included in other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMS0xLTEtOTIxNTA_5c34c9c5-9263-4d65-893d-d4bc0dc9e50e">17,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMy0xLTEtOTIxNTA_64a980b6-b3a1-4297-a9d3-fe91b22b3717">5,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzYtMS0xLTEtOTIxNTA_3119f709-41c4-45e3-accd-bc50ce12fed3">190,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzYtMy0xLTEtOTIxNTA_e37fc5c1-e00b-485c-84e7-1b9282d2e833">51,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzctMS0xLTEtOTIxNTA_a00c16ad-63a1-4246-b5b8-ce3bf7216b08">207,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzctMy0xLTEtOTIxNTA_01739c93-a87c-4956-a5cd-d04a2ad25f46">56,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzEzMjc3_973a2d7c-4476-47ef-8e7c-5ad8e2860cad" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease costs were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzItNS0xLTEtOTIxNTA_fe1081f8-8b7d-48c4-84de-21ea824f24ea">18,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzItNy0xLTEtOTIxNTA_01531ec1-d817-4d8a-8984-5ba476f00ac9">5,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzItOS0xLTEtOTIxNTA_518e1646-4b98-4a7c-b5bb-7e20e3052266">4,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzMtNS0xLTEtOTIxNTA_a0335307-a86f-4de0-af7a-e2ef7b873ce8">3,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzMtNy0xLTEtOTIxNTA_bc81892b-410e-4f8d-9780-96c5462e4067">2,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzMtOS0xLTEtOTIxNTA_d77e5e8c-9a84-4406-a07b-79aa71d8f6e1">2,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzUtNS0xLTEtOTIxNTA_ece6df93-7c87-48f0-bd8e-2e0064c884d6">21,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzUtNy0xLTEtOTIxNTA_b2c5f329-89fa-4c26-8896-6084c28a122a">8,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzUtOS0xLTEtOTIxNTA_debae5e0-a88b-4fae-bb05-dc7992008ae9">7,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities for the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzE5NDE_d5e72191-7d8b-4d5e-a578-f5a8f7571b11">11.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzE5NDU_2452768e-5f1e-4522-b5a3-ab755fb0f3c1">5.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzE5NTI_ed67b691-38ea-4e20-8aca-e6dd25c468fd">4.6</ix:nonFraction>&#160;million, respectively, and was included in net cash provided by operating activities in our Consolidated Statements of Cash Flows.</span></div><ix:nonNumeric contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzEzMjcz_ad8f25ff-dd26-48bf-9c93-2f2ded0dd701" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the maturities of our operating lease liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.186%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzItMi0xLTEtOTIxNTA_74f5fcb7-7359-4885-86c0-18b75ac8544a">18,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzMtMi0xLTEtOTIxNTA_c631624e-79b9-401c-965e-cbbec8562b5e">23,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzQtMi0xLTEtOTIxNTA_8727c5e4-6af6-4ae6-8e68-426a6dcd9ea1">23,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzUtMi0xLTEtOTIxNTA_904ed13e-99be-4f52-bcae-708ff021012a">23,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzYtMi0xLTEtOTU1ODk_091c2702-c35b-469d-a428-ce473b9a924b">24,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzYtMi0xLTEtOTIxNTA_5f7997cd-12dc-48bc-9499-90e70f1c5458">206,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzctMi0xLTEtOTIxNTA_32c10125-a2c0-4bc9-be36-3a1246e8a8b6">319,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzktMi0xLTEtOTIxNTA_8ab82643-58a1-4795-9d10-b03ef2181524">88,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future tenant improvement reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzEwLTItMS0xLTkyMTUw_6b320452-99d8-4ee4-9101-0e61dc531a42">23,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzExLTItMS0xLTkyMTUw_f25983a9-a302-4d72-87d5-d77a098bd0c4">207,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="ie795cda754a849ffa7b7fbccbf28f04c" continuedAt="id560feff6b8940908d25cad874171fc0"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the weighted average discount rate used to determine the operating lease liability was <ix:nonFraction unitRef="number" contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzIyNjk_34becf71-00c8-4368-9015-b6b026bc8532">5.3</ix:nonFraction>% and the weighted average remaining lease term was <ix:nonNumeric contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzIzMjI_caca8231-fe5c-4f37-a350-d78bd2b32e60">12.7</ix:nonNumeric> years. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease cost for leases with initial terms less than 1 year for the year ended December 31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzM4NDgyOTA3NzUwMzE_73f0e8d4-0681-401b-bd76-736d850e95b1">0.4</ix:nonFraction>&#160;million, and <ix:nonFraction unitRef="usd" contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzU0OTc1NTg5MDk2Nw_a2a19350-99ac-44d8-9462-2c37d339dd4d"><ix:nonFraction unitRef="usd" contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzU0OTc1NTg5MDk2Nw_c4028482-2ae0-4c97-8475-ecb9f8fb67aa">immaterial</ix:nonFraction></ix:nonFraction> for the years ended December 31, 2021 and 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MSN I ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (individually and collectively with certain of its affiliates, including MSN Laboratories Private Limited, referred to as MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the May 5, 2020 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. The two lawsuits comprising this litigation (collectively referred to as MSN I), numbered Civil Action Nos. 19-02017 and 20-00633, were consolidated in April 2021.</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our MSN I complaints, we sought, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties narrowed their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the trial addressed two issues: (1) infringement of claim 1 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A bench trial for MSN I occurred in May 2022, and on January 19, 2023, the Delaware District Court issued a ruling rejecting MSN&#8217;s invalidity challenge to U.S. Patent No. 7,759,473. The Delaware District Court also ruled that MSN&#8217;s proposed ANDA product does not infringe U.S. Patent No. 8,877,776 and entered judgment that the effective date of any final FDA approval of MSN&#8217;s ANDA shall not be a date earlier than August 14, 2026, the expiration date of U.S. Patent No. 7,759,473. This ruling in MSN I does not impact our separate and ongoing MSN II lawsuit.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MSN II ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. In particular, the January 11, 2022 amended ANDA requested approval to market a generic </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="id560feff6b8940908d25cad874171fc0" continuedAt="i1afe5298d2f84b059d4d873ecd650152"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment). On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 are invalid and not infringed. On June 7, 2022, we received notice from MSN that it had further amended its ANDA to assert an additional Paragraph IV certification. As currently amended, MSN&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. 11,298,349 (pharmaceutical composition). On July 18, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 11,298,349 arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. On August 9, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 11,298,349 are invalid and not infringed and amended its challenges to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 to allege that these patents are not enforceable based on equitable grounds. The <ix:nonFraction unitRef="lawsuit" contextRef="i46d4a2a715724209a705ccaf6ae07793_I20221031" decimals="INF" name="exel:LossContingencyNumberOfLawsuitsConsolidated" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzM4NDgyOTA3NzQxMTQ_e204a11e-d8c6-4a60-8150-8bf031cbbded">two</ix:nonFraction> lawsuits comprising this litigation (collectively referred to as MSN II), numbered Civil Action Nos. 22-00228 and 22-00945, were consolidated in October 2022 and involve Exelixis patents that are different from those asserted in the MSN I litigation described above.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 would also infringe certain claims of each patent, if those claims are not found to be invalid. In our MSN II complaints, we are seeking, among other remedies, equitable relief enjoining MSN from infringing the asserted patents, as well as an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patents No. 11,091,439, 11,091,440, 11,098,015 and 11,298,349, the latest of which expires on February 10, 2032. A bench trial for MSN II has been scheduled for October 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teva ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. On July 29, 2022, we received notice from Teva that it had amended its ANDA to assert an additional Paragraph IV certification. As amended, Teva&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. 11,298,349 (pharmaceutical composition). On September 2, 2022, we filed a complaint in the Delaware District Court for patent infringement against Teva, asserting infringement of U.S. Patent No. 11,298,349 arising from Teva&#8217;s amended ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873, 10,039,757 and 11,298,349, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva from infringing these patents. On September 30, 2022, the parties filed a stipulation to consolidate the <ix:nonFraction unitRef="lawsuit" contextRef="i787ca4c1857e40088e47d31bcee1d60b_I20220930" decimals="INF" name="exel:LossContingencyNumberOfLawsuitsConsolidated" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzM4NDgyOTA3NzQxMTU_6ef6fc7c-3a74-4643-aa9d-5ecc5cbfb4a8">two</ix:nonFraction> lawsuits, numbered Civil Action Nos. 21-00871 and 22-01168, and to stay all proceedings, which was granted by the Delaware District Court on October 3, 2022. Following a similar order granted by the Delaware District Court on February 9, 2022 to stay all proceedings with respect to Civil Action No. 21-00871, this case remained administratively closed, and Civil Action No. 22-01168 was administratively closed on October 3, 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 6, 2023, we received a notice letter regarding an ANDA submitted to the FDA by Cipla Limited (Cipla), including a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><ix:continuation id="i1afe5298d2f84b059d4d873ecd650152"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,724,342 (formulations), 10,039,757 (methods of treatment), 11,098,015 (methods of treatment), 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,298,349 (pharmaceutical composition).</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cipla&#8217;s ANDA requests approval to market a generic version of CABOMETYX tablets prior to the expiration of the aforementioned patents. We have not yet responded to this Paragraph IV certification notice letter but are evaluating it.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div></ix:continuation><div id="ia855702135904005a41d208deb24e60a_121"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="ia855702135904005a41d208deb24e60a_124"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on the evaluation of our disclosure controls and procedures (as defined under Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended) required by Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended, our Chief Executive Officer and our Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the Effectiveness of Controls.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f). Our internal control over financial reporting is a process designed under the supervision of our principal executive and principal financial officers to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S.&#160;generally accepted accounting principles.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of our 2022 fiscal year, management conducted an assessment of the effectiveness of our internal control over financial reporting based on the framework established in the original </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;&#8211; Integrated Framework</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO). Based on this assessment, management has determined that our internal control over financial reporting as of December&#160;31, 2022 was effective. There were no material weaknesses in internal control over financial reporting identified by management.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The independent registered public accounting firm Ernst&#160;&amp; Young LLP has issued an audit report on our internal control over financial reporting, which is included on the following page.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Exelixis, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control </span><span style="color:#333333;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Over</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Exelixis, Inc.&#8217;s internal control over financial reporting as of December 30, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Exelixis, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 30, 2022, based on the COSO criteria.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 30, 2022 and December 31, 2021, the related consolidated statements of income, comprehensive income, stockholders&#8216; equity and cash flows for each of the three fiscal years in the period ended December 30, 2022, and the related notes and our report dated February 7, 2023 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Mateo, California</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 7, 2023</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><div id="ia855702135904005a41d208deb24e60a_127"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ia855702135904005a41d208deb24e60a_1302"></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="ia855702135904005a41d208deb24e60a_130"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="ia855702135904005a41d208deb24e60a_133"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item relating to our directors and nominees, including information with respect to our audit committee, audit committee financial experts and procedures by which stockholders may recommend nominees to our Board of Directors, is incorporated by reference to the section entitled &#8220;Proposal&#160;1&#160;&#8211; Election of Directors&#8221; appearing in our Proxy Statement for our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days after December&#160;30, 2022, which we refer to as our 2023 Proxy Statement. The information required by this item regarding our executive officers is incorporated by reference to the section entitled &#8220;Information about our Executive Officers&#8221; appearing in our 2023 Proxy Statement. The information, if any, required by this item regarding compliance with Section&#160;16(a) of the Securities Exchange Act of 1934, as amended, is incorporated by reference to the section entitled &#8220;Delinquent Section 16(a) Reports&#8221; appearing in our 2023 Proxy Statement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Ethics</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Corporate Code of Conduct that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. The Corporate Code of Conduct is posted on our website at www.exelixis.com under the caption &#8220;Investors &amp; Media&#8212;Corporate Governance&#8212;Corporate Governance Documents and information.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to satisfy the disclosure requirement under Item&#160;5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of this Corporate Code of Conduct by posting such information on our website, at the address and location specified above and, to the extent required by the listing standards of the Nasdaq Stock Market, by filing a Current Report on Form 8-K with the SEC, disclosing such information.</span></div><div id="ia855702135904005a41d208deb24e60a_136"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the sections entitled &#8220;Compensation of Executive Officers,&#8221; &#8220;Compensation of Directors,&#8221; &#8220;Compensation Committee Interlocks and Insider Participation&#8221; and &#8220;Compensation Committee Report&#8221; appearing in our 2023 Proxy Statement.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><div id="ia855702135904005a41d208deb24e60a_139"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item relating to security ownership of certain beneficial owners and management is incorporated by reference to the section entitled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; appearing in our 2023 Proxy Statement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain information about our common stock that may be issued upon the exercise of stock options and other rights under all of our existing equity compensation plans as of December&#160;31, 2022, which consists of our 2000 Employee Stock Purchase Plan (the ESPP), our 2014 Equity Incentive Plan (the 2014 Plan), our 2016 Inducement Award Plan (the 2016 Plan) and our 2017 Equity Incentive Plan (the 2017 Plan):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:52.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">securities to&#160;be issued upon exercise of outstanding&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">options, warrants and rights</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average exercise&#160;price of outstanding&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">options, warrants&#160;and&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">rights</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by stockholders</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,000,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,532,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved by stockholders</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,140,905&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,532,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Equity plans approved by our shareholders include the 2014 Plan, the 2017 Plan and the ESPP. As of December&#160;31, 2022, a total of 2,561,567 shares of our common stock remained available for issuance under the ESPP, and up to a maximum of 1,221,398 shares of our common stock may be purchased in the current purchase period. The shares issuable pursuant to our ESPP are not included in the number of shares to be issued pursuant to rights outstanding and the weighted-average exercise&#160;price of such rights as of December&#160;31, 2022, as those numbers are not known.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The weighted-average exercise price takes into account the shares subject to outstanding restricted stock units (RSUs), including such awards with performance conditions, which have no exercise price. The weighted-average exercise price, excluding such outstanding RSUs, is $19.48.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents shares of our common stock issuable pursuant to the 2016 Plan. As of December&#160;31, 2022, no shares of our common stock remained available for additional grants under the 2016 Plan. In November 2016, the Board of Directors adopted the 2016 Plan pursuant to which we reserved 1,500,000 shares of our common stock for issuance under the 2016 Plan. The only persons eligible to receive grants of Awards under the 2016 Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1 - that is, generally, a person not previously an employee or director of Exelixis, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with Exelixis. An &#8220;Award&#8221; is any right to receive Exelixis common stock pursuant to the 2016 Plan, consisting of non-statutory stock options, stock appreciation rights, RSUs, or any other stock award.</span></div><div id="ia855702135904005a41d208deb24e60a_142"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the sections entitled &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Proposal 1 &#8211; Election of Directors&#8221; appearing in our 2023 Proxy Statement.</span></div><div id="ia855702135904005a41d208deb24e60a_145"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the section entitled &#8220;Proposal 2&#160;&#8211; Ratification of Selection of Independent Registered Public Accounting Firm&#8221; appearing in our 2023 Proxy Statement. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><div id="ia855702135904005a41d208deb24e60a_148"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ia855702135904005a41d208deb24e60a_151"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.15pt">The following documents are being filed as part of this report:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;The following financial statements and the Report of Independent Registered Public Accounting Firm are included in Part II, Item&#160;8:</span></div><div style="margin-top:5pt;padding-left:54pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.285%"><tr><td style="width:1.0%"></td><td style="width:83.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_61">Report of Independent Registered Public Accounting Firm (PCAOB ID:</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 42)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_61">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_64">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_64">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_67">Consolidated Statements of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_67">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_70">Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_70">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_73">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_73">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_76">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_76">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_79">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_79">85</a></span></div></td></tr></table></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;All financial statement schedules are omitted because the information is inapplicable or presented in the Notes to Consolidated Financial Statements.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;The following Exhibits are filed as part of this report.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex31.htm">Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/5/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000024/exhibit31amendedandres.htm">Amended and Restated Bylaws of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/3/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000076/exhibit41exel20210630sto.htm">Specimen Common Stock Certificate.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/5/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976722000026/exel20211231exhibit42.htm">Description of the Common Stock of Exelixis, Inc. Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/18/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976722000026/exel20211231exhibit101.htm">Form of Indemnification Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/18/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000170/def14a-20160413xproxy.htm">Exelixis, Inc. 2000 Employee Stock Purchase Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 14A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/13/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000117/exel20200630exhibit101.htm">Exelixis, Inc. 2014 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit102.htm">Form of Stock Option Agreement under the Exelixis, Inc. 2014 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit104.htm">Form of Stock Option Agreement (Non-Employee Director) under the Exelixis, Inc. 2014 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit105.htm">Form of Restricted Stock Unit Agreement under the Exelixis, Inc. 2014 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000117/exel20200630exhibit102.htm">Exelixis, Inc. 2016 Inducement Award Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000278/exel201611218-kexhibit102.htm">Form of Stock Option Agreement under the 2016 Inducement Award Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/22/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000278/exel201611218-kexhibit102.htm">Form of Restricted Stock Unit Agreement under the 2016 Inducement Award Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/22/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976722000097/exel2022630exhibit10110q.htm">Exelixis, Inc. 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/9/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000939767/000162828021001852/exel20201231exhibit1011.htm">Form of Stock Option Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/11/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1022.htm">Form of Stock Option Agreement (Non-Employee Director) under the Exelixis, Inc. 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/26/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000117/exel20200630exhibit105.htm">Form of Restricted Stock Unit Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000117/exel20200630exhibit106.htm">Form of Restricted Stock Unit Agreement (Non-Employee Director) under the Exelixis, Inc. 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000068/exel20200331exhibit104.htm">Non-Employee Director Equity Compensation Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/5/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000110465904022709/a04-8650_1ex10d43.htm">Offer Letter Agreement, dated February 3, 2000, between Exelixis, Inc. and Michael Morrissey, Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/5/2004</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976715000102/exel20150930exhibit105.htm">Offer Letter Agreement, dated June 30, 2015, between Exelixis, Inc. and Christopher Senner</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/10/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976722000026/exel20211231exhibit1018.htm">Offer Letter Agreement, dated December 2, 2021, between Exelixis, Inc. and Vicki L. Goodman,&#160;M.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/18/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000018/exel20140331exhibit104.htm">Offer Letter Agreement, dated February 10, 2014, between Exelixis, Inc. and Jeffrey J. Hessekiel.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/1/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20221230exhibit1020.htm">Terms of Employment Offer, dated December 15, 2022, for Dana T. Aftab, Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1026.htm">Offer Letter Agreement, dated August 19, 2010, between Exelixis, Inc. and Patrick J. Haley</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000013/exel20180212exhibit101.htm">Annual Cash Bonus Compensation Plan for Executives</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976722000110/exel2022930exhibit10110q.htm">Cash Compensation Information for Non-Employee Directors.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/1/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000069/exel20180331exhibit105.htm">Exelixis, Inc. Change in Control and Severance Benefit Plan, as amended and restated.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/2/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000109/exel20190331exhibit104.htm">Policy for Recoupment of Variable Compensation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/1/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000137/exel20170630exhibit101.htm">Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/2/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1039.htm">First Amendment dated October 16, 2017, to Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/26/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000136/exel20180630exhibit102.htm">Second Amendment dated June 13, 2018, to Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/1/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000090/exel20190401exhibit101.htm">Third Amendment dated April 1, 2019, to Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/5/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000190/exel20190930exhibit102.htm">Fourth Amendment dated August 30, 2019, to Lease Agreement dated May 2, 2017, between Hillwood Enterprises, L.P. (as successor in interest to Ascentris 105, LLC) and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/30/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000035/exel20191231exhibit1037.htm">Fifth Amendment dated January 16, 2020, to Lease Agreement dated May 2, 2017, between Waterfront EDP, LLC (as successor in interest to Hillwood Enterprises, L.P.) and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000939767/000162828021001852/exel20201231exhibit1032.htm">Sixth Amendment dated December 11, 2020, to Lease Agreement dated May 2, 2017, between SCG Harbor Bay Parkway Phase I, LLC (as successor in interest to Waterfront EDP, LLC) and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/10/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976722000097/exel2022630exhibit10310q.htm">Seventh Amendment dated May 16, 2022, to Lease Agreement dated May 2, 2017, between SCG Harbor Bay Parkway Phase I, LLC and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/9/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000190/exel20190930exhibit103.htm">Lease Agreement dated October 25, 2019, between Ernst Development Partners, Inc. and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/30/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000035/exel20191231exhibit1039.htm">First Amendment dated January 16, 2020, to Lease Agreement dated May 2, 2017, between Alameda BTS EDP, LLC (as successor in interest to Ernst Development Partners, Inc.) and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000045/exhibit101ipsencollaborati.htm">Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/6/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000045/exhibit102firstamendmentto.htm">First Amendment dated December 20, 2016, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/6/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000045/exhibit103secondamendmentt.htm">Second Amendment dated September 14, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/6/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000045/exhibit104thirdamendmentto.htm">Third Amendment dated October 26, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/6/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20221230exhibit1040.htm">Fourth Amendment dated October 11, 2022, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000045/exhibit105ipsensupplyagree.htm">Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/6/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000045/exhibit106firstamendmentto.htm">First Amendment dated October 26, 2017, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/6/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000157/exel20190630exhibit102.htm">Second Amendment dated May 17, 2019, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976722000026/exel20211231exhibit1042.htm">Third Amendment dated December 10, 2021, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/18/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976722000058/exel20210331exhibit10110q.htm">Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/10/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000136/exel20180630exhibit101.htm">First Amendment dated March 22, 2018, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/1/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976722000058/exel20210331exhibit10210q.htm">Second Amendment dated May 7, 2019, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/10/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976720000150/exel20200930exhibit101.htm">Third Amendment dated September 3, 2020, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/5/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976720000035/exel20191231exhibit1062.htm">Joint Clinical Research Agreement dated December 18, 2019, by and between Exelixis, Inc. and F. Hoffmann-La Roche Ltd</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.62</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20221230exhibit211.htm">Subsidiaries of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20221230exhibit231.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_157">Power of Attorney (contained on signature page)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20221230exhibit311.htm">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20221230exhibit312.htm">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#8225;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20221230exhibit321.htm">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The XBRL instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formatted as Inline XBRL and contained in Exhibit 101.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment granted for certain portions of this exhibit.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portions of this exhibit have been omitted as being immaterial and would be competitively harmful if publicly disclosed.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies this Annual Report on Form 10-K, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Annual Report on Form 10-K), irrespective of any general incorporation language contained in such filing.</span></td></tr></table></div><div id="ia855702135904005a41d208deb24e60a_154"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;None provided.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><div id="ia855702135904005a41d208deb24e60a_157"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized</span></div><div style="margin-top:5pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.428%"><tr><td style="width:1.0%"></td><td style="width:26.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/    M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ICHAEL </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">M. M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ORRISSEY        </span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that each person whose signature appears below constitutes and appoints </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MICHAEL M. MORRISSEY</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHRISTOPHER J. SENNER </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> JEFFREY J. HESSEKIEL </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.521%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Signatures</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHAEL </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M. M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ORRISSEY</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director, President and Chief&#160;Executive&#160;Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal&#160;Executive&#160;Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/    C</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">HRISTOPHER</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">J. S</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ENNER</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief&#160;Financial&#160;Officer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal&#160;Financial and Accounting&#160;Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/    S</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">TELIOS</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> P</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">APADOPOULOS </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">       </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stelios Papadopoulos, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/    C</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ARL </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">B. F</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ELDBAUM        </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carl B. Feldbaum, Esq.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ARIA </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">C. F</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">REIRE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maria C. Freire, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">Table of Co</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia855702135904005a41d208deb24e60a_7">ntents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.521%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signatures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    A</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LAN</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. G</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARBER </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">       </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Alan M. Garber, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    V</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">INCENT</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> T. M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARCHESI</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vincent T. Marchesi, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    G</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EORGE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> P</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OSTE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">George Poste, DVM, Ph.D., FRS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    J</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ULIE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A. S</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MITH</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Julie A. Smith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    L</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ANCE </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">W</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ILLSEY </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">       </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lance Willsey, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    J</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACQUELINE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RIGHT</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jacqueline Wright</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/    J</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACK</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> L. W</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">YSZOMIERSKI</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">       </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jack L. Wyszomierski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>2
<FILENAME>exel20221230exhibit1020.htm
<DESCRIPTION>EX-10.20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8275c4a89f654b9189244fd1c9f9742c_1"></div><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.20</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TERMS OF EMPLOYMENT &#8211; DANA T. AFTAB</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(as of December 15, 2022)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TITLE</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; Executive Vice President, Discovery and Translational Research, and Chief Scientific Officer</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ANNUAL BASE SALARY&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$560,000.22 annually</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BONUS TARGET&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">50% of Annual Base salary</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INITIAL RESTRICTED STOCK UNIT (RSU) AWARD&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100,000 shares of Exelixis, Inc. common stock pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The vesting schedule for this RSU award is 1&#47;4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> on the first established RSU vesting date following the one year anniversary of the grant date (the &#8220;Initial RSU Vesting Date&#8221;) and 1&#47;4th of the original number of shares subject to the RSU award on each succeeding annual anniversary of the Initial RSU Vesting Date until fully-vested, provided that vesting ceases upon termination of &#8220;continuous service&#8221; with Exelixis, Inc., as such term is defined in the Exelixis, Inc. 2017 Equity Incentive Plan.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.40
<SEQUENCE>3
<FILENAME>exel20221230exhibit1040.htm
<DESCRIPTION>EX-10.40
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie6b377ae375641d99808ec0522b04ffc_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.40</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FOURTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Fourth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment to the Collaboration and License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Fourth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of October 11, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Fourth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware company having an address at 1851 Harbor Bay Parkway, Alameda, CA 94502, USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Ipsen Pharma SAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a French corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Exelixis and Licensee may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div id="ie6b377ae375641d99808ec0522b04ffc_4"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Recitals</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Exelixis and Licensee are parties to that certain Collaboration and License Agreement dated February 29, 2016, as amended by First Amendment dated effective December 20, 2016, Second Amendment dated effective September 14, 2017, and Third Amendment dated effective October 26, 2017 (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), under which the Parties have been collaborating on the development and commercialization of cabozantinib&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Parties desire to enter into this Fourth Amendment to update certain definitions and payment terms related to the PV Costs under the License Agreement, all on the terms and conditions set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Now, Therefore,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;Definitions  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">All capitalized terms used herein but not defined shall have their respective meanings set forth in the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Section 5.5 of the License Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.5 Adverse Event Reporting&#59; Pharmacovigilance Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Within sixty (60) days after the Effective Date, but in any case prior to transfer of the marketing authorization,  the Parties shall enter into a pharmacovigilance agreement setting forth the worldwide pharmacovigilance procedures for the Parties with respect to the Products, such as Safety Data sharing, adverse events reporting and safety signal and risk management (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which agreement shall be amended by the Parties &#91; * &#93; to comply with any changes in Applicable Laws or any guidance received from Regulatory Authorities.  Such procedures shall be in accordance with, and enable the Parties to fulfill, local and national regulatory reporting obligations under Applicable Laws (including to the extent applicable, those obligations contained in ICH guidelines, E2A, E2B, E2C, E2D and E2F) to monitor the patients&#8217; safety.  Exelixis has established and shall continue to hold at its costs and expenses the global safety database for the Products, and shall maintain such global safety database for so long as such Product is under Development and&#47;or Commercialization by the Parties.  The Parties will collaboratively agree on data cut points for periodic aggregate safety reports and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exelixis will author such reports&#59; the Parties will jointly review and approve such reports before submission to worldwide Regulatory Authorities as required.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;Parties&#8217; Respective Contributions to PV Costs.</font></div><div style="margin-bottom:6pt;padding-left:144pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">From the Effective Date through &#91; * &#93;, Exelixis shall bear one hundred percent (100%) of the cost and expense for establishing and maintaining such global database and the preparation of periodic aggregate safety reports (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PV Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:6pt;padding-left:144pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">For the &#91; * &#93; commencing on &#91; * &#93;, Licensee shall pay Exelixis, as a contribution towards the PV Costs, an amount equal to &#91; * &#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">PV Contribution Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;), in the manner set forth in clauses (A) and (B) immediately below, which amount shall not be subject in any respect to audit or renegotiation.</font></div><div style="margin-bottom:6pt;padding-left:180pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Within &#91; * &#93; of the Fourth Amendment Effective Date, Licensee shall pay Exelixis the previously invoiced and outstanding PV Costs for the Calendar Quarters ending &#91; * &#93;, which aggregate amount shall equal &#91; * </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:125%">&#93;.</font></div><div style="margin-bottom:6pt;padding-left:180pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Licensee shall pay Exelixis an amount equal to &#91; * </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:125%">&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> within &#91; * &#93; of receipt of the invoice for such amount.</font></div><div style="margin-bottom:6pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">For each Calendar Quarter commencing on &#91; * &#93; through the end of the Calendar Quarter in which the First LOE Event (as defined below) occurs, Licensee shall pay Exelixis an amount equal to &#91; * &#93; within &#91; * &#93; of the end of such quarter, which amount shall be invoiced and shall not be subject in any respect to audit or renegotiation. For purposes of this Fourth Amendment, LOE Event, U.S. LOE Event, EU LOE Event, First LOE Event and Second LOE Event shall be defined as follows&#58;</font></div><div style="margin-bottom:6pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;Loss of exclusivity (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">LOE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;) occurs at the earliest of (i) the latest of expiration of the last-to-expire Valid Claim of the Exelixis Patents or Licensee Patents covering the Product in either the US or the EU, as applicable, &#91; * &#93; and (ii) the first time there is a Generic Entry with respect to such Product in either the US or any country of the Top 5 EU.  For purposes of this definition, &#8220;Generic Entry&#8221; means, with respect to a particular Product, that one or more Generic Products to such Product &#91; * &#93;.</font></div><div style="margin-bottom:6pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;There are two separate LOE Events based on the following Territories&#58; the U.S. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">U.S. LOE Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;), and the EU (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">EU LOE Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;).  </font></div><div style="margin-bottom:6pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;The earliest to occur of either the U.S. LOE Event or the EU LOE Event is the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">First LOE Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.&#8221;  The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">latest to occur of either the U.S. LOE Event or the EU LOE Event is the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Second LOE Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For each Calendar Quarter following the First LOE Event through the end of the Calendar Quarter in which the Second LOE Event occurs, Licensee shall pay Exelixis an amount equal to &#91; * &#93; within &#91; * &#93; of the end of such quarter, which amount shall be &#91; * &#93; at the end of &#91; * &#93; Calendar Quarters, which shall be invoiced and shall not be subject in any respect to audit or renegotiation.  For the sake of clarity, by way of example, after the occurrence of the First LOE Event, Licensee pays Exelixis &#91; * &#93; for &#91; * &#93; Calendar Quarters, then &#91; * &#93; for &#91; * &#93; Calendar Quarters, and so on until the end of the Calendar Quarter in which the Second LOE Event occurs.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Further, for the sake of clarity, Licensee shall have no obligation to pay Exelixis &#91; * &#93; under this Section 5.5(a) for any Calendar Quarter from, and after, the end of the Calendar Quarter in which the Second LOE Event occurs.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Exelixis will ensure that each Party and any Future Exelixis Licensee are able to access the data, if necessary indirectly, from the global safety database in order to meet legal and regulatory obligations.  The Parties agree that Exelixis shall not transfer the responsibility or holding of the global safety database to any CRO, sublicensee, Future Exelixis Licensee or any Third Party without Licensee&#8217;s prior written consent and approval, which shall not be unreasonably withheld, conditioned or delayed if such transferee (and its Affiliates) is a pharmaceutical company of comparable size as Licensee and agrees to grant Licensee access and other rights to the global safety database substantially equivalent to those granted by Exelixis under the Pharmacovigilance Agreement.  The use by Exelixis of a CRO, sublicensee, Future Exelixis Licensee shall be at Exelixis&#8217; sole cost and expenses.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The JDC shall establish a joint safety subcommittee which shall have the role and responsibility of reviewing and maintaining up to date the Pharmacovigilance Agreement. As per the applicable Pharmacovigilance Agreement each Party shall be primarily responsible for reporting quality complaints, adverse events and Safety Data related to the Products to any Regulatory Authorities and responding to safety issues and to all requests of Regulatory Authorities related to the Products under any MAA or Regulatory Approval for the Product held by such Party and filed with such Regulatory Authorities, in each case at its own cost.  Each Party agrees to comply with its respective obligations under the Pharmacovigilance Agreement and to cause its Affiliates, licensees and sublicensees to comply with such obligations.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Section 9.2(e) (PV Costs) of the License Agreement is hereby deleted in its entirety.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;General Provisions</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.1&#160;&#160;&#160;&#160;Effect of Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as expressly modified herein, all terms and conditions set forth in the License Agreement, as in effect on the Fourth Amendment Effective Date, shall remain in full force and effect.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.2&#160;&#160;&#160;&#160;Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The License Agreement as modified by this Fourth Amendment is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to its subject matter.  This Fourth Amendment supersedes all prior and contemporaneous agreements and communications, whether written or oral, of the Parties regarding this subject matter.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.3&#160;&#160;&#160;&#160; Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, for any reason, any part of this Fourth Amendment is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Fourth Amendment.  All remaining portions shall remain in full force and effect as if the original Fourth Amendment had been executed without the invalidated, unenforceable, or illegal part.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.4&#160;&#160;&#160;&#160;Counterparts&#59; Electronic or Facsimile Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Fourth Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Fourth Amendment may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">In Witness Whereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties hereto have caused this Fourth Amendment to be executed and entered into by their duly authorized representatives as of the Fourth Amendment Effective Date.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXELIXIS, INC.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IPSEN PHARMA S.A.S</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Jeffrey J. Hessekiel</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Francois Garnier</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Jeffrey J. Hessekiel</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Francois Garnier</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; EVP &#38; General Counsel</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; EVP General Counsel</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>exel20221230exhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie74b7828ac6541679eb540955dd2ab39_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES OF EXELIXIS, INC.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:504.00pt"><tr><td style="width:1.0pt"></td><td style="width:298.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:201.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">State or Other Jurisdiction of Incorporation or Organization</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis Patent Company, LLC</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis Plant Sciences, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis U.S., LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>exel20221230exhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icc9bac077def41288521956376ce3b28_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-266707, 333-241667, 333-226493, 333-223225, 333-218236, 333-214766, 333-212866, 333-209824, 333-203758, 333-196761, 333-176674, 333-165389, 333-159280, 333-157825, 333-149834, 333-147063, 333-133237, 333-124536, 333-113472, 333-102770, 333-82724, 333-82722, 333-57026 and 333-35862) of Exelixis, Inc. and the Registration Statement  (Form S-3 No. 333-205397) and related Prospectus of Exelixis, Inc. of our reports dated February 7, 2023, with respect to the consolidated financial statements of Exelixis, Inc. and the effectiveness of internal control over financial reporting of Exelixis, Inc., included in this Annual Report (Form 10-K) for the year ended December 30, 2022.</font></div><div style="margin-top:9pt"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst&#160;&#38; Young&#160;LLP</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redwood City, California</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;7, 2023</font></div><div style="margin-top:9pt"><font><br></font></div><div style="margin-top:9pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>exel20221230exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8549af1ac5cb477ea873acac23ad6c99_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael M. Morrissey, Ph.D., certify that&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Form 10-K of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; M</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHAEL</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. M</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ORRISSEY</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February 7, 2023</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>exel20221230exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6dfbb100e84d4d8ea6355febd230c4fd_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher J. Senner, certify that&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Form 10-K of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;C</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HRISTOPHER</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. S</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ENNER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February 7, 2023 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>exel20221230exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie3d14f8aa2e7479aa9f0a83c3d6f8025_1"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   1. &#160;&#160;&#160;&#160;The Company&#8217;s Annual Report on Form 10-K for the period ended December 30, 2022, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   2. &#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In Witness Whereof, the undersigned have set their hands hereto as of the 7th day of February 2023.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;M</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHAEL</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. M</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;C</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HRISTOPHER</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. S</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ENNER&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>exel-20221230.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:72618e96-9a19-4b18-ab04-d375d7716d96,g:fc8ea608-bee1-4b83-89de-139db7d65bef-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20221230" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20221230">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20221230_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20221230_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20221230_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20221230_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.exelixis.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofIncome">
        <link:definition>0000005 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000006 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>0000007 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000008 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.exelixis.com/role/Revenues">
        <link:definition>0000011 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivities" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities">
        <link:definition>0000012 - Disclosure - Collaboration Agreements And Business Development Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestments" roleURI="http://www.exelixis.com/role/CashandInvestments">
        <link:definition>0000013 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>0000014 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>0000015 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.exelixis.com/role/PropertyandEquipment">
        <link:definition>0000016 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlans">
        <link:definition>0000017 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxes" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxes">
        <link:definition>0000018 - Disclosure - Provision For Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.exelixis.com/role/NetIncomePerShare">
        <link:definition>0000019 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.exelixis.com/role/CommitmentsandContingencies">
        <link:definition>0000020 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000021 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.exelixis.com/role/RevenuesTables">
        <link:definition>0000022 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables">
        <link:definition>0000023 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsTables" roleURI="http://www.exelixis.com/role/CashandInvestmentsTables">
        <link:definition>0000024 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>0000025 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>0000026 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.exelixis.com/role/PropertyandEquipmentTables">
        <link:definition>0000027 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansTables" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansTables">
        <link:definition>0000028 - Disclosure - Employee Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxesTables" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesTables">
        <link:definition>0000029 - Disclosure - Provision For Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.exelixis.com/role/NetIncomePerShareTables">
        <link:definition>0000030 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000031 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>0000032 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyDisaggregatedCategoryDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails">
        <link:definition>0000033 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNetProductRevenuesDisaggregatedbyProductDetails" roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
        <link:definition>0000034 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails">
        <link:definition>0000035 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
        <link:definition>0000036 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
        <link:definition>0000037 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesContractAssetsandLiabilitiesDetails" roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails">
        <link:definition>0000038 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails">
        <link:definition>0000039 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
        <link:definition>0000040 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails">
        <link:definition>0000041 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
        <link:definition>0000042 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails">
        <link:definition>0000043 - Disclosure - Collaboration Agreements And Business Development Activities - GSK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails">
        <link:definition>0000044 - Disclosure - Collaboration Agreements And Business Development Activities - Other Collaborations Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>0000045 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails">
        <link:definition>0000046 - Disclosure - Cash and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails">
        <link:definition>0000047 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
        <link:definition>0000048 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails">
        <link:definition>0000049 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails">
        <link:definition>0000050 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativesDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails">
        <link:definition>0000051 - Disclosure - Fair Value Measurements - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.exelixis.com/role/InventoryDetails">
        <link:definition>0000052 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofPropertyandEquipmentDetails" roleURI="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
        <link:definition>0000053 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>0000054 - Disclosure - Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>0000055 - Disclosure - Employee Benefit Plans - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails">
        <link:definition>0000056 - Disclosure - Employee Benefit Plans - Schedule of Employee Service Share - Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansNarrativeDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails">
        <link:definition>0000057 - Disclosure - Employee Benefit Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails">
        <link:definition>0000058 - Disclosure - Employee Benefit Plans - Weighted Average Grant Date Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails">
        <link:definition>0000059 - Disclosure - Employee Benefit Plans - Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails">
        <link:definition>0000060 - Disclosure - Employee Benefit Plans - Summary of All Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails">
        <link:definition>0000061 - Disclosure - Employee Benefit Plans - Summary of All RSU &amp; PSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansEstimateGrantDateFairValueDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails">
        <link:definition>0000062 - Disclosure - Employee Benefit Plans - Estimate Grant-Date Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>0000063 - Disclosure - Provision For Income Taxes - Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails">
        <link:definition>0000064 - Disclosure - Provision For Income Taxes - Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails">
        <link:definition>0000065 - Disclosure - Provision For Income Taxes - Schedule of Deferred Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxesNarrativeDetails" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails">
        <link:definition>0000066 - Disclosure - Provision For Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>0000067 - Disclosure - Provision For Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails">
        <link:definition>0000068 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails" roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails">
        <link:definition>0000069 - Disclosure - Net Income Per Share - Potentially Dilutive Shares of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>0000070 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails">
        <link:definition>0000071 - Disclosure - Commitments and Contingencies - Balance Sheet Classification of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesComponentsofLeaseExpenseDetails" roleURI="http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails">
        <link:definition>0000072 - Disclosure - Commitments And Contingencies - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>0000073 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>0000073 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exel_CollaborationMember" abstract="true" name="CollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AmendedAndRestated2017EquityIncentivePlanMember" abstract="true" name="AmendedAndRestated2017EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_SairopaBVSairopaMember" abstract="true" name="SairopaBVSairopaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" abstract="false" name="MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" abstract="true" name="LesseeOperatingLeaseReductionOfPaymentsDueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_PercentOfRoyaltyOnNetSale" abstract="false" name="PercentOfRoyaltyOnNetSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_CabometyxMember" abstract="true" name="CabometyxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_HeadquartersLeaseMember" abstract="true" name="HeadquartersLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ProductsDerivedFromOtherCompoundsMember" abstract="true" name="ProductsDerivedFromOtherCompoundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_SalesRevenuePercentDiscountForPromptPayment" abstract="false" name="SalesRevenuePercentDiscountForPromptPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_SalesRevenueDiscountExpectedtobeEarnedPercent" abstract="false" name="SalesRevenueDiscountExpectedtobeEarnedPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AffiliatesofOptumSpecialtyPharmacyMember" abstract="true" name="AffiliatesofOptumSpecialtyPharmacyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_LeaseArrangementsDomain" abstract="true" name="LeaseArrangementsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_UpfrontPayments" abstract="false" name="UpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_StatusDomain" abstract="true" name="StatusDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AccredoHealthIncorporatedMember" abstract="true" name="AccredoHealthIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsExerciseAmount" abstract="false" name="CollaborativeArrangementRightsAndObligationsExerciseAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_IpsenMember" abstract="true" name="IpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_NumberofProductsinCommercialMarket" abstract="false" name="NumberofProductsinCommercialMarket" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_MilestonePaymentsEarned" abstract="false" name="MilestonePaymentsEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_OtherLongtermAssetsMember" abstract="true" name="OtherLongtermAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember" abstract="true" name="CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_RevenueFromContractWithCustomerRegulatoryMilestone" abstract="false" name="RevenueFromContractWithCustomerRegulatoryMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_OperatingLeaseAssetsAbstract" abstract="true" name="OperatingLeaseAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AccruedClinicalLiabilitiesCurrent" abstract="false" name="AccruedClinicalLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_RoyaltyTier" abstract="false" name="RoyaltyTier" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" abstract="false" name="CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_InitialMember" abstract="true" name="InitialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_NoncashLeaseExpense" abstract="false" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" abstract="false" name="ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ChargebacksAndDiscountsForPromptPaymentMember" abstract="true" name="ChargebacksAndDiscountsForPromptPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_MedicarePartDFundingMandate" abstract="false" name="MedicarePartDFundingMandate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_LeaseArrangementsAxis" abstract="true" name="LeaseArrangementsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_LossContingencyNumberOfLawsuitsConsolidated" abstract="false" name="LossContingencyNumberOfLawsuitsConsolidated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember" abstract="true" name="LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" abstract="false" name="ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exel_ProductGrossMember" abstract="true" name="ProductGrossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CotellicMember" abstract="true" name="CotellicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AccruedCollaborationLiabilityCurrent" abstract="false" name="AccruedCollaborationLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CybrexaTherapeuticsLLCCybrexaMember" abstract="true" name="CybrexaTherapeuticsLLCCybrexaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AchievedMember" abstract="true" name="AchievedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" abstract="true" name="ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_IncreaseInDilutedEarningsPerShare" abstract="false" name="IncreaseInDilutedEarningsPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" abstract="true" name="AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_RevenueFromContractWithCustomerCommercialSalesMilestone" abstract="false" name="RevenueFromContractWithCustomerCommercialSalesMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_PerformanceSharesClinicalTrialResultsMember" abstract="true" name="PerformanceSharesClinicalTrialResultsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_StatusAxis" abstract="true" name="StatusAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_TSRBasedRestrictedStockUnitsMember" abstract="true" name="TSRBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProbableMember" abstract="true" name="ProbableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AffiliatesofMcKessonCorporationMember" abstract="true" name="AffiliatesofMcKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_NotProbableMember" abstract="true" name="NotProbableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" abstract="false" name="CollaborationAgreementPercentOfRoyaltyOnNetSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" abstract="false" name="LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" abstract="false" name="NumberOfCountriesWithDrugApprovalExcludingTheUS" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ResultingFromDiscoveryEffortsMember" abstract="true" name="ResultingFromDiscoveryEffortsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_OperatingLeaseLiabilitiesAbstract" abstract="true" name="OperatingLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithTakedaMember" abstract="true" name="CollaborativeArrangementwithTakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_IncreaseDecreaseInResearchAndDevelopmentExpense" abstract="false" name="IncreaseDecreaseInResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_RoyaltyTierDomain" abstract="true" name="RoyaltyTierDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_FinalTierMember" abstract="true" name="FinalTierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_RoyaltyTierAxis" abstract="true" name="RoyaltyTierAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithGenentechMember" abstract="true" name="CollaborativeArrangementwithGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithIpsenMember" abstract="true" name="CollaborativeArrangementwithIpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_TaxCreditCarryforwardAmountWithExpirationPeriod" abstract="false" name="TaxCreditCarryforwardAmountWithExpirationPeriod" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_NumberOfBondSecurities" abstract="false" name="NumberOfBondSecurities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" abstract="false" name="EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_IncreaseInBasicEarningsPerShare" abstract="false" name="IncreaseInBasicEarningsPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" abstract="true" name="ValuationAllowancesAndReservesAdditionsToProvisionAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_ProductSalesDiscountsAndAllowancesMember" abstract="true" name="ProductSalesDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AffiliatesOfAmerisourceBergenCorporationMember" abstract="true" name="AffiliatesOfAmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementMaximumAmountOfWarrantExercise" abstract="false" name="CollaborativeArrangementMaximumAmountOfWarrantExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AffiliatesofCVSHealthCorporationMember" abstract="true" name="AffiliatesofCVSHealthCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" abstract="false" name="ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" abstract="false" name="ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AllowanceForProductRebatesMember" abstract="true" name="AllowanceForProductRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_MilestonePaymentsEarnedToDate" abstract="false" name="MilestonePaymentsEarnedToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_CatalentIncMember" abstract="true" name="CatalentIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_NumberOfSponsoredEnterprises" abstract="false" name="NumberOfSponsoredEnterprises" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CometriqMember" abstract="true" name="CometriqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_A2021AwardsMember" abstract="true" name="A2021AwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AccountsReceivableForUnsettledInvestmentSales" abstract="false" name="AccountsReceivableForUnsettledInvestmentSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_OperatingLeaseRightOfUseAssetAndOtherAssets" abstract="false" name="OperatingLeaseRightOfUseAssetAndOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" abstract="false" name="EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_BioInventInternationalABBioInventMember" abstract="true" name="BioInventInternationalABBioInventMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>exel-20221230_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:72618e96-9a19-4b18-ab04-d375d7716d96,g:fc8ea608-bee1-4b83-89de-139db7d65bef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20221230.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_27c43648-c51b-4949-9ba1-407bf5a5487c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_848487e1-2c1a-428e-8af4-8a994750934f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_27c43648-c51b-4949-9ba1-407bf5a5487c" xlink:to="loc_us-gaap_PreferredStockValue_848487e1-2c1a-428e-8af4-8a994750934f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_483f51be-8410-477a-9f0b-d0934f2f3a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_27c43648-c51b-4949-9ba1-407bf5a5487c" xlink:to="loc_us-gaap_CommonStockValue_483f51be-8410-477a-9f0b-d0934f2f3a66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ee382ee1-7e9d-4060-8ddc-2a895f38d409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_27c43648-c51b-4949-9ba1-407bf5a5487c" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ee382ee1-7e9d-4060-8ddc-2a895f38d409" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_62126300-e0cf-4bb2-b129-b71be71b33e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_27c43648-c51b-4949-9ba1-407bf5a5487c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_62126300-e0cf-4bb2-b129-b71be71b33e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bd80ef6a-a718-4b89-be12-e913e2fbcd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_27c43648-c51b-4949-9ba1-407bf5a5487c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bd80ef6a-a718-4b89-be12-e913e2fbcd6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_df7037f6-04ba-4821-bc1f-2b32366e3f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6ced2de1-fdd7-48db-b8a0-e5a9b00936f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_df7037f6-04ba-4821-bc1f-2b32366e3f95" xlink:to="loc_us-gaap_AssetsCurrent_6ced2de1-fdd7-48db-b8a0-e5a9b00936f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_c2a37107-ef1a-4ccf-9243-d9369701f72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_df7037f6-04ba-4821-bc1f-2b32366e3f95" xlink:to="loc_us-gaap_LongTermInvestments_c2a37107-ef1a-4ccf-9243-d9369701f72e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_49d5e143-4bbf-4c8f-8f47-460c59d6f9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_df7037f6-04ba-4821-bc1f-2b32366e3f95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_49d5e143-4bbf-4c8f-8f47-460c59d6f9dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_6cd9e1b0-84ad-4f4c-ad5a-5fd307d0f20a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_df7037f6-04ba-4821-bc1f-2b32366e3f95" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_6cd9e1b0-84ad-4f4c-ad5a-5fd307d0f20a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_09443e2d-e7fe-43d4-8a90-f24539bb881b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_df7037f6-04ba-4821-bc1f-2b32366e3f95" xlink:to="loc_us-gaap_Goodwill_09443e2d-e7fe-43d4-8a90-f24539bb881b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseRightOfUseAssetAndOtherAssets_bb6457dd-02fb-4943-ba44-4afc9b471789" xlink:href="exel-20221230.xsd#exel_OperatingLeaseRightOfUseAssetAndOtherAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_df7037f6-04ba-4821-bc1f-2b32366e3f95" xlink:to="loc_exel_OperatingLeaseRightOfUseAssetAndOtherAssets_bb6457dd-02fb-4943-ba44-4afc9b471789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4846ee62-3f8f-4afc-9d5f-acaf3d3602b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8b1584d7-3794-486c-8722-d61d560398f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4846ee62-3f8f-4afc-9d5f-acaf3d3602b3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8b1584d7-3794-486c-8722-d61d560398f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_2035a4a1-c8ad-4ce5-afcf-810ee57b850e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4846ee62-3f8f-4afc-9d5f-acaf3d3602b3" xlink:to="loc_us-gaap_ShortTermInvestments_2035a4a1-c8ad-4ce5-afcf-810ee57b850e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_95739ec5-bfcd-44a4-8769-22df93af34ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4846ee62-3f8f-4afc-9d5f-acaf3d3602b3" xlink:to="loc_us-gaap_ReceivablesNetCurrent_95739ec5-bfcd-44a4-8769-22df93af34ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8fd5be9c-c10e-4af3-9786-ab732fe5554b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4846ee62-3f8f-4afc-9d5f-acaf3d3602b3" xlink:to="loc_us-gaap_InventoryNet_8fd5be9c-c10e-4af3-9786-ab732fe5554b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_01ccc29c-2f52-4fb7-9267-6850f93f9700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4846ee62-3f8f-4afc-9d5f-acaf3d3602b3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_01ccc29c-2f52-4fb7-9267-6850f93f9700" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3ea0112a-54ba-46ef-9f5a-5e32b8477f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f7f942c7-df9b-4396-a4fd-c667004be864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3ea0112a-54ba-46ef-9f5a-5e32b8477f59" xlink:to="loc_us-gaap_Liabilities_f7f942c7-df9b-4396-a4fd-c667004be864" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b05c0912-31b4-432a-beb1-440613d1a526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3ea0112a-54ba-46ef-9f5a-5e32b8477f59" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b05c0912-31b4-432a-beb1-440613d1a526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8732082a-d1df-49fd-8333-1891a1bb26a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3ea0112a-54ba-46ef-9f5a-5e32b8477f59" xlink:to="loc_us-gaap_StockholdersEquity_8732082a-d1df-49fd-8333-1891a1bb26a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_10daf3ec-ee34-405b-91ca-36aa7eee9476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e1b3dd5d-bb75-4337-967b-c85108bc8143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_10daf3ec-ee34-405b-91ca-36aa7eee9476" xlink:to="loc_us-gaap_LiabilitiesCurrent_e1b3dd5d-bb75-4337-967b-c85108bc8143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bae0ed94-f509-41bc-abb1-cf5219b9afb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_10daf3ec-ee34-405b-91ca-36aa7eee9476" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bae0ed94-f509-41bc-abb1-cf5219b9afb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8cd1fa28-05dc-4ece-afa2-cdd4908b80b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_10daf3ec-ee34-405b-91ca-36aa7eee9476" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8cd1fa28-05dc-4ece-afa2-cdd4908b80b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_289e61e3-3df3-48c6-acd7-aade1b71e18f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_10daf3ec-ee34-405b-91ca-36aa7eee9476" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_289e61e3-3df3-48c6-acd7-aade1b71e18f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f86e039f-039b-4e40-8e8d-9f05bdc228c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2a77b06e-259e-4402-bcc4-bb3c735082f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f86e039f-039b-4e40-8e8d-9f05bdc228c2" xlink:to="loc_us-gaap_AccountsPayableCurrent_2a77b06e-259e-4402-bcc4-bb3c735082f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_df9a2e8f-78fd-4cde-b547-dcc944842494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f86e039f-039b-4e40-8e8d-9f05bdc228c2" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_df9a2e8f-78fd-4cde-b547-dcc944842494" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_7d24374a-9e21-45e4-8a10-85f81bf7c9fc" xlink:href="exel-20221230.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f86e039f-039b-4e40-8e8d-9f05bdc228c2" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_7d24374a-9e21-45e4-8a10-85f81bf7c9fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_ba6262d3-d4ac-47a0-9f0d-1b6f19f4c750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f86e039f-039b-4e40-8e8d-9f05bdc228c2" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_ba6262d3-d4ac-47a0-9f0d-1b6f19f4c750" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_9d58810f-d1a4-4be9-8d2f-691e256e813f" xlink:href="exel-20221230.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f86e039f-039b-4e40-8e8d-9f05bdc228c2" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_9d58810f-d1a4-4be9-8d2f-691e256e813f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_30fa41a7-91d2-43cf-bf3c-708aec8c43c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f86e039f-039b-4e40-8e8d-9f05bdc228c2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_30fa41a7-91d2-43cf-bf3c-708aec8c43c7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20221230.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_d3c528cd-6c22-41cc-bb60-ac5b836d88d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_29c5689a-368a-4a96-a082-d190f7fabb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_d3c528cd-6c22-41cc-bb60-ac5b836d88d8" xlink:to="loc_us-gaap_OperatingIncomeLoss_29c5689a-368a-4a96-a082-d190f7fabb6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_d752bade-d882-4e98-a565-53726cdd0775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_d3c528cd-6c22-41cc-bb60-ac5b836d88d8" xlink:to="loc_us-gaap_InterestIncomeOther_d752bade-d882-4e98-a565-53726cdd0775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e4eb56af-b7b0-4f43-ba44-ddcd77c85c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_d3c528cd-6c22-41cc-bb60-ac5b836d88d8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e4eb56af-b7b0-4f43-ba44-ddcd77c85c3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ad51d539-c2dd-489d-bb6b-89df7b54583c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4b276443-7236-42ac-b9a3-2bd2a5b117d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ad51d539-c2dd-489d-bb6b-89df7b54583c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4b276443-7236-42ac-b9a3-2bd2a5b117d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_77460451-df7e-44e4-a959-58770aab4993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ad51d539-c2dd-489d-bb6b-89df7b54583c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_77460451-df7e-44e4-a959-58770aab4993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3ce1e797-1436-4f54-bed2-07e2eed2db76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ad51d539-c2dd-489d-bb6b-89df7b54583c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3ce1e797-1436-4f54-bed2-07e2eed2db76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e3e9df45-a18b-4d10-93b0-001ff59cc72a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9e08cee5-eb0e-423b-8a8a-52398439da21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e3e9df45-a18b-4d10-93b0-001ff59cc72a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9e08cee5-eb0e-423b-8a8a-52398439da21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_be91a374-4d4d-44c0-9e89-6b5172bb3cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e3e9df45-a18b-4d10-93b0-001ff59cc72a" xlink:to="loc_us-gaap_CostsAndExpenses_be91a374-4d4d-44c0-9e89-6b5172bb3cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fa089d67-0fed-45f0-8d56-00c1248f811d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_8ee507c2-530a-4041-8d22-5adbc7f4ac3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fa089d67-0fed-45f0-8d56-00c1248f811d" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_8ee507c2-530a-4041-8d22-5adbc7f4ac3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_54b936c0-679d-43bd-aeb6-5c2fdeab7fac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fa089d67-0fed-45f0-8d56-00c1248f811d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_54b936c0-679d-43bd-aeb6-5c2fdeab7fac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="exel-20221230.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c9896a72-1552-45dd-8102-119a8c02df54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ccde33fa-4906-41e5-8808-f2ddfb5605b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c9896a72-1552-45dd-8102-119a8c02df54" xlink:to="loc_us-gaap_NetIncomeLoss_ccde33fa-4906-41e5-8808-f2ddfb5605b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_63221629-0aaf-46ac-9f89-f1bbf2e9149f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c9896a72-1552-45dd-8102-119a8c02df54" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_63221629-0aaf-46ac-9f89-f1bbf2e9149f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20221230.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b24272d-8987-498e-89be-8c8d0871fbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_95ce3c1b-644b-445a-a241-a80f16adf737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b24272d-8987-498e-89be-8c8d0871fbf2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_95ce3c1b-644b-445a-a241-a80f16adf737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_c3a0e1d2-4b6c-47db-a7bf-e47447d6e52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b24272d-8987-498e-89be-8c8d0871fbf2" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_c3a0e1d2-4b6c-47db-a7bf-e47447d6e52b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_dcbdfb87-ae79-4b49-9252-cd3dc7db0545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b24272d-8987-498e-89be-8c8d0871fbf2" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_dcbdfb87-ae79-4b49-9252-cd3dc7db0545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_9028cfc1-7771-48a0-8992-232a8d153ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b24272d-8987-498e-89be-8c8d0871fbf2" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_9028cfc1-7771-48a0-8992-232a8d153ace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d525de3-a999-49cf-8f77-bea0aad3384b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1b928ac8-c645-4413-aef6-a1a85c064387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d525de3-a999-49cf-8f77-bea0aad3384b" xlink:to="loc_us-gaap_NetIncomeLoss_1b928ac8-c645-4413-aef6-a1a85c064387" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c4eaf87a-6eb4-492f-a2f8-fc5dc925c228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d525de3-a999-49cf-8f77-bea0aad3384b" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c4eaf87a-6eb4-492f-a2f8-fc5dc925c228" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b617c7b8-245d-4cb3-bf09-4f9f977db9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d525de3-a999-49cf-8f77-bea0aad3384b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b617c7b8-245d-4cb3-bf09-4f9f977db9ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_8e17390f-f2ea-4181-9812-e74a1c2bdbe0" xlink:href="exel-20221230.xsd#exel_NoncashLeaseExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d525de3-a999-49cf-8f77-bea0aad3384b" xlink:to="loc_exel_NoncashLeaseExpense_8e17390f-f2ea-4181-9812-e74a1c2bdbe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_70ca26b5-c20a-4f37-a8f0-e27c2bf8bad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d525de3-a999-49cf-8f77-bea0aad3384b" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_70ca26b5-c20a-4f37-a8f0-e27c2bf8bad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8b2a96cf-20be-42bb-a929-7b975836213e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d525de3-a999-49cf-8f77-bea0aad3384b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8b2a96cf-20be-42bb-a929-7b975836213e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_193eac76-d7f6-40d1-8150-2edd359f4b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d525de3-a999-49cf-8f77-bea0aad3384b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_193eac76-d7f6-40d1-8150-2edd359f4b06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1df35616-65a9-4a27-b71f-623df2cbccc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d525de3-a999-49cf-8f77-bea0aad3384b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1df35616-65a9-4a27-b71f-623df2cbccc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f5ce13ed-13f2-4628-bc75-02c6713f30a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d525de3-a999-49cf-8f77-bea0aad3384b" xlink:to="loc_us-gaap_ShareBasedCompensation_f5ce13ed-13f2-4628-bc75-02c6713f30a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e9437447-298b-4eee-a351-bf4d4da28d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d525de3-a999-49cf-8f77-bea0aad3384b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e9437447-298b-4eee-a351-bf4d4da28d3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_feba7cb7-e9df-4d6c-8397-2ec01bf94ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d525de3-a999-49cf-8f77-bea0aad3384b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_feba7cb7-e9df-4d6c-8397-2ec01bf94ac2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_83685895-0e93-4501-8208-96ca7e0b94a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d525de3-a999-49cf-8f77-bea0aad3384b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_83685895-0e93-4501-8208-96ca7e0b94a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_fff7b751-2a3a-439c-8948-b48e9870c45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d525de3-a999-49cf-8f77-bea0aad3384b" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_fff7b751-2a3a-439c-8948-b48e9870c45a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa4c4cc4-0144-49ca-8972-1d2d924d9dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8ff871f8-93b4-4c57-aee0-c469ae7b7a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa4c4cc4-0144-49ca-8972-1d2d924d9dd6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8ff871f8-93b4-4c57-aee0-c469ae7b7a81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a1119252-a19f-4c40-9247-702edc48161f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa4c4cc4-0144-49ca-8972-1d2d924d9dd6" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a1119252-a19f-4c40-9247-702edc48161f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c0eb8dde-c803-4769-863f-e5637934cc06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bc72a32-d444-47ee-bb60-f795681332ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c0eb8dde-c803-4769-863f-e5637934cc06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bc72a32-d444-47ee-bb60-f795681332ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23081100-c589-403f-84bc-1edacaa63947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c0eb8dde-c803-4769-863f-e5637934cc06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23081100-c589-403f-84bc-1edacaa63947" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4d929f04-9a99-4b98-81bd-9f5164731b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c0eb8dde-c803-4769-863f-e5637934cc06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4d929f04-9a99-4b98-81bd-9f5164731b0f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f697c138-dfb5-49b0-a164-10c69587a167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ffe9583b-d985-464a-b157-913f587a5796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_f697c138-dfb5-49b0-a164-10c69587a167" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ffe9583b-d985-464a-b157-913f587a5796" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_78860bd9-c5ea-4321-a96a-6c9ea7e8f28c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_f697c138-dfb5-49b0-a164-10c69587a167" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_78860bd9-c5ea-4321-a96a-6c9ea7e8f28c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6896a15c-69de-484f-9a10-43930e7eedd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bb148d81-977b-42b1-99f5-9cb55a9d4556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6896a15c-69de-484f-9a10-43930e7eedd6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bb148d81-977b-42b1-99f5-9cb55a9d4556" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_12dfc840-2b49-4ed7-a55d-379233f2508d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6896a15c-69de-484f-9a10-43930e7eedd6" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_12dfc840-2b49-4ed7-a55d-379233f2508d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_519b41b7-c509-4a9d-9bcf-a5f6a086b020" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_85dfcd72-aa24-4216-9d72-d82ef73cd295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_519b41b7-c509-4a9d-9bcf-a5f6a086b020" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_85dfcd72-aa24-4216-9d72-d82ef73cd295" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_08ba4ab3-2f1a-4647-99ba-54fb6371b210" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_519b41b7-c509-4a9d-9bcf-a5f6a086b020" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_08ba4ab3-2f1a-4647-99ba-54fb6371b210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6f3d346b-b8ef-46e3-9a2c-de0f01b3d388" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d7c9eb27-08f7-41bb-b127-9d0152065611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6f3d346b-b8ef-46e3-9a2c-de0f01b3d388" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d7c9eb27-08f7-41bb-b127-9d0152065611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_fc8ce3cf-40fb-43d1-813f-948a147b1148" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6f3d346b-b8ef-46e3-9a2c-de0f01b3d388" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_fc8ce3cf-40fb-43d1-813f-948a147b1148" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_ed64b72e-374b-4613-a3f7-06ccb7712aeb" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b0e09cf-71df-4471-a713-9a835c8536b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_ed64b72e-374b-4613-a3f7-06ccb7712aeb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b0e09cf-71df-4471-a713-9a835c8536b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_edba72f7-30bd-4cd9-836e-085844071829" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_ed64b72e-374b-4613-a3f7-06ccb7712aeb" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_edba72f7-30bd-4cd9-836e-085844071829" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_efbefa33-bdb5-44ef-9812-0b2ca59f1e4c" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_1ba73d47-8e42-4552-a40c-fc720e5f7712" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_efbefa33-bdb5-44ef-9812-0b2ca59f1e4c" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_1ba73d47-8e42-4552-a40c-fc720e5f7712" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_5f521463-9276-44e3-a1b6-2fbda969c73d" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_efbefa33-bdb5-44ef-9812-0b2ca59f1e4c" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_5f521463-9276-44e3-a1b6-2fbda969c73d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_2b8e4db4-384f-411c-a640-9c582de1ec3f" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_efbefa33-bdb5-44ef-9812-0b2ca59f1e4c" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_2b8e4db4-384f-411c-a640-9c582de1ec3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_35ae361c-d384-4e24-98ca-8e4800237492" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d0f04ab4-6c24-4fbf-830a-af28e92ab224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_35ae361c-d384-4e24-98ca-8e4800237492" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d0f04ab4-6c24-4fbf-830a-af28e92ab224" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_aadb9e4a-5794-4ca9-8020-0269f9d04c08" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_35ae361c-d384-4e24-98ca-8e4800237492" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_aadb9e4a-5794-4ca9-8020-0269f9d04c08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7f1ae9ee-c937-40e4-8711-207edb626caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8dbcb7e0-c33c-4553-a9e7-cfcec92347a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7f1ae9ee-c937-40e4-8711-207edb626caf" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8dbcb7e0-c33c-4553-a9e7-cfcec92347a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c6088259-7c95-4cdd-aaa9-6762a6330254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7f1ae9ee-c937-40e4-8711-207edb626caf" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c6088259-7c95-4cdd-aaa9-6762a6330254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2f7005d2-f6a8-4435-8dc4-ca4a4f3dca99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7f1ae9ee-c937-40e4-8711-207edb626caf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2f7005d2-f6a8-4435-8dc4-ca4a4f3dca99" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6c16c051-d2d1-46d5-ab71-7793e348198e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f1f9edcf-9c95-4a52-b2ef-f90501276516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6c16c051-d2d1-46d5-ab71-7793e348198e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f1f9edcf-9c95-4a52-b2ef-f90501276516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_bdf3af68-68f5-48ad-b0ba-30ecf83823c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6c16c051-d2d1-46d5-ab71-7793e348198e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_bdf3af68-68f5-48ad-b0ba-30ecf83823c1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_42958198-c3bc-489f-8be2-43554273a433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cf89a43a-f5aa-4acf-9056-a1eb01aa332a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_42958198-c3bc-489f-8be2-43554273a433" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cf89a43a-f5aa-4acf-9056-a1eb01aa332a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8530188f-4274-411f-8716-2f4052dcc1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_42958198-c3bc-489f-8be2-43554273a433" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8530188f-4274-411f-8716-2f4052dcc1cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_2f472953-6798-403f-aeca-221d1d304a35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_9f9bf99e-60dc-4896-b807-6dae8f1411fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2f472953-6798-403f-aeca-221d1d304a35" xlink:to="loc_us-gaap_InventoryRawMaterials_9f9bf99e-60dc-4896-b807-6dae8f1411fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_d381b7f3-be84-4136-8a60-397df16c0157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2f472953-6798-403f-aeca-221d1d304a35" xlink:to="loc_us-gaap_InventoryWorkInProcess_d381b7f3-be84-4136-8a60-397df16c0157" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_635c5529-98f9-4160-85d2-1b3a36483f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2f472953-6798-403f-aeca-221d1d304a35" xlink:to="loc_us-gaap_InventoryFinishedGoods_635c5529-98f9-4160-85d2-1b3a36483f7f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1b2f04fa-d967-4bba-aa5c-ede178afe976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_46e8c967-ecae-477e-82bb-e8f786fda23c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1b2f04fa-d967-4bba-aa5c-ede178afe976" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_46e8c967-ecae-477e-82bb-e8f786fda23c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_15338036-223b-4825-83ea-f5c23c8a1803" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1b2f04fa-d967-4bba-aa5c-ede178afe976" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_15338036-223b-4825-83ea-f5c23c8a1803" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_764e2daa-55c3-4890-8e79-91a06c6da640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_992b7262-3d8d-47ea-871b-2ab5bae70a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_764e2daa-55c3-4890-8e79-91a06c6da640" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_992b7262-3d8d-47ea-871b-2ab5bae70a03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ab302f13-e647-4d6f-955d-b73c0e9582d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_764e2daa-55c3-4890-8e79-91a06c6da640" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ab302f13-e647-4d6f-955d-b73c0e9582d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_726bac35-4e04-4933-8fe8-e3b049347bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_62db2643-ad6d-40b0-8fa5-c097e32d2b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_726bac35-4e04-4933-8fe8-e3b049347bfd" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_62db2643-ad6d-40b0-8fa5-c097e32d2b14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_72ae40b9-7777-4607-98fd-7955ed66f105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_726bac35-4e04-4933-8fe8-e3b049347bfd" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_72ae40b9-7777-4607-98fd-7955ed66f105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e4c2e58a-c029-4d1a-86d6-75050d702cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b073dbf3-16db-4d9d-9606-b8fd2047374a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e4c2e58a-c029-4d1a-86d6-75050d702cf7" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b073dbf3-16db-4d9d-9606-b8fd2047374a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b4411fcb-22b0-4299-ab68-7f16b601276b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e4c2e58a-c029-4d1a-86d6-75050d702cf7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b4411fcb-22b0-4299-ab68-7f16b601276b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_46f334d9-b013-4ca5-b7a9-11b501d4a6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_d5690813-80a2-4350-b485-6a23f2ad351a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_46f334d9-b013-4ca5-b7a9-11b501d4a6b6" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_d5690813-80a2-4350-b485-6a23f2ad351a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_74293c5c-ee59-41aa-9175-fa6ec87613fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_46f334d9-b013-4ca5-b7a9-11b501d4a6b6" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_74293c5c-ee59-41aa-9175-fa6ec87613fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2156e9ed-cc5e-4c15-a5a6-76f8a3c74d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_46f334d9-b013-4ca5-b7a9-11b501d4a6b6" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2156e9ed-cc5e-4c15-a5a6-76f8a3c74d14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_bac68e42-09cb-487c-b4dc-7686b68ea2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_46f334d9-b013-4ca5-b7a9-11b501d4a6b6" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_bac68e42-09cb-487c-b4dc-7686b68ea2ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_52793834-6165-4ca0-ba8c-4f0632f712c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_46f334d9-b013-4ca5-b7a9-11b501d4a6b6" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_52793834-6165-4ca0-ba8c-4f0632f712c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_7e524c3c-0243-419c-99e0-0f605390602e" xlink:href="exel-20221230.xsd#exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_46f334d9-b013-4ca5-b7a9-11b501d4a6b6" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_7e524c3c-0243-419c-99e0-0f605390602e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_e18a0f46-c1c4-4e2d-a8b8-a5df3e7c3099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_46f334d9-b013-4ca5-b7a9-11b501d4a6b6" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_e18a0f46-c1c4-4e2d-a8b8-a5df3e7c3099" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_a159f8e4-231c-40b1-b674-8b8fb26a1ae2" xlink:href="exel-20221230.xsd#exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_46f334d9-b013-4ca5-b7a9-11b501d4a6b6" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_a159f8e4-231c-40b1-b674-8b8fb26a1ae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase_f206b081-f375-4022-bc7d-915201f18542" xlink:href="exel-20221230.xsd#exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_46f334d9-b013-4ca5-b7a9-11b501d4a6b6" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase_f206b081-f375-4022-bc7d-915201f18542" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_243c1a46-972b-4ecd-9995-903f36d08e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_3fc5a352-5c8e-4d08-aa60-2b7d0f3d0335" xlink:href="exel-20221230.xsd#exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_243c1a46-972b-4ecd-9995-903f36d08e2f" xlink:to="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_3fc5a352-5c8e-4d08-aa60-2b7d0f3d0335" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_be1b45c5-a89e-4e4c-a763-f38981030184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_243c1a46-972b-4ecd-9995-903f36d08e2f" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_be1b45c5-a89e-4e4c-a763-f38981030184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_de641f3b-4fce-46b6-b166-0d41bdb9dd5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_979a4cea-f626-46b1-83ad-83f2bfe4a111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_de641f3b-4fce-46b6-b166-0d41bdb9dd5d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_979a4cea-f626-46b1-83ad-83f2bfe4a111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_11f91225-e4cf-4c6a-8737-bcba9faa2769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_de641f3b-4fce-46b6-b166-0d41bdb9dd5d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_11f91225-e4cf-4c6a-8737-bcba9faa2769" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_10046a6d-dc19-48e6-984b-c607116f8e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_fc05dc55-fa6b-48b1-8851-4f4597cd214e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_10046a6d-dc19-48e6-984b-c607116f8e4b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_fc05dc55-fa6b-48b1-8851-4f4597cd214e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_fd0340b6-8cfb-43d3-a83a-1af18dcc82c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_10046a6d-dc19-48e6-984b-c607116f8e4b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_fd0340b6-8cfb-43d3-a83a-1af18dcc82c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_371ec06a-f8d5-4ae7-b0d7-b6b8ddb6a281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_10046a6d-dc19-48e6-984b-c607116f8e4b" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_371ec06a-f8d5-4ae7-b0d7-b6b8ddb6a281" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxAssetsLeaseLiabilities_271e5ca7-faac-4d06-99f4-836c4c8aa262" xlink:href="exel-20221230.xsd#exel_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_10046a6d-dc19-48e6-984b-c607116f8e4b" xlink:to="loc_exel_DeferredTaxAssetsLeaseLiabilities_271e5ca7-faac-4d06-99f4-836c4c8aa262" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_2b893d53-789c-484b-a9d5-eeb32fac2692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_10046a6d-dc19-48e6-984b-c607116f8e4b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_2b893d53-789c-484b-a9d5-eeb32fac2692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_35fc589d-28f2-4796-9df8-823323892b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_10046a6d-dc19-48e6-984b-c607116f8e4b" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_35fc589d-28f2-4796-9df8-823323892b12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_99757211-77b9-4d49-9177-3c60300a583e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_10046a6d-dc19-48e6-984b-c607116f8e4b" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_99757211-77b9-4d49-9177-3c60300a583e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7167642f-5602-4b0b-8764-b63646529e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_10046a6d-dc19-48e6-984b-c607116f8e4b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7167642f-5602-4b0b-8764-b63646529e9c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b9ee9a8-71b8-49d5-81b2-cc637bcbb2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_88bb6fc7-3edd-48dc-a1cd-bbc060f3f66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b9ee9a8-71b8-49d5-81b2-cc637bcbb2d9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_88bb6fc7-3edd-48dc-a1cd-bbc060f3f66a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_92ed9815-2118-44a8-9c35-daeb16affc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b9ee9a8-71b8-49d5-81b2-cc637bcbb2d9" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_92ed9815-2118-44a8-9c35-daeb16affc2f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_41d534c2-8062-4cad-b49e-5930e7f198d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b6ace789-3b0c-46df-b343-5fe4c21fcff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_41d534c2-8062-4cad-b49e-5930e7f198d7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b6ace789-3b0c-46df-b343-5fe4c21fcff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e9bf90fe-010d-4b51-9695-872b5fc90f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_41d534c2-8062-4cad-b49e-5930e7f198d7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e9bf90fe-010d-4b51-9695-872b5fc90f95" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CommitmentsAndContingenciesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_0c8aafcb-cc8d-4150-9519-4d8d48373626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_1e725628-0d51-442b-aa5f-4001ea8414e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0c8aafcb-cc8d-4150-9519-4d8d48373626" xlink:to="loc_us-gaap_OperatingLeaseCost_1e725628-0d51-442b-aa5f-4001ea8414e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_9612266a-fab0-41c7-b2d0-d0f1414d4b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0c8aafcb-cc8d-4150-9519-4d8d48373626" xlink:to="loc_us-gaap_VariableLeaseCost_9612266a-fab0-41c7-b2d0-d0f1414d4b25" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eb96c3de-9394-4783-82fd-037fe2e944bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1517d203-8a76-43c0-9567-89d3c86be7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eb96c3de-9394-4783-82fd-037fe2e944bd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1517d203-8a76-43c0-9567-89d3c86be7e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_4f7bafe0-9e7c-4e5e-80a2-ed030b84ed5f" xlink:href="exel-20221230.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eb96c3de-9394-4783-82fd-037fe2e944bd" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_4f7bafe0-9e7c-4e5e-80a2-ed030b84ed5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_93406070-97fb-4a32-99b0-fc34bd2e3915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eb96c3de-9394-4783-82fd-037fe2e944bd" xlink:to="loc_us-gaap_OperatingLeaseLiability_93406070-97fb-4a32-99b0-fc34bd2e3915" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="exel-20221230.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0c357a51-94b6-4a65-8567-d77cbf025da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6c1a065c-bd47-402f-be26-e71509723ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0c357a51-94b6-4a65-8567-d77cbf025da7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6c1a065c-bd47-402f-be26-e71509723ef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3cc318b6-56d1-4b87-9a58-4f80958cbae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0c357a51-94b6-4a65-8567-d77cbf025da7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3cc318b6-56d1-4b87-9a58-4f80958cbae3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_37116d6b-ddd8-44ec-9bf0-735351dfbb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0c357a51-94b6-4a65-8567-d77cbf025da7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_37116d6b-ddd8-44ec-9bf0-735351dfbb4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8766ae3a-ecb2-4bc4-9b61-3943e9ee0fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0c357a51-94b6-4a65-8567-d77cbf025da7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8766ae3a-ecb2-4bc4-9b61-3943e9ee0fcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_bdc96bff-1fdf-4f26-93c4-7bcd6088a24c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0c357a51-94b6-4a65-8567-d77cbf025da7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_bdc96bff-1fdf-4f26-93c4-7bcd6088a24c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ff88f7af-8a2a-40a3-b096-fe3477c60ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0c357a51-94b6-4a65-8567-d77cbf025da7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ff88f7af-8a2a-40a3-b096-fe3477c60ca8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>exel-20221230_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:72618e96-9a19-4b18-ab04-d375d7716d96,g:fc8ea608-bee1-4b83-89de-139db7d65bef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20221230.xsd#ConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="extended" id="i3b605b117cde41d994d208562e5b9d4b_ConsolidatedStatementsofIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_df4997bb-7712-4d2b-bdef-dcee1cdbefd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_RevenuesAbstract_df4997bb-7712-4d2b-bdef-dcee1cdbefd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_625cc0bf-cd90-4cb3-80d2-187eba524eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_df4997bb-7712-4d2b-bdef-dcee1cdbefd4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_625cc0bf-cd90-4cb3-80d2-187eba524eaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c12af3f4-3ea7-4755-896a-52ddbdfcfe67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c12af3f4-3ea7-4755-896a-52ddbdfcfe67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6ee9a52b-c429-40c9-87c3-4b85c8f82c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c12af3f4-3ea7-4755-896a-52ddbdfcfe67" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6ee9a52b-c429-40c9-87c3-4b85c8f82c51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3a338a90-70ef-45b2-b72b-38e3d448fbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c12af3f4-3ea7-4755-896a-52ddbdfcfe67" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3a338a90-70ef-45b2-b72b-38e3d448fbb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d880e492-349f-49ca-9a4f-dcec5c3ec8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c12af3f4-3ea7-4755-896a-52ddbdfcfe67" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d880e492-349f-49ca-9a4f-dcec5c3ec8b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_40457a03-6c7d-4c43-8805-9afa6b7705d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c12af3f4-3ea7-4755-896a-52ddbdfcfe67" xlink:to="loc_us-gaap_CostsAndExpenses_40457a03-6c7d-4c43-8805-9afa6b7705d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_20662add-5fac-45c4-a4f4-a127a4e17f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_OperatingIncomeLoss_20662add-5fac-45c4-a4f4-a127a4e17f14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_799ae11f-6c04-438d-9cb0-155bd9494f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_InterestIncomeOther_799ae11f-6c04-438d-9cb0-155bd9494f3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_34ed8f64-63c7-49d9-a829-136a3bf61784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_34ed8f64-63c7-49d9-a829-136a3bf61784" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_f256349a-99e9-49a0-9cf4-180197c57800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_f256349a-99e9-49a0-9cf4-180197c57800" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ccfe58fd-c5ab-413e-9eaf-185c191dc852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ccfe58fd-c5ab-413e-9eaf-185c191dc852" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1a161034-6a56-44e0-b98f-79b95f84524e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_NetIncomeLoss_1a161034-6a56-44e0-b98f-79b95f84524e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2be2c736-6527-429c-978a-78be74b0edbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_EarningsPerShareAbstract_2be2c736-6527-429c-978a-78be74b0edbe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3aa0e408-329e-43e0-af62-d46c773e5662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2be2c736-6527-429c-978a-78be74b0edbe" xlink:to="loc_us-gaap_EarningsPerShareBasic_3aa0e408-329e-43e0-af62-d46c773e5662" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_cd94441c-ef7a-4692-921d-5ddb00c5bc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2be2c736-6527-429c-978a-78be74b0edbe" xlink:to="loc_us-gaap_EarningsPerShareDiluted_cd94441c-ef7a-4692-921d-5ddb00c5bc0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_bf23b43a-c0a0-408c-9506-718fd2c7bf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_bf23b43a-c0a0-408c-9506-718fd2c7bf3a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f67340fa-5d8b-4170-b38a-8262ca32f99e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_bf23b43a-c0a0-408c-9506-718fd2c7bf3a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f67340fa-5d8b-4170-b38a-8262ca32f99e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c37e4e4b-2610-493b-8c0f-b9cc8c9eb5da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_bf23b43a-c0a0-408c-9506-718fd2c7bf3a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c37e4e4b-2610-493b-8c0f-b9cc8c9eb5da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_df94ea2c-6673-444d-8395-4d3c9fbc8099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_StatementTable_df94ea2c-6673-444d-8395-4d3c9fbc8099" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aa9c3122-b078-4023-a545-1d51bde6fb0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_df94ea2c-6673-444d-8395-4d3c9fbc8099" xlink:to="loc_srt_ProductOrServiceAxis_aa9c3122-b078-4023-a545-1d51bde6fb0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aa9c3122-b078-4023-a545-1d51bde6fb0d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_aa9c3122-b078-4023-a545-1d51bde6fb0d" xlink:to="loc_srt_ProductsAndServicesDomain_aa9c3122-b078-4023-a545-1d51bde6fb0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7bacdcf6-fc48-478d-b564-c0752925c25f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_aa9c3122-b078-4023-a545-1d51bde6fb0d" xlink:to="loc_srt_ProductsAndServicesDomain_7bacdcf6-fc48-478d-b564-c0752925c25f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_031ccedf-b720-4564-a3ed-499010c1ff75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7bacdcf6-fc48-478d-b564-c0752925c25f" xlink:to="loc_us-gaap_ProductMember_031ccedf-b720-4564-a3ed-499010c1ff75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_da6cd2a5-d2cf-48b7-af2f-2a24e7df67f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7bacdcf6-fc48-478d-b564-c0752925c25f" xlink:to="loc_us-gaap_LicenseMember_da6cd2a5-d2cf-48b7-af2f-2a24e7df67f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_609bd5a5-d2a7-47fc-9839-e5bd1b29c4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7bacdcf6-fc48-478d-b564-c0752925c25f" xlink:to="loc_us-gaap_ServiceMember_609bd5a5-d2a7-47fc-9839-e5bd1b29c4fe" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20221230.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ic02811d1f1434b10aa9dbea9fd806245_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ea9e8b8c-592a-44de-8d29-171cecbc8a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ea9e8b8c-592a-44de-8d29-171cecbc8a7e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_76c746aa-510e-485c-a318-05dca91ba4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_76c746aa-510e-485c-a318-05dca91ba4c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f9fe2aee-bb93-4fb5-bb89-6bf9934dc689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_StockholdersEquity_f9fe2aee-bb93-4fb5-bb89-6bf9934dc689" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5479b57f-c63f-4622-9a3a-7bd5bc67c577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_NetIncomeLoss_5479b57f-c63f-4622-9a3a-7bd5bc67c577" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7f2a2649-cc0d-4489-954a-a52c1fe3ab7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7f2a2649-cc0d-4489-954a-a52c1fe3ab7e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b8fe0129-76d8-487a-b887-fdde52b2be3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b8fe0129-76d8-487a-b887-fdde52b2be3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2a138135-6698-453e-bc57-52f59621d878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2a138135-6698-453e-bc57-52f59621d878" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ded4e6ea-5ae8-4818-aff7-00e1e3b42f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ded4e6ea-5ae8-4818-aff7-00e1e3b42f09" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eb291419-f8f5-40a6-a3ea-564737122690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eb291419-f8f5-40a6-a3ea-564737122690" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d94a3aab-1013-4541-a8ac-7d46a661e59f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e9c2ea5b-67a7-43a1-b71b-03b661d5997c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ec0b18d3-c07a-42c0-bca4-eeb10a3ad3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ea9e8b8c-592a-44de-8d29-171cecbc8a7e" xlink:to="loc_us-gaap_StatementTable_ec0b18d3-c07a-42c0-bca4-eeb10a3ad3db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eb0677ba-481a-45a5-b999-d1c16cd2b78c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ec0b18d3-c07a-42c0-bca4-eeb10a3ad3db" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eb0677ba-481a-45a5-b999-d1c16cd2b78c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eb0677ba-481a-45a5-b999-d1c16cd2b78c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb0677ba-481a-45a5-b999-d1c16cd2b78c" xlink:to="loc_us-gaap_EquityComponentDomain_eb0677ba-481a-45a5-b999-d1c16cd2b78c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f340826d-07b3-4205-a0fe-989b9fac1ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb0677ba-481a-45a5-b999-d1c16cd2b78c" xlink:to="loc_us-gaap_EquityComponentDomain_f340826d-07b3-4205-a0fe-989b9fac1ff5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f8b07eaf-d6d6-4e5f-8526-684057a0a261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f340826d-07b3-4205-a0fe-989b9fac1ff5" xlink:to="loc_us-gaap_CommonStockMember_f8b07eaf-d6d6-4e5f-8526-684057a0a261" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_da5484d4-e717-4017-8a16-3456d404e1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f340826d-07b3-4205-a0fe-989b9fac1ff5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_da5484d4-e717-4017-8a16-3456d404e1f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_704fbe10-d612-489d-ad92-53437a8f831a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f340826d-07b3-4205-a0fe-989b9fac1ff5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_704fbe10-d612-489d-ad92-53437a8f831a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_95121019-a427-4f6b-83ca-e5790fafd5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f340826d-07b3-4205-a0fe-989b9fac1ff5" xlink:to="loc_us-gaap_RetainedEarningsMember_95121019-a427-4f6b-83ca-e5790fafd5fb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i30061051179e480e919597d0690df316_OrganizationandSummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:href="exel-20221230.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_e4fa833f-fc25-45fc-9f38-54d0c72e17ce" xlink:href="exel-20221230.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_exel_NumberofProductsinCommercialMarket_e4fa833f-fc25-45fc-9f38-54d0c72e17ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_b1ebefea-9cba-471f-95c1-56b7e6ddfe66" xlink:href="exel-20221230.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_b1ebefea-9cba-471f-95c1-56b7e6ddfe66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_26da5f8c-937a-4ce7-b7c3-e49755e9d772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_us-gaap_NumberOfOperatingSegments_26da5f8c-937a-4ce7-b7c3-e49755e9d772" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_81922b35-8b54-489d-85f4-d8a0595cdf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_81922b35-8b54-489d-85f4-d8a0595cdf2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_96677024-3381-4b3e-9765-f5ce547f8fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_96677024-3381-4b3e-9765-f5ce547f8fc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_8e64ce24-c077-4d44-ab19-2f9464d449ca" xlink:href="exel-20221230.xsd#exel_SalesRevenuePercentDiscountForPromptPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_exel_SalesRevenuePercentDiscountForPromptPayment_8e64ce24-c077-4d44-ab19-2f9464d449ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_65f2e750-3cd0-4f6f-829e-fd240f37725a" xlink:href="exel-20221230.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_65f2e750-3cd0-4f6f-829e-fd240f37725a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MedicarePartDFundingMandate_5c0039e5-89dc-40bd-bb09-66bdbdcd4e54" xlink:href="exel-20221230.xsd#exel_MedicarePartDFundingMandate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_exel_MedicarePartDFundingMandate_5c0039e5-89dc-40bd-bb09-66bdbdcd4e54" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_ce061e93-4ac5-47bb-89a2-3ee1072bfd5c" xlink:href="exel-20221230.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_ce061e93-4ac5-47bb-89a2-3ee1072bfd5c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_7113e61d-3c94-4134-baa8-a976cecbf615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_us-gaap_AdvertisingExpense_7113e61d-3c94-4134-baa8-a976cecbf615" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_e5939c54-a26d-41a3-9707-30fcbca96048" xlink:href="exel-20221230.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_e5939c54-a26d-41a3-9707-30fcbca96048" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_36e9c202-98c4-4eaf-b849-84dbb3b16699" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_e5939c54-a26d-41a3-9707-30fcbca96048" xlink:to="loc_srt_ProductOrServiceAxis_36e9c202-98c4-4eaf-b849-84dbb3b16699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_36e9c202-98c4-4eaf-b849-84dbb3b16699_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_36e9c202-98c4-4eaf-b849-84dbb3b16699" xlink:to="loc_srt_ProductsAndServicesDomain_36e9c202-98c4-4eaf-b849-84dbb3b16699_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_62d53b10-653b-47f4-a767-3f7a7c823aeb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_36e9c202-98c4-4eaf-b849-84dbb3b16699" xlink:to="loc_srt_ProductsAndServicesDomain_62d53b10-653b-47f4-a767-3f7a7c823aeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_578865e5-d63a-4ce0-b931-67278102cc41" xlink:href="exel-20221230.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_62d53b10-653b-47f4-a767-3f7a7c823aeb" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_578865e5-d63a-4ce0-b931-67278102cc41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_288caf24-015d-4186-bdc4-2e86c7f8da11" xlink:href="exel-20221230.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_62d53b10-653b-47f4-a767-3f7a7c823aeb" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_288caf24-015d-4186-bdc4-2e86c7f8da11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b7f18324-cb33-4837-bbf5-94024e6be0d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_e5939c54-a26d-41a3-9707-30fcbca96048" xlink:to="loc_srt_RangeAxis_b7f18324-cb33-4837-bbf5-94024e6be0d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b7f18324-cb33-4837-bbf5-94024e6be0d2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b7f18324-cb33-4837-bbf5-94024e6be0d2" xlink:to="loc_srt_RangeMember_b7f18324-cb33-4837-bbf5-94024e6be0d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fe91d47b-1970-4867-be94-6c009707ee64" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b7f18324-cb33-4837-bbf5-94024e6be0d2" xlink:to="loc_srt_RangeMember_fe91d47b-1970-4867-be94-6c009707ee64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_db60c6b9-72ad-4c36-8671-cda13a0a6488" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fe91d47b-1970-4867-be94-6c009707ee64" xlink:to="loc_srt_MaximumMember_db60c6b9-72ad-4c36-8671-cda13a0a6488" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended" id="i71f4a1f172d14f92bc42e641fe30cad1_RevenuesRevenuesbyDisaggregatedCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0e4e81d0-e5b6-4bb1-8781-1c6d2bc0f7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2b6cbb10-41ef-4e82-ad44-8110b3646cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e4e81d0-e5b6-4bb1-8781-1c6d2bc0f7a3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2b6cbb10-41ef-4e82-ad44-8110b3646cf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_36d87764-2e29-4325-bc6f-5552d19592f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e4e81d0-e5b6-4bb1-8781-1c6d2bc0f7a3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_36d87764-2e29-4325-bc6f-5552d19592f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b226466e-72c6-457f-aec3-ee47fc287654" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_36d87764-2e29-4325-bc6f-5552d19592f5" xlink:to="loc_srt_ProductOrServiceAxis_b226466e-72c6-457f-aec3-ee47fc287654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b226466e-72c6-457f-aec3-ee47fc287654_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b226466e-72c6-457f-aec3-ee47fc287654" xlink:to="loc_srt_ProductsAndServicesDomain_b226466e-72c6-457f-aec3-ee47fc287654_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b1dcdf13-a37e-4021-85dc-eabfaeb6d061" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b226466e-72c6-457f-aec3-ee47fc287654" xlink:to="loc_srt_ProductsAndServicesDomain_b1dcdf13-a37e-4021-85dc-eabfaeb6d061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_b8b830db-7bd4-4e51-995b-c2bc0d39e611" xlink:href="exel-20221230.xsd#exel_ProductGrossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1dcdf13-a37e-4021-85dc-eabfaeb6d061" xlink:to="loc_exel_ProductGrossMember_b8b830db-7bd4-4e51-995b-c2bc0d39e611" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_b96bab9a-9f7c-4df2-a60b-824f2eac1b80" xlink:href="exel-20221230.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1dcdf13-a37e-4021-85dc-eabfaeb6d061" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_b96bab9a-9f7c-4df2-a60b-824f2eac1b80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e8a03353-a620-4d6f-8b63-a03658466cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1dcdf13-a37e-4021-85dc-eabfaeb6d061" xlink:to="loc_us-gaap_ProductMember_e8a03353-a620-4d6f-8b63-a03658466cb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_dbd4b188-a241-4328-8e7f-961f33006318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1dcdf13-a37e-4021-85dc-eabfaeb6d061" xlink:to="loc_us-gaap_LicenseMember_dbd4b188-a241-4328-8e7f-961f33006318" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_004e1026-7ff2-4f7b-b574-53d2e0eea305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1dcdf13-a37e-4021-85dc-eabfaeb6d061" xlink:to="loc_us-gaap_ServiceMember_004e1026-7ff2-4f7b-b574-53d2e0eea305" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_28101c9b-fcf5-4928-838d-78f9458dfaf4" xlink:href="exel-20221230.xsd#exel_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1dcdf13-a37e-4021-85dc-eabfaeb6d061" xlink:to="loc_exel_CollaborationMember_28101c9b-fcf5-4928-838d-78f9458dfaf4" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended" id="i5549688c9bc1402c9803c6b1140f86d4_RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5fc06afe-f16b-4353-82ec-3dfdb0c17236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_885b467c-c134-41f1-999e-51ac2736c56b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5fc06afe-f16b-4353-82ec-3dfdb0c17236" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_885b467c-c134-41f1-999e-51ac2736c56b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5ec73d1c-d731-40f8-9f9b-cce18ec94abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5fc06afe-f16b-4353-82ec-3dfdb0c17236" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5ec73d1c-d731-40f8-9f9b-cce18ec94abc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6085ee7b-4151-45bf-9623-d20c342b9a92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5ec73d1c-d731-40f8-9f9b-cce18ec94abc" xlink:to="loc_srt_ProductOrServiceAxis_6085ee7b-4151-45bf-9623-d20c342b9a92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6085ee7b-4151-45bf-9623-d20c342b9a92_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6085ee7b-4151-45bf-9623-d20c342b9a92" xlink:to="loc_srt_ProductsAndServicesDomain_6085ee7b-4151-45bf-9623-d20c342b9a92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2ba381ef-b88c-49bf-b06c-384935487fbc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6085ee7b-4151-45bf-9623-d20c342b9a92" xlink:to="loc_srt_ProductsAndServicesDomain_2ba381ef-b88c-49bf-b06c-384935487fbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_00b81186-afd8-42c2-b472-73ff3796246d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2ba381ef-b88c-49bf-b06c-384935487fbc" xlink:to="loc_us-gaap_ProductMember_00b81186-afd8-42c2-b472-73ff3796246d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_4cf9ebbd-3bb3-4001-bc9f-10cbdb8e266a" xlink:href="exel-20221230.xsd#exel_CabometyxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_00b81186-afd8-42c2-b472-73ff3796246d" xlink:to="loc_exel_CabometyxMember_4cf9ebbd-3bb3-4001-bc9f-10cbdb8e266a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_fce61479-ad9e-4418-ac0c-6d8d4214c052" xlink:href="exel-20221230.xsd#exel_CometriqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_00b81186-afd8-42c2-b472-73ff3796246d" xlink:to="loc_exel_CometriqMember_fce61479-ad9e-4418-ac0c-6d8d4214c052" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="extended" id="ibaeb0cb0c4bb4ebca2f60ba760e08579_RevenuesRevenuesDisaggregatedbySignificantCustomerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_83c7ac2e-4deb-4694-9545-bdf6461f7342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e56e9ac3-5b54-45e4-8b87-d53ad733df46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_83c7ac2e-4deb-4694-9545-bdf6461f7342" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e56e9ac3-5b54-45e4-8b87-d53ad733df46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_01858808-d53d-401a-92e4-973b25a473b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_83c7ac2e-4deb-4694-9545-bdf6461f7342" xlink:to="loc_us-gaap_ConcentrationRiskTable_01858808-d53d-401a-92e4-973b25a473b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_93f4f45a-48ef-4490-a5e1-fc2ae8e7b948" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_01858808-d53d-401a-92e4-973b25a473b3" xlink:to="loc_srt_MajorCustomersAxis_93f4f45a-48ef-4490-a5e1-fc2ae8e7b948" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_93f4f45a-48ef-4490-a5e1-fc2ae8e7b948_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_93f4f45a-48ef-4490-a5e1-fc2ae8e7b948" xlink:to="loc_srt_NameOfMajorCustomerDomain_93f4f45a-48ef-4490-a5e1-fc2ae8e7b948_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_93f4f45a-48ef-4490-a5e1-fc2ae8e7b948" xlink:to="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_60a32260-1a8f-4206-bb91-013fe020795d" xlink:href="exel-20221230.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_60a32260-1a8f-4206-bb91-013fe020795d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_a5e674c2-f53b-4de9-a575-eb239737a38c" xlink:href="exel-20221230.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_a5e674c2-f53b-4de9-a575-eb239737a38c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_5b109645-5558-4ae2-a4b6-1b9a6c9a4ca3" xlink:href="exel-20221230.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_5b109645-5558-4ae2-a4b6-1b9a6c9a4ca3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_60578a11-e215-46b7-ab9c-60299f390162" xlink:href="exel-20221230.xsd#exel_IpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:to="loc_exel_IpsenMember_60578a11-e215-46b7-ab9c-60299f390162" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember_c9e6693c-5e9a-42da-b4b7-a7f477305763" xlink:href="exel-20221230.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:to="loc_exel_AccredoHealthIncorporatedMember_c9e6693c-5e9a-42da-b4b7-a7f477305763" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_87535dfb-da17-4d63-99fe-54246d60fc95" xlink:href="exel-20221230.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_87535dfb-da17-4d63-99fe-54246d60fc95" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CardinalHealthIncMember_cbc8bb9a-323e-49a7-a8c4-5fd365af8ddd" xlink:href="exel-20221230.xsd#exel_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:to="loc_exel_CardinalHealthIncMember_cbc8bb9a-323e-49a7-a8c4-5fd365af8ddd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_11a309fd-2c25-4ef6-b297-ab7c926c5524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_01858808-d53d-401a-92e4-973b25a473b3" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_11a309fd-2c25-4ef6-b297-ab7c926c5524" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_11a309fd-2c25-4ef6-b297-ab7c926c5524_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_11a309fd-2c25-4ef6-b297-ab7c926c5524" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_11a309fd-2c25-4ef6-b297-ab7c926c5524_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c008640f-e2e3-4ea2-80e2-a3f6547d1500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_11a309fd-2c25-4ef6-b297-ab7c926c5524" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c008640f-e2e3-4ea2-80e2-a3f6547d1500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_6e85304e-7d3c-4fcf-b085-76b91491bec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c008640f-e2e3-4ea2-80e2-a3f6547d1500" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_6e85304e-7d3c-4fcf-b085-76b91491bec6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_5cc13030-79f8-4f19-8613-5deb2ac6c01d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c008640f-e2e3-4ea2-80e2-a3f6547d1500" xlink:to="loc_us-gaap_AccountsReceivableMember_5cc13030-79f8-4f19-8613-5deb2ac6c01d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0f3768-1ac7-4634-8b85-a6b2c9c4bb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_01858808-d53d-401a-92e4-973b25a473b3" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0f3768-1ac7-4634-8b85-a6b2c9c4bb9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8e0f3768-1ac7-4634-8b85-a6b2c9c4bb9f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0f3768-1ac7-4634-8b85-a6b2c9c4bb9f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8e0f3768-1ac7-4634-8b85-a6b2c9c4bb9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_15654fb9-f0cf-4873-95ed-e8bc1a168e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0f3768-1ac7-4634-8b85-a6b2c9c4bb9f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_15654fb9-f0cf-4873-95ed-e8bc1a168e8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_331ae497-683b-4044-a733-cb6d4868cf88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_15654fb9-f0cf-4873-95ed-e8bc1a168e8f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_331ae497-683b-4044-a733-cb6d4868cf88" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended" id="ic035f4a4abc84e98866e97bd95f1e896_RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_86dda6c4-dfc8-49b6-a2bb-02643611a126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44152a42-8b4a-4283-93fa-52cd77742197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86dda6c4-dfc8-49b6-a2bb-02643611a126" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44152a42-8b4a-4283-93fa-52cd77742197" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_780bac0b-868b-4503-ade5-1dfdfb117f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86dda6c4-dfc8-49b6-a2bb-02643611a126" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_780bac0b-868b-4503-ade5-1dfdfb117f35" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a221850a-1d6b-446d-9b2a-096637704c66" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_780bac0b-868b-4503-ade5-1dfdfb117f35" xlink:to="loc_srt_StatementGeographicalAxis_a221850a-1d6b-446d-9b2a-096637704c66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a221850a-1d6b-446d-9b2a-096637704c66_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a221850a-1d6b-446d-9b2a-096637704c66" xlink:to="loc_srt_SegmentGeographicalDomain_a221850a-1d6b-446d-9b2a-096637704c66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4df26a21-3494-47c1-ae43-ecf9b5c6363e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a221850a-1d6b-446d-9b2a-096637704c66" xlink:to="loc_srt_SegmentGeographicalDomain_4df26a21-3494-47c1-ae43-ecf9b5c6363e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_72e994af-d91c-44db-98c5-74545a9adf2b" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4df26a21-3494-47c1-ae43-ecf9b5c6363e" xlink:to="loc_country_US_72e994af-d91c-44db-98c5-74545a9adf2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_cd16f147-1f8d-4f39-bfb4-6fff2143037d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4df26a21-3494-47c1-ae43-ecf9b5c6363e" xlink:to="loc_srt_EuropeMember_cd16f147-1f8d-4f39-bfb4-6fff2143037d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_ef817103-1fd8-4e84-ac22-da849c0d3217" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4df26a21-3494-47c1-ae43-ecf9b5c6363e" xlink:to="loc_country_JP_ef817103-1fd8-4e84-ac22-da849c0d3217" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended" id="i435e21ca6b9d483dbee7c895ab6a914b_RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_41b134b1-0a88-4792-a81b-fa8f43248f85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f23e7fa0-80ff-4db3-af62-ebd3b12eaf3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_41b134b1-0a88-4792-a81b-fa8f43248f85" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f23e7fa0-80ff-4db3-af62-ebd3b12eaf3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8ee4de35-7623-4740-b9d9-36866fb6e158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f23e7fa0-80ff-4db3-af62-ebd3b12eaf3e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8ee4de35-7623-4740-b9d9-36866fb6e158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_24450b55-665e-4c73-96f6-c1f145841dc3" xlink:href="exel-20221230.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f23e7fa0-80ff-4db3-af62-ebd3b12eaf3e" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_24450b55-665e-4c73-96f6-c1f145841dc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_8e3a72f5-3c40-401d-a162-3f9e5d8efaa1" xlink:href="exel-20221230.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_24450b55-665e-4c73-96f6-c1f145841dc3" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_8e3a72f5-3c40-401d-a162-3f9e5d8efaa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_1a053f6a-e136-4e54-976a-c10b5319c426" xlink:href="exel-20221230.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_24450b55-665e-4c73-96f6-c1f145841dc3" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_1a053f6a-e136-4e54-976a-c10b5319c426" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9ae45927-b710-4d39-a4d4-5daa4a1760d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f23e7fa0-80ff-4db3-af62-ebd3b12eaf3e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9ae45927-b710-4d39-a4d4-5daa4a1760d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_390b12c8-726d-49c6-adc0-c5de2a00316f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_36436b3a-c2ba-44d5-82ee-514e1413c61f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_41b134b1-0a88-4792-a81b-fa8f43248f85" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_36436b3a-c2ba-44d5-82ee-514e1413c61f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9ef2b8c6-a554-4f99-9309-80db28afd87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_36436b3a-c2ba-44d5-82ee-514e1413c61f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9ef2b8c6-a554-4f99-9309-80db28afd87f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_9ef2b8c6-a554-4f99-9309-80db28afd87f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9ef2b8c6-a554-4f99-9309-80db28afd87f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_9ef2b8c6-a554-4f99-9309-80db28afd87f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_e64a0bd5-f6e0-48bb-813f-7cf02324ef8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9ef2b8c6-a554-4f99-9309-80db28afd87f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_e64a0bd5-f6e0-48bb-813f-7cf02324ef8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_7410645c-dae5-44b6-a0b6-47e0a82d47c0" xlink:href="exel-20221230.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e64a0bd5-f6e0-48bb-813f-7cf02324ef8b" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_7410645c-dae5-44b6-a0b6-47e0a82d47c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_a923145a-6393-4eca-85b9-362959e0327d" xlink:href="exel-20221230.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e64a0bd5-f6e0-48bb-813f-7cf02324ef8b" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_a923145a-6393-4eca-85b9-362959e0327d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_dc6fd6e9-b69a-423a-8c47-c7b4b8cdbeed" xlink:href="exel-20221230.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e64a0bd5-f6e0-48bb-813f-7cf02324ef8b" xlink:to="loc_exel_AllowanceForProductRebatesMember_dc6fd6e9-b69a-423a-8c47-c7b4b8cdbeed" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="extended" id="i4270a6655f7948788d06117ffbe79f07_CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dcb1daa6-11ed-4341-bc11-de623970cfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dcb1daa6-11ed-4341-bc11-de623970cfd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_f540465c-2fbc-4f40-a22c-a1cbe4079c33" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_f540465c-2fbc-4f40-a22c-a1cbe4079c33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontPayments_4b7d4201-4050-491e-9287-68f3df0abb73" xlink:href="exel-20221230.xsd#exel_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_UpfrontPayments_4b7d4201-4050-491e-9287-68f3df0abb73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarnedToDate_7d0c121b-5ac7-4194-baac-7d2fe41ed82a" xlink:href="exel-20221230.xsd#exel_MilestonePaymentsEarnedToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_MilestonePaymentsEarnedToDate_7d0c121b-5ac7-4194-baac-7d2fe41ed82a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned_2066f3bd-2216-4d9f-bfcd-0b04297721f8" xlink:href="exel-20221230.xsd#exel_MilestonePaymentsEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_MilestonePaymentsEarned_2066f3bd-2216-4d9f-bfcd-0b04297721f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_82a91a03-6669-4658-a020-64c7040c5342" xlink:href="exel-20221230.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_82a91a03-6669-4658-a020-64c7040c5342" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_50ed65d4-142d-4f4a-9415-0cad4f7aece9" xlink:href="exel-20221230.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_50ed65d4-142d-4f4a-9415-0cad4f7aece9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_0158af52-8021-4257-87fd-ba1ba5332587" xlink:href="exel-20221230.xsd#exel_PercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_0158af52-8021-4257-87fd-ba1ba5332587" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_cfbac941-154f-41ca-af16-b7269e55cb8b" xlink:href="exel-20221230.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_cfbac941-154f-41ca-af16-b7269e55cb8b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_02b9049a-9cdd-49ca-80f3-09a26226278a" xlink:href="exel-20221230.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_02b9049a-9cdd-49ca-80f3-09a26226278a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_413aa546-6b4f-42b4-827d-76ad9007962b" xlink:href="exel-20221230.xsd#exel_RevenueFromContractWithCustomerCommercialSalesMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_413aa546-6b4f-42b4-827d-76ad9007962b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestone_4efa7627-273a-4b69-9089-bbac2b08d37e" xlink:href="exel-20221230.xsd#exel_RevenueFromContractWithCustomerRegulatoryMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestone_4efa7627-273a-4b69-9089-bbac2b08d37e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_58f1b79c-3607-4495-b89b-4a4ea07bb8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_58f1b79c-3607-4495-b89b-4a4ea07bb8bb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_096b4efe-db91-41aa-aa21-b7b3971f7583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_096b4efe-db91-41aa-aa21-b7b3971f7583" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4c84690a-3550-4a58-851f-e8ae87fcb389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_096b4efe-db91-41aa-aa21-b7b3971f7583" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4c84690a-3550-4a58-851f-e8ae87fcb389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4c84690a-3550-4a58-851f-e8ae87fcb389_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4c84690a-3550-4a58-851f-e8ae87fcb389" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4c84690a-3550-4a58-851f-e8ae87fcb389_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2a17295-32b5-4d39-894c-2f1d8a240b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4c84690a-3550-4a58-851f-e8ae87fcb389" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2a17295-32b5-4d39-894c-2f1d8a240b18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_fe482b4d-0957-4d68-a327-24cdf0586f6b" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2a17295-32b5-4d39-894c-2f1d8a240b18" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_fe482b4d-0957-4d68-a327-24cdf0586f6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_540a7d7c-7c8f-4a77-a4e4-a8ccbc866b49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_096b4efe-db91-41aa-aa21-b7b3971f7583" xlink:to="loc_srt_ProductOrServiceAxis_540a7d7c-7c8f-4a77-a4e4-a8ccbc866b49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_540a7d7c-7c8f-4a77-a4e4-a8ccbc866b49_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_540a7d7c-7c8f-4a77-a4e4-a8ccbc866b49" xlink:to="loc_srt_ProductsAndServicesDomain_540a7d7c-7c8f-4a77-a4e4-a8ccbc866b49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1f952ee5-4b64-436b-9ad7-2d3f72ac816f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_540a7d7c-7c8f-4a77-a4e4-a8ccbc866b49" xlink:to="loc_srt_ProductsAndServicesDomain_1f952ee5-4b64-436b-9ad7-2d3f72ac816f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_04fa9029-5764-4375-9b4b-1b004eb735ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1f952ee5-4b64-436b-9ad7-2d3f72ac816f" xlink:to="loc_us-gaap_ServiceMember_04fa9029-5764-4375-9b4b-1b004eb735ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f60b0602-728d-42ce-aa1d-4ccf15edeebb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_096b4efe-db91-41aa-aa21-b7b3971f7583" xlink:to="loc_srt_RangeAxis_f60b0602-728d-42ce-aa1d-4ccf15edeebb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f60b0602-728d-42ce-aa1d-4ccf15edeebb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f60b0602-728d-42ce-aa1d-4ccf15edeebb" xlink:to="loc_srt_RangeMember_f60b0602-728d-42ce-aa1d-4ccf15edeebb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ef62ed8a-bca5-46c8-a2bd-53cef22961e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f60b0602-728d-42ce-aa1d-4ccf15edeebb" xlink:to="loc_srt_RangeMember_ef62ed8a-bca5-46c8-a2bd-53cef22961e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9a4fa7de-3b1d-42ca-ab72-807cf057c33c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ef62ed8a-bca5-46c8-a2bd-53cef22961e5" xlink:to="loc_srt_MinimumMember_9a4fa7de-3b1d-42ca-ab72-807cf057c33c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_011b8f46-f7b8-49ba-b928-dc3681e7b4a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ef62ed8a-bca5-46c8-a2bd-53cef22961e5" xlink:to="loc_srt_MaximumMember_011b8f46-f7b8-49ba-b928-dc3681e7b4a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierAxis_d5548a34-c465-40a4-acbe-cb4cf2234e9e" xlink:href="exel-20221230.xsd#exel_RoyaltyTierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_096b4efe-db91-41aa-aa21-b7b3971f7583" xlink:to="loc_exel_RoyaltyTierAxis_d5548a34-c465-40a4-acbe-cb4cf2234e9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierDomain_d5548a34-c465-40a4-acbe-cb4cf2234e9e_default" xlink:href="exel-20221230.xsd#exel_RoyaltyTierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_RoyaltyTierAxis_d5548a34-c465-40a4-acbe-cb4cf2234e9e" xlink:to="loc_exel_RoyaltyTierDomain_d5548a34-c465-40a4-acbe-cb4cf2234e9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierDomain_03394794-48cd-4b62-8792-53de38d63705" xlink:href="exel-20221230.xsd#exel_RoyaltyTierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_RoyaltyTierAxis_d5548a34-c465-40a4-acbe-cb4cf2234e9e" xlink:to="loc_exel_RoyaltyTierDomain_03394794-48cd-4b62-8792-53de38d63705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalTierMember_758ee3e6-9916-42bc-a8c6-9f59fd4f20ed" xlink:href="exel-20221230.xsd#exel_FinalTierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltyTierDomain_03394794-48cd-4b62-8792-53de38d63705" xlink:to="loc_exel_FinalTierMember_758ee3e6-9916-42bc-a8c6-9f59fd4f20ed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended" id="i2dfc7f2464104c249de2ac2d40ce3269_CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_466c58e0-d6f0-452f-844c-8a1f0044963b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_29cb8505-7664-4f27-bb60-14140706d3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_466c58e0-d6f0-452f-844c-8a1f0044963b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_29cb8505-7664-4f27-bb60-14140706d3af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b51ceed5-56d4-4fb1-8c38-bae1c9d7b782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_466c58e0-d6f0-452f-844c-8a1f0044963b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b51ceed5-56d4-4fb1-8c38-bae1c9d7b782" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c5aded43-f58e-491c-800f-0d870fa47652" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b51ceed5-56d4-4fb1-8c38-bae1c9d7b782" xlink:to="loc_srt_ProductOrServiceAxis_c5aded43-f58e-491c-800f-0d870fa47652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5aded43-f58e-491c-800f-0d870fa47652_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c5aded43-f58e-491c-800f-0d870fa47652" xlink:to="loc_srt_ProductsAndServicesDomain_c5aded43-f58e-491c-800f-0d870fa47652_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5d841c2f-3ac6-41e7-a837-8588c610705b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c5aded43-f58e-491c-800f-0d870fa47652" xlink:to="loc_srt_ProductsAndServicesDomain_5d841c2f-3ac6-41e7-a837-8588c610705b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_f1799105-c0d5-4553-87f8-bad2d27bd1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5d841c2f-3ac6-41e7-a837-8588c610705b" xlink:to="loc_us-gaap_LicenseMember_f1799105-c0d5-4553-87f8-bad2d27bd1c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_1d49c1ee-ff1b-4a40-b37d-6d30dc526831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5d841c2f-3ac6-41e7-a837-8588c610705b" xlink:to="loc_us-gaap_ServiceMember_1d49c1ee-ff1b-4a40-b37d-6d30dc526831" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b9024c51-fca4-454e-9076-ccaa9ab1fa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b51ceed5-56d4-4fb1-8c38-bae1c9d7b782" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b9024c51-fca4-454e-9076-ccaa9ab1fa9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b9024c51-fca4-454e-9076-ccaa9ab1fa9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b9024c51-fca4-454e-9076-ccaa9ab1fa9a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b9024c51-fca4-454e-9076-ccaa9ab1fa9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54bd60fe-b03c-4334-8b08-541b185239e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b9024c51-fca4-454e-9076-ccaa9ab1fa9a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54bd60fe-b03c-4334-8b08-541b185239e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_d24aa465-056a-4381-bcde-11bac4bfdb13" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54bd60fe-b03c-4334-8b08-541b185239e7" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_d24aa465-056a-4381-bcde-11bac4bfdb13" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="extended" id="i67b2cf121f8a417a92a6be9db903acdb_CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_4d5d6211-6f46-4fb3-92fe-230f734de9b1" xlink:href="exel-20221230.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_4d5d6211-6f46-4fb3-92fe-230f734de9b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_dbabd6ae-ce4e-4328-8506-2ef125073d4d" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_dbabd6ae-ce4e-4328-8506-2ef125073d4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontPayments_2b8a8cdc-58b5-4802-8ad6-620245e3e927" xlink:href="exel-20221230.xsd#exel_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_UpfrontPayments_2b8a8cdc-58b5-4802-8ad6-620245e3e927" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarnedToDate_33ed5c9c-bbd2-46c4-9d66-cb6cc151fec8" xlink:href="exel-20221230.xsd#exel_MilestonePaymentsEarnedToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_MilestonePaymentsEarnedToDate_33ed5c9c-bbd2-46c4-9d66-cb6cc151fec8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned_2c3b6440-ebb1-49d3-a35b-6ebdfe086829" xlink:href="exel-20221230.xsd#exel_MilestonePaymentsEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_MilestonePaymentsEarned_2c3b6440-ebb1-49d3-a35b-6ebdfe086829" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_c1054100-3c17-457a-a5ce-774f1c21c479" xlink:href="exel-20221230.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_c1054100-3c17-457a-a5ce-774f1c21c479" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_1479fd59-68e4-4566-b961-5662ed288a36" xlink:href="exel-20221230.xsd#exel_PercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_1479fd59-68e4-4566-b961-5662ed288a36" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTier_dcc9f286-2306-4c4a-bdf4-84121e241789" xlink:href="exel-20221230.xsd#exel_RoyaltyTier"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_RoyaltyTier_dcc9f286-2306-4c4a-bdf4-84121e241789" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_15829451-d19e-4b08-9fce-7627a2cda2df" xlink:href="exel-20221230.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_15829451-d19e-4b08-9fce-7627a2cda2df" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_cce94a29-93b4-4fcb-8aba-1869aaa9724a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_cce94a29-93b4-4fcb-8aba-1869aaa9724a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_921dbe71-89f7-48db-b065-060120264945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_921dbe71-89f7-48db-b065-060120264945" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6d31b7cf-dbdf-45c2-b97a-e3b5c1f97124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_921dbe71-89f7-48db-b065-060120264945" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6d31b7cf-dbdf-45c2-b97a-e3b5c1f97124" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d31b7cf-dbdf-45c2-b97a-e3b5c1f97124_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6d31b7cf-dbdf-45c2-b97a-e3b5c1f97124" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d31b7cf-dbdf-45c2-b97a-e3b5c1f97124_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fabba6a3-5184-486a-b42f-de35e0b4a012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6d31b7cf-dbdf-45c2-b97a-e3b5c1f97124" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fabba6a3-5184-486a-b42f-de35e0b4a012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_a77a8ea2-f891-49a5-a7d6-180d1e95699d" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fabba6a3-5184-486a-b42f-de35e0b4a012" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_a77a8ea2-f891-49a5-a7d6-180d1e95699d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_18e7e51d-cd20-411f-b3bd-ee74c6c56e99" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_921dbe71-89f7-48db-b065-060120264945" xlink:to="loc_srt_StatementGeographicalAxis_18e7e51d-cd20-411f-b3bd-ee74c6c56e99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_18e7e51d-cd20-411f-b3bd-ee74c6c56e99_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_18e7e51d-cd20-411f-b3bd-ee74c6c56e99" xlink:to="loc_srt_SegmentGeographicalDomain_18e7e51d-cd20-411f-b3bd-ee74c6c56e99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7fe5a9c5-c1ba-40c9-b0be-d2daff601084" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_18e7e51d-cd20-411f-b3bd-ee74c6c56e99" xlink:to="loc_srt_SegmentGeographicalDomain_7fe5a9c5-c1ba-40c9-b0be-d2daff601084" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_2abcabc7-6e0d-4ca6-bdc2-61b11bed5d7a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7fe5a9c5-c1ba-40c9-b0be-d2daff601084" xlink:to="loc_country_JP_2abcabc7-6e0d-4ca6-bdc2-61b11bed5d7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierAxis_271d9e8c-5b60-484a-b0f0-142bcfa38f53" xlink:href="exel-20221230.xsd#exel_RoyaltyTierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_921dbe71-89f7-48db-b065-060120264945" xlink:to="loc_exel_RoyaltyTierAxis_271d9e8c-5b60-484a-b0f0-142bcfa38f53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierDomain_271d9e8c-5b60-484a-b0f0-142bcfa38f53_default" xlink:href="exel-20221230.xsd#exel_RoyaltyTierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_RoyaltyTierAxis_271d9e8c-5b60-484a-b0f0-142bcfa38f53" xlink:to="loc_exel_RoyaltyTierDomain_271d9e8c-5b60-484a-b0f0-142bcfa38f53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierDomain_24de7ea4-443f-4b85-b30d-48dff2b5a5dd" xlink:href="exel-20221230.xsd#exel_RoyaltyTierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_RoyaltyTierAxis_271d9e8c-5b60-484a-b0f0-142bcfa38f53" xlink:to="loc_exel_RoyaltyTierDomain_24de7ea4-443f-4b85-b30d-48dff2b5a5dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_InitialMember_071a045c-a8eb-436c-83fa-ffc57fdeb321" xlink:href="exel-20221230.xsd#exel_InitialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltyTierDomain_24de7ea4-443f-4b85-b30d-48dff2b5a5dd" xlink:to="loc_exel_InitialMember_071a045c-a8eb-436c-83fa-ffc57fdeb321" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalTierMember_44b06531-9414-4340-8d7f-10656bced578" xlink:href="exel-20221230.xsd#exel_FinalTierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltyTierDomain_24de7ea4-443f-4b85-b30d-48dff2b5a5dd" xlink:to="loc_exel_FinalTierMember_44b06531-9414-4340-8d7f-10656bced578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_402f6a7d-5f21-4e21-a3b9-9241ed6cf2c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_921dbe71-89f7-48db-b065-060120264945" xlink:to="loc_srt_RangeAxis_402f6a7d-5f21-4e21-a3b9-9241ed6cf2c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_402f6a7d-5f21-4e21-a3b9-9241ed6cf2c7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_402f6a7d-5f21-4e21-a3b9-9241ed6cf2c7" xlink:to="loc_srt_RangeMember_402f6a7d-5f21-4e21-a3b9-9241ed6cf2c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1192cc13-43b6-4b96-a3d0-14a1be449715" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_402f6a7d-5f21-4e21-a3b9-9241ed6cf2c7" xlink:to="loc_srt_RangeMember_1192cc13-43b6-4b96-a3d0-14a1be449715" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_01198d86-f2cf-4110-af36-f269aa4db978" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1192cc13-43b6-4b96-a3d0-14a1be449715" xlink:to="loc_srt_MinimumMember_01198d86-f2cf-4110-af36-f269aa4db978" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_550f78d4-f13e-45d5-8212-cb667f7335f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1192cc13-43b6-4b96-a3d0-14a1be449715" xlink:to="loc_srt_MaximumMember_550f78d4-f13e-45d5-8212-cb667f7335f1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended" id="i3544cd0fb3f341a6922f09eac08c73dd_CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54223d46-f057-4414-989a-1af39ea1c350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c09f4b4-292d-431d-959e-3b8d577bf4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54223d46-f057-4414-989a-1af39ea1c350" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c09f4b4-292d-431d-959e-3b8d577bf4c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4645871-5587-4eac-800f-59991cd51077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54223d46-f057-4414-989a-1af39ea1c350" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4645871-5587-4eac-800f-59991cd51077" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_545a63c0-683e-4447-8da1-cb8d0040173d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4645871-5587-4eac-800f-59991cd51077" xlink:to="loc_srt_ProductOrServiceAxis_545a63c0-683e-4447-8da1-cb8d0040173d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_545a63c0-683e-4447-8da1-cb8d0040173d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_545a63c0-683e-4447-8da1-cb8d0040173d" xlink:to="loc_srt_ProductsAndServicesDomain_545a63c0-683e-4447-8da1-cb8d0040173d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a8a4f127-86a2-4183-906e-0ef8bf8611dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_545a63c0-683e-4447-8da1-cb8d0040173d" xlink:to="loc_srt_ProductsAndServicesDomain_a8a4f127-86a2-4183-906e-0ef8bf8611dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_027ab23d-eba1-4aa7-b4e8-59ea64eb8468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a8a4f127-86a2-4183-906e-0ef8bf8611dd" xlink:to="loc_us-gaap_LicenseMember_027ab23d-eba1-4aa7-b4e8-59ea64eb8468" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_e554769d-c28c-4a28-b424-b329ab4f2f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a8a4f127-86a2-4183-906e-0ef8bf8611dd" xlink:to="loc_us-gaap_ServiceMember_e554769d-c28c-4a28-b424-b329ab4f2f51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9bf4f975-96b2-43b0-bddc-c9c506a8f654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4645871-5587-4eac-800f-59991cd51077" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9bf4f975-96b2-43b0-bddc-c9c506a8f654" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9bf4f975-96b2-43b0-bddc-c9c506a8f654_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9bf4f975-96b2-43b0-bddc-c9c506a8f654" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9bf4f975-96b2-43b0-bddc-c9c506a8f654_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96a72fc5-7acb-4da1-8a71-cdfb61d1c9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9bf4f975-96b2-43b0-bddc-c9c506a8f654" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96a72fc5-7acb-4da1-8a71-cdfb61d1c9cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_3651b965-36a1-4dc5-9811-6650739b7f65" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96a72fc5-7acb-4da1-8a71-cdfb61d1c9cc" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_3651b965-36a1-4dc5-9811-6650739b7f65" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails" xlink:type="extended" id="id1bb1be82a88481abaf9750befddf0bd_CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bfd7f1b-fc5f-4403-8773-eee236314a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_3e4af39b-982c-432c-a349-8dbbe11bd861" xlink:href="exel-20221230.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bfd7f1b-fc5f-4403-8773-eee236314a1e" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_3e4af39b-982c-432c-a349-8dbbe11bd861" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_8ac474d5-0c34-4bb6-9704-3d0c6de64d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bfd7f1b-fc5f-4403-8773-eee236314a1e" xlink:to="loc_us-gaap_RoyaltyExpense_8ac474d5-0c34-4bb6-9704-3d0c6de64d65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bdf34bb9-5923-4051-af39-468b7fb7bd12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bfd7f1b-fc5f-4403-8773-eee236314a1e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bdf34bb9-5923-4051-af39-468b7fb7bd12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4b539500-6890-4e5e-a13f-eb7b9f4b446f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bdf34bb9-5923-4051-af39-468b7fb7bd12" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4b539500-6890-4e5e-a13f-eb7b9f4b446f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4b539500-6890-4e5e-a13f-eb7b9f4b446f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4b539500-6890-4e5e-a13f-eb7b9f4b446f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4b539500-6890-4e5e-a13f-eb7b9f4b446f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_74d1412d-dfde-4526-b97e-b51141258c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4b539500-6890-4e5e-a13f-eb7b9f4b446f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_74d1412d-dfde-4526-b97e-b51141258c2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember_220df922-66ca-43c5-a8b5-b1fabae24819" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_74d1412d-dfde-4526-b97e-b51141258c2d" xlink:to="loc_exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember_220df922-66ca-43c5-a8b5-b1fabae24819" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails" xlink:type="extended" id="ib68853b2648e4aed93d0d92d69afcf9f_CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94fe9a18-120f-4ece-a4ac-9ea798b206de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94fe9a18-120f-4ece-a4ac-9ea798b206de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_9417931f-6673-4c3c-b866-d1817377f649" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_9417931f-6673-4c3c-b866-d1817377f649" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_0f21cfe6-dc0f-41dc-8119-c65d3f13ed4c" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_0f21cfe6-dc0f-41dc-8119-c65d3f13ed4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise_18420e76-6b43-4d89-b6fc-c6e4bb2d73fc" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementMaximumAmountOfWarrantExercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise_18420e76-6b43-4d89-b6fc-c6e4bb2d73fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments_41441c70-b52a-4cf8-a1eb-936a1c6b3261" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments_41441c70-b52a-4cf8-a1eb-936a1c6b3261" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount_915a6594-d716-4945-9c9f-c7492dce8401" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsExerciseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount_915a6594-d716-4945-9c9f-c7492dce8401" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0505f6b6-a14e-4488-ba0b-d3bec7815003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0505f6b6-a14e-4488-ba0b-d3bec7815003" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseDecreaseInResearchAndDevelopmentExpense_1c6f58ce-cbfa-46e0-8f10-edfec6d514eb" xlink:href="exel-20221230.xsd#exel_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_IncreaseDecreaseInResearchAndDevelopmentExpense_1c6f58ce-cbfa-46e0-8f10-edfec6d514eb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseInBasicEarningsPerShare_f085624b-5309-4430-ad5b-240fddf64e32" xlink:href="exel-20221230.xsd#exel_IncreaseInBasicEarningsPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_IncreaseInBasicEarningsPerShare_f085624b-5309-4430-ad5b-240fddf64e32" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseInDilutedEarningsPerShare_78b35e6b-b58a-4992-8f44-928adc3cb5e0" xlink:href="exel-20221230.xsd#exel_IncreaseInDilutedEarningsPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_IncreaseInDilutedEarningsPerShare_78b35e6b-b58a-4992-8f44-928adc3cb5e0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_def46109-bc54-4176-94d8-1f3815172e0a" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_ea8077ff-64cc-412a-9096-8d7e66315ee1" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_ea8077ff-64cc-412a-9096-8d7e66315ee1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_9288b458-ab5e-4796-8775-7fec4f5d7139" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_9288b458-ab5e-4796-8775-7fec4f5d7139" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1275b34f-6a2d-49a2-bd28-309dad88af8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1275b34f-6a2d-49a2-bd28-309dad88af8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1595851e-4d29-41eb-8c4c-3a4d92515c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1275b34f-6a2d-49a2-bd28-309dad88af8c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1595851e-4d29-41eb-8c4c-3a4d92515c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1595851e-4d29-41eb-8c4c-3a4d92515c23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1595851e-4d29-41eb-8c4c-3a4d92515c23" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1595851e-4d29-41eb-8c4c-3a4d92515c23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2cc8154-2c73-49f6-b2a9-f577589bcf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1595851e-4d29-41eb-8c4c-3a4d92515c23" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2cc8154-2c73-49f6-b2a9-f577589bcf6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_679b12ed-4ec8-4af0-b532-0d5404bdf654" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2cc8154-2c73-49f6-b2a9-f577589bcf6d" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_679b12ed-4ec8-4af0-b532-0d5404bdf654" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BioInventInternationalABBioInventMember_e2ddea98-5e70-4c7c-842a-aea08624e4b4" xlink:href="exel-20221230.xsd#exel_BioInventInternationalABBioInventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2cc8154-2c73-49f6-b2a9-f577589bcf6d" xlink:to="loc_exel_BioInventInternationalABBioInventMember_e2ddea98-5e70-4c7c-842a-aea08624e4b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CybrexaTherapeuticsLLCCybrexaMember_eeb04bcb-11c9-4f4d-a647-5bc7e1edfd8e" xlink:href="exel-20221230.xsd#exel_CybrexaTherapeuticsLLCCybrexaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2cc8154-2c73-49f6-b2a9-f577589bcf6d" xlink:to="loc_exel_CybrexaTherapeuticsLLCCybrexaMember_eeb04bcb-11c9-4f4d-a647-5bc7e1edfd8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SairopaBVSairopaMember_40e138fb-8630-4504-b105-25a0e7e17992" xlink:href="exel-20221230.xsd#exel_SairopaBVSairopaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2cc8154-2c73-49f6-b2a9-f577589bcf6d" xlink:to="loc_exel_SairopaBVSairopaMember_40e138fb-8630-4504-b105-25a0e7e17992" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CatalentIncMember_a6ff3117-8b85-41fe-8a3c-3e4d24a38f3b" xlink:href="exel-20221230.xsd#exel_CatalentIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2cc8154-2c73-49f6-b2a9-f577589bcf6d" xlink:to="loc_exel_CatalentIncMember_a6ff3117-8b85-41fe-8a3c-3e4d24a38f3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_2a8221f1-da13-4b3e-9368-3054421ccd31" xlink:href="exel-20221230.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2cc8154-2c73-49f6-b2a9-f577589bcf6d" xlink:to="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_2a8221f1-da13-4b3e-9368-3054421ccd31" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_92448030-07fe-4560-918e-821536d10665" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1275b34f-6a2d-49a2-bd28-309dad88af8c" xlink:to="loc_srt_ProductOrServiceAxis_92448030-07fe-4560-918e-821536d10665" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_92448030-07fe-4560-918e-821536d10665_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_92448030-07fe-4560-918e-821536d10665" xlink:to="loc_srt_ProductsAndServicesDomain_92448030-07fe-4560-918e-821536d10665_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f6c165c9-a596-4b19-a7c6-7b5f240e0492" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_92448030-07fe-4560-918e-821536d10665" xlink:to="loc_srt_ProductsAndServicesDomain_f6c165c9-a596-4b19-a7c6-7b5f240e0492" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember_9e413a38-4a26-45b4-a6e6-1cb1849ce4c7" xlink:href="exel-20221230.xsd#exel_CotellicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f6c165c9-a596-4b19-a7c6-7b5f240e0492" xlink:to="loc_exel_CotellicMember_9e413a38-4a26-45b4-a6e6-1cb1849ce4c7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended" id="ie0682c503544415ba14b29b225929f7e_CashandInvestmentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_fcb46ee3-b838-45ce-ad86-4d4947ddc3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:to="loc_us-gaap_InterestReceivable_fcb46ee3-b838-45ce-ad86-4d4947ddc3b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_c229072a-f77f-4623-a970-579e681f2e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_c229072a-f77f-4623-a970-579e681f2e25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfBondSecurities_203b98d3-088e-4c72-8293-5bdd4cd15cc6" xlink:href="exel-20221230.xsd#exel_NumberOfBondSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:to="loc_exel_NumberOfBondSecurities_203b98d3-088e-4c72-8293-5bdd4cd15cc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfSponsoredEnterprises_2ddcb2ec-93e4-4b05-85ae-2f0858af9c11" xlink:href="exel-20221230.xsd#exel_NumberOfSponsoredEnterprises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:to="loc_exel_NumberOfSponsoredEnterprises_2ddcb2ec-93e4-4b05-85ae-2f0858af9c11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_68b2291d-6ab5-4391-b9f9-ab6ba359d449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_68b2291d-6ab5-4391-b9f9-ab6ba359d449" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_ac9ca1a8-e229-4696-a289-3d904fb70938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_ac9ca1a8-e229-4696-a289-3d904fb70938" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_825bb06f-3791-4694-9686-8a7711a16f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_825bb06f-3791-4694-9686-8a7711a16f63" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_014e847a-10b9-431b-baf0-c3512e9ec0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_014e847a-10b9-431b-baf0-c3512e9ec0cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_18576c88-8970-4ebd-9b5e-5274f09a33a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_014e847a-10b9-431b-baf0-c3512e9ec0cd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_18576c88-8970-4ebd-9b5e-5274f09a33a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_18576c88-8970-4ebd-9b5e-5274f09a33a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_18576c88-8970-4ebd-9b5e-5274f09a33a2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_18576c88-8970-4ebd-9b5e-5274f09a33a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5aa0bfdf-d652-4a37-b3f6-8308f2b2b1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_18576c88-8970-4ebd-9b5e-5274f09a33a2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5aa0bfdf-d652-4a37-b3f6-8308f2b2b1c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_25c04f84-ec05-4ce2-8350-2374d2d0897b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5aa0bfdf-d652-4a37-b3f6-8308f2b2b1c5" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_25c04f84-ec05-4ce2-8350-2374d2d0897b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_623201d9-369f-47b4-9f05-f7daf2812637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5aa0bfdf-d652-4a37-b3f6-8308f2b2b1c5" xlink:to="loc_us-gaap_MunicipalBondsMember_623201d9-369f-47b4-9f05-f7daf2812637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_01301df3-e3b1-4579-aaa0-cbbccb4958c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5aa0bfdf-d652-4a37-b3f6-8308f2b2b1c5" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_01301df3-e3b1-4579-aaa0-cbbccb4958c3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended" id="i7bafa247016c41b69d1a047d4553a36f_CashandInvestmentsInvestmentsbySecurityTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4d1f1bf6-56d1-4b4d-a354-ebc9d7537d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2603af44-73f9-4551-b4eb-d039ac12940c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4d1f1bf6-56d1-4b4d-a354-ebc9d7537d95" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2603af44-73f9-4551-b4eb-d039ac12940c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4aeb141d-dae2-4bcd-804c-6fa30d2f5bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2603af44-73f9-4551-b4eb-d039ac12940c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4aeb141d-dae2-4bcd-804c-6fa30d2f5bed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fa4d3bf5-b3af-4884-aac0-601499ff0a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2603af44-73f9-4551-b4eb-d039ac12940c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fa4d3bf5-b3af-4884-aac0-601499ff0a01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_94b34459-a5aa-473c-9a26-7a4aed39231a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2603af44-73f9-4551-b4eb-d039ac12940c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_94b34459-a5aa-473c-9a26-7a4aed39231a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6c5c1969-a1d4-4a5f-8f44-874fd7b86b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2603af44-73f9-4551-b4eb-d039ac12940c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6c5c1969-a1d4-4a5f-8f44-874fd7b86b09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aced967d-ba67-49e5-9cc8-765589f6a637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4d1f1bf6-56d1-4b4d-a354-ebc9d7537d95" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aced967d-ba67-49e5-9cc8-765589f6a637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a7c737ed-a3cf-4f3d-b1dd-b66a1d31d0ea" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aced967d-ba67-49e5-9cc8-765589f6a637" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a7c737ed-a3cf-4f3d-b1dd-b66a1d31d0ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_1c6ab54c-5cd4-4611-8c57-99fc4e1e113f" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aced967d-ba67-49e5-9cc8-765589f6a637" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_1c6ab54c-5cd4-4611-8c57-99fc4e1e113f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_67685003-d4ec-462b-9a6b-c49db3ebce6c" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aced967d-ba67-49e5-9cc8-765589f6a637" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_67685003-d4ec-462b-9a6b-c49db3ebce6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_d23274cc-d746-421e-a015-416e137a2d78" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aced967d-ba67-49e5-9cc8-765589f6a637" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_d23274cc-d746-421e-a015-416e137a2d78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_d7f01db9-2dd3-4605-85ec-d1293d1ba43f" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4d1f1bf6-56d1-4b4d-a354-ebc9d7537d95" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_d7f01db9-2dd3-4605-85ec-d1293d1ba43f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dd8acb98-20bb-401f-8cab-b9115c2e1510" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4d1f1bf6-56d1-4b4d-a354-ebc9d7537d95" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dd8acb98-20bb-401f-8cab-b9115c2e1510" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cd3120a1-9818-4da3-9d93-c648c56ae0e6" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4d1f1bf6-56d1-4b4d-a354-ebc9d7537d95" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cd3120a1-9818-4da3-9d93-c648c56ae0e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_5eeee5f7-52cb-433f-ac3f-3520e5664653" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4d1f1bf6-56d1-4b4d-a354-ebc9d7537d95" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_5eeee5f7-52cb-433f-ac3f-3520e5664653" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9a2d21f8-f1a1-4843-ae23-c34421345396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4d1f1bf6-56d1-4b4d-a354-ebc9d7537d95" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9a2d21f8-f1a1-4843-ae23-c34421345396" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f8167ceb-5e31-4090-93fb-a565f1f2d3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9a2d21f8-f1a1-4843-ae23-c34421345396" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f8167ceb-5e31-4090-93fb-a565f1f2d3d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f8167ceb-5e31-4090-93fb-a565f1f2d3d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f8167ceb-5e31-4090-93fb-a565f1f2d3d2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f8167ceb-5e31-4090-93fb-a565f1f2d3d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f8167ceb-5e31-4090-93fb-a565f1f2d3d2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8f9e0612-6590-49dd-9be6-231895fb3d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:to="loc_us-gaap_CommercialPaperMember_8f9e0612-6590-49dd-9be6-231895fb3d36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_7d5bcd13-6e2c-41cd-939e-6836860da10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_7d5bcd13-6e2c-41cd-939e-6836860da10c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_4c24691c-f2f7-4afc-b5bc-83b94ae7fdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_4c24691c-f2f7-4afc-b5bc-83b94ae7fdfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_34cf12d2-5c05-4f65-aab6-de80a7f768f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:to="loc_us-gaap_MunicipalBondsMember_34cf12d2-5c05-4f65-aab6-de80a7f768f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_7cc8e4e7-5309-482c-a45d-40783c8ff403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:to="loc_us-gaap_CashMember_7cc8e4e7-5309-482c-a45d-40783c8ff403" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a6eeb89c-048b-46c8-9c73-d8acf7594646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a6eeb89c-048b-46c8-9c73-d8acf7594646" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d58b33c2-688a-4dd1-985f-143e2dec6c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d58b33c2-688a-4dd1-985f-143e2dec6c53" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended" id="i7353c026ec2b4649afed7a18bc2fbfaa_CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f019f9c-561c-48bd-ae2d-6d5ed074d0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a7926761-dab5-4bca-8392-5b07b17bd2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f019f9c-561c-48bd-ae2d-6d5ed074d0fe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a7926761-dab5-4bca-8392-5b07b17bd2dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_8a33b0c4-6f6d-4614-bd04-2cfe4d8a9a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f019f9c-561c-48bd-ae2d-6d5ed074d0fe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_8a33b0c4-6f6d-4614-bd04-2cfe4d8a9a10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3e52993b-d5e7-46fb-bc9a-8faf7eb8460d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f019f9c-561c-48bd-ae2d-6d5ed074d0fe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3e52993b-d5e7-46fb-bc9a-8faf7eb8460d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d2e986df-98ee-4bf8-b7c1-9cd7b38d025d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3e52993b-d5e7-46fb-bc9a-8faf7eb8460d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d2e986df-98ee-4bf8-b7c1-9cd7b38d025d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d2e986df-98ee-4bf8-b7c1-9cd7b38d025d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d2e986df-98ee-4bf8-b7c1-9cd7b38d025d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d2e986df-98ee-4bf8-b7c1-9cd7b38d025d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90fe907e-f1d5-4b58-8a19-ae18563077b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d2e986df-98ee-4bf8-b7c1-9cd7b38d025d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90fe907e-f1d5-4b58-8a19-ae18563077b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_2f60c950-77dd-4def-8fc3-5e3c30c9c7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90fe907e-f1d5-4b58-8a19-ae18563077b7" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_2f60c950-77dd-4def-8fc3-5e3c30c9c7ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_80f85ac5-d57f-4ed0-b9b8-9300979fd04a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90fe907e-f1d5-4b58-8a19-ae18563077b7" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_80f85ac5-d57f-4ed0-b9b8-9300979fd04a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_bb67ea9e-12e3-47f7-ad25-654820f65fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90fe907e-f1d5-4b58-8a19-ae18563077b7" xlink:to="loc_us-gaap_CommercialPaperMember_bb67ea9e-12e3-47f7-ad25-654820f65fb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_d348dfad-b8e3-4dc1-b017-3c82bb965e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90fe907e-f1d5-4b58-8a19-ae18563077b7" xlink:to="loc_us-gaap_MunicipalBondsMember_d348dfad-b8e3-4dc1-b017-3c82bb965e75" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="if34366bcf2e14c1cb176fe9e0721edf7_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f862051-bf56-4a2b-9bf4-1ee78b361e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4194c060-4ad7-4690-954d-50bdf3cfc232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f862051-bf56-4a2b-9bf4-1ee78b361e79" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4194c060-4ad7-4690-954d-50bdf3cfc232" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d0a50f80-f17f-430c-bac0-28a33458bf65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f862051-bf56-4a2b-9bf4-1ee78b361e79" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d0a50f80-f17f-430c-bac0-28a33458bf65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_fe94ed32-db13-4daa-8606-0ee32d3494fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f862051-bf56-4a2b-9bf4-1ee78b361e79" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_fe94ed32-db13-4daa-8606-0ee32d3494fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b71c965-89b1-4853-a261-b7f37c938e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f862051-bf56-4a2b-9bf4-1ee78b361e79" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b71c965-89b1-4853-a261-b7f37c938e3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3c7086af-9855-4393-b194-1000593e6412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b71c965-89b1-4853-a261-b7f37c938e3b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3c7086af-9855-4393-b194-1000593e6412" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c7086af-9855-4393-b194-1000593e6412_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3c7086af-9855-4393-b194-1000593e6412" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c7086af-9855-4393-b194-1000593e6412_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb102395-995d-4fcf-ae18-5377dca522f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3c7086af-9855-4393-b194-1000593e6412" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb102395-995d-4fcf-ae18-5377dca522f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3e5fdc4c-befb-4793-8fdf-d3733561af05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb102395-995d-4fcf-ae18-5377dca522f1" xlink:to="loc_us-gaap_CommercialPaperMember_3e5fdc4c-befb-4793-8fdf-d3733561af05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_32d87417-9ecc-47b1-aebc-2d298cb9ef39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb102395-995d-4fcf-ae18-5377dca522f1" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_32d87417-9ecc-47b1-aebc-2d298cb9ef39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_dd3b737f-b82b-4a5d-8337-417074f6f37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb102395-995d-4fcf-ae18-5377dca522f1" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_dd3b737f-b82b-4a5d-8337-417074f6f37b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_8f31349a-c35f-4807-91b8-b52216b03e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb102395-995d-4fcf-ae18-5377dca522f1" xlink:to="loc_us-gaap_MunicipalBondsMember_8f31349a-c35f-4807-91b8-b52216b03e51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7a2fa62a-a481-4fc8-824b-dfba9d34344b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb102395-995d-4fcf-ae18-5377dca522f1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7a2fa62a-a481-4fc8-824b-dfba9d34344b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_ac34f4ac-69e6-4bc2-9813-2844f48c727c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb102395-995d-4fcf-ae18-5377dca522f1" xlink:to="loc_us-gaap_CertificatesOfDepositMember_ac34f4ac-69e6-4bc2-9813-2844f48c727c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_129e43e7-253b-428d-9b9e-3b4f4b16e4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b71c965-89b1-4853-a261-b7f37c938e3b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_129e43e7-253b-428d-9b9e-3b4f4b16e4b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_129e43e7-253b-428d-9b9e-3b4f4b16e4b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_129e43e7-253b-428d-9b9e-3b4f4b16e4b1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_129e43e7-253b-428d-9b9e-3b4f4b16e4b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0d52be1-e825-443b-805b-fa7ddb040682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_129e43e7-253b-428d-9b9e-3b4f4b16e4b1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0d52be1-e825-443b-805b-fa7ddb040682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7b14c9c2-ea0f-4ea9-9a3c-30c24cc778c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0d52be1-e825-443b-805b-fa7ddb040682" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7b14c9c2-ea0f-4ea9-9a3c-30c24cc778c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1619d4c5-2ae0-4b20-bd01-d86781491b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0d52be1-e825-443b-805b-fa7ddb040682" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1619d4c5-2ae0-4b20-bd01-d86781491b92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_daacdd23-2226-42b2-9e4d-e5e85bcd97ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b71c965-89b1-4853-a261-b7f37c938e3b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_daacdd23-2226-42b2-9e4d-e5e85bcd97ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_daacdd23-2226-42b2-9e4d-e5e85bcd97ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_daacdd23-2226-42b2-9e4d-e5e85bcd97ce" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_daacdd23-2226-42b2-9e4d-e5e85bcd97ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c3d1e945-bf53-4fa0-b37c-a18c0634e624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_daacdd23-2226-42b2-9e4d-e5e85bcd97ce" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c3d1e945-bf53-4fa0-b37c-a18c0634e624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_39ea89e7-688a-4408-a691-e764b614aa33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c3d1e945-bf53-4fa0-b37c-a18c0634e624" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_39ea89e7-688a-4408-a691-e764b614aa33" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#FairValueMeasurementsNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="extended" id="i5c1f62e4f10344029e8602723fedf917_FairValueMeasurementsNarrativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c41b9555-8283-46df-921f-8ddf55763756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_1d1021df-cc61-4869-91e0-487420ee1ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c41b9555-8283-46df-921f-8ddf55763756" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_1d1021df-cc61-4869-91e0-487420ee1ad0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_760d75cb-e3f7-4d94-9ba0-7932bcfd8449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c41b9555-8283-46df-921f-8ddf55763756" xlink:to="loc_us-gaap_DerivativeNotionalAmount_760d75cb-e3f7-4d94-9ba0-7932bcfd8449" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_fa464a9c-65e9-4242-9da8-81f72460cabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c41b9555-8283-46df-921f-8ddf55763756" xlink:to="loc_us-gaap_DerivativeTermOfContract_fa464a9c-65e9-4242-9da8-81f72460cabf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_a5cbf59e-9678-4b5e-aceb-e006283f0907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c41b9555-8283-46df-921f-8ddf55763756" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_a5cbf59e-9678-4b5e-aceb-e006283f0907" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75017d57-ac1e-45bb-bfef-7668f8d30f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c41b9555-8283-46df-921f-8ddf55763756" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75017d57-ac1e-45bb-bfef-7668f8d30f4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_43e8437a-6b2e-4f6f-b305-f0dce3c5810e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75017d57-ac1e-45bb-bfef-7668f8d30f4a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_43e8437a-6b2e-4f6f-b305-f0dce3c5810e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_43e8437a-6b2e-4f6f-b305-f0dce3c5810e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_43e8437a-6b2e-4f6f-b305-f0dce3c5810e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_43e8437a-6b2e-4f6f-b305-f0dce3c5810e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ec313687-dd41-410f-945a-fe637c154e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_43e8437a-6b2e-4f6f-b305-f0dce3c5810e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ec313687-dd41-410f-945a-fe637c154e7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_d131eacd-b5f7-4b1a-8915-642c0052c0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ec313687-dd41-410f-945a-fe637c154e7c" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_d131eacd-b5f7-4b1a-8915-642c0052c0e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended" id="i0b460e3aed264aa8af104bb36aef29f7_InventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_c5cbdd38-1fb1-4fc0-93ed-8f73eb054ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_5fd0485c-5d38-4253-a789-ee8ac20845d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_c5cbdd38-1fb1-4fc0-93ed-8f73eb054ca2" xlink:to="loc_us-gaap_InventoryRawMaterials_5fd0485c-5d38-4253-a789-ee8ac20845d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_241d90f3-c263-4345-aa63-2a0173172334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_c5cbdd38-1fb1-4fc0-93ed-8f73eb054ca2" xlink:to="loc_us-gaap_InventoryWorkInProcess_241d90f3-c263-4345-aa63-2a0173172334" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_bb6ef5a1-c1d4-4b6e-907e-8b14104cf16a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_c5cbdd38-1fb1-4fc0-93ed-8f73eb054ca2" xlink:to="loc_us-gaap_InventoryFinishedGoods_bb6ef5a1-c1d4-4b6e-907e-8b14104cf16a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_eea68058-467d-43f2-9b28-078e226f8973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_c5cbdd38-1fb1-4fc0-93ed-8f73eb054ca2" xlink:to="loc_us-gaap_InventoryGross_eea68058-467d-43f2-9b28-078e226f8973" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_4085e3d7-819e-41c3-8af3-6809d00c810a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_c5cbdd38-1fb1-4fc0-93ed-8f73eb054ca2" xlink:to="loc_us-gaap_InventoryCurrentTable_4085e3d7-819e-41c3-8af3-6809d00c810a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_cba39496-2ef7-4e1b-9306-c5bc6dd97a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_4085e3d7-819e-41c3-8af3-6809d00c810a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_cba39496-2ef7-4e1b-9306-c5bc6dd97a08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cba39496-2ef7-4e1b-9306-c5bc6dd97a08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cba39496-2ef7-4e1b-9306-c5bc6dd97a08" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cba39496-2ef7-4e1b-9306-c5bc6dd97a08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fb942464-404d-4b9d-b921-81c48a3513a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cba39496-2ef7-4e1b-9306-c5bc6dd97a08" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fb942464-404d-4b9d-b921-81c48a3513a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_f305ab5e-a786-4f96-9569-6214dc9074a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fb942464-404d-4b9d-b921-81c48a3513a1" xlink:to="loc_us-gaap_InventoriesMember_f305ab5e-a786-4f96-9569-6214dc9074a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_34155acd-6b4a-4c6c-a422-48e66e558844" xlink:href="exel-20221230.xsd#exel_OtherLongtermAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fb942464-404d-4b9d-b921-81c48a3513a1" xlink:to="loc_exel_OtherLongtermAssetsMember_34155acd-6b4a-4c6c-a422-48e66e558844" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended" id="i68d595d7063c47eeabb2741a56690557_PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06eac9a1-fb18-42e6-a2e8-24697a220bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8fb51158-b337-4fd6-ab44-3512beda05b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06eac9a1-fb18-42e6-a2e8-24697a220bc8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8fb51158-b337-4fd6-ab44-3512beda05b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c049b88e-6728-4602-99c0-13a9415287fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06eac9a1-fb18-42e6-a2e8-24697a220bc8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c049b88e-6728-4602-99c0-13a9415287fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_93e74736-7cc8-476f-9233-25f8991011a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06eac9a1-fb18-42e6-a2e8-24697a220bc8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_93e74736-7cc8-476f-9233-25f8991011a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_49d20b93-716f-4b03-aa7a-ec932f81e957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06eac9a1-fb18-42e6-a2e8-24697a220bc8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_49d20b93-716f-4b03-aa7a-ec932f81e957" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e3489772-8b95-4551-a895-e26b8b28b52a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06eac9a1-fb18-42e6-a2e8-24697a220bc8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e3489772-8b95-4551-a895-e26b8b28b52a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a93b682d-3b10-4309-b976-110d88920a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e3489772-8b95-4551-a895-e26b8b28b52a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a93b682d-3b10-4309-b976-110d88920a23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a93b682d-3b10-4309-b976-110d88920a23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a93b682d-3b10-4309-b976-110d88920a23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a93b682d-3b10-4309-b976-110d88920a23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6fd5a78-03ad-46ac-900b-28a737711b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a93b682d-3b10-4309-b976-110d88920a23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6fd5a78-03ad-46ac-900b-28a737711b6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0e26b9a1-7b2d-49c9-932b-345ce369d614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6fd5a78-03ad-46ac-900b-28a737711b6c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0e26b9a1-7b2d-49c9-932b-345ce369d614" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_c49816af-1b85-438b-b77b-7dd8e3328092" xlink:href="exel-20221230.xsd#exel_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6fd5a78-03ad-46ac-900b-28a737711b6c" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_c49816af-1b85-438b-b77b-7dd8e3328092" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_e10aa799-e511-4a43-b370-869c98508c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6fd5a78-03ad-46ac-900b-28a737711b6c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_e10aa799-e511-4a43-b370-869c98508c05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LaboratoryEquipmentMember_7c824482-d290-42bf-b7ea-c42c5687fdc9" xlink:href="exel-20221230.xsd#exel_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6fd5a78-03ad-46ac-900b-28a737711b6c" xlink:to="loc_exel_LaboratoryEquipmentMember_7c824482-d290-42bf-b7ea-c42c5687fdc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ab804c35-8aa6-47da-9cd6-b948ae096c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6fd5a78-03ad-46ac-900b-28a737711b6c" xlink:to="loc_us-gaap_ConstructionInProgressMember_ab804c35-8aa6-47da-9cd6-b948ae096c6c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" id="i6a222de92ba64664ba393ebfe2098f67_EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a696f01-9f36-4ddb-ac2c-0a0e1e73150e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ace77a7e-0655-40b2-8967-ae8f0419074b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a696f01-9f36-4ddb-ac2c-0a0e1e73150e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ace77a7e-0655-40b2-8967-ae8f0419074b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0606f92b-1be5-4184-b5e3-836940204783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a696f01-9f36-4ddb-ac2c-0a0e1e73150e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0606f92b-1be5-4184-b5e3-836940204783" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fecef8d3-931e-409d-a3a0-29c3cad41fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0606f92b-1be5-4184-b5e3-836940204783" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fecef8d3-931e-409d-a3a0-29c3cad41fa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fecef8d3-931e-409d-a3a0-29c3cad41fa9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fecef8d3-931e-409d-a3a0-29c3cad41fa9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fecef8d3-931e-409d-a3a0-29c3cad41fa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2357fd78-9b0b-41c1-9a61-0d314ccf334e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fecef8d3-931e-409d-a3a0-29c3cad41fa9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2357fd78-9b0b-41c1-9a61-0d314ccf334e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7baf544a-8024-4cb3-adb4-bd999ecbc0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2357fd78-9b0b-41c1-9a61-0d314ccf334e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7baf544a-8024-4cb3-adb4-bd999ecbc0dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_faf54e77-5913-4bfb-b03a-84f5dbc14849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2357fd78-9b0b-41c1-9a61-0d314ccf334e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_faf54e77-5913-4bfb-b03a-84f5dbc14849" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="extended" id="i0ed6eb39e0814b3a8d3c888ec9edcf13_EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33fd64c2-7dc5-4f64-a7f6-aecd199973f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2a68b0a9-cdf8-4fdb-917c-11352c1db9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33fd64c2-7dc5-4f64-a7f6-aecd199973f8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2a68b0a9-cdf8-4fdb-917c-11352c1db9a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8c72998a-ae09-40a1-8ef6-6f18922ca205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33fd64c2-7dc5-4f64-a7f6-aecd199973f8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8c72998a-ae09-40a1-8ef6-6f18922ca205" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_632da1e1-dda1-4065-b367-8ab98ac12a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8c72998a-ae09-40a1-8ef6-6f18922ca205" xlink:to="loc_us-gaap_AwardTypeAxis_632da1e1-dda1-4065-b367-8ab98ac12a70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_632da1e1-dda1-4065-b367-8ab98ac12a70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_632da1e1-dda1-4065-b367-8ab98ac12a70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_632da1e1-dda1-4065-b367-8ab98ac12a70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abcab0ab-f915-4642-8721-62becc01beae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_632da1e1-dda1-4065-b367-8ab98ac12a70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abcab0ab-f915-4642-8721-62becc01beae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_11653cbc-2a5a-4b0a-8842-3892efc437af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abcab0ab-f915-4642-8721-62becc01beae" xlink:to="loc_us-gaap_EmployeeStockOptionMember_11653cbc-2a5a-4b0a-8842-3892efc437af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d03c88f6-52c7-43ff-9320-6750c846cd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abcab0ab-f915-4642-8721-62becc01beae" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d03c88f6-52c7-43ff-9320-6750c846cd8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ee9f413a-67da-4a01-8c25-a95021e5692a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abcab0ab-f915-4642-8721-62becc01beae" xlink:to="loc_us-gaap_PerformanceSharesMember_ee9f413a-67da-4a01-8c25-a95021e5692a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4d0350a4-ba09-44ca-8f0a-215ee4efb24c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abcab0ab-f915-4642-8721-62becc01beae" xlink:to="loc_us-gaap_EmployeeStockMember_4d0350a4-ba09-44ca-8f0a-215ee4efb24c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#EmployeeBenefitPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended" id="ibc6cf053fe9f49db96e55aeccaa5b122_EmployeeBenefitPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_acbd2bb6-39db-4700-a2dd-66c241c84d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_acbd2bb6-39db-4700-a2dd-66c241c84d03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_207ddce9-3cbf-4e4d-b159-139ee9d79aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_207ddce9-3cbf-4e4d-b159-139ee9d79aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_2849ae7b-a842-4ee7-b137-3b896d2399a5" xlink:href="exel-20221230.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_2849ae7b-a842-4ee7-b137-3b896d2399a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_1823b57f-60c9-45cf-82c7-f9e3edc924e8" xlink:href="exel-20221230.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_1823b57f-60c9-45cf-82c7-f9e3edc924e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_26fcf7fb-f070-4536-bd80-3946cceb05e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_26fcf7fb-f070-4536-bd80-3946cceb05e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_13d0cd54-fc58-4ba8-8dab-1ccf294714a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_13d0cd54-fc58-4ba8-8dab-1ccf294714a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod_8f28a148-f74b-48dc-b2d2-3e5bc8ed0430" xlink:href="exel-20221230.xsd#exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod_8f28a148-f74b-48dc-b2d2-3e5bc8ed0430" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_c02fa55c-2887-4858-b9fb-a46993e3cb65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_c02fa55c-2887-4858-b9fb-a46993e3cb65" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_4f0c9e8f-c238-45e4-bb24-fa740486370c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_4f0c9e8f-c238-45e4-bb24-fa740486370c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_84dcdb7b-3806-4580-949c-9442ea1822a6" xlink:href="exel-20221230.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_84dcdb7b-3806-4580-949c-9442ea1822a6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_38757b15-93bb-474a-a826-113e095c0730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_38757b15-93bb-474a-a826-113e095c0730" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_60f8530a-4a5c-4967-aea7-17f16ea86c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_60f8530a-4a5c-4967-aea7-17f16ea86c8d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_c4d22c9c-0845-4cf8-a5ce-3c7b706c8f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ProceedsFromStockPlans_c4d22c9c-0845-4cf8-a5ce-3c7b706c8f14" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1f2de7bc-8dd7-4b6c-8610-b9190f51f1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1f2de7bc-8dd7-4b6c-8610-b9190f51f1e4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f46edc26-cc5a-43fd-8f7d-2dd2070d5c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f46edc26-cc5a-43fd-8f7d-2dd2070d5c15" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_56e03e04-4233-446e-8714-b0684a5a9c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_56e03e04-4233-446e-8714-b0684a5a9c6a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a0e4006b-5098-4dd4-8223-5090a388222b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a0e4006b-5098-4dd4-8223-5090a388222b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3469bd59-4fa0-4bad-bc28-890fdcdf8ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3469bd59-4fa0-4bad-bc28-890fdcdf8ee2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_27f7015e-874e-4e95-ab32-97b0c771685e" xlink:href="exel-20221230.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_27f7015e-874e-4e95-ab32-97b0c771685e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_cb53f3c4-756d-4ebf-a6b7-2427ab1023ca" xlink:href="exel-20221230.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_cb53f3c4-756d-4ebf-a6b7-2427ab1023ca" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_062a83b5-0fba-41bb-a945-dfbb4a810d21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_062a83b5-0fba-41bb-a945-dfbb4a810d21" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3d15fadb-43b6-4871-a8e6-419b66eeb1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3d15fadb-43b6-4871-a8e6-419b66eeb1eb" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_d58c43f2-f8f6-42fb-b3ff-935e0463bc82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_d58c43f2-f8f6-42fb-b3ff-935e0463bc82" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f553c530-9ede-4235-b67e-76f44a607c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f553c530-9ede-4235-b67e-76f44a607c8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_47a75d1b-7b80-4527-867d-13eb43c68f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f553c530-9ede-4235-b67e-76f44a607c8c" xlink:to="loc_us-gaap_AwardTypeAxis_47a75d1b-7b80-4527-867d-13eb43c68f74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47a75d1b-7b80-4527-867d-13eb43c68f74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_47a75d1b-7b80-4527-867d-13eb43c68f74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47a75d1b-7b80-4527-867d-13eb43c68f74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbd60d73-67c2-4eb4-83a0-59bfda5e5698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_47a75d1b-7b80-4527-867d-13eb43c68f74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbd60d73-67c2-4eb4-83a0-59bfda5e5698" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_760a39c3-8bb2-4a27-855d-bcd2b6be4938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbd60d73-67c2-4eb4-83a0-59bfda5e5698" xlink:to="loc_us-gaap_EmployeeStockOptionMember_760a39c3-8bb2-4a27-855d-bcd2b6be4938" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_af63b5c9-26a5-4e68-95e9-ea0c934e2426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbd60d73-67c2-4eb4-83a0-59bfda5e5698" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_af63b5c9-26a5-4e68-95e9-ea0c934e2426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember_62271758-2f86-4c56-8b40-60b8c3d2129c" xlink:href="exel-20221230.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_af63b5c9-26a5-4e68-95e9-ea0c934e2426" xlink:to="loc_exel_TSRBasedRestrictedStockUnitsMember_62271758-2f86-4c56-8b40-60b8c3d2129c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_9c59aaa6-a8f5-4888-aa4b-52bfd89ca529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbd60d73-67c2-4eb4-83a0-59bfda5e5698" xlink:to="loc_us-gaap_EmployeeStockMember_9c59aaa6-a8f5-4888-aa4b-52bfd89ca529" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a257ded9-c78c-4b5a-8ffe-a0c2a16c8036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbd60d73-67c2-4eb4-83a0-59bfda5e5698" xlink:to="loc_us-gaap_PerformanceSharesMember_a257ded9-c78c-4b5a-8ffe-a0c2a16c8036" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesClinicalTrialResultsMember_b09beb82-b71c-4a60-90a5-a243426860ae" xlink:href="exel-20221230.xsd#exel_PerformanceSharesClinicalTrialResultsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PerformanceSharesMember_a257ded9-c78c-4b5a-8ffe-a0c2a16c8036" xlink:to="loc_exel_PerformanceSharesClinicalTrialResultsMember_b09beb82-b71c-4a60-90a5-a243426860ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_0aac8247-a9ab-4d01-a17d-08e6201243d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f553c530-9ede-4235-b67e-76f44a607c8c" xlink:to="loc_us-gaap_GranteeStatusAxis_0aac8247-a9ab-4d01-a17d-08e6201243d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_0aac8247-a9ab-4d01-a17d-08e6201243d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_0aac8247-a9ab-4d01-a17d-08e6201243d2" xlink:to="loc_us-gaap_GranteeStatusDomain_0aac8247-a9ab-4d01-a17d-08e6201243d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_8b8e1b82-1c97-4d48-9d54-4520ed2954b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_0aac8247-a9ab-4d01-a17d-08e6201243d2" xlink:to="loc_us-gaap_GranteeStatusDomain_8b8e1b82-1c97-4d48-9d54-4520ed2954b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_566163b2-e06b-4032-8f1e-ecb5c65888b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_8b8e1b82-1c97-4d48-9d54-4520ed2954b0" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_566163b2-e06b-4032-8f1e-ecb5c65888b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_73357a2f-abd8-467e-b362-3676d8ec7458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_8b8e1b82-1c97-4d48-9d54-4520ed2954b0" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_73357a2f-abd8-467e-b362-3676d8ec7458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3e295b35-3706-41ea-8d27-8130742b03a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f553c530-9ede-4235-b67e-76f44a607c8c" xlink:to="loc_srt_RangeAxis_3e295b35-3706-41ea-8d27-8130742b03a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3e295b35-3706-41ea-8d27-8130742b03a0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3e295b35-3706-41ea-8d27-8130742b03a0" xlink:to="loc_srt_RangeMember_3e295b35-3706-41ea-8d27-8130742b03a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d4d47c3-4cfe-4a63-af9d-9fe7b4d91d58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3e295b35-3706-41ea-8d27-8130742b03a0" xlink:to="loc_srt_RangeMember_5d4d47c3-4cfe-4a63-af9d-9fe7b4d91d58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cd9f18b6-6584-4f0d-a3c7-1cb1758efed0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5d4d47c3-4cfe-4a63-af9d-9fe7b4d91d58" xlink:to="loc_srt_MinimumMember_cd9f18b6-6584-4f0d-a3c7-1cb1758efed0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7a9d7177-6a78-412d-8365-8f15a0793a19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5d4d47c3-4cfe-4a63-af9d-9fe7b4d91d58" xlink:to="loc_srt_MaximumMember_7a9d7177-6a78-412d-8365-8f15a0793a19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_6ade20b6-f6c7-422d-91fe-f8589116cfa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f553c530-9ede-4235-b67e-76f44a607c8c" xlink:to="loc_us-gaap_VestingAxis_6ade20b6-f6c7-422d-91fe-f8589116cfa6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_6ade20b6-f6c7-422d-91fe-f8589116cfa6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_6ade20b6-f6c7-422d-91fe-f8589116cfa6" xlink:to="loc_us-gaap_VestingDomain_6ade20b6-f6c7-422d-91fe-f8589116cfa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_62fc6285-93e7-4bba-b825-671dfb13d772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_6ade20b6-f6c7-422d-91fe-f8589116cfa6" xlink:to="loc_us-gaap_VestingDomain_62fc6285-93e7-4bba-b825-671dfb13d772" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_41b6b9c9-319b-45c9-8a93-9f8ecfc6ef3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_62fc6285-93e7-4bba-b825-671dfb13d772" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_41b6b9c9-319b-45c9-8a93-9f8ecfc6ef3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis_364a3a67-d39c-4464-974c-814e914e607f" xlink:href="exel-20221230.xsd#exel_StatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f553c530-9ede-4235-b67e-76f44a607c8c" xlink:to="loc_exel_StatusAxis_364a3a67-d39c-4464-974c-814e914e607f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_364a3a67-d39c-4464-974c-814e914e607f_default" xlink:href="exel-20221230.xsd#exel_StatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_StatusAxis_364a3a67-d39c-4464-974c-814e914e607f" xlink:to="loc_exel_StatusDomain_364a3a67-d39c-4464-974c-814e914e607f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_7a93fcee-d666-4556-ab89-e0cb373b31b8" xlink:href="exel-20221230.xsd#exel_StatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_StatusAxis_364a3a67-d39c-4464-974c-814e914e607f" xlink:to="loc_exel_StatusDomain_7a93fcee-d666-4556-ab89-e0cb373b31b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedMember_76288c2d-427d-4be3-a635-3a56b0008fb5" xlink:href="exel-20221230.xsd#exel_AchievedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_7a93fcee-d666-4556-ab89-e0cb373b31b8" xlink:to="loc_exel_AchievedMember_76288c2d-427d-4be3-a635-3a56b0008fb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember_255f0578-a624-413c-8467-57f61643ff4b" xlink:href="exel-20221230.xsd#exel_ProbableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_7a93fcee-d666-4556-ab89-e0cb373b31b8" xlink:to="loc_exel_ProbableMember_255f0578-a624-413c-8467-57f61643ff4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NotProbableMember_a912766b-b070-4c6c-a60b-b0c68dfce68c" xlink:href="exel-20221230.xsd#exel_NotProbableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_7a93fcee-d666-4556-ab89-e0cb373b31b8" xlink:to="loc_exel_NotProbableMember_a912766b-b070-4c6c-a60b-b0c68dfce68c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_13a8b687-5238-4acd-85bc-9454639ce6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f553c530-9ede-4235-b67e-76f44a607c8c" xlink:to="loc_us-gaap_PlanNameAxis_13a8b687-5238-4acd-85bc-9454639ce6cc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_13a8b687-5238-4acd-85bc-9454639ce6cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_13a8b687-5238-4acd-85bc-9454639ce6cc" xlink:to="loc_us-gaap_PlanNameDomain_13a8b687-5238-4acd-85bc-9454639ce6cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_59acb091-d037-4955-a309-1ee3b4535061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_13a8b687-5238-4acd-85bc-9454639ce6cc" xlink:to="loc_us-gaap_PlanNameDomain_59acb091-d037-4955-a309-1ee3b4535061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AmendedAndRestated2017EquityIncentivePlanMember_eef16a91-1f23-4b7e-8ca0-9d0dee8f1743" xlink:href="exel-20221230.xsd#exel_AmendedAndRestated2017EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_59acb091-d037-4955-a309-1ee3b4535061" xlink:to="loc_exel_AmendedAndRestated2017EquityIncentivePlanMember_eef16a91-1f23-4b7e-8ca0-9d0dee8f1743" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="extended" id="iaa203ed7b9d44179aff9ec89c68cccb1_EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4acd2206-04c8-459c-a85c-86d1cf9b4c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a4e55dba-d20a-420f-ac93-eb2244cb9b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4acd2206-04c8-459c-a85c-86d1cf9b4c88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a4e55dba-d20a-420f-ac93-eb2244cb9b4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f5247242-c917-4bee-adc6-020130a6b661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4acd2206-04c8-459c-a85c-86d1cf9b4c88" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f5247242-c917-4bee-adc6-020130a6b661" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8f7a6190-9808-4543-b9c8-275dc5e8105e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f5247242-c917-4bee-adc6-020130a6b661" xlink:to="loc_us-gaap_AwardTypeAxis_8f7a6190-9808-4543-b9c8-275dc5e8105e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f7a6190-9808-4543-b9c8-275dc5e8105e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8f7a6190-9808-4543-b9c8-275dc5e8105e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f7a6190-9808-4543-b9c8-275dc5e8105e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_edf8ca71-dfc5-4639-bf34-b8ea9030c8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8f7a6190-9808-4543-b9c8-275dc5e8105e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_edf8ca71-dfc5-4639-bf34-b8ea9030c8fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b9918b5a-8b8b-4f57-8e63-5cec8d170885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_edf8ca71-dfc5-4639-bf34-b8ea9030c8fa" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b9918b5a-8b8b-4f57-8e63-5cec8d170885" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_edd4dd49-a9b2-44f2-8167-433d7faa41cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_edf8ca71-dfc5-4639-bf34-b8ea9030c8fa" xlink:to="loc_us-gaap_EmployeeStockMember_edd4dd49-a9b2-44f2-8167-433d7faa41cb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails" xlink:type="extended" id="i26c1d7cfdec245169f1fd95b90ccb805_EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24df2f66-82ed-4839-9bf9-c11a29fc7b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1208981f-a793-4152-a87c-b082af2b60ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24df2f66-82ed-4839-9bf9-c11a29fc7b53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1208981f-a793-4152-a87c-b082af2b60ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b7712890-29b5-48ca-9cc8-64a2620b3723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24df2f66-82ed-4839-9bf9-c11a29fc7b53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b7712890-29b5-48ca-9cc8-64a2620b3723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_acb17905-7d47-451e-a4e2-5a9cef80f038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24df2f66-82ed-4839-9bf9-c11a29fc7b53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_acb17905-7d47-451e-a4e2-5a9cef80f038" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_422df7ef-a0bc-4abe-b0c5-4c36ab0642b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24df2f66-82ed-4839-9bf9-c11a29fc7b53" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_422df7ef-a0bc-4abe-b0c5-4c36ab0642b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b154560b-221d-4610-89d9-44d8593ddaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24df2f66-82ed-4839-9bf9-c11a29fc7b53" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b154560b-221d-4610-89d9-44d8593ddaf8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d40736c8-e6fe-445b-98d4-18073c58135c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b154560b-221d-4610-89d9-44d8593ddaf8" xlink:to="loc_us-gaap_AwardTypeAxis_d40736c8-e6fe-445b-98d4-18073c58135c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d40736c8-e6fe-445b-98d4-18073c58135c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d40736c8-e6fe-445b-98d4-18073c58135c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d40736c8-e6fe-445b-98d4-18073c58135c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87a784e1-3957-4929-b9e3-a649e58fc781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d40736c8-e6fe-445b-98d4-18073c58135c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87a784e1-3957-4929-b9e3-a649e58fc781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_03c50b38-1b84-463a-a9f4-0342ae14d7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87a784e1-3957-4929-b9e3-a649e58fc781" xlink:to="loc_us-gaap_EmployeeStockOptionMember_03c50b38-1b84-463a-a9f4-0342ae14d7fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d86f7f94-8cf4-4251-83d2-6f2b7d25f530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87a784e1-3957-4929-b9e3-a649e58fc781" xlink:to="loc_us-gaap_EmployeeStockMember_d86f7f94-8cf4-4251-83d2-6f2b7d25f530" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails" xlink:type="extended" id="if2f7bb0ddd3c4d92b4d419936b735274_EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53c5f8e-c235-452a-930e-4c936f70e0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b134f802-7850-463c-969b-b35763876091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53c5f8e-c235-452a-930e-4c936f70e0eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b134f802-7850-463c-969b-b35763876091" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_983470d2-e729-4e38-a2ee-d0c861b903d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b134f802-7850-463c-969b-b35763876091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_983470d2-e729-4e38-a2ee-d0c861b903d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d6eeae65-bb8e-4664-afe2-67e6440b975d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b134f802-7850-463c-969b-b35763876091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d6eeae65-bb8e-4664-afe2-67e6440b975d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_7e3b1de1-a60b-4ca3-81b2-8cb6babe621b" xlink:href="exel-20221230.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b134f802-7850-463c-969b-b35763876091" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_7e3b1de1-a60b-4ca3-81b2-8cb6babe621b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cb50aae7-ad00-4cf1-99a7-64ed5e0ed4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b134f802-7850-463c-969b-b35763876091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cb50aae7-ad00-4cf1-99a7-64ed5e0ed4df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9111c134-4a2d-474a-b521-bcdb5adc9155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a19aa777-441b-433c-b7c0-3d23f56ab7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53c5f8e-c235-452a-930e-4c936f70e0eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a19aa777-441b-433c-b7c0-3d23f56ab7ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f55e01df-d6ea-4774-89c2-158fd85eee77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a19aa777-441b-433c-b7c0-3d23f56ab7ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f55e01df-d6ea-4774-89c2-158fd85eee77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_291cb7c1-d50e-44c0-a6ed-48ea90150f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a19aa777-441b-433c-b7c0-3d23f56ab7ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_291cb7c1-d50e-44c0-a6ed-48ea90150f86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_eab232b7-2a49-4f6b-8f97-3a767c58e124" xlink:href="exel-20221230.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a19aa777-441b-433c-b7c0-3d23f56ab7ea" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_eab232b7-2a49-4f6b-8f97-3a767c58e124" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8f34b14c-318c-42cb-8448-a704fa025886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a19aa777-441b-433c-b7c0-3d23f56ab7ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8f34b14c-318c-42cb-8448-a704fa025886" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_50a65e8c-21d9-4576-a836-b81f44858df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_29985248-6644-4548-ad23-6adc3d2855bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53c5f8e-c235-452a-930e-4c936f70e0eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_29985248-6644-4548-ad23-6adc3d2855bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_06cfebff-9cf6-4c56-bc37-bb14d4957976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53c5f8e-c235-452a-930e-4c936f70e0eb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_06cfebff-9cf6-4c56-bc37-bb14d4957976" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_788d2f3b-cf15-4511-8405-3fc59d2d156c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53c5f8e-c235-452a-930e-4c936f70e0eb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_788d2f3b-cf15-4511-8405-3fc59d2d156c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d8c801b0-d9dd-4b4d-937e-7624add467d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_788d2f3b-cf15-4511-8405-3fc59d2d156c" xlink:to="loc_us-gaap_AwardTypeAxis_d8c801b0-d9dd-4b4d-937e-7624add467d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8c801b0-d9dd-4b4d-937e-7624add467d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d8c801b0-d9dd-4b4d-937e-7624add467d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8c801b0-d9dd-4b4d-937e-7624add467d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58557ca9-d4dd-4c75-a7cc-22f9e1fdd0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d8c801b0-d9dd-4b4d-937e-7624add467d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58557ca9-d4dd-4c75-a7cc-22f9e1fdd0e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_81c19d87-c375-4b17-9ead-9e194066dfd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58557ca9-d4dd-4c75-a7cc-22f9e1fdd0e8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_81c19d87-c375-4b17-9ead-9e194066dfd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_fca37f6f-f609-4280-a231-f94a8b92e8de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58557ca9-d4dd-4c75-a7cc-22f9e1fdd0e8" xlink:to="loc_us-gaap_PerformanceSharesMember_fca37f6f-f609-4280-a231-f94a8b92e8de" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#EmployeeBenefitPlansEstimateGrantDateFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails" xlink:type="extended" id="i57ece9b2250b4e4bbca31e90ce0300f8_EmployeeBenefitPlansEstimateGrantDateFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_607e5d64-f4a6-4ab2-9485-34ecaa333645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1e5f5b8e-422d-4aaf-9162-8007d0a3938c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_607e5d64-f4a6-4ab2-9485-34ecaa333645" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1e5f5b8e-422d-4aaf-9162-8007d0a3938c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_82f6bb66-e1eb-4683-843c-a5b00f673ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_607e5d64-f4a6-4ab2-9485-34ecaa333645" xlink:to="loc_us-gaap_SharePrice_82f6bb66-e1eb-4683-843c-a5b00f673ddf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_868ffd41-5644-4c27-b575-6989ad76a5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_607e5d64-f4a6-4ab2-9485-34ecaa333645" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_868ffd41-5644-4c27-b575-6989ad76a5d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_050f5ee6-3601-486b-8a8e-791844d81620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_607e5d64-f4a6-4ab2-9485-34ecaa333645" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_050f5ee6-3601-486b-8a8e-791844d81620" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_33050762-009f-4b5c-8390-0934dc046109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_607e5d64-f4a6-4ab2-9485-34ecaa333645" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_33050762-009f-4b5c-8390-0934dc046109" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca73dd9a-6481-4c59-945b-956f2a42493b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_607e5d64-f4a6-4ab2-9485-34ecaa333645" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca73dd9a-6481-4c59-945b-956f2a42493b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_efd50a76-3286-4ad3-88cf-e93f299d21a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca73dd9a-6481-4c59-945b-956f2a42493b" xlink:to="loc_us-gaap_AwardTypeAxis_efd50a76-3286-4ad3-88cf-e93f299d21a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_efd50a76-3286-4ad3-88cf-e93f299d21a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_efd50a76-3286-4ad3-88cf-e93f299d21a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_efd50a76-3286-4ad3-88cf-e93f299d21a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01c2d8bd-21f2-4476-a546-b0db8b2e24b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_efd50a76-3286-4ad3-88cf-e93f299d21a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01c2d8bd-21f2-4476-a546-b0db8b2e24b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d4c6ddd0-97b9-4716-9b90-4cf6ccf04d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01c2d8bd-21f2-4476-a546-b0db8b2e24b8" xlink:to="loc_us-gaap_PerformanceSharesMember_d4c6ddd0-97b9-4716-9b90-4cf6ccf04d03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember_dff898e7-ebac-48c9-bb39-7e2c2d46d8f7" xlink:href="exel-20221230.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01c2d8bd-21f2-4476-a546-b0db8b2e24b8" xlink:to="loc_exel_TSRBasedRestrictedStockUnitsMember_dff898e7-ebac-48c9-bb39-7e2c2d46d8f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_c20888a4-e625-4dae-9f90-0087029fffc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca73dd9a-6481-4c59-945b-956f2a42493b" xlink:to="loc_us-gaap_AwardDateAxis_c20888a4-e625-4dae-9f90-0087029fffc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_c20888a4-e625-4dae-9f90-0087029fffc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_c20888a4-e625-4dae-9f90-0087029fffc5" xlink:to="loc_us-gaap_AwardDateDomain_c20888a4-e625-4dae-9f90-0087029fffc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_b2690784-b142-4a75-b3ef-f3ea492353f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_c20888a4-e625-4dae-9f90-0087029fffc5" xlink:to="loc_us-gaap_AwardDateDomain_b2690784-b142-4a75-b3ef-f3ea492353f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_A2021AwardsMember_9975f097-e429-4a95-af87-f41888c20011" xlink:href="exel-20221230.xsd#exel_A2021AwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_b2690784-b142-4a75-b3ef-f3ea492353f1" xlink:to="loc_exel_A2021AwardsMember_9975f097-e429-4a95-af87-f41888c20011" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#ProvisionForIncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails" xlink:type="extended" id="i66963c4df7014fac87f2c8c757d45cac_ProvisionForIncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_74bb8fed-8eac-405d-86d3-9e60fa7964a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_74bb8fed-8eac-405d-86d3-9e60fa7964a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_115cd507-af77-406f-a5cd-791901adfda6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_115cd507-af77-406f-a5cd-791901adfda6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_d076d8fb-a88d-478c-b20c-e08f43ca35dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:to="loc_us-gaap_OperatingLossCarryforwards_d076d8fb-a88d-478c-b20c-e08f43ca35dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_346ca060-7255-4418-940f-f34e0dc7ceb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_346ca060-7255-4418-940f-f34e0dc7ceb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_ce3fdcf3-901f-40ef-88fe-ee8a38cdc5dc" xlink:href="exel-20221230.xsd#exel_TaxCreditCarryforwardAmountWithExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:to="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_ce3fdcf3-901f-40ef-88fe-ee8a38cdc5dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_17ecadcc-1345-4db7-877e-36ba89edaa81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_17ecadcc-1345-4db7-877e-36ba89edaa81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ff2d9373-f7bf-4146-85fe-facc3ed04a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ff2d9373-f7bf-4146-85fe-facc3ed04a2c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_8b904e1c-55f2-4c70-ac15-6bd816452d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_8b904e1c-55f2-4c70-ac15-6bd816452d2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6c98b1b8-35d4-4091-a23c-27ca211db46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_8b904e1c-55f2-4c70-ac15-6bd816452d2d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6c98b1b8-35d4-4091-a23c-27ca211db46d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6c98b1b8-35d4-4091-a23c-27ca211db46d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6c98b1b8-35d4-4091-a23c-27ca211db46d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6c98b1b8-35d4-4091-a23c-27ca211db46d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1c160fe1-6f01-45db-88f4-76162691e287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6c98b1b8-35d4-4091-a23c-27ca211db46d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1c160fe1-6f01-45db-88f4-76162691e287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_03319fba-5b72-4d30-9389-8510db219548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1c160fe1-6f01-45db-88f4-76162691e287" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_03319fba-5b72-4d30-9389-8510db219548" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_f16037b6-6dc1-4045-afdc-fafa05ecd6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_8b904e1c-55f2-4c70-ac15-6bd816452d2d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_f16037b6-6dc1-4045-afdc-fafa05ecd6ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f16037b6-6dc1-4045-afdc-fafa05ecd6ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_f16037b6-6dc1-4045-afdc-fafa05ecd6ed" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f16037b6-6dc1-4045-afdc-fafa05ecd6ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_ff1eba36-9efe-4675-9f42-f1a2c7f1bae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_f16037b6-6dc1-4045-afdc-fafa05ecd6ed" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_ff1eba36-9efe-4675-9f42-f1a2c7f1bae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_edf41724-005d-4561-88dd-01f357406b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_ff1eba36-9efe-4675-9f42-f1a2c7f1bae2" xlink:to="loc_us-gaap_ResearchMember_edf41724-005d-4561-88dd-01f357406b29" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails" xlink:type="extended" id="i095abe00276b4ee493571bc062f9e6ba_NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b3de7e08-b1a2-4cb9-877f-42626d85f86a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c14263c6-0346-4205-81a1-64766448750c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b3de7e08-b1a2-4cb9-877f-42626d85f86a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c14263c6-0346-4205-81a1-64766448750c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_42496853-1ef3-4fb0-b94b-00cb3e787993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b3de7e08-b1a2-4cb9-877f-42626d85f86a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_42496853-1ef3-4fb0-b94b-00cb3e787993" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8fb4ea12-621f-4c9b-8706-7550aabce282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_42496853-1ef3-4fb0-b94b-00cb3e787993" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8fb4ea12-621f-4c9b-8706-7550aabce282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8fb4ea12-621f-4c9b-8706-7550aabce282_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8fb4ea12-621f-4c9b-8706-7550aabce282" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8fb4ea12-621f-4c9b-8706-7550aabce282_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad47a1c-eb90-4315-8b07-77b05d7f8f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8fb4ea12-621f-4c9b-8706-7550aabce282" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad47a1c-eb90-4315-8b07-77b05d7f8f10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_60214c48-796a-494a-9665-c96f37a1dd61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad47a1c-eb90-4315-8b07-77b05d7f8f10" xlink:to="loc_us-gaap_StockCompensationPlanMember_60214c48-796a-494a-9665-c96f37a1dd61" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i6fe9df0241f1446797eda8f413a81493_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9b502d5-a40b-43d5-a1cb-049a918485c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_e2278d6d-c646-404b-91ff-8caf79171612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9b502d5-a40b-43d5-a1cb-049a918485c3" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_e2278d6d-c646-404b-91ff-8caf79171612" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_c1cd89e7-e8c5-4718-b9d7-8194bc089231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9b502d5-a40b-43d5-a1cb-049a918485c3" xlink:to="loc_us-gaap_OperatingLeasePayments_c1cd89e7-e8c5-4718-b9d7-8194bc089231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c6b23761-a3c9-4eaf-9ee0-e4872c84c1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9b502d5-a40b-43d5-a1cb-049a918485c3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c6b23761-a3c9-4eaf-9ee0-e4872c84c1f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_060bdcb6-c191-4fa9-aa66-8678e04fc258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9b502d5-a40b-43d5-a1cb-049a918485c3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_060bdcb6-c191-4fa9-aa66-8678e04fc258" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_bc8bf9e7-8a5f-483d-9426-e25ab4285086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9b502d5-a40b-43d5-a1cb-049a918485c3" xlink:to="loc_us-gaap_ShortTermLeaseCost_bc8bf9e7-8a5f-483d-9426-e25ab4285086" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LossContingencyNumberOfLawsuitsConsolidated_9476a668-4594-483d-b34d-ffa2e9433388" xlink:href="exel-20221230.xsd#exel_LossContingencyNumberOfLawsuitsConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9b502d5-a40b-43d5-a1cb-049a918485c3" xlink:to="loc_exel_LossContingencyNumberOfLawsuitsConsolidated_9476a668-4594-483d-b34d-ffa2e9433388" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_c7f69278-cb9e-4dab-9b82-599df8c6d399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9b502d5-a40b-43d5-a1cb-049a918485c3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_c7f69278-cb9e-4dab-9b82-599df8c6d399" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis_b074ce47-8589-49e4-ac26-3eafd55713a0" xlink:href="exel-20221230.xsd#exel_LeaseArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c7f69278-cb9e-4dab-9b82-599df8c6d399" xlink:to="loc_exel_LeaseArrangementsAxis_b074ce47-8589-49e4-ac26-3eafd55713a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_b074ce47-8589-49e4-ac26-3eafd55713a0_default" xlink:href="exel-20221230.xsd#exel_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_LeaseArrangementsAxis_b074ce47-8589-49e4-ac26-3eafd55713a0" xlink:to="loc_exel_LeaseArrangementsDomain_b074ce47-8589-49e4-ac26-3eafd55713a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_5f1ff9e3-8728-4a69-81d8-331e8860508b" xlink:href="exel-20221230.xsd#exel_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_LeaseArrangementsAxis_b074ce47-8589-49e4-ac26-3eafd55713a0" xlink:to="loc_exel_LeaseArrangementsDomain_5f1ff9e3-8728-4a69-81d8-331e8860508b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLeaseMember_e3c69fb9-1490-4ead-863e-550ca6376c7e" xlink:href="exel-20221230.xsd#exel_HeadquartersLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_LeaseArrangementsDomain_5f1ff9e3-8728-4a69-81d8-331e8860508b" xlink:to="loc_exel_HeadquartersLeaseMember_e3c69fb9-1490-4ead-863e-550ca6376c7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember_96a89903-5146-4b39-ab8f-563f28607b31" xlink:href="exel-20221230.xsd#exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_LeaseArrangementsDomain_5f1ff9e3-8728-4a69-81d8-331e8860508b" xlink:to="loc_exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember_96a89903-5146-4b39-ab8f-563f28607b31" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseRightOfUseAssetAndOtherAssets_9a71842f-21fa-4d74-9843-2d1c6c11b176" xlink:href="exel-20221230.xsd#exel_OperatingLeaseRightOfUseAssetAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_exel_OperatingLeaseRightOfUseAssetAndOtherAssets_9a71842f-21fa-4d74-9843-2d1c6c11b176" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>exel-20221230_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:72618e96-9a19-4b18-ab04-d375d7716d96,g:fc8ea608-bee1-4b83-89de-139db7d65bef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_51120b7c-5dd0-4971-b591-f528c396d7d1_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProbableMember_220747f9-c592-4483-8311-d6e1ed9a0121_terseLabel_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable</link:label>
    <link:label id="lab_exel_ProbableMember_label_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable [Member]</link:label>
    <link:label id="lab_exel_ProbableMember_documentation_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember" xlink:href="exel-20221230.xsd#exel_ProbableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProbableMember" xlink:to="lab_exel_ProbableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd10c778-e8d2-4886-883d-02e8803977c2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9d133bb-ff11-4b58-8741-4db1ede180dc_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_d56b5e0e-2560-4469-9de4-330c1517cb33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e030ca13-f557-4268-a00b-15da7c9966b2_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Remeasurement</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_60f5a3c5-3dbd-4ed5-a51a-1bb21a26cb95_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_e17011ed-9c9f-462c-b881-5fbc7943b452_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_51c59faa-ffc7-4afc-ab85-97bb02bf0a2f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_3ed3c564-1040-447d-b19e-2d9346955575_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of leased property (in sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_c3291be7-345a-407e-867e-47722239c58e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_42f64210-c53f-4dc1-8e7a-52d51e7302fd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5dc0791-4b4c-46a1-bc1b-779ca3ee52a8_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_ea9da698-b9ba-49d1-997b-594a32cc2e55_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_bddaf548-7913-4e24-8a5b-95b000d608dd_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_label_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:href="exel-20221230.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:to="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IpsenMember_8bf09271-0cdf-499f-88b3-2d1cab2590c3_terseLabel_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Pharma SAS</link:label>
    <link:label id="lab_exel_IpsenMember_label_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_documentation_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember" xlink:href="exel-20221230.xsd#exel_IpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember" xlink:to="lab_exel_IpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_bed7d213-5957-4ecc-a79e-5ee2d3939e10_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_bd5c81ca-62f4-4a8f-82a4-358f45fb11dd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and customer credits issued</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_84e994cb-d2b4-4069-a194-52b88dff866f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_bff2de95-fe9a-4eeb-8207-b92cf7f44013_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_c9b75f48-cfed-4e91-b9a5-4510f7c09307_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_9019a4eb-35af-4584-bfb7-fdc5995741e2_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized for performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_9436696d-9d63-4ce7-9741-5a5f466a3632_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future development milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a3ae888e-8169-433b-8795-8ee626d49ddf_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_86a553dd-14cc-417f-8569-041132569241_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development technology</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4a797429-afed-43ba-a264-f55dfe9ee5c7_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_4b39f5dd-5355-4328-a274-df3b53c91c51_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a5717b2b-4666-4657-9148-cccafe7e0667_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_5fa263f7-0077-4c4f-896d-470576df269d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c597cdae-196a-4307-aaa8-e5c395d6748f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average operating discount rate used to determine the operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bb193ae1-8a63-45a9-94fd-9fa2e031071f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_e39a8846-803d-4036-bf69-5756feacf87b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions based on the lapse of the applicable statutes of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_74783dd2-f0d1-41fc-a024-65f0ebd0da77_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6208cd67-32ef-45fe-9955-7329c2c53fa4_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OtherLongtermAssetsMember_ea3d4e41-98ee-4aaf-9275-e5e439bc4a12_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion included in other long-term assets</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember" xlink:href="exel-20221230.xsd#exel_OtherLongtermAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember" xlink:to="lab_exel_OtherLongtermAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_267d8724-f1e6-43c0-b570-40ed8592312a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6f0b1492-8950-485b-b9e7-d0ea91e2766b_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2d45811e-8926-4b2c-81b1-8168e75b4833_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_67b8359e-97b5-4ef7-977c-d3b7859b84ac_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_c519e226-60ab-4b94-9337-404a9579d712_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:href="exel-20221230.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e071dd12-4501-462d-9a77-9d0a13718c82_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_aa17d6f4-eeb1-4f96-8d71-f0ea0af538fe_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_de0a1656-e1f4-44e0-9e89-6dac81e5c4f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_4a415765-b7c3-4f86-9e85-b423187c8f2c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_05edba71-8098-4146-ba90-a189ddcb5fe7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities and contingently issuable shares excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f486a5e3-e5f7-4783-8336-a8c3cf848e7c_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MedicarePartDFundingMandate_1c8ca74e-8499-4725-bdb6-480029a54c4a_terseLabel_en-US" xlink:label="lab_exel_MedicarePartDFundingMandate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Part D funding mandate</link:label>
    <link:label id="lab_exel_MedicarePartDFundingMandate_label_en-US" xlink:label="lab_exel_MedicarePartDFundingMandate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Part D Funding Mandate</link:label>
    <link:label id="lab_exel_MedicarePartDFundingMandate_documentation_en-US" xlink:label="lab_exel_MedicarePartDFundingMandate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Part D Funding Mandate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MedicarePartDFundingMandate" xlink:href="exel-20221230.xsd#exel_MedicarePartDFundingMandate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MedicarePartDFundingMandate" xlink:to="lab_exel_MedicarePartDFundingMandate" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_HeadquartersLeaseMember_e035c9f9-a3aa-4686-9248-1ff26dd262a1_terseLabel_en-US" xlink:label="lab_exel_HeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease</link:label>
    <link:label id="lab_exel_HeadquartersLeaseMember_label_en-US" xlink:label="lab_exel_HeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease [Member]</link:label>
    <link:label id="lab_exel_HeadquartersLeaseMember_documentation_en-US" xlink:label="lab_exel_HeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLeaseMember" xlink:href="exel-20221230.xsd#exel_HeadquartersLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_HeadquartersLeaseMember" xlink:to="lab_exel_HeadquartersLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_c1491eba-ec83-47b8-9fbc-db96f3e18738_terseLabel_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_label_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_documentation_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember" xlink:href="exel-20221230.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForProductRebatesMember" xlink:to="lab_exel_AllowanceForProductRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1b70fd09-82f2-4c22-b2de-1cedf0c633e3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e3e4acc7-f20f-493d-87eb-7e6f2e937191_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e1a8b0de-a3f4-4a5c-a1a0-664c0604f5ce_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_2603e362-8577-4348-8da5-5f108660b19b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock_5026d0f5-4168-46c7-848d-d217d50d4930_terseLabel_en-US" xlink:label="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Balance Sheet Classification of Lease Liabilities</link:label>
    <link:label id="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="exel-20221230.xsd#exel_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_b3c27e7d-729f-4f96-9a9c-090b2f69cc1b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_5bb19863-a228-4781-a5a4-64bf23c53455_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets carried at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_38845bc7-38d4-44d1-b473-38aa1e24782a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change relating to current year provision</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cfbfa47d-7975-4a4e-86d5-7a44473c54a3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting award percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_9a0f7ad5-0fcf-4a04-b46e-b21a2488f941_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_73777dd2-430e-4124-adfe-5c745e31a27f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c150b6e5-a669-47f1-accc-20d30b90210c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0a0fde58-9e24-4867-bc3d-65cde93652cf_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c92d52ff-2f6f-41b9-b092-c89077647248_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_78994163-0ced-485a-a87e-33005e880feb_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential regulatory milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_a3292c88-cebd-4914-a2e9-28db8316c437_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_55e460f4-0476-4be3-9539-2af43e62c35c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_282390fc-e5f6-4f90-875d-c2bff9679407_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_aca1fe60-b988-4944-919e-9e5539c0229b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_a89a9c84-547b-4c61-81b8-29dc24a394e2_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_9c05c3ad-e592-4ea8-a629-60fdeeae23a7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod_a0314b97-71e5-43b6-b542-b2fa49c9f569_terseLabel_en-US" xlink:label="lab_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of months following change in control in which an employee was terminated</link:label>
    <link:label id="lab_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod_label_en-US" xlink:label="lab_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement By Share-Based Payment Award, Termination Of Employment Following Change In Control, Period</link:label>
    <link:label id="lab_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod_documentation_en-US" xlink:label="lab_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement By Share-Based Payment Award, Termination Of Employment Following Change In Control, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" xlink:href="exel-20221230.xsd#exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" xlink:to="lab_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0e1a75eb-7322-465e-aa02-c208b440bd0a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_823c5121-e7a3-46e1-9766-3cc1657ea131_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_65385235-ebfd-4d8a-b740-dc4fadb1fab8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_66297c62-239c-46bd-84df-6ed50388d60b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_334fd900-10d3-4531-a7d7-aa7dfcbc239d_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_BioInventInternationalABBioInventMember_a0a9ad4a-eca5-40c4-9170-cf94777b5262_terseLabel_en-US" xlink:label="lab_exel_BioInventInternationalABBioInventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioInvent International AB (BioInvent)</link:label>
    <link:label id="lab_exel_BioInventInternationalABBioInventMember_label_en-US" xlink:label="lab_exel_BioInventInternationalABBioInventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioInvent International AB (BioInvent) [Member]</link:label>
    <link:label id="lab_exel_BioInventInternationalABBioInventMember_documentation_en-US" xlink:label="lab_exel_BioInventInternationalABBioInventMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioInvent International AB (BioInvent)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BioInventInternationalABBioInventMember" xlink:href="exel-20221230.xsd#exel_BioInventInternationalABBioInventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_BioInventInternationalABBioInventMember" xlink:to="lab_exel_BioInventInternationalABBioInventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c32b243e-119f-4de1-a65a-a2431db62d5c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_135e2550-c057-47ba-914b-55770cc7e8d6_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationMember_c4ce8809-05e2-44de-a6ba-ace62b3bb956_verboseLabel_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total collaboration revenues</link:label>
    <link:label id="lab_exel_CollaborationMember_label_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_exel_CollaborationMember_documentation_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember" xlink:href="exel-20221230.xsd#exel_CollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember" xlink:to="lab_exel_CollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a0805c1-f03c-4591-8dec-6c1e772bc7f2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_632b48a5-bf48-4299-898e-6a42bdd8a761_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8dde161c-fe05-40be-a9ca-adbebb8357d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_0331080b-63ac-4357-ae11-4bcb3818fc87_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2085daf9-3dae-4ffd-8104-df3e6745af18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_26da0ab4-c018-4df8-8940-85641b20e005_negatedTerseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future tenant improvement reimbursements</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:href="exel-20221230.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:to="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments_ed7ba690-ac6a-4bc6-9c12-7e0915abab6a_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional development regulatory and commercial milestones payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development, Regulatory And Commercial Milestones Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development, Regulatory And Commercial Milestones Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_5483da69-d83e-4822-97a2-4279d25227d0_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_645abce5-653e-430b-8341-e491a34f9603_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_ba9aa951-d3e1-419f-94a5-359471a1422a_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8978b73f-9bb0-4f4d-8f6d-ae775b430ced_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4ae2cbd0-6fd1-450a-ba47-d4deb12c7676_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term for operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_de074a08-c05b-4b9d-8e9a-0460a168ba98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_646c6516-01b6-441a-875b-0b43af11521f_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5a1029ae-e96b-4e8b-90a7-44eb51cff137_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_96c3ae75-ed9a-44de-8594-1d2c368f2c33_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ffd39261-502a-4688-93d0-cdf79290ce6d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_64c9fa80-6137-498b-847d-392eb0ab5eae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ffac0b41-6bf9-4869-a5ce-96d87edcdb74_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_35349e8d-a1e3-4caa-9b6e-e18772fef14b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_58cd8994-f4cc-40c1-b80f-8d21e84d45ef_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_bf8d2ada-f66b-48c6-98e5-234c33ea25c8_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_80ac7bda-0e24-4b24-9629-15e2aa9f343b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_55cdcd28-385c-46ec-82a3-1d99dbea24e0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d74210ae-8136-43bf-99d5-94ff9b9ea13d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160; Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_c528b7d5-d9de-4970-93bc-63ceed27e770_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3819c02d-3544-4bcf-ab73-1dd5b3995b9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_0ccd9334-0a18-4767-912a-b48c8df8364a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5b5aa613-af83-463b-9b0b-d187a1d57bda_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c023471a-bcc0-42d6-ac24-ee3c7e6c3aae_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_acb60cd6-499f-4d86-944e-fd9609606be8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_86a280ca-96b7-48b7-9a60-018eef9e96d9_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2e0d4e36-58ce-4179-95cc-f550ace68ad4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2b84edaa-c05f-4f0a-a159-2cb12f022fd5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_9e1353f6-da28-4137-a231-98a03591a8f1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_32899417-4d79-4d31-b831-b4ca89e0e6a5_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after stock option or stock appreciation award (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:href="exel-20221230.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_8db9c1ce-1770-469a-a571-3eb9d3448f96_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3eb0a519-9eeb-477a-af95-b902892ba1b5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_c37556b4-4b76-4c37-ac06-327a1ee74176_terseLabel_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and allowances</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:href="exel-20221230.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:to="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_165d5dea-39a7-45a1-83d1-3222ea7e3294_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_061550ff-d9d0-42c8-8829-bd11774b4402_terseLabel_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customer Credits/Fees and Co-pay Assistance</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_label_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_documentation_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:href="exel-20221230.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:to="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_5f46357b-d271-4ee5-9a1f-dffc7f907da3_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration period to achieve specified levels of commercial performance</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_label_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:to="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_10b9ac41-9ea4-4519-a991-a80e97e54c27_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LeaseArrangementsDomain_05700588-9afa-4fba-965f-8f57205511c5_terseLabel_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_exel_LeaseArrangementsDomain_label_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_exel_LeaseArrangementsDomain_documentation_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Lease Arrangements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain" xlink:href="exel-20221230.xsd#exel_LeaseArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseArrangementsDomain" xlink:to="lab_exel_LeaseArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_25bf46c6-4e1a-4bea-95a1-c3d6c52d6755_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonemployee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_c905be6e-3f90-4eba-b344-c09a32f24b7b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ef2bba0b-1b27-402b-8f6e-7928c958a64e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_87d3e5ae-c1cb-4445-a0b4-1979843a9c5e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_9cef3136-7b8a-4d6f-807f-53f8db2b12b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_dc3ba7a8-c684-421c-b903-a887ad08fa6a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_1b49b27f-1094-4e49-85df-173e21c8280b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_6a0d7a69-9a5c-40ca-ab96-7e73df1bfb3a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_01a4cbc5-6c53-49f8-9a69-70e04e5d56b0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_c7a9d179-d930-42e9-a71e-1caba0e4354e_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_31279ae6-795b-4347-b1b7-5b532e6c323c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_99031fc9-e72d-457b-bd2e-77bdc28c95b3_terseLabel_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible executive compensation</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_label_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_documentation_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:href="exel-20221230.xsd#exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:to="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_75b9baa4-5530-4a58-a02e-19201096e0d3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_ba261814-4686-481a-a8f5-a50cb5ed6f80_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_5e28fb19-bc8e-488f-85b5-f27a12b12a3e_terseLabel_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</link:label>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_label_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities [Member]</link:label>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_documentation_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:href="exel-20221230.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:to="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_01480a1e-2e62-440f-9853-1e97f916d7cd_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5e9c4b0d-9d87-4544-a90c-e73f9c56b1d1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cbf815b4-e284-4971-b736-412f7431c73c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_b0f94400-2e33-4586-a85d-8e37d9561b73_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_b77db018-3049-4caf-9880-c72394329df1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_09978973-a5e2-4b9d-8cef-082e768ed515_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:href="exel-20221230.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_c6451f54-ba6d-4a15-876e-bf79ac13b3ae_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_fe81d97b-19c2-4ffb-b999-60c7fd1e7cd7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_59efee2d-1dbe-45c6-b208-834782018383_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0faac903-68d9-4732-9902-9a038cadc847_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_c0269c2c-9fc7-437c-9baf-4123defef302_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1d3f964e-e160-4c06-9197-f408a9466c64_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_2e420577-3419-48b4-99f0-84cdf2e5e5de_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_5bc3e34f-08cf-499c-ba9b-7da92c6a4201_verboseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_60f92f49-6119-4bbb-a365-28bc7b3361e5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax impact of available-for-sale, unrealized holding gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberOfBondSecurities_05a692d5-8dcc-480e-a45f-ac50bd8be9c8_terseLabel_en-US" xlink:label="lab_exel_NumberOfBondSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of bond securities</link:label>
    <link:label id="lab_exel_NumberOfBondSecurities_label_en-US" xlink:label="lab_exel_NumberOfBondSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Bond Securities</link:label>
    <link:label id="lab_exel_NumberOfBondSecurities_documentation_en-US" xlink:label="lab_exel_NumberOfBondSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Bond Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfBondSecurities" xlink:href="exel-20221230.xsd#exel_NumberOfBondSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberOfBondSecurities" xlink:to="lab_exel_NumberOfBondSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b557457a-b19c-4b0a-81db-994cec55cc8d_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_418bd7c7-05e3-49b5-b933-dcb8110ebc3a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ac5af10-a6fd-474e-b1af-ab181299f00d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_1b0f0272-50e4-4d25-850c-1f304d36598a_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IncreaseInDilutedEarningsPerShare_c63d20c7-d7ae-4828-8715-45b9ebc41442_terseLabel_en-US" xlink:label="lab_exel_IncreaseInDilutedEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in diluted earnings per share (in dollars per share)</link:label>
    <link:label id="lab_exel_IncreaseInDilutedEarningsPerShare_label_en-US" xlink:label="lab_exel_IncreaseInDilutedEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Diluted Earnings Per Share</link:label>
    <link:label id="lab_exel_IncreaseInDilutedEarningsPerShare_documentation_en-US" xlink:label="lab_exel_IncreaseInDilutedEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Diluted Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseInDilutedEarningsPerShare" xlink:href="exel-20221230.xsd#exel_IncreaseInDilutedEarningsPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseInDilutedEarningsPerShare" xlink:to="lab_exel_IncreaseInDilutedEarningsPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6ccf28f7-71de-4157-85d9-d04162222338_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense weighted-average period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_4b131d0b-da3a-46e8-9062-212e3f194240_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ba72101b-a25c-4539-98ee-fe006a505a74_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, exercisable at end of the year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_32db0ef1-adfe-46cd-a88c-33a8a9101419_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_a4637907-5bcc-468b-9e42-400756068baf_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_label_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliatesof Optum Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliatesof Optum Specialty Pharmacy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:href="exel-20221230.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:to="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_fcd64e89-a4a7-4f49-9820-b7dd581755fc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_a7f99c90-48b0-4c73-9756-a7e4526e7299_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1ff93953-87b9-460c-8124-d41cf4aa8154_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AmendedAndRestated2017EquityIncentivePlanMember_b4c49e8a-36c3-4122-acd2-fbaf86a132d1_terseLabel_en-US" xlink:label="lab_exel_AmendedAndRestated2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2017 Equity Incentive Plan</link:label>
    <link:label id="lab_exel_AmendedAndRestated2017EquityIncentivePlanMember_label_en-US" xlink:label="lab_exel_AmendedAndRestated2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated 2017 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_exel_AmendedAndRestated2017EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_exel_AmendedAndRestated2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated 2017 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AmendedAndRestated2017EquityIncentivePlanMember" xlink:href="exel-20221230.xsd#exel_AmendedAndRestated2017EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AmendedAndRestated2017EquityIncentivePlanMember" xlink:to="lab_exel_AmendedAndRestated2017EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_8e5a6a9b-45ce-405b-8366-95a19d083689_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_dd6a4b9b-2153-42a0-9249-260b20560ad1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_e713f283-9b53-462f-8f4a-54f8848fd66b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NoncashLeaseExpense_70485d3d-b81e-4bd4-a6ac-0bf0467cfb01_terseLabel_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_label_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_documentation_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense" xlink:href="exel-20221230.xsd#exel_NoncashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NoncashLeaseExpense" xlink:to="lab_exel_NoncashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2e7b8573-8fcd-44e3-b574-9ec7dc8f0570_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ff42bed5-82bd-4f02-ab15-6e113d18044b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_221bbde4-1ab7-4af5-9786-59dc30852b9e_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_715962a3-1827-4fcd-8018-33dbf0f59231_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_e52d225a-b476-48f5-b5ff-75a36fabe080_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2f8bd35a-ca66-4fb4-a6bc-4ce8978b6d14_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_59b738cd-118f-4ba3-9219-639ac92826fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_80dd3ca1-269e-40ef-8922-d42bbc0bf651_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseLiabilitiesAbstract" xlink:href="exel-20221230.xsd#exel_OperatingLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract" xlink:to="lab_exel_OperatingLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_396de272-ec87-47f1-a9a1-b2e27f641244_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_2be940d5-42d7-4d14-bd7f-4afd6a5f18c5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8908d323-44ed-4032-9090-e01e532ecf47_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5c0a50d3-474c-4779-ade8-9cc9eddd0559_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_032577d2-8aa2-4a8b-b050-c1e7df54b0e9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_801bdb91-8157-42be-9b0f-4010c7c26786_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_039bcd85-5b65-414d-ab02-b3b8c265ad1c_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8df925c0-d922-427f-b81a-75105d09ac50_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_b8c94caa-64a8-4fec-9f7c-4cef2bece600_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1ff1efae-310a-41e6-9e33-768196738996_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_26fa0c31-e6da-4319-afeb-a621c961b755_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Exelixis common stock on grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_0f45dd22-f20c-4300-a5be-9784f810d7a5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_880cab1c-1102-4757-ac7c-9fbe483ed395_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_cc93c665-34dc-4cf5-a65a-34076f706ce3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_56863c4b-e242-413b-8632-d339057e0f00_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_UpfrontPayments_14312641-55cd-4d0a-b4a5-d89192f47ed1_terseLabel_en-US" xlink:label="lab_exel_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments</link:label>
    <link:label id="lab_exel_UpfrontPayments_label_en-US" xlink:label="lab_exel_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment(s)</link:label>
    <link:label id="lab_exel_UpfrontPayments_documentation_en-US" xlink:label="lab_exel_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment(s)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontPayments" xlink:href="exel-20221230.xsd#exel_UpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UpfrontPayments" xlink:to="lab_exel_UpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_42ebf37e-4fed-40cb-8ee8-bb27fda9c757_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_eeeaaf62-f7ef-448e-b538-0cadf38b0d3d_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_c03fbcef-7536-4bf6-ac2e-a1b15102772a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_fd666d45-57bb-445a-9a0c-77d28230ff4f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change relating to prior year provision</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_bd3a58e3-d35b-487c-979c-0fbc3136515b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c75e33fb-0ed6-4a56-99cb-1eee98cd4d5c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_66cd7a40-ddcc-4548-b623-7fbe40f16a71_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3d7fb7ce-36f0-4934-b550-3b8ab5047c01_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OperatingLeaseAssetsAbstract_0ed5b0f5-2344-45d2-8ece-a8e2c70ee529_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_exel_OperatingLeaseAssetsAbstract_label_en-US" xlink:label="lab_exel_OperatingLeaseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Assets [Abstract]</link:label>
    <link:label id="lab_exel_OperatingLeaseAssetsAbstract_documentation_en-US" xlink:label="lab_exel_OperatingLeaseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseAssetsAbstract" xlink:href="exel-20221230.xsd#exel_OperatingLeaseAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseAssetsAbstract" xlink:to="lab_exel_OperatingLeaseAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_9f5edf4e-d1bc-40c7-8223-d6ca1d46b46e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_dc5e9384-dbba-4911-8d1f-efa7fbbdab95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_2e20ba7a-800b-4a8b-87e7-21812ca4a2a6_terseLabel_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_label_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory, Milestone Achievement Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_documentation_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory, Milestone Achievement Under Collaborations Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:href="exel-20221230.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:to="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1943263c-e102-4a95-bed3-46c5c6248e33_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6e1beece-6f03-414c-a4c1-75c7cf850919_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_fc960267-d089-43fc-b945-cf6ffa0b4e5c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_7a597e31-6dd2-4f64-8578-64fe43d7dd54_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_750f7f24-1e95-4731-87c4-13642a17fcdc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_621fcb4d-7ef3-462c-83bc-686493e82eb9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SairopaBVSairopaMember_a9cbb269-61b7-43ac-80e0-e6d1d1e071db_terseLabel_en-US" xlink:label="lab_exel_SairopaBVSairopaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sairopa, B.V. (Sairopa)</link:label>
    <link:label id="lab_exel_SairopaBVSairopaMember_label_en-US" xlink:label="lab_exel_SairopaBVSairopaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sairopa, B.V. (Sairopa) [Member]</link:label>
    <link:label id="lab_exel_SairopaBVSairopaMember_documentation_en-US" xlink:label="lab_exel_SairopaBVSairopaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sairopa, B.V. (Sairopa)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SairopaBVSairopaMember" xlink:href="exel-20221230.xsd#exel_SairopaBVSairopaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SairopaBVSairopaMember" xlink:to="lab_exel_SairopaBVSairopaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_e30afb5f-033b-40fd-9a8b-53d94de8c347_terseLabel_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development arrangement performed for others, reimbursement for costs incurred, percent</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_label_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_documentation_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:href="exel-20221230.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:to="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_81babfdd-6a6a-41b8-ab22-5b756036510b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_02904058-8e3b-4242-9c2b-5d53d713b797_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_189c484e-9a32-4415-9e31-f9bd893d2d48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in share reserve under 2017 plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_12258377-5e31-49f8-90cb-4a02a9511317_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROVISION FOR INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_17f28c08-d760-404a-868d-dfa6d8e94921_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_e88454a4-0056-40ff-9a1a-57d6496e5004_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_5c3c862a-7e3c-46fd-9cc4-e62a2859a5e4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9d3c481e-cda2-40dd-96a9-a67e84920ec5_netLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_c1528dd6-62dd-4f48-99c7-82cf4dd6f62b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9c445ced-0fb8-453b-8b7b-cb8baaff7300_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f8e188cd-15ef-49d5-8dd6-f673bf33943f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_948d1090-cb2d-4727-9b28-e4bbef846a3d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_07310a65-63c0-4d3e-a563-ccecc134bff6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_40ffee81-56eb-41e1-b2dc-11d08afdda7b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_aacdb49f-bf47-4f17-aff6-f48add6877b2_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_fd47d441-3644-4db0-a9d6-a26c48ef31df_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_b7558e63-d9b4-409a-95ad-b2c721d4da8b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_437949eb-c7b9-470d-b5a7-0d074032623b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_929f8d4b-5bb6-449b-8bd1-72301c6d22a1_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_fd881220-8a3c-441d-b8f9-c54ad1bd3f20_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_09043c18-87b3-4056-8f81-cc20689e93b6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_a74bf750-497a-4f8e-aff2-c6e732bbc0af_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a7148850-8505-4331-ad79-cca87ec71e7d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CardinalHealthIncMember_6fbcb7d9-3b74-49f8-ac22-acba2ffbcdd5_terseLabel_en-US" xlink:label="lab_exel_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc.</link:label>
    <link:label id="lab_exel_CardinalHealthIncMember_label_en-US" xlink:label="lab_exel_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc. [Member]</link:label>
    <link:label id="lab_exel_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_exel_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CardinalHealthIncMember" xlink:href="exel-20221230.xsd#exel_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CardinalHealthIncMember" xlink:to="lab_exel_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1ff96cb0-bde0-4cf3-8155-ce1c9ad851fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount_a872feb5-70b9-4d40-a844-5c65e7de59c4_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to exercise, amount</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Exercise Amount</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Exercise Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsExerciseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bff36ded-0834-4fe8-a9e1-bf17ad665582_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_23714543-945c-4e6a-8c5f-2811372f3fee_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_cab83739-c253-4c47-b902-f32362ba029a_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_17515009-7ed0-4e21-88e0-7ab60a3561db_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_2c12741f-2627-41b7-976f-1e20f0047f9f_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_246b7812-2065-494e-8488-fccf8b4b6590_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:href="exel-20221230.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_5f31098c-1ee6-4439-bb94-ae4a337e0f6e_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in dollars per share)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:href="exel-20221230.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_3d911710-8f2e-494c-8d7b-5e9a88963400_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_PerformanceSharesClinicalTrialResultsMember_3595fb5a-f791-440e-897d-6920d39103ad_terseLabel_en-US" xlink:label="lab_exel_PerformanceSharesClinicalTrialResultsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Clinical Trial Results</link:label>
    <link:label id="lab_exel_PerformanceSharesClinicalTrialResultsMember_label_en-US" xlink:label="lab_exel_PerformanceSharesClinicalTrialResultsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Clinical Trial Results [Member]</link:label>
    <link:label id="lab_exel_PerformanceSharesClinicalTrialResultsMember_documentation_en-US" xlink:label="lab_exel_PerformanceSharesClinicalTrialResultsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Clinical Trial Results [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesClinicalTrialResultsMember" xlink:href="exel-20221230.xsd#exel_PerformanceSharesClinicalTrialResultsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceSharesClinicalTrialResultsMember" xlink:to="lab_exel_PerformanceSharesClinicalTrialResultsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_0f662217-008f-42e8-9152-7d63a1b17d92_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_91549bef-e49e-4f1a-be65-66196a2d20e5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bd358772-52a3-45b3-adee-ca848a945257_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ab10afb4-6c9b-4c28-98d7-5f5cf6e23aa2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_5d717255-84c8-42d5-85d7-414b939c835c_negatedTerseLabel_en-US" xlink:label="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease right-of-use assets</link:label>
    <link:label id="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_label_en-US" xlink:label="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Lease Right-Of-Use Assets</link:label>
    <link:label id="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Lease Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:href="exel-20221230.xsd#exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:to="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_bc0b1944-e2b2-4e2d-b5df-6ee3e118df8f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_600daf3a-81b9-4b93-a005-5cbb8727f150_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_eaad5982-577d-4006-a13f-044da1888ed6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_caa2a8b8-ddf5-4731-8cad-7f9fe17bc572_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of All RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_39e8024a-8a98-4dab-8519-1101a7a496f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d4a774bb-08f4-4bc9-8e3c-2839629c1acc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestone_c7c23baa-d1a3-4b16-82f1-c0235014d6e4_terseLabel_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestone</link:label>
    <link:label id="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestone_label_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Regulatory Milestone</link:label>
    <link:label id="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestone_documentation_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Regulatory Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestone" xlink:href="exel-20221230.xsd#exel_RevenueFromContractWithCustomerRegulatoryMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestone" xlink:to="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_9332f9ac-e7a9-4069-b8f7-102c682c7418_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_5e898848-de00-48b3-a235-b5a4d88246f4_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_5c8f7ac0-265a-4e91-ba7f-4a97404fb414_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember_03c87330-0e32-480d-8e19-2c8203e49ba1_terseLabel_en-US" xlink:label="lab_exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreements for Laboratory Spaces in Pennsylvania</link:label>
    <link:label id="lab_exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember_label_en-US" xlink:label="lab_exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreements For Laboratory Spaces In Pennsylvania [Member]</link:label>
    <link:label id="lab_exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember_documentation_en-US" xlink:label="lab_exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreements For Laboratory Spaces In Pennsylvania</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember" xlink:href="exel-20221230.xsd#exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember" xlink:to="lab_exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_ca66739b-52a7-4dce-9847-c124e984ec0e_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_272e5013-d5b4-4510-a9e2-aaecb87ecea8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_eaa55005-3a35-49ba-981b-a032e2dc41e5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_60f35744-7257-48fa-85db-8661f176a383_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AuditInformationAbstract_label_en-US" xlink:label="lab_exel_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_exel_AuditInformationAbstract_documentation_en-US" xlink:label="lab_exel_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AuditInformationAbstract" xlink:href="exel-20221230.xsd#exel_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AuditInformationAbstract" xlink:to="lab_exel_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CometriqMember_99afa015-6583-4cbc-b609-dd788255766a_terseLabel_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMETRIQ</link:label>
    <link:label id="lab_exel_CometriqMember_label_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_documentation_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember" xlink:href="exel-20221230.xsd#exel_CometriqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember" xlink:to="lab_exel_CometriqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_a08c34f9-8de9-4e9d-ae76-7be4f70d79a4_terseLabel_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount expected to be earned</link:label>
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_label_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Discount Expected to be Earned, Percent</link:label>
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_documentation_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Discount Expected to be Earned, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:href="exel-20221230.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:to="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_4602cde7-3758-410d-af55-6a9afa714708_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses relating to stock match</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_e8f47b8f-89d9-421d-9f18-ea2d80f16544_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_40422826-91eb-4b67-a6ff-d0f6b415439a_negatedLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_eefaa249-4861-41e4-b10e-76542f2d5fed_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_8b6c0c5f-0d16-428b-a749-cf2fca4d94f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate from market value on offering date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_705fc881-4027-4095-967d-ffa744c26805_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_d8e934a6-88f5-414f-961c-e7efa8504ba6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract other long-term assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_a749fd9e-36b2-4cc4-88c9-f3d75a222362_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues Disaggregated by Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a4c9f96d-e082-437a-8152-234780fee483_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_4f7e015a-cf5c-4cc1-8b8e-1ca634233c35_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_4f55b325-8492-4024-80eb-55a7e5636a60_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_cce1a5bb-0ad7-43fb-803b-9fef779b8245_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_641166e3-8d5d-4a2f-a4aa-83ca0c7d44ad_terseLabel_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_label_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_documentation_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:href="exel-20221230.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:to="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_a71705cd-8c0b-465d-8825-d798ea485540_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e47b38b3-0326-4337-ae2c-c17c10b1d9a2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RoyaltyTier_3779cc28-4b86-42b4-b61c-e06a50fd711d_terseLabel_en-US" xlink:label="lab_exel_RoyaltyTier" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty tier</link:label>
    <link:label id="lab_exel_RoyaltyTier_label_en-US" xlink:label="lab_exel_RoyaltyTier" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Tier</link:label>
    <link:label id="lab_exel_RoyaltyTier_documentation_en-US" xlink:label="lab_exel_RoyaltyTier" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Tier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTier" xlink:href="exel-20221230.xsd#exel_RoyaltyTier"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltyTier" xlink:to="lab_exel_RoyaltyTier" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_c4349614-9c18-4bbe-b73e-e87e1b7ec442_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_bf6c56f8-bf08-4f52-9d2b-c40ce7063bdb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_a2a11ee2-a869-468c-bac8-c1fca008b25f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f8d39e97-900e-4f9b-9ebe-856079d179ab_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_416156f1-48d1-4612-8bf5-a8980f4c33b2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_149c5245-99de-4890-a292-b759f8d7ccd3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9ef8d92f-4970-42e3-a12b-aa027dff8e0f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d77ef34-55c8-47a9-8c2a-d62aff2f8d6b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CatalentIncMember_17855812-8c56-4322-8472-7dfddcdb00dc_terseLabel_en-US" xlink:label="lab_exel_CatalentIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Catalent, Inc.</link:label>
    <link:label id="lab_exel_CatalentIncMember_label_en-US" xlink:label="lab_exel_CatalentIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Catalent, Inc. [Member]</link:label>
    <link:label id="lab_exel_CatalentIncMember_documentation_en-US" xlink:label="lab_exel_CatalentIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Catalent, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CatalentIncMember" xlink:href="exel-20221230.xsd#exel_CatalentIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CatalentIncMember" xlink:to="lab_exel_CatalentIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3ec06af4-2a6e-4ced-8dca-d36ffc8392d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_f2ec451c-f50b-41c5-bd96-9eca09d965a8_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_676fde38-8d10-4ac6-b3c0-10bc8b2b66d5_terseLabel_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries with FDA approval, excluding the U.S.</link:label>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_label_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Countries With Drug Approval, Excluding The U.S.</link:label>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_documentation_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Countries With Drug Approval, Excluding The U.S.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:href="exel-20221230.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:to="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductGrossMember_8ae18ee4-0029-4c3c-a6d9-543526ff4afc_terseLabel_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product revenues</link:label>
    <link:label id="lab_exel_ProductGrossMember_label_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:label id="lab_exel_ProductGrossMember_documentation_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember" xlink:href="exel-20221230.xsd#exel_ProductGrossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductGrossMember" xlink:to="lab_exel_ProductGrossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_78dc6331-8e18-4595-9d94-b26a8b57c0ae_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets included in other long-term assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_7c52fe9c-22a2-40a6-8fb6-0e6642f37d2f_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_28a59ee5-2ad0-4d96-b106-9c8a859ef283_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_7bdec8f0-cd67-4d5a-a7b5-a2dc9e950cd3_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_ac11e53d-2770-41cc-a322-2e50121859bf_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_df0c4139-0eb5-40c8-b4f5-30646ed9febd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_49668f76-31a2-4e75-a676-d5e6c008e3f6_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_6f5f8125-c8e2-4224-bee5-09f066658127_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_f1cf8064-8e1b-40a1-8169-7c2457fb8965_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a569d6e1-6eec-4bc7-97ca-d1be21462cfe_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_0094e8ec-ef1f-4b29-a662-4b96a772f383_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d386c5f7-1ca6-4a6f-a18e-aba53d342577_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of All Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f8876b0c-f71a-4ac9-8a50-d1be9c13ce9c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_56661c98-bb98-4df3-a549-71757d0a060e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_14046992-1c08-4237-990a-e995e3057b6c_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, upfront payment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1ff5fdaf-047c-404f-9f38-e95b15dd01bb_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b5f818e9-4344-430b-ab72-38ec177c437c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_34d39268-4f20-4fc2-aa35-f634b7675875_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_d80fd5a1-0634-4282-96ed-b210b09d9ae7_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e52f5f8b-4376-4714-b182-bc7803579f88_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_af6457f0-5e12-4087-8bce-998e90721ae4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f733789f-c9c8-4b18-b4a7-3726d7934e3f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6adcb919-733f-425a-bd8b-8a38d2f8c7d1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d7c36d6f-1701-4062-a78d-14e96c6886ff_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_36adb3ea-c94b-4bc9-b3d2-d4f0957f4e71_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_42d16373-33ae-4bc0-a83c-5fc94df11568_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_7fb56d61-1403-4519-9ff5-93697c4a0ce5_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a0926a80-fefc-4ec4-9a7e-96b131bf5876_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_InitialMember_e7e7bc62-4d54-4869-92fe-5ef986878f77_terseLabel_en-US" xlink:label="lab_exel_InitialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial</link:label>
    <link:label id="lab_exel_InitialMember_label_en-US" xlink:label="lab_exel_InitialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial [Member]</link:label>
    <link:label id="lab_exel_InitialMember_documentation_en-US" xlink:label="lab_exel_InitialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_InitialMember" xlink:href="exel-20221230.xsd#exel_InitialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InitialMember" xlink:to="lab_exel_InitialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_baced12b-2f28-46f7-a685-c36ecbce68aa_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_8acc864c-08e5-43e5-b22b-5cd5e54cdb10_terseLabel_en-US" xlink:label="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward amount with expiration dates</link:label>
    <link:label id="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_label_en-US" xlink:label="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount With Expiration Period</link:label>
    <link:label id="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_documentation_en-US" xlink:label="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount With Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:href="exel-20221230.xsd#exel_TaxCreditCarryforwardAmountWithExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:to="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CotellicMember_eb8244a8-bd5a-4999-af9a-76277b3916b3_terseLabel_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic</link:label>
    <link:label id="lab_exel_CotellicMember_label_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:label id="lab_exel_CotellicMember_documentation_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember" xlink:href="exel-20221230.xsd#exel_CotellicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CotellicMember" xlink:to="lab_exel_CotellicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_359345a3-bd92-493e-bf18-8a5823a9851c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ed7e1472-f8aa-432d-9505-62496de8496d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IncreaseDecreaseInResearchAndDevelopmentExpense_005e42b9-e2f8-4ce3-900e-d12bc9d61aa2_negatedLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in research and development</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Research And Development Expense</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:href="exel-20221230.xsd#exel_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:to="lab_exel_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_3d1e61bd-1167-4ae0-b54e-77d57cc0332f_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_71423a16-8264-454d-afe1-029304018bfe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_07c927af-2296-4699-b315-e813c602ad5b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70b14af0-32f2-4ec0-a5f4-6333c9fd6f48_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b5a5c9e9-27b2-449a-b93d-dda54ffb67a9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_b5f89474-177d-4d06-b59d-8a1c6048c6b2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f06b59e4-a981-46f1-8482-add8f870b7af_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_10ed37ed-35a9-41ad-902a-8c9e95120068_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_41dfb76f-f60b-45db-98c8-74743c3759eb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_edd1255e-6f6b-40ee-8907-590d914ec715_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8f1bccac-40c5-49aa-af1c-89ef652e9dec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_c85fd6a6-63a5-4a9a-805c-f21ef243b1a2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_7f449e55-518b-4d13-bd38-e5b6cdb0b427_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c5efcc5c-2cb2-426e-88a0-0aa6134e2f9a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_7f757119-7ea3-49dc-89b4-503b0e99675d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash equivalents included in other long-term assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_436bd284-54a3-4cd4-8004-f80eba22c93c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_c96e4726-dd72-4fe0-8c30-c8e2187a6df1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4baa43e0-97e6-4562-8a3b-9ada08087210_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8e62f44c-9415-4282-992d-d4e755c63a96_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ec536754-4c88-4b2e-8071-81b7f4f99243_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_95eda643-3d2e-4609-9a1b-f558a6739e80_terseLabel_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded prescription drug fee</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_label_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Branded Prescription Drug Fee</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_documentation_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Branded Prescription Drug Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:href="exel-20221230.xsd#exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:to="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1c097579-4335-4ccc-8324-83b257bf982c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d31ed957-2252-40f2-8792-6ba00e4f6fa2_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_c54d9c80-a4e4-402d-96c4-0808fc399c19_verboseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold is related to product</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_d2e0d5a3-bd3e-4049-8859-6866efcee648_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement percent of royalty on net sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_label_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:href="exel-20221230.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:to="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase_9f073498-9bce-49c5-a45c-035d281fb356_terseLabel_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible warrant purchase</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase_label_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible, Warrant Purchase</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase_documentation_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible, Warrant Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase" xlink:href="exel-20221230.xsd#exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase" xlink:to="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_d194279d-1c1d-459c-b7f5-768e818882f9_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract revenue recognized, including revenue from deferred revenue beginning balance</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:href="exel-20221230.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:to="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6de92ec1-ee63-47a2-bba3-7a6ab5d08525_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fe4a488d-e94d-490a-ab72-252a2bf8cc0b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_ae638709-73f5-4319-9ca2-449f025ae15c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_6981c862-d14f-4d17-853b-286275ce6428_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_5a99dde0-45d2-4ce6-8023-2cbd26ba7b88_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:href="exel-20221230.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_02857b6d-dd60-4fa3-8997-8899bbfd2403_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 323,951 and 318,842 at December&#160;31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AchievedMember_033fa8be-a665-4cc2-ba5f-c13c16a4d5e7_terseLabel_en-US" xlink:label="lab_exel_AchievedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved</link:label>
    <link:label id="lab_exel_AchievedMember_label_en-US" xlink:label="lab_exel_AchievedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved [Member]</link:label>
    <link:label id="lab_exel_AchievedMember_documentation_en-US" xlink:label="lab_exel_AchievedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedMember" xlink:href="exel-20221230.xsd#exel_AchievedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AchievedMember" xlink:to="lab_exel_AchievedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_4ea01d04-59e8-481b-82fb-2559798e324a_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to sales made in:</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:href="exel-20221230.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_FinalTierMember_cf1e17d5-1639-4cc7-a469-9b10d96a10dd_terseLabel_en-US" xlink:label="lab_exel_FinalTierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final tier</link:label>
    <link:label id="lab_exel_FinalTierMember_label_en-US" xlink:label="lab_exel_FinalTierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Tier [Member]</link:label>
    <link:label id="lab_exel_FinalTierMember_documentation_en-US" xlink:label="lab_exel_FinalTierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Tier[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalTierMember" xlink:href="exel-20221230.xsd#exel_FinalTierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FinalTierMember" xlink:to="lab_exel_FinalTierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_d63617ec-d40a-466e-958e-74c4550422dc_negatedLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:href="exel-20221230.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_4e813487-fef6-462c-82f3-b97b24a023ae_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:href="exel-20221230.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11348d8e-cddf-4e81-a573-cef4b4797871_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e656a679-d548-4383-9926-a5b6b62de26c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_94eca1d0-500c-4011-82ae-3f5fb5dd5860_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Shares of Common Stock Not Included In Computation of Diluted Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4bfd2d6c-1443-4feb-9be4-2c98039813a1_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable at end of the year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_68616d7a-8bb9-483e-9f6c-814662676b1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_d9123887-5877-4056-b82a-34c91648c46d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_115a2ca8-9a29-41af-a442-40a7143525ff_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a575bc90-fe10-4698-9677-5afe6d7f6cf9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb81ce02-854b-4a94-b718-79a4c4bd981c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1a10b0af-adb3-459b-b7d2-c611d7206785_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6148a98f-7319-482e-a26f-a036535a8514_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_4da526c8-4dd6-4eeb-b8bb-fe8eb463fa41_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from option exercises and purchases under the ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_44994e4c-79ad-4f22-840e-70df9b0a6260_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3b40e9fa-bc99-4450-b9cf-04db54d31e4c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_84e31062-c4fa-40a1-905d-40c219797e8f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_e0b2ae87-7207-4f15-91bd-20ababd9ed3c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_b29b8e0f-b7cd-43c4-a275-7a85a6acefbd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_c1ba7bdd-6ddf-4ff0-affe-f9d300c54eb4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_3b129c74-7f6d-415b-82b0-8edd98b56c60_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares to be earned (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:href="exel-20221230.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_603183dc-28be-41cb-846a-52042c890e43_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7e99e6ec-e028-45f0-a1d0-330bb17ba31f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160; Average Remaining Contractual&#160; Term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58fc88e3-65cf-4dce-949d-967d1b78d221_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_32bf6ca8-7fe3-42b8-bb2d-4c1e404c342f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of investments in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_9f8502af-db59-4b17-bf0e-b2bf6cfbeb04_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a551b24d-331a-4246-877e-8e979864019a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_45a42e89-61f8-4611-9501-e2bc05b756bf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_c1438025-98d7-4e54-8ae9-e457936b26aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_f7e9c816-9fd6-4247-80b1-68455409e8be_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Investment Impairment</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RoyaltyTierDomain_c793614f-ad5a-4925-b7fc-b7beabbac193_terseLabel_en-US" xlink:label="lab_exel_RoyaltyTierDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Tier [Domain]</link:label>
    <link:label id="lab_exel_RoyaltyTierDomain_label_en-US" xlink:label="lab_exel_RoyaltyTierDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Tier [Domain]</link:label>
    <link:label id="lab_exel_RoyaltyTierDomain_documentation_en-US" xlink:label="lab_exel_RoyaltyTierDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for royalty tier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierDomain" xlink:href="exel-20221230.xsd#exel_RoyaltyTierDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltyTierDomain" xlink:to="lab_exel_RoyaltyTierDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_300967bf-74a1-4b39-9331-c1e2345e3152_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_a464fd22-4ad0-482d-b463-d85b7af1f16d_terseLabel_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_label_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_documentation_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:href="exel-20221230.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:to="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_104f49d3-dc00-4ca7-952e-ba8454d5f247_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_A2021AwardsMember_a70c46f6-f750-4de8-bde5-61762b4e5fad_terseLabel_en-US" xlink:label="lab_exel_A2021AwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Awards</link:label>
    <link:label id="lab_exel_A2021AwardsMember_label_en-US" xlink:label="lab_exel_A2021AwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Awards [Member]</link:label>
    <link:label id="lab_exel_A2021AwardsMember_documentation_en-US" xlink:label="lab_exel_A2021AwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_A2021AwardsMember" xlink:href="exel-20221230.xsd#exel_A2021AwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_A2021AwardsMember" xlink:to="lab_exel_A2021AwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_2fb67e2a-055d-479d-ac29-837c49d82658_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a2166bfc-77ef-4611-8c59-e0c8c1581f0f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_fdc2045d-4435-41b2-8b0f-ee2448c17266_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_ee4a7c7b-b26f-43b6-bcac-d4574b49cbaf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LaboratoryEquipmentMember_b9d9e8dc-74b5-4023-a7ea-fd7224374f88_terseLabel_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LaboratoryEquipmentMember" xlink:href="exel-20221230.xsd#exel_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LaboratoryEquipmentMember" xlink:to="lab_exel_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_744e3401-8ef9-481b-82fc-cbea6e09db79_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating activities:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements, Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_900f57bb-0573-434a-ac44-8e922beb2d97_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_3fa77541-b645-4a45-b0c3-11ab2d44a617_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_b0aa8769-e21d-4631-90c3-eacb95ed8889_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_dad43c22-4940-4320-98e2-6b2239908c49_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CybrexaTherapeuticsLLCCybrexaMember_de997c07-b2ff-4e85-9ed0-c0d8f5b951ed_terseLabel_en-US" xlink:label="lab_exel_CybrexaTherapeuticsLLCCybrexaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cybrexa Therapeutics, LLC (Cybrexa)</link:label>
    <link:label id="lab_exel_CybrexaTherapeuticsLLCCybrexaMember_label_en-US" xlink:label="lab_exel_CybrexaTherapeuticsLLCCybrexaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cybrexa Therapeutics, LLC (Cybrexa) [Member]</link:label>
    <link:label id="lab_exel_CybrexaTherapeuticsLLCCybrexaMember_documentation_en-US" xlink:label="lab_exel_CybrexaTherapeuticsLLCCybrexaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cybrexa Therapeutics, LLC (Cybrexa)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CybrexaTherapeuticsLLCCybrexaMember" xlink:href="exel-20221230.xsd#exel_CybrexaTherapeuticsLLCCybrexaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CybrexaTherapeuticsLLCCybrexaMember" xlink:to="lab_exel_CybrexaTherapeuticsLLCCybrexaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_553d944f-7562-4ca1-9a3a-b3ce1a25b56e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at beginning of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638d524c-d3f0-41d1-be00-e434ef3dfdec_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at ending of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_d792bae6-68da-45c0-9c63-c3b588671412_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of forward contract outstanding</link:label>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_label_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Number of Instruments Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:to="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_fc0acbfa-920a-4705-94e1-7bbb87f319d8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f1ec1dc2-e0db-412f-8259-a1ed7824be55_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_b50f8f2a-b062-46dc-8e5b-1e33d0576daf_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket" xlink:href="exel-20221230.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket" xlink:to="lab_exel_NumberofProductsinCommercialMarket" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2d475113-c64a-4fdb-a84b-4f5a1225dfb9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_78711f44-80b9-48c7-9043-fd7297f341f8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_60321a07-b28a-498c-9e65-8897c02263b4_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_dc4ca780-8dee-45ee-98c9-211fa89ea3a9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5dddfcea-6653-43b2-b70e-5cd8c44ba377_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_dd3aba00-c204-4e99-afd9-80045f77d069_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e38598fe-7ba7-446c-ae4d-f178291c9754_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_98f2974e-6022-4ee9-93bc-fadc20c98597_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities:</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NotProbableMember_213576f5-b978-4e72-b6e2-6f13cdf7400c_terseLabel_en-US" xlink:label="lab_exel_NotProbableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Probable</link:label>
    <link:label id="lab_exel_NotProbableMember_label_en-US" xlink:label="lab_exel_NotProbableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Probable [Member]</link:label>
    <link:label id="lab_exel_NotProbableMember_documentation_en-US" xlink:label="lab_exel_NotProbableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Probable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NotProbableMember" xlink:href="exel-20221230.xsd#exel_NotProbableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NotProbableMember" xlink:to="lab_exel_NotProbableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_e4e12ce3-1797-40c2-81b8-1a9b1e9b8eb5_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:href="exel-20221230.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:to="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bd3c8114-60f3-491a-8711-412ef02df08d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9f86d279-89b6-420f-9633-22276b9b114f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_6a7c8f69-4fa8-4b32-b6d5-fbd0c0dd57b0_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_93f586cb-2326-4d43-89b9-af901ee6a387_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_b4a8a8ca-ce08-48de-bf8a-0c424c5cafb1_terseLabel_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent discount for prompt payment</link:label>
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_label_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Percent Discount for Prompt Payment</link:label>
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_documentation_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Percent Discount for Prompt Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:href="exel-20221230.xsd#exel_SalesRevenuePercentDiscountForPromptPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:to="lab_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ae7df732-ac85-4ba0-ac96-c5208e981fe0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_1533d858-908a-4d1e-9747-0fd6e925d307_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a8294fc4-1796-453e-ad69-a2e3c9f8d8c7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CabometyxMember_d5e8bf78-6535-4547-9644-f4e324a4a072_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CABOMETYX</link:label>
    <link:label id="lab_exel_CabometyxMember_label_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_documentation_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember" xlink:href="exel-20221230.xsd#exel_CabometyxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember" xlink:to="lab_exel_CabometyxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_564302c1-6583-4641-b0b6-b2968c9e4011_terseLabel_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial sales milestone</link:label>
    <link:label id="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_label_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Commercial Sales Milestone</link:label>
    <link:label id="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_documentation_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Commercial Sales Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestone" xlink:href="exel-20221230.xsd#exel_RevenueFromContractWithCustomerCommercialSalesMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestone" xlink:to="lab_exel_RevenueFromContractWithCustomerCommercialSalesMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_15dd767c-65b2-40af-a3a8-477756366fd9_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_ab1330c7-ffd1-4227-8a41-3b80be86d7b1_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after all other awards (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:href="exel-20221230.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_abf968c1-0d57-407c-bd36-afe5097d292f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_666571e1-f832-4994-8621-d0645528eb51_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_46ad0a16-8fb3-45e8-9806-59aea2add95b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiscalPeriod_b0dac8a3-e7e1-444f-a7a2-22a7a9e51533_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiscalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod" xlink:to="lab_us-gaap_FiscalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fd51c1fe-9c85-4ca6-b2f2-45a91ffa4f72_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3a143596-fa2f-4630-904d-c95eee45ac49_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_469f8700-897b-4414-8aed-3f800a742168_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_5f3e8364-0438-4df3-8ec8-d0809f32b478_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:href="exel-20221230.xsd#exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:to="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MilestonePaymentsEarned_49593bf6-ef82-4172-bc46-49c454f853e5_terseLabel_en-US" xlink:label="lab_exel_MilestonePaymentsEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarned_label_en-US" xlink:label="lab_exel_MilestonePaymentsEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarned_documentation_en-US" xlink:label="lab_exel_MilestonePaymentsEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned" xlink:href="exel-20221230.xsd#exel_MilestonePaymentsEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestonePaymentsEarned" xlink:to="lab_exel_MilestonePaymentsEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_05d04993-6555-4e75-b371-63c5ea5b5b92_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative catch-up revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_eefe0d7a-4d70-4b46-b1cc-933d9722989a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_59027672-00cf-4f6c-bfa4-f0a87eb8c1e1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_34918cc8-99ba-4b92-9a8a-6fbf09292af8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_cc059727-dfef-43eb-84b1-0b32cfafe71e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_11fb3d2b-b0d1-4d68-aeec-3797b404d6aa_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MilestonePaymentsEarnedToDate_973e21a3-9174-464a-97ad-0892bc062b1a_terseLabel_en-US" xlink:label="lab_exel_MilestonePaymentsEarnedToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments earned to date</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarnedToDate_label_en-US" xlink:label="lab_exel_MilestonePaymentsEarnedToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Earned To Date</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarnedToDate_documentation_en-US" xlink:label="lab_exel_MilestonePaymentsEarnedToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Earned To Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarnedToDate" xlink:href="exel-20221230.xsd#exel_MilestonePaymentsEarnedToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestonePaymentsEarnedToDate" xlink:to="lab_exel_MilestonePaymentsEarnedToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_bf04bf90-2ba7-43aa-a129-4cb02305744b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_StatusDomain_d3517c56-ac1e-4883-bb63-f186a4a44aaf_terseLabel_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_label_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_documentation_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain" xlink:href="exel-20221230.xsd#exel_StatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusDomain" xlink:to="lab_exel_StatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0ea8bbd7-1be0-4e8c-bec2-85861fead312_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_f111d1ab-c10c-4093-a501-27c290c0e02a_terseLabel_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember" xlink:href="exel-20221230.xsd#exel_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ComputerEquipmentAndSoftwareMember" xlink:to="lab_exel_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_00ee98d2-502c-4f2c-83bc-beced7064d2f_terseLabel_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_label_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_documentation_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:href="exel-20221230.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:to="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ce30e202-aa63-42ca-bbf4-62cae875a5c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f12cb52b-12d6-4fec-a9b8-32ee39018148_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_cd521ed2-7cb6-431b-8b47-e18aa24d4fe5_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration Risks</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7e4e6cf8-566b-4fa2-b571-8afc288cab1b_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_7865d79a-3265-4126-85b5-b3a925fc15d1_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:href="exel-20221230.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_7c7e03b8-0285-4af7-89ea-8031a93976fc_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1516555c-40ad-42d8-85dd-7b501f9142e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_6285c11a-cd54-46c0-90fc-7586eddaad5f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f4940cc9-3dc0-41d7-bc90-ac3723f69105_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0e3bfb8d-7071-45b2-9155-a7fd8bb8843d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b729a84b-2550-405e-a442-31b5c6b5e5e5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_ea20524a-ae9a-4082-9d84-6c58932a1b55_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_3b812ed9-1690-4330-b70c-535e22d4bc5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_c5cd2f2b-888c-4c8f-84b2-262727957374_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_4825190b-6055-4f61-b503-997483a2aac5_terseLabel_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Discounts for Prompt Payment and Other</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_label_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_documentation_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:href="exel-20221230.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:to="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_73042e2e-8aeb-4577-b8ca-098f2a5dfcef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a9b7e7e3-07df-42c8-9269-7598f9652fe6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_1b721dbc-b4e3-4847-8ec2-d8bd9a9717f7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5c8ac9f8-9c42-4a5c-baa4-f71fba3063e6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_60034af0-e7dd-4541-918f-652a262370f5_terseLabel_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:href="exel-20221230.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:to="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_23e4b99c-ee18-49ff-9eb9-0c5aba495c07_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:href="exel-20221230.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_07a5bfbf-887c-4ef5-aa96-90387905c7a8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_a6da50eb-c24f-4c7e-aea5-7fee3b7cee94_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_95a293a4-c142-45e7-b9d7-ac63cbeb43be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ffeac3c2-1f2f-4174-bc3a-e7f1884c6b58_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_21fc566c-837c-4b97-841f-78b814a5c722_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_9e4c1209-94b2-41c9-af7e-8c79fb2c362f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain (loss) on maturity of forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b4c4082b-6e39-42c5-855b-a5879013333b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb82531d-0a08-4998-9ce2-d1edeacfceb8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_db5b54a7-04d2-4d4a-9c19-238108077e87_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01714bb8-8d16-46a7-8a10-1cefc37ee4b2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4598b84b-0647-4417-871e-52e81752d2d4_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_213c246c-6aba-41ac-a5ce-97dec342a6fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_45408175-a03c-4a1a-921a-74b799ca9373_terseLabel_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="exel-20221230.xsd#exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_f10d145c-f47b-4f26-a020-a2da7feb9cef_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_9303977f-6175-42dc-9ced-5d70a6c41734_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6987dc6a-93d5-4a41-b38f-fb6450c4366a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_2f128502-44e9-4aee-a14b-8b09847ae3fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7adaecc3-db0f-4e39-8d45-a1979c67a8f0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_39d37378-de2c-47af-b6b7-c6b2141e579d_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_e7024fa3-994d-4584-b238-8a86939d1d97_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement with Takeda</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c82d5dae-0133-4022-b330-fc43731f31d6_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_01a8e355-af1d-4ae2-b4f2-d2f342a3bac2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0caf3c26-1aaa-4772-acac-80efa0202e03_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_c41bb82d-d85a-4940-8d3e-f3e43ee39f68_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_27b13e4e-5c75-41cc-92f6-dbbf4f53f657_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_edf87772-7cb1-40ea-a050-bcd01adeaf0d_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_72fdd526-8e51-43dd-8437-8a6b2b091ec9_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_5cbd2b7a-0698-48cd-9f0f-b83a69d23ce8_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_84fc79f4-ea4c-417e-8b48-6a01e2ac7b24_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4542314a-17f1-4a25-a96c-cf4f006834d8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bf02cceb-125e-46bb-bd15-a0428f4324d0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at beginning of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9b0a5e9d-aca7-4ccf-8fc2-21f334921b22_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at ending of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_32f7dc57-55a6-42b9-8472-f07591643d82_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IncreaseInBasicEarningsPerShare_d21da275-9bcf-4f48-8386-f39bf14ff1a8_terseLabel_en-US" xlink:label="lab_exel_IncreaseInBasicEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in basic earnings per share (in dollars per share)</link:label>
    <link:label id="lab_exel_IncreaseInBasicEarningsPerShare_label_en-US" xlink:label="lab_exel_IncreaseInBasicEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Basic Earnings Per Share</link:label>
    <link:label id="lab_exel_IncreaseInBasicEarningsPerShare_documentation_en-US" xlink:label="lab_exel_IncreaseInBasicEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Basic Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseInBasicEarningsPerShare" xlink:href="exel-20221230.xsd#exel_IncreaseInBasicEarningsPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseInBasicEarningsPerShare" xlink:to="lab_exel_IncreaseInBasicEarningsPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_d6791931-3a0a-409f-a7c2-d564e9305006_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contract outstanding, amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_7a6b297c-f086-4faa-b73e-d52920a1f10a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_ac823c2f-7848-4593-95a6-766b4fbfcd63_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c3a78684-f80e-4692-bfe9-bfc96c0bcba8_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b0eb8238-9a1a-44bf-b17a-30f6a4524410_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_f0f49c54-7c67-4c1a-809a-3f4c2018a437_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_1e4292d1-50fd-4ba2-8594-a0c5b2a671ce_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_4eb60179-3bb5-434c-801d-eff44a008106_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_7bfd641e-087f-42f3-af2c-61c288bb2810_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_db92dbf0-2479-447a-90d5-ca0f18a56d36_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_fb78a3c0-ec92-4244-917a-f88d4e0a3467_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_72be1a55-8e59-4084-860e-b66b7955a77c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charge on goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f756e257-307c-4324-ae1b-c919880a9108_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2cd0a838-77de-468b-b35d-96c490887547_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_fb74787c-fdbd-45e6-a65c-d4d43fc6eb0a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_9b0d2034-6714-41d8-9421-badd94cd864b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_215f75e0-07c4-499e-b300-c9d9acea2732_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_3af1f6ab-74cf-43de-9d43-59a1dc9bc73f_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential to vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:href="exel-20221230.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:to="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f5c970da-61c6-401e-9309-304ed41485c6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4a571551-c21e-44a4-9d2f-3105000dcb0c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_02196d30-a1e4-4d43-ad1c-d74b04eaba17_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_5cdb275d-d824-4ab3-a999-f0085b39401d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_95022aa6-138d-4848-b947-311e536f227e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2819988f-8024-491d-a235-2c923bef6296_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_StatusAxis_096b5f56-afa3-4282-9607-2eb581d333ae_terseLabel_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_label_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_documentation_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis" xlink:href="exel-20221230.xsd#exel_StatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusAxis" xlink:to="lab_exel_StatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_80742bd3-aab2-4eaa-9efe-8a3754fac222_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_4c7d4c2b-8edf-4614-ab58-083dd3b1edd7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_6efbe3c3-b445-4278-bb2a-ea19461c1625_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_867d2497-0150-44b2-b94f-ad6e5498d2dc_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4ead8f3e-5444-47c4-9aeb-879e710e5650_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LossContingencyNumberOfLawsuitsConsolidated_3f353967-248b-498e-a681-a83778096b12_terseLabel_en-US" xlink:label="lab_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits</link:label>
    <link:label id="lab_exel_LossContingencyNumberOfLawsuitsConsolidated_label_en-US" xlink:label="lab_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Number Of Lawsuits Consolidated</link:label>
    <link:label id="lab_exel_LossContingencyNumberOfLawsuitsConsolidated_documentation_en-US" xlink:label="lab_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Number Of Lawsuits Consolidated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:href="exel-20221230.xsd#exel_LossContingencyNumberOfLawsuitsConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:to="lab_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_33acde45-2249-42a2-a29c-f3cd5d54bcf4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OperatingLeaseRightOfUseAssetAndOtherAssets_fa2efdd4-8e20-4b6b-bc8c-60d4b6433135_verboseLabel_en-US" xlink:label="lab_exel_OperatingLeaseRightOfUseAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets and other</link:label>
    <link:label id="lab_exel_OperatingLeaseRightOfUseAssetAndOtherAssets_label_en-US" xlink:label="lab_exel_OperatingLeaseRightOfUseAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset And Other Assets</link:label>
    <link:label id="lab_exel_OperatingLeaseRightOfUseAssetAndOtherAssets_documentation_en-US" xlink:label="lab_exel_OperatingLeaseRightOfUseAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset And Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseRightOfUseAssetAndOtherAssets" xlink:href="exel-20221230.xsd#exel_OperatingLeaseRightOfUseAssetAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseRightOfUseAssetAndOtherAssets" xlink:to="lab_exel_OperatingLeaseRightOfUseAssetAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b1a7850f-bf06-48a1-8101-376ace44c248_negatedTotalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c49fb55a-b392-4824-9f4e-08ab2fb5de31_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_23d47757-be7f-4824-8c82-bc0ac170c064_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_f122b74b-9021-4063-a4fa-78d95e2f6a94_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_0416cfe2-762c-4481-8937-1121262e8e87_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7904cbda-d98a-482f-aa2e-51d2d28bf773_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_ff37f3f2-a332-47cf-8b87-c6cbaece0c85_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_60bb2415-34e8-459e-b2d3-bafae78617a8_netLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f569653c-f8b3-4f67-b479-fa7547629cbc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_0baedd7b-695a-49c3-9ff1-e63eab6fcd0a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_ddb5505c-03bb-44d0-99e5-de4a3dfd3e78_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and reserves not currently deductible</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4dd7d1b5-4cca-481f-a2c9-d0581105a37b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ad5d7f07-2fcd-4be5-926b-a82ccc77a4de_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_d526585e-e643-43b2-b054-5775930d7bbe_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d1f24f4f-d497-41ca-8909-9410d3bb871a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fed83c16-4bca-4c01-ac96-6db1eeef06b1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_baf23043-e1a5-4172-8de0-fe39fea95b0b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_f98ab928-cbcd-4f22-8c32-de8c97d5edb8_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_38b6b653-5b94-473d-9f73-847e64e2bd43_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_4d12a02d-23a1-42a5-ad1c-6aa7ff8b6553_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_ce1eb9ae-38ee-4d46-b375-0306bbd9247d_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_42f95282-d7ed-4f83-bb82-9a39bb6c483e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e8840476-71bc-4fc7-8837-cfcd44a66998_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would reduce income tax provision and effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_DeferredTaxAssetsLeaseLiabilities_07d5560a-83b5-422d-a00d-317d87bc77f3_terseLabel_en-US" xlink:label="lab_exel_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_exel_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_exel_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:label id="lab_exel_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_exel_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxAssetsLeaseLiabilities" xlink:href="exel-20221230.xsd#exel_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_exel_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_c2e069e0-431b-4669-bc55-2716054d09d8_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price allocated to our performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_3a40b1bf-5006-4899-ab7a-fcd4c61ba331_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8849dfc5-7607-40c2-a3ee-af7a20d8a8e6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_0d976bf3-600d-441f-878b-c89fb55a0315_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales revenue, net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_87625e1d-ba90-4c96-aaba-60111e932080_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a85f8d94-0e78-48fd-8128-8673c83e3166_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_d4d089c0-445c-49c2-a957-69f71ef7c4ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_aa66890c-0596-438b-9c29-dd8cc1d1a008_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND INVESTMENTS</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_93af094f-00e9-40c2-983a-b4952e351cd9_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_f8c6d75a-b42f-4314-bfea-542bccb1214f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_1ab7db0e-8f8f-4cb0-b695-f13bface4f70_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_05a762af-9027-4820-b461-7b82d2433444_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_f4811143-2627-47f7-9fc1-7bca66c00ea4_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance increase (decrease)</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_1eba3fe1-22a3-4cff-8016-224fd1f3ca2b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LeaseArrangementsAxis_49d137c7-0f06-4554-9b45-08349640330c_terseLabel_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_exel_LeaseArrangementsAxis_label_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_exel_LeaseArrangementsAxis_documentation_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis" xlink:href="exel-20221230.xsd#exel_LeaseArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseArrangementsAxis" xlink:to="lab_exel_LeaseArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_8194b553-0be4-48af-8a64-c9d4596e9599_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_770834f8-c1f9-4210-8ec3-b26b82a38d2c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $3,886, $1,481, and $(394), respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_4c2f152f-69aa-4cdf-9eb3-d349c81d6cbc_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_3f7383ab-335f-430b-9f9a-4ba8c3ce489d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccountsReceivableForUnsettledInvestmentSales_73ad50bf-7366-4931-8123-9ab52a94c5b6_terseLabel_en-US" xlink:label="lab_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable for unsettled investment sales</link:label>
    <link:label id="lab_exel_AccountsReceivableForUnsettledInvestmentSales_label_en-US" xlink:label="lab_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable For Unsettled Investment Sales</link:label>
    <link:label id="lab_exel_AccountsReceivableForUnsettledInvestmentSales_documentation_en-US" xlink:label="lab_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable For Unsettled Investment Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:href="exel-20221230.xsd#exel_AccountsReceivableForUnsettledInvestmentSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:to="lab_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise_c1025687-7188-4139-8996-3f4c9598258b_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of warrant to be exercised</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise_label_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Amount Of Warrant Exercise</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Amount Of Warrant Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementMaximumAmountOfWarrantExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise" xlink:to="lab_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_c0932cee-61b1-40b2-aa70-665945e5f622_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a34a79cc-0c4a-485c-aee7-7ec77926f323_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_b9baab9f-8413-4981-bc58-c332e8e9890b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3a052a2d-c46f-4acb-9eee-ac1a1265d069_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate from market value on purchase date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RoyaltyTierAxis_5afa10e7-41d9-4838-8987-a56b594e6bbf_terseLabel_en-US" xlink:label="lab_exel_RoyaltyTierAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Tier [Axis]</link:label>
    <link:label id="lab_exel_RoyaltyTierAxis_label_en-US" xlink:label="lab_exel_RoyaltyTierAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Tier [Axis]</link:label>
    <link:label id="lab_exel_RoyaltyTierAxis_documentation_en-US" xlink:label="lab_exel_RoyaltyTierAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">royalty tier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierAxis" xlink:href="exel-20221230.xsd#exel_RoyaltyTierAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltyTierAxis" xlink:to="lab_exel_RoyaltyTierAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_a18cb68e-6c5e-4d22-b7af-1f30cbd33892_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_feace3d8-9de8-4e1c-87fe-f15c73520635_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_26659729-3552-4862-9178-08716a316247_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_8a8a1b7c-8fe5-4e21-a6e3-ff80da21e63b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_7028ee17-9383-4730-bb00-56b20779932c_terseLabel_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_label_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_documentation_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of royalty on net sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale" xlink:href="exel-20221230.xsd#exel_PercentOfRoyaltyOnNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PercentOfRoyaltyOnNetSale" xlink:to="lab_exel_PercentOfRoyaltyOnNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_2558624b-b1a7-4bbd-b48f-fdd27fc8a29c_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_7d456bf0-01ca-441e-bf70-e0902b823ca5_terseLabel_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredo Health, Incorporated</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_label_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_documentation_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredo Health, Incorporated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember" xlink:href="exel-20221230.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccredoHealthIncorporatedMember" xlink:to="lab_exel_AccredoHealthIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_9c4c9b6b-c642-4cdb-a2fa-3cc5c4536e07_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:href="exel-20221230.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:to="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ff1eefac-d367-40ce-a414-a063a8f88026_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Income Taxes At The Statutory Federal Income Tax Rate to Net Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a6a3d535-6356-4fb7-9018-cc3f42f0c2bd_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_dd6139aa-c2ae-4ac5-984f-8c7f7fce2ab9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e7978783-062d-46a0-a221-74629eccadc3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember_cb625ae3-4928-4a01-bb42-972038dac3a0_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with GSK and Royalty Pharma</link:label>
    <link:label id="lab_exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with GSK And Royalty Pharma [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with GSK And Royalty Pharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember" xlink:to="lab_exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_51fcd042-104f-414e-bfde-49f50b25d864_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_0469e39f-1d57-456d-9a37-6d7399b4334c_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_7dfb1057-2de5-4c94-8582-759a6eec89c2_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6566e082-7544-4815-a41b-dd2fb59473cb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_bd9e610b-bd18-422a-ad93-5c7320f318d2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_f8046397-f507-4fc3-b860-8383c2d152a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_57ff2c4b-a662-4a55-b08b-60264b21d96c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_194cff31-c257-4fdb-9f7a-2b1a2ccf17a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160; Average Grant&#160;Date Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_32df4930-bcd1-48ef-8cd6-7c268b2ab40c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock transactions associated with taxes withheld on equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80c473bc-a65e-4e6e-8a37-49899b9e05f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_52bc9eb6-8c48-497b-a457-03a56948529c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_5332f29a-b2e7-4718-ae7c-56b8305d2732_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9ccc41b6-8abf-4f04-b988-b47cac086003_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_59eca28a-eba2-42af-bbeb-6a8f7f9af047_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_b2067f2e-274e-4365-9803-08b8da52b967_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ed5100d8-404e-48a8-a8b9-7e1a7f468a37_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. federal income tax provision at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_b3647e06-8f4a-417a-9919-fc1451394354_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_94c7f096-0cd6-487d-8f94-7c54d2182ff0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_62b9b56c-6e76-47c2-84ed-2670f880c276_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development technology</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3f1c1483-1383-4203-b5a4-5dacf5890db3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberOfSponsoredEnterprises_2f77bc7b-c4c4-4c54-8ec7-e49d9b28e044_terseLabel_en-US" xlink:label="lab_exel_NumberOfSponsoredEnterprises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of sponsored enterprises</link:label>
    <link:label id="lab_exel_NumberOfSponsoredEnterprises_label_en-US" xlink:label="lab_exel_NumberOfSponsoredEnterprises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Sponsored Enterprises</link:label>
    <link:label id="lab_exel_NumberOfSponsoredEnterprises_documentation_en-US" xlink:label="lab_exel_NumberOfSponsoredEnterprises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Sponsored Enterprises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfSponsoredEnterprises" xlink:href="exel-20221230.xsd#exel_NumberOfSponsoredEnterprises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberOfSponsoredEnterprises" xlink:to="lab_exel_NumberOfSponsoredEnterprises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5c86577e-9781-4976-b426-09bb4f683f43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d13d2851-4e44-4df1-bbdc-0bb8a1a3449e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TSRBasedRestrictedStockUnitsMember_d194c541-7c2c-424c-9640-265146d614a0_terseLabel_en-US" xlink:label="lab_exel_TSRBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR-Based Restricted Stock Units</link:label>
    <link:label id="lab_exel_TSRBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_exel_TSRBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_exel_TSRBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_exel_TSRBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember" xlink:href="exel-20221230.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TSRBasedRestrictedStockUnitsMember" xlink:to="lab_exel_TSRBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e813f50e-8533-4ae9-badc-b5e31245f178_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and other</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_ea4c1959-d664-411f-b3cf-aeccd3e8ee2a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_6259eb1f-bb1c-43b5-9583-57d8ec532fb2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contract maturity (in months)</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_5040c1d5-e2ed-4f6f-9daf-93eb629d8a50_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_045640ea-a5a3-4942-8292-c42c6a91f7e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Basic and Diluted Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_25793269-755e-48ef-b48b-f76f30b19719_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_a4136629-b700-4ccb-8388-aa65a00814d6_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>exel-20221230_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:72618e96-9a19-4b18-ab04-d375d7716d96,g:fc8ea608-bee1-4b83-89de-139db7d65bef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20221230.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8ee26661-3698-4481-8f3f-9ccaab7681f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_DocumentType_8ee26661-3698-4481-8f3f-9ccaab7681f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_36c1e6cd-384d-4ba4-b527-9a6aefd08944" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_DocumentAnnualReport_36c1e6cd-384d-4ba4-b527-9a6aefd08944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f5ae69d3-40cd-4e0f-ab89-f4cd72a4283d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_DocumentPeriodEndDate_f5ae69d3-40cd-4e0f-ab89-f4cd72a4283d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5ce6dacd-525f-4d3d-b371-38a1f3cb4ad3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_CurrentFiscalYearEndDate_5ce6dacd-525f-4d3d-b371-38a1f3cb4ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_66b69122-fec5-42e7-bef4-40ac08d062ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_DocumentTransitionReport_66b69122-fec5-42e7-bef4-40ac08d062ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7ca94fd5-6f2c-40b4-847f-ee9af0a8bed7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityFileNumber_7ca94fd5-6f2c-40b4-847f-ee9af0a8bed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f059f36c-f98f-4367-a178-4c5bee2b8f01" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityRegistrantName_f059f36c-f98f-4367-a178-4c5bee2b8f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_451144ab-d16b-4393-8d66-1de8bd89cda9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityIncorporationStateCountryCode_451144ab-d16b-4393-8d66-1de8bd89cda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_20c122cd-6066-416a-9201-9b9d08e414dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityTaxIdentificationNumber_20c122cd-6066-416a-9201-9b9d08e414dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_80269ec6-2286-4714-b975-1d7ef6048cb9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityAddressAddressLine1_80269ec6-2286-4714-b975-1d7ef6048cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f99872bb-d440-4c8b-974f-2578a6f2d823" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityAddressCityOrTown_f99872bb-d440-4c8b-974f-2578a6f2d823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e73297a3-15b2-4418-a25c-064cb08458e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityAddressStateOrProvince_e73297a3-15b2-4418-a25c-064cb08458e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_36e1ce7d-d447-4fea-a9f9-936cd2942987" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityAddressPostalZipCode_36e1ce7d-d447-4fea-a9f9-936cd2942987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_76d1c670-65b3-4d52-988f-f86d9cbcacb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_CityAreaCode_76d1c670-65b3-4d52-988f-f86d9cbcacb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ff94749e-a2d7-4e97-acc4-98ac2c37cb5b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_LocalPhoneNumber_ff94749e-a2d7-4e97-acc4-98ac2c37cb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2941a6ed-2ce2-4394-a335-3a3d56109fd4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_Security12bTitle_2941a6ed-2ce2-4394-a335-3a3d56109fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ab05c550-4406-42d5-9889-77ff4d27e73b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_TradingSymbol_ab05c550-4406-42d5-9889-77ff4d27e73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_923648db-3472-4575-8bbf-61fbdf8c747e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_SecurityExchangeName_923648db-3472-4575-8bbf-61fbdf8c747e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_cb8adfc6-cede-4a68-861e-55828f33d3aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_cb8adfc6-cede-4a68-861e-55828f33d3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_c40f2fb9-d25e-48b8-8c9b-88e6922b5ed7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityVoluntaryFilers_c40f2fb9-d25e-48b8-8c9b-88e6922b5ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_181cda0e-b768-4b52-a269-1374b4cfe951" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityCurrentReportingStatus_181cda0e-b768-4b52-a269-1374b4cfe951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_cf2cfff6-ac66-4f4d-a16d-6fa3165a2813" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityInteractiveDataCurrent_cf2cfff6-ac66-4f4d-a16d-6fa3165a2813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a7977e75-cdca-45c3-bb13-64a3e5e137dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityFilerCategory_a7977e75-cdca-45c3-bb13-64a3e5e137dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_77e9d654-1499-4fa4-b6c3-e9104ca9476b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntitySmallBusiness_77e9d654-1499-4fa4-b6c3-e9104ca9476b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_81dd283e-2881-4c31-b462-92ff4b89ab03" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityEmergingGrowthCompany_81dd283e-2881-4c31-b462-92ff4b89ab03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_3418981e-6b69-44ed-969e-741161415656" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_IcfrAuditorAttestationFlag_3418981e-6b69-44ed-969e-741161415656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_9d4a98de-644f-40f5-a361-54edbaab45a0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityShellCompany_9d4a98de-644f-40f5-a361-54edbaab45a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_559cc2ca-7667-4414-bc62-9feab830c66a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityPublicFloat_559cc2ca-7667-4414-bc62-9feab830c66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ef6cac79-b046-4960-bf32-a21609f5cc7c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ef6cac79-b046-4960-bf32-a21609f5cc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_484ace1b-a829-447a-918f-535fd05989eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_484ace1b-a829-447a-918f-535fd05989eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b6c67a81-27d8-4f95-8dc1-91a07ee6fbec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_AmendmentFlag_b6c67a81-27d8-4f95-8dc1-91a07ee6fbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_89efbb62-94a4-4514-b787-9a72a0cd960d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_DocumentFiscalYearFocus_89efbb62-94a4-4514-b787-9a72a0cd960d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1267599f-ac1f-4fa6-8fdc-b86da7380436" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1267599f-ac1f-4fa6-8fdc-b86da7380436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d08c12cf-d6d7-4d28-86a6-dcbade6302f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95ae2946-8732-4b7a-8ecc-b90c2ae29bec" xlink:to="loc_dei_EntityCentralIndexKey_d08c12cf-d6d7-4d28-86a6-dcbade6302f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/AuditInformation" xlink:type="simple" xlink:href="exel-20221230.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exel_AuditInformationAbstract_e7e42358-1883-4d95-b835-2ad8e7e6c046" xlink:href="exel-20221230.xsd#exel_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_a09964fa-2229-488d-b1cc-f1d210f3b60e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_AuditInformationAbstract_e7e42358-1883-4d95-b835-2ad8e7e6c046" xlink:to="loc_dei_AuditorName_a09964fa-2229-488d-b1cc-f1d210f3b60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_25da9cca-30d6-47b7-b80d-e04ba57369a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_AuditInformationAbstract_e7e42358-1883-4d95-b835-2ad8e7e6c046" xlink:to="loc_dei_AuditorLocation_25da9cca-30d6-47b7-b80d-e04ba57369a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_484fc222-9e8c-43ce-9cda-159e268b75fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_AuditInformationAbstract_e7e42358-1883-4d95-b835-2ad8e7e6c046" xlink:to="loc_dei_AuditorFirmId_484fc222-9e8c-43ce-9cda-159e268b75fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20221230.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9843a4e9-f027-4a98-af53-ec1740e5084d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d20ff025-4a48-45a1-8720-d51690fe62e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9843a4e9-f027-4a98-af53-ec1740e5084d" xlink:to="loc_us-gaap_AssetsAbstract_d20ff025-4a48-45a1-8720-d51690fe62e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_27b9c12f-88ec-44a0-a9e0-d0ed41dcfb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d20ff025-4a48-45a1-8720-d51690fe62e9" xlink:to="loc_us-gaap_AssetsCurrentAbstract_27b9c12f-88ec-44a0-a9e0-d0ed41dcfb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2ebb5411-0f40-4f06-8483-884baabc7c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27b9c12f-88ec-44a0-a9e0-d0ed41dcfb8c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2ebb5411-0f40-4f06-8483-884baabc7c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_48e5aaa9-c376-4e2f-be2f-0add45eea829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27b9c12f-88ec-44a0-a9e0-d0ed41dcfb8c" xlink:to="loc_us-gaap_ShortTermInvestments_48e5aaa9-c376-4e2f-be2f-0add45eea829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_85c5db1b-9260-4b94-bdbd-5f3ce728eddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27b9c12f-88ec-44a0-a9e0-d0ed41dcfb8c" xlink:to="loc_us-gaap_ReceivablesNetCurrent_85c5db1b-9260-4b94-bdbd-5f3ce728eddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e989b44f-4919-4cfe-b5a3-b0f4b1e7a904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27b9c12f-88ec-44a0-a9e0-d0ed41dcfb8c" xlink:to="loc_us-gaap_InventoryNet_e989b44f-4919-4cfe-b5a3-b0f4b1e7a904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2c8c1c6c-7ae7-49b2-b51c-99569e2d8440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27b9c12f-88ec-44a0-a9e0-d0ed41dcfb8c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2c8c1c6c-7ae7-49b2-b51c-99569e2d8440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0ea958a2-2be2-4b45-9005-8f07503bb20e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27b9c12f-88ec-44a0-a9e0-d0ed41dcfb8c" xlink:to="loc_us-gaap_AssetsCurrent_0ea958a2-2be2-4b45-9005-8f07503bb20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_30258a3a-5068-4f74-8cf2-1897c0650779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d20ff025-4a48-45a1-8720-d51690fe62e9" xlink:to="loc_us-gaap_LongTermInvestments_30258a3a-5068-4f74-8cf2-1897c0650779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b0fae884-2dca-49dd-bfc3-6fe1d1501283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d20ff025-4a48-45a1-8720-d51690fe62e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b0fae884-2dca-49dd-bfc3-6fe1d1501283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_6abfde97-0183-4925-8fee-549b57e40163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d20ff025-4a48-45a1-8720-d51690fe62e9" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_6abfde97-0183-4925-8fee-549b57e40163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b956d149-d289-4063-bf9d-f5368d94359c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d20ff025-4a48-45a1-8720-d51690fe62e9" xlink:to="loc_us-gaap_Goodwill_b956d149-d289-4063-bf9d-f5368d94359c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseRightOfUseAssetAndOtherAssets_b0fe18d2-79cb-4dd6-b004-bd8ab5d106a3" xlink:href="exel-20221230.xsd#exel_OperatingLeaseRightOfUseAssetAndOtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d20ff025-4a48-45a1-8720-d51690fe62e9" xlink:to="loc_exel_OperatingLeaseRightOfUseAssetAndOtherAssets_b0fe18d2-79cb-4dd6-b004-bd8ab5d106a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8044f3e1-8f8f-4153-9b7a-6fdd92f82b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d20ff025-4a48-45a1-8720-d51690fe62e9" xlink:to="loc_us-gaap_Assets_8044f3e1-8f8f-4153-9b7a-6fdd92f82b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3272809a-9bea-4c46-b367-299747f1ed52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9843a4e9-f027-4a98-af53-ec1740e5084d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3272809a-9bea-4c46-b367-299747f1ed52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c923b349-f329-46ae-ad75-7d07475ea153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3272809a-9bea-4c46-b367-299747f1ed52" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c923b349-f329-46ae-ad75-7d07475ea153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d78c43dc-436c-408b-95b3-d6fa2515d859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c923b349-f329-46ae-ad75-7d07475ea153" xlink:to="loc_us-gaap_AccountsPayableCurrent_d78c43dc-436c-408b-95b3-d6fa2515d859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_e1d07537-75c1-4d8c-bbfb-bde282c18218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c923b349-f329-46ae-ad75-7d07475ea153" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_e1d07537-75c1-4d8c-bbfb-bde282c18218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_c321b32a-fbd0-448d-b232-73471c373122" xlink:href="exel-20221230.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c923b349-f329-46ae-ad75-7d07475ea153" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_c321b32a-fbd0-448d-b232-73471c373122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_2ef2b497-2916-46d4-95ce-7aafe8c2b76a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c923b349-f329-46ae-ad75-7d07475ea153" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_2ef2b497-2916-46d4-95ce-7aafe8c2b76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_418a58eb-fc95-4e20-b7e4-92dfe7153df9" xlink:href="exel-20221230.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c923b349-f329-46ae-ad75-7d07475ea153" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_418a58eb-fc95-4e20-b7e4-92dfe7153df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6de4475e-264b-460c-b89e-0bfb8f39f9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c923b349-f329-46ae-ad75-7d07475ea153" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6de4475e-264b-460c-b89e-0bfb8f39f9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6052a7c5-271b-4fc2-a5ae-92f38898be1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c923b349-f329-46ae-ad75-7d07475ea153" xlink:to="loc_us-gaap_LiabilitiesCurrent_6052a7c5-271b-4fc2-a5ae-92f38898be1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3425867c-ce22-4f5d-8b58-7f9cbc50c62c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3272809a-9bea-4c46-b367-299747f1ed52" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3425867c-ce22-4f5d-8b58-7f9cbc50c62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_20436171-daeb-4b21-bb19-8d90aa49d50c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3272809a-9bea-4c46-b367-299747f1ed52" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_20436171-daeb-4b21-bb19-8d90aa49d50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_fb4a7c23-a736-4bb3-b251-f808e5c419fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3272809a-9bea-4c46-b367-299747f1ed52" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_fb4a7c23-a736-4bb3-b251-f808e5c419fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b7602ab7-cd06-4291-b97e-04c1a81c4cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3272809a-9bea-4c46-b367-299747f1ed52" xlink:to="loc_us-gaap_Liabilities_b7602ab7-cd06-4291-b97e-04c1a81c4cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_457d284c-47f5-4037-ac01-fcf83809660f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3272809a-9bea-4c46-b367-299747f1ed52" xlink:to="loc_us-gaap_CommitmentsAndContingencies_457d284c-47f5-4037-ac01-fcf83809660f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e098b508-aec1-4e34-be9e-79208c5bb158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3272809a-9bea-4c46-b367-299747f1ed52" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e098b508-aec1-4e34-be9e-79208c5bb158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1094fcf0-87df-4235-a58d-868a7d58b29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e098b508-aec1-4e34-be9e-79208c5bb158" xlink:to="loc_us-gaap_PreferredStockValue_1094fcf0-87df-4235-a58d-868a7d58b29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1f6b818d-26ea-408b-ba53-ee809e13a3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e098b508-aec1-4e34-be9e-79208c5bb158" xlink:to="loc_us-gaap_CommonStockValue_1f6b818d-26ea-408b-ba53-ee809e13a3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_412e99b2-f2bb-4336-9d3a-7d5326463a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e098b508-aec1-4e34-be9e-79208c5bb158" xlink:to="loc_us-gaap_AdditionalPaidInCapital_412e99b2-f2bb-4336-9d3a-7d5326463a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_66aa3fc4-49e9-4dc7-b56b-fc6c0fe75f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e098b508-aec1-4e34-be9e-79208c5bb158" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_66aa3fc4-49e9-4dc7-b56b-fc6c0fe75f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2b7fbde0-cd4d-4cc1-87a3-e223ea429fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e098b508-aec1-4e34-be9e-79208c5bb158" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2b7fbde0-cd4d-4cc1-87a3-e223ea429fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7e5b1a55-6db2-460d-95c8-584fca958b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e098b508-aec1-4e34-be9e-79208c5bb158" xlink:to="loc_us-gaap_StockholdersEquity_7e5b1a55-6db2-460d-95c8-584fca958b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_df5d1e30-f063-4201-8fbe-a7e2bd7f58d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3272809a-9bea-4c46-b367-299747f1ed52" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_df5d1e30-f063-4201-8fbe-a7e2bd7f58d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exel-20221230.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e8e7181b-bf76-43ba-b98e-0e6da2ed458c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_b4454945-25d7-4134-bb1e-6df57f072671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e8e7181b-bf76-43ba-b98e-0e6da2ed458c" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_b4454945-25d7-4134-bb1e-6df57f072671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_aa5158e8-9f01-49da-baf5-aeeda74a505f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_b4454945-25d7-4134-bb1e-6df57f072671" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_aa5158e8-9f01-49da-baf5-aeeda74a505f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9d1e82b8-c63d-44bd-957d-0a2bbc66a9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_b4454945-25d7-4134-bb1e-6df57f072671" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9d1e82b8-c63d-44bd-957d-0a2bbc66a9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8282269d-4e9a-4d2b-9be0-f558a4fd62f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_b4454945-25d7-4134-bb1e-6df57f072671" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8282269d-4e9a-4d2b-9be0-f558a4fd62f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_de5838bb-e186-458d-9371-03f980fa579a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e8e7181b-bf76-43ba-b98e-0e6da2ed458c" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_de5838bb-e186-458d-9371-03f980fa579a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_00198048-755e-4d57-bd79-1acd345af285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_de5838bb-e186-458d-9371-03f980fa579a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_00198048-755e-4d57-bd79-1acd345af285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1043651e-4ba2-4eb6-9671-8f87736a25c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_de5838bb-e186-458d-9371-03f980fa579a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1043651e-4ba2-4eb6-9671-8f87736a25c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_9ac92f97-439d-4778-9862-503752b8bdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_de5838bb-e186-458d-9371-03f980fa579a" xlink:to="loc_us-gaap_CommonStockSharesIssued_9ac92f97-439d-4778-9862-503752b8bdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d5b28248-46e0-41ac-bd6f-b90826d202be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_de5838bb-e186-458d-9371-03f980fa579a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d5b28248-46e0-41ac-bd6f-b90826d202be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20221230.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_3e18c65e-71bb-4c3c-abab-3a50f9d0b346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_df94ea2c-6673-444d-8395-4d3c9fbc8099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3e18c65e-71bb-4c3c-abab-3a50f9d0b346" xlink:to="loc_us-gaap_StatementTable_df94ea2c-6673-444d-8395-4d3c9fbc8099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aa9c3122-b078-4023-a545-1d51bde6fb0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_df94ea2c-6673-444d-8395-4d3c9fbc8099" xlink:to="loc_srt_ProductOrServiceAxis_aa9c3122-b078-4023-a545-1d51bde6fb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7bacdcf6-fc48-478d-b564-c0752925c25f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_aa9c3122-b078-4023-a545-1d51bde6fb0d" xlink:to="loc_srt_ProductsAndServicesDomain_7bacdcf6-fc48-478d-b564-c0752925c25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_031ccedf-b720-4564-a3ed-499010c1ff75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7bacdcf6-fc48-478d-b564-c0752925c25f" xlink:to="loc_us-gaap_ProductMember_031ccedf-b720-4564-a3ed-499010c1ff75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_da6cd2a5-d2cf-48b7-af2f-2a24e7df67f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7bacdcf6-fc48-478d-b564-c0752925c25f" xlink:to="loc_us-gaap_LicenseMember_da6cd2a5-d2cf-48b7-af2f-2a24e7df67f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_609bd5a5-d2a7-47fc-9839-e5bd1b29c4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7bacdcf6-fc48-478d-b564-c0752925c25f" xlink:to="loc_us-gaap_ServiceMember_609bd5a5-d2a7-47fc-9839-e5bd1b29c4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_df94ea2c-6673-444d-8395-4d3c9fbc8099" xlink:to="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_df4997bb-7712-4d2b-bdef-dcee1cdbefd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_RevenuesAbstract_df4997bb-7712-4d2b-bdef-dcee1cdbefd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_625cc0bf-cd90-4cb3-80d2-187eba524eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_df4997bb-7712-4d2b-bdef-dcee1cdbefd4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_625cc0bf-cd90-4cb3-80d2-187eba524eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c12af3f4-3ea7-4755-896a-52ddbdfcfe67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c12af3f4-3ea7-4755-896a-52ddbdfcfe67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6ee9a52b-c429-40c9-87c3-4b85c8f82c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c12af3f4-3ea7-4755-896a-52ddbdfcfe67" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6ee9a52b-c429-40c9-87c3-4b85c8f82c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3a338a90-70ef-45b2-b72b-38e3d448fbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c12af3f4-3ea7-4755-896a-52ddbdfcfe67" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3a338a90-70ef-45b2-b72b-38e3d448fbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d880e492-349f-49ca-9a4f-dcec5c3ec8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c12af3f4-3ea7-4755-896a-52ddbdfcfe67" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d880e492-349f-49ca-9a4f-dcec5c3ec8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_40457a03-6c7d-4c43-8805-9afa6b7705d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c12af3f4-3ea7-4755-896a-52ddbdfcfe67" xlink:to="loc_us-gaap_CostsAndExpenses_40457a03-6c7d-4c43-8805-9afa6b7705d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_20662add-5fac-45c4-a4f4-a127a4e17f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_OperatingIncomeLoss_20662add-5fac-45c4-a4f4-a127a4e17f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_799ae11f-6c04-438d-9cb0-155bd9494f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_InterestIncomeOther_799ae11f-6c04-438d-9cb0-155bd9494f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_34ed8f64-63c7-49d9-a829-136a3bf61784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_34ed8f64-63c7-49d9-a829-136a3bf61784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_f256349a-99e9-49a0-9cf4-180197c57800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_f256349a-99e9-49a0-9cf4-180197c57800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ccfe58fd-c5ab-413e-9eaf-185c191dc852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ccfe58fd-c5ab-413e-9eaf-185c191dc852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1a161034-6a56-44e0-b98f-79b95f84524e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_NetIncomeLoss_1a161034-6a56-44e0-b98f-79b95f84524e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2be2c736-6527-429c-978a-78be74b0edbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_EarningsPerShareAbstract_2be2c736-6527-429c-978a-78be74b0edbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3aa0e408-329e-43e0-af62-d46c773e5662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2be2c736-6527-429c-978a-78be74b0edbe" xlink:to="loc_us-gaap_EarningsPerShareBasic_3aa0e408-329e-43e0-af62-d46c773e5662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_cd94441c-ef7a-4692-921d-5ddb00c5bc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2be2c736-6527-429c-978a-78be74b0edbe" xlink:to="loc_us-gaap_EarningsPerShareDiluted_cd94441c-ef7a-4692-921d-5ddb00c5bc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_bf23b43a-c0a0-408c-9506-718fd2c7bf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12be61cd-24e3-4a1c-94b0-37acddc50fbd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_bf23b43a-c0a0-408c-9506-718fd2c7bf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f67340fa-5d8b-4170-b38a-8262ca32f99e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_bf23b43a-c0a0-408c-9506-718fd2c7bf3a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f67340fa-5d8b-4170-b38a-8262ca32f99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c37e4e4b-2610-493b-8c0f-b9cc8c9eb5da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_bf23b43a-c0a0-408c-9506-718fd2c7bf3a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c37e4e4b-2610-493b-8c0f-b9cc8c9eb5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="exel-20221230.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f31e4313-7e73-49d0-8753-3c633d5ca147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2cbc0de2-2b24-41a0-a85f-5997c01d79c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f31e4313-7e73-49d0-8753-3c633d5ca147" xlink:to="loc_us-gaap_NetIncomeLoss_2cbc0de2-2b24-41a0-a85f-5997c01d79c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_bae45174-09a7-4cdb-9269-fc6bcfbb4d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f31e4313-7e73-49d0-8753-3c633d5ca147" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_bae45174-09a7-4cdb-9269-fc6bcfbb4d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_01fe45b5-332b-40b7-b46e-b5ffc0e68cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_bae45174-09a7-4cdb-9269-fc6bcfbb4d18" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_01fe45b5-332b-40b7-b46e-b5ffc0e68cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4a331d98-fafa-4231-88c1-1486d9811bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_bae45174-09a7-4cdb-9269-fc6bcfbb4d18" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_4a331d98-fafa-4231-88c1-1486d9811bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="exel-20221230.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7975a715-bc5d-4e11-9b3d-446b366c838c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_613392e8-f6e3-4f5e-b922-b31d792dd5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7975a715-bc5d-4e11-9b3d-446b366c838c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_613392e8-f6e3-4f5e-b922-b31d792dd5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20221230.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5738ca1d-11e8-4bca-8176-910291012638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ec0b18d3-c07a-42c0-bca4-eeb10a3ad3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5738ca1d-11e8-4bca-8176-910291012638" xlink:to="loc_us-gaap_StatementTable_ec0b18d3-c07a-42c0-bca4-eeb10a3ad3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eb0677ba-481a-45a5-b999-d1c16cd2b78c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ec0b18d3-c07a-42c0-bca4-eeb10a3ad3db" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eb0677ba-481a-45a5-b999-d1c16cd2b78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f340826d-07b3-4205-a0fe-989b9fac1ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb0677ba-481a-45a5-b999-d1c16cd2b78c" xlink:to="loc_us-gaap_EquityComponentDomain_f340826d-07b3-4205-a0fe-989b9fac1ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f8b07eaf-d6d6-4e5f-8526-684057a0a261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f340826d-07b3-4205-a0fe-989b9fac1ff5" xlink:to="loc_us-gaap_CommonStockMember_f8b07eaf-d6d6-4e5f-8526-684057a0a261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_da5484d4-e717-4017-8a16-3456d404e1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f340826d-07b3-4205-a0fe-989b9fac1ff5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_da5484d4-e717-4017-8a16-3456d404e1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_704fbe10-d612-489d-ad92-53437a8f831a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f340826d-07b3-4205-a0fe-989b9fac1ff5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_704fbe10-d612-489d-ad92-53437a8f831a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_95121019-a427-4f6b-83ca-e5790fafd5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f340826d-07b3-4205-a0fe-989b9fac1ff5" xlink:to="loc_us-gaap_RetainedEarningsMember_95121019-a427-4f6b-83ca-e5790fafd5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ea9e8b8c-592a-44de-8d29-171cecbc8a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ec0b18d3-c07a-42c0-bca4-eeb10a3ad3db" xlink:to="loc_us-gaap_StatementLineItems_ea9e8b8c-592a-44de-8d29-171cecbc8a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ea9e8b8c-592a-44de-8d29-171cecbc8a7e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_76c746aa-510e-485c-a318-05dca91ba4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_76c746aa-510e-485c-a318-05dca91ba4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f9fe2aee-bb93-4fb5-bb89-6bf9934dc689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_StockholdersEquity_f9fe2aee-bb93-4fb5-bb89-6bf9934dc689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5479b57f-c63f-4622-9a3a-7bd5bc67c577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_NetIncomeLoss_5479b57f-c63f-4622-9a3a-7bd5bc67c577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7f2a2649-cc0d-4489-954a-a52c1fe3ab7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7f2a2649-cc0d-4489-954a-a52c1fe3ab7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b8fe0129-76d8-487a-b887-fdde52b2be3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b8fe0129-76d8-487a-b887-fdde52b2be3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2a138135-6698-453e-bc57-52f59621d878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2a138135-6698-453e-bc57-52f59621d878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ded4e6ea-5ae8-4818-aff7-00e1e3b42f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ded4e6ea-5ae8-4818-aff7-00e1e3b42f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eb291419-f8f5-40a6-a3ea-564737122690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eb291419-f8f5-40a6-a3ea-564737122690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d94a3aab-1013-4541-a8ac-7d46a661e59f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d94a3aab-1013-4541-a8ac-7d46a661e59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e9c2ea5b-67a7-43a1-b71b-03b661d5997c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7722a80a-6bef-4bd4-ae6a-b8a6ac2863bd" xlink:to="loc_us-gaap_StockholdersEquity_e9c2ea5b-67a7-43a1-b71b-03b661d5997c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20221230.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6b7a33b6-9a22-4df3-8417-c1e7fde8c71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7608df7-8806-4b4e-9f09-93dea197c916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6b7a33b6-9a22-4df3-8417-c1e7fde8c71e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7608df7-8806-4b4e-9f09-93dea197c916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9b412a02-311b-4eef-867b-6081852e55b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7608df7-8806-4b4e-9f09-93dea197c916" xlink:to="loc_us-gaap_NetIncomeLoss_9b412a02-311b-4eef-867b-6081852e55b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_648d5bd4-5dc5-4df6-8c4d-b790796cdc70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7608df7-8806-4b4e-9f09-93dea197c916" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_648d5bd4-5dc5-4df6-8c4d-b790796cdc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f0955797-d567-4b8b-b520-e85b8bbde6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_648d5bd4-5dc5-4df6-8c4d-b790796cdc70" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f0955797-d567-4b8b-b520-e85b8bbde6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fb8488a6-72c0-4a13-844f-3506755745c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_648d5bd4-5dc5-4df6-8c4d-b790796cdc70" xlink:to="loc_us-gaap_ShareBasedCompensation_fb8488a6-72c0-4a13-844f-3506755745c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_92ad6354-3781-4695-a3df-bab3a4803a24" xlink:href="exel-20221230.xsd#exel_NoncashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_648d5bd4-5dc5-4df6-8c4d-b790796cdc70" xlink:to="loc_exel_NoncashLeaseExpense_92ad6354-3781-4695-a3df-bab3a4803a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_30813c4c-6d6d-42ce-bf8e-68b7067e5874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_648d5bd4-5dc5-4df6-8c4d-b790796cdc70" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_30813c4c-6d6d-42ce-bf8e-68b7067e5874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_764ff533-8186-4692-bca8-4a5600212aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_648d5bd4-5dc5-4df6-8c4d-b790796cdc70" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_764ff533-8186-4692-bca8-4a5600212aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_82501144-865e-4038-8e2b-058b322e33cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_648d5bd4-5dc5-4df6-8c4d-b790796cdc70" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_82501144-865e-4038-8e2b-058b322e33cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95996f38-7262-47b8-af83-18feeb570755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_648d5bd4-5dc5-4df6-8c4d-b790796cdc70" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95996f38-7262-47b8-af83-18feeb570755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_48f983b0-deab-4de0-8210-32cf05d21a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95996f38-7262-47b8-af83-18feeb570755" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_48f983b0-deab-4de0-8210-32cf05d21a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3c1849f1-4e85-4c98-9173-648e889ff1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95996f38-7262-47b8-af83-18feeb570755" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3c1849f1-4e85-4c98-9173-648e889ff1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ac6e6dd2-b617-49bf-848b-75a26f422b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95996f38-7262-47b8-af83-18feeb570755" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ac6e6dd2-b617-49bf-848b-75a26f422b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_87ef6579-3796-4ba9-9026-988e392719f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95996f38-7262-47b8-af83-18feeb570755" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_87ef6579-3796-4ba9-9026-988e392719f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_878f76f8-7e72-45f3-934f-a5fcca8a811e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95996f38-7262-47b8-af83-18feeb570755" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_878f76f8-7e72-45f3-934f-a5fcca8a811e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_42975201-162f-4e64-b599-edd8d56878a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95996f38-7262-47b8-af83-18feeb570755" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_42975201-162f-4e64-b599-edd8d56878a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_32402dbb-40f3-4806-b926-b45a05fadf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7608df7-8806-4b4e-9f09-93dea197c916" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_32402dbb-40f3-4806-b926-b45a05fadf9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9a0d3037-1b7f-4be9-9f7e-238597ac9a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6b7a33b6-9a22-4df3-8417-c1e7fde8c71e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9a0d3037-1b7f-4be9-9f7e-238597ac9a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e535f0e2-272a-40d4-a689-692900117374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9a0d3037-1b7f-4be9-9f7e-238597ac9a1f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e535f0e2-272a-40d4-a689-692900117374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8b831fa1-3167-4aff-9ec7-4f1c3aceefb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9a0d3037-1b7f-4be9-9f7e-238597ac9a1f" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8b831fa1-3167-4aff-9ec7-4f1c3aceefb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_4ec27262-1e86-4d9a-98b4-c347a43f4d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9a0d3037-1b7f-4be9-9f7e-238597ac9a1f" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_4ec27262-1e86-4d9a-98b4-c347a43f4d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_766d47f9-6291-4be6-bf34-f3d9f8995d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9a0d3037-1b7f-4be9-9f7e-238597ac9a1f" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_766d47f9-6291-4be6-bf34-f3d9f8995d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7a0ce785-8b01-4f8e-89ca-debc722b37cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9a0d3037-1b7f-4be9-9f7e-238597ac9a1f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7a0ce785-8b01-4f8e-89ca-debc722b37cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_204c6665-d472-4517-aaf5-b237391367ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6b7a33b6-9a22-4df3-8417-c1e7fde8c71e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_204c6665-d472-4517-aaf5-b237391367ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0b0337e7-1f14-43ed-bfe4-a1f874d8dfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_204c6665-d472-4517-aaf5-b237391367ae" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0b0337e7-1f14-43ed-bfe4-a1f874d8dfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0893a59e-6b9f-40df-b085-1cdea5599f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_204c6665-d472-4517-aaf5-b237391367ae" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0893a59e-6b9f-40df-b085-1cdea5599f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_17f070a4-76f2-49cb-a70f-1aa921ee5fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_204c6665-d472-4517-aaf5-b237391367ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_17f070a4-76f2-49cb-a70f-1aa921ee5fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f38ad690-0b9a-400e-9cdc-907145d590e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6b7a33b6-9a22-4df3-8417-c1e7fde8c71e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f38ad690-0b9a-400e-9cdc-907145d590e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_da644724-2d86-4f86-9bb3-82b93f1cd1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6b7a33b6-9a22-4df3-8417-c1e7fde8c71e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_da644724-2d86-4f86-9bb3-82b93f1cd1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_966d3f2a-999c-4aab-8349-ce389668f491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6b7a33b6-9a22-4df3-8417-c1e7fde8c71e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_966d3f2a-999c-4aab-8349-ce389668f491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_a581b4ef-0d97-4adc-8d64-0338f259c098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6b7a33b6-9a22-4df3-8417-c1e7fde8c71e" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_a581b4ef-0d97-4adc-8d64-0338f259c098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_74383c75-6239-4a67-9557-22891838fd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a581b4ef-0d97-4adc-8d64-0338f259c098" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_74383c75-6239-4a67-9557-22891838fd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_0d71a4ee-0b76-4b07-950f-658095c6b187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a581b4ef-0d97-4adc-8d64-0338f259c098" xlink:to="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_0d71a4ee-0b76-4b07-950f-658095c6b187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_53671e08-cfe2-43f4-adb2-5ebcce4a6d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_0d71a4ee-0b76-4b07-950f-658095c6b187" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_53671e08-cfe2-43f4-adb2-5ebcce4a6d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54e541b1-712f-40dc-8fbc-160cc10f915f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a581b4ef-0d97-4adc-8d64-0338f259c098" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54e541b1-712f-40dc-8fbc-160cc10f915f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccountsReceivableForUnsettledInvestmentSales_82842e20-435b-4def-977a-5c08667acc56" xlink:href="exel-20221230.xsd#exel_AccountsReceivableForUnsettledInvestmentSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54e541b1-712f-40dc-8fbc-160cc10f915f" xlink:to="loc_exel_AccountsReceivableForUnsettledInvestmentSales_82842e20-435b-4def-977a-5c08667acc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exel-20221230.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1774c784-6b77-464a-b2b7-495dca3685b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_944472d2-8007-46bb-ae82-e179ee03af60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1774c784-6b77-464a-b2b7-495dca3685b1" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_944472d2-8007-46bb-ae82-e179ee03af60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:type="simple" xlink:href="exel-20221230.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c93364f5-64e7-4063-a677-a745ac1f4e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_34220502-310e-4ddc-a2bf-c6c02fca1ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c93364f5-64e7-4063-a677-a745ac1f4e77" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_34220502-310e-4ddc-a2bf-c6c02fca1ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities" xlink:type="simple" xlink:href="exel-20221230.xsd#CollaborationAgreementsAndBusinessDevelopmentActivities"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81688dca-18db-4ea8-8681-c243f288413d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_27855fe6-d5d9-4139-8e89-594113cb5c42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81688dca-18db-4ea8-8681-c243f288413d" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_27855fe6-d5d9-4139-8e89-594113cb5c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestments" xlink:type="simple" xlink:href="exel-20221230.xsd#CashandInvestments"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d4e82b41-b219-4a8f-838a-a2e3f42e289f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_70127370-83ba-4929-aa44-27e43434f789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d4e82b41-b219-4a8f-838a-a2e3f42e289f" xlink:to="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_70127370-83ba-4929-aa44-27e43434f789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exel-20221230.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7756941a-65be-408d-b788-6b1b945ae122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ffac66b7-a697-4efc-8c3a-4b5f41ee1d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7756941a-65be-408d-b788-6b1b945ae122" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ffac66b7-a697-4efc-8c3a-4b5f41ee1d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:type="simple" xlink:href="exel-20221230.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_63fd6deb-3ed8-4fb1-856f-eda77eca386e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_c38ccbbf-b57d-4c3b-a6b6-fec5db79df09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_63fd6deb-3ed8-4fb1-856f-eda77eca386e" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_c38ccbbf-b57d-4c3b-a6b6-fec5db79df09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="exel-20221230.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1cb1e581-437d-44b6-b92a-5ad45c15fb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b8266116-039f-406e-ab46-843e4a868c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1cb1e581-437d-44b6-b92a-5ad45c15fb7d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b8266116-039f-406e-ab46-843e4a868c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="exel-20221230.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8d767360-9de2-47e3-b2a5-15a95efba6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_58cabfbe-9102-4e53-87ed-56c8c9ac7fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8d767360-9de2-47e3-b2a5-15a95efba6f9" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_58cabfbe-9102-4e53-87ed-56c8c9ac7fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxes" xlink:type="simple" xlink:href="exel-20221230.xsd#ProvisionForIncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fa48b928-55a6-4891-9b2f-2b4df1c70a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_698bbf4b-0f8a-4b4a-bff8-43161f57280b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fa48b928-55a6-4891-9b2f-2b4df1c70a59" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_698bbf4b-0f8a-4b4a-bff8-43161f57280b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="exel-20221230.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c951ac78-c1da-458c-bf11-cf55bcdedebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_314a74fb-3704-4ad2-99a9-ab3320d6270a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c951ac78-c1da-458c-bf11-cf55bcdedebf" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_314a74fb-3704-4ad2-99a9-ab3320d6270a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exel-20221230.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1487c9ee-98fe-4870-bc43-39a70d6c3e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_80723ffe-4660-4404-bede-ee5a480f3605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1487c9ee-98fe-4870-bc43-39a70d6c3e14" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_80723ffe-4660-4404-bede-ee5a480f3605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exel-20221230.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_aea57366-602c-4102-8c69-42dcab258680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_aea57366-602c-4102-8c69-42dcab258680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod_8556d719-f324-4df7-a796-4b8ca105f357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiscalPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_FiscalPeriod_8556d719-f324-4df7-a796-4b8ca105f357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_c92814af-51a5-48e9-b8b2-7671dcbe77d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_c92814af-51a5-48e9-b8b2-7671dcbe77d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_1fb5b480-e431-4b6a-9a85-d63cbd1565ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_UseOfEstimates_1fb5b480-e431-4b6a-9a85-d63cbd1565ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ceb30665-bb84-4ebc-bee5-864c0c1733b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ceb30665-bb84-4ebc-bee5-864c0c1733b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ba6295b4-3217-430b-8afb-c639f26b5426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ba6295b4-3217-430b-8afb-c639f26b5426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_e293fd05-8761-4c00-b426-067597ce97a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_e293fd05-8761-4c00-b426-067597ce97a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_d6138cbe-3b96-4a5d-bde1-ea02f4774c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_d6138cbe-3b96-4a5d-bde1-ea02f4774c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_04c65859-7c4e-465d-9c10-d4b7d0a7e18b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_04c65859-7c4e-465d-9c10-d4b7d0a7e18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_f90a4f6a-772b-41fb-a1c9-70d8db8246fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_f90a4f6a-772b-41fb-a1c9-70d8db8246fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_f500b665-5f60-41f1-b313-87814c87f11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_f500b665-5f60-41f1-b313-87814c87f11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4987337a-e17c-498b-b4e4-72d5df818dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4987337a-e17c-498b-b4e4-72d5df818dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_cbecdeb5-5b55-4acc-a63d-a19854c3fd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_cbecdeb5-5b55-4acc-a63d-a19854c3fd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_c403df96-3f4b-4d7c-bed8-939842afa119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_c403df96-3f4b-4d7c-bed8-939842afa119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_07b8559f-bd0e-430f-8069-69ea25dca968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_07b8559f-bd0e-430f-8069-69ea25dca968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b06a9d28-ad09-4ff9-9586-2c4dc0eb2d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b06a9d28-ad09-4ff9-9586-2c4dc0eb2d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_c69ed8d6-d142-49f0-b023-aecb94c148f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_c69ed8d6-d142-49f0-b023-aecb94c148f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_40636400-e75d-4554-b68b-6150853db5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_40636400-e75d-4554-b68b-6150853db5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a222f1e4-1238-4fe4-9c28-72db83a5a533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a222f1e4-1238-4fe4-9c28-72db83a5a533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_fbe9c1b0-f287-4505-bbdb-4482a968ff63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_fbe9c1b0-f287-4505-bbdb-4482a968ff63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_c2bff730-672b-44b8-ab88-22962e448c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df80c2b0-5714-4352-ac17-3e4db512ae78" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_c2bff730-672b-44b8-ab88-22962e448c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:type="simple" xlink:href="exel-20221230.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ebc9d3a6-5f62-4461-9801-51f061cbc242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_a09a83d4-8ee7-42d0-bdb0-2a6d02012a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ebc9d3a6-5f62-4461-9801-51f061cbc242" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_a09a83d4-8ee7-42d0-bdb0-2a6d02012a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_891bcc12-df57-4e11-8abf-a8eeac6bcbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ebc9d3a6-5f62-4461-9801-51f061cbc242" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_891bcc12-df57-4e11-8abf-a8eeac6bcbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_1440d0a8-7cc4-4486-b7d2-8ca2e8a846ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ebc9d3a6-5f62-4461-9801-51f061cbc242" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_1440d0a8-7cc4-4486-b7d2-8ca2e8a846ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_6067240e-9c12-4515-8e02-4265484b707e" xlink:href="exel-20221230.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ebc9d3a6-5f62-4461-9801-51f061cbc242" xlink:to="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_6067240e-9c12-4515-8e02-4265484b707e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_91803ef3-d8da-43f5-80c8-d30b53d218a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ebc9d3a6-5f62-4461-9801-51f061cbc242" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_91803ef3-d8da-43f5-80c8-d30b53d218a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" xlink:type="simple" xlink:href="exel-20221230.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a97d0f03-7d39-49de-9c8b-ec9d74cfe086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_ae636956-01c9-4498-8441-c72466f1ce1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a97d0f03-7d39-49de-9c8b-ec9d74cfe086" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_ae636956-01c9-4498-8441-c72466f1ce1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="simple" xlink:href="exel-20221230.xsd#CashandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fcfd77f0-b0ab-4e6c-8a39-24372ccecd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_22d8fe34-6b63-4f15-bd15-08593705e867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fcfd77f0-b0ab-4e6c-8a39-24372ccecd4d" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_22d8fe34-6b63-4f15-bd15-08593705e867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_5376acbe-cd36-4d0a-9d9c-87b33f36da42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fcfd77f0-b0ab-4e6c-8a39-24372ccecd4d" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_5376acbe-cd36-4d0a-9d9c-87b33f36da42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_e82fea9f-3fa7-4be2-ac31-d4fabd11270d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fcfd77f0-b0ab-4e6c-8a39-24372ccecd4d" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_e82fea9f-3fa7-4be2-ac31-d4fabd11270d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_30182018-5194-4cd9-afe9-bd04a2fb280f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fcfd77f0-b0ab-4e6c-8a39-24372ccecd4d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_30182018-5194-4cd9-afe9-bd04a2fb280f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_ad3395ad-a1b6-428d-bd43-ed5113b56b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fcfd77f0-b0ab-4e6c-8a39-24372ccecd4d" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_ad3395ad-a1b6-428d-bd43-ed5113b56b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exel-20221230.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1f5b8469-15b4-4d49-8b0f-7a55d6136e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_1d1c0127-0211-4f1a-b868-c37f9510222b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1f5b8469-15b4-4d49-8b0f-7a55d6136e73" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_1d1c0127-0211-4f1a-b868-c37f9510222b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:type="simple" xlink:href="exel-20221230.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_10c1ee53-4d42-4e43-9600-2839a41239b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2ff11312-687a-4b68-9c8b-38893c148e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_10c1ee53-4d42-4e43-9600-2839a41239b8" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2ff11312-687a-4b68-9c8b-38893c148e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="exel-20221230.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_603a4d8c-e170-4675-bec8-cd43a62f2b11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7c03d2ef-1483-4ebd-b115-2c2da478a865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_603a4d8c-e170-4675-bec8-cd43a62f2b11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7c03d2ef-1483-4ebd-b115-2c2da478a865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansTables" xlink:type="simple" xlink:href="exel-20221230.xsd#EmployeeBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7131d562-66d4-433d-8e10-6bed42f02cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a9dedcd5-3b46-437b-9f50-eae8f0bb5ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7131d562-66d4-433d-8e10-6bed42f02cb4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a9dedcd5-3b46-437b-9f50-eae8f0bb5ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_67240cd5-b9c9-48e3-b2b5-57c67ce9132b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7131d562-66d4-433d-8e10-6bed42f02cb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_67240cd5-b9c9-48e3-b2b5-57c67ce9132b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b3fdc6be-75e8-4658-9b43-69c406c84413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7131d562-66d4-433d-8e10-6bed42f02cb4" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b3fdc6be-75e8-4658-9b43-69c406c84413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_f1b77bdd-0fb5-44e8-a8ad-9777ff8e2565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7131d562-66d4-433d-8e10-6bed42f02cb4" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_f1b77bdd-0fb5-44e8-a8ad-9777ff8e2565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5607428d-eb5c-4ded-886c-b843fa1e3e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7131d562-66d4-433d-8e10-6bed42f02cb4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5607428d-eb5c-4ded-886c-b843fa1e3e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ce9271d0-5c65-41f2-a816-4faeed5c9f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7131d562-66d4-433d-8e10-6bed42f02cb4" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ce9271d0-5c65-41f2-a816-4faeed5c9f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_ebcd754d-fd5b-4eff-aef4-51ea08cc38d1" xlink:href="exel-20221230.xsd#exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7131d562-66d4-433d-8e10-6bed42f02cb4" xlink:to="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_ebcd754d-fd5b-4eff-aef4-51ea08cc38d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesTables" xlink:type="simple" xlink:href="exel-20221230.xsd#ProvisionForIncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bfffa6e0-8af5-49f4-8a41-677fb48b0cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_dae8ae3f-42e5-49d9-bb55-bfa84fb0af4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bfffa6e0-8af5-49f4-8a41-677fb48b0cdd" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_dae8ae3f-42e5-49d9-bb55-bfa84fb0af4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_fb5ce308-7004-4c0a-aed0-e4c3ef7b8623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bfffa6e0-8af5-49f4-8a41-677fb48b0cdd" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_fb5ce308-7004-4c0a-aed0-e4c3ef7b8623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_56f572b1-39e7-45de-9602-0e2ba31a17c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bfffa6e0-8af5-49f4-8a41-677fb48b0cdd" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_56f572b1-39e7-45de-9602-0e2ba31a17c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_83ff380c-26e5-4536-bf1e-41a633218362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bfffa6e0-8af5-49f4-8a41-677fb48b0cdd" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_83ff380c-26e5-4536-bf1e-41a633218362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="exel-20221230.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4eb4346c-c7c6-4057-a5af-3062c0f430f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ecb9475a-408b-4315-aaba-35d4a7be02dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4eb4346c-c7c6-4057-a5af-3062c0f430f7" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ecb9475a-408b-4315-aaba-35d4a7be02dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_aa2580a4-3e13-483e-8f7a-346b4a98f649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4eb4346c-c7c6-4057-a5af-3062c0f430f7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_aa2580a4-3e13-483e-8f7a-346b4a98f649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="exel-20221230.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_46405372-2381-4601-bd1d-cc86e17c5831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetsAndLiabilitiesLesseeTableTextBlock_f5746457-a0d7-42cb-bfc2-4eaafc68d3e6" xlink:href="exel-20221230.xsd#exel_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_46405372-2381-4601-bd1d-cc86e17c5831" xlink:to="loc_exel_AssetsAndLiabilitiesLesseeTableTextBlock_f5746457-a0d7-42cb-bfc2-4eaafc68d3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_6500618a-c062-40ee-8031-5de54a377f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_46405372-2381-4601-bd1d-cc86e17c5831" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_6500618a-c062-40ee-8031-5de54a377f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7e42e81e-62e8-4c9a-b118-aa3463d43c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_46405372-2381-4601-bd1d-cc86e17c5831" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7e42e81e-62e8-4c9a-b118-aa3463d43c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6229cf16-2981-42d7-8c13-f3cd18a2d44e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_e5939c54-a26d-41a3-9707-30fcbca96048" xlink:href="exel-20221230.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6229cf16-2981-42d7-8c13-f3cd18a2d44e" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_e5939c54-a26d-41a3-9707-30fcbca96048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_36e9c202-98c4-4eaf-b849-84dbb3b16699" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_e5939c54-a26d-41a3-9707-30fcbca96048" xlink:to="loc_srt_ProductOrServiceAxis_36e9c202-98c4-4eaf-b849-84dbb3b16699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_62d53b10-653b-47f4-a767-3f7a7c823aeb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_36e9c202-98c4-4eaf-b849-84dbb3b16699" xlink:to="loc_srt_ProductsAndServicesDomain_62d53b10-653b-47f4-a767-3f7a7c823aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_578865e5-d63a-4ce0-b931-67278102cc41" xlink:href="exel-20221230.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_62d53b10-653b-47f4-a767-3f7a7c823aeb" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_578865e5-d63a-4ce0-b931-67278102cc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_288caf24-015d-4186-bdc4-2e86c7f8da11" xlink:href="exel-20221230.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_62d53b10-653b-47f4-a767-3f7a7c823aeb" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_288caf24-015d-4186-bdc4-2e86c7f8da11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b7f18324-cb33-4837-bbf5-94024e6be0d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_e5939c54-a26d-41a3-9707-30fcbca96048" xlink:to="loc_srt_RangeAxis_b7f18324-cb33-4837-bbf5-94024e6be0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fe91d47b-1970-4867-be94-6c009707ee64" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b7f18324-cb33-4837-bbf5-94024e6be0d2" xlink:to="loc_srt_RangeMember_fe91d47b-1970-4867-be94-6c009707ee64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_db60c6b9-72ad-4c36-8671-cda13a0a6488" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fe91d47b-1970-4867-be94-6c009707ee64" xlink:to="loc_srt_MaximumMember_db60c6b9-72ad-4c36-8671-cda13a0a6488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:href="exel-20221230.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_e5939c54-a26d-41a3-9707-30fcbca96048" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_e4fa833f-fc25-45fc-9f38-54d0c72e17ce" xlink:href="exel-20221230.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_exel_NumberofProductsinCommercialMarket_e4fa833f-fc25-45fc-9f38-54d0c72e17ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_b1ebefea-9cba-471f-95c1-56b7e6ddfe66" xlink:href="exel-20221230.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_b1ebefea-9cba-471f-95c1-56b7e6ddfe66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_26da5f8c-937a-4ce7-b7c3-e49755e9d772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_us-gaap_NumberOfOperatingSegments_26da5f8c-937a-4ce7-b7c3-e49755e9d772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_81922b35-8b54-489d-85f4-d8a0595cdf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_81922b35-8b54-489d-85f4-d8a0595cdf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_96677024-3381-4b3e-9765-f5ce547f8fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_96677024-3381-4b3e-9765-f5ce547f8fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_8e64ce24-c077-4d44-ab19-2f9464d449ca" xlink:href="exel-20221230.xsd#exel_SalesRevenuePercentDiscountForPromptPayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_exel_SalesRevenuePercentDiscountForPromptPayment_8e64ce24-c077-4d44-ab19-2f9464d449ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_65f2e750-3cd0-4f6f-829e-fd240f37725a" xlink:href="exel-20221230.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_65f2e750-3cd0-4f6f-829e-fd240f37725a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MedicarePartDFundingMandate_5c0039e5-89dc-40bd-bb09-66bdbdcd4e54" xlink:href="exel-20221230.xsd#exel_MedicarePartDFundingMandate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_exel_MedicarePartDFundingMandate_5c0039e5-89dc-40bd-bb09-66bdbdcd4e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_ce061e93-4ac5-47bb-89a2-3ee1072bfd5c" xlink:href="exel-20221230.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_ce061e93-4ac5-47bb-89a2-3ee1072bfd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_7113e61d-3c94-4134-baa8-a976cecbf615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3db95a6f-bbc6-412b-9efe-0365b4283efa" xlink:to="loc_us-gaap_AdvertisingExpense_7113e61d-3c94-4134-baa8-a976cecbf615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b85b87ee-801a-4220-8011-5949f800e26f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_36d87764-2e29-4325-bc6f-5552d19592f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b85b87ee-801a-4220-8011-5949f800e26f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_36d87764-2e29-4325-bc6f-5552d19592f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b226466e-72c6-457f-aec3-ee47fc287654" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_36d87764-2e29-4325-bc6f-5552d19592f5" xlink:to="loc_srt_ProductOrServiceAxis_b226466e-72c6-457f-aec3-ee47fc287654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b1dcdf13-a37e-4021-85dc-eabfaeb6d061" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b226466e-72c6-457f-aec3-ee47fc287654" xlink:to="loc_srt_ProductsAndServicesDomain_b1dcdf13-a37e-4021-85dc-eabfaeb6d061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_b8b830db-7bd4-4e51-995b-c2bc0d39e611" xlink:href="exel-20221230.xsd#exel_ProductGrossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1dcdf13-a37e-4021-85dc-eabfaeb6d061" xlink:to="loc_exel_ProductGrossMember_b8b830db-7bd4-4e51-995b-c2bc0d39e611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_b96bab9a-9f7c-4df2-a60b-824f2eac1b80" xlink:href="exel-20221230.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1dcdf13-a37e-4021-85dc-eabfaeb6d061" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_b96bab9a-9f7c-4df2-a60b-824f2eac1b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e8a03353-a620-4d6f-8b63-a03658466cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1dcdf13-a37e-4021-85dc-eabfaeb6d061" xlink:to="loc_us-gaap_ProductMember_e8a03353-a620-4d6f-8b63-a03658466cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_dbd4b188-a241-4328-8e7f-961f33006318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1dcdf13-a37e-4021-85dc-eabfaeb6d061" xlink:to="loc_us-gaap_LicenseMember_dbd4b188-a241-4328-8e7f-961f33006318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_004e1026-7ff2-4f7b-b574-53d2e0eea305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1dcdf13-a37e-4021-85dc-eabfaeb6d061" xlink:to="loc_us-gaap_ServiceMember_004e1026-7ff2-4f7b-b574-53d2e0eea305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_28101c9b-fcf5-4928-838d-78f9458dfaf4" xlink:href="exel-20221230.xsd#exel_CollaborationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1dcdf13-a37e-4021-85dc-eabfaeb6d061" xlink:to="loc_exel_CollaborationMember_28101c9b-fcf5-4928-838d-78f9458dfaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0e4e81d0-e5b6-4bb1-8781-1c6d2bc0f7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_36d87764-2e29-4325-bc6f-5552d19592f5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0e4e81d0-e5b6-4bb1-8781-1c6d2bc0f7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2b6cbb10-41ef-4e82-ad44-8110b3646cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0e4e81d0-e5b6-4bb1-8781-1c6d2bc0f7a3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2b6cbb10-41ef-4e82-ad44-8110b3646cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_71b49cee-61d8-4b94-a7a9-18e068b8cf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5ec73d1c-d731-40f8-9f9b-cce18ec94abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_71b49cee-61d8-4b94-a7a9-18e068b8cf4b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5ec73d1c-d731-40f8-9f9b-cce18ec94abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6085ee7b-4151-45bf-9623-d20c342b9a92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5ec73d1c-d731-40f8-9f9b-cce18ec94abc" xlink:to="loc_srt_ProductOrServiceAxis_6085ee7b-4151-45bf-9623-d20c342b9a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2ba381ef-b88c-49bf-b06c-384935487fbc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6085ee7b-4151-45bf-9623-d20c342b9a92" xlink:to="loc_srt_ProductsAndServicesDomain_2ba381ef-b88c-49bf-b06c-384935487fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_00b81186-afd8-42c2-b472-73ff3796246d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2ba381ef-b88c-49bf-b06c-384935487fbc" xlink:to="loc_us-gaap_ProductMember_00b81186-afd8-42c2-b472-73ff3796246d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_4cf9ebbd-3bb3-4001-bc9f-10cbdb8e266a" xlink:href="exel-20221230.xsd#exel_CabometyxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_00b81186-afd8-42c2-b472-73ff3796246d" xlink:to="loc_exel_CabometyxMember_4cf9ebbd-3bb3-4001-bc9f-10cbdb8e266a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_fce61479-ad9e-4418-ac0c-6d8d4214c052" xlink:href="exel-20221230.xsd#exel_CometriqMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_00b81186-afd8-42c2-b472-73ff3796246d" xlink:to="loc_exel_CometriqMember_fce61479-ad9e-4418-ac0c-6d8d4214c052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5fc06afe-f16b-4353-82ec-3dfdb0c17236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5ec73d1c-d731-40f8-9f9b-cce18ec94abc" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5fc06afe-f16b-4353-82ec-3dfdb0c17236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_885b467c-c134-41f1-999e-51ac2736c56b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5fc06afe-f16b-4353-82ec-3dfdb0c17236" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_885b467c-c134-41f1-999e-51ac2736c56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_94b9eae0-9371-457d-aaea-c1284b06ecf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_01858808-d53d-401a-92e4-973b25a473b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_94b9eae0-9371-457d-aaea-c1284b06ecf6" xlink:to="loc_us-gaap_ConcentrationRiskTable_01858808-d53d-401a-92e4-973b25a473b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_93f4f45a-48ef-4490-a5e1-fc2ae8e7b948" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_01858808-d53d-401a-92e4-973b25a473b3" xlink:to="loc_srt_MajorCustomersAxis_93f4f45a-48ef-4490-a5e1-fc2ae8e7b948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_93f4f45a-48ef-4490-a5e1-fc2ae8e7b948" xlink:to="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_60a32260-1a8f-4206-bb91-013fe020795d" xlink:href="exel-20221230.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_60a32260-1a8f-4206-bb91-013fe020795d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_a5e674c2-f53b-4de9-a575-eb239737a38c" xlink:href="exel-20221230.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_a5e674c2-f53b-4de9-a575-eb239737a38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_5b109645-5558-4ae2-a4b6-1b9a6c9a4ca3" xlink:href="exel-20221230.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_5b109645-5558-4ae2-a4b6-1b9a6c9a4ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_60578a11-e215-46b7-ab9c-60299f390162" xlink:href="exel-20221230.xsd#exel_IpsenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:to="loc_exel_IpsenMember_60578a11-e215-46b7-ab9c-60299f390162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember_c9e6693c-5e9a-42da-b4b7-a7f477305763" xlink:href="exel-20221230.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:to="loc_exel_AccredoHealthIncorporatedMember_c9e6693c-5e9a-42da-b4b7-a7f477305763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_87535dfb-da17-4d63-99fe-54246d60fc95" xlink:href="exel-20221230.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_87535dfb-da17-4d63-99fe-54246d60fc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CardinalHealthIncMember_cbc8bb9a-323e-49a7-a8c4-5fd365af8ddd" xlink:href="exel-20221230.xsd#exel_CardinalHealthIncMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec9fc2c1-0dea-4aca-b9e2-eebc6dc947d6" xlink:to="loc_exel_CardinalHealthIncMember_cbc8bb9a-323e-49a7-a8c4-5fd365af8ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_11a309fd-2c25-4ef6-b297-ab7c926c5524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_01858808-d53d-401a-92e4-973b25a473b3" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_11a309fd-2c25-4ef6-b297-ab7c926c5524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c008640f-e2e3-4ea2-80e2-a3f6547d1500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_11a309fd-2c25-4ef6-b297-ab7c926c5524" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c008640f-e2e3-4ea2-80e2-a3f6547d1500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_6e85304e-7d3c-4fcf-b085-76b91491bec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c008640f-e2e3-4ea2-80e2-a3f6547d1500" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_6e85304e-7d3c-4fcf-b085-76b91491bec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_5cc13030-79f8-4f19-8613-5deb2ac6c01d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c008640f-e2e3-4ea2-80e2-a3f6547d1500" xlink:to="loc_us-gaap_AccountsReceivableMember_5cc13030-79f8-4f19-8613-5deb2ac6c01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0f3768-1ac7-4634-8b85-a6b2c9c4bb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_01858808-d53d-401a-92e4-973b25a473b3" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0f3768-1ac7-4634-8b85-a6b2c9c4bb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_15654fb9-f0cf-4873-95ed-e8bc1a168e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0f3768-1ac7-4634-8b85-a6b2c9c4bb9f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_15654fb9-f0cf-4873-95ed-e8bc1a168e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_331ae497-683b-4044-a733-cb6d4868cf88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_15654fb9-f0cf-4873-95ed-e8bc1a168e8f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_331ae497-683b-4044-a733-cb6d4868cf88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_83c7ac2e-4deb-4694-9545-bdf6461f7342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_01858808-d53d-401a-92e4-973b25a473b3" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_83c7ac2e-4deb-4694-9545-bdf6461f7342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e56e9ac3-5b54-45e4-8b87-d53ad733df46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_83c7ac2e-4deb-4694-9545-bdf6461f7342" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e56e9ac3-5b54-45e4-8b87-d53ad733df46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ed443818-1909-408c-8fc4-b63e01138c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_780bac0b-868b-4503-ade5-1dfdfb117f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ed443818-1909-408c-8fc4-b63e01138c63" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_780bac0b-868b-4503-ade5-1dfdfb117f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a221850a-1d6b-446d-9b2a-096637704c66" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_780bac0b-868b-4503-ade5-1dfdfb117f35" xlink:to="loc_srt_StatementGeographicalAxis_a221850a-1d6b-446d-9b2a-096637704c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4df26a21-3494-47c1-ae43-ecf9b5c6363e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a221850a-1d6b-446d-9b2a-096637704c66" xlink:to="loc_srt_SegmentGeographicalDomain_4df26a21-3494-47c1-ae43-ecf9b5c6363e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_72e994af-d91c-44db-98c5-74545a9adf2b" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4df26a21-3494-47c1-ae43-ecf9b5c6363e" xlink:to="loc_country_US_72e994af-d91c-44db-98c5-74545a9adf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_cd16f147-1f8d-4f39-bfb4-6fff2143037d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4df26a21-3494-47c1-ae43-ecf9b5c6363e" xlink:to="loc_srt_EuropeMember_cd16f147-1f8d-4f39-bfb4-6fff2143037d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_ef817103-1fd8-4e84-ac22-da849c0d3217" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4df26a21-3494-47c1-ae43-ecf9b5c6363e" xlink:to="loc_country_JP_ef817103-1fd8-4e84-ac22-da849c0d3217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_86dda6c4-dfc8-49b6-a2bb-02643611a126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_780bac0b-868b-4503-ade5-1dfdfb117f35" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_86dda6c4-dfc8-49b6-a2bb-02643611a126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44152a42-8b4a-4283-93fa-52cd77742197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86dda6c4-dfc8-49b6-a2bb-02643611a126" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44152a42-8b4a-4283-93fa-52cd77742197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_32530c98-ee90-4845-89b8-d68918ba6291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_36436b3a-c2ba-44d5-82ee-514e1413c61f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_32530c98-ee90-4845-89b8-d68918ba6291" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_36436b3a-c2ba-44d5-82ee-514e1413c61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9ef2b8c6-a554-4f99-9309-80db28afd87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_36436b3a-c2ba-44d5-82ee-514e1413c61f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9ef2b8c6-a554-4f99-9309-80db28afd87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_e64a0bd5-f6e0-48bb-813f-7cf02324ef8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9ef2b8c6-a554-4f99-9309-80db28afd87f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_e64a0bd5-f6e0-48bb-813f-7cf02324ef8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_7410645c-dae5-44b6-a0b6-47e0a82d47c0" xlink:href="exel-20221230.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e64a0bd5-f6e0-48bb-813f-7cf02324ef8b" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_7410645c-dae5-44b6-a0b6-47e0a82d47c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_a923145a-6393-4eca-85b9-362959e0327d" xlink:href="exel-20221230.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e64a0bd5-f6e0-48bb-813f-7cf02324ef8b" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_a923145a-6393-4eca-85b9-362959e0327d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_dc6fd6e9-b69a-423a-8c47-c7b4b8cdbeed" xlink:href="exel-20221230.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e64a0bd5-f6e0-48bb-813f-7cf02324ef8b" xlink:to="loc_exel_AllowanceForProductRebatesMember_dc6fd6e9-b69a-423a-8c47-c7b4b8cdbeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_41b134b1-0a88-4792-a81b-fa8f43248f85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_36436b3a-c2ba-44d5-82ee-514e1413c61f" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_41b134b1-0a88-4792-a81b-fa8f43248f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f23e7fa0-80ff-4db3-af62-ebd3b12eaf3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_41b134b1-0a88-4792-a81b-fa8f43248f85" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f23e7fa0-80ff-4db3-af62-ebd3b12eaf3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8ee4de35-7623-4740-b9d9-36866fb6e158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f23e7fa0-80ff-4db3-af62-ebd3b12eaf3e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8ee4de35-7623-4740-b9d9-36866fb6e158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_24450b55-665e-4c73-96f6-c1f145841dc3" xlink:href="exel-20221230.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f23e7fa0-80ff-4db3-af62-ebd3b12eaf3e" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_24450b55-665e-4c73-96f6-c1f145841dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_8e3a72f5-3c40-401d-a162-3f9e5d8efaa1" xlink:href="exel-20221230.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_24450b55-665e-4c73-96f6-c1f145841dc3" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_8e3a72f5-3c40-401d-a162-3f9e5d8efaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_1a053f6a-e136-4e54-976a-c10b5319c426" xlink:href="exel-20221230.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_24450b55-665e-4c73-96f6-c1f145841dc3" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_1a053f6a-e136-4e54-976a-c10b5319c426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9ae45927-b710-4d39-a4d4-5daa4a1760d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f23e7fa0-80ff-4db3-af62-ebd3b12eaf3e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9ae45927-b710-4d39-a4d4-5daa4a1760d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_390b12c8-726d-49c6-adc0-c5de2a00316f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f23e7fa0-80ff-4db3-af62-ebd3b12eaf3e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_390b12c8-726d-49c6-adc0-c5de2a00316f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0fd52ed6-1009-45b5-ad3d-323b98b7e649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_7d2d0ac6-4456-43f5-b89d-c355261d8cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0fd52ed6-1009-45b5-ad3d-323b98b7e649" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_7d2d0ac6-4456-43f5-b89d-c355261d8cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_53fee59d-979b-4e3b-88ef-f1a32363f6db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0fd52ed6-1009-45b5-ad3d-323b98b7e649" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityAbstract_53fee59d-979b-4e3b-88ef-f1a32363f6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b6f85988-b15a-4114-9f7c-2829fdffbfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_53fee59d-979b-4e3b-88ef-f1a32363f6db" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b6f85988-b15a-4114-9f7c-2829fdffbfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d6b468cc-9950-49af-b512-55487a98d251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_53fee59d-979b-4e3b-88ef-f1a32363f6db" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d6b468cc-9950-49af-b512-55487a98d251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_970cccaa-f923-4f18-9521-ec43fb98d92c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_53fee59d-979b-4e3b-88ef-f1a32363f6db" xlink:to="loc_us-gaap_ContractWithCustomerLiability_970cccaa-f923-4f18-9521-ec43fb98d92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_d33d723c-f248-4a98-bef2-ead0ebe88b31" xlink:href="exel-20221230.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0fd52ed6-1009-45b5-ad3d-323b98b7e649" xlink:to="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_d33d723c-f248-4a98-bef2-ead0ebe88b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_df97c051-5640-4259-8207-5cf2335639a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0fd52ed6-1009-45b5-ad3d-323b98b7e649" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_df97c051-5640-4259-8207-5cf2335639a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_ada99791-19e5-4f3a-bfcc-cfbdb4010dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0fd52ed6-1009-45b5-ad3d-323b98b7e649" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_ada99791-19e5-4f3a-bfcc-cfbdb4010dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_527b57c3-b263-421a-ad82-f40448d945ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_096b4efe-db91-41aa-aa21-b7b3971f7583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_527b57c3-b263-421a-ad82-f40448d945ea" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_096b4efe-db91-41aa-aa21-b7b3971f7583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4c84690a-3550-4a58-851f-e8ae87fcb389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_096b4efe-db91-41aa-aa21-b7b3971f7583" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4c84690a-3550-4a58-851f-e8ae87fcb389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2a17295-32b5-4d39-894c-2f1d8a240b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4c84690a-3550-4a58-851f-e8ae87fcb389" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2a17295-32b5-4d39-894c-2f1d8a240b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_fe482b4d-0957-4d68-a327-24cdf0586f6b" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2a17295-32b5-4d39-894c-2f1d8a240b18" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_fe482b4d-0957-4d68-a327-24cdf0586f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_540a7d7c-7c8f-4a77-a4e4-a8ccbc866b49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_096b4efe-db91-41aa-aa21-b7b3971f7583" xlink:to="loc_srt_ProductOrServiceAxis_540a7d7c-7c8f-4a77-a4e4-a8ccbc866b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1f952ee5-4b64-436b-9ad7-2d3f72ac816f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_540a7d7c-7c8f-4a77-a4e4-a8ccbc866b49" xlink:to="loc_srt_ProductsAndServicesDomain_1f952ee5-4b64-436b-9ad7-2d3f72ac816f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_04fa9029-5764-4375-9b4b-1b004eb735ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1f952ee5-4b64-436b-9ad7-2d3f72ac816f" xlink:to="loc_us-gaap_ServiceMember_04fa9029-5764-4375-9b4b-1b004eb735ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f60b0602-728d-42ce-aa1d-4ccf15edeebb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_096b4efe-db91-41aa-aa21-b7b3971f7583" xlink:to="loc_srt_RangeAxis_f60b0602-728d-42ce-aa1d-4ccf15edeebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ef62ed8a-bca5-46c8-a2bd-53cef22961e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f60b0602-728d-42ce-aa1d-4ccf15edeebb" xlink:to="loc_srt_RangeMember_ef62ed8a-bca5-46c8-a2bd-53cef22961e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9a4fa7de-3b1d-42ca-ab72-807cf057c33c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ef62ed8a-bca5-46c8-a2bd-53cef22961e5" xlink:to="loc_srt_MinimumMember_9a4fa7de-3b1d-42ca-ab72-807cf057c33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_011b8f46-f7b8-49ba-b928-dc3681e7b4a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ef62ed8a-bca5-46c8-a2bd-53cef22961e5" xlink:to="loc_srt_MaximumMember_011b8f46-f7b8-49ba-b928-dc3681e7b4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierAxis_d5548a34-c465-40a4-acbe-cb4cf2234e9e" xlink:href="exel-20221230.xsd#exel_RoyaltyTierAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_096b4efe-db91-41aa-aa21-b7b3971f7583" xlink:to="loc_exel_RoyaltyTierAxis_d5548a34-c465-40a4-acbe-cb4cf2234e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierDomain_03394794-48cd-4b62-8792-53de38d63705" xlink:href="exel-20221230.xsd#exel_RoyaltyTierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltyTierAxis_d5548a34-c465-40a4-acbe-cb4cf2234e9e" xlink:to="loc_exel_RoyaltyTierDomain_03394794-48cd-4b62-8792-53de38d63705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalTierMember_758ee3e6-9916-42bc-a8c6-9f59fd4f20ed" xlink:href="exel-20221230.xsd#exel_FinalTierMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltyTierDomain_03394794-48cd-4b62-8792-53de38d63705" xlink:to="loc_exel_FinalTierMember_758ee3e6-9916-42bc-a8c6-9f59fd4f20ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_096b4efe-db91-41aa-aa21-b7b3971f7583" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dcb1daa6-11ed-4341-bc11-de623970cfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dcb1daa6-11ed-4341-bc11-de623970cfd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_f540465c-2fbc-4f40-a22c-a1cbe4079c33" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_f540465c-2fbc-4f40-a22c-a1cbe4079c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontPayments_4b7d4201-4050-491e-9287-68f3df0abb73" xlink:href="exel-20221230.xsd#exel_UpfrontPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_UpfrontPayments_4b7d4201-4050-491e-9287-68f3df0abb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarnedToDate_7d0c121b-5ac7-4194-baac-7d2fe41ed82a" xlink:href="exel-20221230.xsd#exel_MilestonePaymentsEarnedToDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_MilestonePaymentsEarnedToDate_7d0c121b-5ac7-4194-baac-7d2fe41ed82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned_2066f3bd-2216-4d9f-bfcd-0b04297721f8" xlink:href="exel-20221230.xsd#exel_MilestonePaymentsEarned"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_MilestonePaymentsEarned_2066f3bd-2216-4d9f-bfcd-0b04297721f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_82a91a03-6669-4658-a020-64c7040c5342" xlink:href="exel-20221230.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_82a91a03-6669-4658-a020-64c7040c5342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_50ed65d4-142d-4f4a-9415-0cad4f7aece9" xlink:href="exel-20221230.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_50ed65d4-142d-4f4a-9415-0cad4f7aece9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_0158af52-8021-4257-87fd-ba1ba5332587" xlink:href="exel-20221230.xsd#exel_PercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_0158af52-8021-4257-87fd-ba1ba5332587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_cfbac941-154f-41ca-af16-b7269e55cb8b" xlink:href="exel-20221230.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_cfbac941-154f-41ca-af16-b7269e55cb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_02b9049a-9cdd-49ca-80f3-09a26226278a" xlink:href="exel-20221230.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_02b9049a-9cdd-49ca-80f3-09a26226278a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_413aa546-6b4f-42b4-827d-76ad9007962b" xlink:href="exel-20221230.xsd#exel_RevenueFromContractWithCustomerCommercialSalesMilestone"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_RevenueFromContractWithCustomerCommercialSalesMilestone_413aa546-6b4f-42b4-827d-76ad9007962b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestone_4efa7627-273a-4b69-9089-bbac2b08d37e" xlink:href="exel-20221230.xsd#exel_RevenueFromContractWithCustomerRegulatoryMilestone"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestone_4efa7627-273a-4b69-9089-bbac2b08d37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_58f1b79c-3607-4495-b89b-4a4ea07bb8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_659aa645-b5c7-4573-90be-49547283df18" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_58f1b79c-3607-4495-b89b-4a4ea07bb8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ebe9a77-7d71-4791-83c1-fb628b0e4288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b51ceed5-56d4-4fb1-8c38-bae1c9d7b782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ebe9a77-7d71-4791-83c1-fb628b0e4288" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b51ceed5-56d4-4fb1-8c38-bae1c9d7b782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c5aded43-f58e-491c-800f-0d870fa47652" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b51ceed5-56d4-4fb1-8c38-bae1c9d7b782" xlink:to="loc_srt_ProductOrServiceAxis_c5aded43-f58e-491c-800f-0d870fa47652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5d841c2f-3ac6-41e7-a837-8588c610705b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c5aded43-f58e-491c-800f-0d870fa47652" xlink:to="loc_srt_ProductsAndServicesDomain_5d841c2f-3ac6-41e7-a837-8588c610705b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_f1799105-c0d5-4553-87f8-bad2d27bd1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5d841c2f-3ac6-41e7-a837-8588c610705b" xlink:to="loc_us-gaap_LicenseMember_f1799105-c0d5-4553-87f8-bad2d27bd1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_1d49c1ee-ff1b-4a40-b37d-6d30dc526831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5d841c2f-3ac6-41e7-a837-8588c610705b" xlink:to="loc_us-gaap_ServiceMember_1d49c1ee-ff1b-4a40-b37d-6d30dc526831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b9024c51-fca4-454e-9076-ccaa9ab1fa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b51ceed5-56d4-4fb1-8c38-bae1c9d7b782" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b9024c51-fca4-454e-9076-ccaa9ab1fa9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54bd60fe-b03c-4334-8b08-541b185239e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b9024c51-fca4-454e-9076-ccaa9ab1fa9a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54bd60fe-b03c-4334-8b08-541b185239e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_d24aa465-056a-4381-bcde-11bac4bfdb13" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54bd60fe-b03c-4334-8b08-541b185239e7" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_d24aa465-056a-4381-bcde-11bac4bfdb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_466c58e0-d6f0-452f-844c-8a1f0044963b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b51ceed5-56d4-4fb1-8c38-bae1c9d7b782" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_466c58e0-d6f0-452f-844c-8a1f0044963b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_29cb8505-7664-4f27-bb60-14140706d3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_466c58e0-d6f0-452f-844c-8a1f0044963b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_29cb8505-7664-4f27-bb60-14140706d3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d5e27495-1fba-4523-a1d4-556296d0586d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_921dbe71-89f7-48db-b065-060120264945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d5e27495-1fba-4523-a1d4-556296d0586d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_921dbe71-89f7-48db-b065-060120264945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6d31b7cf-dbdf-45c2-b97a-e3b5c1f97124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_921dbe71-89f7-48db-b065-060120264945" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6d31b7cf-dbdf-45c2-b97a-e3b5c1f97124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fabba6a3-5184-486a-b42f-de35e0b4a012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6d31b7cf-dbdf-45c2-b97a-e3b5c1f97124" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fabba6a3-5184-486a-b42f-de35e0b4a012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_a77a8ea2-f891-49a5-a7d6-180d1e95699d" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fabba6a3-5184-486a-b42f-de35e0b4a012" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_a77a8ea2-f891-49a5-a7d6-180d1e95699d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_18e7e51d-cd20-411f-b3bd-ee74c6c56e99" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_921dbe71-89f7-48db-b065-060120264945" xlink:to="loc_srt_StatementGeographicalAxis_18e7e51d-cd20-411f-b3bd-ee74c6c56e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7fe5a9c5-c1ba-40c9-b0be-d2daff601084" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_18e7e51d-cd20-411f-b3bd-ee74c6c56e99" xlink:to="loc_srt_SegmentGeographicalDomain_7fe5a9c5-c1ba-40c9-b0be-d2daff601084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_2abcabc7-6e0d-4ca6-bdc2-61b11bed5d7a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7fe5a9c5-c1ba-40c9-b0be-d2daff601084" xlink:to="loc_country_JP_2abcabc7-6e0d-4ca6-bdc2-61b11bed5d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierAxis_271d9e8c-5b60-484a-b0f0-142bcfa38f53" xlink:href="exel-20221230.xsd#exel_RoyaltyTierAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_921dbe71-89f7-48db-b065-060120264945" xlink:to="loc_exel_RoyaltyTierAxis_271d9e8c-5b60-484a-b0f0-142bcfa38f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierDomain_24de7ea4-443f-4b85-b30d-48dff2b5a5dd" xlink:href="exel-20221230.xsd#exel_RoyaltyTierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltyTierAxis_271d9e8c-5b60-484a-b0f0-142bcfa38f53" xlink:to="loc_exel_RoyaltyTierDomain_24de7ea4-443f-4b85-b30d-48dff2b5a5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_InitialMember_071a045c-a8eb-436c-83fa-ffc57fdeb321" xlink:href="exel-20221230.xsd#exel_InitialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltyTierDomain_24de7ea4-443f-4b85-b30d-48dff2b5a5dd" xlink:to="loc_exel_InitialMember_071a045c-a8eb-436c-83fa-ffc57fdeb321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalTierMember_44b06531-9414-4340-8d7f-10656bced578" xlink:href="exel-20221230.xsd#exel_FinalTierMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltyTierDomain_24de7ea4-443f-4b85-b30d-48dff2b5a5dd" xlink:to="loc_exel_FinalTierMember_44b06531-9414-4340-8d7f-10656bced578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_402f6a7d-5f21-4e21-a3b9-9241ed6cf2c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_921dbe71-89f7-48db-b065-060120264945" xlink:to="loc_srt_RangeAxis_402f6a7d-5f21-4e21-a3b9-9241ed6cf2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1192cc13-43b6-4b96-a3d0-14a1be449715" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_402f6a7d-5f21-4e21-a3b9-9241ed6cf2c7" xlink:to="loc_srt_RangeMember_1192cc13-43b6-4b96-a3d0-14a1be449715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_01198d86-f2cf-4110-af36-f269aa4db978" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1192cc13-43b6-4b96-a3d0-14a1be449715" xlink:to="loc_srt_MinimumMember_01198d86-f2cf-4110-af36-f269aa4db978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_550f78d4-f13e-45d5-8212-cb667f7335f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1192cc13-43b6-4b96-a3d0-14a1be449715" xlink:to="loc_srt_MaximumMember_550f78d4-f13e-45d5-8212-cb667f7335f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_921dbe71-89f7-48db-b065-060120264945" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_4d5d6211-6f46-4fb3-92fe-230f734de9b1" xlink:href="exel-20221230.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_4d5d6211-6f46-4fb3-92fe-230f734de9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_dbabd6ae-ce4e-4328-8506-2ef125073d4d" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_dbabd6ae-ce4e-4328-8506-2ef125073d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontPayments_2b8a8cdc-58b5-4802-8ad6-620245e3e927" xlink:href="exel-20221230.xsd#exel_UpfrontPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_UpfrontPayments_2b8a8cdc-58b5-4802-8ad6-620245e3e927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarnedToDate_33ed5c9c-bbd2-46c4-9d66-cb6cc151fec8" xlink:href="exel-20221230.xsd#exel_MilestonePaymentsEarnedToDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_MilestonePaymentsEarnedToDate_33ed5c9c-bbd2-46c4-9d66-cb6cc151fec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned_2c3b6440-ebb1-49d3-a35b-6ebdfe086829" xlink:href="exel-20221230.xsd#exel_MilestonePaymentsEarned"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_MilestonePaymentsEarned_2c3b6440-ebb1-49d3-a35b-6ebdfe086829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_c1054100-3c17-457a-a5ce-774f1c21c479" xlink:href="exel-20221230.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_c1054100-3c17-457a-a5ce-774f1c21c479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_1479fd59-68e4-4566-b961-5662ed288a36" xlink:href="exel-20221230.xsd#exel_PercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_1479fd59-68e4-4566-b961-5662ed288a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTier_dcc9f286-2306-4c4a-bdf4-84121e241789" xlink:href="exel-20221230.xsd#exel_RoyaltyTier"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_RoyaltyTier_dcc9f286-2306-4c4a-bdf4-84121e241789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_15829451-d19e-4b08-9fce-7627a2cda2df" xlink:href="exel-20221230.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_15829451-d19e-4b08-9fce-7627a2cda2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_cce94a29-93b4-4fcb-8aba-1869aaa9724a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea6db8b8-e642-4dec-8623-5d55d1bae438" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_cce94a29-93b4-4fcb-8aba-1869aaa9724a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6bbc686-9b06-47f3-906d-7c409b918398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4645871-5587-4eac-800f-59991cd51077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6bbc686-9b06-47f3-906d-7c409b918398" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4645871-5587-4eac-800f-59991cd51077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_545a63c0-683e-4447-8da1-cb8d0040173d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4645871-5587-4eac-800f-59991cd51077" xlink:to="loc_srt_ProductOrServiceAxis_545a63c0-683e-4447-8da1-cb8d0040173d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a8a4f127-86a2-4183-906e-0ef8bf8611dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_545a63c0-683e-4447-8da1-cb8d0040173d" xlink:to="loc_srt_ProductsAndServicesDomain_a8a4f127-86a2-4183-906e-0ef8bf8611dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_027ab23d-eba1-4aa7-b4e8-59ea64eb8468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a8a4f127-86a2-4183-906e-0ef8bf8611dd" xlink:to="loc_us-gaap_LicenseMember_027ab23d-eba1-4aa7-b4e8-59ea64eb8468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_e554769d-c28c-4a28-b424-b329ab4f2f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a8a4f127-86a2-4183-906e-0ef8bf8611dd" xlink:to="loc_us-gaap_ServiceMember_e554769d-c28c-4a28-b424-b329ab4f2f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9bf4f975-96b2-43b0-bddc-c9c506a8f654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4645871-5587-4eac-800f-59991cd51077" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9bf4f975-96b2-43b0-bddc-c9c506a8f654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96a72fc5-7acb-4da1-8a71-cdfb61d1c9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9bf4f975-96b2-43b0-bddc-c9c506a8f654" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96a72fc5-7acb-4da1-8a71-cdfb61d1c9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_3651b965-36a1-4dc5-9811-6650739b7f65" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96a72fc5-7acb-4da1-8a71-cdfb61d1c9cc" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_3651b965-36a1-4dc5-9811-6650739b7f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54223d46-f057-4414-989a-1af39ea1c350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c4645871-5587-4eac-800f-59991cd51077" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54223d46-f057-4414-989a-1af39ea1c350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c09f4b4-292d-431d-959e-3b8d577bf4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54223d46-f057-4414-989a-1af39ea1c350" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c09f4b4-292d-431d-959e-3b8d577bf4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a155b499-dc9e-44b5-8634-f8225ad938f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bdf34bb9-5923-4051-af39-468b7fb7bd12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a155b499-dc9e-44b5-8634-f8225ad938f1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bdf34bb9-5923-4051-af39-468b7fb7bd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4b539500-6890-4e5e-a13f-eb7b9f4b446f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bdf34bb9-5923-4051-af39-468b7fb7bd12" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4b539500-6890-4e5e-a13f-eb7b9f4b446f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_74d1412d-dfde-4526-b97e-b51141258c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4b539500-6890-4e5e-a13f-eb7b9f4b446f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_74d1412d-dfde-4526-b97e-b51141258c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember_220df922-66ca-43c5-a8b5-b1fabae24819" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_74d1412d-dfde-4526-b97e-b51141258c2d" xlink:to="loc_exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember_220df922-66ca-43c5-a8b5-b1fabae24819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bfd7f1b-fc5f-4403-8773-eee236314a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bdf34bb9-5923-4051-af39-468b7fb7bd12" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bfd7f1b-fc5f-4403-8773-eee236314a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_3e4af39b-982c-432c-a349-8dbbe11bd861" xlink:href="exel-20221230.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bfd7f1b-fc5f-4403-8773-eee236314a1e" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_3e4af39b-982c-432c-a349-8dbbe11bd861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_8ac474d5-0c34-4bb6-9704-3d0c6de64d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bfd7f1b-fc5f-4403-8773-eee236314a1e" xlink:to="loc_us-gaap_RoyaltyExpense_8ac474d5-0c34-4bb6-9704-3d0c6de64d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6e4db82-0504-4477-a4f3-59b3936cb4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1275b34f-6a2d-49a2-bd28-309dad88af8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6e4db82-0504-4477-a4f3-59b3936cb4f8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1275b34f-6a2d-49a2-bd28-309dad88af8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1595851e-4d29-41eb-8c4c-3a4d92515c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1275b34f-6a2d-49a2-bd28-309dad88af8c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1595851e-4d29-41eb-8c4c-3a4d92515c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2cc8154-2c73-49f6-b2a9-f577589bcf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1595851e-4d29-41eb-8c4c-3a4d92515c23" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2cc8154-2c73-49f6-b2a9-f577589bcf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_679b12ed-4ec8-4af0-b532-0d5404bdf654" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2cc8154-2c73-49f6-b2a9-f577589bcf6d" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_679b12ed-4ec8-4af0-b532-0d5404bdf654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BioInventInternationalABBioInventMember_e2ddea98-5e70-4c7c-842a-aea08624e4b4" xlink:href="exel-20221230.xsd#exel_BioInventInternationalABBioInventMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2cc8154-2c73-49f6-b2a9-f577589bcf6d" xlink:to="loc_exel_BioInventInternationalABBioInventMember_e2ddea98-5e70-4c7c-842a-aea08624e4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CybrexaTherapeuticsLLCCybrexaMember_eeb04bcb-11c9-4f4d-a647-5bc7e1edfd8e" xlink:href="exel-20221230.xsd#exel_CybrexaTherapeuticsLLCCybrexaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2cc8154-2c73-49f6-b2a9-f577589bcf6d" xlink:to="loc_exel_CybrexaTherapeuticsLLCCybrexaMember_eeb04bcb-11c9-4f4d-a647-5bc7e1edfd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SairopaBVSairopaMember_40e138fb-8630-4504-b105-25a0e7e17992" xlink:href="exel-20221230.xsd#exel_SairopaBVSairopaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2cc8154-2c73-49f6-b2a9-f577589bcf6d" xlink:to="loc_exel_SairopaBVSairopaMember_40e138fb-8630-4504-b105-25a0e7e17992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CatalentIncMember_a6ff3117-8b85-41fe-8a3c-3e4d24a38f3b" xlink:href="exel-20221230.xsd#exel_CatalentIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2cc8154-2c73-49f6-b2a9-f577589bcf6d" xlink:to="loc_exel_CatalentIncMember_a6ff3117-8b85-41fe-8a3c-3e4d24a38f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_2a8221f1-da13-4b3e-9368-3054421ccd31" xlink:href="exel-20221230.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2cc8154-2c73-49f6-b2a9-f577589bcf6d" xlink:to="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_2a8221f1-da13-4b3e-9368-3054421ccd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_92448030-07fe-4560-918e-821536d10665" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1275b34f-6a2d-49a2-bd28-309dad88af8c" xlink:to="loc_srt_ProductOrServiceAxis_92448030-07fe-4560-918e-821536d10665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f6c165c9-a596-4b19-a7c6-7b5f240e0492" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_92448030-07fe-4560-918e-821536d10665" xlink:to="loc_srt_ProductsAndServicesDomain_f6c165c9-a596-4b19-a7c6-7b5f240e0492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember_9e413a38-4a26-45b4-a6e6-1cb1849ce4c7" xlink:href="exel-20221230.xsd#exel_CotellicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f6c165c9-a596-4b19-a7c6-7b5f240e0492" xlink:to="loc_exel_CotellicMember_9e413a38-4a26-45b4-a6e6-1cb1849ce4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1275b34f-6a2d-49a2-bd28-309dad88af8c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94fe9a18-120f-4ece-a4ac-9ea798b206de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94fe9a18-120f-4ece-a4ac-9ea798b206de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_9417931f-6673-4c3c-b866-d1817377f649" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_9417931f-6673-4c3c-b866-d1817377f649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_0f21cfe6-dc0f-41dc-8119-c65d3f13ed4c" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_0f21cfe6-dc0f-41dc-8119-c65d3f13ed4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise_18420e76-6b43-4d89-b6fc-c6e4bb2d73fc" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementMaximumAmountOfWarrantExercise"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise_18420e76-6b43-4d89-b6fc-c6e4bb2d73fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments_41441c70-b52a-4cf8-a1eb-936a1c6b3261" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments_41441c70-b52a-4cf8-a1eb-936a1c6b3261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount_915a6594-d716-4945-9c9f-c7492dce8401" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsExerciseAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount_915a6594-d716-4945-9c9f-c7492dce8401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0505f6b6-a14e-4488-ba0b-d3bec7815003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0505f6b6-a14e-4488-ba0b-d3bec7815003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseDecreaseInResearchAndDevelopmentExpense_1c6f58ce-cbfa-46e0-8f10-edfec6d514eb" xlink:href="exel-20221230.xsd#exel_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_IncreaseDecreaseInResearchAndDevelopmentExpense_1c6f58ce-cbfa-46e0-8f10-edfec6d514eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseInBasicEarningsPerShare_f085624b-5309-4430-ad5b-240fddf64e32" xlink:href="exel-20221230.xsd#exel_IncreaseInBasicEarningsPerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_IncreaseInBasicEarningsPerShare_f085624b-5309-4430-ad5b-240fddf64e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseInDilutedEarningsPerShare_78b35e6b-b58a-4992-8f44-928adc3cb5e0" xlink:href="exel-20221230.xsd#exel_IncreaseInDilutedEarningsPerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_IncreaseInDilutedEarningsPerShare_78b35e6b-b58a-4992-8f44-928adc3cb5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_def46109-bc54-4176-94d8-1f3815172e0a" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_ea8077ff-64cc-412a-9096-8d7e66315ee1" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_ea8077ff-64cc-412a-9096-8d7e66315ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_9288b458-ab5e-4796-8775-7fec4f5d7139" xlink:href="exel-20221230.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_16d6cb6d-8021-403f-85b8-f714e85708a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_9288b458-ab5e-4796-8775-7fec4f5d7139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9ab5de75-9f33-4f7f-b6e2-26974901a015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7b93c4ab-10f4-40f9-b69c-59d7ae241bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9ab5de75-9f33-4f7f-b6e2-26974901a015" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7b93c4ab-10f4-40f9-b69c-59d7ae241bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e0242638-fe58-4671-a93f-fe22712e8e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9ab5de75-9f33-4f7f-b6e2-26974901a015" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e0242638-fe58-4671-a93f-fe22712e8e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6e4aaf29-fd00-4410-9c34-27cb8675030a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9ab5de75-9f33-4f7f-b6e2-26974901a015" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6e4aaf29-fd00-4410-9c34-27cb8675030a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b267a02d-e5e0-4c21-af47-0244b078309c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_014e847a-10b9-431b-baf0-c3512e9ec0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b267a02d-e5e0-4c21-af47-0244b078309c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_014e847a-10b9-431b-baf0-c3512e9ec0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_18576c88-8970-4ebd-9b5e-5274f09a33a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_014e847a-10b9-431b-baf0-c3512e9ec0cd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_18576c88-8970-4ebd-9b5e-5274f09a33a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5aa0bfdf-d652-4a37-b3f6-8308f2b2b1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_18576c88-8970-4ebd-9b5e-5274f09a33a2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5aa0bfdf-d652-4a37-b3f6-8308f2b2b1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_25c04f84-ec05-4ce2-8350-2374d2d0897b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5aa0bfdf-d652-4a37-b3f6-8308f2b2b1c5" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_25c04f84-ec05-4ce2-8350-2374d2d0897b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_623201d9-369f-47b4-9f05-f7daf2812637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5aa0bfdf-d652-4a37-b3f6-8308f2b2b1c5" xlink:to="loc_us-gaap_MunicipalBondsMember_623201d9-369f-47b4-9f05-f7daf2812637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_01301df3-e3b1-4579-aaa0-cbbccb4958c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5aa0bfdf-d652-4a37-b3f6-8308f2b2b1c5" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_01301df3-e3b1-4579-aaa0-cbbccb4958c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_014e847a-10b9-431b-baf0-c3512e9ec0cd" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_fcb46ee3-b838-45ce-ad86-4d4947ddc3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:to="loc_us-gaap_InterestReceivable_fcb46ee3-b838-45ce-ad86-4d4947ddc3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_c229072a-f77f-4623-a970-579e681f2e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_c229072a-f77f-4623-a970-579e681f2e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfBondSecurities_203b98d3-088e-4c72-8293-5bdd4cd15cc6" xlink:href="exel-20221230.xsd#exel_NumberOfBondSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:to="loc_exel_NumberOfBondSecurities_203b98d3-088e-4c72-8293-5bdd4cd15cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfSponsoredEnterprises_2ddcb2ec-93e4-4b05-85ae-2f0858af9c11" xlink:href="exel-20221230.xsd#exel_NumberOfSponsoredEnterprises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:to="loc_exel_NumberOfSponsoredEnterprises_2ddcb2ec-93e4-4b05-85ae-2f0858af9c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_68b2291d-6ab5-4391-b9f9-ab6ba359d449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_68b2291d-6ab5-4391-b9f9-ab6ba359d449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_ac9ca1a8-e229-4696-a289-3d904fb70938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_ac9ca1a8-e229-4696-a289-3d904fb70938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_825bb06f-3791-4694-9686-8a7711a16f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9414435b-dc33-438b-9a4d-f9246b429d20" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_825bb06f-3791-4694-9686-8a7711a16f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c9080141-3229-4bcf-8007-97880509b8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9a2d21f8-f1a1-4843-ae23-c34421345396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c9080141-3229-4bcf-8007-97880509b8c4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9a2d21f8-f1a1-4843-ae23-c34421345396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f8167ceb-5e31-4090-93fb-a565f1f2d3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9a2d21f8-f1a1-4843-ae23-c34421345396" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f8167ceb-5e31-4090-93fb-a565f1f2d3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f8167ceb-5e31-4090-93fb-a565f1f2d3d2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8f9e0612-6590-49dd-9be6-231895fb3d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:to="loc_us-gaap_CommercialPaperMember_8f9e0612-6590-49dd-9be6-231895fb3d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_7d5bcd13-6e2c-41cd-939e-6836860da10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_7d5bcd13-6e2c-41cd-939e-6836860da10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_4c24691c-f2f7-4afc-b5bc-83b94ae7fdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_4c24691c-f2f7-4afc-b5bc-83b94ae7fdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_34cf12d2-5c05-4f65-aab6-de80a7f768f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:to="loc_us-gaap_MunicipalBondsMember_34cf12d2-5c05-4f65-aab6-de80a7f768f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_7cc8e4e7-5309-482c-a45d-40783c8ff403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:to="loc_us-gaap_CashMember_7cc8e4e7-5309-482c-a45d-40783c8ff403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a6eeb89c-048b-46c8-9c73-d8acf7594646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a6eeb89c-048b-46c8-9c73-d8acf7594646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d58b33c2-688a-4dd1-985f-143e2dec6c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f5e46ca-2b92-49f8-a4fc-ded3938d81ee" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d58b33c2-688a-4dd1-985f-143e2dec6c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4d1f1bf6-56d1-4b4d-a354-ebc9d7537d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9a2d21f8-f1a1-4843-ae23-c34421345396" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4d1f1bf6-56d1-4b4d-a354-ebc9d7537d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2603af44-73f9-4551-b4eb-d039ac12940c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4d1f1bf6-56d1-4b4d-a354-ebc9d7537d95" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2603af44-73f9-4551-b4eb-d039ac12940c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4aeb141d-dae2-4bcd-804c-6fa30d2f5bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2603af44-73f9-4551-b4eb-d039ac12940c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4aeb141d-dae2-4bcd-804c-6fa30d2f5bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fa4d3bf5-b3af-4884-aac0-601499ff0a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2603af44-73f9-4551-b4eb-d039ac12940c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fa4d3bf5-b3af-4884-aac0-601499ff0a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_94b34459-a5aa-473c-9a26-7a4aed39231a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2603af44-73f9-4551-b4eb-d039ac12940c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_94b34459-a5aa-473c-9a26-7a4aed39231a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6c5c1969-a1d4-4a5f-8f44-874fd7b86b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2603af44-73f9-4551-b4eb-d039ac12940c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6c5c1969-a1d4-4a5f-8f44-874fd7b86b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aced967d-ba67-49e5-9cc8-765589f6a637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4d1f1bf6-56d1-4b4d-a354-ebc9d7537d95" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aced967d-ba67-49e5-9cc8-765589f6a637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a7c737ed-a3cf-4f3d-b1dd-b66a1d31d0ea" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aced967d-ba67-49e5-9cc8-765589f6a637" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a7c737ed-a3cf-4f3d-b1dd-b66a1d31d0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_1c6ab54c-5cd4-4611-8c57-99fc4e1e113f" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aced967d-ba67-49e5-9cc8-765589f6a637" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_1c6ab54c-5cd4-4611-8c57-99fc4e1e113f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_67685003-d4ec-462b-9a6b-c49db3ebce6c" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aced967d-ba67-49e5-9cc8-765589f6a637" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_67685003-d4ec-462b-9a6b-c49db3ebce6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_d23274cc-d746-421e-a015-416e137a2d78" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aced967d-ba67-49e5-9cc8-765589f6a637" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_d23274cc-d746-421e-a015-416e137a2d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_d7f01db9-2dd3-4605-85ec-d1293d1ba43f" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4d1f1bf6-56d1-4b4d-a354-ebc9d7537d95" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_d7f01db9-2dd3-4605-85ec-d1293d1ba43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dd8acb98-20bb-401f-8cab-b9115c2e1510" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4d1f1bf6-56d1-4b4d-a354-ebc9d7537d95" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dd8acb98-20bb-401f-8cab-b9115c2e1510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cd3120a1-9818-4da3-9d93-c648c56ae0e6" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4d1f1bf6-56d1-4b4d-a354-ebc9d7537d95" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cd3120a1-9818-4da3-9d93-c648c56ae0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_5eeee5f7-52cb-433f-ac3f-3520e5664653" xlink:href="exel-20221230.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4d1f1bf6-56d1-4b4d-a354-ebc9d7537d95" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_5eeee5f7-52cb-433f-ac3f-3520e5664653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_491b58be-ca83-4345-849e-3717fe2f7a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3e52993b-d5e7-46fb-bc9a-8faf7eb8460d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_491b58be-ca83-4345-849e-3717fe2f7a75" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3e52993b-d5e7-46fb-bc9a-8faf7eb8460d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d2e986df-98ee-4bf8-b7c1-9cd7b38d025d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3e52993b-d5e7-46fb-bc9a-8faf7eb8460d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d2e986df-98ee-4bf8-b7c1-9cd7b38d025d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90fe907e-f1d5-4b58-8a19-ae18563077b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d2e986df-98ee-4bf8-b7c1-9cd7b38d025d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90fe907e-f1d5-4b58-8a19-ae18563077b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_2f60c950-77dd-4def-8fc3-5e3c30c9c7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90fe907e-f1d5-4b58-8a19-ae18563077b7" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_2f60c950-77dd-4def-8fc3-5e3c30c9c7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_80f85ac5-d57f-4ed0-b9b8-9300979fd04a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90fe907e-f1d5-4b58-8a19-ae18563077b7" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_80f85ac5-d57f-4ed0-b9b8-9300979fd04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_bb67ea9e-12e3-47f7-ad25-654820f65fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90fe907e-f1d5-4b58-8a19-ae18563077b7" xlink:to="loc_us-gaap_CommercialPaperMember_bb67ea9e-12e3-47f7-ad25-654820f65fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_d348dfad-b8e3-4dc1-b017-3c82bb965e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90fe907e-f1d5-4b58-8a19-ae18563077b7" xlink:to="loc_us-gaap_MunicipalBondsMember_d348dfad-b8e3-4dc1-b017-3c82bb965e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f019f9c-561c-48bd-ae2d-6d5ed074d0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3e52993b-d5e7-46fb-bc9a-8faf7eb8460d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f019f9c-561c-48bd-ae2d-6d5ed074d0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a7926761-dab5-4bca-8392-5b07b17bd2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f019f9c-561c-48bd-ae2d-6d5ed074d0fe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a7926761-dab5-4bca-8392-5b07b17bd2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_8a33b0c4-6f6d-4614-bd04-2cfe4d8a9a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1f019f9c-561c-48bd-ae2d-6d5ed074d0fe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_8a33b0c4-6f6d-4614-bd04-2cfe4d8a9a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c0d6fa42-3384-4bae-a1b7-295b48c77e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fba3748e-f114-4c75-8fbe-ef007f397c69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c0d6fa42-3384-4bae-a1b7-295b48c77e91" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fba3748e-f114-4c75-8fbe-ef007f397c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_aeadd447-b22a-44db-9c29-299940908ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c0d6fa42-3384-4bae-a1b7-295b48c77e91" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_aeadd447-b22a-44db-9c29-299940908ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e7841520-6214-4031-904e-87ffbeff9bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c0d6fa42-3384-4bae-a1b7-295b48c77e91" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e7841520-6214-4031-904e-87ffbeff9bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e3da8da2-d384-45fd-a4cc-64dc467abf9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b71c965-89b1-4853-a261-b7f37c938e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e3da8da2-d384-45fd-a4cc-64dc467abf9f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b71c965-89b1-4853-a261-b7f37c938e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3c7086af-9855-4393-b194-1000593e6412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b71c965-89b1-4853-a261-b7f37c938e3b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3c7086af-9855-4393-b194-1000593e6412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb102395-995d-4fcf-ae18-5377dca522f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3c7086af-9855-4393-b194-1000593e6412" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb102395-995d-4fcf-ae18-5377dca522f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3e5fdc4c-befb-4793-8fdf-d3733561af05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb102395-995d-4fcf-ae18-5377dca522f1" xlink:to="loc_us-gaap_CommercialPaperMember_3e5fdc4c-befb-4793-8fdf-d3733561af05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_32d87417-9ecc-47b1-aebc-2d298cb9ef39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb102395-995d-4fcf-ae18-5377dca522f1" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_32d87417-9ecc-47b1-aebc-2d298cb9ef39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_dd3b737f-b82b-4a5d-8337-417074f6f37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb102395-995d-4fcf-ae18-5377dca522f1" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_dd3b737f-b82b-4a5d-8337-417074f6f37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_8f31349a-c35f-4807-91b8-b52216b03e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb102395-995d-4fcf-ae18-5377dca522f1" xlink:to="loc_us-gaap_MunicipalBondsMember_8f31349a-c35f-4807-91b8-b52216b03e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7a2fa62a-a481-4fc8-824b-dfba9d34344b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb102395-995d-4fcf-ae18-5377dca522f1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7a2fa62a-a481-4fc8-824b-dfba9d34344b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_ac34f4ac-69e6-4bc2-9813-2844f48c727c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb102395-995d-4fcf-ae18-5377dca522f1" xlink:to="loc_us-gaap_CertificatesOfDepositMember_ac34f4ac-69e6-4bc2-9813-2844f48c727c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_129e43e7-253b-428d-9b9e-3b4f4b16e4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b71c965-89b1-4853-a261-b7f37c938e3b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_129e43e7-253b-428d-9b9e-3b4f4b16e4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0d52be1-e825-443b-805b-fa7ddb040682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_129e43e7-253b-428d-9b9e-3b4f4b16e4b1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0d52be1-e825-443b-805b-fa7ddb040682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7b14c9c2-ea0f-4ea9-9a3c-30c24cc778c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0d52be1-e825-443b-805b-fa7ddb040682" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7b14c9c2-ea0f-4ea9-9a3c-30c24cc778c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1619d4c5-2ae0-4b20-bd01-d86781491b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0d52be1-e825-443b-805b-fa7ddb040682" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1619d4c5-2ae0-4b20-bd01-d86781491b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_daacdd23-2226-42b2-9e4d-e5e85bcd97ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b71c965-89b1-4853-a261-b7f37c938e3b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_daacdd23-2226-42b2-9e4d-e5e85bcd97ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c3d1e945-bf53-4fa0-b37c-a18c0634e624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_daacdd23-2226-42b2-9e4d-e5e85bcd97ce" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c3d1e945-bf53-4fa0-b37c-a18c0634e624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_39ea89e7-688a-4408-a691-e764b614aa33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c3d1e945-bf53-4fa0-b37c-a18c0634e624" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_39ea89e7-688a-4408-a691-e764b614aa33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f862051-bf56-4a2b-9bf4-1ee78b361e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b71c965-89b1-4853-a261-b7f37c938e3b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f862051-bf56-4a2b-9bf4-1ee78b361e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4194c060-4ad7-4690-954d-50bdf3cfc232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f862051-bf56-4a2b-9bf4-1ee78b361e79" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4194c060-4ad7-4690-954d-50bdf3cfc232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d0a50f80-f17f-430c-bac0-28a33458bf65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f862051-bf56-4a2b-9bf4-1ee78b361e79" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d0a50f80-f17f-430c-bac0-28a33458bf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_fe94ed32-db13-4daa-8606-0ee32d3494fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f862051-bf56-4a2b-9bf4-1ee78b361e79" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_fe94ed32-db13-4daa-8606-0ee32d3494fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#FairValueMeasurementsNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_29865f18-06d0-41b7-a247-408250689531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75017d57-ac1e-45bb-bfef-7668f8d30f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_29865f18-06d0-41b7-a247-408250689531" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75017d57-ac1e-45bb-bfef-7668f8d30f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_43e8437a-6b2e-4f6f-b305-f0dce3c5810e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75017d57-ac1e-45bb-bfef-7668f8d30f4a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_43e8437a-6b2e-4f6f-b305-f0dce3c5810e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ec313687-dd41-410f-945a-fe637c154e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_43e8437a-6b2e-4f6f-b305-f0dce3c5810e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ec313687-dd41-410f-945a-fe637c154e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_d131eacd-b5f7-4b1a-8915-642c0052c0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ec313687-dd41-410f-945a-fe637c154e7c" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_d131eacd-b5f7-4b1a-8915-642c0052c0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c41b9555-8283-46df-921f-8ddf55763756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75017d57-ac1e-45bb-bfef-7668f8d30f4a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c41b9555-8283-46df-921f-8ddf55763756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_1d1021df-cc61-4869-91e0-487420ee1ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c41b9555-8283-46df-921f-8ddf55763756" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_1d1021df-cc61-4869-91e0-487420ee1ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_760d75cb-e3f7-4d94-9ba0-7932bcfd8449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c41b9555-8283-46df-921f-8ddf55763756" xlink:to="loc_us-gaap_DerivativeNotionalAmount_760d75cb-e3f7-4d94-9ba0-7932bcfd8449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_fa464a9c-65e9-4242-9da8-81f72460cabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c41b9555-8283-46df-921f-8ddf55763756" xlink:to="loc_us-gaap_DerivativeTermOfContract_fa464a9c-65e9-4242-9da8-81f72460cabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_a5cbf59e-9678-4b5e-aceb-e006283f0907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c41b9555-8283-46df-921f-8ddf55763756" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_a5cbf59e-9678-4b5e-aceb-e006283f0907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_bb9b17e4-5e6b-4203-abb9-190faa6b3c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_4085e3d7-819e-41c3-8af3-6809d00c810a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bb9b17e4-5e6b-4203-abb9-190faa6b3c95" xlink:to="loc_us-gaap_InventoryCurrentTable_4085e3d7-819e-41c3-8af3-6809d00c810a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_cba39496-2ef7-4e1b-9306-c5bc6dd97a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_4085e3d7-819e-41c3-8af3-6809d00c810a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_cba39496-2ef7-4e1b-9306-c5bc6dd97a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fb942464-404d-4b9d-b921-81c48a3513a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cba39496-2ef7-4e1b-9306-c5bc6dd97a08" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fb942464-404d-4b9d-b921-81c48a3513a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_f305ab5e-a786-4f96-9569-6214dc9074a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fb942464-404d-4b9d-b921-81c48a3513a1" xlink:to="loc_us-gaap_InventoriesMember_f305ab5e-a786-4f96-9569-6214dc9074a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_34155acd-6b4a-4c6c-a422-48e66e558844" xlink:href="exel-20221230.xsd#exel_OtherLongtermAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fb942464-404d-4b9d-b921-81c48a3513a1" xlink:to="loc_exel_OtherLongtermAssetsMember_34155acd-6b4a-4c6c-a422-48e66e558844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_c5cbdd38-1fb1-4fc0-93ed-8f73eb054ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_4085e3d7-819e-41c3-8af3-6809d00c810a" xlink:to="loc_us-gaap_InventoryLineItems_c5cbdd38-1fb1-4fc0-93ed-8f73eb054ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_5fd0485c-5d38-4253-a789-ee8ac20845d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_c5cbdd38-1fb1-4fc0-93ed-8f73eb054ca2" xlink:to="loc_us-gaap_InventoryRawMaterials_5fd0485c-5d38-4253-a789-ee8ac20845d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_241d90f3-c263-4345-aa63-2a0173172334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_c5cbdd38-1fb1-4fc0-93ed-8f73eb054ca2" xlink:to="loc_us-gaap_InventoryWorkInProcess_241d90f3-c263-4345-aa63-2a0173172334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_bb6ef5a1-c1d4-4b6e-907e-8b14104cf16a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_c5cbdd38-1fb1-4fc0-93ed-8f73eb054ca2" xlink:to="loc_us-gaap_InventoryFinishedGoods_bb6ef5a1-c1d4-4b6e-907e-8b14104cf16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_eea68058-467d-43f2-9b28-078e226f8973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_c5cbdd38-1fb1-4fc0-93ed-8f73eb054ca2" xlink:to="loc_us-gaap_InventoryGross_eea68058-467d-43f2-9b28-078e226f8973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2ddbbe49-a2d8-4a15-bdb2-db1057b29add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e3489772-8b95-4551-a895-e26b8b28b52a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2ddbbe49-a2d8-4a15-bdb2-db1057b29add" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e3489772-8b95-4551-a895-e26b8b28b52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a93b682d-3b10-4309-b976-110d88920a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e3489772-8b95-4551-a895-e26b8b28b52a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a93b682d-3b10-4309-b976-110d88920a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6fd5a78-03ad-46ac-900b-28a737711b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a93b682d-3b10-4309-b976-110d88920a23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6fd5a78-03ad-46ac-900b-28a737711b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0e26b9a1-7b2d-49c9-932b-345ce369d614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6fd5a78-03ad-46ac-900b-28a737711b6c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0e26b9a1-7b2d-49c9-932b-345ce369d614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_c49816af-1b85-438b-b77b-7dd8e3328092" xlink:href="exel-20221230.xsd#exel_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6fd5a78-03ad-46ac-900b-28a737711b6c" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_c49816af-1b85-438b-b77b-7dd8e3328092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_e10aa799-e511-4a43-b370-869c98508c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6fd5a78-03ad-46ac-900b-28a737711b6c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_e10aa799-e511-4a43-b370-869c98508c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LaboratoryEquipmentMember_7c824482-d290-42bf-b7ea-c42c5687fdc9" xlink:href="exel-20221230.xsd#exel_LaboratoryEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6fd5a78-03ad-46ac-900b-28a737711b6c" xlink:to="loc_exel_LaboratoryEquipmentMember_7c824482-d290-42bf-b7ea-c42c5687fdc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ab804c35-8aa6-47da-9cd6-b948ae096c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6fd5a78-03ad-46ac-900b-28a737711b6c" xlink:to="loc_us-gaap_ConstructionInProgressMember_ab804c35-8aa6-47da-9cd6-b948ae096c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06eac9a1-fb18-42e6-a2e8-24697a220bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e3489772-8b95-4551-a895-e26b8b28b52a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06eac9a1-fb18-42e6-a2e8-24697a220bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8fb51158-b337-4fd6-ab44-3512beda05b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06eac9a1-fb18-42e6-a2e8-24697a220bc8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8fb51158-b337-4fd6-ab44-3512beda05b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c049b88e-6728-4602-99c0-13a9415287fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06eac9a1-fb18-42e6-a2e8-24697a220bc8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c049b88e-6728-4602-99c0-13a9415287fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_93e74736-7cc8-476f-9233-25f8991011a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06eac9a1-fb18-42e6-a2e8-24697a220bc8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_93e74736-7cc8-476f-9233-25f8991011a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_49d20b93-716f-4b03-aa7a-ec932f81e957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06eac9a1-fb18-42e6-a2e8-24697a220bc8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_49d20b93-716f-4b03-aa7a-ec932f81e957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fca8bce6-744d-4785-82f8-3f682e8aa0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a2e52e90-ad29-4934-9a0e-c8a18d528a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fca8bce6-744d-4785-82f8-3f682e8aa0e9" xlink:to="loc_us-gaap_Depreciation_a2e52e90-ad29-4934-9a0e-c8a18d528a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d453247-7881-4e93-88d8-a7052cb88ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0606f92b-1be5-4184-b5e3-836940204783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d453247-7881-4e93-88d8-a7052cb88ba2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0606f92b-1be5-4184-b5e3-836940204783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fecef8d3-931e-409d-a3a0-29c3cad41fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0606f92b-1be5-4184-b5e3-836940204783" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fecef8d3-931e-409d-a3a0-29c3cad41fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2357fd78-9b0b-41c1-9a61-0d314ccf334e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fecef8d3-931e-409d-a3a0-29c3cad41fa9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2357fd78-9b0b-41c1-9a61-0d314ccf334e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7baf544a-8024-4cb3-adb4-bd999ecbc0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2357fd78-9b0b-41c1-9a61-0d314ccf334e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7baf544a-8024-4cb3-adb4-bd999ecbc0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_faf54e77-5913-4bfb-b03a-84f5dbc14849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2357fd78-9b0b-41c1-9a61-0d314ccf334e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_faf54e77-5913-4bfb-b03a-84f5dbc14849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a696f01-9f36-4ddb-ac2c-0a0e1e73150e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0606f92b-1be5-4184-b5e3-836940204783" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a696f01-9f36-4ddb-ac2c-0a0e1e73150e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ace77a7e-0655-40b2-8967-ae8f0419074b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3a696f01-9f36-4ddb-ac2c-0a0e1e73150e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ace77a7e-0655-40b2-8967-ae8f0419074b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ce0d4bf-f038-4d00-9e64-aa1619369d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8c72998a-ae09-40a1-8ef6-6f18922ca205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ce0d4bf-f038-4d00-9e64-aa1619369d1d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8c72998a-ae09-40a1-8ef6-6f18922ca205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_632da1e1-dda1-4065-b367-8ab98ac12a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8c72998a-ae09-40a1-8ef6-6f18922ca205" xlink:to="loc_us-gaap_AwardTypeAxis_632da1e1-dda1-4065-b367-8ab98ac12a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abcab0ab-f915-4642-8721-62becc01beae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_632da1e1-dda1-4065-b367-8ab98ac12a70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abcab0ab-f915-4642-8721-62becc01beae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_11653cbc-2a5a-4b0a-8842-3892efc437af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abcab0ab-f915-4642-8721-62becc01beae" xlink:to="loc_us-gaap_EmployeeStockOptionMember_11653cbc-2a5a-4b0a-8842-3892efc437af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d03c88f6-52c7-43ff-9320-6750c846cd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abcab0ab-f915-4642-8721-62becc01beae" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d03c88f6-52c7-43ff-9320-6750c846cd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ee9f413a-67da-4a01-8c25-a95021e5692a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abcab0ab-f915-4642-8721-62becc01beae" xlink:to="loc_us-gaap_PerformanceSharesMember_ee9f413a-67da-4a01-8c25-a95021e5692a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4d0350a4-ba09-44ca-8f0a-215ee4efb24c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abcab0ab-f915-4642-8721-62becc01beae" xlink:to="loc_us-gaap_EmployeeStockMember_4d0350a4-ba09-44ca-8f0a-215ee4efb24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33fd64c2-7dc5-4f64-a7f6-aecd199973f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8c72998a-ae09-40a1-8ef6-6f18922ca205" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33fd64c2-7dc5-4f64-a7f6-aecd199973f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2a68b0a9-cdf8-4fdb-917c-11352c1db9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33fd64c2-7dc5-4f64-a7f6-aecd199973f8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2a68b0a9-cdf8-4fdb-917c-11352c1db9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#EmployeeBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f016b4b-c74b-44a7-8588-7dfc7d96d62a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f553c530-9ede-4235-b67e-76f44a607c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f016b4b-c74b-44a7-8588-7dfc7d96d62a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f553c530-9ede-4235-b67e-76f44a607c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_47a75d1b-7b80-4527-867d-13eb43c68f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f553c530-9ede-4235-b67e-76f44a607c8c" xlink:to="loc_us-gaap_AwardTypeAxis_47a75d1b-7b80-4527-867d-13eb43c68f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbd60d73-67c2-4eb4-83a0-59bfda5e5698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_47a75d1b-7b80-4527-867d-13eb43c68f74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbd60d73-67c2-4eb4-83a0-59bfda5e5698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_760a39c3-8bb2-4a27-855d-bcd2b6be4938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbd60d73-67c2-4eb4-83a0-59bfda5e5698" xlink:to="loc_us-gaap_EmployeeStockOptionMember_760a39c3-8bb2-4a27-855d-bcd2b6be4938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_af63b5c9-26a5-4e68-95e9-ea0c934e2426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbd60d73-67c2-4eb4-83a0-59bfda5e5698" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_af63b5c9-26a5-4e68-95e9-ea0c934e2426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember_62271758-2f86-4c56-8b40-60b8c3d2129c" xlink:href="exel-20221230.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_af63b5c9-26a5-4e68-95e9-ea0c934e2426" xlink:to="loc_exel_TSRBasedRestrictedStockUnitsMember_62271758-2f86-4c56-8b40-60b8c3d2129c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_9c59aaa6-a8f5-4888-aa4b-52bfd89ca529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbd60d73-67c2-4eb4-83a0-59bfda5e5698" xlink:to="loc_us-gaap_EmployeeStockMember_9c59aaa6-a8f5-4888-aa4b-52bfd89ca529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a257ded9-c78c-4b5a-8ffe-a0c2a16c8036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbd60d73-67c2-4eb4-83a0-59bfda5e5698" xlink:to="loc_us-gaap_PerformanceSharesMember_a257ded9-c78c-4b5a-8ffe-a0c2a16c8036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesClinicalTrialResultsMember_b09beb82-b71c-4a60-90a5-a243426860ae" xlink:href="exel-20221230.xsd#exel_PerformanceSharesClinicalTrialResultsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PerformanceSharesMember_a257ded9-c78c-4b5a-8ffe-a0c2a16c8036" xlink:to="loc_exel_PerformanceSharesClinicalTrialResultsMember_b09beb82-b71c-4a60-90a5-a243426860ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_0aac8247-a9ab-4d01-a17d-08e6201243d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f553c530-9ede-4235-b67e-76f44a607c8c" xlink:to="loc_us-gaap_GranteeStatusAxis_0aac8247-a9ab-4d01-a17d-08e6201243d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_8b8e1b82-1c97-4d48-9d54-4520ed2954b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_0aac8247-a9ab-4d01-a17d-08e6201243d2" xlink:to="loc_us-gaap_GranteeStatusDomain_8b8e1b82-1c97-4d48-9d54-4520ed2954b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_566163b2-e06b-4032-8f1e-ecb5c65888b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_8b8e1b82-1c97-4d48-9d54-4520ed2954b0" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_566163b2-e06b-4032-8f1e-ecb5c65888b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_73357a2f-abd8-467e-b362-3676d8ec7458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_8b8e1b82-1c97-4d48-9d54-4520ed2954b0" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_73357a2f-abd8-467e-b362-3676d8ec7458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3e295b35-3706-41ea-8d27-8130742b03a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f553c530-9ede-4235-b67e-76f44a607c8c" xlink:to="loc_srt_RangeAxis_3e295b35-3706-41ea-8d27-8130742b03a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d4d47c3-4cfe-4a63-af9d-9fe7b4d91d58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3e295b35-3706-41ea-8d27-8130742b03a0" xlink:to="loc_srt_RangeMember_5d4d47c3-4cfe-4a63-af9d-9fe7b4d91d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cd9f18b6-6584-4f0d-a3c7-1cb1758efed0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5d4d47c3-4cfe-4a63-af9d-9fe7b4d91d58" xlink:to="loc_srt_MinimumMember_cd9f18b6-6584-4f0d-a3c7-1cb1758efed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7a9d7177-6a78-412d-8365-8f15a0793a19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5d4d47c3-4cfe-4a63-af9d-9fe7b4d91d58" xlink:to="loc_srt_MaximumMember_7a9d7177-6a78-412d-8365-8f15a0793a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_6ade20b6-f6c7-422d-91fe-f8589116cfa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f553c530-9ede-4235-b67e-76f44a607c8c" xlink:to="loc_us-gaap_VestingAxis_6ade20b6-f6c7-422d-91fe-f8589116cfa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_62fc6285-93e7-4bba-b825-671dfb13d772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_6ade20b6-f6c7-422d-91fe-f8589116cfa6" xlink:to="loc_us-gaap_VestingDomain_62fc6285-93e7-4bba-b825-671dfb13d772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_41b6b9c9-319b-45c9-8a93-9f8ecfc6ef3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_62fc6285-93e7-4bba-b825-671dfb13d772" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_41b6b9c9-319b-45c9-8a93-9f8ecfc6ef3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis_364a3a67-d39c-4464-974c-814e914e607f" xlink:href="exel-20221230.xsd#exel_StatusAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f553c530-9ede-4235-b67e-76f44a607c8c" xlink:to="loc_exel_StatusAxis_364a3a67-d39c-4464-974c-814e914e607f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_7a93fcee-d666-4556-ab89-e0cb373b31b8" xlink:href="exel-20221230.xsd#exel_StatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusAxis_364a3a67-d39c-4464-974c-814e914e607f" xlink:to="loc_exel_StatusDomain_7a93fcee-d666-4556-ab89-e0cb373b31b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedMember_76288c2d-427d-4be3-a635-3a56b0008fb5" xlink:href="exel-20221230.xsd#exel_AchievedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_7a93fcee-d666-4556-ab89-e0cb373b31b8" xlink:to="loc_exel_AchievedMember_76288c2d-427d-4be3-a635-3a56b0008fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember_255f0578-a624-413c-8467-57f61643ff4b" xlink:href="exel-20221230.xsd#exel_ProbableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_7a93fcee-d666-4556-ab89-e0cb373b31b8" xlink:to="loc_exel_ProbableMember_255f0578-a624-413c-8467-57f61643ff4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NotProbableMember_a912766b-b070-4c6c-a60b-b0c68dfce68c" xlink:href="exel-20221230.xsd#exel_NotProbableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_7a93fcee-d666-4556-ab89-e0cb373b31b8" xlink:to="loc_exel_NotProbableMember_a912766b-b070-4c6c-a60b-b0c68dfce68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_13a8b687-5238-4acd-85bc-9454639ce6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f553c530-9ede-4235-b67e-76f44a607c8c" xlink:to="loc_us-gaap_PlanNameAxis_13a8b687-5238-4acd-85bc-9454639ce6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_59acb091-d037-4955-a309-1ee3b4535061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_13a8b687-5238-4acd-85bc-9454639ce6cc" xlink:to="loc_us-gaap_PlanNameDomain_59acb091-d037-4955-a309-1ee3b4535061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AmendedAndRestated2017EquityIncentivePlanMember_eef16a91-1f23-4b7e-8ca0-9d0dee8f1743" xlink:href="exel-20221230.xsd#exel_AmendedAndRestated2017EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_59acb091-d037-4955-a309-1ee3b4535061" xlink:to="loc_exel_AmendedAndRestated2017EquityIncentivePlanMember_eef16a91-1f23-4b7e-8ca0-9d0dee8f1743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f553c530-9ede-4235-b67e-76f44a607c8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_acbd2bb6-39db-4700-a2dd-66c241c84d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_acbd2bb6-39db-4700-a2dd-66c241c84d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_207ddce9-3cbf-4e4d-b159-139ee9d79aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_207ddce9-3cbf-4e4d-b159-139ee9d79aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_2849ae7b-a842-4ee7-b137-3b896d2399a5" xlink:href="exel-20221230.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_2849ae7b-a842-4ee7-b137-3b896d2399a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_1823b57f-60c9-45cf-82c7-f9e3edc924e8" xlink:href="exel-20221230.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_1823b57f-60c9-45cf-82c7-f9e3edc924e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_26fcf7fb-f070-4536-bd80-3946cceb05e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_26fcf7fb-f070-4536-bd80-3946cceb05e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_13d0cd54-fc58-4ba8-8dab-1ccf294714a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_13d0cd54-fc58-4ba8-8dab-1ccf294714a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod_8f28a148-f74b-48dc-b2d2-3e5bc8ed0430" xlink:href="exel-20221230.xsd#exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod_8f28a148-f74b-48dc-b2d2-3e5bc8ed0430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_c02fa55c-2887-4858-b9fb-a46993e3cb65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_c02fa55c-2887-4858-b9fb-a46993e3cb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_4f0c9e8f-c238-45e4-bb24-fa740486370c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_4f0c9e8f-c238-45e4-bb24-fa740486370c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_84dcdb7b-3806-4580-949c-9442ea1822a6" xlink:href="exel-20221230.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_84dcdb7b-3806-4580-949c-9442ea1822a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_38757b15-93bb-474a-a826-113e095c0730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_38757b15-93bb-474a-a826-113e095c0730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_60f8530a-4a5c-4967-aea7-17f16ea86c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_60f8530a-4a5c-4967-aea7-17f16ea86c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_c4d22c9c-0845-4cf8-a5ce-3c7b706c8f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ProceedsFromStockPlans_c4d22c9c-0845-4cf8-a5ce-3c7b706c8f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1f2de7bc-8dd7-4b6c-8610-b9190f51f1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1f2de7bc-8dd7-4b6c-8610-b9190f51f1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f46edc26-cc5a-43fd-8f7d-2dd2070d5c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f46edc26-cc5a-43fd-8f7d-2dd2070d5c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_56e03e04-4233-446e-8714-b0684a5a9c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_56e03e04-4233-446e-8714-b0684a5a9c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a0e4006b-5098-4dd4-8223-5090a388222b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a0e4006b-5098-4dd4-8223-5090a388222b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3469bd59-4fa0-4bad-bc28-890fdcdf8ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3469bd59-4fa0-4bad-bc28-890fdcdf8ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_27f7015e-874e-4e95-ab32-97b0c771685e" xlink:href="exel-20221230.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_27f7015e-874e-4e95-ab32-97b0c771685e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_cb53f3c4-756d-4ebf-a6b7-2427ab1023ca" xlink:href="exel-20221230.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_cb53f3c4-756d-4ebf-a6b7-2427ab1023ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_062a83b5-0fba-41bb-a945-dfbb4a810d21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_062a83b5-0fba-41bb-a945-dfbb4a810d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3d15fadb-43b6-4871-a8e6-419b66eeb1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3d15fadb-43b6-4871-a8e6-419b66eeb1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_d58c43f2-f8f6-42fb-b3ff-935e0463bc82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06e5d7c8-b448-4741-bc0a-d90e6c959fb3" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_d58c43f2-f8f6-42fb-b3ff-935e0463bc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_397bd1af-214a-44f5-beb0-1ead8f69492a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f5247242-c917-4bee-adc6-020130a6b661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_397bd1af-214a-44f5-beb0-1ead8f69492a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f5247242-c917-4bee-adc6-020130a6b661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8f7a6190-9808-4543-b9c8-275dc5e8105e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f5247242-c917-4bee-adc6-020130a6b661" xlink:to="loc_us-gaap_AwardTypeAxis_8f7a6190-9808-4543-b9c8-275dc5e8105e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_edf8ca71-dfc5-4639-bf34-b8ea9030c8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8f7a6190-9808-4543-b9c8-275dc5e8105e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_edf8ca71-dfc5-4639-bf34-b8ea9030c8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b9918b5a-8b8b-4f57-8e63-5cec8d170885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_edf8ca71-dfc5-4639-bf34-b8ea9030c8fa" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b9918b5a-8b8b-4f57-8e63-5cec8d170885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_edd4dd49-a9b2-44f2-8167-433d7faa41cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_edf8ca71-dfc5-4639-bf34-b8ea9030c8fa" xlink:to="loc_us-gaap_EmployeeStockMember_edd4dd49-a9b2-44f2-8167-433d7faa41cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4acd2206-04c8-459c-a85c-86d1cf9b4c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f5247242-c917-4bee-adc6-020130a6b661" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4acd2206-04c8-459c-a85c-86d1cf9b4c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a4e55dba-d20a-420f-ac93-eb2244cb9b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4acd2206-04c8-459c-a85c-86d1cf9b4c88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a4e55dba-d20a-420f-ac93-eb2244cb9b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92f2716d-4f7d-4492-8df6-049890f21edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b154560b-221d-4610-89d9-44d8593ddaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92f2716d-4f7d-4492-8df6-049890f21edd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b154560b-221d-4610-89d9-44d8593ddaf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d40736c8-e6fe-445b-98d4-18073c58135c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b154560b-221d-4610-89d9-44d8593ddaf8" xlink:to="loc_us-gaap_AwardTypeAxis_d40736c8-e6fe-445b-98d4-18073c58135c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87a784e1-3957-4929-b9e3-a649e58fc781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d40736c8-e6fe-445b-98d4-18073c58135c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87a784e1-3957-4929-b9e3-a649e58fc781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_03c50b38-1b84-463a-a9f4-0342ae14d7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87a784e1-3957-4929-b9e3-a649e58fc781" xlink:to="loc_us-gaap_EmployeeStockOptionMember_03c50b38-1b84-463a-a9f4-0342ae14d7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d86f7f94-8cf4-4251-83d2-6f2b7d25f530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87a784e1-3957-4929-b9e3-a649e58fc781" xlink:to="loc_us-gaap_EmployeeStockMember_d86f7f94-8cf4-4251-83d2-6f2b7d25f530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24df2f66-82ed-4839-9bf9-c11a29fc7b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b154560b-221d-4610-89d9-44d8593ddaf8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24df2f66-82ed-4839-9bf9-c11a29fc7b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1208981f-a793-4152-a87c-b082af2b60ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24df2f66-82ed-4839-9bf9-c11a29fc7b53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1208981f-a793-4152-a87c-b082af2b60ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b7712890-29b5-48ca-9cc8-64a2620b3723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24df2f66-82ed-4839-9bf9-c11a29fc7b53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b7712890-29b5-48ca-9cc8-64a2620b3723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_acb17905-7d47-451e-a4e2-5a9cef80f038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24df2f66-82ed-4839-9bf9-c11a29fc7b53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_acb17905-7d47-451e-a4e2-5a9cef80f038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_422df7ef-a0bc-4abe-b0c5-4c36ab0642b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24df2f66-82ed-4839-9bf9-c11a29fc7b53" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_422df7ef-a0bc-4abe-b0c5-4c36ab0642b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19edb300-7954-4c01-a5e8-6a777b3a4583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0593d487-ff34-4c5a-ade1-716e4a43f142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19edb300-7954-4c01-a5e8-6a777b3a4583" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0593d487-ff34-4c5a-ade1-716e4a43f142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5b024f8c-e01a-4282-b670-755b1880333e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0593d487-ff34-4c5a-ade1-716e4a43f142" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5b024f8c-e01a-4282-b670-755b1880333e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4de6b062-59ec-435e-aa5d-2caf4ca4360b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0593d487-ff34-4c5a-ade1-716e4a43f142" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4de6b062-59ec-435e-aa5d-2caf4ca4360b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_74ed78d7-f7fc-43c9-b614-6057c4fcc946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0593d487-ff34-4c5a-ade1-716e4a43f142" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_74ed78d7-f7fc-43c9-b614-6057c4fcc946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_74a59ced-06d0-4f88-8094-76cb2b517e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0593d487-ff34-4c5a-ade1-716e4a43f142" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_74a59ced-06d0-4f88-8094-76cb2b517e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d95904af-7f1e-49f4-aa07-04a3575056dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0593d487-ff34-4c5a-ade1-716e4a43f142" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d95904af-7f1e-49f4-aa07-04a3575056dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2efaac83-2d4b-45f4-99e3-f5a27ebab9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19edb300-7954-4c01-a5e8-6a777b3a4583" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2efaac83-2d4b-45f4-99e3-f5a27ebab9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_df99b191-b071-4198-bf39-d60eb7491023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19edb300-7954-4c01-a5e8-6a777b3a4583" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_df99b191-b071-4198-bf39-d60eb7491023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_86df8f6d-9071-4152-a1c7-d0eae273f7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_df99b191-b071-4198-bf39-d60eb7491023" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_86df8f6d-9071-4152-a1c7-d0eae273f7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_edc81a16-4eee-499f-8513-b06ae9bcb064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_df99b191-b071-4198-bf39-d60eb7491023" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_edc81a16-4eee-499f-8513-b06ae9bcb064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3f814c3c-c9c3-43d4-b894-6067a666c677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_df99b191-b071-4198-bf39-d60eb7491023" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3f814c3c-c9c3-43d4-b894-6067a666c677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_02575670-ba7d-4447-afe8-682b1d61cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_df99b191-b071-4198-bf39-d60eb7491023" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_02575670-ba7d-4447-afe8-682b1d61cd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8c3f28c5-2a6d-4a8b-b948-af5547946191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_df99b191-b071-4198-bf39-d60eb7491023" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8c3f28c5-2a6d-4a8b-b948-af5547946191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_16166512-5588-41d7-a11d-ec49d22d9e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19edb300-7954-4c01-a5e8-6a777b3a4583" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_16166512-5588-41d7-a11d-ec49d22d9e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e123881b-3867-4a95-adba-c11ba5b7db7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19edb300-7954-4c01-a5e8-6a777b3a4583" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e123881b-3867-4a95-adba-c11ba5b7db7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2798a903-f74a-43c7-9070-b9fd032457d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19edb300-7954-4c01-a5e8-6a777b3a4583" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2798a903-f74a-43c7-9070-b9fd032457d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d053ba36-6dbc-4954-822d-82ee0c9b0325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19edb300-7954-4c01-a5e8-6a777b3a4583" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d053ba36-6dbc-4954-822d-82ee0c9b0325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d0ae5263-3137-4e57-a42c-d2337733e036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19edb300-7954-4c01-a5e8-6a777b3a4583" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d0ae5263-3137-4e57-a42c-d2337733e036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8020ab4a-ff6d-463e-af4a-bcbe0933bf23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_788d2f3b-cf15-4511-8405-3fc59d2d156c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8020ab4a-ff6d-463e-af4a-bcbe0933bf23" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_788d2f3b-cf15-4511-8405-3fc59d2d156c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d8c801b0-d9dd-4b4d-937e-7624add467d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_788d2f3b-cf15-4511-8405-3fc59d2d156c" xlink:to="loc_us-gaap_AwardTypeAxis_d8c801b0-d9dd-4b4d-937e-7624add467d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58557ca9-d4dd-4c75-a7cc-22f9e1fdd0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d8c801b0-d9dd-4b4d-937e-7624add467d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58557ca9-d4dd-4c75-a7cc-22f9e1fdd0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_81c19d87-c375-4b17-9ead-9e194066dfd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58557ca9-d4dd-4c75-a7cc-22f9e1fdd0e8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_81c19d87-c375-4b17-9ead-9e194066dfd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_fca37f6f-f609-4280-a231-f94a8b92e8de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58557ca9-d4dd-4c75-a7cc-22f9e1fdd0e8" xlink:to="loc_us-gaap_PerformanceSharesMember_fca37f6f-f609-4280-a231-f94a8b92e8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53c5f8e-c235-452a-930e-4c936f70e0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_788d2f3b-cf15-4511-8405-3fc59d2d156c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53c5f8e-c235-452a-930e-4c936f70e0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b134f802-7850-463c-969b-b35763876091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53c5f8e-c235-452a-930e-4c936f70e0eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b134f802-7850-463c-969b-b35763876091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_983470d2-e729-4e38-a2ee-d0c861b903d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b134f802-7850-463c-969b-b35763876091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_983470d2-e729-4e38-a2ee-d0c861b903d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d6eeae65-bb8e-4664-afe2-67e6440b975d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b134f802-7850-463c-969b-b35763876091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d6eeae65-bb8e-4664-afe2-67e6440b975d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_7e3b1de1-a60b-4ca3-81b2-8cb6babe621b" xlink:href="exel-20221230.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b134f802-7850-463c-969b-b35763876091" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_7e3b1de1-a60b-4ca3-81b2-8cb6babe621b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cb50aae7-ad00-4cf1-99a7-64ed5e0ed4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b134f802-7850-463c-969b-b35763876091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cb50aae7-ad00-4cf1-99a7-64ed5e0ed4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9111c134-4a2d-474a-b521-bcdb5adc9155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b134f802-7850-463c-969b-b35763876091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9111c134-4a2d-474a-b521-bcdb5adc9155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a19aa777-441b-433c-b7c0-3d23f56ab7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53c5f8e-c235-452a-930e-4c936f70e0eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a19aa777-441b-433c-b7c0-3d23f56ab7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f55e01df-d6ea-4774-89c2-158fd85eee77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a19aa777-441b-433c-b7c0-3d23f56ab7ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f55e01df-d6ea-4774-89c2-158fd85eee77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_291cb7c1-d50e-44c0-a6ed-48ea90150f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a19aa777-441b-433c-b7c0-3d23f56ab7ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_291cb7c1-d50e-44c0-a6ed-48ea90150f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_eab232b7-2a49-4f6b-8f97-3a767c58e124" xlink:href="exel-20221230.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a19aa777-441b-433c-b7c0-3d23f56ab7ea" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_eab232b7-2a49-4f6b-8f97-3a767c58e124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8f34b14c-318c-42cb-8448-a704fa025886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a19aa777-441b-433c-b7c0-3d23f56ab7ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8f34b14c-318c-42cb-8448-a704fa025886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_50a65e8c-21d9-4576-a836-b81f44858df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a19aa777-441b-433c-b7c0-3d23f56ab7ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_50a65e8c-21d9-4576-a836-b81f44858df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_29985248-6644-4548-ad23-6adc3d2855bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53c5f8e-c235-452a-930e-4c936f70e0eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_29985248-6644-4548-ad23-6adc3d2855bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_06cfebff-9cf6-4c56-bc37-bb14d4957976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53c5f8e-c235-452a-930e-4c936f70e0eb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_06cfebff-9cf6-4c56-bc37-bb14d4957976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#EmployeeBenefitPlansEstimateGrantDateFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5ad76a16-eced-4087-9cd2-39e63ff0465c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca73dd9a-6481-4c59-945b-956f2a42493b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5ad76a16-eced-4087-9cd2-39e63ff0465c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca73dd9a-6481-4c59-945b-956f2a42493b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_efd50a76-3286-4ad3-88cf-e93f299d21a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca73dd9a-6481-4c59-945b-956f2a42493b" xlink:to="loc_us-gaap_AwardTypeAxis_efd50a76-3286-4ad3-88cf-e93f299d21a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01c2d8bd-21f2-4476-a546-b0db8b2e24b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_efd50a76-3286-4ad3-88cf-e93f299d21a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01c2d8bd-21f2-4476-a546-b0db8b2e24b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d4c6ddd0-97b9-4716-9b90-4cf6ccf04d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01c2d8bd-21f2-4476-a546-b0db8b2e24b8" xlink:to="loc_us-gaap_PerformanceSharesMember_d4c6ddd0-97b9-4716-9b90-4cf6ccf04d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember_dff898e7-ebac-48c9-bb39-7e2c2d46d8f7" xlink:href="exel-20221230.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01c2d8bd-21f2-4476-a546-b0db8b2e24b8" xlink:to="loc_exel_TSRBasedRestrictedStockUnitsMember_dff898e7-ebac-48c9-bb39-7e2c2d46d8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_c20888a4-e625-4dae-9f90-0087029fffc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca73dd9a-6481-4c59-945b-956f2a42493b" xlink:to="loc_us-gaap_AwardDateAxis_c20888a4-e625-4dae-9f90-0087029fffc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_b2690784-b142-4a75-b3ef-f3ea492353f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_c20888a4-e625-4dae-9f90-0087029fffc5" xlink:to="loc_us-gaap_AwardDateDomain_b2690784-b142-4a75-b3ef-f3ea492353f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_A2021AwardsMember_9975f097-e429-4a95-af87-f41888c20011" xlink:href="exel-20221230.xsd#exel_A2021AwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_b2690784-b142-4a75-b3ef-f3ea492353f1" xlink:to="loc_exel_A2021AwardsMember_9975f097-e429-4a95-af87-f41888c20011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_607e5d64-f4a6-4ab2-9485-34ecaa333645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca73dd9a-6481-4c59-945b-956f2a42493b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_607e5d64-f4a6-4ab2-9485-34ecaa333645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1e5f5b8e-422d-4aaf-9162-8007d0a3938c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_607e5d64-f4a6-4ab2-9485-34ecaa333645" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1e5f5b8e-422d-4aaf-9162-8007d0a3938c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_82f6bb66-e1eb-4683-843c-a5b00f673ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_607e5d64-f4a6-4ab2-9485-34ecaa333645" xlink:to="loc_us-gaap_SharePrice_82f6bb66-e1eb-4683-843c-a5b00f673ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_868ffd41-5644-4c27-b575-6989ad76a5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_607e5d64-f4a6-4ab2-9485-34ecaa333645" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_868ffd41-5644-4c27-b575-6989ad76a5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_050f5ee6-3601-486b-8a8e-791844d81620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_607e5d64-f4a6-4ab2-9485-34ecaa333645" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_050f5ee6-3601-486b-8a8e-791844d81620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_33050762-009f-4b5c-8390-0934dc046109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_607e5d64-f4a6-4ab2-9485-34ecaa333645" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_33050762-009f-4b5c-8390-0934dc046109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c53e6e95-4730-47ef-9873-67990ec36a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5c2f8700-9351-48bf-b343-142df6e5a53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c53e6e95-4730-47ef-9873-67990ec36a86" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5c2f8700-9351-48bf-b343-142df6e5a53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2eadfd03-50d6-498c-a48a-ab2732def0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5c2f8700-9351-48bf-b343-142df6e5a53a" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2eadfd03-50d6-498c-a48a-ab2732def0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2ea30833-5aa7-47b6-b6c2-0d5ca179e41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5c2f8700-9351-48bf-b343-142df6e5a53a" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2ea30833-5aa7-47b6-b6c2-0d5ca179e41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_225de1b6-0903-4b84-b493-704db38633db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5c2f8700-9351-48bf-b343-142df6e5a53a" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_225de1b6-0903-4b84-b493-704db38633db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_17ea8435-6e70-405c-97ed-60e9475cf9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c53e6e95-4730-47ef-9873-67990ec36a86" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_17ea8435-6e70-405c-97ed-60e9475cf9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0aa7cb9b-e300-48a6-bc56-6cdb6f74dfff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_17ea8435-6e70-405c-97ed-60e9475cf9d2" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0aa7cb9b-e300-48a6-bc56-6cdb6f74dfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_42114137-f241-4c79-983e-b8f906d793a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_17ea8435-6e70-405c-97ed-60e9475cf9d2" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_42114137-f241-4c79-983e-b8f906d793a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_64deca10-732d-47e1-8adc-383376d97389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_17ea8435-6e70-405c-97ed-60e9475cf9d2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_64deca10-732d-47e1-8adc-383376d97389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0b1197f2-2ddc-49b5-baa1-a983af3589c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c53e6e95-4730-47ef-9873-67990ec36a86" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0b1197f2-2ddc-49b5-baa1-a983af3589c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3e9fe1b0-096b-4f06-9ff9-9b58dbc60507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_379ad96d-c96c-4a89-97c6-dc36c268711d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e9fe1b0-096b-4f06-9ff9-9b58dbc60507" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_379ad96d-c96c-4a89-97c6-dc36c268711d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_b6f60e97-b632-4941-9e33-282eb92a2282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e9fe1b0-096b-4f06-9ff9-9b58dbc60507" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_b6f60e97-b632-4941-9e33-282eb92a2282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c07541ff-8bbb-4343-b12f-783f39e0c58a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e9fe1b0-096b-4f06-9ff9-9b58dbc60507" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c07541ff-8bbb-4343-b12f-783f39e0c58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_ebf645d1-b880-444c-8127-5558856a3ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e9fe1b0-096b-4f06-9ff9-9b58dbc60507" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_ebf645d1-b880-444c-8127-5558856a3ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_b5d4272f-8de3-4bfb-b201-245ae02427a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e9fe1b0-096b-4f06-9ff9-9b58dbc60507" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_b5d4272f-8de3-4bfb-b201-245ae02427a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_f7ca1c2b-e015-4c4c-9b6c-93e6f306737c" xlink:href="exel-20221230.xsd#exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e9fe1b0-096b-4f06-9ff9-9b58dbc60507" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_f7ca1c2b-e015-4c4c-9b6c-93e6f306737c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_9c618962-fc1a-4d0a-a51e-e7d3e9f192a8" xlink:href="exel-20221230.xsd#exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e9fe1b0-096b-4f06-9ff9-9b58dbc60507" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_9c618962-fc1a-4d0a-a51e-e7d3e9f192a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase_6edd235f-87a0-4b60-8ce0-709df191400e" xlink:href="exel-20221230.xsd#exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e9fe1b0-096b-4f06-9ff9-9b58dbc60507" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase_6edd235f-87a0-4b60-8ce0-709df191400e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_07dcdcce-7689-48ca-bf0f-af848acbce6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e9fe1b0-096b-4f06-9ff9-9b58dbc60507" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_07dcdcce-7689-48ca-bf0f-af848acbce6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4be083db-d9c0-4ede-b99a-2563ee48f865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e9fe1b0-096b-4f06-9ff9-9b58dbc60507" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4be083db-d9c0-4ede-b99a-2563ee48f865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_32d2dc72-8546-4faf-866c-4195dae8db92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_080a0056-b3ba-4e50-82a8-60975baa45b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32d2dc72-8546-4faf-866c-4195dae8db92" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_080a0056-b3ba-4e50-82a8-60975baa45b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_fffd5e74-0cdb-422d-8c1e-6b825e4ed362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_080a0056-b3ba-4e50-82a8-60975baa45b1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_fffd5e74-0cdb-422d-8c1e-6b825e4ed362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_87836b36-1dc8-460e-bf47-d3952d717b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_080a0056-b3ba-4e50-82a8-60975baa45b1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_87836b36-1dc8-460e-bf47-d3952d717b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_f8375f5a-2618-4a46-a642-8e3533d27537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_080a0056-b3ba-4e50-82a8-60975baa45b1" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_f8375f5a-2618-4a46-a642-8e3533d27537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9a292da6-c72e-4072-a9f5-c8b6e43f6cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_080a0056-b3ba-4e50-82a8-60975baa45b1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9a292da6-c72e-4072-a9f5-c8b6e43f6cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxAssetsLeaseLiabilities_567db1d5-1bde-4dc7-84f9-b647e8221e97" xlink:href="exel-20221230.xsd#exel_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_080a0056-b3ba-4e50-82a8-60975baa45b1" xlink:to="loc_exel_DeferredTaxAssetsLeaseLiabilities_567db1d5-1bde-4dc7-84f9-b647e8221e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_b31b1d12-16d2-4357-bc35-1ebd4c4c32c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_080a0056-b3ba-4e50-82a8-60975baa45b1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_b31b1d12-16d2-4357-bc35-1ebd4c4c32c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_c3dc29e2-2b4c-47da-a12d-e655d2247a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_080a0056-b3ba-4e50-82a8-60975baa45b1" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_c3dc29e2-2b4c-47da-a12d-e655d2247a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_27285841-1daf-48d6-88b4-6f6d955fdae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_080a0056-b3ba-4e50-82a8-60975baa45b1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_27285841-1daf-48d6-88b4-6f6d955fdae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7b18c1f8-b7f1-4bd6-aa31-37e7b259eb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_080a0056-b3ba-4e50-82a8-60975baa45b1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_7b18c1f8-b7f1-4bd6-aa31-37e7b259eb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7fda5e8d-a0bf-4884-bc3a-5a07bfcb0ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_080a0056-b3ba-4e50-82a8-60975baa45b1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7fda5e8d-a0bf-4884-bc3a-5a07bfcb0ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_f8a7fec0-7930-4095-a437-756243e77cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_080a0056-b3ba-4e50-82a8-60975baa45b1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_f8a7fec0-7930-4095-a437-756243e77cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_a75db050-736f-4eef-a78c-5ef67e91ac12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32d2dc72-8546-4faf-866c-4195dae8db92" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_a75db050-736f-4eef-a78c-5ef67e91ac12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_5ec47913-c874-45d7-b546-4ba4a4d32109" xlink:href="exel-20221230.xsd#exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_a75db050-736f-4eef-a78c-5ef67e91ac12" xlink:to="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_5ec47913-c874-45d7-b546-4ba4a4d32109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d27770a5-e232-4996-9f33-7561f51ad414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_32d2dc72-8546-4faf-866c-4195dae8db92" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d27770a5-e232-4996-9f33-7561f51ad414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#ProvisionForIncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9605b8ca-f5fd-43e6-b9fb-97de09ee7142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_8b904e1c-55f2-4c70-ac15-6bd816452d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9605b8ca-f5fd-43e6-b9fb-97de09ee7142" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_8b904e1c-55f2-4c70-ac15-6bd816452d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6c98b1b8-35d4-4091-a23c-27ca211db46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_8b904e1c-55f2-4c70-ac15-6bd816452d2d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6c98b1b8-35d4-4091-a23c-27ca211db46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1c160fe1-6f01-45db-88f4-76162691e287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6c98b1b8-35d4-4091-a23c-27ca211db46d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1c160fe1-6f01-45db-88f4-76162691e287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_03319fba-5b72-4d30-9389-8510db219548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1c160fe1-6f01-45db-88f4-76162691e287" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_03319fba-5b72-4d30-9389-8510db219548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_f16037b6-6dc1-4045-afdc-fafa05ecd6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_8b904e1c-55f2-4c70-ac15-6bd816452d2d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_f16037b6-6dc1-4045-afdc-fafa05ecd6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_ff1eba36-9efe-4675-9f42-f1a2c7f1bae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_f16037b6-6dc1-4045-afdc-fafa05ecd6ed" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_ff1eba36-9efe-4675-9f42-f1a2c7f1bae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_edf41724-005d-4561-88dd-01f357406b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_ff1eba36-9efe-4675-9f42-f1a2c7f1bae2" xlink:to="loc_us-gaap_ResearchMember_edf41724-005d-4561-88dd-01f357406b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_8b904e1c-55f2-4c70-ac15-6bd816452d2d" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_74bb8fed-8eac-405d-86d3-9e60fa7964a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_74bb8fed-8eac-405d-86d3-9e60fa7964a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_115cd507-af77-406f-a5cd-791901adfda6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_115cd507-af77-406f-a5cd-791901adfda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_d076d8fb-a88d-478c-b20c-e08f43ca35dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:to="loc_us-gaap_OperatingLossCarryforwards_d076d8fb-a88d-478c-b20c-e08f43ca35dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_346ca060-7255-4418-940f-f34e0dc7ceb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_346ca060-7255-4418-940f-f34e0dc7ceb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_ce3fdcf3-901f-40ef-88fe-ee8a38cdc5dc" xlink:href="exel-20221230.xsd#exel_TaxCreditCarryforwardAmountWithExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:to="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_ce3fdcf3-901f-40ef-88fe-ee8a38cdc5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_17ecadcc-1345-4db7-877e-36ba89edaa81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_17ecadcc-1345-4db7-877e-36ba89edaa81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ff2d9373-f7bf-4146-85fe-facc3ed04a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f6e92197-06fb-4d43-9aac-b5b73eab7a93" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ff2d9373-f7bf-4146-85fe-facc3ed04a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2a6ddc38-e769-4155-8f2b-ca3d9ff4d771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1840abed-c992-4229-a004-15d6b4ac1f44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a6ddc38-e769-4155-8f2b-ca3d9ff4d771" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1840abed-c992-4229-a004-15d6b4ac1f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6a275a68-6ae5-4c1e-a4ec-35b9105d0b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1840abed-c992-4229-a004-15d6b4ac1f44" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6a275a68-6ae5-4c1e-a4ec-35b9105d0b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2535e873-99a6-4647-ad7c-e55297a5fe36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1840abed-c992-4229-a004-15d6b4ac1f44" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2535e873-99a6-4647-ad7c-e55297a5fe36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_32759627-86fb-4525-a9f4-940332faf195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1840abed-c992-4229-a004-15d6b4ac1f44" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_32759627-86fb-4525-a9f4-940332faf195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_b4210218-38ff-4789-b722-625b7c7a9b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1840abed-c992-4229-a004-15d6b4ac1f44" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_b4210218-38ff-4789-b722-625b7c7a9b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7f89c21c-ced7-4b75-9bff-d21aa727a70b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1840abed-c992-4229-a004-15d6b4ac1f44" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7f89c21c-ced7-4b75-9bff-d21aa727a70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3aedf28d-8c47-4d72-8fae-3d1c3d966693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_16e0bb90-4238-4546-aaf8-fe024a87fb36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3aedf28d-8c47-4d72-8fae-3d1c3d966693" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_16e0bb90-4238-4546-aaf8-fe024a87fb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3c57187b-eb60-4d2d-b0ee-36856d42eebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_16e0bb90-4238-4546-aaf8-fe024a87fb36" xlink:to="loc_us-gaap_NetIncomeLoss_3c57187b-eb60-4d2d-b0ee-36856d42eebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_75d6d166-ac9b-4d41-8be0-d9a3d2e6efba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3aedf28d-8c47-4d72-8fae-3d1c3d966693" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_75d6d166-ac9b-4d41-8be0-d9a3d2e6efba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cff60a3f-0380-4e7a-a9eb-c52dcf83995c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_75d6d166-ac9b-4d41-8be0-d9a3d2e6efba" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cff60a3f-0380-4e7a-a9eb-c52dcf83995c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f6275e8b-4e5a-4fb4-9ff7-873961e25d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_75d6d166-ac9b-4d41-8be0-d9a3d2e6efba" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f6275e8b-4e5a-4fb4-9ff7-873961e25d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5990223f-11b0-4809-ae1b-31907f632842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_75d6d166-ac9b-4d41-8be0-d9a3d2e6efba" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5990223f-11b0-4809-ae1b-31907f632842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_923174ad-eefa-4e75-a851-da4f1f46e6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_75d6d166-ac9b-4d41-8be0-d9a3d2e6efba" xlink:to="loc_us-gaap_EarningsPerShareBasic_923174ad-eefa-4e75-a851-da4f1f46e6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_868efba2-6293-465a-ae79-62e6104d43fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_75d6d166-ac9b-4d41-8be0-d9a3d2e6efba" xlink:to="loc_us-gaap_EarningsPerShareDiluted_868efba2-6293-465a-ae79-62e6104d43fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0917b655-c1ed-4564-9774-b5abf3883626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_42496853-1ef3-4fb0-b94b-00cb3e787993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0917b655-c1ed-4564-9774-b5abf3883626" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_42496853-1ef3-4fb0-b94b-00cb3e787993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8fb4ea12-621f-4c9b-8706-7550aabce282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_42496853-1ef3-4fb0-b94b-00cb3e787993" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8fb4ea12-621f-4c9b-8706-7550aabce282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad47a1c-eb90-4315-8b07-77b05d7f8f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8fb4ea12-621f-4c9b-8706-7550aabce282" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad47a1c-eb90-4315-8b07-77b05d7f8f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_60214c48-796a-494a-9665-c96f37a1dd61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aad47a1c-eb90-4315-8b07-77b05d7f8f10" xlink:to="loc_us-gaap_StockCompensationPlanMember_60214c48-796a-494a-9665-c96f37a1dd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b3de7e08-b1a2-4cb9-877f-42626d85f86a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_42496853-1ef3-4fb0-b94b-00cb3e787993" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b3de7e08-b1a2-4cb9-877f-42626d85f86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c14263c6-0346-4205-81a1-64766448750c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b3de7e08-b1a2-4cb9-877f-42626d85f86a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c14263c6-0346-4205-81a1-64766448750c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_17b7374a-aa59-4486-850a-a2f9cb989ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_c7f69278-cb9e-4dab-9b82-599df8c6d399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_17b7374a-aa59-4486-850a-a2f9cb989ba7" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_c7f69278-cb9e-4dab-9b82-599df8c6d399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis_b074ce47-8589-49e4-ac26-3eafd55713a0" xlink:href="exel-20221230.xsd#exel_LeaseArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c7f69278-cb9e-4dab-9b82-599df8c6d399" xlink:to="loc_exel_LeaseArrangementsAxis_b074ce47-8589-49e4-ac26-3eafd55713a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_5f1ff9e3-8728-4a69-81d8-331e8860508b" xlink:href="exel-20221230.xsd#exel_LeaseArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsAxis_b074ce47-8589-49e4-ac26-3eafd55713a0" xlink:to="loc_exel_LeaseArrangementsDomain_5f1ff9e3-8728-4a69-81d8-331e8860508b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLeaseMember_e3c69fb9-1490-4ead-863e-550ca6376c7e" xlink:href="exel-20221230.xsd#exel_HeadquartersLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsDomain_5f1ff9e3-8728-4a69-81d8-331e8860508b" xlink:to="loc_exel_HeadquartersLeaseMember_e3c69fb9-1490-4ead-863e-550ca6376c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember_96a89903-5146-4b39-ab8f-563f28607b31" xlink:href="exel-20221230.xsd#exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsDomain_5f1ff9e3-8728-4a69-81d8-331e8860508b" xlink:to="loc_exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember_96a89903-5146-4b39-ab8f-563f28607b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9b502d5-a40b-43d5-a1cb-049a918485c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c7f69278-cb9e-4dab-9b82-599df8c6d399" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9b502d5-a40b-43d5-a1cb-049a918485c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_e2278d6d-c646-404b-91ff-8caf79171612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9b502d5-a40b-43d5-a1cb-049a918485c3" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_e2278d6d-c646-404b-91ff-8caf79171612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_c1cd89e7-e8c5-4718-b9d7-8194bc089231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9b502d5-a40b-43d5-a1cb-049a918485c3" xlink:to="loc_us-gaap_OperatingLeasePayments_c1cd89e7-e8c5-4718-b9d7-8194bc089231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c6b23761-a3c9-4eaf-9ee0-e4872c84c1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9b502d5-a40b-43d5-a1cb-049a918485c3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c6b23761-a3c9-4eaf-9ee0-e4872c84c1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_060bdcb6-c191-4fa9-aa66-8678e04fc258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9b502d5-a40b-43d5-a1cb-049a918485c3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_060bdcb6-c191-4fa9-aa66-8678e04fc258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_bc8bf9e7-8a5f-483d-9426-e25ab4285086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9b502d5-a40b-43d5-a1cb-049a918485c3" xlink:to="loc_us-gaap_ShortTermLeaseCost_bc8bf9e7-8a5f-483d-9426-e25ab4285086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LossContingencyNumberOfLawsuitsConsolidated_9476a668-4594-483d-b34d-ffa2e9433388" xlink:href="exel-20221230.xsd#exel_LossContingencyNumberOfLawsuitsConsolidated"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9b502d5-a40b-43d5-a1cb-049a918485c3" xlink:to="loc_exel_LossContingencyNumberOfLawsuitsConsolidated_9476a668-4594-483d-b34d-ffa2e9433388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b929db75-ad4a-4737-a7d7-d0c4332aae9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseAssetsAbstract_e1ec62bb-269a-4ba8-b101-a6e3e0f5edc4" xlink:href="exel-20221230.xsd#exel_OperatingLeaseAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b929db75-ad4a-4737-a7d7-d0c4332aae9a" xlink:to="loc_exel_OperatingLeaseAssetsAbstract_e1ec62bb-269a-4ba8-b101-a6e3e0f5edc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4e15c1d2-18bb-41de-a669-8777ca39128b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseAssetsAbstract_e1ec62bb-269a-4ba8-b101-a6e3e0f5edc4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4e15c1d2-18bb-41de-a669-8777ca39128b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_f3d50139-ff95-4262-9b21-c8573abf33a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseAssetsAbstract_e1ec62bb-269a-4ba8-b101-a6e3e0f5edc4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_f3d50139-ff95-4262-9b21-c8573abf33a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseLiabilitiesAbstract_6ad0d7ed-86a2-413e-af35-1abe964a7919" xlink:href="exel-20221230.xsd#exel_OperatingLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b929db75-ad4a-4737-a7d7-d0c4332aae9a" xlink:to="loc_exel_OperatingLeaseLiabilitiesAbstract_6ad0d7ed-86a2-413e-af35-1abe964a7919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3190a6c8-3376-4e32-af36-4c3899e1bce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_6ad0d7ed-86a2-413e-af35-1abe964a7919" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3190a6c8-3376-4e32-af36-4c3899e1bce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0ee6a7d8-bde6-4732-8fb8-266ab7bd3fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_6ad0d7ed-86a2-413e-af35-1abe964a7919" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0ee6a7d8-bde6-4732-8fb8-266ab7bd3fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1892b8a2-5bd3-4ff6-bb5d-c1719b2585db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_6ad0d7ed-86a2-413e-af35-1abe964a7919" xlink:to="loc_us-gaap_OperatingLeaseLiability_1892b8a2-5bd3-4ff6-bb5d-c1719b2585db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_48c9cb14-84ce-4441-bf09-09192440b814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_6ad0d7ed-86a2-413e-af35-1abe964a7919" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_48c9cb14-84ce-4441-bf09-09192440b814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CommitmentsAndContingenciesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a053dbed-4f12-4ed2-b52d-adfd9174660f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_5c080053-6e48-4cf2-bc0b-769e6855d716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a053dbed-4f12-4ed2-b52d-adfd9174660f" xlink:to="loc_us-gaap_OperatingLeaseCost_5c080053-6e48-4cf2-bc0b-769e6855d716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_5a10b06e-a02e-4780-bb88-d15bb57495fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a053dbed-4f12-4ed2-b52d-adfd9174660f" xlink:to="loc_us-gaap_VariableLeaseCost_5a10b06e-a02e-4780-bb88-d15bb57495fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_24549fd7-bd8a-4a2e-aace-677dcdb87527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a053dbed-4f12-4ed2-b52d-adfd9174660f" xlink:to="loc_us-gaap_LeaseCost_24549fd7-bd8a-4a2e-aace-677dcdb87527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20221230.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8a05e11-993b-4c4c-95bc-d91cdda0bab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_829e13b1-ef27-44cc-8543-5924fcbe6ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8a05e11-993b-4c4c-95bc-d91cdda0bab0" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_829e13b1-ef27-44cc-8543-5924fcbe6ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_55262d7b-ec01-4ad4-81b3-7bca7bdd4b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_829e13b1-ef27-44cc-8543-5924fcbe6ccd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_55262d7b-ec01-4ad4-81b3-7bca7bdd4b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3f4a0173-0bdd-4037-abca-41f0e8bbb85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_829e13b1-ef27-44cc-8543-5924fcbe6ccd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3f4a0173-0bdd-4037-abca-41f0e8bbb85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e7123a2b-4e34-4832-b996-48993ec48a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_829e13b1-ef27-44cc-8543-5924fcbe6ccd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e7123a2b-4e34-4832-b996-48993ec48a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8f88f87d-ea89-4347-9b59-799da6e3765a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_829e13b1-ef27-44cc-8543-5924fcbe6ccd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8f88f87d-ea89-4347-9b59-799da6e3765a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9e8655bd-bcf3-4eef-8e4c-1670aca3ee9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_829e13b1-ef27-44cc-8543-5924fcbe6ccd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9e8655bd-bcf3-4eef-8e4c-1670aca3ee9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_40b93e8d-0d8d-413a-9923-a0c329682077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_829e13b1-ef27-44cc-8543-5924fcbe6ccd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_40b93e8d-0d8d-413a-9923-a0c329682077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_07699276-6a34-45b9-b0c9-f89d42974ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_829e13b1-ef27-44cc-8543-5924fcbe6ccd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_07699276-6a34-45b9-b0c9-f89d42974ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_488073de-3295-4c1b-926e-c6ce7bd5f10f" xlink:href="exel-20221230.xsd#exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_829e13b1-ef27-44cc-8543-5924fcbe6ccd" xlink:to="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_488073de-3295-4c1b-926e-c6ce7bd5f10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b60c10af-d733-4d99-9d39-f94d27e21134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_488073de-3295-4c1b-926e-c6ce7bd5f10f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b60c10af-d733-4d99-9d39-f94d27e21134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_ba4d0b30-423e-4f91-872b-0b621ba43001" xlink:href="exel-20221230.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_488073de-3295-4c1b-926e-c6ce7bd5f10f" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_ba4d0b30-423e-4f91-872b-0b621ba43001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9debd79b-6591-43a3-8be1-2d8e62aa3201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_488073de-3295-4c1b-926e-c6ce7bd5f10f" xlink:to="loc_us-gaap_OperatingLeaseLiability_9debd79b-6591-43a3-8be1-2d8e62aa3201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="exel-20221230.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exel-20221230_g1.jpg
<TEXT>
begin 644 exel-20221230_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
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MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
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MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
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MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
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M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
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M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
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M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
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MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
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MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
M"BBB@#A?VH/^3:?B)_V+.I?^DLM?SJ?-[5_17^U!_P FT_$3_L6=2_\ 266O
MYU/F]JVI&=0/F]J/F]J/F]J/F]JU,P^;VH^;VH^;VH^;VH /F]J/F]J/F]J/
MF]J /3?V*?\ D\CX2_\ 8Y:/_P"ET-?T,5_//^Q3_P GD?"7_L<M'_\ 2Z&O
MZ&*PJ;FM/8****S+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M^9?^"Q7_ "CC^(W_ '#?_3G:5]-5\R_\%BO^4<?Q&_[AO_ISM*J.Z _#3YO:
MCYO:CYO:CYO:NDYP^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:NG^"O_
M "6/PE_V&;/_ -'I7,?-[5T_P5_Y+'X2_P"PS9_^CTI ?T?4445RG0%%%% !
M1110 5S'QA^%&D?'#X8ZUX3UR$S:7K=N;>7;]Z(]4D7T9&"L#ZJ*Z>BLZU&%
M:G*E55XR333V:>C3]3;#8FKAZT<10DXSBTTUNFG=->:>I^"/QV^#6K_L^_%G
M6O".MIMOM'G,?F*,)<1D;HY5_P!ET*L/3.#R#7(U^JW_  5T_9"_X7)\*1X[
MT2U\SQ)X/@8W*1KE[ZP!+./=HLM(/]DR#DD"ORIK^)^..%ZF19I/"Z^SE[T'
MWB^GJMG]^S1_I=X8<=4N*<CIX[15H^[4CVFEJTNTOB7K;=,****^//T0****
M "BBB@ K[ _X)(?M??\ "E/BO_P@^M77E^&?&4ZK TC82ROSA4?V63 C;W$9
MX -?'].1VC<,I*LIR"#R#7L9!G6(RG'T\?AOB@]NC75/R:T_X)\[Q7PUA,_R
MJME.-7NU%:_6+WC)><79^>ST9_0U17S;_P $S?VO1^U!\#8[35+GS/%_A54L
M]3W'Y[M,$17/_ P"&_VU8\ @5])5_<63YKA\RP=/'85WA-77EW3\T]'YH_S"
MXAR'%Y+F-;*\=&U2E)I]GV:\I*S7DT%%%%>D>,%%%% !1110 4444 %%%% !
M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
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M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
M@IIK7[1]\OPV\;6UYJ/B;3[-KBTUV*,NM[!'@$76!A)!D8D/$F0#A\&3[TKY
MN_X)I_L*6?[%GP71;Z.&;QOXB1+C6[I<-Y)QE+5&_N1Y.2/O,6/3:!](US2M
M?0VC>VH5P?[4OAJX\:?LR?$;1[4,UUJWAC4[*$*NXEY+25%P._)'%=Y0RAUP
M>0>H]:DH_%'_ ((D>,X?"G[>NCVLS(G_  D&EWNG1EA_'Y?G@9[$^01SUSCJ
M17[75^"/QY\'ZM_P3^_;SOETZ)HV\'Z]'JVCALJEQ:%Q-"N>ZF,A&QD9#CL:
M_<KX0_%31_C?\,=#\7:#<?:-)\06:7ENW\2AARC#LZME6'9E([5I4[D0['YD
M_P#!PO\ \EE^'?\ V!;C_P!'BN?_ &0/^",5O^UG^S-X8\?+\1)O#UQKQNO,
MLSH8O$B$-U-;C#>?&3GRMW3^+';-=!_P<+_\EE^'?_8%N/\ T>*^P/\ @CK_
M ,HX_AS_ -Q+_P!.=W3YFHJPK7EJ?D?^VO\ LAZS^Q5\;[GPAJET-4MF@2\T
M[4T@\E-1MWR-X3<VPJZNC+N."O4@@G]>O^"6NC_#%OV4-#UOX:Z+::0NK1*N
MM#S#->?;HQB6.:5OG;:Q)0'"['!55#5F_P#!5_\ 8V_X:Q_9ON+C2;7SO&/@
M[?J6D;5_>728'GVH/7]XJ@@=WCCZ FO@7_@C5^V8?V=?C[_PANMW7D^$_'DR
M6SF5L1V%^/EAEY^Z'SY;=.J$\)1\40V9^SE?GW_P<(^-X;'X"^ _#;,OVC5-
M?DU)%_B*6UN\;'\[I:_02OQ%_P""M/[2@_:I_;#N-/T%VU#1?"BC0-,$'[S[
M9.'/G2(!G=OE.Q2,AEC0CK4T]RI;'W)_P08\-3:'^Q-?7<H^76?%%Y=PDKC*
M+#;0]>_S0O\ K]:^UJ\Q_8U^!W_#-_[+W@KP7(JK=Z-IJ?;=IRINI"99\'N/
M-D?!],5Z=4R=W<I;!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /Y^?^"@?_ ">Y\5?^QFOO_1K5Y!\WM7K_ /P4#_Y/<^*O
M_8S7W_HUJ\@^;VKJCL<X?-[4?-[4?-[4?-[4P#YO:CYO:CYO:CYO:@ ^;VH^
M;VH^;VH^;VH /F]J/F]J_;3]B;]B;X0^-OV1/AOJVK_#?P?J6J:EX?L[BZNK
MC3(I);B1H@6=F(R6)ZFO4?\ AW]\$?\ HE?@7_P41?X5E[1%\C/Y^OF]J/F]
MJ_H%_P"'?WP1_P"B5^!?_!1%_A1_P[^^"/\ T2OP+_X*(O\ "CVJ'[-G\_7S
M>U'S>U?T"_\ #O[X(_\ 1*_ O_@HB_PH_P"'?WP1_P"B5^!?_!1%_A1[5![-
MG\_7S>U'S>U?T"_\._O@C_T2OP+_ ."B+_"C_AW]\$?^B5^!?_!1%_A1[5![
M-G\_7S>U'S>U?T"_\._O@C_T2OP+_P""B+_"C_AW]\$?^B5^!?\ P41?X4>U
M0>S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\ "C_AW]\$?^B5^!?_  41
M?X4>U0>S9_/U\WM1\WM7] O_  [^^"/_ $2OP+_X*(O\*/\ AW]\$?\ HE?@
M7_P41?X4>U0>S9_/U\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=_?!'_HE?
M@7_P41?X4>U0>S9^ .F:7=:UJ$-I9V\]W=7#!(H88S))*QZ!5')/L*^R?V.?
M^"+GQ!^.FI6FJ^.H;GP#X3.)'6Y3&J7B]=L<!YBSTW2X(R"$?I7ZV_#[X)>#
M?A+%L\+>$_#?AQ2-I_LS38;4L/<HH)_'K745+J/H"I]SD_@G\$/#'[/'PYL?
M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
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MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
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M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
M"C_AW]\$?^B5^!?_  41?X4>U0>S9_/U\WM1\WM7] O_  [^^"/_ $2OP+_X
M*(O\*/\ AW]\$?\ HE?@7_P41?X4>U0>S9_/U\WM1\WM7] O_#O[X(_]$K\"
M_P#@HB_PH_X=_?!'_HE?@7_P41?X4>U0>S9_/U\WM1\WM7] O_#O[X(_]$K\
M"_\ @HB_PH_X=_?!'_HE?@7_ ,%$7^%'M4'LV?S]?-[4?-[5_0+_ ,._O@C_
M -$K\"_^"B+_  H_X=_?!'_HE?@7_P %$7^%'M4'LV?S]?-[4?-[5_0+_P .
M_O@C_P!$K\"_^"B+_"C_ (=_?!'_ *)7X%_\%$7^%'M4'LV?S]?-[4?-[5_0
M+_P[^^"/_1*_ O\ X*(O\*UO"?[&WPE\"WRW6D_#7P-8W2G<L\>B6_FH?]ER
MA8?@11[5![-GXC_LT_L$?%+]JW4+?_A%_#-XNDS-A]9OU-KIT2YP6\UA\^/[
ML8=O:OUO_8'_ .":OA/]B+1VOUD'B'QM?0^7>:S-%M$*'!,-NG/EQY')R6?'
M) PJ_2:J$7 X Z#THK.4VRHQ2"BBBI*"BBB@ HHHH **** .%_:@_P"3:?B)
M_P!BSJ7_ *2RU_.I\WM7]%?[4'_)M/Q$_P"Q9U+_ -)9:_G4^;VK:D9U ^;V
MH^;VH^;VH^;VK4S#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH ]-_8I_Y/(^
M$O\ V.6C_P#I=#7]#%?SS_L4_P#)Y'PE_P"QRT?_ -+H:_H8K"IN:T]@HHHK
M,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYE_P""Q7_*./XC
M?]PW_P!.=I7TU7S+_P %BO\ E''\1O\ N&_^G.TJH[H#\-/F]J/F]J/F]J/F
M]JZ3G#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]JZ?X*_P#)8_"7_89L
M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
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M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
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M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
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MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
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MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
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M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
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M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
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M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
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MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
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M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
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M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
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MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
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M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
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MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
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M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
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MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
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M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
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M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
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MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
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MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
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MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
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MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
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M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
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M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
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M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
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M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
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M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
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M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
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M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
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M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
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M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
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M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exel-20221230_g2.jpg
<TEXT>
begin 644 exel-20221230_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **YWXI_%SX8_!'P
M?/X_^+OCO3/#NC6S!9=0U6[6*/><X1<\NYP<(N6.. :\I^$7_!3?]A+XZ^-H
M/AU\,_VB]*N]9NIO*L[*]LKNQ-S(3@)$UU#&LK$\!4))[ T >\4444 %%%%
M!1110 45S.E_&/X::U\5=4^".E^*H9O%.BZ;#J&J:0(9 ]O;2G$<A8KL(8]@
MQ/J*Z:@ HJAXF\5>&?!>C2^(_&'B&RTK3X"HFO=0NDAB0L0J@LY !)( '<D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_#7X9^%K_P 'WMUI7B4^*)+RY36-7MB3)#91PN/)@VF,%Y'8[Y"H.$+GN/\
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M7.C>,RUW?:/-;M;?Z$T($RNH,19T8+NQNX(SD4 >I_L:_M5>+/C!X.\>Z?\
M'ZTT71?%OPR\7ZAH_BN/28I8;000_O(;Q%EDD=8I(LD$N<^6Q&!@5Y=H7_!2
M+XN2?LEZ-\>=0^%>EW_B;XH_$*;0?@SX3M!+:_:;:2=HK66^>21SD".21W0(
MK Q@! VX<'_P4;^&7QS\"?M%:M9?L]>&[V>T_:9\*VG@_P 1W=G;N\6F:A!=
M00F]G*C"H=/FFBR<=';/&*[7_@I9^QY;:E^SW\*H/ 'PBNO&?AOX0:_8MJW@
M6PW&YU/0DA6"=(1&59Y@B(0%Y.6/;! -WQ9^TA^V]^R1J_ACQA^V#9?#?7O
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MZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\
M/C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?
MV=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ
M%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_
M]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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M#%>NT4 0Z;ING:-IUOI&D6$-I:6L*PVMK;1"..&-0%5$50 J@   < "IJ**
M"BBB@#POP#_RD$\?_P#8B:5_Z,:O=*\+\ _\I!/'_P#V(FE?^C&KW2@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BOSM_X?X_]6H_^7U_]PT?\/\ '_JU'_R^O_N&
MOTC_ (A'XA_] 7_E2C_\L/'_ +?RG_GY^$O\C]$J*^=OV!_V^/\ AN'_ (2S
M_BU'_"+_ /"+_8/^8[]M^T_:?M'_ $PBV;?(_P!K._MCGZ)KXG-\HS'(<QG@
M<=#DJPMS1NG:Z4EK%M;-/1_B>EA\11Q5%5:3O%[/\.H4445YIL%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7X!_Y2
M">/_ /L1-*_]&-7NE>%^ ?\ E()X_P#^Q$TK_P!&-7NE !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !113+BX@M8'NKJ9(XHT+222, JJ!DDD] !WH2;8#Z*^7?VC_P#@K1^S!\#/
M/T3PCJK>.==BRHLM F7[+&X[271R@'_7,2$'J!7SH?%'_!47_@I"?*\-6;^
MO EYQY\32:?:2Q'UE.;B[!'!" QD]0M?>Y7X>9UB\,L9F$HX3#_\_*SY;_X8
M_%)OIHD^C/+KYMAJ<_9TKU)]HZ_>]D?!%%%%?W&?F9^B7_! [_FJ_P#W O\
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MBBO@#U0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[VBBOSS%8O%8ZO*OB:CG.6\I-MOU;U/6A3A2BHP5EV04445SEA1110 4444
M%%%%  0",$5\.?MM_P#!+V^N=?;]HW]C"5_#_BVQG^VW&@:=-]G2XE!W>=:,
M"!#-ZIPC]MIR'^XZ*][A[B3->&<=]9P4[7TE%ZQG'K&4>J?WKHTSEQ>#H8VE
MR5%Z/JGW3/C+]A7_ (*A67Q+U.'X#?M1QKX=\=6TWV.'4+N'[-#J4RG:8I4(
M'V>YR,;2 K-PNTD)7V;7S7^W5_P3B^'/[6VF2^+_  X;?0/'<$.+;64CQ%?[
M1A8KI5&6&  ) -Z\?> VUX!^RU_P4&^+G[)/CI?V5?V\M,U"&WL66'3O$=VI
MEGLH^B&1QG[3;''RRKN90,?,.$^TQW#N4\8X2>9<-QY*T5>KA>J[RH_S1_N[
MK9)743S:6+KY=45'&.\7\,_TEV?G_P .?HG15;1]8TGQ!I5MKN@ZG;WME>0K
M-:7=I,LD4T;#*NC*2&4@Y!'!JS7Y=*,HR::LT>XFF@HHHI %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!X7X!_Y2">/_P#L1-*_]&-7NE>%
M^ ?^4@GC_P#[$32O_1C5[I0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:7+4BK4L5:\H=HU?YX>;U6[>KDO$JX.O@*CKX)73^*'1^<>S_KR/LRBOS_\
MV1?^"E_Q$\+^+5_9H_;1OFT#7M/F%G!XCUJTV'>,!8[P\;21C$_W6!!8C[[?
M<T=MXSFC66+7K%D9059;<D$'H0<U\=Q%PSFG#&-^KXR.CUA-:PG'I*,NJ_%=
M4>A@\;0QM/GIOU3W3[-&U16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_X
MU\^=9L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_N9^=O\ PX._ZNN_\L7_ .[J^B?V!_V!_P#AA[_A+/\ BZ__  E'_"4?8/\
MF!?8OLWV;[1_TWEW[O/_ -G&SOGCZ)HKR<W\1>,L^RZ>!QV*YZ4[<T>2FKV:
MDM8P3W2>C_ WP^49=A:RJTH6DMG=^G5A1117Q)Z04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 9_BKPKX:\<>';SPCXPT*UU/2]0@,-[87L(DBF0]593P?Z'FOSK_ &B?
MV*OCO_P3\\?R_M1_L4ZU?7'ARW)DU;13NGDLH,[GBF3_ )>;7_:^_& "3E?,
MK])*" P*L,@]0:^HX9XLS#AFM)4TJE"II4I2UA-=;KH^TEJO-73X<;@*6-BK
MZ26TENOZ['@7[$W_  4 ^%G[87A]=.@>/1?&-I!NU3PW/-DL!UFMV./-BSU_
MB3HPQAF]]KX:_;9_X)?:BWB!OVC_ -BR5] \5V$_VVX\/Z;-]G6>4<F:T8$"
M&7UCX1^VT\/M?L*?\%0M/^*6HP_ G]IV-/#OCJVE^R0W]U#]GAU.93M,<BL!
M]GN<C!0X5FX7:2$KZ'..$\OS; 2SGAEN=%:U*+UJ4?EO*':2NTM[V;7)A\?6
MH55A\;I+I+I+_)^1]ET445^;'LA1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7X!_P"4
M@GC_ /[$32O_ $8U>Z5X7X!_Y2">/_\ L1-*_P#1C5[I0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^:/VZ_P#@F_\
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M^FX3C]S71Q>S3Z-?F>OAL30Q=)5*3NF%%%%>4;A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7X!_P"4@GC_
M /[$32O_ $8U>Z5X7X!_Y2">/_\ L1-*_P#1C5[I0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2%8E3C#9)'^Z:^CO^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\
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M^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\
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M_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBN-\?\
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ME?6*'\Z^]'>45PZ_'OP<W26/\;I!_6G+\=/"+#(FA_&^B']:M9IECVKP_P#
MH_YC]M1_F7WG;45QJ_&OPJQP+BU_'4X!_P"S4]/C'X<D&4EM6'J-4@/_ +-6
MBQ^!>U6/_@2_S'[2G_,OO.OHKE5^*VCN0$AB.>F-0AY_\>J1/B792?ZO3PV.
MN+V(_P#LU:+%8:6TU]Z'SP[G345SJ_$!7 9-&<@]"+J/_&I5\9W3G:GANX)]
M!,G^-:*K3EM)?>.Z9NT5BIXHU2093PE=L/4.I_K3O^$EU?\ Z%"]_P"^EJQF
MQ16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T
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M!K_P,_X2S^P_[<^R_P#$T^P?:?(\FZAN/]7YD>[/E;?O#&[/.,'XQ_X<'?\
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MZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\
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M^#]UKXU?58Y)[[Q#K 4J+[4+B1I9Y #SM#-L7.#M1<\YKU>BB@ HHHH \+\
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M;("[ *<2=:^]/@=^SU\(/V<?"*>"_A!X*M=)M< W,R+NGNW ^_-*WS2-UZG
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M/^U]\#OVOO%WPN^%WQ=_LO0M+^P?8;'^P-/G\KS-/MIG^>:!G;+R.>6.,X&
M *\8_P"'K_[?O_1>_P#RUM*_^1:YW_@H3\5O GQM_;!\8_$WX9ZW_:6B:C)8
MK97P@>,2^38V\#D+(JL!OC< D#(&1P:\8K^WN&>#>&_]7,%];RZE[7V5/GYJ
M,.;FY%S<UXWYKWO?6^Y^:XW,<9]<J>SK2Y>9VM)VM?2VNQ]/^!O^"I__  4/
MUCQ3:Z/HWQ%/B.\O-]O::.OA&Q=IY71E0JMO LC,K$.H!P60;@RY4_0'[/\
M_P $J/B=\;/%8^.O[?WC?4;^^O&64^&Q?E[B5>H2XF4XA0=!##T! W)@K7S3
M_P $H/\ D_WP#_W%?_35>5^S=?E/BCGW^I69QR_(</2PTJM)2E4IPC&=G*:Y
M4TER_#=M>\[JS5CW,DPO]I475Q4Y34962;;6R=_/?T,OP9X)\(?#KPU:^#O
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_ /_*03Q_\
M]B)I7_HQJ]TKPOP#_P I!/'_ /V(FE?^C&KW2@ HHHH **** "BBB@ HHHH
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M;NVR=PTJ&\%]=QJ>J+@_9[8?]<]X_P!FOK;X!?L(_LO?LW"&\^'?PRM)-5A
M_P")]J_^EWI;^\LCC$1]HP@]J]?HKPLZX\XESRE["I5]G1V5.FN2FEVM'=?X
MFSJPV5X/#2YU&\OYGJ_Q_0****^./0"BBJ6I^)?#NB@G6->L[7'47%RJ']34
M5*E.E'FFTEW>@FU%79=KB?\ A;ME_P +;_X0#<GV;R?*\[_IZZ[<^F/E_P!Z
MF>+/CWX#T?2KDZ+K:7E\(F^S10Q,5+]LMC;C/)YZ5\_?VA>_VA_:OVI_M/G>
M;YV?FWYSNSZYYK\_XHXQI9?5HT\%-3?-S3Y6FN5?9NNK_"WF>9C,?&DXJF[Z
MZ^G8^NJQ_$GC[P=X24G7_$%O X&?)W[I#_P!<M^E>4:5??';XR6QN+#5X[/3
M]YC>6&40ID8R#MS(?ITYKH?#?[,GART87/BK5[C4)2<M%%^ZC)[Y.2Q^N17J
M0S_-LTBGEF$?*]IU7RQ]4EJUZ&RQ->LOW,-.[T17UW]IJ"6;[!X'\,37<S'$
M<ET" 3[(F2WYBL__ (1[]H/XF?-K.H-I-F_6-V\@8]-B?.?^!?G7JVA>%?#?
MAB'R/#^B6UH,88PQ ,WU;J?Q-:%/_5[,L?KF>+E)?R4_<CZ-[R7K8/JM6K_&
MFWY+1'F_AK]FCP?IFV?Q%?7&I2CDIGRHOR4[C_WU^%=YH_A_0_#UM]DT/2;>
MTC[K!$%S]<=3[FKE%>W@,FRO*XVPM&,?.VOWN[_$Z*6'HT5[D;!1117IFP44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'S>!O"=T<#4[(M91F,]S?2_O)2,\_9P/]VO1/@=_P11^'>EWJ^+/VF?B+?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,9V2(P#QM@@[6 ."#TKDOBK^WQ^QQ\$/'X^%WQ4_:$\/:/KV4$VG3W#.UL6
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M?]MB6'X4?\*:^,_B3GQ1X^\N-NL1O99,?\! "_K7J'_"8^&/^@U!_P!]4?\
M"8^&/^@U!_WU7Q7^J="MKB\35J^3FTON5OS/2^HQE\<Y2^9Y]IG[+.@1$-K7
MBB\N#W%O$L6?SW5T6E_ ;X8:9ACX>-RX_CNKAWS^&0OZ5O\ _"8^&/\ H-0?
M]]4?\)CX8_Z#4'_?5=V&X8X?PG\/#1^:YO\ TJYI#!X6&T%^?YDFF>&/#FB@
M?V/H%E:XZ&WME0_F!5ZLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZKVZ=.G2CR
MP22[+0Z$E%61I45F_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5C-*BLW_ (3'
MPQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^
MJ -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A
M,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ
M_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ
M@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^
M$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'
MPQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^
MJ -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A
M,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ
M_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ
M@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^
M$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'
MPQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^
MJ -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A
M,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ
M_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ
M@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^
M$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'
MPQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^
MJ -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A
M,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ
M_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ
M@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^
M$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'
MPQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^
MJ -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJK&G
MZWI.JNT>G7\<S(,L$/04 6J*** "BBB@ HHHH **** /EO2=!UU?^"S.J^)F
MT6[&FM^SI';+J!MF\@S?VTC>7YF-N_;SMSG'-8?QUU:]_8W_ ."@H_:[\6>%
M-9O?AQXZ\!1Z!XGUG1-*FO6T+4;:<20SSQ0JTGD/$ @95)W9] #]@44 ?'GP
M(:?]M']O+5?VN])\(:Q9_#;PS\.F\)^%M0UO3);)]?NKBX:6XNH8IE600K&S
M1991DD=PP''?LH?M1:-_P3H^"-Y^QS^T9X#\8CQ-X(U748O!B:1X6N[R/Q?9
M374MQ;O:30QM&&8RE"KLH7 !.X,J_>E% 'SW_P $R?@?X_\ @A^R[ OQ9TDZ
M?XI\7>(=0\3^(-,8_-9SWDNY86_VEB6/<.S;AVKZ$HHH *Q)?AI\.)Y6GG^'
M^B.[L6=WTJ$EB>I)V\FMNB@#Y^^&/AWP_I/[?/CVPTK0K.V@3P-I92&WM41%
M)D;)  P,X'Y5[W_9VG_\^,/_ 'Z%>(^ ?^4@GC__ +$32O\ T8U>Z4 0_P!G
M:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\
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MKA8_HT+^P</TJS7_ &]_P#\SG\-_\%F=*XO_ (1:==;>,C2=!;..O^I(Z_\
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M\=ESPF&=65:3BK7T7==M26O*OVQOA)=?%GX+7UOHRR'4])S?6,<9.9M@.^+
MZ[DS@?W@M>1?\/0_^J'?^7-_]S4?\/0_^J'?^7-_]S5^:<->!?CSPMG^&S?!
MY7:K0G&:_?X:SL]4_P!]M)73\FSQ:F+P=2#BY;^3_P C[=^ /_!*;]DSX'B'
M5-5\)MXQUB+#'4/% 6:)6_V+8 1 9Y&Y78?WJ^C+?1M(M($M;72K:**-0L<<
M<"JJJ.   .!3/#^GWNDZ):Z9J.I?;)K>$1O=>5L,F. 2,GG&,\\GFKE?7YCG
MN<Y]46(S&K*<W_,[\M^B2]U?]NZ=C[O#X>AAJ?+2@H_UU[D/]G:?_P ^,/\
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MX!XPX/G;-L'.G'I.W-3?I.-X/TO?R.IHHHKT3Y **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNC#*LIR#^-?H49PG\+N?R%5P]?#RM5@XOS37YCJ***HR"BBB@ HHHH ****
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M=:*]]4\3W2Y^OV=XA1[?BFK\-&G#_%)O_P!)#^R_ K!?QLPQF(_Z]4J=._\
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MU_XCGQG4_P!YI8:K_CP]-_DD?F+_ ,*<_P"#@[PEQHWQ3_M/;T_XGFDS9_\
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MROO#&5OR<;'P]I'_  <*_LK3X&N_![X@6V>IM;:QFQ_WU<I[5U.C_P#!>/\
M84U,C[;_ ,)GI^>OVSP\C8_[]3/7T?J_[)7[*OB#/]N_LS_#^\SU-UX-L9#_
M ./1&N6UC_@G)^PIK@(O?V5O!B;NOV/2%M__ $5MQ1]7XHAM7IR]8M?D']L>
M!N(_B97BZ7^"O&7_ *6C@M'_ ."T/_!.K5-JW/QONK!FZ+>>%=1Z\=3' P'7
MUQQ74Z/_ ,%2?^"?^N8^Q?M/Z F[I]LCN+?_ -&QKBLK6/\ @D)_P3JUO<;G
M]G"UA8]&L_$&I08//0)< =_3'Y5RNL?\$._^"?\ J>?L7@GQ!I^>GV/Q-<-C
M_OZ7HOQ9#=49?^!H/9^ 6(^&>8TGYK#R7X:GM&D?MS_L7Z[@:=^U=\.RQZ)+
MXPLXF/\ P%Y :ZK2/CQ\#O$&/[!^,OA2^ST^Q^(K:7/7^ZY]#^5?(FK_ /!O
M[^QA?Y?3O'7Q$L6["+6;-U[=0]H3^O>N6U?_ (-W?@?-G^P?VA?%=MZ?;-.M
MI\?]\B.CZWQ-#?#0EZ3M^8?ZO^">(_AYUB*7^/#<W_I#/T)LM1T_4X?M&FWT
M-Q'_ 'X)0X_,5-7YEWW_  ;KSV4WVSPG^V#-!(OW!/X,(/\ WVEX,=OX:A_X
M<D?MF^%_^1 _;E$6S_5_Z5J-G]/]7(^.B_Y%']J9Y'X\"_E4BP_U%\+J_P#N
M_%,?2>$K0_&[1^G5%?F+_P .U/\ @LCX3Y\+?MV_:8E^Y#_PLC6A_P".20%!
MV[URGQN^ _\ P7)^'7PHUV^\3?&'5]?T&/3I/[8AT/Q*ES<FVV_O"H*K,PVD
MYV?-C/&*F>?XNE!RJ8*HK=K,WPWA/P_C\3"EA>),')R:2YG.#U=M$UJ^RNKO
M2YU?_!6;_@K-C^T_V6_V6_$O]^U\7>+K";_@+V=JZ_B))1[JIZFOA3]DS]K/
MXL?L<_%BV^*7PMU/TBU?2)W/V;5+;.6AE4?FKCYD;D=P?,**_+L=G6/QV/6*
ME*TE\-OL^GZ]S^Y^%_#7A7A;A660TJ*J4JBM5<TFZK:U<O\ VU+X=+:ZG]$W
M[)G[6?PG_;%^$]M\4OA;J?I%J^D3N/M.EW.,M#*H_-7'RNO([@>G5_/9^Q9\
M>?VE/V<?BH?B9^SCHNI:I-;0A==TFVT^:ZM;RU)_U=PD7(7/*MD%6&0>N?MJ
M/_@X,^(?AEUA^(7[&!A;.&*^)YK4@^RRVC=NV:_0\LXQP57")XUN$^KLVGYJ
MR?W'\@<<?1TXFP.?5(<-QCB,.]8Q=2G&I"_V9*<HWMTDMUOKO^G-%?G3H?\
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MXE"7_I46?F-)_P &^?Q#\,NTWP]_;/,+9RH;PQ-:D'W:*[;MWQ33_P $CO\
M@IWX2_Y)S^WKY07[@_X3/6K+_P!%(^.*_3NBL/\ 57)H_P .,H^DY?YL]/\
MXCSXCU?]ZK4JW^.A1?Y01^8G_#(/_!=SP5_R OVH#J^WI_Q6S3Y_\#(A^M'_
M !T5^"CWU:!?^Q;N,G])/Z5^G=%'^K=*/\/$UH^D_P#@!_Q&?'5O][R;+ZW^
M+"J_WJ2/S$_X:^_X+N>"O^0[^R^=7V]?^*):?/\ X!RC]*!_P5Q_X*=^$O\
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M"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH
MQ_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0
M?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!
M](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F
M]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?
MF]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK
M8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"V
MH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,
M?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2
M/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](
M_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_
M\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_
M ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV
M** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_
MX0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\
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M#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\
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M;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%%
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M[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__  @^D?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!X7X!_Y2">/_P#L1-*_]&-7
MNE>%^ ?^4@GC_P#[$32O_1C5[I0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 >%^ ?\ E()X_P#^Q$TK_P!&-7NE>%^ ?^4@GC__ +$32O\
MT8U>Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?@'_E(
M)X__ .Q$TK_T8U>Z5X7X!_Y2">/_ /L1-*_]&-7NE !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M //O#7A;_@H7XA\.:?K\/Q_\#HE]917"))X7;<H= P!QQGGM5[_A7W_!0_\
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MB>$_A'\/=;^*/CO4OLFC>'],FO\ 4[C:6*0Q(7;"CEFP,!1R20!UKY-\3_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@W?.8USEN23@ >R4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)W,D]U,1QN=CT[*%'.,D ]!HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% !117BOQK^,'Q"^'?[4GP[^'<NJP6W@_XAZ-K&D17
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M49( P)VC8KL 0 2#SG QOT %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXOTJST;0/!EM?I=R:3I=N=V;F=/DDGEDPQ"\( !DDX7Z-HHH **** "BBB@
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M 4444 %%%% !1110 4444 %03Z9IMS?0:G<Z?!)<VH<6UP\0+Q!P P5B,KG
MSCK@9J>B@#Y%_:C^'?CO]D_]J'2/V\/@+X/U+6-)\23VN@_&3PAH5F\\]_;N
MZQVVIPPH"7GB8JI &6&T<!Y&KTK]J3]@3X#?MD?$'P5X\^-EMJ%[;^#8[L0Z
M+!<F&WU$3F%@MQ@;RBF'.U2N=Q#$@8/N%% %+P[X<\/>$-"M/"_A/0[/3--L
M(%AL=/L+988;>-1@(B( JJ/0#%7:** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** ,W_A#_"?VS4]0/AG3S/K4*1:Q,;--U]&B%%68X_>
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MI\D8 .!NW$9KW:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3PG\.?">H>.O'7B"UTK1]*M6N-0U"]E"101*,EB3^0'4D@#)-?BA_P %,?\
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M/XS/2-<\;?L_?\$V/V8++7/#'A/Q1JO@&RU4+=7VAW0U9].2YE.ZZF>><.T
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M%^B)XZN=0T37-);/GJVY[C,P&-A!P-Q88(4UB_M=_ _P+^TI_P %:/ _P?\
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MID$=NB-E&9G(W*VW<%)'S5\3-3T[1/AG^P1K&LW\-I:0ZAH'G75S*$CCSH\
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MZ;Y%"@EW(^E?&^H7Z_\ !9WP5IBWLPMF^!=[(UN)3L+_ -H2C<5Z9QWKS?\
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M.W@'7?%VG:=I.B>)=$A76G$[%4FLKF%F-U*JDGS&)^]]W!->@_L@:QI7@?\
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M(G\2Q@CD$$Y%<+_P4,_;D@O/^";6I?'G]E;6?$=Q'XGA@@T[Q=X=MU3^PO\
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M\37UA0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'BB8F*)@>044%>,8Q78?'#]FWX$_M*:+:>'OCK\+]*\36NGW!FL4U&$EK=R
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MSFF_"+X:Z/\ $[4?C/IG@ZSA\4ZOI\=CJ6MHI\ZXMHR"D;'.-HVC'':NCHH
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M]Q/*^9\W/.>];6N:+I7B71;SP[KMBEU8ZA:R6UY;2CY98G4JZ'V*DC\:M44
M8WP]^'G@KX4>#-/^'?PY\.6^D:)I4)BT_3;12(X$+%MJ@D\9)/XUF:Y\"OA%
MXD^*ND_''6O 5A-XOT.T:UTKQ#L*W-O P<-$'4C*$22?*<CYV]37644 >/\
MQ;_8!_8T^.GC0_$3XJ_L\^'M6UN1E:XU)H'ADN2!@&8Q,OG'  R^[@ =!7?7
MGPB^%M_\,W^#-U\/-&;PE)I_V%O#@T^-;(6V,>4(@-H4=@!P1D<UT5% 'F-M
M^QE^RU:_!=OV=U^"&AR>"FNVNAX?N(&EA2=B294+DLCY)PRD$9.",FH/AO\
ML._LD_" :4?AM\!= TF31-3.HZ;<V]NQGBNC&T?FF5F+NP1F4;R<!CC&37JM
M% '/>%/A3\.O WBOQ#XX\)>$;2PU?Q7<PW'B*_@4B2_EB0I&TF3R54D#&.M'
MA3X4_#KP-XK\0>./"/A*TL-6\5W,-QXBOX%(DOY8D*1M)D\E5) QCK70T4 <
M]X4^%/PZ\#>*_$'CCPCX2M+#5O%=S#<>(K^!2)+^6)"D;29/)520,8ZUT-%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170871919696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Jan. 30, 2023</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,831,299,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,087,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Certain portions of the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than April 29, 2023, in connection with the registrant&#8217;s 2023 Annual Meeting of Stockholders are incorporated herein by reference into Part III of this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170977284608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Mateo, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170872213856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 501,195<span></span>
</td>
<td class="nump">$ 647,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">807,273<span></span>
</td>
<td class="nump">819,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">214,784<span></span>
</td>
<td class="nump">282,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">33,299<span></span>
</td>
<td class="nump">27,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">62,211<span></span>
</td>
<td class="nump">57,530<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,618,762<span></span>
</td>
<td class="nump">1,834,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">756,731<span></span>
</td>
<td class="nump">371,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">110,624<span></span>
</td>
<td class="nump">104,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">231,110<span></span>
</td>
<td class="nump">111,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="nump">63,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_OperatingLeaseRightOfUseAssetAndOtherAssets', window );">Right-of-use assets and other</a></td>
<td class="nump">290,578<span></span>
</td>
<td class="nump">131,002<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,071,489<span></span>
</td>
<td class="nump">2,616,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">32,667<span></span>
</td>
<td class="nump">24,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">77,158<span></span>
</td>
<td class="nump">61,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">65,072<span></span>
</td>
<td class="nump">77,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">50,350<span></span>
</td>
<td class="nump">33,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">20,188<span></span>
</td>
<td class="nump">86,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">78,924<span></span>
</td>
<td class="nump">53,366<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">324,359<span></span>
</td>
<td class="nump">337,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">6,582<span></span>
</td>
<td class="nump">8,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">190,170<span></span>
</td>
<td class="nump">51,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">61,951<span></span>
</td>
<td class="nump">8,023<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">583,062<span></span>
</td>
<td class="nump">405,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 323,951 and 318,842 at December&#160;31, 2022 and 2021, respectively</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,536,849<span></span>
</td>
<td class="nump">2,427,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(14,521)<span></span>
</td>
<td class="num">(758)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(34,225)<span></span>
</td>
<td class="num">(216,507)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">2,488,427<span></span>
</td>
<td class="nump">2,210,615<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 3,071,489<span></span>
</td>
<td class="nump">$ 2,616,239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseRightOfUseAssetAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset And Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseRightOfUseAssetAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170875945968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">323,951,000<span></span>
</td>
<td class="nump">318,842,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">323,951,000<span></span>
</td>
<td class="nump">318,842,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170868494224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,611,062<span></span>
</td>
<td class="nump">$ 1,434,970<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">57,909<span></span>
</td>
<td class="nump">52,873<span></span>
</td>
<td class="nump">36,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">891,813<span></span>
</td>
<td class="nump">693,716<span></span>
</td>
<td class="nump">547,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">459,856<span></span>
</td>
<td class="nump">401,715<span></span>
</td>
<td class="nump">293,355<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,409,578<span></span>
</td>
<td class="nump">1,148,304<span></span>
</td>
<td class="nump">877,478<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">201,484<span></span>
</td>
<td class="nump">286,666<span></span>
</td>
<td class="nump">110,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">33,065<span></span>
</td>
<td class="nump">7,672<span></span>
</td>
<td class="nump">19,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(197)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="nump">912<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Income before income taxes</a></td>
<td class="nump">234,352<span></span>
</td>
<td class="nump">294,154<span></span>
</td>
<td class="nump">130,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">52,070<span></span>
</td>
<td class="nump">63,091<span></span>
</td>
<td class="nump">19,056<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 182,282<span></span>
</td>
<td class="nump">$ 231,063<span></span>
</td>
<td class="nump">$ 111,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">321,526<span></span>
</td>
<td class="nump">314,884<span></span>
</td>
<td class="nump">308,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">324,556<span></span>
</td>
<td class="nump">322,359<span></span>
</td>
<td class="nump">318,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,401,243<span></span>
</td>
<td class="nump">$ 1,077,256<span></span>
</td>
<td class="nump">$ 741,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">162,056<span></span>
</td>
<td class="nump">249,956<span></span>
</td>
<td class="nump">167,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 47,763<span></span>
</td>
<td class="nump">$ 107,758<span></span>
</td>
<td class="nump">$ 78,693<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170871811872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 182,282<span></span>
</td>
<td class="nump">$ 231,063<span></span>
</td>
<td class="nump">$ 111,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $3,886, $1,481, and $(394), respectively</a></td>
<td class="num">(13,763)<span></span>
</td>
<td class="num">(5,234)<span></span>
</td>
<td class="nump">1,407<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 168,519<span></span>
</td>
<td class="nump">$ 225,829<span></span>
</td>
<td class="nump">$ 113,188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170877063248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Tax impact of available-for-sale, unrealized holding gain (loss)</a></td>
<td class="nump">$ 3,886<span></span>
</td>
<td class="nump">$ 1,481<span></span>
</td>
<td class="num">$ (394)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170875865264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jan. 03, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jan. 03, 2020</a></td>
<td class="nump">$ 1,685,970<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">$ 2,241,947<span></span>
</td>
<td class="nump">$ 3,069<span></span>
</td>
<td class="num">$ (559,351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">111,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">24,903<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">24,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(50,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">105,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jan. 01, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jan. 01, 2021</a></td>
<td class="nump">1,879,113<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
<td class="nump">2,321,895<span></span>
</td>
<td class="nump">4,476<span></span>
</td>
<td class="num">(447,570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">231,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(5,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">24,367<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">24,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(39,142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 120,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">318,842<span></span>
</td>
<td class="nump">318,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 2,210,615<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
<td class="nump">2,427,561<span></span>
</td>
<td class="num">(758)<span></span>
</td>
<td class="num">(216,507)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">182,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(13,763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">23,981<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">23,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(23,344)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,344)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 108,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 30, 2022</a></td>
<td class="nump">323,951<span></span>
</td>
<td class="nump">323,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 30, 2022</a></td>
<td class="nump">$ 2,488,427<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
<td class="nump">$ 2,536,849<span></span>
</td>
<td class="num">$ (14,521)<span></span>
</td>
<td class="num">$ (34,225)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170868441600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 182,282<span></span>
</td>
<td class="nump">$ 231,063<span></span>
</td>
<td class="nump">$ 111,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">20,875<span></span>
</td>
<td class="nump">13,630<span></span>
</td>
<td class="nump">9,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">107,574<span></span>
</td>
<td class="nump">119,820<span></span>
</td>
<td class="nump">105,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">18,315<span></span>
</td>
<td class="nump">5,332<span></span>
</td>
<td class="nump">4,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="num">(60,358)<span></span>
</td>
<td class="nump">46,529<span></span>
</td>
<td class="nump">15,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development technology</a></td>
<td class="nump">107,250<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="num">(525)<span></span>
</td>
<td class="nump">9,443<span></span>
</td>
<td class="nump">3,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="nump">66,849<span></span>
</td>
<td class="num">(122,324)<span></span>
</td>
<td class="num">(42,470)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(11,683)<span></span>
</td>
<td class="num">(13,209)<span></span>
</td>
<td class="num">(21,897)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(28,259)<span></span>
</td>
<td class="num">(39,875)<span></span>
</td>
<td class="num">(25,831)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(2,483)<span></span>
</td>
<td class="nump">11,008<span></span>
</td>
<td class="num">(1,051)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued collaboration liabilities</a></td>
<td class="num">(63,065)<span></span>
</td>
<td class="nump">70,297<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and other liabilities</a></td>
<td class="nump">25,842<span></span>
</td>
<td class="nump">55,090<span></span>
</td>
<td class="nump">50,509<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">362,614<span></span>
</td>
<td class="nump">400,804<span></span>
</td>
<td class="nump">208,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and other</a></td>
<td class="num">(27,706)<span></span>
</td>
<td class="num">(54,225)<span></span>
</td>
<td class="num">(30,345)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in-process research and development technology</a></td>
<td class="num">(110,750)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(1,450,716)<span></span>
</td>
<td class="num">(1,357,168)<span></span>
</td>
<td class="num">(1,070,269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities and sales of investments</a></td>
<td class="nump">1,064,758<span></span>
</td>
<td class="nump">1,378,509<span></span>
</td>
<td class="nump">969,399<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(524,414)<span></span>
</td>
<td class="num">(42,884)<span></span>
</td>
<td class="num">(131,215)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">23,886<span></span>
</td>
<td class="nump">24,307<span></span>
</td>
<td class="nump">24,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(23,300)<span></span>
</td>
<td class="num">(39,108)<span></span>
</td>
<td class="num">(50,018)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">586<span></span>
</td>
<td class="num">(14,801)<span></span>
</td>
<td class="num">(25,132)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash equivalents</a></td>
<td class="num">(161,214)<span></span>
</td>
<td class="nump">343,119<span></span>
</td>
<td class="nump">52,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at beginning of period</a></td>
<td class="nump">663,891<span></span>
</td>
<td class="nump">320,772<span></span>
</td>
<td class="nump">268,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at end of period</a></td>
<td class="nump">502,677<span></span>
</td>
<td class="nump">663,891<span></span>
</td>
<td class="nump">320,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">127,870<span></span>
</td>
<td class="nump">12,960<span></span>
</td>
<td class="nump">4,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract', window );"><strong>Non-cash operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">155,935<span></span>
</td>
<td class="nump">4,893<span></span>
</td>
<td class="nump">4,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_AccountsReceivableForUnsettledInvestmentSales', window );">Accounts receivable for unsettled investment sales</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccountsReceivableForUnsettledInvestmentSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable For Unsettled Investment Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccountsReceivableForUnsettledInvestmentSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170877013312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and combination regimens at the forefront of cancer care. Through the commitment of our drug discovery, development and commercialization resources, we have produced four marketed pharmaceutical products, including our flagship molecule, cabozantinib. We continue to evolve our product portfolio, leveraging our investments, expertise and strategic partnerships, to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sales related to cabozantinib account for the majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 62 other countries as: CABOMETYX&#174; (cabozantinib) tablets approved both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab) for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA and European Commission (EC), for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo). See &#8220;&#8212;Collaborations and Business Development Activities&#8212;Other Collaborations.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue leveraging our operating cash flows to support the ongoing investigation of cabozantinib in phase 3 trials for new indications and the advancement of a broad array of diverse biotherapeutics and small molecule programs for the treatment of cancer exploring multiple modalities and mechanisms of action. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2022, which was a 52-week fiscal year, ended December&#160;30, 2022, fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended January&#160;1, 2021. For convenience, references in this report as of and for the fiscal years ended December&#160;30, 2022 and January&#160;1, 2021 are indicated as being as of and for the years ended December&#160;31, 2022 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reclassifications to our prior years&#8217; Consolidated Financial Statements to conform to the current year&#8217;s presentation. These reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities, total operating, investing or financing cash flows or total stockholders&#8217; equity.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements adopted by us since our filing of the Annual Report on Form 10-K for the year ended December 31, 2021, which could have a significant effect on our Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include realized gains and losses on the sale of investments in other income, net in the accompanying Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. The classification of restricted cash equivalents as short-term or long-term is dependent upon the longer of the remaining term to maturity of the investment or the remaining term of the related restriction.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment Impairment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarterly, we assess each of our investments in available-for-sale debt securities whose fair value is below its cost basis to determine if the investment&#8217;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded as a reduction of other comprehensive income (loss), net of applicable taxes. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to exclude accrued interest from both the fair value and the amortized cost basis of the available-for-sale debt securities for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income, net in the accompanying Consolidated Statements of Income. Net foreign currency gains or losses were immaterial for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables, net, contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current economic conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers. We write off trade receivables and related allowances for credit losses when it becomes probable we will not collect the amount receivable. Write-offs for the years ended December&#160;31, 2022 and December&#160;31, 2021 were immaterial.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration services revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to 15 years and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize any material impairment charges in any of the periods presented. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded goodwill amounts as the excess of purchase price over identifiable net assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in one business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did not recognize any impairment charges in any of the periods presented.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of our long-lived assets, which includes property and equipment, right-of-use assets and leasehold improvements, is reviewed for impairment whenever events or changes in circumstances indicate that the </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carrying value of the asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenues under the guidance of ASU Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 606). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established primarily from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discounts for Prompt Payment:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Customers in the U.S. receive a discount of 2% for prompt payment. We expect our Customers will earn 100% of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our Customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2020, the</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to Customer, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Customer Credits: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Up-front License Fees: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory and Development Milestone Payments: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development Cost Reimbursements:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation, which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Arrangements: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Sales-based Milestone Payments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty we are required to pay on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees and option exercise fees, funded research and milestone payments incurred or probable to be incurred for our in-licensing arrangements with our collaboration partners for research programs in development and prior to regulatory approval; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial projects have been executed with support from third-party CROs, who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected not to apply the recognition requirements of </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2016-02</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842) for short-term leases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expenses were $41.6 million, $31.8 million and $25.1 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in selling, general and administrative expenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;units (RSUs), performance-based restricted&#160;stock&#160;units (PSUs), service-based&#160;stock&#160;options and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock&#160;Compensation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of RSUs and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for certain PSUs and RSUs with market vesting conditions and a Black-Scholes Merton option pricing model for stock options. Both pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatility when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense related to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis. Compensation expense related to RSUs with market vesting conditions is recognized regardless of the outcome of the market conditions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess our ownership, contractual and other interests in entities that are not wholly-owned whether we are the primary beneficiary of a variable interest entity (VIE) and therefore we must consolidate the entity. We apply a qualitative approach that determines whether we have both (1) the power to direct the activities that most significantly impact the economic performance of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We perform this assessment, as changes to existing relationships or future transactions may result in consolidation or deconsolidation of a VIE.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes is computed under the asset and liability method. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our provision for income taxes in the period of such reversal. Based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 31, 2022 and forecasts of future operating results, we do not have a valuation allowance against our deferred tax assets as described in &#8220;Note 9. Provision For Income Taxes&#8221;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2021, which could have a significant effect on our Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170873189184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,951,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(549,926)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401,243&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077,256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,819&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,988&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,970&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with Topic 606. License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with Topic 808. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375,909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401,243&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo Health, Incorporated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611,062&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238,283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,021)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,564)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357,868)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,625&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,825&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(344,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,094)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,881&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,426&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. As of December&#160;31, 2022 and 2021, respectively, contract assets are primarily related to contract assets from Ipsen Pharma SAS (Ipsen) and c</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ontract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,070&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Presented in other long-term assets in the accompanying Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Presented in other current liabilities in the accompanying Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, we recognized $8.1&#160;million, $8.5&#160;million and $9.2&#160;million, respectively, in revenues that were included in the beginning deferred revenues balance for those years. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2022, 2021 and 2020, we recognized $161.6&#160;million, $148.7&#160;million and $169.7&#160;million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to milestone and royalty payments allocated to our license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, $73.0 million of the combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements&#8212; Cabozantinib Collaborations &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information about the expected timing to satisfy these performance obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170873008672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</a></td>
<td class="text">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading biopharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have made considerable progress under our existing research collaboration and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading biopharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, to receive payments for product supply services, development cost reimbursements, and/or profit-sharing payments. See &#8220;Note 2. Revenues&#8221; for additional information on revenues recognized under our collaboration agreements during the years ended December&#160;31, 2022, 2021 and 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Commercial Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, we entered into a collaboration and license agreement with Ipsen, which was subsequently amended, for the commercialization and further development of cabozantinib. Under the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, Ipsen opted into and is now co-funding the development costs for COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with RAI-refractory DTC who have progressed after up to two VEGF receptor-targeted therapies. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ipsen </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s obligated to reimburse us for their share of COSMIC-311 global development costs, as well as an additional payment calculated as a percentage of such costs, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">triggered by the timing of the exercise of its option. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the decision to opt in and co-fund the development costs for COSMIC-311 represented a contract modification for additional distinct services at their standalone selling price and therefore was treated as a separate contract under Topic 606. Accordingly, collaboration services revenues for the year ended December&#160;31, 2021, includes a cumulative catch-up of $43.2 million for Ipsen&#8217;s share of global development costs incurred since the beginning of the study and through the opt-in date.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (1) the expiration of patent claims related to cabozantinib, (2) the expiration of regulatory exclusivity covering cabozantinib or (3) ten years after the first commercial sale of cabozantinib, other than COMETRIQ. A related supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the FDA or European Medicines Agency orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration under the Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, we received aggregate upfront payments of $210.0 million from Ipsen in 2016. As of December&#160;31, 2022, we have achieved aggregate milestones of $489.5&#160;million related to regulatory, development and sales-based threshold by Ipsen since the inception of the collaboration agreement, including $27.0&#160;million, $112.5 million, and $20.0 million in milestones achieved during the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we are eligible to receive additional regulatory and development milestone payments from Ipsen totaling an aggregate of $19.5 million, as well as sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to $350.0 million and CAD$26.5 million. We excluded these milestones from the transaction price as of December&#160;31, 2022 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will adjust the constraint applied to the variable consideration at each reporting period as uncertain events are resolved or other changes in circumstances occur. See </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;&#8212;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, below, for additional information related to the revenue recognition for this collaboration.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receive royalty revenues on the net sales of cabozantinib by Ipsen outside of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he U.S. and Japan. During the year ended December&#160;31, 2022 and going forward, we are entitled to receive a tiered royalty of 22% to 26% on annual net sales, with separate tiers for Canada; these royalty tiers reset each calendar year.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to pay a 3% royalty on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for 35% of such costs, provided Ipsen chooses to opt into such trials. Ipsen has opted into and is co-funding certain clinical trials, including: CheckMate-9ER, COSMIC-021, COSMIC-311, COSMIC-312, CONTACT-01 and CONTACT-02.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain responsible for manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. Relatedly, we entered into a supply agreement with Ipsen to supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. The product is supplied at our cost, as defined in the agreement. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from territories outside of U.S. and Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Japan.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from the Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,592&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,073&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,631&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, we recognized $25.8&#160;million in revenues in connection with two regulatory milestones totaling $27.0&#160;million upon approval by the EC and Health Canada, of cabozantinib a monotherapy for the treatment of adult patients with locally advanced or metastatic DTC, refractory or not eligible to RAI who have progressed during or after prior systemic therapy.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, $35.4 million of the transaction price was allocated to our research and development services performance obligation that has not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended effective March 2018, May 2019 and September 2020, to, among other things, modify the amount of reimbursements we receive, for costs associated with our required pharmacovigilance activities and milestones we are eligible to receive, as well as modify certain cost-sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda is responsible for a portion of the costs associated with the cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and 100% of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Takeda has opted into and is co-funding CheckMate-9ER, certain cohorts of COSMIC-021, CONTACT-01 and CONTACT-02. Under the collaboration agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (1) two years after first generic entry with respect to such product in Japan or (2) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration under the Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received an upfront payment of $50.0 million from Takeda in 2017. As of December&#160;31, 2022, we have also achieved regulatory and development milestones in the aggregate of $127.0&#160;million since the inception of the collaboration agreement, including $0, $35.0 million and $66.0 million in milestones achieved during the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, as amended in 2020, we are eligible to receive additional regulatory and development milestone payments, without contractual limit, for additional potential future indications. We are further eligible to receive commercial milestones, including milestone payments earned for the first commercial sale of a product, </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $119.0 million. We excluded these milestones from the transaction price as of December&#160;31, 2022 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will adjust the constraint applied to the variable consideration at each reporting period as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also receive royalty revenues on the net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of 15% to 24% on the initial $300.0&#160;million of net sales, and following this initial $300.0&#160;million of net sales, we are then entitled to receive a tiered royalty of 20% to 30% on annual net sales thereafter; these 20% to 30% royalty tiers reset each calendar year. Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to pay a 3% royalty on all net sales of any product incorporating cabozantinib, including net sales by Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, we are responsible for the manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. Relatedly, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a safety data exchange agreement, which defines each partner&#8217;s responsibility for safety reporting. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from the Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt;text-indent:36pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt;text-indent:36pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,725&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, $37.6&#160;million of the transaction price was allocated to our research and development services performance obligations that have not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is one remaining performance obligation for the Ipsen collaboration agreement: the research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements). As part of the original contract, we also had a performance obligation associated with exclusive license for the commercialization and further development of cabozantinib, which was transferred in 2016. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are two remaining performance obligations for the Takeda collaboration agreement: (1) the research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements) and (2) the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. As part of the original contract, we had a performance obligation associated with the exclusive license for the commercialization and further development of cabozantinib, which was transferred in 2017.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have allocated the transaction price for each of these collaborations to the originally identified performance obligations based on our best estimate of their relative standalone selling price. For the licenses, the estimate of the relative standalone selling price was determined using a discounted cash flow valuation utilizing forecasted revenues and </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs. For research and development services the estimate of the relative standalone selling price was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The portion of the transaction price allocated to our license performance obligation is recorded immediately as our license represents functional intellectual property that was transferred at a point in time. The portion of the transaction price allocated to our research and development services performance obligation is being recognized as revenue using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union for the Ipsen collaboration and Japan for the Takeda collaboration, both of which are early 2030. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust the constraint applied to the variable consideration for the collaboration agreements in each reporting period as uncertain events are resolved or other changes in circumstances occur and we allocate those changes in the transaction price between our performance obligations. During the years ended December&#160;31, 2022, 2021 and 2020, the transaction price of the Ipsen and Takeda collaboration agreements increased as a result of the achievement of various milestones, and the reimbursements of research and development services related to committed and opt-in studies. We further updated the transaction price based upon the actual research and development services performed during the period and changes in our estimated reimbursements for our future research and development services. The portion of the increase in transaction price that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license was recognized during the period and the portion allocated to research and development services will be recognized in future periods as those services are delivered through early 2030. As of December&#160;31, 2022, variable consideration related to the remaining unearned regulatory and development milestones for both agreements remained constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Development Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BMS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#8217;s immune checkpoint inhibitors (ICIs), nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab as a treatment option for RCC in the COSMIC-313 trial. Under the collaboration agreement with BMS, we may also evaluate these combinations in other phase 3 pivotal trials in various other tumor types. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement with BMS, as amended, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts are governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial is conducted under a combination Investigational New Drug application, unless otherwise required by a regulatory authority. Each party is responsible for supplying finished drug product for the applicable clinical trial, and responsibility for the payment of costs for each such trial will be determined on a trial-by-trial basis. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">F. Hoffmann-La Roche Ltd. (Roche) Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#8217;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. Under this agreement with Roche, in June 2017, we initiated COSMIC-021, a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors, and in December 2018, we initiated COSMIC-312, a multicenter, randomized, controlled phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC. We are the sponsor of both trials, and Roche is providing atezolizumab free of charge.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a joint clinical research agreement with Roche for the purpose of further evaluating the combination of cabozantinib with atezolizumab in patients with locally advanced or metastatic solid tumors, </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including in the phase 3 pivotal clinical trials in advanced non-small cell lung cancer (CONTACT-01), metastatic castration-resistant prostate cancer (CONTACT-02) and RCC (CONTACT-03). If a party to the joint clinical research agreement proposes any additional combined therapy trials beyond these phase 3 pivotal trials, the joint clinical research agreement provides that such proposing party must notify the other party and that if agreed to, any such additional combined therapy trial will become part of the collaboration, or if not agreed to, the proposing party may conduct such additional combined therapy trial independently, subject to specified restrictions set forth in the joint clinical research agreement.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, a supplement to the joint clinical research agreement was signed amongst us, Roche and Takeda due to Takeda opting into fund the combined therapy trial of CONTACT-01 sponsored by Roche. Chugai was added as an affiliate of Roche.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All parties including Chugai conduct combined therapy trials in Japan upon the terms of the joint clinical research agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the joint clinical research agreement, each party granted to the other a non-exclusive, worldwide (excluding, in our case, territory already the subject of a license by us to Takeda), non-transferable, royalty-free license, with a right to sublicense (subject to limitations), to use the other party&#8217;s intellectual property and compounds solely as necessary for the party to perform its obligations under the joint clinical research agreement. The parties&#8217; efforts will be governed through a joint steering committee established to guide and oversee the collaboration and the conduct of the combined therapy trials. Each party will be responsible for providing clinical supply of their drug for all combined therapy trials, and the cost of the supply will be borne by such party. The clinical trial expenses for each combined therapy trial agreed to be conducted jointly under the joint clinical research agreement will be shared equally between the parties, and the clinical trial expenses for each additional combined therapy trial not agreed to be conducted jointly under the joint clinical research agreement will be borne by the proposing party, except that the cost of clinical supply for all combined therapy trials will be borne by the party that owns the applicable product. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the contract is within the scope of Topic 808 as it involves joint operating activities where both parties have active participation in the arrangement and are exposed to significant risks and rewards. Payments between us and Roche under this arrangement are not subject to other accounting literature. Payments due to Roche for our share of clinical trial costs incurred by Roche will be recorded as research and development expense and payments due from Roche for their share of clinical trial costs incurred by us will be recorded as a reduction of research and development expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the joint clinical research agreement provides that it will remain in effect until the completion of all combined therapy trials under the collaboration, the delivery of all related trial data to both parties, and the completion of any then agreed-upon additional analyses. The joint clinical research agreement may be terminated for cause by&#160;either party based on any uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party will terminate upon completion of any ongoing activities under the joint clinical research agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK and Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GlaxoSmithKline (GSK), that required us to pay a 3% royalty to GSK on the total worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. Effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on total net sales of any product containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalty fees earned by GSK and Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalty fees earned by GSK and Royalty Pharma were $58.2 million, $46.6 million and $32.7 million during the years ended December&#160;31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have out-licensed to Genentech under a worldwide collaboration agreement, the development and commercialization of cobimetinib, under the brand name COTELLIC. The terms of the collaboration agreement require that we share in the profits and losses received or incurred in connection with the commercialization of COTELLIC in the U.S. In </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition to our profit share in the U.S., we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, we recognized $12.5 million, $12.1 million, and $11.3 million, in revenues from profits and losses on U.S commercialization and royalties on ex-U.S. sales under the collaboration agreement with Genentech and are included within license revenues on our Consolidated Statements of Income.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into collaborative arrangements with other pharmaceutical or biotechnology companies to develop and commercialize drug candidates or intellectual property. Our research collaborations and in-licensing arrangements are intended to enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Our research collaborations, in-licensing arrangements and other strategic transactions include upfront payments, development, regulatory, commercial milestone payments and royalty payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations provide us exclusive options that give us the right to license programs or acquire the intellectual property developed under the research collaborations for further discovery and development. When we decide to exercise the options, we are required to pay an exercise fee and then assume the responsibilities for all subsequent clinical development, manufacturing and commercialization. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we entered into an exclusive option and license agreement with BioInvent International AB (BioInvent), upon which we paid an upfront payment of $25.0&#160;million. If we decide to exercise the option, we will pay BioInvent an option exercise fee, and BioInvent would be eligible for additional payments from us for future development and commercial milestones, as well as royalties on future net sales of products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we entered into an agreement with Cybrexa Therapeutics, LLC (Cybrexa), which provides us the right to acquire CBX-12 (alphalex&#8482; exatecan), a clinical-stage peptide-drug conjugate that utilizes Cybrexa&#8217;s proprietary alphalex technology to enhance delivery of exatecan to tumor cells. Under the terms of the agreement, we made an upfront payment of $60.0&#160;million for a warrant entitling us to the right to acquire the Cybrexa affiliate that controls CBX-12 and related assets, and to fund certain development and manufacturing expenses incurred by Cybrexa to advance CBX-12 during the warrant period. Cybrexa will continue the development of CBX-12 according to an agreed development plan, including phase 1 studies, and may be eligible to receive up to $65.0&#160;million in additional development milestone payments, during the warrant period. We may exercise the warrant for up to $300.0&#160;million based upon our evaluation of a pre-specified clinical data package to be delivered by Cybrexa. Following exercise of the warrant, Cybrexa would be eligible to receive up to $277.5&#160;million in additional payments upon achievement of further regulatory and commercial milestones.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined our arrangement with Cybrexa constitutes a variable interest in the Cybrexa affiliate that controls CBX-12 and related assets, and that the Cybrexa affiliate is a VIE; however, we are not the primary beneficiary of the Cybrexa affiliate as we do not control the activities that are most significant to the Cybrexa affiliate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accounted for our arrangement with Cybrexa as an acquisition of in-process research and development technology that does not have an alternative future use, and accordingly, recognized the upfront payment of $60.0&#160;million in research and development expenses during the year-ended December 31, 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we entered into an exclusive option and license agreement with Sairopa, B.V. (Sairopa). Under the terms of the agreement, we made an upfront payment of $40.0&#160;million for an option to obtain an exclusive, worldwide license to develop and commercialize ADU-1805 and other anti-SIRP&#945; antibodies. Sairopa is eligible to receive additional development milestone payments during the option period totaling up to $97.5&#160;million. Following the completion of the clinical studies, we may exercise the option for $225.0&#160;million based upon our evaluation of a pre-specified clinical data package to be delivered by Sairopa. Following the exercise of the option, Sairopa would be eligible to receive up to $465.0&#160;million in additional payments upon achievement of further development and commercial milestones, as well as royalties on future net sales of products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we entered into a new license agreement with Catalent, Inc.&#8217;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc., (individually and collectively referred to as Catalent). Under the terms of the agreement, we made an upfront payment of $30.0&#160;million in exchange for rights to three biologics programs. We will also contribute research funding to Catalent for discovery and preclinical </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development work. Catalent would be eligible to receive potential future development, regulatory and commercial milestone payments, as well as royalties on future net sales of products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, we recognized $203.9&#160;million, $176.1&#160;million and $96.4&#160;million, respectively, relating to upfront license payments, research and development funding, development milestones, option fees and other fees within research and development expenses on the Consolidated Statements of Income. During the year ended December&#160;31, 2022, we reversed $12.5&#160;million of previously recorded research and development expenses associated with a development milestone. The impact of the change in estimate on our basic and diluted earnings per share for the fiscal year ended December&#160;31, 2022 was an increase of $0.04 per share. The milestone was reversed as the compound has not progressed as expected and therefore we are no longer able to predict when the milestone will occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, in conjunction with these collaborative in-licensing arrangements we are subject to potential future development milestones of up to $652.0&#160;million, regulatory milestones of up to $634.3&#160;million and commercial milestones of up to $3,153.0&#160;million, each in the aggregate per product or target, as well as royalties on future net sales of products.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170873195280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">CASH AND INVESTMENTS</a></td>
<td class="text">CASH AND INVESTMENTS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502,677&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit agreements and are invested in short-term certificates of deposit with original maturity of 90 days or less as of December 31, 2022 and money market fund securities as of December 31, 2021. The restricted cash equivalents are classified as other long-term assets. The standby letter of credit entered into in January 2021, as a guarantee of our obligation to fund our portion of the tenant improvements related to our Alameda build-to-suit lease was extinguished and the related collateral was returned in the third quarter of 2022, following the substantial completion of the building and the commencement of the lease. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,679)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887,060&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,034)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,615&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,085,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,034)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066,681&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $7.3 million and $2.9 million as of December&#160;31, 2022 and 2021, respectively, and is included in prepaid and other current assets in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the years ended December&#160;31, 2022, 2021 and 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,132)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,679)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030,810&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,034)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were 285 and 133 debt securities available-for-sale in an unrealized loss position as of December&#160;31, 2022 and 2021, respectively. All securities presented above have been in an unrealized loss position for less than twelve months except for 76 corporate bond securities, 4 municipal bond securities and 1 U.S. Treasury and government-sponsored enterprises security with an aggregate fair value of $237.6&#160;million and an aggregate $6.1&#160;million unrealized losses as of December&#160;31, 2022. During the years ended December&#160;31, 2022 and 2021, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170873154928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS <div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066,640&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652,724&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719,255&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Foreign Currency Contracts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we initiated an operational hedging program and entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchange rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had one forward contract outstanding to sell &#8364;3.6&#160;million. The forward contract with a maturity of three months is recorded at fair value and is included in prepaid expenses and other current assets in the Consolidated Balance Sheets. The unrealized loss on the forward contract is not material as of December&#160;31, 2022. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the years ended December&#160;31, 2022 and 2021 we recognized $1.2 million and $0.8 million of net gains on the maturity of forward contracts, which were included in other income (expense), net on our Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170872991728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,276&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170873002816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">up to 15 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">up to 3 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,862&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,031&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $20.9 million, $13.6 million and $9.1 million during the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170873052128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans and ESPP</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,574&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,574&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several equity incentive plans under which we granted stock options and RSUs, including PSUs, to employees and directors. On May 25, 2022, at the 2022 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The amendment and restatement increased the share reserve under the 2017 Plan by 28,500,000 shares. As of December&#160;31, 2022, 31,971,047 shares were available for grant under the 2017 Plan. The share reserve is reduced by 1 share for each share issued pursuant to a stock option and 2 shares for full value awards, including RSUs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors delegated responsibility for administration of our equity incentive plans to the Compensation Committee of our Board of Directors, including the authority to determine the term, exercise price and vesting requirements of each grant. Stock options granted to our employees and directors generally have a four-year vesting term and a one-year vesting term, respectively, an exercise price equal to the fair market value on the date of grant, and a seven-year life from the date of grant. RSUs granted to our employees and directors generally have a four-year vesting term and a one-year vesting term, respectively. PSUs granted pursuant to our equity incentive plans vest upon specified service conditions and the achievement of a performance target or market condition. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Change in Control and Severance Benefit Plan for certain executive officers. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&#8217;s employment is terminated without cause during a period commencing one month before and ending thirteen months following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all their outstanding equity awards accelerated and the exercise period for their stock options extended to no more than one year.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of 85% of the closing price at the beginning of the offering period or 85% of the closing price at the end of each six-month purchase period. As of December&#160;31, 2022, we had </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,561,567</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares available for issuance under our ESPP. Pursuant to the ESPP, we issued 606,787, 536,226 and 534,419 shares of common stock at an average price per share of $16.63, $17.76 and $14.55 during the years ended December&#160;31, 2022, 2021 and 2020, respectively. Cash received </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from purchases under the ESPP for the years ended December 31, 2022, 2021 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $10.1 million, $9.5 million and $7.8 million, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used a Black-Scholes Merton option pricing model to value stock options and ESPP purchases. The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.04&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We considered both implied and historical volatility in developing our estimate of expected volatility. The assumption for the expected life of stock options is based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#8217; current expectations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs, including PSUs, was based on the closing price of the underlying common stock on the date of grant. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for stock options during the year ended December&#160;31, 2022 was as follows (in thousands</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,743)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(635)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options exercisable at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $16.6 million of unrecognized compensation expense related to our unvested stock options. The compensation expense for the unvested stock options will be recognized over a weighted-average period of 2.2 years.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal year 2022 and the exercise prices, multiplied by the number of in-the-money stock options) that would have been received by the stock option holders had all stock option holders exercised their stock options on December&#160;31, 2022. The total intrinsic value of stock options exercised during the years ended December&#160;31, 2022, 2021 and 2020 was $36.5 million, $76.0 million and $106.5 million, respectively. Cash received from stock option exercises during the years ended December&#160;31, 2022, 2021 and 2020 was $13.9 million, $14.8 million and $26.9 million, respectively.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Activity for RSUs during the year ended December&#160;31, 2022 was as follows (in thousands, except per share amounts):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $183.6 million of unrecognized compensation expense related to our unvested RSUs which will be recognized over a weighted-average period of 2.9 years.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for PSUs, during the year ended December&#160;31, 2022 was as follows (in thousands</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, in connection with our long-term incentive compensation program, we awarded to certain employees an aggregate of 1,003,482 (the 2022 target amount) RSUs that are subject to a total shareholder return (TSR) market condition (the 2022 TSR-based RSUs). The TSR market condition for the 2022 TSR-based RSUs is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 1, 2022 through January 3, 2025. Depending on the results relative to the TSR market condition, the holders of the 2022 TSR-based RSUs may earn up to 175% of the 2022 target amount of shares. 50% of the shares earned pursuant to the 2022 TSR-based RSU awards will vest at the end of the performance period, and the remainder will vest approximately one year later, subject to employee&#8217;s continuous service. These TSR-based RSUs will be forfeited if the market condition at or above a threshold level is not achieved at the end of the performance period on January 3, 2025.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $33.17 per share for the 2022 TSR-based RSUs:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of Exelixis common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Monte Carlo simulation model also assumed correlations of returns of the stock prices of Exelixis common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, in connection with our long-term incentive compensation program, we awarded certain employees 1,027,650 (the 2021 target amount) PSUs, subject to a performance and a market condition (the 2021 PSUs). Pursuant to the terms of 2021 PSUs, the holders of the awards may earn up to 200% of the 2021 target amount, or up to 2,055,300 total shares, depending on the level of achievement of the performance condition related to certain net product revenues and a TSR market condition. The TSR market condition for the 2021 PSUs is based on our relative TSR percentile rank compared to companies in the Nasdaq Biotechnology Index during the performance period, which is January 2, 2021 through December 29, 2023. 50% percent of the shares earned subject to the performance and market conditions will vest at the end of the performance period and the remainder will vest approximately one year later subject to an employee&#8217;s continuous service. The 2021 PSUs will be forfeited if the performance condition at or above a threshold level is not achieved by December 29, 2023. The performance condition for target achievement of net product revenues relative to the 2021 PSUs was deemed probable of achievement in the fourth quarter of 2022 representing 100% of the 2021 PSUs target amount.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of Exelixis common stock on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the year ended December&#160;31, 2020, in connection with our long-term incentive compensation program, we awarded 2,327,840 PSUs (the 2020 target amount) that will vest upon the achievement of performance targets related to (i) clinical trial positive top-line results and (ii) product approvals by the FDA (the 2020 PSUs). Pursuant to the terms of the 2020 PSUs, employees may earn up to 200% of the 2020 target amount, or 4,655,680 total shares, depending on the volume and timing of achievement of the performance targets. The 2020 PSUs will be forfeited if the performance targets are not met by December 31, 2024. The performance condition for threshold achievement of a product approval by the FDA relative to the 2020 PSUs occurred in the third quarter of 2021, representing 25% of the 2020 target amount. The performance condition for threshold achievement of positive top-line results by the FDA relative to the 2020 PSUs occurred in the third quarter of 2022, representing 25% of the 2020 target amount.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognition for PSUs commences when it is determined that attainment of the performance target is probable. Of the outstanding PSUs as of December&#160;31, 2022, 869,502 relate to awards for which we achieved the performance target. As of December&#160;31, 2022, the remaining unrecognized compensation expense for the PSUs achieved or deemed probable of achievement related to the PSUs was $11.0 million, which will be recognized over a weighted-average period of 2.3 years. The total unrecognized compensation expense for the PSUs for which we have not yet determined that attainment of the performance target is probable was $79.5 million as of December&#160;31, 2022.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exelixis, Inc. 401(k) Plan (the 401(k) Plan)</span></div>We sponsor the 401(k) Plan under which we make matching cash contributions to our employees&#8217; 401(k) accounts. We recorded compensation expense of $11.7 million, $9.5 million and $6.7 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively, for matching contributions<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170873052128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">PROVISION FOR INCOME TAXES</a></td>
<td class="text">PROVISION FOR INCOME TAXES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income before income taxes is derived solely from within the U.S. Our provision for income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,562&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,358)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,529&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,056&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the years ended December&#160;31, 2022, 2021, and 2020 primarily relates to the utilization of federal tax attributes and state taxes in jurisdictions outside of California, for which we do not have net operating loss carryforwards due to a limited operating history.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our historical net operating losses were sufficient to fully offset any federal taxable income for the year ended December 31, 2020 but were not sufficient to fully offset federal taxable income for the years ended December&#160;31, 2022 and 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the U.S. federal income tax provision at the statutory federal income tax rate of 21% for each of the years ended December 31, 2022, 2021 and 2020, respectively, to our provision for income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal income tax provision at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax (benefit) expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,356)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,864)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible warrant purchase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(562)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,070&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,091&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,056&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves not currently deductible</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,638&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,068)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,940&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,907)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,110&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 740: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December&#160;31, 2022, based on the evaluation and weighting of both positive and negative evidence, including our achievement of a cumulative three-year income position as of December&#160;31, 2022 and forecasts of future operating results, as well as considering the utilization of net operating losses and tax credits prior to their expiration, management has continued to determine that there is sufficient positive evidence to conclude that it is more likely than not the deferred tax assets are realizable. As of December&#160;31, 2022 and 2021, we continue to carry a valuation allowance of $77.2 million and $70.1 million, respectively, against our California state deferred tax assets. The valuation allowance increased by $7.2 million and $2.9 million during the years ended December 31, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had state net operating loss carryforwards of approximately $414&#160;million, which expire in the years 2023 through 2036, California research and development tax credits of approximately $52&#160;million, which do not expire, and California Competes Tax Credits of approximately $1&#160;million, which begin to expire in 2028.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. We completed a Section 382 analysis through December&#160;31, 2022, and concluded that an ownership change, as defined under Section 382, had not occurred.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our unrecognized tax benefits (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to prior year provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to current year provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on the lapse of the applicable statutes of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(721)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(301)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,033)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,706&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,583&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,941&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify unrecognized tax benefits as a reduction of deferred tax assets or as other long-term liabilities in the accompanying consolidated balance sheets. We do not anticipate that the amount of unrecognized tax benefits existing as of December&#160;31, 2022 will significantly change over the next 12 months. As of December&#160;31, 2022, we had $87.7 million in unrecognized tax benefits, of which $55.4 million would reduce our income tax provision and effective tax rate, if recognized. Interest and penalties were nominal or zero for all periods presented. We have elected to record interest and penalties in the accompanying Consolidated Statements of Income as a component of income taxes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 2001 through 2022 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170873092128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME PER SHARE</a></td>
<td class="text">NET INCOME PER SHARE<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,556&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,001&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.56&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.72&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options, unvested RSUs, unvested RSUs with market conditions, PSUs and ESPP contributions. Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. See &#8220;Note 8. Employee Benefit Plans&#8221; for a further description of our equity awards. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170873116224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have noncancellable operating leases of corporate headquarters, office and laboratory space in California and Pennsylvania totaling 673,978 square feet with lease terms ending in 2024 through 2037. Certain of our leases include options to renew the lease or to early terminate the lease. As of December&#160;31, 2022, it is not probable we will exercise our options to renew these leases, nor is it probable that we will not exercise our option to terminate certain of our leases before the end of the lease term. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we have lease agreements for laboratory spaces located in Pennsylvania totaling 28,228 square feet for which the leases of the premises have not commenced. We expect these leases to commence upon substantial completion of leasehold improvements by the lessor and upon receiving access to those premises.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMC0xLTEtOTIxNTA_96cbace8-4798-438d-bd6a-d3ce92ddad69"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMC0xLTEtOTIxNTA_bf05f744-ae2c-4625-a413-f24a3f80b54d">Right-of-use assets included in other long-term assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMC0xLTEtOTIxNTA_3805e340-1810-45ae-9746-eaa8274e40f1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMC0xLTEtOTIxNTA_4cf525be-b16c-489c-b6e4-ee90a9a764d7">Current portion included in other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,829&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease costs were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,413&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities for the years ended December&#160;31, 2022, 2021 and 2020 was $11.4 million, $5.0 million and $4.6&#160;million, respectively, and was included in net cash provided by operating activities in our Consolidated Statements of Cash Flows.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the maturities of our operating lease liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.186%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future tenant improvement reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,829&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the weighted average discount rate used to determine the operating lease liability was 5.3% and the weighted average remaining lease term was 12.7 years. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease cost for leases with initial terms less than 1 year for the year ended December 31, 2022 was $0.4&#160;million, and immaterial for the years ended December 31, 2021 and 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MSN I ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (individually and collectively with certain of its affiliates, including MSN Laboratories Private Limited, referred to as MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the May 5, 2020 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. The two lawsuits comprising this litigation (collectively referred to as MSN I), numbered Civil Action Nos. 19-02017 and 20-00633, were consolidated in April 2021.</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our MSN I complaints, we sought, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties narrowed their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the trial addressed two issues: (1) infringement of claim 1 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A bench trial for MSN I occurred in May 2022, and on January 19, 2023, the Delaware District Court issued a ruling rejecting MSN&#8217;s invalidity challenge to U.S. Patent No. 7,759,473. The Delaware District Court also ruled that MSN&#8217;s proposed ANDA product does not infringe U.S. Patent No. 8,877,776 and entered judgment that the effective date of any final FDA approval of MSN&#8217;s ANDA shall not be a date earlier than August 14, 2026, the expiration date of U.S. Patent No. 7,759,473. This ruling in MSN I does not impact our separate and ongoing MSN II lawsuit.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MSN II ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. In particular, the January 11, 2022 amended ANDA requested approval to market a generic </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment). On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 are invalid and not infringed. On June 7, 2022, we received notice from MSN that it had further amended its ANDA to assert an additional Paragraph IV certification. As currently amended, MSN&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. 11,298,349 (pharmaceutical composition). On July 18, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 11,298,349 arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. On August 9, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 11,298,349 are invalid and not infringed and amended its challenges to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 to allege that these patents are not enforceable based on equitable grounds. The two lawsuits comprising this litigation (collectively referred to as MSN II), numbered Civil Action Nos. 22-00228 and 22-00945, were consolidated in October 2022 and involve Exelixis patents that are different from those asserted in the MSN I litigation described above.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 would also infringe certain claims of each patent, if those claims are not found to be invalid. In our MSN II complaints, we are seeking, among other remedies, equitable relief enjoining MSN from infringing the asserted patents, as well as an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patents No. 11,091,439, 11,091,440, 11,098,015 and 11,298,349, the latest of which expires on February 10, 2032. A bench trial for MSN II has been scheduled for October 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teva ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. On July 29, 2022, we received notice from Teva that it had amended its ANDA to assert an additional Paragraph IV certification. As amended, Teva&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. 11,298,349 (pharmaceutical composition). On September 2, 2022, we filed a complaint in the Delaware District Court for patent infringement against Teva, asserting infringement of U.S. Patent No. 11,298,349 arising from Teva&#8217;s amended ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873, 10,039,757 and 11,298,349, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva from infringing these patents. On September 30, 2022, the parties filed a stipulation to consolidate the two lawsuits, numbered Civil Action Nos. 21-00871 and 22-01168, and to stay all proceedings, which was granted by the Delaware District Court on October 3, 2022. Following a similar order granted by the Delaware District Court on February 9, 2022 to stay all proceedings with respect to Civil Action No. 21-00871, this case remained administratively closed, and Civil Action No. 22-01168 was administratively closed on October 3, 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 6, 2023, we received a notice letter regarding an ANDA submitted to the FDA by Cipla Limited (Cipla), including a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,724,342 (formulations), 10,039,757 (methods of treatment), 11,098,015 (methods of treatment), 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,298,349 (pharmaceutical composition).</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cipla&#8217;s ANDA requests approval to market a generic version of CABOMETYX tablets prior to the expiration of the aforementioned patents. We have not yet responded to this Paragraph IV certification notice letter but are evaluating it.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170871701984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text">We have made reclassifications to our prior years&#8217; Consolidated Financial Statements to conform to the current year&#8217;s presentation. These reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities, total operating, investing or financing cash flows or total stockholders&#8217; equity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements adopted by us since our filing of the Annual Report on Form 10-K for the year ended December 31, 2021, which could have a significant effect on our Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2021, which could have a significant effect on our Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments and Investment Impairment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include realized gains and losses on the sale of investments in other income, net in the accompanying Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. The classification of restricted cash equivalents as short-term or long-term is dependent upon the longer of the remaining term to maturity of the investment or the remaining term of the related restriction.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment Impairment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarterly, we assess each of our investments in available-for-sale debt securities whose fair value is below its cost basis to determine if the investment&#8217;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded as a reduction of other comprehensive income (loss), net of applicable taxes. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to exclude accrued interest from both the fair value and the amortized cost basis of the available-for-sale debt securities for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text">We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Remeasurement</a></td>
<td class="text">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income, net in the accompanying Consolidated Statements of Income.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text">Trade receivables, net, contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current economic conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers. We write off trade receivables and related allowances for credit losses when it becomes probable we will not collect the amount receivable. Write-offs for the years ended December&#160;31, 2022 and December&#160;31, 2021 were immaterial.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration services revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to 15 years and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize any material impairment charges in any of the periods presented.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">We recorded goodwill amounts as the excess of purchase price over identifiable net assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in one business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text">The carrying value of our long-lived assets, which includes property and equipment, right-of-use assets and leasehold improvements, is reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenues under the guidance of ASU Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 606). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established primarily from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discounts for Prompt Payment:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Customers in the U.S. receive a discount of 2% for prompt payment. We expect our Customers will earn 100% of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our Customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2020, the</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to Customer, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Customer Credits: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Up-front License Fees: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory and Development Milestone Payments: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development Cost Reimbursements:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation, which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Arrangements: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Sales-based Milestone Payments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty we are required to pay on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. </span></div>We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees and option exercise fees, funded research and milestone payments incurred or probable to be incurred for our in-licensing arrangements with our collaboration partners for research programs in development and prior to regulatory approval; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial projects have been executed with support from third-party CROs, who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating </span></div>accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected not to apply the recognition requirements of </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2016-02</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842) for short-term leases.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text">We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in selling, general and administrative expenses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;units (RSUs), performance-based restricted&#160;stock&#160;units (PSUs), service-based&#160;stock&#160;options and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock&#160;Compensation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of RSUs and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for certain PSUs and RSUs with market vesting conditions and a Black-Scholes Merton option pricing model for stock options. Both pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatility when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense related to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis. Compensation expense related to RSUs with market vesting conditions is recognized regardless of the outcome of the market conditions.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text">We continually assess our ownership, contractual and other interests in entities that are not wholly-owned whether we are the primary beneficiary of a variable interest entity (VIE) and therefore we must consolidate the entity. We apply a qualitative approach that determines whether we have both (1) the power to direct the activities that most significantly impact the economic performance of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We perform this assessment, as changes to existing relationships or future transactions may result in consolidation or deconsolidation of a VIE.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Provision for Income Taxes</a></td>
<td class="text">Our provision for income taxes is computed under the asset and liability method. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or <div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our provision for income taxes in the period of such reversal. Based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 31, 2022 and forecasts of future operating results, we do not have a valuation allowance against our deferred tax assets as described in &#8220;Note 9. Provision For Income Taxes&#8221;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=d3e5291-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170872225840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,951,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(549,926)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401,243&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077,256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,819&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,988&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,970&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375,909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401,243&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration Risks</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo Health, Incorporated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenues Disaggregated by Geographic Region</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611,062&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock', window );">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238,283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,021)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,564)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357,868)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,625&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,825&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(344,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,094)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,881&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,426&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Other Assets and Other Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,070&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Presented in other long-term assets in the accompanying Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Presented in other current liabilities in the accompanying Consolidated Balance Sheets.</span></div>(3)&#160;&#160;&#160;&#160;Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170872916960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,592&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,073&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,631&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt;text-indent:36pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt;text-indent:36pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,725&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170872227856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502,677&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502,677&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of Investments by Security Type</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,679)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887,060&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,034)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,615&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,085,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,034)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066,681&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</a></td>
<td class="text">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):<div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,132)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,679)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030,810&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,034)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170873008672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066,640&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652,724&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719,255&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170872991728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,276&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170872975360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">up to 15 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">up to 3 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,862&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,031&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170870638592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,574&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,574&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.04&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of All Stock Option Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for stock options during the year ended December&#160;31, 2022 was as follows (in thousands</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,743)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(635)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options exercisable at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of All RSU Activity</a></td>
<td class="text">Activity for RSUs during the year ended December&#160;31, 2022 was as follows (in thousands, except per share amounts):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for PSUs, during the year ended December&#160;31, 2022 was as follows (in thousands</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $33.17 per share for the 2022 TSR-based RSUs:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of Exelixis common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of Exelixis common stock on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170872334288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income before income taxes is derived solely from within the U.S. Our provision for income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,562&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,358)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,529&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,056&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Taxes At The Statutory Federal Income Tax Rate to Net Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the U.S. federal income tax provision at the statutory federal income tax rate of 21% for each of the years ended December 31, 2022, 2021 and 2020, respectively, to our provision for income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal income tax provision at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax (benefit) expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,356)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,864)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible warrant purchase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(562)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,070&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,091&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,056&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves not currently deductible</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,638&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,068)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,940&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,907)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,110&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our unrecognized tax benefits (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to prior year provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to current year provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on the lapse of the applicable statutes of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(721)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(301)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,033)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,706&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,583&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,941&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170873007968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Reconciliation of Basic and Diluted Net Income Per Share</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,556&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,001&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.56&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.72&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock Not Included In Computation of Diluted Net Income Per Share</a></td>
<td class="text">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170877066112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Balance Sheet Classification of Lease Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMC0xLTEtOTIxNTA_96cbace8-4798-438d-bd6a-d3ce92ddad69"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMC0xLTEtOTIxNTA_bf05f744-ae2c-4625-a413-f24a3f80b54d">Right-of-use assets included in other long-term assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMC0xLTEtOTIxNTA_3805e340-1810-45ae-9746-eaa8274e40f1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMC0xLTEtOTIxNTA_4cf525be-b16c-489c-b6e4-ee90a9a764d7">Current portion included in other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,829&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease costs were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,413&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the maturities of our operating lease liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.186%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future tenant improvement reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,829&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170868299248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 30, 2022 </div>
<div>USD ($) </div>
<div>product </div>
<div>segment </div>
<div>country</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS', window );">Number of countries with FDA approval, excluding the U.S. | country</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charge on goodwill | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_SalesRevenuePercentDiscountForPromptPayment', window );">Percent discount for prompt payment</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_SalesRevenueDiscountExpectedtobeEarnedPercent', window );">Discount expected to be earned</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_MedicarePartDFundingMandate', window );">Medicare Part D funding mandate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Cost of goods sold is related to product</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense | $</a></td>
<td class="nump">$ 41,600,000<span></span>
</td>
<td class="nump">$ 31,800,000<span></span>
</td>
<td class="nump">$ 25,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember', window );">Resulting From Discovery Efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember', window );">Products Derived From Other Compounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MedicarePartDFundingMandate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medicare Part D Funding Mandate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MedicarePartDFundingMandate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Countries With Drug Approval, Excluding The U.S.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberOfCountriesWithDrugApprovalExcludingTheUS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SalesRevenueDiscountExpectedtobeEarnedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Revenue, Discount Expected to be Earned, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SalesRevenueDiscountExpectedtobeEarnedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SalesRevenuePercentDiscountForPromptPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Revenue, Percent Discount for Prompt Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SalesRevenuePercentDiscountForPromptPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170875801712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by Disaggregated Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,611,062<span></span>
</td>
<td class="nump">$ 1,434,970<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductGrossMember', window );">Gross product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,951,169<span></span>
</td>
<td class="nump">1,452,913<span></span>
</td>
<td class="nump">962,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="num">(549,926)<span></span>
</td>
<td class="num">(375,657)<span></span>
</td>
<td class="num">(221,041)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,401,243<span></span>
</td>
<td class="nump">1,077,256<span></span>
</td>
<td class="nump">741,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">162,056<span></span>
</td>
<td class="nump">249,956<span></span>
</td>
<td class="nump">167,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">47,763<span></span>
</td>
<td class="nump">107,758<span></span>
</td>
<td class="nump">78,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Total collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 209,819<span></span>
</td>
<td class="nump">$ 357,714<span></span>
</td>
<td class="nump">$ 245,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170867280512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Net Product Revenues Disaggregated by Product (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 1,611,062<span></span>
</td>
<td class="nump">$ 1,434,970<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">1,401,243<span></span>
</td>
<td class="nump">1,077,256<span></span>
</td>
<td class="nump">741,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CabometyxMember', window );">CABOMETYX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">1,375,909<span></span>
</td>
<td class="nump">1,054,050<span></span>
</td>
<td class="nump">718,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CometriqMember', window );">COMETRIQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 25,334<span></span>
</td>
<td class="nump">$ 23,206<span></span>
</td>
<td class="nump">$ 22,863<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170875909616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Significant Customer (Details) - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Sales revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Sales revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Sales revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Sales revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember', window );">Accredo Health, Incorporated | Sales revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember', window );">Affiliates of Optum Specialty Pharmacy | Sales revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_CardinalHealthIncMember', window );">Cardinal Health, Inc. | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170870613568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,611,062<span></span>
</td>
<td class="nump">$ 1,434,970<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,413,743<span></span>
</td>
<td class="nump">1,089,396<span></span>
</td>
<td class="nump">752,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">168,592<span></span>
</td>
<td class="nump">302,073<span></span>
</td>
<td class="nump">151,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 28,727<span></span>
</td>
<td class="nump">$ 43,501<span></span>
</td>
<td class="nump">$ 83,017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170875816848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 48,325<span></span>
</td>
<td class="nump">$ 30,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">549,693<span></span>
</td>
<td class="nump">374,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(521,020)<span></span>
</td>
<td class="num">(357,868)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">77,231<span></span>
</td>
<td class="nump">48,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks, Discounts for Prompt Payment and Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">14,625<span></span>
</td>
<td class="nump">9,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">355,865<span></span>
</td>
<td class="nump">243,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">611<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(344,220)<span></span>
</td>
<td class="num">(238,283)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">26,881<span></span>
</td>
<td class="nump">14,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember', window );">Other Customer Credits/Fees and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">8,875<span></span>
</td>
<td class="nump">3,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">50,312<span></span>
</td>
<td class="nump">30,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(44,094)<span></span>
</td>
<td class="num">(25,021)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">14,924<span></span>
</td>
<td class="nump">8,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">24,825<span></span>
</td>
<td class="nump">17,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">143,516<span></span>
</td>
<td class="nump">100,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(209)<span></span>
</td>
<td class="nump">1,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(132,706)<span></span>
</td>
<td class="num">(94,564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 35,426<span></span>
</td>
<td class="nump">$ 24,825<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Current Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Prior Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions To Provision [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170872223760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Contract other long-term assets</a></td>
<td class="nump">$ 1,659<span></span>
</td>
<td class="nump">$ 1,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">7,488<span></span>
</td>
<td class="nump">7,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion</a></td>
<td class="nump">6,582<span></span>
</td>
<td class="nump">8,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total contract liabilities</a></td>
<td class="nump">14,070<span></span>
</td>
<td class="nump">16,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized', window );">Contract revenue recognized, including revenue from deferred revenue beginning balance</a></td>
<td class="nump">8,100<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="nump">$ 9,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized for performance obligations satisfied in previous periods</a></td>
<td class="nump">161,600<span></span>
</td>
<td class="nump">$ 148,700<span></span>
</td>
<td class="nump">$ 169,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to our performance obligations</a></td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Including New Contract Revenue, Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170871609472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)<br> $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2022 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_MilestonePaymentsEarnedToDate', window );">Milestone payments earned to date</a></td>
<td class="nump">$ 489.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Collaboration agreement percent of royalty on net sale</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 73.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod', window );">Collaboration period to achieve specified levels of commercial performance</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="nump">$ 27.0<span></span>
</td>
<td class="nump">$ 112.5<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">19.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">$ 350.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_RevenueFromContractWithCustomerCommercialSalesMilestone', window );">Commercial sales milestone</a></td>
<td class="nump">$ 25.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_RevenueFromContractWithCustomerRegulatoryMilestone', window );">Regulatory milestone</a></td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 35.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen | Minimum | Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen | Maximum | Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen | Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Cumulative catch-up revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory, Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for commercial milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarnedToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned To Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarnedToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RevenueFromContractWithCustomerCommercialSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Commercial Sales Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RevenueFromContractWithCustomerCommercialSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RevenueFromContractWithCustomerRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Regulatory Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RevenueFromContractWithCustomerRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment(s)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_FinalTierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_FinalTierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170875062160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,611,062<span></span>
</td>
<td class="nump">$ 1,434,970<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">168,592<span></span>
</td>
<td class="nump">302,073<span></span>
</td>
<td class="nump">151,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">162,056<span></span>
</td>
<td class="nump">249,956<span></span>
</td>
<td class="nump">167,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">133,732<span></span>
</td>
<td class="nump">207,982<span></span>
</td>
<td class="nump">93,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">47,763<span></span>
</td>
<td class="nump">107,758<span></span>
</td>
<td class="nump">78,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 34,860<span></span>
</td>
<td class="nump">$ 94,091<span></span>
</td>
<td class="nump">$ 58,136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170868222784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_MilestonePaymentsEarnedToDate', window );">Milestone payments earned to date</a></td>
<td class="nump">$ 489.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Collaboration agreement percent of royalty on net sale</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 73.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_MilestonePaymentsEarnedToDate', window );">Milestone payments earned to date</a></td>
<td class="nump">127.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="nump">$ 66.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">119.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">37.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Initial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Royalty tier</a></td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Initial | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Initial | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Final tier | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Final tier | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod', window );">Collaboration period to achieve specified levels of commercial performance</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for commercial milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarnedToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned To Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarnedToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Tier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment(s)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_InitialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_InitialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_FinalTierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_FinalTierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170875932048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,611,062<span></span>
</td>
<td class="nump">$ 1,434,970<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">24,238<span></span>
</td>
<td class="nump">39,725<span></span>
</td>
<td class="nump">81,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">162,056<span></span>
</td>
<td class="nump">249,956<span></span>
</td>
<td class="nump">167,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">11,335<span></span>
</td>
<td class="nump">26,058<span></span>
</td>
<td class="nump">61,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">47,763<span></span>
</td>
<td class="nump">107,758<span></span>
</td>
<td class="nump">78,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 12,903<span></span>
</td>
<td class="nump">$ 13,667<span></span>
</td>
<td class="nump">$ 20,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170871828192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - GSK (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Collaboration agreement percent of royalty on net sale</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember', window );">Collaborative Arrangements with GSK and Royalty Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 58.2<span></span>
</td>
<td class="nump">$ 46.6<span></span>
</td>
<td class="nump">$ 32.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170868048352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Other Collaborations Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,611,062<span></span>
</td>
<td class="nump">$ 1,434,970<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 891,813<span></span>
</td>
<td class="nump">693,716<span></span>
</td>
<td class="nump">547,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_IncreaseInDilutedEarningsPerShare', window );">Increase in diluted earnings per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech | Cotellic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="nump">12,100<span></span>
</td>
<td class="nump">11,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_BioInventInternationalABBioInventMember', window );">BioInvent International AB (BioInvent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Collaborative arrangement, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CybrexaTherapeuticsLLCCybrexaMember', window );">Cybrexa Therapeutics, LLC (Cybrexa)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Collaborative arrangement, upfront payment</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments', window );">Potential future development milestone payments</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise', window );">Maximum amount of warrant to be exercised</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments', window );">Additional development regulatory and commercial milestones payments</a></td>
<td class="nump">277,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_SairopaBVSairopaMember', window );">Sairopa, B.V. (Sairopa)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Collaborative arrangement, upfront payment</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments', window );">Potential future development milestone payments</a></td>
<td class="nump">97,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments', window );">Additional development regulatory and commercial milestones payments</a></td>
<td class="nump">465,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount', window );">Option to exercise, amount</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CatalentIncMember', window );">Catalent, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Collaborative arrangement, upfront payment</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember', window );">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments', window );">Potential future development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">652,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,900<span></span>
</td>
<td class="nump">$ 176,100<span></span>
</td>
<td class="nump">$ 96,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_IncreaseDecreaseInResearchAndDevelopmentExpense', window );">Decrease in research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_IncreaseInBasicEarningsPerShare', window );">Increase in basic earnings per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments', window );">Potential regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 634,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments', window );">Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,153,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Amount Of Warrant Exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountOfWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Exercise Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsExerciseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development, Regulatory And Commercial Milestones Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseInBasicEarningsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase In Basic Earnings Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseInBasicEarningsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseInDilutedEarningsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase In Diluted Earnings Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseInDilutedEarningsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CotellicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CotellicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_BioInventInternationalABBioInventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_BioInventInternationalABBioInventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CybrexaTherapeuticsLLCCybrexaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CybrexaTherapeuticsLLCCybrexaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_SairopaBVSairopaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_SairopaBVSairopaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CatalentIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CatalentIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170871844480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 501,195<span></span>
</td>
<td class="nump">$ 647,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash equivalents included in other long-term assets</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">16,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 502,677<span></span>
</td>
<td class="nump">$ 663,891<span></span>
</td>
<td class="nump">$ 320,772<span></span>
</td>
<td class="nump">$ 268,137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170870621808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 30, 2022 </div>
<div>USD ($) </div>
<div>numberOfSponsoredEnterprise </div>
<div>bond </div>
<div>investment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in an unrealized loss position | investment</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer</a></td>
<td class="nump">$ 237,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Accumulated loss</a></td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NumberOfBondSecurities', window );">Number of bond securities | bond</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NumberOfBondSecurities', window );">Number of bond securities | bond</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NumberOfSponsoredEnterprises', window );">Number of sponsored enterprises | numberOfSponsoredEnterprise</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberOfBondSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Bond Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberOfBondSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberOfSponsoredEnterprises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Sponsored Enterprises</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberOfSponsoredEnterprises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170875041456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Investments by Security Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,887,060<span></span>
</td>
<td class="nump">$ 1,534,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(19,034)<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,868,615<span></span>
</td>
<td class="nump">1,533,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,085,126<span></span>
</td>
<td class="nump">1,855,704<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(19,034)<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Fair Value</a></td>
<td class="nump">2,066,681<span></span>
</td>
<td class="nump">1,854,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">722,018<span></span>
</td>
<td class="nump">945,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">722,018<span></span>
</td>
<td class="nump">945,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">810,439<span></span>
</td>
<td class="nump">541,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(13,132)<span></span>
</td>
<td class="num">(1,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">797,848<span></span>
</td>
<td class="nump">540,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">338,218<span></span>
</td>
<td class="nump">33,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5,679)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">332,587<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">16,385<span></span>
</td>
<td class="nump">12,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(223)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">16,162<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">135,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">135,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">94,344<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">94,344<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">103,681<span></span>
</td>
<td class="nump">119,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 103,681<span></span>
</td>
<td class="nump">$ 119,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170868427488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">$ 1,030,810<span></span>
</td>
<td class="nump">$ 454,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(19,034)<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">706,711<span></span>
</td>
<td class="nump">385,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(13,132)<span></span>
</td>
<td class="num">(1,672)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">308,307<span></span>
</td>
<td class="nump">18,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(5,679)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">15,792<span></span>
</td>
<td class="nump">7,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (223)<span></span>
</td>
<td class="num">$ (35)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170872217040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 1,114,884<span></span>
</td>
<td class="nump">$ 1,168,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">753,731<span></span>
</td>
<td class="nump">365,412<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,868,615<span></span>
</td>
<td class="nump">$ 1,533,668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170874834704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,868,615<span></span>
</td>
<td class="nump">$ 1,533,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,868,615<span></span>
</td>
<td class="nump">1,533,668<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">2,066,640<span></span>
</td>
<td class="nump">1,719,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">94,344<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,868,615<span></span>
</td>
<td class="nump">1,533,668<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,972,296<span></span>
</td>
<td class="nump">1,652,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">722,018<span></span>
</td>
<td class="nump">945,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">722,018<span></span>
</td>
<td class="nump">945,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">722,018<span></span>
</td>
<td class="nump">945,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">797,848<span></span>
</td>
<td class="nump">540,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">797,848<span></span>
</td>
<td class="nump">540,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">797,848<span></span>
</td>
<td class="nump">540,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">332,587<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">332,587<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">332,587<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">16,162<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">16,162<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">16,162<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">94,344<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">94,344<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">103,681<span></span>
</td>
<td class="nump">119,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 103,681<span></span>
</td>
<td class="nump">$ 119,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170977247568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narratives (Details) - Foreign Exchange Forward<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2022 </div>
<div>EUR (&#8364;) </div>
<div>derivative_instrument</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of forward contract outstanding | derivative_instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Forward contract outstanding, amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Forward contract maturity (in months)</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Net gain (loss) on maturity of forward contracts | $</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNumberOfInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of derivative instruments of a particular group held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNumberOfInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170871940480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 8,077<span></span>
</td>
<td class="nump">$ 8,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">43,564<span></span>
</td>
<td class="nump">27,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">10,635<span></span>
</td>
<td class="nump">12,927<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">62,276<span></span>
</td>
<td class="nump">49,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Current portion included in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">33,299<span></span>
</td>
<td class="nump">27,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Long-term portion included in other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 28,977<span></span>
</td>
<td class="nump">$ 22,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170875951744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 171,496<span></span>
</td>
<td class="nump">$ 144,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(60,872)<span></span>
</td>
<td class="num">(40,831)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 110,624<span></span>
</td>
<td class="nump">104,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 83,334<span></span>
</td>
<td class="nump">73,589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 19,569<span></span>
</td>
<td class="nump">14,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 24,054<span></span>
</td>
<td class="nump">15,780<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 39,606<span></span>
</td>
<td class="nump">23,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 4,933<span></span>
</td>
<td class="nump">$ 16,872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170872991296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 20.9<span></span>
</td>
<td class="nump">$ 13.6<span></span>
</td>
<td class="nump">$ 9.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170876681248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Schedule of Allocated Employee Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 107,574<span></span>
</td>
<td class="nump">$ 119,820<span></span>
</td>
<td class="nump">$ 105,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">45,350<span></span>
</td>
<td class="nump">46,654<span></span>
</td>
<td class="nump">37,198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 62,224<span></span>
</td>
<td class="nump">$ 73,166<span></span>
</td>
<td class="nump">$ 67,872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170876808240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Schedule of Employee Service Share - Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 107,574<span></span>
</td>
<td class="nump">$ 119,820<span></span>
</td>
<td class="nump">$ 105,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">12,790<span></span>
</td>
<td class="nump">19,048<span></span>
</td>
<td class="nump">19,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">69,775<span></span>
</td>
<td class="nump">53,629<span></span>
</td>
<td class="nump">35,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">21,616<span></span>
</td>
<td class="nump">43,428<span></span>
</td>
<td class="nump">47,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,393<span></span>
</td>
<td class="nump">$ 3,715<span></span>
</td>
<td class="nump">$ 2,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170865290800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 25, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Maximum potential to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expenses relating to stock match</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exel_AmendedAndRestated2017EquityIncentivePlanMember', window );">Amended and Restated 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in share reserve under 2017 plan (in shares)</a></td>
<td class="nump">28,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,971,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,971,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward', window );">Reduction in share reserve after stock option or stock appreciation award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards', window );">Reduction in share reserve after all other awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod', window );">Number of months following change in control in which an employee was terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod', window );">Number of months following change in control in which an employee was terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.5<span></span>
</td>
<td class="nump">76.0<span></span>
</td>
<td class="nump">106.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from option exercises and purchases under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="nump">$ 14.8<span></span>
</td>
<td class="nump">$ 26.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Share-based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Share-based Payment Arrangement, Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,933,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,294,000<span></span>
</td>
<td class="nump">6,828,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Share-based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Share-based Payment Arrangement, Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember', window );">TSR-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,003,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Maximum potential to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember', window );">TSR-Based Restricted Stock Units | Share-based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting award percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,561,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,561,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Discount rate from market value on purchase date (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Discount rate from market value on offering date (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod', window );">Purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">606,787<span></span>
</td>
<td class="nump">536,226<span></span>
</td>
<td class="nump">534,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Average price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.63<span></span>
</td>
<td class="nump">$ 17.76<span></span>
</td>
<td class="nump">$ 14.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,027,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Maximum potential to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest', window );">Additional shares to be earned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,055,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,655,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,964,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,964,000<span></span>
</td>
<td class="nump">6,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">869,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">869,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Probable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Not Probable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Share-based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting award percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesClinicalTrialResultsMember', window );">Performance Shares, Clinical Trial Results</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,327,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement By Share-Based Payment Award, Termination Of Employment Following Change In Control, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=exel_AmendedAndRestated2017EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=exel_AmendedAndRestated2017EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_AchievedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_AchievedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_ProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_ProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_NotProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_NotProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesClinicalTrialResultsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceSharesClinicalTrialResultsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170871592736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Weighted Average Grant Date Fair Value (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 8.36<span></span>
</td>
<td class="nump">$ 9.04<span></span>
</td>
<td class="nump">$ 9.44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 6.12<span></span>
</td>
<td class="nump">$ 6.12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170867462272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.35%<span></span>
</td>
<td class="nump">0.74%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.49%<span></span>
</td>
<td class="nump">0.08%<span></span>
</td>
<td class="nump">0.79%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170875866656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Summary of All Stock Option Activity (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of the year (in shares) | shares</a></td>
<td class="nump">13,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(2,743)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(635)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at ending of the year (in shares) | shares</a></td>
<td class="nump">10,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of the year (in shares) | shares</a></td>
<td class="nump">8,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted&#160; Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of the year (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">19.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">5.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">21.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at ending of the year (in dollars per share) | $ / shares</a></td>
<td class="nump">19.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of the year (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 19.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, options outstanding</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, exercisable at end of the year</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding | $</a></td>
<td class="nump">$ 9,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable at end of the year | $</a></td>
<td class="nump">$ 9,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170865263312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Summary of All RSU &amp; PSU Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,828,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,933,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased', window );">Vested and released (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,164,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,303,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,294,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted&#160; Average Grant&#160;Date Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at beginning of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted&#160; Average Remaining Contractual&#160; Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,310,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares)</a></td>
<td class="nump">1,027,650<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased', window );">Vested and released (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(942,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(404,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,964,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted&#160; Average Grant&#160;Date Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at beginning of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted&#160; Average Remaining Contractual&#160; Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,628<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170875043792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Estimate Grant-Date Fair Value (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 30, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of Exelixis common stock on grant date (in dollars per share)</a></td>
<td class="nump">$ 21.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">49.21%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.29%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | 2021 Awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="nump">$ 24.54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember', window );">TSR-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>ESPP</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="nump">33.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of Exelixis common stock on grant date (in dollars per share)</a></td>
<td class="nump">$ 20.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">46.85%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.59%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=exel_A2021AwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=exel_A2021AwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170868425808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 100,525<span></span>
</td>
<td class="nump">$ 11,338<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">11,903<span></span>
</td>
<td class="nump">5,224<span></span>
</td>
<td class="nump">3,791<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">112,428<span></span>
</td>
<td class="nump">16,562<span></span>
</td>
<td class="nump">3,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(54,223)<span></span>
</td>
<td class="nump">46,416<span></span>
</td>
<td class="nump">14,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(6,135)<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">379<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="num">(60,358)<span></span>
</td>
<td class="nump">46,529<span></span>
</td>
<td class="nump">15,265<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 52,070<span></span>
</td>
<td class="nump">$ 63,091<span></span>
</td>
<td class="nump">$ 19,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170871611264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes - Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal income tax provision at statutory rate</a></td>
<td class="nump">$ 49,213<span></span>
</td>
<td class="nump">$ 61,772<span></span>
</td>
<td class="nump">$ 27,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax (benefit) expense</a></td>
<td class="num">(2,632)<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
<td class="num">(2,232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">7,162<span></span>
</td>
<td class="nump">2,883<span></span>
</td>
<td class="nump">5,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
<td class="num">(14,130)<span></span>
</td>
<td class="num">(6,263)<span></span>
</td>
<td class="num">(11,356)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(2,864)<span></span>
</td>
<td class="num">(11,831)<span></span>
</td>
<td class="num">(20,399)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation', window );">Non-deductible executive compensation</a></td>
<td class="nump">4,549<span></span>
</td>
<td class="nump">11,182<span></span>
</td>
<td class="nump">18,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee', window );">Branded prescription drug fee</a></td>
<td class="nump">3,855<span></span>
</td>
<td class="nump">2,897<span></span>
</td>
<td class="nump">2,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase', window );">Non-deductible warrant purchase</a></td>
<td class="nump">6,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
<td class="num">(562)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 52,070<span></span>
</td>
<td class="nump">$ 63,091<span></span>
</td>
<td class="nump">$ 19,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Branded Prescription Drug Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible, Warrant Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170871609712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provision For Income Taxes - Schedule of Deferred Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 33,635<span></span>
</td>
<td class="nump">$ 17,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">40,217<span></span>
</td>
<td class="nump">101,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">176,208<span></span>
</td>
<td class="nump">7,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">27,531<span></span>
</td>
<td class="nump">23,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">46,759<span></span>
</td>
<td class="nump">12,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">Accruals and reserves not currently deductible</a></td>
<td class="nump">22,418<span></span>
</td>
<td class="nump">19,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">7,656<span></span>
</td>
<td class="nump">8,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other assets</a></td>
<td class="nump">6,746<span></span>
</td>
<td class="nump">1,303<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">361,170<span></span>
</td>
<td class="nump">191,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(77,230)<span></span>
</td>
<td class="num">(70,068)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">283,940<span></span>
</td>
<td class="nump">121,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets', window );">Lease right-of-use assets</a></td>
<td class="num">(52,830)<span></span>
</td>
<td class="num">(9,907)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 231,110<span></span>
</td>
<td class="nump">$ 111,663<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Lease Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170874652480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 77,230<span></span>
</td>
<td class="nump">$ 70,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase (decrease)</a></td>
<td class="nump">7,200<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">87,706<span></span>
</td>
<td class="nump">$ 83,583<span></span>
</td>
<td class="nump">$ 80,941<span></span>
</td>
<td class="nump">$ 79,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would reduce income tax provision and effective tax rate</a></td>
<td class="nump">55,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">414,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credits</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_TaxCreditCarryforwardAmountWithExpirationPeriod', window );">Tax credit carryforward amount with expiration dates</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_TaxCreditCarryforwardAmountWithExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Amount With Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_TaxCreditCarryforwardAmountWithExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170875800096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 83,583<span></span>
</td>
<td class="nump">$ 80,941<span></span>
</td>
<td class="nump">$ 79,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Change relating to prior year provision</a></td>
<td class="nump">715<span></span>
</td>
<td class="nump">728<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Change relating to current year provision</a></td>
<td class="nump">4,129<span></span>
</td>
<td class="nump">2,215<span></span>
</td>
<td class="nump">3,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Reductions based on the lapse of the applicable statutes of limitations</a></td>
<td class="num">(721)<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="num">(2,033)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 87,706<span></span>
</td>
<td class="nump">$ 83,583<span></span>
</td>
<td class="nump">$ 80,941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170876726336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 182,282<span></span>
</td>
<td class="nump">$ 231,063<span></span>
</td>
<td class="nump">$ 111,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">321,526<span></span>
</td>
<td class="nump">314,884<span></span>
</td>
<td class="nump">308,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive securities (in shares)</a></td>
<td class="nump">3,030<span></span>
</td>
<td class="nump">7,475<span></span>
</td>
<td class="nump">9,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">324,556<span></span>
</td>
<td class="nump">322,359<span></span>
</td>
<td class="nump">318,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170872159280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Potentially Dilutive Shares of Common Stock (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Share-based Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities and contingently issuable shares excluded (in shares)</a></td>
<td class="nump">17,063<span></span>
</td>
<td class="nump">14,305<span></span>
</td>
<td class="nump">10,959<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170868306704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities | $</a></td>
<td class="nump">$ 11.4<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average operating discount rate used to determine the operating lease liability</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating lease</a></td>
<td class="text">12 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Lease cost | $</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_LossContingencyNumberOfLawsuitsConsolidated', window );">Number of lawsuits | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_LeaseArrangementsAxis=exel_HeadquartersLeaseMember', window );">Headquarters Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft) | ft&#178;</a></td>
<td class="nump">673,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_LeaseArrangementsAxis=exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember', window );">Lease Agreements for Laboratory Spaces in Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft) | ft&#178;</a></td>
<td class="nump">28,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LossContingencyNumberOfLawsuitsConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency Number Of Lawsuits Consolidated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LossContingencyNumberOfLawsuitsConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LeaseArrangementsAxis=exel_HeadquartersLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LeaseArrangementsAxis=exel_HeadquartersLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LeaseArrangementsAxis=exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LeaseArrangementsAxis=exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170875866960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Balance Sheet Classification of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_OperatingLeaseAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets included in other long-term assets</a></td>
<td class="nump">$ 234,811<span></span>
</td>
<td class="nump">$ 45,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Operating Lease, Right-Of-Use Asset And Other Assets<span></span>
</td>
<td class="text">Operating Lease, Right-Of-Use Asset And Other Assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_OperatingLeaseLiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion included in other current liabilities</a></td>
<td class="nump">$ 17,659<span></span>
</td>
<td class="nump">$ 5,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">190,170<span></span>
</td>
<td class="nump">51,272<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 207,829<span></span>
</td>
<td class="nump">$ 56,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170870666144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments And Contingencies - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 18,315<span></span>
</td>
<td class="nump">$ 5,332<span></span>
</td>
<td class="nump">$ 4,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">3,098<span></span>
</td>
<td class="nump">2,685<span></span>
</td>
<td class="nump">2,830<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease costs</a></td>
<td class="nump">$ 21,413<span></span>
</td>
<td class="nump">$ 8,017<span></span>
</td>
<td class="nump">$ 7,655<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140170872164384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 18,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">23,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">23,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">23,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">24,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">206,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">319,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="num">(88,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements', window );">Future tenant improvement reimbursements</a></td>
<td class="num">(23,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 207,829<span></span>
</td>
<td class="nump">$ 56,409<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>exel-20221230_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:exel="http://www.exelixis.com/20221230"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exel-20221230.xsd" xlink:type="simple"/>
    <context id="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="ife95f2dac98345e09e30688f417dfefd_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="ia7a2db918d5e4f25a57dfd066511af97_I20230130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2023-01-30</instant>
        </period>
    </context>
    <context id="if9edbc96fe6e479bbcc59afd221a28fc_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd975ad7811c4bdbb2315643b04037a2_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="ia2e996a9f240456487cb91fc0c52e1a1_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3d55e02ba3ae4c8999e690629fe6d584_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ib9ff1b0e91924c73b4c456c2235ab6cf_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i47a0764d353e4fb3a7ec06de9aca7c16_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib8380d5f4f944a18a412a44050718011_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i968c32c71952402cb10bdb7c8f5f4c8e_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="iad8294bfd197493791fd98694c5266f2_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i663037ccb1ec482e8ebc1bbf359c95b4_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="iee90ac3decac457ea10ccb1f57c3be9f_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i316600a670354ae9bed12cb08f90fbad_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i4d397c56f7c747a1b4c4ee65c9dca93f_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ied0a8550944e400eb840fecf7a697f8a_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i7a3670052766460e8f6681bfb2fe46da_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ie7bb9a335486433c81f3f5733d3aaad8_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i36ea7ff7478a47f29ac8ddc870f601a1_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ic0deb65d8e8541f4befd56d486e027aa_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="iac71ca2b42784a9596529526d80870fe_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i8b022f123e124eebacb65e193a7ca348_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i30d6ea6119494ce99990ec9f421bf661_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i6b916a4ad0de4c3ea7891d04e8a0e888_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ibf9048c142784771b43942a372d1013d_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i0958ab0a7b904c6abbc804e49a0e9544_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i2f9dad1068314e4a821e9fa7b5dfc712_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic1d8b28295254e3c9d72be053782f1f6_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idfd5463291344fadbad875183adfc559_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i61bccae84739493aa433b75b3289741b_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8ebcf341e8d14a8d8af6c5f7a8d997dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d4b232e8fca4e8d9de8920ba88d1665_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i86a7ae9225ca4247aa92ff18efbb1e3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic180e4d772ed46dc825b7445c7893c6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d92019d1cca43aebdc002637f9a8e0a_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="ia138b200885a4b769244acdf9eeab22d_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="ibd740e63081e4029889559bc739aee7d_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i564bbd54548d41f68982fea9945c6519_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="ic6372aa2efa047d3814f185d55ca1da9_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i2ae29c61f4c04cdda5f6e25561c082eb_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i7de5204d64db4e1094ecd5b8bfca36d1_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i28cc46cb8b1541b3b1c30a1b510db95d_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i43e43644871943ca80e12287cd11f468_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i4e1b3f5f23e243f1b8637a1014a5195a_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i4c2389c4c21e47d38ba918260c486bdd_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i89478d8e53974982878b9f548166f990_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i1dafc9c29ab84bcc889c1cf9052a086e_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib74e5ab8178d4970b8e0465f6fa0028c_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i71aecadc693d426fb5b155f638d21467_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="idc1b4ef9e9b84a8ebf2dfd01a3004c70_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic649dcb8633a451880ff42451fc2f3ab_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i47c31e24d2c0403d83cfc5c2eb92f86f_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="iae02cfb8959147e8a8be84c7f06c568f_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie7fd8bc4b5b142a1a7297763d8461fc6_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="if237b256b8c34d6f87bec83d450b03ab_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i5d8ad44c76d84c439d5d4844f913bf36_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b45a28b3ddd4011af15bed2146cd292_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ied57fc239c1a4a7b97626aba030a42ad_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="id94aae6775c049b5b2b45d949aafa52c_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaed8d85227d3483f90cb59be9e884d22_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ide7ae702d2f94f168ad5eb6d613db43b_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i9229604d9ad94d6fa4aaff91b181d1fa_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i85155e2e92604cd8af2bbc12fed76b09_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ifb94516f996c436291373f1bb4adcaf9_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i0831affdb6f74cd590e4619e798c6ede_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4f5b33e3f9374a4080cdf99a2599aa23_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i09e575bca46c4ee7b2977bb349efda52_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="if8451b3d5bb240c7a4b4e0fc57e84305_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9cd9ed86ff6d4038bcad39e7fb9d9344_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ibdcd0d0a9429406cbdb4291bcd54d608_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i119efb5fb69c4904bcc940dbd2963d2b_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i04453331d42244feaf8b6ea4c41db316_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i5d85564049e049b68f2010d3e0f72113_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i820e2862a6184ec388d2114fd98baf4a_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iff9f443812b14ed79359b92769535720_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ifbbcd4f4e254417c814ceb83cd2b0472_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i99b39711f74648d78882998f94841261_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3365323e5089466b94bbb9251d2fff94_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ied54335b6e124ce78abd0708eb3c5f6a_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i262b07d55db34a90b4349cb8911e546e_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic7239796cf414e5b9d7107ff0f6c6ba5_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i72ae7ad08b2a48ae9bbf227c4be302ca_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id368c47c3f5d481db02eba2d8009c964_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i19da7b7d320c44d5b7e1755d3f209f69_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0d6fe72170844659b8059e439eb16e3c_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i1e7719032719481b9bb97d521869817b_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i82d900845d714ced98be563122eec84e_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="ic7e319ed079a4b688272f575c6d79fb7_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia505016291bc4b92966a63cb457f79cf_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i3fc646f54374425da47c013312f9a8e2_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie7afa411719d4768beb18974c2d9df7d_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="if8173bdcf6bc42f08c968eda65dfc2a6_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i9c0ed898ca774d77b13b623d417de030_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iabb415230cfe48b99b7d9b8d3f6efd7e_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ifb1d7000657e4ce4b150b18dd4413a53_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i1f2783aaa2794de7bb52b691c9662d08_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ied38d86192994bb4b9a4d9a3b0c3fa39_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="if2acaaacb5c8468bb06c3310cf75f928_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="iaf3671d9a5af4d39a8d091071f92b7ff_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i33892ff3208246fab5f7275cef00bcf7_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i991465767e2240f6921b76dcc130c033_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i60160fe976124e808a313207fe175c03_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3fec469537054a23b86c5d87638062e6_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i966ed994207841c3950965f3ec961e93_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic667289b49764b95a7d7f096cb54a98b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1326a18371364e4d964deea38459c405_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11f3424e5d624831b1f13418acf4a9c2_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i793cb0fdacf74d2d8650c8f711d32ff7_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i3a6accba75744f11a98c8b6488700e99_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i58f96bba653a49e1ae627198e6f38b55_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i27f15e30b5a74aa49673c0f2c8433728_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="ic81d2dff655c411a851f03dcaae0e471_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i70318e17c7ab4b68b6b925151523736a_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id4f5961955974e53a8d6b5ad85acfe4d_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i39c122c614074046abcfbcc446a1fa98_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ibad41c5a867e42328f87a6be4ab95e02_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibce8519fb88b4643a598a9f10397b3fb_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i9fc4fe1515e740b5b2fedc80ab3c29d8_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i850883eb6ca848ccbe6e3680f28bee20_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i125cc20cc74341a5b27b3efd37225cf0_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="icd9cf65a286f4e7da9b13796a041f58f_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="ib11873105d5440f2b04ad3921ee0e374_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4810c81a75b84f8b964fb340d02890c0_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ie49ad1f5b50641398e4bd5e6a19ec508_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i0b1223169902474aafc57a25d19dcaff_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i1d5c30fce06545d9a3baacb0b0ab774e_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="ifaedfc761d77477d83685f07ca670fc4_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i337a214cbd1b44929248114a2eb85662_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i5e5a7fdf85fc4fc7bfa8e4d51f47e59b_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="id1f50051810c4c1faeb0643d2151e699_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i071e191539a447ab937022c70f4066ae_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ia3ca226cd81a48daacc85597ee8e0f61_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i2ae1f8be861d4b04aa760182f4297029_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i4d556ca23f9e45b4b9ed6c03f967c59b_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="idc4a5bca80f542428c9f79064ba8ff59_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i3a65d7d772494943b214d873b45da310_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="ice176fd5f4104315b8f2c270962294fa_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i206233ca66af4b1a9cf478e3d8d24963_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6aa5c591d2414c088c15c92ff3156418_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ibbc3624e7a294295a982185658426bfe_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i82f90a00897a46f1957e0414cc090bbe_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5276ec4d64fb4ba49c9c540fea11a982_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i41fe2331cabe4050a30129ee051c2799_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i8bc9a78c8ba049f1946264d1c52f58e9_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d753c4338ff47ef84b0c40394bd5147_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i2c3596696fae4d9fb41163e7ddd3e386_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i7048757da4c04483a7c963e440b237a5_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b2a018fee9e45548471c0835e50f5b6_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i02a9e43c4eda4262b8e648fb4debd1eb_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:BioInventInternationalABBioInventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1d84069f159b428fbda44b41dd831144_D20221101-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CybrexaTherapeuticsLLCCybrexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="i5ec846e4aef84ad2ae39d1d13246bfc6_I20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CybrexaTherapeuticsLLCCybrexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="ifd58ac0e41e340fc877768fad90c5f62_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CybrexaTherapeuticsLLCCybrexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i3334291a8ef14e57a8f54daf44f344c8_D20221101-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:SairopaBVSairopaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="id6fd500061c74be88ef95fc875ef99af_I20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:SairopaBVSairopaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="ia026be7c5b9b41a3a54316d617e77f69_D20221101-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CatalentIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="ia0f7c864ef914e8b9ebcaa0c64e1ece3_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="id82fc91049724181b2a5e0f40253e48c_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i361ef59b0f2e4fddaf4c38b878d30ec0_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="if09743b2bc6e41bdb6f96e1e3fef767b_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i7f1d4c0db61942b98ec8d831869eff8a_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i1b10b0b7dac44f40b1acc72e8f727bc8_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i57b0ec642b2d416d99ecaed9d2670965_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="ic56eac004a664b27807f0d574730e620_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i20c6ba758c364e9cbc586045aa0a9faa_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i191d7158380c4447a4808cab8812db7f_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i1b13e9beb6b943898d6cef7a1e02fc9e_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="ic5acd41dc9f24b53b18e9a7c0319506c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf3d41d8f12c40e4baaa791aadb41393_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32b96a13da9e4c34a6911c04c05af3e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78d5da90485a4254a56630c577874e45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i972ae3af601c4166b2b7375fcce4b2f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97a943d0ee094645bee3a1a59e2108dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic81da6fcbafc408f85a016575fc626ad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieebb4571285b4760b2d6ffadd98aa2a3_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i678fac2def204c018d03c82ac9dbc312_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i2a347ff0104c4e37a0b5967300b9b308_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i2525f5b5cbe34620878e5e9e6f0c1c1e_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i4cd2228030e9433ab02d7801959e3ef3_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i40eb4f16efe747339fc781b4b8ab1d9d_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="ic099aa5b5a354fd0bc57f4dfc1f82f5f_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i6ff0318ea05d43dc8f548eb4b0abeaab_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="iace46fa599fd439ea6f6a1a2dd79a719_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="ia52f875fc7ea48afad6c5d1f838e319a_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i6a1f30ef6bf04adebfc61920cd8a412a_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i199c2fdbc09541b98fa084e45047c999_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="ie569dd4e72ad4efea4960bffc82ca79e_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i1a4566d6932b48aa8902d306c989ff52_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="ia82be6e971604c2da30b378bdf9985c9_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="if3fc431dacf844f38ad9667dc0e877c2_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="ic96a10d99c47408289f5ad833d6120b8_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i75ea1cc7d48743c88632a3cf80cbd319_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i6a1d047b86f24d2083f214d75c5134ef_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i51fb172e52eb436f82f975928b0d6479_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="ia20e3dbd8a4d45d884a2d75792ca5567_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i471e33a44e454a859ed17e9d46754e8e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibfd0873a4a96461ba27862f3c00db9c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f0f51588cc244e6bc024c642a236d9e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i726e2aeff8e4434ab43684910d66fa92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10af3e3a1cd64127a91cee9c3a18360c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6aefb57539a84853a9275b9c5978a13c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ef8749612e74ad38eff74f7f8441bae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9fd89a3bfdd74436bbebaf5f5a836492_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iebe7e70eb57b4339a8a7e41055b873ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iada6509b74ef42d1ab3a02e9916aa003_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97e1a85481df47c6ba245c6579743863_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73559db97810456c9b104a736adc72f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i35acff8b86c74ab6877bd2ff37df8915_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3b577aa781240a89ea986321d268054_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2bc81f428a0846d484b97bfeeb05fb15_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b4bcecee8844c49bc7fe25f8b70e6b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i333e0adca8ad4c98adc9303eaa294dee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia12585f72d404b3b9451798d475c2669_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d2966ecc3e24e2cb9545a4f31ab7a68_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4dfc0620ff1b4f0d83f4e9ed4f789075_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iddcafb03f418408d86fae11b5091d968_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12667066e7cc4662b0936e2e393953fd_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i042731f45c434908a7097f420a97138c_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i4218de4396fe4f889b222285008565ab_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf9ed26c4ba2489591ac9c39a8bf7ce1_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i6e4b169888c84090b5422b97549cd20c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08940ae14c044060b10d9ea3213210f3_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i54d01b1ebd6a4b07bfe50d2f94bef6b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i29abdea0de484029b656cfe3041033c3_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="ied09a4ba58274c3596cc89a3777f1174_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i7215386183c44fd2aa5b09fe609d09a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb968a7ec21c46bda8be17bee6c569df_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i89d86279d8cf4c6688a69b3db5f0650e_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i261b348dea0344bc94589101e7e53f5e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd4ba0df5aff4776bc4e4486814a14a1_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i3a48c86b35e6435ea5fd025596c4038e_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i5e43db2475c746e19470fa095df95b14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e7aa72456ac4985a26e7ee7471b2167_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i44a51d0f954f47abb686f58842236e4b_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i0ebe5b3d3ea6429d897818f4d64c6c70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e2afee13177452697583dfe3fb2e778_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="ib510a5b7f321419fafd9bcd1b30bce22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5160dca23cbd4534bbd8f0c6583551eb_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i14b02cd880bf4d00b829d7485dae8233_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iee5871015bd64ea0a1cea69d5451681c_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i37ff342a670f4b08a73196e2c605fefd_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="ic2297486cdd248d085cac7850abaaf71_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5491aa8fe4e24ba3ac8e4aaa781cce6a_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i53d5d9f5ba5145de91b7ed6cafe85f4b_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i001bf94dda6a471d908297d31da5650a_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i8b2da2883e9244eb867ae85f79b46942_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i448f6fe1dd7842a5b8a72af4bafcacbe_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i265887804270466a84b8183ec8c715b9_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i078320950f3f4080b9cc748699315beb_D20220525-20220525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exel:AmendedAndRestated2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-25</startDate>
            <endDate>2022-05-25</endDate>
        </period>
    </context>
    <context id="i3874dd04524f404cad068734350f1731_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exel:AmendedAndRestated2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i4fad33a89ad640298188cf7bb295b4ae_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exel:AmendedAndRestated2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i3a61f81952984a76817f7077b77e352c_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i94edb7e6d39c450a954861e65f48c315_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="ie4196c2fa72f4675a1c7dc4470ac938f_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i1d192ee0ba8049e2a30c45ffc397e321_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="if0d9106c860342c6a5490820d5ac452c_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i8ab3ba9b700146e8a378297f9a6ef6c5_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i2d394ecf14b74946a77659139d5f4878_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4d13e607a19484395fc6a707a9c2df9_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i1665a438e56445b78cb7452df0643ba1_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i4c54a7d88c1f429ba5559d7d2282d65c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5de3dc69b844f86ba1ee22cce4ea5c9_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="ie3d7d02ac4d34267a1d46e90f45bef37_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9aae7ba847d34422b359963bd9dc87f5_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i2fb2e18c946f487ea024e74f846cd36a_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia6d07a5ce0b943d9851f70f5a1bc4058_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia1b5d625613f4f5d933afddd77da19b7_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="id8a52c2ef07a4489ad93e8b30e5e3368_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i63901f6ae4fb4bcbb543c24cd2c4216a_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib652a5d9ce3a49709aea2941cebaac3b_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i04f2cc9dcfa7426e99f081418b205d0e_D20221001-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="id33e4bb7f86d4f63bb3483974950eb21_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">exel:A2021AwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i053c349bf2894f5c9e19fc0cf85fe118_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesClinicalTrialResultsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i4a76d7c8a8dc41cfa3f976f8a86b8ac3_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ic5603f2e0fff4c849973ffaeafa13517_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i425a3fc9ca83455daa4acf0026125185_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="if2fc11d4d2754631a3733ccac92d04e3_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="ic4e6cc8bacaf4594895d5bbfc9c89791_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:NotProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i7f5be490ad62428386485550713032a7_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="ic95667d6b2e54d3fa5b025ecb0ffea4b_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i71c697b2f65940fa81b21b627eb077fb_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i56ed82a42994483c92b32ba299673685_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib28ac370d4ef4ca68b7bea32798fe004_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i124df26053054aa2bdf51a23778af8d1_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i4ca72b16cd354168a6373fa5107c1cb5_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i46d4a2a715724209a705ccaf6ae07793_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i787ca4c1857e40088e47d31bcee1d60b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>exel:product</measure>
    </unit>
    <unit id="country">
        <measure>exel:country</measure>
    </unit>
    <unit id="segment">
        <measure>exel:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="investment">
        <measure>exel:investment</measure>
    </unit>
    <unit id="bond">
        <measure>exel:bond</measure>
    </unit>
    <unit id="numberofsponsoredenterprise">
        <measure>exel:numberOfSponsoredEnterprise</measure>
    </unit>
    <unit id="derivative_instrument">
        <measure>exel:derivative_instrument</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="lawsuit">
        <measure>exel:lawsuit</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV80L2ZyYWc6YWRkZjY3N2E4MWJhNDFiY2I1Y2ExMDAyYjcwMjMxMmQvdGFibGU6N2NhMDU2YzBjNTBkNDliZGFjZmVmODBiYzY1ZjAzMjAvdGFibGVyYW5nZTo3Y2EwNTZjMGM1MGQ0OWJkYWNmZWY4MGJjNjVmMDMyMF8yLTEtMS0xLTkyMTUw_5610300f-162b-45d5-8814-2ef5b4ad3680">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV80L2ZyYWc6YWRkZjY3N2E4MWJhNDFiY2I1Y2ExMDAyYjcwMjMxMmQvdGFibGU6N2NhMDU2YzBjNTBkNDliZGFjZmVmODBiYzY1ZjAzMjAvdGFibGVyYW5nZTo3Y2EwNTZjMGM1MGQ0OWJkYWNmZWY4MGJjNjVmMDMyMF80LTEtMS0xLTkyMTUw_ddde23dc-65c1-4652-ae18-165675d43c5a">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV80L2ZyYWc6YWRkZjY3N2E4MWJhNDFiY2I1Y2ExMDAyYjcwMjMxMmQvdGFibGU6N2NhMDU2YzBjNTBkNDliZGFjZmVmODBiYzY1ZjAzMjAvdGFibGVyYW5nZTo3Y2EwNTZjMGM1MGQ0OWJkYWNmZWY4MGJjNjVmMDMyMF81LTEtMS0xLTkyMTUw_662a7c46-655e-4294-8449-dd1e3193937e">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV80L2ZyYWc6YWRkZjY3N2E4MWJhNDFiY2I1Y2ExMDAyYjcwMjMxMmQvdGFibGU6N2NhMDU2YzBjNTBkNDliZGFjZmVmODBiYzY1ZjAzMjAvdGFibGVyYW5nZTo3Y2EwNTZjMGM1MGQ0OWJkYWNmZWY4MGJjNjVmMDMyMF82LTEtMS0xLTkyMTUw_5eac582c-f8c5-4286-a7cf-04b49a8e2354">0000939767</dei:EntityCentralIndexKey>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMC0xLTEtOTIxNTA_96cbace8-4798-438d-bd6a-d3ce92ddad69">http://www.exelixis.com/20221230#OperatingLeaseRightOfUseAssetAndOtherAssets</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMC0xLTEtOTIxNTA_bf05f744-ae2c-4625-a413-f24a3f80b54d">http://www.exelixis.com/20221230#OperatingLeaseRightOfUseAssetAndOtherAssets</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMC0xLTEtOTIxNTA_3805e340-1810-45ae-9746-eaa8274e40f1">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMC0xLTEtOTIxNTA_4cf525be-b16c-489c-b6e4-ee90a9a764d7">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6NTE0YjVjOTFmMTdjNDA5MGFmN2VmNDMyZmY0YzEzYzMvdGFibGVyYW5nZTo1MTRiNWM5MWYxN2M0MDkwYWY3ZWY0MzJmZjRjMTNjM18wLTEtMS0xLTkyMTUw_c419ca7d-8ab4-4ece-8044-c324d9f8b716">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTY3_851ec150-92ec-4456-8130-27df67121c3a">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl81NDk3NTU4MTc5NTQ_a2895cf6-3d51-4ed0-a0b2-a8f3ac752678">2022-12-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl81NDk3NTU4MTc5NTQ_a794da58-d11b-401e-b69f-895b33aef7e2">--12-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTcy_c0014a1f-773a-4047-8c8e-a7f88b8946c4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zODU_4ecf8373-c73a-4056-bb4e-dedfd9982eae">000-30235</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6ZWI0ZWU4YzFiZTYyNDRkMzlmZTQ0MmUxYWE5MTE5MzEvdGFibGVyYW5nZTplYjRlZThjMWJlNjI0NGQzOWZlNDQyZTFhYTkxMTkzMV8xLTAtMS0xLTkyMTUw_6697713e-4e51-4d60-9001-c83fec2f9f4c">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6ZGUwMDMzYzIxY2ZiNDQ3OWJjZGIwYmQwYTY4NDY4NGQvdGFibGVyYW5nZTpkZTAwMzNjMjFjZmI0NDc5YmNkYjBiZDBhNjg0Njg0ZF8wLTAtMS0xLTkyMTUw_786653ca-5c1b-4324-9ab4-74e17c860288">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6ZGUwMDMzYzIxY2ZiNDQ3OWJjZGIwYmQwYTY4NDY4NGQvdGFibGVyYW5nZTpkZTAwMzNjMjFjZmI0NDc5YmNkYjBiZDBhNjg0Njg0ZF8wLTEtMS0xLTkyMTUw_fc0a92c2-3ba2-44a3-8b10-c04aaceda475">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTU_5b7a6974-d3d3-405d-acec-0fce47b76809">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTk_c51bf921-7571-45b0-9b53-6761d4abd301">Alameda,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl80MDI_68fd953c-6e93-4231-8b08-7cb5fc44ec3d">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl80MDU_b693fbb2-86b5-47a7-a2d2-fdca12064168">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl80MTA_6b0ebf6d-1994-424c-bf37-251e0180a201">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl80MTQ_0f10cfd9-3466-426d-9f5a-547cb7af8585">837-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6YzBmNDcxNDY3MzZjNDhhNjhmYzBiYjU5ZmMzMDcxZDkvdGFibGVyYW5nZTpjMGY0NzE0NjczNmM0OGE2OGZjMGJiNTlmYzMwNzFkOV8xLTAtMS0xLTkyMTUw_723f8982-f5bf-4e32-91af-7d2878c6fa9f">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6YzBmNDcxNDY3MzZjNDhhNjhmYzBiYjU5ZmMzMDcxZDkvdGFibGVyYW5nZTpjMGY0NzE0NjczNmM0OGE2OGZjMGJiNTlmYzMwNzFkOV8xLTEtMS0xLTkyMTUw_382f1f77-7263-4999-8695-7fe5b2c3d9fc">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6YzBmNDcxNDY3MzZjNDhhNjhmYzBiYjU5ZmMzMDcxZDkvdGFibGVyYW5nZTpjMGY0NzE0NjczNmM0OGE2OGZjMGJiNTlmYzMwNzFkOV8xLTItMS0xLTkyMTUw_bde82e10-9ff4-4b4a-aabb-711e3fc66edb">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTY4_1b2bdb6a-24fe-41bc-a78e-229692794403">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTY5_e6a2349b-ade3-4f87-8c7d-3eb80b4a9e18">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTcw_c9e0f615-4725-4ddd-a511-1f500d554a22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTcz_e18865cc-07e8-4028-8a2b-19968a1b6427">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6M2EwMmE1YTRlYzliNDA4OTg4NDIzZTg3MjI4NDRiMjkvdGFibGVyYW5nZTozYTAyYTVhNGVjOWI0MDg5ODg0MjNlODcyMjg0NGIyOV8wLTAtMS0xLTkyMTUw_34c545a5-0f9d-4068-bb0b-5d92ee5b1a94">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6M2EwMmE1YTRlYzliNDA4OTg4NDIzZTg3MjI4NDRiMjkvdGFibGVyYW5nZTozYTAyYTVhNGVjOWI0MDg5ODg0MjNlODcyMjg0NGIyOV8xLTQtMS0xLTkyMTUw_08116f63-d6ca-4a87-8e03-9a5db068c585">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGFibGU6M2EwMmE1YTRlYzliNDA4OTg4NDIzZTg3MjI4NDRiMjkvdGFibGVyYW5nZTozYTAyYTVhNGVjOWI0MDg5ODg0MjNlODcyMjg0NGIyOV8yLTQtMS0xLTkyMTUw_7365cbe4-5c02-441b-9514-89b5b1fe9ab5">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTc0_d613466c-0f81-4c1b-beb6-dc98bfc3abd3">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTc1_7910bf5f-466b-4849-9aad-05872a73e349">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ife95f2dac98345e09e30688f417dfefd_I20220701"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8yOTk5_7bff524c-d59e-4123-8e40-8e5a9c94457b"
      unitRef="usd">6831299691</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia7a2db918d5e4f25a57dfd066511af97_I20230130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zODQ4MjkwNzEyMTIw_e951e337-3b34-420a-a796-ff29b29c7b6b"
      unitRef="shares">324087337</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xL2ZyYWc6MjQ3ZDRiNWU4NmU2NDk4ZmI2YmY4MjliMjNmZWZiOGIvdGV4dHJlZ2lvbjoyNDdkNGI1ZTg2ZTY0OThmYjZiZjgyOWIyM2ZlZmI4Yl8zOTcx_f2dbae03-fee2-4d8c-8705-8c5fca8a4ebf">Certain portions of the registrant&#x2019;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than April 29, 2023, in connection with the registrant&#x2019;s 2023 Annual Meeting of Stockholders are incorporated herein by reference into Part III of this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV81OC9mcmFnOjM3MTNjMTE3MWE4ODRiM2NhYzBkYzJjNjg2ZWYzNTMzL3RhYmxlOjY5ZGNjMmNmMDU3YjQ5MmE5NGNiN2M3NTY0MDRjZjQ2L3RhYmxlcmFuZ2U6NjlkY2MyY2YwNTdiNDkyYTk0Y2I3Yzc1NjQwNGNmNDZfMS0wLTEtMS05MjE1MC90ZXh0cmVnaW9uOjEwNzA5MTkwNmEwNDQ2ZGFhNGYyMWJkOWVhNjM4YWZkXzcx_45146d0d-8f1b-4210-a2a1-a00f36f45f72">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82MS9mcmFnOjgwOWI2ZWIyNWVhMjRmOTQ4ZTE0MzA0YTg2N2I4YjcwL3RleHRyZWdpb246ODA5YjZlYjI1ZWEyNGY5NDhlMTQzMDRhODY3YjhiNzBfMzU2MQ_a8ab26c4-186a-4e62-98da-c559eb6fcdd5">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82MS9mcmFnOjgwOWI2ZWIyNWVhMjRmOTQ4ZTE0MzA0YTg2N2I4YjcwL3RleHRyZWdpb246ODA5YjZlYjI1ZWEyNGY5NDhlMTQzMDRhODY3YjhiNzBfMzU2Mg_40169825-1fbd-4710-9cc8-4bd65aa29a5d">San Mateo, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfNi0xLTEtMS05MjE1MA_de489bba-66b9-441a-9ac4-10e8e59e4648"
      unitRef="usd">501195000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfNi0zLTEtMS05MjE1MA_587c4d7e-fbd2-487a-b944-985da759a51c"
      unitRef="usd">647169000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfNy0xLTEtMS05MjE1MA_414e0bec-6970-49a8-839e-6c60141fe4a7"
      unitRef="usd">807273000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfNy0zLTEtMS05MjE1MA_f07f5e71-5d14-4299-986b-71d8558cd237"
      unitRef="usd">819905000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfOC0xLTEtMS05MjE1MA_92bb8135-0d4f-4e68-ae7c-732077e10871"
      unitRef="usd">214784000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfOC0zLTEtMS05MjE1MA_efc2c9aa-47a2-4323-a1a6-b6bf04d1df46"
      unitRef="usd">282650000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfOS0xLTEtMS05MjE1MA_f98e598e-e22c-4f55-9341-3311a9da546b"
      unitRef="usd">33299000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfOS0zLTEtMS05MjE1MA_985f0e37-2daf-4329-b4f8-0d5607cc08e1"
      unitRef="usd">27493000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTEtMS0xLTEtOTIxNTA_6f11fd40-776c-4e64-b455-b5c04f32e946"
      unitRef="usd">62211000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTEtMy0xLTEtOTIxNTA_dd4e0162-fbc8-4d46-9792-c75399baf522"
      unitRef="usd">57530000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTItMS0xLTEtOTIxNTA_97f3572f-8b31-4862-b343-21fb32c0d99c"
      unitRef="usd">1618762000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTItMy0xLTEtOTIxNTA_0906981f-29b5-40af-8772-f973c1928fa1"
      unitRef="usd">1834747000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTMtMS0xLTEtOTIxNTA_24023728-9c70-45ca-90bc-6f205e80cfc8"
      unitRef="usd">756731000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTMtMy0xLTEtOTIxNTA_3541aedf-6417-4fa7-9fca-62e8d3f97ee8"
      unitRef="usd">371112000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTQtMS0xLTEtOTIxNTA_bcae3203-d68a-445f-92b4-dd5ee954221b"
      unitRef="usd">110624000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTQtMy0xLTEtOTIxNTA_88a43b02-74a0-4865-b9ba-e78c0826010f"
      unitRef="usd">104031000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTUtMS0xLTEtOTIxNTA_c6abb1d1-479f-4b81-b66f-3087c591e08d"
      unitRef="usd">231110000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTUtMy0xLTEtOTIxNTA_caf971cb-6be6-48fc-aef0-c7d1abcff172"
      unitRef="usd">111663000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Goodwill
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTYtMS0xLTEtOTIxNTA_2bd12415-1f37-4b89-baa9-9fde6b54424b"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTYtMy0xLTEtOTIxNTA_ede15ed7-6d4c-495d-9c93-8b466bfca208"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <exel:OperatingLeaseRightOfUseAssetAndOtherAssets
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTctMS0xLTEtOTIxNTA_9b2b7cea-2601-4dcc-b6e4-274094c7e36a"
      unitRef="usd">290578000</exel:OperatingLeaseRightOfUseAssetAndOtherAssets>
    <exel:OperatingLeaseRightOfUseAssetAndOtherAssets
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTctMy0xLTEtOTIxNTA_6f896e11-4e83-4f31-945a-3eeaded7ba1a"
      unitRef="usd">131002000</exel:OperatingLeaseRightOfUseAssetAndOtherAssets>
    <us-gaap:Assets
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTgtMS0xLTEtOTIxNTA_19eb547c-f2d5-44a7-a2fd-cae9423dd5c9"
      unitRef="usd">3071489000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMTgtMy0xLTEtOTIxNTA_3cf415a9-95e9-4aae-8168-6f0c1f2667d7"
      unitRef="usd">2616239000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjEtMS0xLTEtOTIxNTA_3a8021a7-76e0-490c-8f80-65c2f819b5fb"
      unitRef="usd">32667000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjEtMy0xLTEtOTIxNTA_fe6394c6-5666-439d-a062-2a1b0b6d673e"
      unitRef="usd">24258000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjItMS0xLTEtOTIxNTA_7ae3b00e-d6cc-4869-aeae-825017957ddc"
      unitRef="usd">77158000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjItMy0xLTEtOTIxNTA_532b7f49-873e-4213-9374-3ffc3159b683"
      unitRef="usd">61969000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjMtMS0xLTEtOTIxNTA_9f180c66-68d5-4380-8860-271ed1f13ce2"
      unitRef="usd">65072000</exel:AccruedClinicalLiabilitiesCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjMtMy0xLTEtOTIxNTA_13b1638a-424f-4ad3-8afc-c168c7f7eaa3"
      unitRef="usd">77544000</exel:AccruedClinicalLiabilitiesCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjQtMS0xLTEtOTIxNTA_09d9a23b-f420-403d-b833-71722f6d2112"
      unitRef="usd">50350000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjQtMy0xLTEtOTIxNTA_4117aab4-4195-4be1-9f7f-21e297ef7db2"
      unitRef="usd">33700000</us-gaap:CustomerRefundLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjUtMS0xLTEtOTIxNTA_364054fe-d858-4b18-b2fc-bceb9f7659b7"
      unitRef="usd">20188000</exel:AccruedCollaborationLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjUtMy0xLTEtOTIxNTA_69936fa3-29c3-4785-8659-70ae6481fde7"
      unitRef="usd">86753000</exel:AccruedCollaborationLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjctMS0xLTEtOTIxNTA_5d474c39-6a1c-498a-a463-45eac2eb611f"
      unitRef="usd">78924000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjctMy0xLTEtOTIxNTA_110c9a0e-52a7-4463-a74b-1b07f0d7b306"
      unitRef="usd">53366000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjgtMS0xLTEtOTIxNTA_a1beae50-a9f8-42ee-a5b2-6fc024866e39"
      unitRef="usd">324359000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjgtMy0xLTEtOTIxNTA_5aa1fdf7-d25d-47c7-95d1-38d7e30ab698"
      unitRef="usd">337590000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjktMS0xLTEtOTIxNTA_9c2f20ec-646a-451a-8b95-cebeb37fe2ae"
      unitRef="usd">6582000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMjktMy0xLTEtOTIxNTA_e8bc5746-ac60-4cc3-a90a-a0027aa1a533"
      unitRef="usd">8739000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzAtMS0xLTEtOTIxNTA_a09b7e62-12c4-49e3-87b5-3edad068aace"
      unitRef="usd">190170000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzAtMy0xLTEtOTIxNTA_99043ca9-b284-4903-b857-f6a3fb638a61"
      unitRef="usd">51272000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzEtMS0xLTEtOTIxNTA_3d4de216-e93a-468d-8def-72fdd1058159"
      unitRef="usd">61951000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzEtMy0xLTEtOTIxNTA_87656948-d905-453a-870d-7b401cc0dd44"
      unitRef="usd">8023000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzItMS0xLTEtOTIxNTA_96b50435-52c6-4c84-a546-81b6648f4aab"
      unitRef="usd">583062000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzItMy0xLTEtOTIxNTA_2464e006-b891-44dc-baa7-5d3fe1e296fb"
      unitRef="usd">405624000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzMtMS0xLTEtOTIxNTA_61757a1a-b661-4257-a1c7-3a9413e73b2b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzMtMy0xLTEtOTIxNTA_579e277c-ed1f-4380-be13-2b006f66af2c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzUtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjo1ZTcxMGZkMzFkYjc0OWJmYTFjYmEyNjFlZjk3NzAyMV8yMQ_1fdf5b4f-e5d9-4fd3-a0ca-73912c3da27f"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzUtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjo1ZTcxMGZkMzFkYjc0OWJmYTFjYmEyNjFlZjk3NzAyMV8yMQ_53c48b67-11af-4f59-b2ae-960536f815bf"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzUtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjo1ZTcxMGZkMzFkYjc0OWJmYTFjYmEyNjFlZjk3NzAyMV8zNQ_1679e573-670e-4ddd-8a11-e1b4c3f18c25"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzUtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjo1ZTcxMGZkMzFkYjc0OWJmYTFjYmEyNjFlZjk3NzAyMV8zNQ_ffdeb3bd-bdfb-478b-bc25-db784857f4a0"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzUtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjo1ZTcxMGZkMzFkYjc0OWJmYTFjYmEyNjFlZjk3NzAyMV82MA_3fc1072f-2837-4019-9c42-6347c865d5a2"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzUtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjo1ZTcxMGZkMzFkYjc0OWJmYTFjYmEyNjFlZjk3NzAyMV82MA_b9d93b62-caaf-4f24-9580-a7a0870f1101"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzUtMS0xLTEtOTIxNTA_ce0cec22-91c1-437f-a50c-2d808bb35ca1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzUtMy0xLTEtOTIxNTA_f7beb331-ed16-4b49-9d62-e5c804c299dd"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjoxMjA0ODIwZTUwZjI0MGJkYTc4ZmQzNzYxNjQ1NzVjYl8xOQ_7a147536-e9c1-4ab4-98f6-cfcbf033c335"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjoxMjA0ODIwZTUwZjI0MGJkYTc4ZmQzNzYxNjQ1NzVjYl8xOQ_8b8261b1-0504-454e-a807-8dae2fb19925"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjoxMjA0ODIwZTUwZjI0MGJkYTc4ZmQzNzYxNjQ1NzVjYl8zMw_557e462a-f1fe-4980-a8a4-38622065a267"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjoxMjA0ODIwZTUwZjI0MGJkYTc4ZmQzNzYxNjQ1NzVjYl8zMw_88582294-ca17-4f56-badb-5192a94b84a7"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjoxMjA0ODIwZTUwZjI0MGJkYTc4ZmQzNzYxNjQ1NzVjYl83OQ_13431a48-e0d1-4ba6-8ebd-b2fdba9be592"
      unitRef="shares">323951000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjoxMjA0ODIwZTUwZjI0MGJkYTc4ZmQzNzYxNjQ1NzVjYl83OQ_6d7eea78-4d79-4617-8905-a3efdeaad379"
      unitRef="shares">323951000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjoxMjA0ODIwZTUwZjI0MGJkYTc4ZmQzNzYxNjQ1NzVjYl84Ng_2c0c3361-cb5c-40ae-965d-47398c39c8f3"
      unitRef="shares">318842000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMC0xLTEtOTIxNTAvdGV4dHJlZ2lvbjoxMjA0ODIwZTUwZjI0MGJkYTc4ZmQzNzYxNjQ1NzVjYl84Ng_aaca37e0-c730-488a-bb15-ef147cf9607f"
      unitRef="shares">318842000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMS0xLTEtOTIxNTA_f701c861-da34-41be-9acf-cc9623ac5501"
      unitRef="usd">324000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzYtMy0xLTEtOTIxNTA_18e2fb6f-6883-4951-bbae-a3b7f87851d3"
      unitRef="usd">319000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzctMS0xLTEtOTIxNTA_b11db80e-e234-4904-8a8a-2ee567ab88f5"
      unitRef="usd">2536849000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzctMy0xLTEtOTIxNTA_4ced9110-bbe8-4407-b410-eec75382cac8"
      unitRef="usd">2427561000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzgtMS0xLTEtOTIxNTA_e17ed8a7-7684-40e4-aa94-1d921165801c"
      unitRef="usd">-14521000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzgtMy0xLTEtOTIxNTA_245eab50-9ce8-4151-8667-59ea0e3347d9"
      unitRef="usd">-758000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzktMS0xLTEtOTIxNTA_1a97d5b8-3c66-4a42-a4a9-578c984f866d"
      unitRef="usd">-34225000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfMzktMy0xLTEtOTIxNTA_d57eaf6e-5ae7-43f3-b29f-58d1be163ac0"
      unitRef="usd">-216507000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfNDAtMS0xLTEtOTIxNTA_c64bb8d5-a608-4535-aa21-5551c7f79a67"
      unitRef="usd">2488427000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfNDAtMy0xLTEtOTIxNTA_4612842b-4505-4d40-93bf-1c68e39ed7be"
      unitRef="usd">2210615000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfNDEtMS0xLTEtOTIxNTA_48fa3f64-f240-4672-ab4a-eb36fa091184"
      unitRef="usd">3071489000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82NC9mcmFnOmU0N2ZjYTQ4Y2UwMzRkNjFiYTdiZmFjZWE5ZmE5N2MyL3RhYmxlOjhiYjRjOWU3ODVlOTQzY2U5MWUwYTIxNjY5MGU5OGI4L3RhYmxlcmFuZ2U6OGJiNGM5ZTc4NWU5NDNjZTkxZTBhMjE2NjkwZTk4YjhfNDEtMy0xLTEtOTIxNTA_c37ba9a7-8447-41de-8af3-a0118982e987"
      unitRef="usd">2616239000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd975ad7811c4bdbb2315643b04037a2_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMy01LTEtMS05MjE1MA_b0fff0b2-6827-4b0e-a5b7-0ecb1ca80275"
      unitRef="usd">1401243000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2e996a9f240456487cb91fc0c52e1a1_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMy03LTEtMS05MjE1MA_51483abd-0522-4fa1-82ee-8e3bf9f43240"
      unitRef="usd">1077256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d55e02ba3ae4c8999e690629fe6d584_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMy05LTEtMS05MjE1MA_3f3b1cf2-381d-4490-a129-7e72684a1a66"
      unitRef="usd">741550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9ff1b0e91924c73b4c456c2235ab6cf_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNC01LTEtMS05MjE1MA_2a9e8891-458f-45bb-8bb1-09d17532eb16"
      unitRef="usd">162056000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47a0764d353e4fb3a7ec06de9aca7c16_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNC03LTEtMS05MjE1MA_73cc83fd-670e-4d24-8fde-02acdacabe91"
      unitRef="usd">249956000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8380d5f4f944a18a412a44050718011_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNC05LTEtMS05MjE1MA_4c068302-0f03-47f8-944b-fe681764d452"
      unitRef="usd">167295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i968c32c71952402cb10bdb7c8f5f4c8e_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNS01LTEtMS05MjE1MA_8df2e5ed-4152-448c-9a0c-08ea4cee77b0"
      unitRef="usd">47763000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad8294bfd197493791fd98694c5266f2_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNS03LTEtMS05MjE1MA_e4ebda26-4825-41b0-96b8-a07ae06fc91c"
      unitRef="usd">107758000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i663037ccb1ec482e8ebc1bbf359c95b4_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNS05LTEtMS05MjE1MA_edfab126-5009-4903-86c0-ef2cd261cdf5"
      unitRef="usd">78693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNi01LTEtMS05MjE1MA_00302604-80ee-421e-9ab4-3356b1761424"
      unitRef="usd">1611062000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNi03LTEtMS05MjE1MA_5e8ff85e-d223-448b-b5a1-49ebd1cab5bc"
      unitRef="usd">1434970000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfNi05LTEtMS05MjE1MA_c7169fdc-ce48-4ba6-a673-d9a7e5b11ce4"
      unitRef="usd">987538000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfOC01LTEtMS05MjE1MA_c96461ec-7ade-49ac-b960-0c4d3ba694c0"
      unitRef="usd">57909000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfOC03LTEtMS05MjE1MA_6cb9e5b3-fe45-4ad4-ae39-213dc9ee3468"
      unitRef="usd">52873000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfOC05LTEtMS05MjE1MA_84ec8947-6d3c-4817-bf37-5d343430e5e9"
      unitRef="usd">36272000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfOS01LTEtMS05MjE1MA_22f310bd-84b0-4f86-a73e-5365b4d6a97e"
      unitRef="usd">891813000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfOS03LTEtMS05MjE1MA_73eb8c6d-2970-47fd-95fb-5b0bf5144902"
      unitRef="usd">693716000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfOS05LTEtMS05MjE1MA_60d51bb4-25a2-4e3f-8955-bcd6b5978db5"
      unitRef="usd">547851000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTAtNS0xLTEtOTIxNTA_103f5945-e9d7-4bda-93bf-6801202764c7"
      unitRef="usd">459856000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTAtNy0xLTEtOTIxNTA_24dbd1df-ff34-4a59-b80d-beb37682195d"
      unitRef="usd">401715000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTAtOS0xLTEtOTIxNTA_864ced3d-9f7c-4b5d-9324-76dcabe5fedf"
      unitRef="usd">293355000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTEtNS0xLTEtOTIxNTA_81151702-8f69-4c86-9a6d-067b639dd070"
      unitRef="usd">1409578000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTEtNy0xLTEtOTIxNTA_213cf0b1-b9a1-4eb1-a099-cdd427a8ce7b"
      unitRef="usd">1148304000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTEtOS0xLTEtOTIxNTA_7d295a45-fc6b-4e49-8e59-85b8065fc0f7"
      unitRef="usd">877478000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTItNS0xLTEtOTIxNTA_e6b1998d-4930-4642-bba1-b3cb17b28116"
      unitRef="usd">201484000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTItNy0xLTEtOTIxNTA_b6737a80-6634-4349-a428-90f926237d9c"
      unitRef="usd">286666000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTItOS0xLTEtOTIxNTA_e7fe72e5-a083-446e-b4af-914ebc6b73ca"
      unitRef="usd">110060000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTMtNS0xLTEtOTIxNTA_48b00b52-03da-4f5f-91bb-f28a7fb3fef0"
      unitRef="usd">33065000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTMtNy0xLTEtOTIxNTA_5c929fc0-2bc0-4bf2-8ded-e867c4fc7f8a"
      unitRef="usd">7672000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTMtOS0xLTEtOTIxNTA_6055e91d-8e87-40ee-a092-c14b14ba5328"
      unitRef="usd">19865000</us-gaap:InterestIncomeOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTQtNS0xLTEtOTIxNTA_d775cae3-6909-4a2f-b05f-d4d9cf1de443"
      unitRef="usd">-197000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTQtNy0xLTEtOTIxNTA_7d2a01d1-b541-49f4-a02e-cd9d6f485e3b"
      unitRef="usd">-184000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTQtOS0xLTEtOTIxNTA_ac531f2a-f46a-4ae1-a7f7-e22a568bc7b4"
      unitRef="usd">912000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTUtNS0xLTEtOTIxNTA_a0b1284c-1675-419f-8131-53f4989cfbe1"
      unitRef="usd">234352000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTUtNy0xLTEtOTIxNTA_d16daec4-3705-4b17-9765-cc128972d0fc"
      unitRef="usd">294154000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTUtOS0xLTEtOTIxNTA_69c3febe-15ea-4525-a990-2b251b9d63cc"
      unitRef="usd">130837000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTYtNS0xLTEtOTIxNTA_28eb00ab-4bc1-44b7-9cf9-0de28e11991c"
      unitRef="usd">52070000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTYtNy0xLTEtOTIxNTA_077f1940-d71b-43fc-8d46-5ac600651824"
      unitRef="usd">63091000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTYtOS0xLTEtOTIxNTA_5c003af4-6ff3-4b02-88f1-fce3701e6475"
      unitRef="usd">19056000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTctNS0xLTEtOTIxNTA_3b15d400-bb92-4d7a-a032-e180ba3a0d41"
      unitRef="usd">182282000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTctNy0xLTEtOTIxNTA_eeb404a6-c5bd-42c9-9d01-e55e48a8fa12"
      unitRef="usd">231063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTctOS0xLTEtOTIxNTA_5db11cc8-9908-4324-abe8-1a5234e2031d"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTktNS0xLTEtOTIxNTA_e7576046-de8c-4e4b-8f1a-a2a5e8fbf66c"
      unitRef="usdPerShare">0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTktNy0xLTEtOTIxNTA_71c71f80-68d4-443f-91bf-679335779fe1"
      unitRef="usdPerShare">0.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMTktOS0xLTEtOTIxNTA_c9a9ab81-b73b-438b-a8cd-3436aef265cf"
      unitRef="usdPerShare">0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjAtNS0xLTEtOTIxNTA_49356d69-ed32-4c36-8acb-b820d315faf2"
      unitRef="usdPerShare">0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjAtNy0xLTEtOTIxNTA_e7e357d4-2b70-412a-af6d-d75deaa70b8f"
      unitRef="usdPerShare">0.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjAtOS0xLTEtOTIxNTA_ad90da54-0329-4889-98f6-3a65995bf613"
      unitRef="usdPerShare">0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjItNS0xLTEtOTIxNTA_0e1dd32b-3a4a-4496-a5b4-d980f96a2213"
      unitRef="shares">321526000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjItNy0xLTEtOTIxNTA_6a626d3b-14f8-4338-ab54-35df5b40ddbe"
      unitRef="shares">314884000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjItOS0xLTEtOTIxNTA_f8910795-c30a-4ec4-ae9d-81d50eb9a1e4"
      unitRef="shares">308271000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjMtNS0xLTEtOTIxNTA_809c5718-643a-4215-aa20-ff06e0828545"
      unitRef="shares">324556000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjMtNy0xLTEtOTIxNTA_f92a657a-84e5-4482-85d8-1408afe7dacb"
      unitRef="shares">322359000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV82Ny9mcmFnOjQ0YzkzNzljNjQzZjQ0NDdhMDg5OGMyNjJmNmZhMjFhL3RhYmxlOmUyNGQyNjdmNWM5NjRkNWY4NzY4YzgzYTA2YjY1Yjc4L3RhYmxlcmFuZ2U6ZTI0ZDI2N2Y1Yzk2NGQ1Zjg3NjhjODNhMDZiNjViNzhfMjMtOS0xLTEtOTIxNTA_220c5542-0292-43aa-adfa-1c5cab6bf597"
      unitRef="shares">318001000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfMi01LTEtMS05MjE1MA_3b15d400-bb92-4d7a-a032-e180ba3a0d41"
      unitRef="usd">182282000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfMi03LTEtMS05MjE1MA_eeb404a6-c5bd-42c9-9d01-e55e48a8fa12"
      unitRef="usd">231063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfMi05LTEtMS05MjE1MA_5db11cc8-9908-4324-abe8-1a5234e2031d"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNC0wLTEtMS05MjE1MC90ZXh0cmVnaW9uOjIxYjAxNmZiYTkxMDQwZGE5NTc4NWZmNDAyZjZlMDhjXzk1_b46b9e4e-47b9-4558-9875-f41855c7f04d"
      unitRef="usd">3886000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNC0wLTEtMS05MjE1MC90ZXh0cmVnaW9uOjIxYjAxNmZiYTkxMDQwZGE5NTc4NWZmNDAyZjZlMDhjXzk5_9accd112-d7d7-4f76-aece-f5cb96f70173"
      unitRef="usd">1481000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNC0wLTEtMS05MjE1MC90ZXh0cmVnaW9uOjIxYjAxNmZiYTkxMDQwZGE5NTc4NWZmNDAyZjZlMDhjXzEwNw_cb9b710d-b349-4fb0-9b43-192177c1a8f2"
      unitRef="usd">-394000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNC01LTEtMS05MjE1MA_44cf54a0-a827-4acc-9638-36a4bc31f5e3"
      unitRef="usd">-13763000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNC03LTEtMS05MjE1MA_d6532486-69ce-4eed-acd0-87437df0cf08"
      unitRef="usd">-5234000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNC05LTEtMS05MjE1MA_781983b1-b93b-47d0-bd43-3580e60405c4"
      unitRef="usd">1407000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNi01LTEtMS05MjE1MA_6189d028-8e32-4173-8349-25c2c46393cc"
      unitRef="usd">168519000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNi03LTEtMS05MjE1MA_88b6d368-3b29-461a-8e67-464cdf4895e7"
      unitRef="usd">225829000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83MC9mcmFnOmVkNjE5NGQ1MWUxODQwYzJiN2E1NGU4YTliOWJlNjhhL3RhYmxlOjBmZTU1ZjE3MTliZjQ0YmQ4ZWJmNzY4MDNlODIyMTUxL3RhYmxlcmFuZ2U6MGZlNTVmMTcxOWJmNDRiZDhlYmY3NjgwM2U4MjIxNTFfNi05LTEtMS05MjE1MA_1808cf58-2382-46b4-bf50-1a0806ca9569"
      unitRef="usd">113188000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iee90ac3decac457ea10ccb1f57c3be9f_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMjgtMS0xLTEtOTIxNTA_457e02b0-eba4-4843-b532-4c47b2b273a3"
      unitRef="shares">304831000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iee90ac3decac457ea10ccb1f57c3be9f_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMjgtMy0xLTEtOTIxNTA_d78bcb52-4fe4-4618-97c8-9ba371e968ab"
      unitRef="usd">305000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i316600a670354ae9bed12cb08f90fbad_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMjgtNS0xLTEtOTIxNTA_a4895d74-359e-420b-9d6a-150659a65eaa"
      unitRef="usd">2241947000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d397c56f7c747a1b4c4ee65c9dca93f_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMjgtNy0xLTEtOTIxNTA_11ff366c-959b-4386-a853-67361224bbd3"
      unitRef="usd">3069000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ied0a8550944e400eb840fecf7a697f8a_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMjgtOS0xLTEtOTIxNTA_ae6648fd-e78b-4342-b635-b517a5b1eaf6"
      unitRef="usd">-559351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a3670052766460e8f6681bfb2fe46da_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMjgtMTEtMS0xLTkyMTUw_57b13d95-e052-4879-99ac-8620e9fb916c"
      unitRef="usd">1685970000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie7bb9a335486433c81f3f5733d3aaad8_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMjktOS0xLTEtOTIxNTA_5fbf0abf-02bc-4ddb-b0b7-38d842aff8b4"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMjktMTEtMS0xLTkyMTUw_ea6d64d9-e7ef-4ffc-a872-10a9f4c3e901"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i36ea7ff7478a47f29ac8ddc870f601a1_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzAtNy0xLTEtOTIxNTA_2102e4c2-2b43-430e-8b7a-3200f8c2e870"
      unitRef="usd">1407000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzAtMTEtMS0xLTkyMTUw_145bfbe4-955b-46e5-8ab0-3dbedf1cf243"
      unitRef="usd">1407000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic0deb65d8e8541f4befd56d486e027aa_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzEtMS0xLTEtOTIxNTA_c105ce1f-a9f8-4e86-8e8e-760495556341"
      unitRef="shares">6796000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic0deb65d8e8541f4befd56d486e027aa_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzEtMy0xLTEtOTIxNTA_3c83c030-6b74-4572-9ed6-dda9bbf0d0a3"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iac71ca2b42784a9596529526d80870fe_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzEtNS0xLTEtOTIxNTA_b1a78749-7f3c-4b60-a0d3-023599b04c0e"
      unitRef="usd">24896000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzEtMTEtMS0xLTkyMTUw_88c05cf0-3d82-4c3e-87bd-8c8f2eadae05"
      unitRef="usd">24903000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iac71ca2b42784a9596529526d80870fe_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzItNS0xLTEtOTIxNTA_e9c198be-08dc-4c60-9b85-57987982440c"
      unitRef="usd">50018000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzItMTEtMS0xLTkyMTUw_7d6e8e7a-e2b3-4e60-833b-04e1f1425bad"
      unitRef="usd">50018000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iac71ca2b42784a9596529526d80870fe_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzMtNS0xLTEtOTIxNTA_6688f41e-85eb-4bec-bf0f-9333295e4923"
      unitRef="usd">105070000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzMtMTEtMS0xLTkyMTUw_04c902c3-3250-498e-923b-70893eab1db3"
      unitRef="usd">105070000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8b022f123e124eebacb65e193a7ca348_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzQtMS0xLTEtOTIxNTA_388d1ac0-85e2-4276-a25b-983179597a14"
      unitRef="shares">311627000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8b022f123e124eebacb65e193a7ca348_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzQtMy0xLTEtOTIxNTA_f8ec19bf-4dc2-4740-bea1-5eaab70fc900"
      unitRef="usd">312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i30d6ea6119494ce99990ec9f421bf661_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzQtNS0xLTEtOTIxNTA_5957fdbc-e778-4aba-9bc5-111b9dff8fc4"
      unitRef="usd">2321895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6b916a4ad0de4c3ea7891d04e8a0e888_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzQtNy0xLTEtOTIxNTA_cbab74b9-9afa-45ee-8eb9-fef2b96890fb"
      unitRef="usd">4476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibf9048c142784771b43942a372d1013d_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzQtOS0xLTEtOTIxNTA_6b95c66a-eadc-4a92-91f6-324ea50ef3ba"
      unitRef="usd">-447570000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0958ab0a7b904c6abbc804e49a0e9544_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzQtMTEtMS0xLTkyMTUw_69a89f1d-6759-4d72-bf4c-96baf1c82376"
      unitRef="usd">1879113000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i2f9dad1068314e4a821e9fa7b5dfc712_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzUtOS0xLTEtOTMyMzE_be7cd87e-34c8-4e4b-8d13-0a1b43d71bd4"
      unitRef="usd">231063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzUtMTEtMS0xLTkyMTUw_7ec89d08-16e7-4f22-b8ff-d8e245b7126f"
      unitRef="usd">231063000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic1d8b28295254e3c9d72be053782f1f6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzYtNy0xLTEtOTMyMzE_d0dae71e-ff97-4069-9d8d-d077083250ad"
      unitRef="usd">-5234000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzYtMTEtMS0xLTkyMTUw_6b180bc3-1221-4c53-b693-78fef33beb2f"
      unitRef="usd">-5234000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="idfd5463291344fadbad875183adfc559_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzctMS0xLTEtOTMyMzE_371e26f3-af34-4420-a093-5175add95be5"
      unitRef="shares">7215000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idfd5463291344fadbad875183adfc559_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzctMy0xLTEtOTMyMzE_86e7079e-4124-45a5-a8a8-a49c7ac91106"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i61bccae84739493aa433b75b3289741b_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzctNS0xLTEtOTMyMzE_3946013b-38f1-4d27-bf8d-b01c2fa952d8"
      unitRef="usd">24360000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzctMTEtMS0xLTkyMTUw_07133055-7422-48bc-ba0a-00cab6b2ef45"
      unitRef="usd">24367000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i61bccae84739493aa433b75b3289741b_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzgtNS0xLTEtOTMyMzE_37cef9bd-52f6-43e2-a100-11c61ecd58e7"
      unitRef="usd">39142000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzgtMTEtMS0xLTkyMTUw_3a921ddf-71cc-42d5-812c-307c6154d385"
      unitRef="usd">39142000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i61bccae84739493aa433b75b3289741b_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzktNS0xLTEtOTMyMzE_dd3ae9c5-1945-43f8-a08c-e77dd3272e90"
      unitRef="usd">120448000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfMzktMTEtMS0xLTkyMTUw_bbf359dd-cbf2-476c-8c76-18203e847ba5"
      unitRef="usd">120448000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8ebcf341e8d14a8d8af6c5f7a8d997dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDAtMS0xLTEtOTIxNTA_d3750c15-e1e5-4fa3-b10f-e1ce21544120"
      unitRef="shares">318842000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8ebcf341e8d14a8d8af6c5f7a8d997dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDAtMy0xLTEtOTIxNTA_089ddf7f-b2c3-4e03-9dc5-1e96c352207d"
      unitRef="usd">319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0d4b232e8fca4e8d9de8920ba88d1665_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDAtNS0xLTEtOTIxNTA_f55c5471-5c16-4ae1-b50f-e5af032836b1"
      unitRef="usd">2427561000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i86a7ae9225ca4247aa92ff18efbb1e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDAtNy0xLTEtOTIxNTA_8f382b8c-8734-4b3d-adf2-61a2dff9d292"
      unitRef="usd">-758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic180e4d772ed46dc825b7445c7893c6a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDAtOS0xLTEtOTIxNTA_79c76d95-cae0-4302-b203-1339707a5cb2"
      unitRef="usd">-216507000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDAtMTEtMS0xLTkyMTUw_5065f869-a55f-4a7e-b900-8d8f09fff997"
      unitRef="usd">2210615000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i2d92019d1cca43aebdc002637f9a8e0a_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDEtOS0xLTEtOTMyMzI_c3400c0f-fbeb-4247-ad5b-2c18bca5bcf4"
      unitRef="usd">182282000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDEtMTEtMS0xLTkzMjMy_b57e3928-39dc-4b08-a5da-6eb3bed10cdf"
      unitRef="usd">182282000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia138b200885a4b769244acdf9eeab22d_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDItNy0xLTEtOTMyMzI_00be67b3-e1e9-44a8-b4a4-fe0d691f48fe"
      unitRef="usd">-13763000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDItMTEtMS0xLTkzMjMy_3c1f1407-6df7-49ff-8212-4bce51f74bc7"
      unitRef="usd">-13763000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ibd740e63081e4029889559bc739aee7d_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDMtMS0xLTEtOTMyMzI_d53e3c37-7bf2-4fa7-8e3b-e4ef5bb65498"
      unitRef="shares">5109000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibd740e63081e4029889559bc739aee7d_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDMtMy0xLTEtOTMyMzI_fc5fde2f-9898-4e31-bf9a-e855b10b8836"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i564bbd54548d41f68982fea9945c6519_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDMtNS0xLTEtOTMyMzI_6f19ccbd-4482-4e0b-afa8-088a5f934501"
      unitRef="usd">23976000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDMtMTEtMS0xLTkzMjMy_45b2b61a-afb7-4f1f-b56a-15f1870100c3"
      unitRef="usd">23981000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i564bbd54548d41f68982fea9945c6519_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDQtNS0xLTEtOTMyMzI_053de087-5c82-44c8-a77a-83a084c47f35"
      unitRef="usd">23344000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDQtMTEtMS0xLTkzMjMy_bb7d6cb6-0d68-4a73-8063-a76c396954c6"
      unitRef="usd">23344000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i564bbd54548d41f68982fea9945c6519_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDUtNS0xLTEtOTMyMzI_2a884296-8160-4eb6-89fa-0c03dfeb6f2a"
      unitRef="usd">108656000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDUtMTEtMS0xLTkzMjMy_13a206b0-e244-44c7-83c2-af7bb90148d9"
      unitRef="usd">108656000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic6372aa2efa047d3814f185d55ca1da9_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDYtMS0xLTEtOTMyMzI_cf9132ed-7b09-4688-acd9-6e6430357f62"
      unitRef="shares">323951000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic6372aa2efa047d3814f185d55ca1da9_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDYtMy0xLTEtOTMyMzI_2b4ea112-4cec-4caa-bbdb-3699dbb5922f"
      unitRef="usd">324000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ae29c61f4c04cdda5f6e25561c082eb_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDYtNS0xLTEtOTMyMzI_1f29d4c8-203e-4858-888f-a02ae284c3c3"
      unitRef="usd">2536849000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7de5204d64db4e1094ecd5b8bfca36d1_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDYtNy0xLTEtOTMyMzI_d67dd596-089c-48a6-9567-9010410db8bd"
      unitRef="usd">-14521000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i28cc46cb8b1541b3b1c30a1b510db95d_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDYtOS0xLTEtOTMyMzI_519ddf36-30dd-4efb-81ed-a6837d777bd7"
      unitRef="usd">-34225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83My9mcmFnOjQ5NDk1YTQ5YmVmYTQ5MjRiMDI5NzY2NDc2ODU3ZWNmL3RhYmxlOjk1M2Q2OTcxMzY0ZTQ5ZmNiNWI2MzVkYTQwNGIxNDM1L3RhYmxlcmFuZ2U6OTUzZDY5NzEzNjRlNDlmY2I1YjYzNWRhNDA0YjE0MzVfNDYtMTEtMS0xLTkzMjMy_d904ebd5-1f14-4b98-bbcd-145051d1ebd5"
      unitRef="usd">2488427000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMi0xLTEtMS05MjE1MA_3b15d400-bb92-4d7a-a032-e180ba3a0d41"
      unitRef="usd">182282000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMi0zLTEtMS05MjE1MA_eeb404a6-c5bd-42c9-9d01-e55e48a8fa12"
      unitRef="usd">231063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMi01LTEtMS05MjE1MA_5db11cc8-9908-4324-abe8-1a5234e2031d"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNC0xLTEtMS05NTc0MA_70466358-dc2b-40df-a85b-2c9966c5a8cc"
      unitRef="usd">20875000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNC0zLTEtMS05MzQ4NA_c59a44eb-64f5-4090-add1-7e671f19f296"
      unitRef="usd">13630000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNC01LTEtMS05MzUwNQ_76337c8c-5687-4510-93ed-c451369336f7"
      unitRef="usd">9141000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNS0xLTEtMS05NTc0MA_2768f6c7-812e-4796-a1d6-3b04594e72e3"
      unitRef="usd">107574000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNS0zLTEtMS05MzQ4NA_f793861e-f2fd-4f96-92a1-a9afb6d65c5a"
      unitRef="usd">119820000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNS01LTEtMS05MzUwNQ_d06d0f6c-d35e-4e5a-b1be-806b68faaa5f"
      unitRef="usd">105070000</us-gaap:ShareBasedCompensation>
    <exel:NoncashLeaseExpense
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNi0xLTEtMS05NTc0MA_4565403c-2d7e-4647-8e12-62ccd1235a82"
      unitRef="usd">18315000</exel:NoncashLeaseExpense>
    <exel:NoncashLeaseExpense
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNi0zLTEtMS05MzQ4NA_b77b3de0-898a-4c57-a7b0-22ec9afe2ddb"
      unitRef="usd">5332000</exel:NoncashLeaseExpense>
    <exel:NoncashLeaseExpense
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNi01LTEtMS05MzUwNQ_47712ab0-cbdf-4f7a-b8dc-dbab5caa0c73"
      unitRef="usd">4830000</exel:NoncashLeaseExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNy0xLTEtMS05NTc0MA_5d271120-d61f-44e7-a913-0b0e23c485e3"
      unitRef="usd">60358000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNy0zLTEtMS05MzQ4NA_3cad82ce-3ebb-461b-8d3d-131fc564b6d8"
      unitRef="usd">-46529000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNy01LTEtMS05MzUxMg_432199aa-ebd5-4fac-b5a2-1046f7fb0961"
      unitRef="usd">-15265000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfOC0xLTEtMS0xMDUzNjY_02722db2-07b2-441a-888d-977a890cb19c"
      unitRef="usd">107250000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfOC0zLTEtMS0xMDUzODM_cafe59a7-098e-4e4f-8ca0-f3eae845b6b1"
      unitRef="usd">14000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfOC01LTEtMS0xMDUzNzU_037578d8-fa92-4a08-b93a-6fe8c289bd11"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfOC0xLTEtMS05NTc0MA_565a0176-0a92-460f-ba84-6d01ac97a3e1"
      unitRef="usd">525000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfOC0zLTEtMS05MzQ4NA_cb56958f-333e-46d7-b4b3-c8f1ac8d05a3"
      unitRef="usd">-9443000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfOC01LTEtMS05MzUxOQ_a237350d-85a0-4596-8e7f-bcced950d870"
      unitRef="usd">-3035000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTAtMS0xLTEtOTU3NDA_c6761d38-d661-4e0b-8725-7d72ac83ce07"
      unitRef="usd">-66849000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTAtMy0xLTEtOTM0ODQ_9795d0cb-d342-4d29-b058-f6bf9fec8c94"
      unitRef="usd">122324000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTAtNS0xLTEtOTM1NzI_ae15e468-d2f9-40b0-8128-19168f93caa3"
      unitRef="usd">42470000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTEtMS0xLTEtOTU3NDA_997bb69b-14b1-4e52-9aec-9b40489ef4d9"
      unitRef="usd">11683000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTEtMy0xLTEtOTM0ODQ_8995dcf4-9ec2-4f57-8971-688f60aaeb19"
      unitRef="usd">13209000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTEtNS0xLTEtOTM1Nzk_5cc3877c-acb7-49fe-ae74-36c362acfc1e"
      unitRef="usd">21897000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTMtMS0xLTEtOTU3NDA_07461712-99b6-4a11-a911-184ba8a5746f"
      unitRef="usd">28259000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTMtMy0xLTEtOTM0ODQ_f10d5d1e-791d-4917-b756-8da2bddd5edc"
      unitRef="usd">39875000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTMtNS0xLTEtOTM1ODY_65cc3fe7-a8a6-4647-876a-ceb567b60d2e"
      unitRef="usd">25831000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTUtMS0xLTEtOTU3NDA_08d35676-8ae1-45b7-b060-90300f8047c7"
      unitRef="usd">-2483000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTUtMy0xLTEtOTM1NjI_3627f58c-4407-4f5d-9d81-271c0b1b5bed"
      unitRef="usd">11008000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTUtNS0xLTEtOTM1OTM_b02fb219-d5e7-432b-bc1e-0ba4a45bbf23"
      unitRef="usd">-1051000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTYtMS0xLTEtOTU3NDA_6204e2ff-4a9b-4c9d-afd0-eb95488052c4"
      unitRef="usd">-63065000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTYtMy0xLTEtOTM1NjU_882eeda8-ee69-4aca-8a95-e85e152e083c"
      unitRef="usd">70297000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTYtNS0xLTEtOTM2MDA_91e1c2ab-93dc-4304-8077-89211d36ddbe"
      unitRef="usd">600000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTctMS0xLTEtOTU3NDA_c65d3c61-940a-4f79-9233-396848e027e0"
      unitRef="usd">25842000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTctMy0xLTEtOTM1Njg_a23acf97-c208-40db-8c65-a924863e6e0d"
      unitRef="usd">55090000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTctNS0xLTEtOTM2MDc_5eba23f4-d3bf-4af4-a0e5-c73ef3044696"
      unitRef="usd">50509000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTgtMS0xLTEtOTU3NDA_73c837c8-dcf4-4f5b-87c1-9992dd863d51"
      unitRef="usd">362614000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTgtMy0xLTEtOTU3NDI_78444ae4-e87b-4304-a0a8-3fb5582d2acd"
      unitRef="usd">400804000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMTgtNS0xLTEtOTU3NDI_73555474-0540-4d14-a54b-f7871bbb8968"
      unitRef="usd">208982000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjAtMS0xLTEtOTU3NDA_ea06d475-ff1c-48b8-a333-e288ebf31c2d"
      unitRef="usd">27706000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjAtMy0xLTEtOTM2MTU_5938e3ca-8bcd-44a9-8ed6-c8c749834f33"
      unitRef="usd">54225000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjAtNS0xLTEtOTM2MjQ_bff8a087-6fd5-4f47-934a-adc3708c240e"
      unitRef="usd">30345000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjItMS0xLTEtMTA1Mzk2_1c9acb44-73ba-4aa5-ba8d-6a0e5d5f5be8"
      unitRef="usd">110750000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjItMy0xLTEtMTA1NDAz_6f492c4d-29cf-473e-84b9-2cdaf40b5dc7"
      unitRef="usd">10000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjItNS0xLTEtMTA1NDEw_d5fab7f5-2289-4120-99c0-022aa3dfa11f"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjItMS0xLTEtOTU3NDA_f31ee549-9456-4431-8d67-1919ce2beeff"
      unitRef="usd">1450716000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjItMy0xLTEtOTM2MTg_7d286817-6411-4f28-a9b8-111a6910daf6"
      unitRef="usd">1357168000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjItNS0xLTEtOTM2MzE_400177cd-de4a-47f3-99c6-6e0a4d846591"
      unitRef="usd">1070269000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjMtMS0xLTEtOTU3NDA_0aded83a-1ac9-49ca-8613-57ffc9acbe05"
      unitRef="usd">1064758000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjMtMy0xLTEtOTM2MjE_6e209f09-3feb-43dc-a233-a4d9c2b7e96c"
      unitRef="usd">1378509000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjMtNS0xLTEtOTM2Mzg_2ac24ad6-0a38-423c-81a2-916a96ee2ce5"
      unitRef="usd">969399000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjQtMS0xLTEtOTU3NDA_43c9f127-dde5-403b-8ad6-0cfca8c03de8"
      unitRef="usd">-524414000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjQtMy0xLTEtOTU3NDI_1226e2c5-012f-4d48-bd53-4a5e34d5fa16"
      unitRef="usd">-42884000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjQtNS0xLTEtOTU3NDI_c66ade58-8887-4ca1-a542-9edd73c3e709"
      unitRef="usd">-131215000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjYtMS0xLTEtOTU3NDA_d9202fd1-2264-48d9-9e42-a42a3d72c061"
      unitRef="usd">23886000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjYtMy0xLTEtOTM2NDk_53f36ade-b2c8-41ba-b136-d7f59a3e686b"
      unitRef="usd">24307000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjYtNS0xLTEtOTM2NjI_4b601ef4-bb5f-4277-8975-6d4a3c618d7a"
      unitRef="usd">24886000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjctMS0xLTEtOTU3NDA_08c0275d-6456-4bbf-9f02-342f904104d4"
      unitRef="usd">23300000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjctMy0xLTEtOTM2NTI_57eab6b4-dd78-4d82-aa71-03cde67aae6a"
      unitRef="usd">39108000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjctNS0xLTEtOTM2Njk_3aeb1030-fe7d-4ce3-8b3d-14d9caa8f5fb"
      unitRef="usd">50018000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjktMS0xLTEtOTU3NDA_792f500d-9f63-474d-9ce7-01c1abdf1e47"
      unitRef="usd">586000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjktMy0xLTEtOTU3NDI_d3130da5-3d22-48c8-9a33-5a046ae7726e"
      unitRef="usd">-14801000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMjktNS0xLTEtOTU3NDI_d09c81e9-781e-4169-acc1-30ca9df8a426"
      unitRef="usd">-25132000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzAtMS0xLTEtOTU3NDA_cc6c3efc-79dd-4e39-8bd1-2deb4baeb6b2"
      unitRef="usd">-161214000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzAtMy0xLTEtOTU3NDI_6be97d53-7054-458b-93f8-5f3af27e71d6"
      unitRef="usd">343119000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzAtNS0xLTEtOTU3NDI_2451fbe1-f472-4657-bc64-07c6b7818b31"
      unitRef="usd">52635000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzEtMS0xLTEtOTU3NDA_fbf30839-1845-4431-9c65-f8c1959f78bc"
      unitRef="usd">663891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0958ab0a7b904c6abbc804e49a0e9544_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzEtMy0xLTEtOTM2ODY_8c33c07c-26cc-466d-8795-b2bc514def21"
      unitRef="usd">320772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7a3670052766460e8f6681bfb2fe46da_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzEtNS0xLTEtOTM2OTM_99fd184c-76c7-434d-b936-82d337a2040b"
      unitRef="usd">268137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzItMS0xLTEtOTU3NDA_f8ef050a-f48f-4a00-95df-1f6d91aac77e"
      unitRef="usd">502677000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzItMy0xLTEtOTU3NDI_a61249aa-a7b7-481a-9e53-202b803919e0"
      unitRef="usd">663891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0958ab0a7b904c6abbc804e49a0e9544_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzItNS0xLTEtOTU3NDI_24e4e23e-250c-48ad-8e62-79bb70762c47"
      unitRef="usd">320772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzUtMS0xLTEtOTU3NDA_8f373c48-cb7b-49fa-bb35-623134160f5a"
      unitRef="usd">127870000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzUtMy0xLTEtOTM3MDI_4bb5b815-bdf0-4076-947a-29c276891e7b"
      unitRef="usd">12960000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzUtNS0xLTEtOTM3MDk_f5cc2a8d-9ca4-417f-b714-5ab1d7121c0a"
      unitRef="usd">4115000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzctMS0xLTEtOTU3NDA_61e2e2c8-ccdd-49b5-9c66-20b99113a3c9"
      unitRef="usd">155935000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzctMy0xLTEtOTM3MTY_d0b05fc7-c152-4708-8eba-8b436d0baadc"
      unitRef="usd">4893000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfMzctNS0xLTEtOTM3MTk_7399ea75-f177-4b93-ae2e-38065a027b9a"
      unitRef="usd">4017000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <exel:AccountsReceivableForUnsettledInvestmentSales
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNDItMS0xLTEtOTU3NDA_b189d2dc-ee4f-4827-b39b-c906e292d33d"
      unitRef="usd">0</exel:AccountsReceivableForUnsettledInvestmentSales>
    <exel:AccountsReceivableForUnsettledInvestmentSales
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNDItMy0xLTEtOTM3NDE_f09a5a83-1094-4dcd-9831-656aac7e68fe"
      unitRef="usd">0</exel:AccountsReceivableForUnsettledInvestmentSales>
    <exel:AccountsReceivableForUnsettledInvestmentSales
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV83Ni9mcmFnOjViNzQzODNiMzJlYjQyNDdiM2IyZjkwNTA5NDc0ZjQxL3RhYmxlOmZlZmE0ZmExZTBiYzRmZWZiZmE4ZGU4YmYwOTg0OTVkL3RhYmxlcmFuZ2U6ZmVmYTRmYTFlMGJjNGZlZmJmYThkZThiZjA5ODQ5NWRfNDItNS0xLTEtOTM3MzE_d87a9b6f-2fa7-4e69-a5d5-3e3b821801f4"
      unitRef="usd">6180000</exel:AccountsReceivableForUnsettledInvestmentSales>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4MzU_6860de19-6c3f-4a99-969f-4f5470d44f31">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and combination regimens at the forefront of cancer care. Through the commitment of our drug discovery, development and commercialization resources, we have produced four marketed pharmaceutical products, including our flagship molecule, cabozantinib. We continue to evolve our product portfolio, leveraging our investments, expertise and strategic partnerships, to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Sales related to cabozantinib account for the majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 62 other countries as: CABOMETYX&#xae; (cabozantinib) tablets approved both alone and in combination with Bristol-Myers Squibb Company&#x2019;s (BMS) OPDIVO&#xae; (nivolumab) for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA and European Commission (EC), for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#xae; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The other two products resulting from our discovery efforts are: COTELLIC&#xae; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#xae; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo). See &#x201c;&#x2014;Collaborations and Business Development Activities&#x2014;Other Collaborations.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We plan to continue leveraging our operating cash flows to support the ongoing investigation of cabozantinib in phase 3 trials for new indications and the advancement of a broad array of diverse biotherapeutics and small molecule programs for the treatment of cancer exploring multiple modalities and mechanisms of action. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2022, which was a 52-week fiscal year, ended December&#160;30, 2022, fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended January&#160;1, 2021. For convenience, references in this report as of and for the fiscal years ended December&#160;30, 2022 and January&#160;1, 2021 are indicated as being as of and for the years ended December&#160;31, 2022 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made reclassifications to our prior years&#x2019; Consolidated Financial Statements to conform to the current year&#x2019;s presentation. These reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities, total operating, investing or financing cash flows or total stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our long-lived assets are located in the U.S. See &#x201c;Note 2. Revenues&#x201d; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements adopted by us since our filing of the Annual Report on Form 10-K for the year ended December 31, 2021, which could have a significant effect on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include realized gains and losses on the sale of investments in other income, net in the accompanying Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. The classification of restricted cash equivalents as short-term or long-term is dependent upon the longer of the remaining term to maturity of the investment or the remaining term of the related restriction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investment Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quarterly, we assess each of our investments in available-for-sale debt securities whose fair value is below its cost basis to determine if the investment&#x2019;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#x2019;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded as a reduction of other comprehensive income (loss), net of applicable taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to exclude accrued interest from both the fair value and the amortized cost basis of the available-for-sale debt securities for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Remeasurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income, net in the accompanying Consolidated Statements of Income. Net foreign currency gains or losses were immaterial for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade receivables, net, contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current economic conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers. We write off trade receivables and related allowances for credit losses when it becomes probable we will not collect the amount receivable. Write-offs for the years ended December&#160;31, 2022 and December&#160;31, 2021 were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration services revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to 15 years and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize any material impairment charges in any of the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded goodwill amounts as the excess of purchase price over identifiable net assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in one business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did not recognize any impairment charges in any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of our long-lived assets, which includes property and equipment, right-of-use assets and leasehold improvements, is reviewed for impairment whenever events or changes in circumstances indicate that the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;carrying value of the asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for revenues under the guidance of ASU Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 606). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established primarily from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discounts for Prompt Payment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our Customers in the U.S. receive a discount of 2% for prompt payment. We expect our Customers will earn 100% of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s shipments to our Customers, plus an accrual balance for known prior quarters&#x2019; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2020, the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s shipments to Customer, plus an accrual balance for known prior quarters&#x2019; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment Assistance: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Customer Credits: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Up-front License Fees: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regulatory and Development Milestone Payments: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Development Cost Reimbursements:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation, which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Profit-sharing Arrangements: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and Sales-based Milestone Payments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty we are required to pay on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees and option exercise fees, funded research and milestone payments incurred or probable to be incurred for our in-licensing arrangements with our collaboration partners for research programs in development and prior to regulatory approval; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our clinical trial projects have been executed with support from third-party CROs, who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected not to apply the recognition requirements of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2016-02&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 842) for short-term leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising expenses were $41.6 million, $31.8 million and $25.1 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;units (RSUs), performance-based restricted&#160;stock&#160;units (PSUs), service-based&#160;stock&#160;options and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation-Stock&#160;Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of RSUs and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for certain PSUs and RSUs with market vesting conditions and a Black-Scholes Merton option pricing model for stock options. Both pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatility when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense related to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis. Compensation expense related to RSUs with market vesting conditions is recognized regardless of the outcome of the market conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continually assess our ownership, contractual and other interests in entities that are not wholly-owned whether we are the primary beneficiary of a variable interest entity (VIE) and therefore we must consolidate the entity. We apply a qualitative approach that determines whether we have both (1) the power to direct the activities that most significantly impact the economic performance of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We perform this assessment, as changes to existing relationships or future transactions may result in consolidation or deconsolidation of a VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Provision for Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our provision for income taxes is computed under the asset and liability method. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our provision for income taxes in the period of such reversal. Based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 31, 2022 and forecasts of future operating results, we do not have a valuation allowance against our deferred tax assets as described in &#x201c;Note 9. Provision For Income Taxes&#x201d;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2021, which could have a significant effect on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <exel:NumberofProductsinCommercialMarket
      contextRef="i43e43644871943ca80e12287cd11f468_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzg0ODI5MDc1NTg5MQ_da7350fd-976b-45d0-957c-27043562e465"
      unitRef="product">4</exel:NumberofProductsinCommercialMarket>
    <exel:NumberOfCountriesWithDrugApprovalExcludingTheUS
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzg0ODI5MDc1NTg5Mw_b85d7e05-a696-4a32-8529-4cbff195e7fa"
      unitRef="country">62</exel:NumberOfCountriesWithDrugApprovalExcludingTheUS>
    <exel:NumberofProductsinCommercialMarket
      contextRef="i4e1b3f5f23e243f1b8637a1014a5195a_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzg0ODI5MDc1NTg5MA_c731372e-470a-4044-9227-8fb0e790e19f"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4NDA_7087a072-d005-44f6-b472-a343fe9010df">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FiscalPeriod
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY5MDM_d627d00d-0479-43e4-a3d1-9803c5a66296">We have made reclassifications to our prior years&#x2019; Consolidated Financial Statements to conform to the current year&#x2019;s presentation. These reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities, total operating, investing or financing cash flows or total stockholders&#x2019; equity.</us-gaap:FiscalPeriod>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4MjE_2b4fcfce-69ef-4b3e-9707-e1295c256c34">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzczNw_e245af80-8a58-4b4e-823f-254b293a377f"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4MDQ_5e2a098e-3c37-420a-a3e9-9866a80ce89a">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4MDc_0557fe3f-6479-403d-8f83-6c1570fe5271">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements adopted by us since our filing of the Annual Report on Form 10-K for the year ended December 31, 2021, which could have a significant effect on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2021, which could have a significant effect on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4MDk_cb433c98-cab5-4677-9d92-be3f5cca20e3">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4Mzg_1e82b142-4c98-481b-ab3c-2573d735720b">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include realized gains and losses on the sale of investments in other income, net in the accompanying Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. The classification of restricted cash equivalents as short-term or long-term is dependent upon the longer of the remaining term to maturity of the investment or the remaining term of the related restriction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investment Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quarterly, we assess each of our investments in available-for-sale debt securities whose fair value is below its cost basis to determine if the investment&#x2019;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#x2019;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded as a reduction of other comprehensive income (loss), net of applicable taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to exclude accrued interest from both the fair value and the amortized cost basis of the available-for-sale debt securities for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY3OTk_389dbd8f-34aa-4b92-8e2b-7114c80a0021">We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4Nzk_32f4a571-9379-4646-b8bd-b4590224cfe3">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income, net in the accompanying Consolidated Statements of Income.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY3Njc_ba16cbde-2721-41fe-91b3-ebe4bde186a9">Trade receivables, net, contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current economic conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers. We write off trade receivables and related allowances for credit losses when it becomes probable we will not collect the amount receivable. Write-offs for the years ended December&#160;31, 2022 and December&#160;31, 2021 were immaterial.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY5MDU_11e951f2-528b-40c3-a004-c7e58d28c3e8">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration services revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4ODA_18304e74-2867-4add-90a6-fc6a4d9bb8f3">We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to 15 years and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize any material impairment charges in any of the periods presented.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4c2389c4c21e47d38ba918260c486bdd_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMTI3MTM_4e639b38-5da2-4c42-84be-2dfb101c7ec8">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY5MDc_e9abb3c4-3938-4469-a049-8de73d020412">We recorded goodwill amounts as the excess of purchase price over identifiable net assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in one business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMTQzMDE_e245af80-8a58-4b4e-823f-254b293a377f"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMTQ0NTg_234c4fd8-fbec-4184-b898-789ab907cc81"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMTQ0NTg_a4f2177a-f4ac-43a9-b0bb-6000bbc6b09f"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMTQ0NTg_cdb4c217-d5df-4eff-af1a-0ebe1008b0e6"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY5MDg_5a2d3001-8823-4b5c-bbb5-7829b5ee8b1e">The carrying value of our long-lived assets, which includes property and equipment, right-of-use assets and leasehold improvements, is reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY3Nzg_136d0e7a-710c-442b-ab74-2589554d1def">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for revenues under the guidance of ASU Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 606). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established primarily from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discounts for Prompt Payment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our Customers in the U.S. receive a discount of 2% for prompt payment. We expect our Customers will earn 100% of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s shipments to our Customers, plus an accrual balance for known prior quarters&#x2019; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2020, the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s shipments to Customer, plus an accrual balance for known prior quarters&#x2019; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment Assistance: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Customer Credits: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Up-front License Fees: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regulatory and Development Milestone Payments: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Development Cost Reimbursements:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation, which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Profit-sharing Arrangements: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and Sales-based Milestone Payments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty we are required to pay on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. &lt;/span&gt;&lt;/div&gt;We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <exel:SalesRevenuePercentDiscountForPromptPayment
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMTk0NjA_a80e26f3-6fdc-47c0-b353-3193bca35567"
      unitRef="number">0.02</exel:SalesRevenuePercentDiscountForPromptPayment>
    <exel:SalesRevenueDiscountExpectedtobeEarnedPercent
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMTk1MTc_0332ddd2-6cfd-4459-acf0-039a9b285686"
      unitRef="number">1</exel:SalesRevenueDiscountExpectedtobeEarnedPercent>
    <exel:MedicarePartDFundingMandate
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMjA5NjQ_6a2c78cc-79a2-4012-8751-3284b4481dd2"
      unitRef="number">0.70</exel:MedicarePartDFundingMandate>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMjg5NjI_5a648cd1-55ae-4694-a849-c97b484311de"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY3OTA_94d5f0e9-31bb-4a84-8f87-ce4d6dc33299">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees and option exercise fees, funded research and milestone payments incurred or probable to be incurred for our in-licensing arrangements with our collaboration partners for research programs in development and prior to regulatory approval; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our clinical trial projects have been executed with support from third-party CROs, who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating &lt;/span&gt;&lt;/div&gt;accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY3NzE_c9d7c9b3-0b85-46dd-90eb-ac0ffbdeff0b">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected not to apply the recognition requirements of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2016-02&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 842) for short-term leases.&lt;/span&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfNTQ5NzU1ODUyMjE3_d20a79bb-f401-4374-b456-928d139c36e7"
      unitRef="usd">41600000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfNTQ5NzU1ODUyMTgy_f1b53c7b-822f-4a87-a98a-7b6b0881162e"
      unitRef="usd">31800000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfNTQ5NzU1ODUzMDMw_0714596f-640d-4aab-b088-c701594051c0"
      unitRef="usd">25100000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY3OTE_4920632c-3f18-4e03-8e12-a455cd8c6b2f">We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in selling, general and administrative expenses.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY4NzA_b398e148-f9a8-4daa-82e6-cb99f5190a75">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;units (RSUs), performance-based restricted&#160;stock&#160;units (PSUs), service-based&#160;stock&#160;options and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation-Stock&#160;Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of RSUs and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for certain PSUs and RSUs with market vesting conditions and a Black-Scholes Merton option pricing model for stock options. Both pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatility when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense related to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis. Compensation expense related to RSUs with market vesting conditions is recognized regardless of the outcome of the market conditions.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzg0ODI5MDc0NDkxOA_1f14daa2-7d5e-47f2-a99a-92ba81e2d1a2">We continually assess our ownership, contractual and other interests in entities that are not wholly-owned whether we are the primary beneficiary of a variable interest entity (VIE) and therefore we must consolidate the entity. We apply a qualitative approach that determines whether we have both (1) the power to direct the activities that most significantly impact the economic performance of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We perform this assessment, as changes to existing relationships or future transactions may result in consolidation or deconsolidation of a VIE.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84Mi9mcmFnOmVjNzMzMjVhZDk5OTRhYTJiNzQ5YTIyZjYxNmIxMzYyL3RleHRyZWdpb246ZWM3MzMyNWFkOTk5NGFhMmI3NDlhMjJmNjE2YjEzNjJfMzY3Nzk_8ce65512-f7a8-4fb9-a9b9-5a199b1f14eb">Our provision for income taxes is computed under the asset and liability method. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or &lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our provision for income taxes in the period of such reversal. Based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 31, 2022 and forecasts of future operating results, we do not have a valuation allowance against our deferred tax assets as described in &#x201c;Note 9. Provision For Income Taxes&#x201d;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTA4MA_712680d0-f829-4078-9e2b-e4dc5dcced04">REVENUES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,951,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(549,926)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(375,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,077,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with Topic 606. License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with Topic 808. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,375,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,054,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,077,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues include net product revenues attributed to geographic regions based on ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(344,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(521,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. As of December&#160;31, 2022 and 2021, respectively, contract assets are primarily related to contract assets from Ipsen Pharma SAS (Ipsen) and c&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ontract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Presented in other long-term assets in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Presented in other current liabilities in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021 and 2020, we recognized $8.1&#160;million, $8.5&#160;million and $9.2&#160;million, respectively, in revenues that were included in the beginning deferred revenues balance for those years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; December&#160;31, 2022, 2021 and 2020, we recognized $161.6&#160;million, $148.7&#160;million and $169.7&#160;million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to milestone and royalty payments allocated to our license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, $73.0 million of the combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#x201c;Note 3. Collaboration Agreements&#x2014; Cabozantinib Collaborations &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information about the expected timing to satisfy these performance obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTA3Mw_6b78a879-f14d-4100-b1a7-aa7ae621fad7">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,951,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(549,926)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(375,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,077,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,375,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,054,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,077,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89478d8e53974982878b9f548166f990_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMy01LTEtMS05MjE1MA_25dddde8-94f0-4949-8e14-6d0b96724f0d"
      unitRef="usd">1951169000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dafc9c29ab84bcc889c1cf9052a086e_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMy03LTEtMS05MjE1MA_90d22212-9f93-4066-b70e-ded4bd6b12e0"
      unitRef="usd">1452913000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib74e5ab8178d4970b8e0465f6fa0028c_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMy05LTEtMS05MjE1MA_5c637e5a-338c-428f-b3cb-f9349cffd18b"
      unitRef="usd">962591000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71aecadc693d426fb5b155f638d21467_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNC01LTEtMS05MjE1MA_5296a389-5ffc-41de-a270-793845c230b4"
      unitRef="usd">-549926000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc1b4ef9e9b84a8ebf2dfd01a3004c70_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNC03LTEtMS05MjE1MA_f2c7cf72-b8c2-454d-b5d7-2baf2d713dbc"
      unitRef="usd">-375657000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic649dcb8633a451880ff42451fc2f3ab_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNC05LTEtMS05MjE1MA_b42cf5cf-c146-4337-8057-55dcd30fa59d"
      unitRef="usd">-221041000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd975ad7811c4bdbb2315643b04037a2_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNS01LTEtMS05MjE1MA_b0fff0b2-6827-4b0e-a5b7-0ecb1ca80275"
      unitRef="usd">1401243000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2e996a9f240456487cb91fc0c52e1a1_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNS03LTEtMS05MjE1MA_51483abd-0522-4fa1-82ee-8e3bf9f43240"
      unitRef="usd">1077256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d55e02ba3ae4c8999e690629fe6d584_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNS05LTEtMS05MjE1MA_3f3b1cf2-381d-4490-a129-7e72684a1a66"
      unitRef="usd">741550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9ff1b0e91924c73b4c456c2235ab6cf_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNy01LTEtMS05MjE1MA_2a9e8891-458f-45bb-8bb1-09d17532eb16"
      unitRef="usd">162056000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47a0764d353e4fb3a7ec06de9aca7c16_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNy03LTEtMS05MjE1MA_73cc83fd-670e-4d24-8fde-02acdacabe91"
      unitRef="usd">249956000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8380d5f4f944a18a412a44050718011_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfNy05LTEtMS05MjE1MA_4c068302-0f03-47f8-944b-fe681764d452"
      unitRef="usd">167295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i968c32c71952402cb10bdb7c8f5f4c8e_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfOC01LTEtMS05MjE1MA_8df2e5ed-4152-448c-9a0c-08ea4cee77b0"
      unitRef="usd">47763000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad8294bfd197493791fd98694c5266f2_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfOC03LTEtMS05MjE1MA_e4ebda26-4825-41b0-96b8-a07ae06fc91c"
      unitRef="usd">107758000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i663037ccb1ec482e8ebc1bbf359c95b4_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfOC05LTEtMS05MjE1MA_edfab126-5009-4903-86c0-ef2cd261cdf5"
      unitRef="usd">78693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47c31e24d2c0403d83cfc5c2eb92f86f_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMTAtNS0xLTEtOTIxNTA_732f8a13-dd7e-404d-9249-8472f27a33b7"
      unitRef="usd">209819000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae02cfb8959147e8a8be84c7f06c568f_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMTAtNy0xLTEtOTIxNTA_9422d73c-7b47-4dca-96dc-a8479096467d"
      unitRef="usd">357714000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7fd8bc4b5b142a1a7297763d8461fc6_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMTAtOS0xLTEtOTIxNTA_5ad1917b-d7c7-4b2c-9dfe-bd686d608452"
      unitRef="usd">245988000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMTEtNS0xLTEtOTIxNTA_00302604-80ee-421e-9ab4-3356b1761424"
      unitRef="usd">1611062000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMTEtNy0xLTEtOTIxNTA_5e8ff85e-d223-448b-b5a1-49ebd1cab5bc"
      unitRef="usd">1434970000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjJkOGUzMWJlZjUwOTQzMmRiZDFhZjRlZDJlZGUzMGIwL3RhYmxlcmFuZ2U6MmQ4ZTMxYmVmNTA5NDMyZGJkMWFmNGVkMmVkZTMwYjBfMTEtOS0xLTEtOTIxNTA_cfe11d31-5beb-4c0e-97b6-43104ef463d2"
      unitRef="usd">987538000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if237b256b8c34d6f87bec83d450b03ab_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfMi01LTEtMS05MzgwMw_065c7e33-0abf-4e25-bcf8-df59e2108064"
      unitRef="usd">1375909000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d8ad44c76d84c439d5d4844f913bf36_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfMi03LTEtMS05Mzc5Mw_d5d2e0e3-b75c-4027-a9fe-7032b25b1444"
      unitRef="usd">1054050000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b45a28b3ddd4011af15bed2146cd292_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfMi05LTEtMS05Mzc5Ng_dac37657-6568-4c58-a3bf-0475b738be0f"
      unitRef="usd">718687000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied57fc239c1a4a7b97626aba030a42ad_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfMy01LTEtMS05MzgwMw_0d60b125-1a50-4169-88e2-7c7918038a9c"
      unitRef="usd">25334000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id94aae6775c049b5b2b45d949aafa52c_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfMy03LTEtMS05Mzc5Mw_5c5b8b97-9ef2-4ddd-b9a0-3b1aa9c196aa"
      unitRef="usd">23206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaed8d85227d3483f90cb59be9e884d22_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfMy05LTEtMS05Mzc5Ng_58b3320a-9658-4fbe-801f-1f6d3932dc81"
      unitRef="usd">22863000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd975ad7811c4bdbb2315643b04037a2_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfNC01LTEtMS05MjE1MA_2048157e-2d43-4e5b-90da-4ec65f97ab52"
      unitRef="usd">1401243000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2e996a9f240456487cb91fc0c52e1a1_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfNC03LTEtMS05MjE1MA_d8f60c08-0a85-444f-a9e2-9ee2d8fc6c52"
      unitRef="usd">1077256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d55e02ba3ae4c8999e690629fe6d584_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjE2OWFhNzZiOTdlYjQ0MzlhZDM5ZmZjZDA2NTJiZTBjL3RhYmxlcmFuZ2U6MTY5YWE3NmI5N2ViNDQzOWFkMzlmZmNkMDY1MmJlMGNfNC05LTEtMS05MjE1MA_f43b2873-4c75-49ac-b74a-34990eead811"
      unitRef="usd">741550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTA4NA_11eb27a7-ef80-4244-9085-a8919160bc12">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ide7ae702d2f94f168ad5eb6d613db43b_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi0xLTEtMS0xMDMxNzk_e7828dbc-8b66-4d26-83f3-79de6655e52d"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9229604d9ad94d6fa4aaff91b181d1fa_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi0zLTEtMS0xMDMxNzk_1a5b5932-78f7-4f6b-abc4-8337528b7a73"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i85155e2e92604cd8af2bbc12fed76b09_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi01LTEtMS0xMDMxNzk_25365a41-75a9-411e-81ff-ed89f7db407d"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifb94516f996c436291373f1bb4adcaf9_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi0xLTEtMS05NzU0Ng_b2b60014-59ec-4693-b1a4-0aa538f4ca90"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0831affdb6f74cd590e4619e798c6ede_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi0zLTEtMS05NzU0Ng_b6edfaf4-4f44-471a-bc6a-25dc6584583b"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4f5b33e3f9374a4080cdf99a2599aa23_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi01LTEtMS05NzU0Ng_857c4153-c22c-4144-ad98-df8cdd4a1335"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i09e575bca46c4ee7b2977bb349efda52_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMy0xLTEtMS05NzU1Ng_ea7f7cf9-2393-4f88-98a5-1e0fd65eee2d"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if8451b3d5bb240c7a4b4e0fc57e84305_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMy0zLTEtMS05NzU1Ng_d4f359f5-5c72-4648-a8d0-c07673637628"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9cd9ed86ff6d4038bcad39e7fb9d9344_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMy01LTEtMS05NzU1Ng_8dc38be0-a204-4309-bee0-cea3a320d1f9"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibdcd0d0a9429406cbdb4291bcd54d608_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi0xLTEtMS05Mzg3MQ_edd85bde-054c-47de-b01a-f1ee7732b2c3"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i119efb5fb69c4904bcc940dbd2963d2b_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi0zLTEtMS05MzgwNg_b305b16c-2597-4c6f-871f-b8ba65d9248a"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i04453331d42244feaf8b6ea4c41db316_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfMi01LTEtMS05MzgwOQ_a6dc3589-c8c6-4d1d-a776-5cc7c2a15c2f"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5d85564049e049b68f2010d3e0f72113_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfNi0xLTEtMS05Mzg4OQ_12acaa39-de95-4713-82cd-078728c14ef7"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i820e2862a6184ec388d2114fd98baf4a_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfNi0zLTEtMS05Mzg4Ng_3f3bf6da-12d3-45f8-afa6-7f8b9442be22"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iff9f443812b14ed79359b92769535720_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfNi01LTEtMS05Mzg3OQ_7fdecb01-a3b3-4778-a5cc-28f0b934cb2b"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifbbcd4f4e254417c814ceb83cd2b0472_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfNi0xLTEtMS05Mzg3NA_66487d2f-f619-49d8-80ff-adb5606695d3"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i99b39711f74648d78882998f94841261_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfNi0zLTEtMS05Mzg1Mg_3d290d88-f5c9-4d9b-827b-94f698152b1e"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3365323e5089466b94bbb9251d2fff94_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOmY2MWYzNzhmYWEyNDQ1NGU4MDdiNWZkMmFjYWMxMWJiL3RhYmxlcmFuZ2U6ZjYxZjM3OGZhYTI0NDU0ZTgwN2I1ZmQyYWNhYzExYmJfNi01LTEtMS05Mzg1NQ_ca092ecc-6ca5-45a0-a3a5-7d0e13d5332c"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ied54335b6e124ce78abd0708eb3c5f6a_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfMy0xLTEtMS05NzU4Nw_172f6497-3289-4e34-b57e-8b85ac0f0566"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i262b07d55db34a90b4349cb8911e546e_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfMy0zLTEtMS05NzU4Nw_a6ed92cd-7865-4f14-a678-6dd7d1857697"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic7239796cf414e5b9d7107ff0f6c6ba5_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfMy0xLTEtMS05Mzk3Ng_aaafcbb2-0242-4be6-a62f-e9daa1738819"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i72ae7ad08b2a48ae9bbf227c4be302ca_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfMy0zLTEtMS05Mzk2MQ_f71af2b1-ffa1-4719-9f0f-a69c971ed519"
      unitRef="number">0.50</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id368c47c3f5d481db02eba2d8009c964_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfNC0xLTEtMS05Mzk4NQ_8beeb1ee-f5df-4c8c-b8ab-abc0fae0252a"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i19da7b7d320c44d5b7e1755d3f209f69_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfNC0zLTEtMS05Mzk1OA_2d1decdc-3b57-471c-b434-eec5ca3b89a7"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0d6fe72170844659b8059e439eb16e3c_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfNy0xLTEtMS05Mzk4Mg_3814248d-2bec-4e93-ba71-6c6312654345"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1e7719032719481b9bb97d521869817b_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfNy0zLTEtMS05Mzk1NQ_183a574a-ff70-40c5-9c74-ef0c61c35d31"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i82d900845d714ced98be563122eec84e_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfOC0xLTEtMS0xMDk4OTE_22b6c31f-e0dc-4660-bb39-e18d66b33f1a"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic7e319ed079a4b688272f575c6d79fb7_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdkZjE5ZmVlZDc2ZjRmNTZhNzgwY2VhZGZiYTJkZmI3L3RhYmxlcmFuZ2U6N2RmMTlmZWVkNzZmNGY1NmE3ODBjZWFkZmJhMmRmYjdfOC0zLTEtMS0xMDk4ODg_b7cef721-d4c2-499f-a7df-ec714c3ed505"
      unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTA3OA_a43ec7d8-982c-4487-939d-862b90794b59">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia505016291bc4b92966a63cb457f79cf_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfMi01LTEtMS05NDAwMQ_4d7293bf-7df5-403c-be72-06bc011994bb"
      unitRef="usd">1413743000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fc646f54374425da47c013312f9a8e2_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfMi03LTEtMS05Mzk5MQ_ba383408-4fd5-421e-b95c-2cdd648639e9"
      unitRef="usd">1089396000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7afa411719d4768beb18974c2d9df7d_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfMi05LTEtMS05Mzk5NA_d7240b5e-7d55-4d99-a92f-728d8f9708aa"
      unitRef="usd">752890000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8173bdcf6bc42f08c968eda65dfc2a6_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfMy01LTEtMS05NDAwMQ_276588bf-b336-47d7-85e8-952f0651f411"
      unitRef="usd">168592000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c0ed898ca774d77b13b623d417de030_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfMy03LTEtMS05Mzk5MQ_c00e350f-6791-4346-8e28-6827bf1b82ed"
      unitRef="usd">302073000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabb415230cfe48b99b7d9b8d3f6efd7e_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfMy05LTEtMS05Mzk5NA_f1c390da-b0d7-4154-8e85-d3ef4033bd04"
      unitRef="usd">151631000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb1d7000657e4ce4b150b18dd4413a53_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfNC01LTEtMS05NDAwMQ_54a75e95-807a-4608-94f0-30c352d1f750"
      unitRef="usd">28727000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f2783aaa2794de7bb52b691c9662d08_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfNC03LTEtMS05Mzk5MQ_fb48080e-9212-4c21-8b1a-f2c4d0366a21"
      unitRef="usd">43501000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied38d86192994bb4b9a4d9a3b0c3fa39_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfNC05LTEtMS05Mzk5NA_b575804d-9542-48ff-9b29-b9ce2de02bc6"
      unitRef="usd">83017000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfNS01LTEtMS05MjE1MA_8ec888e9-fadd-4aa2-be52-4a78c9452151"
      unitRef="usd">1611062000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfNS03LTEtMS05MjE1MA_9f746fad-8c41-4c60-bc5f-e348827a9c7f"
      unitRef="usd">1434970000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjIzNTljYjE2ZmZkODQ0ZGViYTIxYmY1NGM4MTViN2E2L3RhYmxlcmFuZ2U6MjM1OWNiMTZmZmQ4NDRkZWJhMjFiZjU0YzgxNWI3YTZfNS05LTEtMS05MjE1MA_4bdac1c5-b2a9-47ae-af95-76fbfb64ba25"
      unitRef="usd">987538000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTA2OQ_06f97281-7032-4f6a-a37c-046ab9be0092">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(344,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(521,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if2acaaacb5c8468bb06c3310cf75f928_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMS0xLTEtMS05MjE1MA_8384881e-94ee-485d-9aa3-39af3f3e555c"
      unitRef="usd">9853000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iaf3671d9a5af4d39a8d091071f92b7ff_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMS0zLTEtMS05MjE1MA_0b10db07-173f-4d8f-951b-460baf108b05"
      unitRef="usd">3279000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i33892ff3208246fab5f7275cef00bcf7_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMS01LTEtMS05MjE1MA_a765354b-7efd-4789-a2cc-d2923023826a"
      unitRef="usd">17404000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0958ab0a7b904c6abbc804e49a0e9544_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMS03LTEtMS05MjE1MA_343b6f08-4448-4d54-8450-d4db072a8385"
      unitRef="usd">30536000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i991465767e2240f6921b76dcc130c033_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMy0xLTEtMS05MjE1MA_8fa966bf-1518-4386-be68-fa27ee664d20"
      unitRef="usd">243119000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i60160fe976124e808a313207fe175c03_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMy0zLTEtMS05MjE1MA_c2bc6562-7e02-48c2-a284-2fdadf7df280"
      unitRef="usd">30728000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i3fec469537054a23b86c5d87638062e6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMy01LTEtMS05MjE1MA_7afbec70-ddbe-4ce8-b233-b1911def945c"
      unitRef="usd">100361000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMy03LTEtMS05MjE1MA_d0cf0c98-ed63-47e2-abc6-0ad622d3946f"
      unitRef="usd">374208000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i991465767e2240f6921b76dcc130c033_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNC0xLTEtMS05MjE1MA_54ad165e-7d68-447b-b330-a5e71296e9a0"
      unitRef="usd">-64000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i60160fe976124e808a313207fe175c03_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNC0zLTEtMS05MjE1MA_349c1d0a-881d-4f55-8d85-c73bd709a4a3"
      unitRef="usd">-111000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i3fec469537054a23b86c5d87638062e6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNC01LTEtMS05MjE1MA_137e2c1f-bad2-4d5f-8c04-988f11edd66d"
      unitRef="usd">1624000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNC03LTEtMS05MjE1MA_b69faf14-d2f6-4add-bd2d-56a7155b67fc"
      unitRef="usd">1449000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i991465767e2240f6921b76dcc130c033_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNS0xLTEtMS05MjE1MA_0d665d7f-25ae-4d4e-bdb0-83e0eec102fa"
      unitRef="usd">238283000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i60160fe976124e808a313207fe175c03_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNS0zLTEtMS05MjE1MA_d3d1bd42-a1ed-433b-9608-3353e91c48b5"
      unitRef="usd">25021000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i3fec469537054a23b86c5d87638062e6_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNS01LTEtMS05MjE1MA_5ed709b9-77f5-4e37-9df4-251879e61f25"
      unitRef="usd">94564000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNS03LTEtMS05MjE1MA_33da7d7a-0dc9-4853-8f47-fcbe504951a1"
      unitRef="usd">357868000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i966ed994207841c3950965f3ec961e93_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNi0xLTEtMS05MjE1MA_4aff04a5-da96-485c-8981-796fc905f65d"
      unitRef="usd">14625000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic667289b49764b95a7d7f096cb54a98b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNi0zLTEtMS05MjE1MA_5231acbe-b2c1-4a66-9f15-5ce3f5aa1077"
      unitRef="usd">8875000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i1326a18371364e4d964deea38459c405_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNi01LTEtMS05MjE1MA_aac7fb1e-d500-4bc3-bdef-4979f710811f"
      unitRef="usd">24825000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfNi03LTEtMS05MjE1MA_2ef2bae4-a6bc-4e02-ac12-a5665400df1b"
      unitRef="usd">48325000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i11f3424e5d624831b1f13418acf4a9c2_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfOC0xLTEtMS05MjE1MA_2b416d1b-ea0a-4a3b-99c5-8004f5581de4"
      unitRef="usd">355865000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i793cb0fdacf74d2d8650c8f711d32ff7_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfOC0zLTEtMS05MjE1MA_794c7e2d-cdbb-4ec6-8d4c-3612821f992c"
      unitRef="usd">50312000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i3a6accba75744f11a98c8b6488700e99_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfOC01LTEtMS05MjE1MA_325a5916-ab3d-4d06-85e1-35e91fc14955"
      unitRef="usd">143516000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfOC03LTEtMS05MjE1MA_bd1b33a5-33ab-415c-bca5-8cd911289af3"
      unitRef="usd">549693000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i11f3424e5d624831b1f13418acf4a9c2_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfOS0xLTEtMS05MjE1MA_43e18f2d-4ab3-49fb-9b55-ae06abdf1474"
      unitRef="usd">611000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i793cb0fdacf74d2d8650c8f711d32ff7_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfOS0zLTEtMS05MjE1MA_3d24fda0-0fde-4707-945c-116a6da6eb3f"
      unitRef="usd">-169000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i3a6accba75744f11a98c8b6488700e99_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfOS01LTEtMS05MjE1MA_689aaf1a-ac80-49b6-a545-66f883c544f9"
      unitRef="usd">-209000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfOS03LTEtMS05MjE1MA_ff3e28d5-9f9f-4407-8cd0-f87ee1c97942"
      unitRef="usd">233000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i11f3424e5d624831b1f13418acf4a9c2_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMTAtMS0xLTEtOTIxNTA_a7e081f1-3909-48b6-925c-185ef20fe696"
      unitRef="usd">344220000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i793cb0fdacf74d2d8650c8f711d32ff7_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMTAtMy0xLTEtOTIxNTA_295c7f42-ff27-4014-8a07-048126ffc646"
      unitRef="usd">44094000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i3a6accba75744f11a98c8b6488700e99_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMTAtNS0xLTEtOTIxNTA_229fcf6c-42a2-4475-85fa-bef3c912b7cb"
      unitRef="usd">132706000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMTAtNy0xLTEtOTIxNTA_c97e1351-779e-4923-b504-bd704b5d75b3"
      unitRef="usd">521020000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i58f96bba653a49e1ae627198e6f38b55_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMTEtMS0xLTEtOTIxNTA_98d4e019-e4f7-41fd-a48b-ee0bf5717944"
      unitRef="usd">26881000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i27f15e30b5a74aa49673c0f2c8433728_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMTEtMy0xLTEtOTIxNTA_13628f41-56de-4597-8b73-add77ebb56ce"
      unitRef="usd">14924000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic81d2dff655c411a851f03dcaae0e471_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMTEtNS0xLTEtOTIxNTA_6f9b1ea9-4fcb-4c5d-94af-3e1752e58ce2"
      unitRef="usd">35426000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjdhNmZkNjdmMTAzNjRlOTRiOWVlODgwOTU2OGFhY2I0L3RhYmxlcmFuZ2U6N2E2ZmQ2N2YxMDM2NGU5NGI5ZWU4ODA5NTY4YWFjYjRfMTEtNy0xLTEtOTIxNTA_ac1db428-af3a-43f9-acfb-9e365ff58594"
      unitRef="usd">77231000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTA3Ng_8e3c01b6-fef4-44e9-a1ff-2270141e1efa">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Presented in other long-term assets in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Presented in other current liabilities in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;(3)&#160;&#160;&#160;&#160;Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets.</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjU1Y2YwYzI5MDU1YTQ2YTFhYWI5YThhNzU4MGMwYjIwL3RhYmxlcmFuZ2U6NTVjZjBjMjkwNTVhNDZhMWFhYjlhOGE3NTgwYzBiMjBfMi0xLTEtMS05MjE1MA_b323861b-2559-44e1-862f-812de1425e74"
      unitRef="usd">1659000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjU1Y2YwYzI5MDU1YTQ2YTFhYWI5YThhNzU4MGMwYjIwL3RhYmxlcmFuZ2U6NTVjZjBjMjkwNTVhNDZhMWFhYjlhOGE3NTgwYzBiMjBfMi0zLTEtMS05MjE1MA_c9340da9-61a2-44ab-a8cd-f646f3e6e678"
      unitRef="usd">1665000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjU1Y2YwYzI5MDU1YTQ2YTFhYWI5YThhNzU4MGMwYjIwL3RhYmxlcmFuZ2U6NTVjZjBjMjkwNTVhNDZhMWFhYjlhOGE3NTgwYzBiMjBfNS0xLTEtMS05MjE1MA_fb395738-6461-465a-a8f5-5ed899d4ca6f"
      unitRef="usd">7488000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjU1Y2YwYzI5MDU1YTQ2YTFhYWI5YThhNzU4MGMwYjIwL3RhYmxlcmFuZ2U6NTVjZjBjMjkwNTVhNDZhMWFhYjlhOGE3NTgwYzBiMjBfNS0zLTEtMS05MjE1MA_e35ebc2c-63a7-4eed-9b1b-5632e337675f"
      unitRef="usd">7814000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjU1Y2YwYzI5MDU1YTQ2YTFhYWI5YThhNzU4MGMwYjIwL3RhYmxlcmFuZ2U6NTVjZjBjMjkwNTVhNDZhMWFhYjlhOGE3NTgwYzBiMjBfNi0xLTEtMS05MjE1MA_9d0e498c-4b30-498c-b589-045684418efd"
      unitRef="usd">6582000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjU1Y2YwYzI5MDU1YTQ2YTFhYWI5YThhNzU4MGMwYjIwL3RhYmxlcmFuZ2U6NTVjZjBjMjkwNTVhNDZhMWFhYjlhOGE3NTgwYzBiMjBfNi0zLTEtMS05MjE1MA_6ba2f695-52bf-4c13-a99b-30df71f64fbf"
      unitRef="usd">8739000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjU1Y2YwYzI5MDU1YTQ2YTFhYWI5YThhNzU4MGMwYjIwL3RhYmxlcmFuZ2U6NTVjZjBjMjkwNTVhNDZhMWFhYjlhOGE3NTgwYzBiMjBfNy0xLTEtMS05MjE1MA_41c20800-ef66-4d64-a552-4fda5e0c1b7c"
      unitRef="usd">14070000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RhYmxlOjU1Y2YwYzI5MDU1YTQ2YTFhYWI5YThhNzU4MGMwYjIwL3RhYmxlcmFuZ2U6NTVjZjBjMjkwNTVhNDZhMWFhYjlhOGE3NTgwYzBiMjBfNy0zLTEtMS05MjE1MA_7c25059b-3a82-4536-9f03-f03d259d4a5f"
      unitRef="usd">16553000</us-gaap:ContractWithCustomerLiability>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTQ5NzU1ODE5MDEx_aa6158e9-ab24-4835-995a-2971ab089204"
      unitRef="usd">8100000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTQ5NzU1ODE4OTg2_fdbc87f3-f9a9-45d1-82a6-4814e2772a51"
      unitRef="usd">8500000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTQ5NzU1ODE4OTkw_2c146725-9498-49e1-bd50-973a2d770efc"
      unitRef="usd">9200000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTQ5NzU1ODE5MDQw_b59dd265-ab43-408b-a841-37cae4fa10db"
      unitRef="usd">161600000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTQ5NzU1ODE5MDM2_e3ce159c-a9d4-4e25-8af2-9c77edaea2c6"
      unitRef="usd">148700000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNTQ5NzU1ODE5MDMy_a622c8e1-83ad-4dda-9580-ba3daf8dfd50"
      unitRef="usd">169700000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84NS9mcmFnOmEwYjVlNTdjOTdlNTRjNzhiZmRkODBlMzIyMmY0M2U1L3RleHRyZWdpb246YTBiNWU1N2M5N2U1NGM3OGJmZGQ4MGUzMjIyZjQzZTVfNDY2Mw_e34cfb0a-9bc7-4ff2-a5f0-0a7a4c10f6e4"
      unitRef="usd">73000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMzI0OTQ_1390e47e-2565-47b3-88fe-dea2577ded95">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established multiple collaborations with leading biopharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have made considerable progress under our existing research collaboration and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading biopharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, to receive payments for product supply services, development cost reimbursements, and/or profit-sharing payments. See &#x201c;Note 2. Revenues&#x201d; for additional information on revenues recognized under our collaboration agreements during the years ended December&#160;31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cabozantinib Commercial Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ipsen Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Description of the Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, we entered into a collaboration and license agreement with Ipsen, which was subsequently amended, for the commercialization and further development of cabozantinib. Under the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#x2019; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#x2019;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#x2019;s ongoing development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2021, Ipsen opted into and is now co-funding the development costs for COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with RAI-refractory DTC who have progressed after up to two VEGF receptor-targeted therapies. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ipsen &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s obligated to reimburse us for their share of COSMIC-311 global development costs, as well as an additional payment calculated as a percentage of such costs, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;triggered by the timing of the exercise of its option. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the decision to opt in and co-fund the development costs for COSMIC-311 represented a contract modification for additional distinct services at their standalone selling price and therefore was treated as a separate contract under Topic 606. Accordingly, collaboration services revenues for the year ended December&#160;31, 2021, includes a cumulative catch-up of $43.2 million for Ipsen&#x2019;s share of global development costs incurred since the beginning of the study and through the opt-in date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (1) the expiration of patent claims related to cabozantinib, (2) the expiration of regulatory exclusivity covering cabozantinib or (3) ten years after the first commercial sale of cabozantinib, other than COMETRIQ. A related supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the FDA or European Medicines Agency orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#x2019;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consideration under the Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, we received aggregate upfront payments of $210.0 million from Ipsen in 2016. As of December&#160;31, 2022, we have achieved aggregate milestones of $489.5&#160;million related to regulatory, development and sales-based threshold by Ipsen since the inception of the collaboration agreement, including $27.0&#160;million, $112.5 million, and $20.0 million in milestones achieved during the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we are eligible to receive additional regulatory and development milestone payments from Ipsen totaling an aggregate of $19.5 million, as well as sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to $350.0 million and CAD$26.5 million. We excluded these milestones from the transaction price as of December&#160;31, 2022 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will adjust the constraint applied to the variable consideration at each reporting period as uncertain events are resolved or other changes in circumstances occur. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;&#x2014;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, below, for additional information related to the revenue recognition for this collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;receive royalty revenues on the net sales of cabozantinib by Ipsen outside of t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he U.S. and Japan. During the year ended December&#160;31, 2022 and going forward, we are entitled to receive a tiered royalty of 22% to 26% on annual net sales, with separate tiers for Canada; these royalty tiers reset each calendar year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to pay a 3% royalty on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for 35% of such costs, provided Ipsen chooses to opt into such trials. Ipsen has opted into and is co-funding certain clinical trials, including: CheckMate-9ER, COSMIC-021, COSMIC-311, COSMIC-312, CONTACT-01 and CONTACT-02.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We remain responsible for manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. Relatedly, we entered into a supply agreement with Ipsen to supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. The product is supplied at our cost, as defined in the agreement. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from territories outside of U.S. and Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues from the Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022, we recognized $25.8&#160;million in revenues in connection with two regulatory milestones totaling $27.0&#160;million upon approval by the EC and Health Canada, of cabozantinib a monotherapy for the treatment of adult patients with locally advanced or metastatic DTC, refractory or not eligible to RAI who have progressed during or after prior systemic therapy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, $35.4 million of the transaction price was allocated to our research and development services performance obligation that has not yet been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Description of the Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended effective March 2018, May 2019 and September 2020, to, among other things, modify the amount of reimbursements we receive, for costs associated with our required pharmacovigilance activities and milestones we are eligible to receive, as well as modify certain cost-sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Takeda is responsible for a portion of the costs associated with the cabozantinib development plan&#x2019;s current and future trials, provided Takeda opts into such trials, and 100% of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Takeda has opted into and is co-funding CheckMate-9ER, certain cohorts of COSMIC-021, CONTACT-01 and CONTACT-02. Under the collaboration agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#x2019; collaboration is governed through a joint executive committee and appropriate subcommittees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (1) two years after first generic entry with respect to such product in Japan or (2) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#x2019; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consideration under the Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the exclusive license and other rights contained in the collaboration agreement, we received an upfront payment of $50.0 million from Takeda in 2017. As of December&#160;31, 2022, we have also achieved regulatory and development milestones in the aggregate of $127.0&#160;million since the inception of the collaboration agreement, including $0, $35.0 million and $66.0 million in milestones achieved during the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement, as amended in 2020, we are eligible to receive additional regulatory and development milestone payments, without contractual limit, for additional potential future indications. We are further eligible to receive commercial milestones, including milestone payments earned for the first commercial sale of a product, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of $119.0 million. We excluded these milestones from the transaction price as of December&#160;31, 2022 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will adjust the constraint applied to the variable consideration at each reporting period as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also receive royalty revenues on the net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of 15% to 24% on the initial $300.0&#160;million of net sales, and following this initial $300.0&#160;million of net sales, we are then entitled to receive a tiered royalty of 20% to 30% on annual net sales thereafter; these 20% to 30% royalty tiers reset each calendar year. Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to pay a 3% royalty on all net sales of any product incorporating cabozantinib, including net sales by Takeda.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement, we are responsible for the manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. Relatedly, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a safety data exchange agreement, which defines each partner&#x2019;s responsibility for safety reporting. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues from the Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration services revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt;text-indent:36pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt;text-indent:36pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, $37.6&#160;million of the transaction price was allocated to our research and development services performance obligations that have not yet been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There is one remaining performance obligation for the Ipsen collaboration agreement: the research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements). As part of the original contract, we also had a performance obligation associated with exclusive license for the commercialization and further development of cabozantinib, which was transferred in 2016. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are two remaining performance obligations for the Takeda collaboration agreement: (1) the research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements) and (2) the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. As part of the original contract, we had a performance obligation associated with the exclusive license for the commercialization and further development of cabozantinib, which was transferred in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have allocated the transaction price for each of these collaborations to the originally identified performance obligations based on our best estimate of their relative standalone selling price. For the licenses, the estimate of the relative standalone selling price was determined using a discounted cash flow valuation utilizing forecasted revenues and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;costs. For research and development services the estimate of the relative standalone selling price was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The portion of the transaction price allocated to our license performance obligation is recorded immediately as our license represents functional intellectual property that was transferred at a point in time. The portion of the transaction price allocated to our research and development services performance obligation is being recognized as revenue using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union for the Ipsen collaboration and Japan for the Takeda collaboration, both of which are early 2030. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adjust the constraint applied to the variable consideration for the collaboration agreements in each reporting period as uncertain events are resolved or other changes in circumstances occur and we allocate those changes in the transaction price between our performance obligations. During the years ended December&#160;31, 2022, 2021 and 2020, the transaction price of the Ipsen and Takeda collaboration agreements increased as a result of the achievement of various milestones, and the reimbursements of research and development services related to committed and opt-in studies. We further updated the transaction price based upon the actual research and development services performed during the period and changes in our estimated reimbursements for our future research and development services. The portion of the increase in transaction price that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license was recognized during the period and the portion allocated to research and development services will be recognized in future periods as those services are delivered through early 2030. As of December&#160;31, 2022, variable consideration related to the remaining unearned regulatory and development milestones for both agreements remained constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cabozantinib Development Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BMS&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#x2019;s immune checkpoint inhibitors (ICIs), nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab as a treatment option for RCC in the COSMIC-313 trial. Under the collaboration agreement with BMS, we may also evaluate these combinations in other phase 3 pivotal trials in various other tumor types. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement with BMS, as amended, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#x2019;s compounds in the conduct of each clinical trial. The parties&#x2019; efforts are governed through a joint development committee established to guide and oversee the collaboration&#x2019;s operation. Each trial is conducted under a combination Investigational New Drug application, unless otherwise required by a regulatory authority. Each party is responsible for supplying finished drug product for the applicable clinical trial, and responsibility for the payment of costs for each such trial will be determined on a trial-by-trial basis. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;F. Hoffmann-La Roche Ltd. (Roche) Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#x2019;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. Under this agreement with Roche, in June 2017, we initiated COSMIC-021, a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#x2019;s atezolizumab in patients with locally advanced or metastatic solid tumors, and in December 2018, we initiated COSMIC-312, a multicenter, randomized, controlled phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC. We are the sponsor of both trials, and Roche is providing atezolizumab free of charge.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, we entered into a joint clinical research agreement with Roche for the purpose of further evaluating the combination of cabozantinib with atezolizumab in patients with locally advanced or metastatic solid tumors, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;including in the phase 3 pivotal clinical trials in advanced non-small cell lung cancer (CONTACT-01), metastatic castration-resistant prostate cancer (CONTACT-02) and RCC (CONTACT-03). If a party to the joint clinical research agreement proposes any additional combined therapy trials beyond these phase 3 pivotal trials, the joint clinical research agreement provides that such proposing party must notify the other party and that if agreed to, any such additional combined therapy trial will become part of the collaboration, or if not agreed to, the proposing party may conduct such additional combined therapy trial independently, subject to specified restrictions set forth in the joint clinical research agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2020, a supplement to the joint clinical research agreement was signed amongst us, Roche and Takeda due to Takeda opting into fund the combined therapy trial of CONTACT-01 sponsored by Roche. Chugai was added as an affiliate of Roche.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All parties including Chugai conduct combined therapy trials in Japan upon the terms of the joint clinical research agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the joint clinical research agreement, each party granted to the other a non-exclusive, worldwide (excluding, in our case, territory already the subject of a license by us to Takeda), non-transferable, royalty-free license, with a right to sublicense (subject to limitations), to use the other party&#x2019;s intellectual property and compounds solely as necessary for the party to perform its obligations under the joint clinical research agreement. The parties&#x2019; efforts will be governed through a joint steering committee established to guide and oversee the collaboration and the conduct of the combined therapy trials. Each party will be responsible for providing clinical supply of their drug for all combined therapy trials, and the cost of the supply will be borne by such party. The clinical trial expenses for each combined therapy trial agreed to be conducted jointly under the joint clinical research agreement will be shared equally between the parties, and the clinical trial expenses for each additional combined therapy trial not agreed to be conducted jointly under the joint clinical research agreement will be borne by the proposing party, except that the cost of clinical supply for all combined therapy trials will be borne by the party that owns the applicable product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined the contract is within the scope of Topic 808 as it involves joint operating activities where both parties have active participation in the arrangement and are exposed to significant risks and rewards. Payments between us and Roche under this arrangement are not subject to other accounting literature. Payments due to Roche for our share of clinical trial costs incurred by Roche will be recorded as research and development expense and payments due from Roche for their share of clinical trial costs incurred by us will be recorded as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the joint clinical research agreement provides that it will remain in effect until the completion of all combined therapy trials under the collaboration, the delivery of all related trial data to both parties, and the completion of any then agreed-upon additional analyses. The joint clinical research agreement may be terminated for cause by&#160;either party based on any uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party will terminate upon completion of any ongoing activities under the joint clinical research agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;GSK and Royalty Pharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2002, we established a product development and commercialization collaboration agreement with GlaxoSmithKline (GSK), that required us to pay a 3% royalty to GSK on the total worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. Effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on total net sales of any product containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalty fees earned by GSK and Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalty fees earned by GSK and Royalty Pharma were $58.2 million, $46.6 million and $32.7 million during the years ended December&#160;31, 2022, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Genentech Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have out-licensed to Genentech under a worldwide collaboration agreement, the development and commercialization of cobimetinib, under the brand name COTELLIC. The terms of the collaboration agreement require that we share in the profits and losses received or incurred in connection with the commercialization of COTELLIC in the U.S. In &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;addition to our profit share in the U.S., we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021 and 2020, we recognized $12.5 million, $12.1 million, and $11.3 million, in revenues from profits and losses on U.S commercialization and royalties on ex-U.S. sales under the collaboration agreement with Genentech and are included within license revenues on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research Collaborations, In-Licensing Arrangements and Other Business Development Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into collaborative arrangements with other pharmaceutical or biotechnology companies to develop and commercialize drug candidates or intellectual property. Our research collaborations and in-licensing arrangements are intended to enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Our research collaborations, in-licensing arrangements and other strategic transactions include upfront payments, development, regulatory, commercial milestone payments and royalty payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations provide us exclusive options that give us the right to license programs or acquire the intellectual property developed under the research collaborations for further discovery and development. When we decide to exercise the options, we are required to pay an exercise fee and then assume the responsibilities for all subsequent clinical development, manufacturing and commercialization. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, we entered into an exclusive option and license agreement with BioInvent International AB (BioInvent), upon which we paid an upfront payment of $25.0&#160;million. If we decide to exercise the option, we will pay BioInvent an option exercise fee, and BioInvent would be eligible for additional payments from us for future development and commercial milestones, as well as royalties on future net sales of products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, we entered into an agreement with Cybrexa Therapeutics, LLC (Cybrexa), which provides us the right to acquire CBX-12 (alphalex&#x2122; exatecan), a clinical-stage peptide-drug conjugate that utilizes Cybrexa&#x2019;s proprietary alphalex technology to enhance delivery of exatecan to tumor cells. Under the terms of the agreement, we made an upfront payment of $60.0&#160;million for a warrant entitling us to the right to acquire the Cybrexa affiliate that controls CBX-12 and related assets, and to fund certain development and manufacturing expenses incurred by Cybrexa to advance CBX-12 during the warrant period. Cybrexa will continue the development of CBX-12 according to an agreed development plan, including phase 1 studies, and may be eligible to receive up to $65.0&#160;million in additional development milestone payments, during the warrant period. We may exercise the warrant for up to $300.0&#160;million based upon our evaluation of a pre-specified clinical data package to be delivered by Cybrexa. Following exercise of the warrant, Cybrexa would be eligible to receive up to $277.5&#160;million in additional payments upon achievement of further regulatory and commercial milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have determined our arrangement with Cybrexa constitutes a variable interest in the Cybrexa affiliate that controls CBX-12 and related assets, and that the Cybrexa affiliate is a VIE; however, we are not the primary beneficiary of the Cybrexa affiliate as we do not control the activities that are most significant to the Cybrexa affiliate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have accounted for our arrangement with Cybrexa as an acquisition of in-process research and development technology that does not have an alternative future use, and accordingly, recognized the upfront payment of $60.0&#160;million in research and development expenses during the year-ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, we entered into an exclusive option and license agreement with Sairopa, B.V. (Sairopa). Under the terms of the agreement, we made an upfront payment of $40.0&#160;million for an option to obtain an exclusive, worldwide license to develop and commercialize ADU-1805 and other anti-SIRP&#x3b1; antibodies. Sairopa is eligible to receive additional development milestone payments during the option period totaling up to $97.5&#160;million. Following the completion of the clinical studies, we may exercise the option for $225.0&#160;million based upon our evaluation of a pre-specified clinical data package to be delivered by Sairopa. Following the exercise of the option, Sairopa would be eligible to receive up to $465.0&#160;million in additional payments upon achievement of further development and commercial milestones, as well as royalties on future net sales of products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, we entered into a new license agreement with Catalent, Inc.&#x2019;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc., (individually and collectively referred to as Catalent). Under the terms of the agreement, we made an upfront payment of $30.0&#160;million in exchange for rights to three biologics programs. We will also contribute research funding to Catalent for discovery and preclinical &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;development work. Catalent would be eligible to receive potential future development, regulatory and commercial milestone payments, as well as royalties on future net sales of products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021 and 2020, we recognized $203.9&#160;million, $176.1&#160;million and $96.4&#160;million, respectively, relating to upfront license payments, research and development funding, development milestones, option fees and other fees within research and development expenses on the Consolidated Statements of Income. During the year ended December&#160;31, 2022, we reversed $12.5&#160;million of previously recorded research and development expenses associated with a development milestone. The impact of the change in estimate on our basic and diluted earnings per share for the fiscal year ended December&#160;31, 2022 was an increase of $0.04 per share. The milestone was reversed as the compound has not progressed as expected and therefore we are no longer able to predict when the milestone will occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, in conjunction with these collaborative in-licensing arrangements we are subject to potential future development milestones of up to $652.0&#160;million, regulatory milestones of up to $634.3&#160;million and commercial milestones of up to $3,153.0&#160;million, each in the aggregate per product or target, as well as royalties on future net sales of products.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i70318e17c7ab4b68b6b925151523736a_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODU1MzQ4_faa055a7-2901-4cc7-a359-4f6cfca318b6"
      unitRef="usd">43200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod
      contextRef="id4f5961955974e53a8d6b5ad85acfe4d_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMzI5Ng_385b4163-e5b1-43fa-b4e9-f58391d44662">P10Y</exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod>
    <exel:UpfrontPayments
      contextRef="i39c122c614074046abcfbcc446a1fa98_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTA2MA_386064b9-2a74-4a42-b1ed-da0ff33a8dfe"
      unitRef="usd">210000000</exel:UpfrontPayments>
    <exel:MilestonePaymentsEarnedToDate
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODQ2NDAy_0651efb8-a988-4913-a9f3-e36cd86adef7"
      unitRef="usd">489500000</exel:MilestonePaymentsEarnedToDate>
    <exel:MilestonePaymentsEarned
      contextRef="id4f5961955974e53a8d6b5ad85acfe4d_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODQ2NDI4_dfcfef91-c408-48ab-a9d9-f7b7eb64c4e1"
      unitRef="usd">27000000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="ibad41c5a867e42328f87a6be4ab95e02_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTI2OQ_cdc96c2a-efe8-4a83-800d-156e7e2e3268"
      unitRef="usd">112500000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="ibce8519fb88b4643a598a9f10397b3fb_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTI3Mw_270edb49-3189-414e-9ef1-b4fcfdc90dd9"
      unitRef="usd">20000000</exel:MilestonePaymentsEarned>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="i9fc4fe1515e740b5b2fedc80ab3c29d8_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ4OA_c79fda68-8f4e-43b7-a111-e9091a805a6f"
      unitRef="usd">19500000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="i9fc4fe1515e740b5b2fedc80ab3c29d8_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTYxNg_57dff7a9-59c9-41c7-bc50-2b9794c0f6f5"
      unitRef="usd">350000000</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="i9fc4fe1515e740b5b2fedc80ab3c29d8_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODU1NDE2_b39b6ab7-451e-48db-9107-371f3e2644b3"
      unitRef="cad">26500000</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="i850883eb6ca848ccbe6e3680f28bee20_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNjYzMw_a909a68c-8e4a-4e2f-9a2d-9613f67c4515"
      unitRef="number">0.22</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="i125cc20cc74341a5b27b3efd37225cf0_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNjYzOQ_cf48603d-7b13-4b51-a813-8d208bc6c3e2"
      unitRef="number">0.26</exel:PercentOfRoyaltyOnNetSale>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNzAzMA_5a648cd1-55ae-4694-a849-c97b484311de"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent
      contextRef="id4f5961955974e53a8d6b5ad85acfe4d_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNzQwOA_1da0493f-c681-4c5e-af86-81a760826778"
      unitRef="number">0.35</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMzI1MDA_2f51d752-e9d0-4ab8-9fcd-d9ee00006f54">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration services revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt;text-indent:36pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt;text-indent:36pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd9cf65a286f4e7da9b13796a041f58f_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfMi01LTEtMS05MjE1MA_8eb0eb64-25cc-4ce7-9771-eb64ec250430"
      unitRef="usd">133732000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib11873105d5440f2b04ad3921ee0e374_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfMi03LTEtMS05MjE1MA_94c0e7c3-a6ab-4fd6-900f-a5fd4644c03b"
      unitRef="usd">207982000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4810c81a75b84f8b964fb340d02890c0_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfMi05LTEtMS05MjE1MA_32fdf79f-35f4-4603-9c1c-467499d18e9f"
      unitRef="usd">93495000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie49ad1f5b50641398e4bd5e6a19ec508_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfMy01LTEtMS05MjE1MA_33c3d9ac-bd66-4c2b-a664-82ddd9516165"
      unitRef="usd">34860000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70318e17c7ab4b68b6b925151523736a_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfMy03LTEtMS05MjE1MA_87636b4b-a00b-4fa9-87f5-eeefc4e12ffb"
      unitRef="usd">94091000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b1223169902474aafc57a25d19dcaff_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfMy05LTEtMS05MjE1MA_5988de9e-01fc-49c3-be87-c9679908644b"
      unitRef="usd">58136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4f5961955974e53a8d6b5ad85acfe4d_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfNC01LTEtMS05MjE1MA_9d64ed07-5cae-4620-8394-013544f88eb9"
      unitRef="usd">168592000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibad41c5a867e42328f87a6be4ab95e02_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfNC03LTEtMS05MjE1MA_cf3cf0f8-e750-4501-ab63-04e2939b04d5"
      unitRef="usd">302073000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibce8519fb88b4643a598a9f10397b3fb_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjY0NjNiMGMwMTk5MzRhNDdiZTQ4NmUyYzhjZjdlM2YzL3RhYmxlcmFuZ2U6NjQ2M2IwYzAxOTkzNGE0N2JlNDg2ZTJjOGNmN2UzZjNfNC05LTEtMS05MjE1MA_82c710ce-b563-44a6-8cf1-08891f7169b2"
      unitRef="usd">151631000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:RevenueFromContractWithCustomerCommercialSalesMilestone
      contextRef="i9fc4fe1515e740b5b2fedc80ab3c29d8_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODU1NzU3_ce189c7d-db5a-4689-bf06-b3e301c84f57"
      unitRef="usd">25800000</exel:RevenueFromContractWithCustomerCommercialSalesMilestone>
    <exel:RevenueFromContractWithCustomerRegulatoryMilestone
      contextRef="i9fc4fe1515e740b5b2fedc80ab3c29d8_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODU1ODMw_c07ccded-e91d-4a3e-ab1f-54c36f67b2a6"
      unitRef="usd">27000000</exel:RevenueFromContractWithCustomerRegulatoryMilestone>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i9fc4fe1515e740b5b2fedc80ab3c29d8_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODU1NTcy_1029cc79-a75d-4180-a883-5cd529a55b41"
      unitRef="usd">35400000</us-gaap:RevenueRemainingPerformanceObligation>
    <exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent
      contextRef="i1d5c30fce06545d9a3baacb0b0ab774e_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTA1MTQ_84e67f75-23f6-42ed-9ce6-a1dfc1636194"
      unitRef="number">1</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
    <exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod
      contextRef="i1d5c30fce06545d9a3baacb0b0ab774e_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTEyODY_51484e6a-42da-4e42-92d6-4d1428d3259a">P2Y</exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod>
    <exel:UpfrontPayments
      contextRef="ifaedfc761d77477d83685f07ca670fc4_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTI2NzA_3b72bf1c-4e7c-4b45-bccb-fef18179ec0a"
      unitRef="usd">50000000</exel:UpfrontPayments>
    <exel:MilestonePaymentsEarnedToDate
      contextRef="i337a214cbd1b44929248114a2eb85662_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODQ2NTAy_df4109e1-0474-45a6-af9b-be25e4b46612"
      unitRef="usd">127000000</exel:MilestonePaymentsEarnedToDate>
    <exel:MilestonePaymentsEarned
      contextRef="i5e5a7fdf85fc4fc7bfa8e4d51f47e59b_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTY0OTI2NzUwMzk5OA_e1714451-4256-4e98-b821-0b9025082032"
      unitRef="usd">0</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="id1f50051810c4c1faeb0643d2151e699_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTI4NDk_594b7049-0ee5-4fba-901b-b816ebaefc31"
      unitRef="usd">35000000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="i071e191539a447ab937022c70f4066ae_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTI4NTM_e531de5a-1787-4d82-bbd1-4ea72fab013b"
      unitRef="usd">66000000</exel:MilestonePaymentsEarned>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="i337a214cbd1b44929248114a2eb85662_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTMyOTU_a173aff2-e0a1-448f-8a48-b57673c748d5"
      unitRef="usd">119000000</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="ia3ca226cd81a48daacc85597ee8e0f61_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTM5MDM_b83e4408-f0fd-4757-a857-d60612f537c9"
      unitRef="number">0.15</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="i2ae1f8be861d4b04aa760182f4297029_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTM5MDk_d371b582-bbd4-43d6-b493-46d6750f252b"
      unitRef="number">0.24</exel:PercentOfRoyaltyOnNetSale>
    <exel:RoyaltyTier
      contextRef="i4d556ca23f9e45b4b9ed6c03f967c59b_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTM5Mjc_cea65172-33c9-4c42-8739-6a09dbc587be"
      unitRef="usd">300000000</exel:RoyaltyTier>
    <exel:RoyaltyTier
      contextRef="i4d556ca23f9e45b4b9ed6c03f967c59b_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTM5NzE_62c8ffc4-d218-4835-877c-66555dea9220"
      unitRef="usd">300000000</exel:RoyaltyTier>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="idc4a5bca80f542428c9f79064ba8ff59_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTQwNDA_2668deec-e143-4a1f-abfa-bbab627c542a"
      unitRef="number">0.20</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="i3a65d7d772494943b214d873b45da310_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTQwNDY_fe5ca1e6-a583-4668-b44b-ca38a02556e9"
      unitRef="number">0.30</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="idc4a5bca80f542428c9f79064ba8ff59_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTQwODc_6fb8802e-4719-4670-85a3-1bdb09130425"
      unitRef="number">0.20</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="i3a65d7d772494943b214d873b45da310_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTQwOTM_c341196b-7538-42de-befa-963302692fb2"
      unitRef="number">0.30</exel:PercentOfRoyaltyOnNetSale>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTQ0MjU_5a648cd1-55ae-4694-a849-c97b484311de"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice176fd5f4104315b8f2c270962294fa_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfMi01LTEtMS05MjE1MA_022467ab-12bf-4c5f-b3bd-8587ca39e21c"
      unitRef="usd">11335000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i206233ca66af4b1a9cf478e3d8d24963_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfMi03LTEtMS05MjE1MA_630314f8-930f-4623-8065-9bb9c6969d52"
      unitRef="usd">26058000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6aa5c591d2414c088c15c92ff3156418_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfMi05LTEtMS05MjE1MA_0f5fb563-295d-4411-b47c-68b5a326cd1e"
      unitRef="usd">61115000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbc3624e7a294295a982185658426bfe_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfMy01LTEtMS05MjE1MA_5ef8f237-78d4-472f-9ec4-1df38dccdaca"
      unitRef="usd">12903000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82f90a00897a46f1957e0414cc090bbe_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfMy03LTEtMS05MjE1MA_ae0bd595-9a32-4d99-bf49-94c777c8223e"
      unitRef="usd">13667000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5276ec4d64fb4ba49c9c540fea11a982_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfMy05LTEtMS05MjE1MA_9db99342-4a8c-400f-bb8e-565d86afb738"
      unitRef="usd">20557000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e5a7fdf85fc4fc7bfa8e4d51f47e59b_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfNC01LTEtMS05MjE1MA_6240280b-4eda-4c0a-9dcf-628ba7683f52"
      unitRef="usd">24238000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1f50051810c4c1faeb0643d2151e699_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfNC03LTEtMS05MjE1MA_a5ae9790-7541-4c25-88e6-953887d5033f"
      unitRef="usd">39725000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i071e191539a447ab937022c70f4066ae_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RhYmxlOjExZjY0ZmVhMjZjODQ2MTZhZjM1NjQ0OWMxZGI4ZDkxL3RhYmxlcmFuZ2U6MTFmNjRmZWEyNmM4NDYxNmFmMzU2NDQ5YzFkYjhkOTFfNC05LTEtMS05MjE1MA_36b2cac9-6cbe-48db-bb93-b397ab95fafd"
      unitRef="usd">81672000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i337a214cbd1b44929248114a2eb85662_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMTU5MTE_a9056b80-819c-4be3-aa16-09709ab72a89"
      unitRef="usd">37600000</us-gaap:RevenueRemainingPerformanceObligation>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMjY4MTE_5a648cd1-55ae-4694-a849-c97b484311de"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RoyaltyExpense
      contextRef="i41fe2331cabe4050a30129ee051c2799_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMjc1NjY_93295342-037a-41c2-a484-17f24ad81631"
      unitRef="usd">58200000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i8bc9a78c8ba049f1946264d1c52f58e9_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMjc1NzA_48aacdf8-ecc3-4032-a0c5-99044ea56818"
      unitRef="usd">46600000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i8d753c4338ff47ef84b0c40394bd5147_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMjc1Nzc_6dccfb19-5426-41dd-b07b-51bb0b0bbcf7"
      unitRef="usd">32700000</us-gaap:RoyaltyExpense>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c3596696fae4d9fb41163e7ddd3e386_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMjgyMTI_803c866e-c884-4d85-96a3-915cc7152601"
      unitRef="usd">12500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7048757da4c04483a7c963e440b237a5_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMjgyMTY_35714d28-afd7-49ee-9676-fd581b4220c9"
      unitRef="usd">12100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b2a018fee9e45548471c0835e50f5b6_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMjgyMjQ_ff12de1b-0ba8-41d5-8a3c-137ada810499"
      unitRef="usd">11300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="i02a9e43c4eda4262b8e648fb4debd1eb_D20220601-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODY1OTI5_34e003d6-6c34-4c6a-a938-803ac4b3289c"
      unitRef="usd">25000000</exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="i1d84069f159b428fbda44b41dd831144_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODU5NzMw_794f4173-d1dd-4223-96ff-9fc0aeff9733"
      unitRef="usd">60000000</exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments
      contextRef="i5ec846e4aef84ad2ae39d1d13246bfc6_I20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODYwMTI1_0ecd9f2a-3259-457f-a4eb-ed68de8c4a4b"
      unitRef="usd">65000000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments>
    <exel:CollaborativeArrangementMaximumAmountOfWarrantExercise
      contextRef="i1d84069f159b428fbda44b41dd831144_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODYwMjQw_991cbff4-4d9a-4ea1-904c-230bf79bd3c2"
      unitRef="usd">300000000</exel:CollaborativeArrangementMaximumAmountOfWarrantExercise>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments
      contextRef="i1d84069f159b428fbda44b41dd831144_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODYwNDE3_919fb5e5-f44e-40c6-832b-3f47ee7295f3"
      unitRef="usd">277500000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments>
    <exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="ifd58ac0e41e340fc877768fad90c5f62_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfMzg0ODI5MDc1NzgzMg_2bb8b665-f7d1-44ba-aaee-7a9277f35fb8"
      unitRef="usd">60000000</exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="i3334291a8ef14e57a8f54daf44f344c8_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODYwNzIx_7252bdad-e03c-4af7-b8d1-9081e47f9622"
      unitRef="usd">40000000</exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments
      contextRef="id6fd500061c74be88ef95fc875ef99af_I20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODYxMDY4_5ebb09ef-7464-4925-abdb-342213fa40f4"
      unitRef="usd">97500000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsExerciseAmount
      contextRef="i3334291a8ef14e57a8f54daf44f344c8_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODYxMTU0_935a577e-1a96-43e2-9481-ecff4ca1fd8b"
      unitRef="usd">225000000</exel:CollaborativeArrangementRightsAndObligationsExerciseAmount>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments
      contextRef="i3334291a8ef14e57a8f54daf44f344c8_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODYxMzM0_66fe142e-e6c4-41c2-90ee-3826aff5a6ce"
      unitRef="usd">465000000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments>
    <exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="ia026be7c5b9b41a3a54316d617e77f69_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODY4MTc4_10932ea2-6fd9-44e1-bdf3-3655f94bbc53"
      unitRef="usd">30000000</exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia0f7c864ef914e8b9ebcaa0c64e1ece3_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODY2Mjk5_7e6f7b08-6e76-4c75-a6f8-db365f061161"
      unitRef="usd">203900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id82fc91049724181b2a5e0f40253e48c_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODY2MzA1_ff9488ad-fa37-4f36-b0ac-cf36a0f22a48"
      unitRef="usd">176100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i361ef59b0f2e4fddaf4c38b878d30ec0_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODY2MzEz_062eede4-af94-46c0-8574-3a5ceb717376"
      unitRef="usd">96400000</us-gaap:ResearchAndDevelopmentExpense>
    <exel:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="ia0f7c864ef914e8b9ebcaa0c64e1ece3_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODc3MDky_c6543642-0415-46cc-9703-d1488f59b0f2"
      unitRef="usd">-12500000</exel:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <exel:IncreaseInBasicEarningsPerShare
      contextRef="ia0f7c864ef914e8b9ebcaa0c64e1ece3_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODc3MTA3_08487562-7cde-41bb-8324-6b4c9d8177f2"
      unitRef="usdPerShare">0.04</exel:IncreaseInBasicEarningsPerShare>
    <exel:IncreaseInDilutedEarningsPerShare
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODc3MTA3_5be26ea7-4d7c-4a69-b94d-f3affbcdf0a1"
      unitRef="usdPerShare">0.04</exel:IncreaseInDilutedEarningsPerShare>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments
      contextRef="if09743b2bc6e41bdb6f96e1e3fef767b_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODc0NTM2_5b1c84ee-b519-4038-a7b1-f2a6eb90723e"
      unitRef="usd">652000000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments
      contextRef="if09743b2bc6e41bdb6f96e1e3fef767b_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODc0NTcx_12b75fe4-a02b-4435-9fa5-0a136c4aceff"
      unitRef="usd">634300000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments
      contextRef="if09743b2bc6e41bdb6f96e1e3fef767b_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV84OC9mcmFnOmMxZmQ1MTNjZDY4ZTQzNDdiMDEzN2EzMTI3YmE0NGQwL3RleHRyZWdpb246YzFmZDUxM2NkNjhlNDM0N2IwMTM3YTMxMjdiYTQ0ZDBfNTQ5NzU1ODc0NjEw_ec7208af-9489-465c-b179-e0e7c3b241bb"
      unitRef="usd">3153000000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments>
    <us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMjcyMA_ddd95f06-07ae-4baa-bba7-1a82ba9831d6">CASH AND INVESTMENTS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash equivalents are used to collateralize letters of credit agreements and are invested in short-term certificates of deposit with original maturity of 90 days or less as of December 31, 2022 and money market fund securities as of December 31, 2021. The restricted cash equivalents are classified as other long-term assets. The standby letter of credit entered into in January 2021, as a guarantee of our obligation to fund our portion of the tenant improvements related to our Alameda build-to-suit lease was extinguished and the related collateral was returned in the third quarter of 2022, following the substantial completion of the building and the commencement of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,887,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,085,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest receivable was $7.3 million and $2.9 million as of December&#160;31, 2022 and 2021, respectively, and is included in prepaid and other current assets in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on the sales of investments were insignificant during the years ended December&#160;31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,030,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were 285 and 133 debt securities available-for-sale in an unrealized loss position as of December&#160;31, 2022 and 2021, respectively. All securities presented above have been in an unrealized loss position for less than twelve months except for 76 corporate bond securities, 4 municipal bond securities and 1 U.S. Treasury and government-sponsored enterprises security with an aggregate fair value of $237.6&#160;million and an aggregate $6.1&#160;million unrealized losses as of December&#160;31, 2022. During the years ended December&#160;31, 2022 and 2021, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMjY5NA_a4f4951d-783e-4697-82b1-9b2d77067571">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMjY5NQ_04624f9a-ad98-4190-a6aa-c1291b1a203b">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmFkZjlmNjE4MzU4OTRhNmM4OTUzOTZlYmM5NDU1Y2IwL3RhYmxlcmFuZ2U6YWRmOWY2MTgzNTg5NGE2Yzg5NTM5NmViYzk0NTVjYjBfMi0xLTEtMS05MjE1MA_de489bba-66b9-441a-9ac4-10e8e59e4648"
      unitRef="usd">501195000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmFkZjlmNjE4MzU4OTRhNmM4OTUzOTZlYmM5NDU1Y2IwL3RhYmxlcmFuZ2U6YWRmOWY2MTgzNTg5NGE2Yzg5NTM5NmViYzk0NTVjYjBfMi0zLTEtMS05MjE1MA_587c4d7e-fbd2-487a-b944-985da759a51c"
      unitRef="usd">647169000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmFkZjlmNjE4MzU4OTRhNmM4OTUzOTZlYmM5NDU1Y2IwL3RhYmxlcmFuZ2U6YWRmOWY2MTgzNTg5NGE2Yzg5NTM5NmViYzk0NTVjYjBfNC0xLTEtMS05MjE1MA_c2fce49a-63ed-40c3-8e60-9155a7cb94cc"
      unitRef="usd">1482000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmFkZjlmNjE4MzU4OTRhNmM4OTUzOTZlYmM5NDU1Y2IwL3RhYmxlcmFuZ2U6YWRmOWY2MTgzNTg5NGE2Yzg5NTM5NmViYzk0NTVjYjBfNC0zLTEtMS05MjE1MA_2e23683a-d2e3-4ba6-94fa-f65e66db14a3"
      unitRef="usd">16722000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmFkZjlmNjE4MzU4OTRhNmM4OTUzOTZlYmM5NDU1Y2IwL3RhYmxlcmFuZ2U6YWRmOWY2MTgzNTg5NGE2Yzg5NTM5NmViYzk0NTVjYjBfNS0xLTEtMS05MjE1MA_b5637d6f-5d0a-4816-8247-5b30705b1fd9"
      unitRef="usd">502677000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmFkZjlmNjE4MzU4OTRhNmM4OTUzOTZlYmM5NDU1Y2IwL3RhYmxlcmFuZ2U6YWRmOWY2MTgzNTg5NGE2Yzg5NTM5NmViYzk0NTVjYjBfNS0zLTEtMS05MjE1MA_0ba83212-68d6-42bd-aa1e-daf80d50faed"
      unitRef="usd">663891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMjcxOA_7c63f789-3fed-4370-be15-d09d3b6de9ce">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,887,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,085,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7f1d4c0db61942b98ec8d831869eff8a_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMy0xLTEtMS05MjE1MA_f4d613af-b9fe-4abb-ae8f-d76d9df06002"
      unitRef="usd">722018000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7f1d4c0db61942b98ec8d831869eff8a_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMy0zLTEtMS05MjE1MA_58f2e6ed-648a-4112-978d-8dbdcf43279d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7f1d4c0db61942b98ec8d831869eff8a_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMy01LTEtMS05MjE1MA_430d8a73-2f3b-4a0a-9f79-5852af77574c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f1d4c0db61942b98ec8d831869eff8a_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMy03LTEtMS05MjE1MA_1cc40f7d-baed-48c4-940f-e4a2c8366e3e"
      unitRef="usd">722018000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1b10b0b7dac44f40b1acc72e8f727bc8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNC0xLTEtMS05MjE1MA_29ac01a0-2e4e-4ca6-a0d4-368042659948"
      unitRef="usd">810439000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1b10b0b7dac44f40b1acc72e8f727bc8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNC0zLTEtMS05MjE1MA_e74a2f5c-b5dc-4f27-8196-9f2e69a138af"
      unitRef="usd">541000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1b10b0b7dac44f40b1acc72e8f727bc8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNC01LTEtMS05MjE1MA_75c4d943-9b8e-4308-abc6-c0922e4bd617"
      unitRef="usd">13132000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1b10b0b7dac44f40b1acc72e8f727bc8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNC03LTEtMS05MjE1MA_8639a94e-e2cc-4e6c-9b22-af542ba934c8"
      unitRef="usd">797848000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i57b0ec642b2d416d99ecaed9d2670965_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNS0xLTEtMS05MjE1MA_145a0565-2846-47e5-bb9e-ae22f9663712"
      unitRef="usd">338218000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i57b0ec642b2d416d99ecaed9d2670965_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNS0zLTEtMS05MjE1MA_30775ee0-d36c-485b-a998-85afa1562734"
      unitRef="usd">48000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i57b0ec642b2d416d99ecaed9d2670965_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNS01LTEtMS05MjE1MA_7d0ab2e1-176a-4e12-bf15-d0693055b00f"
      unitRef="usd">5679000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57b0ec642b2d416d99ecaed9d2670965_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNS03LTEtMS05MjE1MA_0a58a070-a7f9-4ba6-9ed8-77a533d9f4d6"
      unitRef="usd">332587000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic56eac004a664b27807f0d574730e620_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNi0xLTEtMS05MjE1MA_5751340f-a624-4791-82b0-3ba623c570ee"
      unitRef="usd">16385000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic56eac004a664b27807f0d574730e620_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNi0zLTEtMS05MjE1MA_e80f40f4-af03-4243-935d-dcb6c07a17b0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic56eac004a664b27807f0d574730e620_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNi01LTEtMS05MjE1MA_2d434522-beaa-4292-b3d1-36a149458d7d"
      unitRef="usd">223000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic56eac004a664b27807f0d574730e620_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNi03LTEtMS05MjE1MA_49eeda93-1aab-4b22-9ac3-38db902bd680"
      unitRef="usd">16162000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNy0xLTEtMS05MjE1MA_8341a45b-e077-423a-9d7c-285ed38ec992"
      unitRef="usd">1887060000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNy0zLTEtMS05MjE1MA_1d61c439-ea80-4a84-a615-9c5af3def8b0"
      unitRef="usd">589000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNy01LTEtMS05MjE1MA_c3eac080-9aba-4f44-915b-dfa8550137da"
      unitRef="usd">19034000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfNy03LTEtMS05MjE1MA_55c4fe68-f9aa-4032-bf96-15a436eedf57"
      unitRef="usd">1868615000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i20c6ba758c364e9cbc586045aa0a9faa_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfOC0xLTEtMS05MjE1MA_047174e6-80ef-4bf6-91dd-d92a8a957e34"
      unitRef="usd">41000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i20c6ba758c364e9cbc586045aa0a9faa_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfOC0zLTEtMS05MjE1MA_25ee9acc-1bf7-460e-ac9d-4e8663674fcc"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i20c6ba758c364e9cbc586045aa0a9faa_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfOC01LTEtMS05MjE1MA_fcb89d40-a6ff-4cbe-9a64-b35745f07003"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i20c6ba758c364e9cbc586045aa0a9faa_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfOC03LTEtMS05MjE1MA_82286207-b186-4b97-af8e-fa4196b540f2"
      unitRef="usd">41000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i191d7158380c4447a4808cab8812db7f_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfOS0xLTEtMS05MjE1MA_243c3739-a0c9-4417-b181-16241476031b"
      unitRef="usd">94344000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i191d7158380c4447a4808cab8812db7f_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfOS0zLTEtMS05MjE1MA_331af498-fd86-45b5-abfc-0a383f165426"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i191d7158380c4447a4808cab8812db7f_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfOS01LTEtMS05MjE1MA_4578e31a-6dae-4483-beb6-4a461448c99f"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i191d7158380c4447a4808cab8812db7f_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfOS03LTEtMS05MjE1MA_211aafc4-513c-4529-8dcc-b05862df325c"
      unitRef="usd">94344000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i1b13e9beb6b943898d6cef7a1e02fc9e_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMTAtMS0xLTEtOTIxNTA_ad5cf0bc-9152-4e22-ac7d-b7284bd35525"
      unitRef="usd">103681000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i1b13e9beb6b943898d6cef7a1e02fc9e_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMTAtMy0xLTEtOTIxNTA_0892d922-ca70-45c5-8cdf-bbd76297d53f"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i1b13e9beb6b943898d6cef7a1e02fc9e_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMTAtNS0xLTEtOTIxNTA_58accac9-9cde-4918-8a12-729e4c3f5322"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i1b13e9beb6b943898d6cef7a1e02fc9e_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMTAtNy0xLTEtOTIxNTA_b55331f3-992d-4bd3-be42-8c853e3e8905"
      unitRef="usd">103681000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMTEtMS0xLTEtOTIxNTA_6b0ed635-198e-4800-98a9-7351b7b0a9b3"
      unitRef="usd">2085126000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMTEtMy0xLTEtOTIxNTA_3e9885d9-dc2e-4b2e-85db-dd99661ceefe"
      unitRef="usd">589000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMTEtNS0xLTEtOTIxNTA_0c68445e-2eb7-41ad-b86e-93d60a81410b"
      unitRef="usd">19034000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjYzMWRiMzEwMzgyNDRmMzc5NWU2ZTAyMGMzNmU0MzEyL3RhYmxlcmFuZ2U6NjMxZGIzMTAzODI0NGYzNzk1ZTZlMDIwYzM2ZTQzMTJfMTEtNy0xLTEtOTIxNTA_89a209b8-74a0-4354-bed1-dea4d53e94bc"
      unitRef="usd">2066681000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic5acd41dc9f24b53b18e9a7c0319506c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMy0xLTEtMS05MjE1MA_2afb4190-ce0d-4ae6-a469-13b357c755cf"
      unitRef="usd">945801000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic5acd41dc9f24b53b18e9a7c0319506c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMy0zLTEtMS05MjE1MA_f5e02a54-76b8-4edf-90b0-e703240dd23f"
      unitRef="usd">42000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic5acd41dc9f24b53b18e9a7c0319506c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMy01LTEtMS05MjE1MA_b4bb10c8-3f82-41b2-bd31-d9fadfbf4e8e"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic5acd41dc9f24b53b18e9a7c0319506c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMy03LTEtMS05MjE1MA_bb0826ef-a77a-4851-9976-ef8df7d2ac0c"
      unitRef="usd">945841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibf3d41d8f12c40e4baaa791aadb41393_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNC0xLTEtMS05MjE1MA_43b2923c-213c-45b4-8044-c80838313a95"
      unitRef="usd">541774000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibf3d41d8f12c40e4baaa791aadb41393_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNC0zLTEtMS05MjE1MA_2a80f24c-336e-48b1-a313-9c9c555be6ad"
      unitRef="usd">876000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibf3d41d8f12c40e4baaa791aadb41393_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNC01LTEtMS05MjE1MA_ad4ddc63-fa96-4467-b331-165355b4ec2b"
      unitRef="usd">1672000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibf3d41d8f12c40e4baaa791aadb41393_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNC03LTEtMS05MjE1MA_d2c5337e-02fd-4433-8659-320e2abc6079"
      unitRef="usd">540978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i32b96a13da9e4c34a6911c04c05af3e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNS0xLTEtMS05MjE1MA_ed444065-c83b-4e1a-b3ce-ca2030438855"
      unitRef="usd">33965000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i32b96a13da9e4c34a6911c04c05af3e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNS0zLTEtMS05MjE1MA_1ebfa874-b90f-45bd-aecf-366f1b4711b3"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i32b96a13da9e4c34a6911c04c05af3e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNS01LTEtMS05MjE1MA_7937eeb9-6661-408d-9a01-cb96c935a75b"
      unitRef="usd">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i32b96a13da9e4c34a6911c04c05af3e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNS03LTEtMS05MjE1MA_00e0bd09-53cf-47ac-a714-007a34510475"
      unitRef="usd">33945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i78d5da90485a4254a56630c577874e45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNi0xLTEtMS05MjE1MA_3818a5b9-d45e-43ed-ad94-6d02fd8774ab"
      unitRef="usd">12924000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i78d5da90485a4254a56630c577874e45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNi0zLTEtMS05MjE1MA_a19c2022-8b44-435d-ba3d-b129280423d9"
      unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i78d5da90485a4254a56630c577874e45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNi01LTEtMS05MjE1MA_c83dca79-91c8-4606-9dc5-152928a2a31b"
      unitRef="usd">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i78d5da90485a4254a56630c577874e45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNi03LTEtMS05MjE1MA_f6c30655-3a43-4436-83cb-07d4ca6eb844"
      unitRef="usd">12904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNy0xLTEtMS05MjE1MA_d2d90b01-c613-4b8c-856f-b13fb6526e3c"
      unitRef="usd">1534464000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNy0zLTEtMS05MjE1MA_00a5c6f5-56d3-4dd6-89f6-0731baaa3452"
      unitRef="usd">934000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNy01LTEtMS05MjE1MA_87bd1e73-8a6b-49bb-bad5-1a2218c44782"
      unitRef="usd">1730000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfNy03LTEtMS05MjE1MA_f9e2dc93-e32a-40a3-9076-45de1393bd75"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i972ae3af601c4166b2b7375fcce4b2f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfOC0xLTEtMS05MjE1MA_50580b40-477d-47fe-b166-8e4d3cc7dcc8"
      unitRef="usd">135653000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i972ae3af601c4166b2b7375fcce4b2f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfOC0zLTEtMS05MjE1MA_3c5a14d1-fa5a-44f7-8437-34173102816c"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i972ae3af601c4166b2b7375fcce4b2f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfOC01LTEtMS05MjE1MA_a1fb9087-318b-4d73-8f0c-a48dec7d4936"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i972ae3af601c4166b2b7375fcce4b2f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfOC03LTEtMS05MjE1MA_cbf668e3-5099-444b-8251-bd2278ef04e8"
      unitRef="usd">135653000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i97a943d0ee094645bee3a1a59e2108dc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfOS0xLTEtMS05MjE1MA_ed092222-77fd-4c6a-b665-51120f05caa1"
      unitRef="usd">66531000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i97a943d0ee094645bee3a1a59e2108dc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfOS0zLTEtMS05MjE1MA_307cb6b7-92c2-4211-86cc-56656c412ce5"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i97a943d0ee094645bee3a1a59e2108dc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfOS01LTEtMS05MjE1MA_1630baa4-6955-44d5-a555-513c98a7fe80"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i97a943d0ee094645bee3a1a59e2108dc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfOS03LTEtMS05MjE1MA_2a93f34d-95a6-424b-91f5-7c28442e4fb5"
      unitRef="usd">66531000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="ic81da6fcbafc408f85a016575fc626ad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMTAtMS0xLTEtOTIxNTA_6706da3a-8f4c-4281-8f9a-8db9a401b631"
      unitRef="usd">119056000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="ic81da6fcbafc408f85a016575fc626ad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMTAtMy0xLTEtOTIxNTA_7768c73e-f12c-4e67-b6d5-2ef8c9ee12ed"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="ic81da6fcbafc408f85a016575fc626ad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMTAtNS0xLTEtOTIxNTA_e7a45be0-016b-46b2-8774-d8dfa4e7dbc2"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="ic81da6fcbafc408f85a016575fc626ad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMTAtNy0xLTEtOTIxNTA_71676153-41d4-43cf-bc99-a31a2945ccd8"
      unitRef="usd">119056000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMTEtMS0xLTEtOTIxNTA_1b5fcf3b-4224-4fe3-a43f-98c046121def"
      unitRef="usd">1855704000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMTEtMy0xLTEtOTIxNTA_4d8e8cde-6c0c-43ee-b9d5-94b59e4a8de2"
      unitRef="usd">934000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMTEtNS0xLTEtOTIxNTA_e3743e8f-447c-4c41-93f6-d4a1fb2fb803"
      unitRef="usd">1730000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjY1NmYyYmNkYmFhYzRkZTQ4MTEzNjE0NTBkOTVjYzBjL3RhYmxlcmFuZ2U6NjU2ZjJiY2RiYWFjNGRlNDgxMTM2MTQ1MGQ5NWNjMGNfMTEtNy0xLTEtOTIxNTA_c91e4afd-2667-4409-bc3c-cda49ce804fb"
      unitRef="usd">1854908000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:InterestReceivable
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMTIzNQ_eda69a76-31ec-4557-9635-acc45cfc792b"
      unitRef="usd">7300000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMTI0Mg_13b6d333-6da6-47cc-a68c-0f0890c86a9c"
      unitRef="usd">2900000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMjcyNA_fa9eaa10-4995-4ee9-acab-31d7245782b3">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,030,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i1b10b0b7dac44f40b1acc72e8f727bc8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjllMTc2YmNjYzdiZDRkOTE4YmE2YmIyNmE1NDJhNThmL3RhYmxlcmFuZ2U6OWUxNzZiY2NjN2JkNGQ5MThiYTZiYjI2YTU0MmE1OGZfMi0xLTEtMS05MjE1MA_950317d6-055b-4bfa-bf13-7ff9b0aa487a"
      unitRef="usd">706711000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i1b10b0b7dac44f40b1acc72e8f727bc8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjllMTc2YmNjYzdiZDRkOTE4YmE2YmIyNmE1NDJhNThmL3RhYmxlcmFuZ2U6OWUxNzZiY2NjN2JkNGQ5MThiYTZiYjI2YTU0MmE1OGZfMi0zLTEtMS05MjE1MA_6bb9c2a5-4d97-401f-9b21-8d8c36ec441e"
      unitRef="usd">13132000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i57b0ec642b2d416d99ecaed9d2670965_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjllMTc2YmNjYzdiZDRkOTE4YmE2YmIyNmE1NDJhNThmL3RhYmxlcmFuZ2U6OWUxNzZiY2NjN2JkNGQ5MThiYTZiYjI2YTU0MmE1OGZfMy0xLTEtMS0xMDYzNjM_177a2e41-4201-4dad-9a97-5961eb3b9032"
      unitRef="usd">308307000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i57b0ec642b2d416d99ecaed9d2670965_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjllMTc2YmNjYzdiZDRkOTE4YmE2YmIyNmE1NDJhNThmL3RhYmxlcmFuZ2U6OWUxNzZiY2NjN2JkNGQ5MThiYTZiYjI2YTU0MmE1OGZfMy0zLTEtMS0xMDYzNjM_b3254282-4af2-4566-bc9e-7cabcba42883"
      unitRef="usd">5679000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ic56eac004a664b27807f0d574730e620_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjllMTc2YmNjYzdiZDRkOTE4YmE2YmIyNmE1NDJhNThmL3RhYmxlcmFuZ2U6OWUxNzZiY2NjN2JkNGQ5MThiYTZiYjI2YTU0MmE1OGZfNS0xLTEtMS05MjE1MA_ac90a56a-3bd7-48bf-8130-85558742cfe4"
      unitRef="usd">15792000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ic56eac004a664b27807f0d574730e620_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjllMTc2YmNjYzdiZDRkOTE4YmE2YmIyNmE1NDJhNThmL3RhYmxlcmFuZ2U6OWUxNzZiY2NjN2JkNGQ5MThiYTZiYjI2YTU0MmE1OGZfNS0zLTEtMS05MjE1MA_1465ec79-d334-45f4-8e45-31f4b7f13274"
      unitRef="usd">223000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjllMTc2YmNjYzdiZDRkOTE4YmE2YmIyNmE1NDJhNThmL3RhYmxlcmFuZ2U6OWUxNzZiY2NjN2JkNGQ5MThiYTZiYjI2YTU0MmE1OGZfNi0xLTEtMS05MjE1MA_8ae91f9c-c7c2-4f3a-92a6-26b784163625"
      unitRef="usd">1030810000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjllMTc2YmNjYzdiZDRkOTE4YmE2YmIyNmE1NDJhNThmL3RhYmxlcmFuZ2U6OWUxNzZiY2NjN2JkNGQ5MThiYTZiYjI2YTU0MmE1OGZfNi0zLTEtMS05MjE1MA_68e679be-d8d8-451c-ae71-946c39070131"
      unitRef="usd">19034000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ibf3d41d8f12c40e4baaa791aadb41393_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfMy0xLTEtMS05MjE1MA_6a1ad48d-2e0e-4a83-ae97-1ca2b6b9e27d"
      unitRef="usd">385053000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ibf3d41d8f12c40e4baaa791aadb41393_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfMy0zLTEtMS05MjE1MA_7599c6f3-93ea-40ff-8642-e84e2995a016"
      unitRef="usd">1672000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ic5acd41dc9f24b53b18e9a7c0319506c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfNC0xLTEtMS05MjE1MA_d58c9ad7-5fba-4ade-a79a-89de1f0b9e02"
      unitRef="usd">43290000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ic5acd41dc9f24b53b18e9a7c0319506c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfNC0zLTEtMS05MjE1MA_de02e308-570f-4488-9a86-852c05de6394"
      unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i32b96a13da9e4c34a6911c04c05af3e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfNS0xLTEtMS05MjE1MA_9dd9fa00-cc6d-4de8-9dd2-41be223e5b59"
      unitRef="usd">18962000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i32b96a13da9e4c34a6911c04c05af3e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfNS0zLTEtMS05MjE1MA_c9dbc710-37c3-4b41-a6d8-936a7f90f30a"
      unitRef="usd">21000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i78d5da90485a4254a56630c577874e45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfNi0xLTEtMS05MjE1MA_67b9ba16-7421-4203-83ee-57775525487f"
      unitRef="usd">7475000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i78d5da90485a4254a56630c577874e45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfNi0zLTEtMS05MjE1MA_896f798b-930a-42e3-8cc3-654b4a362b74"
      unitRef="usd">35000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfNy0xLTEtMS05MjE1MA_a0eacc5b-e84a-4fd1-9590-70fb05bbe36e"
      unitRef="usd">454780000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOjRiMzg5YTk3M2JkOTQ5ZTg4MTc1NzBkMzkxNTNkZjc5L3RhYmxlcmFuZ2U6NGIzODlhOTczYmQ5NDllODgxNzU3MGQzOTE1M2RmNzlfNy0zLTEtMS05MjE1MA_524eaaba-abe8-4f13-89d4-538c573cae5a"
      unitRef="usd">1730000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMTk1OQ_1ef845a1-c966-4ad0-ba3f-e0ad07357015"
      unitRef="investment">285</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMTk2Ng_3fd94db6-f875-4a5a-8908-793c4424984c"
      unitRef="investment">133</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <exel:NumberOfBondSecurities
      contextRef="i1b10b0b7dac44f40b1acc72e8f727bc8_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfNTQ5NzU1ODE3ODg3_fad596fa-b6d3-40da-8f9c-17870eec5f9a"
      unitRef="bond">76</exel:NumberOfBondSecurities>
    <exel:NumberOfBondSecurities
      contextRef="ic56eac004a664b27807f0d574730e620_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfNTQ5NzU1ODE3ODk1_8bca7657-d416-43fe-bb5e-3a0f7b2cc274"
      unitRef="bond">4</exel:NumberOfBondSecurities>
    <exel:NumberOfSponsoredEnterprises
      contextRef="i57b0ec642b2d416d99ecaed9d2670965_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfNTQ5NzU1ODE3OTY4_b0e0f9bc-f809-42f8-8203-19604a770664"
      unitRef="numberofsponsoredenterprise">1</exel:NumberOfSponsoredEnterprises>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfNTQ5NzU1ODE3OTg2_23703ec1-4d37-454d-b5ec-12e6194e6594"
      unitRef="usd">237600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfNTQ5NzU1ODE3OTk1_523a143c-7e24-429c-881b-3d984fcbe1d2"
      unitRef="usd">6100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMjA3OQ_975b6538-a8ec-48a9-92e5-3cb6f436c3bd"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMjA3OQ_98e4cac8-e79a-4162-92a5-9ba3521eb737"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RleHRyZWdpb246MjMxODY5MjZmMzVlNDVmNzk2MzBhYzY2ODBlZDk4ZDdfMjcwOQ_1066a96a-985d-4717-ad77-fd55bf6990ab">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmRiNDZkODIxNmY2NTRkZWVhMDQzNGQ0NjI4NmU2ZmY1L3RhYmxlcmFuZ2U6ZGI0NmQ4MjE2ZjY1NGRlZWEwNDM0ZDQ2Mjg2ZTZmZjVfMi0xLTEtMS05MjE1MA_45a41a10-6255-4395-add5-20f13f2d76d1"
      unitRef="usd">1114884000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmRiNDZkODIxNmY2NTRkZWVhMDQzNGQ0NjI4NmU2ZmY1L3RhYmxlcmFuZ2U6ZGI0NmQ4MjE2ZjY1NGRlZWEwNDM0ZDQ2Mjg2ZTZmZjVfMi0zLTEtMS05MjE1MA_2a2a366e-4cc7-468e-9ce9-b8e24c564c78"
      unitRef="usd">1168256000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmRiNDZkODIxNmY2NTRkZWVhMDQzNGQ0NjI4NmU2ZmY1L3RhYmxlcmFuZ2U6ZGI0NmQ4MjE2ZjY1NGRlZWEwNDM0ZDQ2Mjg2ZTZmZjVfMy0xLTEtMS05MjE1MA_316bb038-3e26-4219-b653-75f4a6ca8660"
      unitRef="usd">753731000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmRiNDZkODIxNmY2NTRkZWVhMDQzNGQ0NjI4NmU2ZmY1L3RhYmxlcmFuZ2U6ZGI0NmQ4MjE2ZjY1NGRlZWEwNDM0ZDQ2Mjg2ZTZmZjVfMy0zLTEtMS05MjE1MA_4013c05e-c819-411c-9cbb-f7dbed3891c8"
      unitRef="usd">365412000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmRiNDZkODIxNmY2NTRkZWVhMDQzNGQ0NjI4NmU2ZmY1L3RhYmxlcmFuZ2U6ZGI0NmQ4MjE2ZjY1NGRlZWEwNDM0ZDQ2Mjg2ZTZmZjVfNC0xLTEtMS05MjE1MA_d514adde-924a-4b50-977a-d87576740fe8"
      unitRef="usd">1868615000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85MS9mcmFnOjIzMTg2OTI2ZjM1ZTQ1Zjc5NjMwYWM2NjgwZWQ5OGQ3L3RhYmxlOmRiNDZkODIxNmY2NTRkZWVhMDQzNGQ0NjI4NmU2ZmY1L3RhYmxlcmFuZ2U6ZGI0NmQ4MjE2ZjY1NGRlZWEwNDM0ZDQ2Mjg2ZTZmZjVfNC0zLTEtMS05MjE1MA_88567324-6d9e-410b-9e85-4852ea5bdf6f"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RleHRyZWdpb246OTlhOGUwYTIwODZiNGYyODhhOGY2NzFlODIyMjUyMjRfMTU1Mg_077efc74-f8fd-47fe-bf47-cb17356aa876">FAIR VALUE MEASUREMENTS &lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt"&gt;Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt"&gt;Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt"&gt;Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Forward Foreign Currency Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we initiated an operational hedging program and entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchange rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we had one forward contract outstanding to sell &#x20ac;3.6&#160;million. The forward contract with a maturity of three months is recorded at fair value and is included in prepaid expenses and other current assets in the Consolidated Balance Sheets. The unrealized loss on the forward contract is not material as of December&#160;31, 2022. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the years ended December&#160;31, 2022 and 2021 we recognized $1.2 million and $0.8 million of net gains on the maturity of forward contracts, which were included in other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RleHRyZWdpb246OTlhOGUwYTIwODZiNGYyODhhOGY2NzFlODIyMjUyMjRfMTU0OQ_d9bfbd37-3e02-481a-8e11-8f933b3055ee">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieebb4571285b4760b2d6ffadd98aa2a3_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfMi0xLTEtMS05MjE1MA_db904178-4835-4bd6-b6e3-490d710e6dc7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i678fac2def204c018d03c82ac9dbc312_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfMi0zLTEtMS05MjE1MA_3ea8eb08-cdf9-43c1-bd05-b0ee61559c91"
      unitRef="usd">722018000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2a347ff0104c4e37a0b5967300b9b308_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfMi01LTEtMS05MjE1MA_a0582d97-7311-4bff-8123-740b8045646e"
      unitRef="usd">722018000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2525f5b5cbe34620878e5e9e6f0c1c1e_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfMy0xLTEtMS05MjE1MA_b33f685d-6c7b-45a4-a3a6-759ae54652b8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4cd2228030e9433ab02d7801959e3ef3_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfMy0zLTEtMS05MjE1MA_d1c7256a-4841-4bb7-b763-e45eb367638e"
      unitRef="usd">797848000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40eb4f16efe747339fc781b4b8ab1d9d_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfMy01LTEtMS05MjE1MA_66dafdc9-1a46-4c04-8883-e48ac860a92e"
      unitRef="usd">797848000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic099aa5b5a354fd0bc57f4dfc1f82f5f_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNC0xLTEtMS05MjE1MA_c1d58d12-3ac2-4f8e-aa00-59173551e755"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6ff0318ea05d43dc8f548eb4b0abeaab_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNC0zLTEtMS05MjE1MA_47b89e58-09a9-4312-bdbb-41341c1fda7c"
      unitRef="usd">332587000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iace46fa599fd439ea6f6a1a2dd79a719_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNC01LTEtMS05MjE1MA_365387d6-86b7-403c-8ad9-5f65575094d0"
      unitRef="usd">332587000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia52f875fc7ea48afad6c5d1f838e319a_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNS0xLTEtMS05MjE1MA_9dceb5fe-c023-4005-8705-abc64e9268f3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a1f30ef6bf04adebfc61920cd8a412a_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNS0zLTEtMS05MjE1MA_e265cfd2-8c39-4d77-8312-7b3bb35461b2"
      unitRef="usd">16162000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i199c2fdbc09541b98fa084e45047c999_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNS01LTEtMS05MjE1MA_b5c85253-151e-40b9-8c71-6a4674a84e75"
      unitRef="usd">16162000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie569dd4e72ad4efea4960bffc82ca79e_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNi0xLTEtMS05MjE1MA_7f599c16-dbee-4206-b6c3-ddd47de97bd1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1a4566d6932b48aa8902d306c989ff52_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNi0zLTEtMS05MjE1MA_9de1b682-d98d-47d5-a521-5bef6d12e23a"
      unitRef="usd">1868615000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia82be6e971604c2da30b378bdf9985c9_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNi01LTEtMS05MjE1MA_12ed3945-8497-4c80-8a1a-8c307d472bce"
      unitRef="usd">1868615000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if3fc431dacf844f38ad9667dc0e877c2_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNy0xLTEtMS05MjE1MA_4548993b-1f82-46a6-ae31-bdcf41f38236"
      unitRef="usd">94344000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic96a10d99c47408289f5ad833d6120b8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNy0zLTEtMS05MjE1MA_a24f984c-4f0c-4e25-adca-d97aff14e7bf"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i75ea1cc7d48743c88632a3cf80cbd319_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfNy01LTEtMS05MjE1MA_df5ebaf3-b870-497a-b311-0b2b2ca45941"
      unitRef="usd">94344000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6a1d047b86f24d2083f214d75c5134ef_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfOC0xLTEtMS05MjE1MA_7a465a42-fbda-4c0d-bcb7-7107efeebee7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i51fb172e52eb436f82f975928b0d6479_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfOC0zLTEtMS05MjE1MA_a373f09f-d692-435f-af3c-5cf70130042d"
      unitRef="usd">103681000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia20e3dbd8a4d45d884a2d75792ca5567_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfOC01LTEtMS05MjE1MA_3b9f6906-bfa6-44a7-98c1-a578cc9da5da"
      unitRef="usd">103681000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie569dd4e72ad4efea4960bffc82ca79e_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfOS0xLTEtMS05MjE1MA_b02cbb2a-37e0-46ac-9824-35d26123f4b9"
      unitRef="usd">94344000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1a4566d6932b48aa8902d306c989ff52_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfOS0zLTEtMS05MjE1MA_fcb4919a-91c9-4bb4-a920-a58480af7336"
      unitRef="usd">1972296000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia82be6e971604c2da30b378bdf9985c9_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOmU1ZmVkYmE5OTdjODQ2MmZiYzIzMzIyNjExYjg4Mjg2L3RhYmxlcmFuZ2U6ZTVmZWRiYTk5N2M4NDYyZmJjMjMzMjI2MTFiODgyODZfOS01LTEtMS05MjE1MA_dcafdeee-fb0b-4706-b4fb-1723b7da7518"
      unitRef="usd">2066640000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i471e33a44e454a859ed17e9d46754e8e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfMi0xLTEtMS05MjE1MA_bf4f56cc-5e3a-440a-9914-0bcf1565df34"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibfd0873a4a96461ba27862f3c00db9c8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfMi0zLTEtMS05MjE1MA_b6b8ae25-81d5-4899-9cfe-82a9257b4f0e"
      unitRef="usd">945841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f0f51588cc244e6bc024c642a236d9e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfMi01LTEtMS05MjE1MA_629bc414-b59a-4cfb-835d-18794ad09de2"
      unitRef="usd">945841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i726e2aeff8e4434ab43684910d66fa92_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfMy0xLTEtMS05MjE1MA_0d156e9f-19e2-460c-9fc5-89e6ee00fc2e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i10af3e3a1cd64127a91cee9c3a18360c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfMy0zLTEtMS05MjE1MA_80d6d19e-0ee3-4225-9344-ff186c46f8e8"
      unitRef="usd">540978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6aefb57539a84853a9275b9c5978a13c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfMy01LTEtMS05MjE1MA_a094adbe-1013-4a31-8c4a-170a27aeb90c"
      unitRef="usd">540978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1ef8749612e74ad38eff74f7f8441bae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNC0xLTEtMS05MjE1MA_87d2704d-81ec-434f-943b-1f6431c0976a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9fd89a3bfdd74436bbebaf5f5a836492_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNC0zLTEtMS05MjE1MA_52918966-7713-4a9e-bc6f-a002b635fa19"
      unitRef="usd">33945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iebe7e70eb57b4339a8a7e41055b873ab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNC01LTEtMS05MjE1MA_873e6efb-3c6e-4f55-9c21-2bf508b23ce8"
      unitRef="usd">33945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iada6509b74ef42d1ab3a02e9916aa003_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNS0xLTEtMS05MjE1MA_8423543a-29f4-4ce9-8d5a-fec1a6809660"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i97e1a85481df47c6ba245c6579743863_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNS0zLTEtMS05MjE1MA_da45bd50-ac4a-42ca-89ca-ffd2193c9eb0"
      unitRef="usd">12904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i73559db97810456c9b104a736adc72f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNS01LTEtMS05MjE1MA_71625a24-742d-4f3f-a013-eba09b1964f6"
      unitRef="usd">12904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i35acff8b86c74ab6877bd2ff37df8915_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNi0xLTEtMS05MjE1MA_a86d3665-506f-4ae7-8ddd-9d3aff6a9961"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic3b577aa781240a89ea986321d268054_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNi0zLTEtMS05MjE1MA_bac7e9fb-8d5f-4340-8829-4380294e9461"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2bc81f428a0846d484b97bfeeb05fb15_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNi01LTEtMS05MjE1MA_58548466-9009-48e3-994b-666f3e08e529"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6b4bcecee8844c49bc7fe25f8b70e6b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNy0xLTEtMS05MjE1MA_0a2f90ef-5d93-4ab3-ac0e-c4d13957d685"
      unitRef="usd">66531000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i333e0adca8ad4c98adc9303eaa294dee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNy0zLTEtMS05MjE1MA_ce3412ab-6802-4131-a0cb-bda0589948a3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia12585f72d404b3b9451798d475c2669_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfNy01LTEtMS05MjE1MA_4d3714eb-a45a-4bdc-82ce-415f2d142d80"
      unitRef="usd">66531000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8d2966ecc3e24e2cb9545a4f31ab7a68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfOC0xLTEtMS05MjE1MA_471d155a-36c5-426f-9173-83f6d89c71aa"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4dfc0620ff1b4f0d83f4e9ed4f789075_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfOC0zLTEtMS05MjE1MA_d1364f0a-1505-4328-bbaa-bab2092a99f3"
      unitRef="usd">119056000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iddcafb03f418408d86fae11b5091d968_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfOC01LTEtMS05MjE1MA_f6bfb835-8906-4a13-b46a-85f384ace19a"
      unitRef="usd">119056000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i35acff8b86c74ab6877bd2ff37df8915_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfOS0xLTEtMS05MjE1MA_3277b793-69ec-4005-9c62-c16301ff1040"
      unitRef="usd">66531000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic3b577aa781240a89ea986321d268054_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfOS0zLTEtMS05MjE1MA_03e27575-d7ba-40fb-a4f9-082b0088d4cc"
      unitRef="usd">1652724000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2bc81f428a0846d484b97bfeeb05fb15_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RhYmxlOjFlYzkyOGU1OTRiYjQ1YTM4NGRmMTQwYTViNDE1ODlmL3RhYmxlcmFuZ2U6MWVjOTI4ZTU5NGJiNDVhMzg0ZGYxNDBhNWI0MTU4OWZfOS01LTEtMS05MjE1MA_3b04e5dd-b4c0-428c-af31-381f714db695"
      unitRef="usd">1719255000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="i12667066e7cc4662b0936e2e393953fd_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RleHRyZWdpb246OTlhOGUwYTIwODZiNGYyODhhOGY2NzFlODIyMjUyMjRfNTQ5NzU1ODE3MzI2_e44b9386-1332-473a-ada2-1f265e3ff960"
      unitRef="derivative_instrument">1</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i12667066e7cc4662b0936e2e393953fd_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RleHRyZWdpb246OTlhOGUwYTIwODZiNGYyODhhOGY2NzFlODIyMjUyMjRfNTQ5NzU1ODE3MzY5_0f2776d3-8eb2-49f4-bf0c-7b96e06c1d79"
      unitRef="eur">3600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeTermOfContract
      contextRef="i042731f45c434908a7097f420a97138c_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RleHRyZWdpb246OTlhOGUwYTIwODZiNGYyODhhOGY2NzFlODIyMjUyMjRfMzg0ODI5MDcwMTMxMA_bb4e8a35-0f7d-4247-9f58-984b692c0287">P3M</us-gaap:DerivativeTermOfContract>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i042731f45c434908a7097f420a97138c_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RleHRyZWdpb246OTlhOGUwYTIwODZiNGYyODhhOGY2NzFlODIyMjUyMjRfNTQ5NzU1ODE4Mjc5_8b3cbb48-75e6-4e56-b745-5db01bfb9d23"
      unitRef="usd">1200000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i4218de4396fe4f889b222285008565ab_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85NC9mcmFnOjk5YThlMGEyMDg2YjRmMjg4YThmNjcxZTgyMjI1MjI0L3RleHRyZWdpb246OTlhOGUwYTIwODZiNGYyODhhOGY2NzFlODIyMjUyMjRfNTQ5NzU1ODE4MTM4_b24dee34-f583-426e-9320-354dadc0dfdf"
      unitRef="usd">800000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RleHRyZWdpb246NDM3YjA1Y2E5ODZmNDNlZWJlZjA5Mzg4OTcyNjZiNDBfODI_8ef94b62-be67-4560-b757-85d773b6e6dc">INVENTORY&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RleHRyZWdpb246NDM3YjA1Y2E5ODZmNDNlZWJlZjA5Mzg4OTcyNjZiNDBfNzg_5999db61-dd30-4a2c-9962-810405e6b310">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfMi0xLTEtMS05MjE1MA_c309b81f-da77-4921-b38a-021803ba868c"
      unitRef="usd">8077000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfMi0zLTEtMS05MjE1MA_37d7ac0a-9f3d-48d8-a983-92dbcdd143dc"
      unitRef="usd">8867000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfMy0xLTEtMS05MjE1MA_0cb509d3-bb7e-4802-a0f1-2eb703b4c250"
      unitRef="usd">43564000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfMy0zLTEtMS05MjE1MA_f6e6b20f-3606-4f69-b2d3-c34cfd458d5b"
      unitRef="usd">27717000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfNC0xLTEtMS05MjE1MA_29b1fc3d-c2c5-4ae4-a7b1-f239495c2c86"
      unitRef="usd">10635000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfNC0zLTEtMS05MjE1MA_b9a22864-9eed-4fcb-af21-a18669e69da5"
      unitRef="usd">12927000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfNS0xLTEtMS05MjE1MA_00701169-3e96-4267-b069-68c3dc8470e7"
      unitRef="usd">62276000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfNS0zLTEtMS05MjE1MA_881f7a5a-a099-4d8b-96a7-9dad54edc2c2"
      unitRef="usd">49511000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ibf9ed26c4ba2489591ac9c39a8bf7ce1_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfOC0xLTEtMS05MjE1MA_7e4e5b03-fac9-419e-b087-f1e30ebc4373"
      unitRef="usd">33299000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i6e4b169888c84090b5422b97549cd20c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfOC0zLTEtMS05NTgwMg_c803b2f2-3d14-4418-8c33-098bec006944"
      unitRef="usd">27493000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i08940ae14c044060b10d9ea3213210f3_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfOS0xLTEtMS05MjE1MA_4cf5975c-672f-4412-8df7-1c9dd3a66392"
      unitRef="usd">28977000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i54d01b1ebd6a4b07bfe50d2f94bef6b4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfOS0zLTEtMS05NTgwMg_b801253c-5bc9-43b6-b00d-b55e3af3c8ad"
      unitRef="usd">22018000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfMTAtMS0xLTEtOTIxNTA_4df37e5f-870e-40db-a230-19b47a206335"
      unitRef="usd">62276000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV85Ny9mcmFnOjQzN2IwNWNhOTg2ZjQzZWViZWYwOTM4ODk3MjY2YjQwL3RhYmxlOjk3NTQ2ZjgwNDllYTRhYThiMGZjYTBjOGE5ZjM0ZTA4L3RhYmxlcmFuZ2U6OTc1NDZmODA0OWVhNGFhOGIwZmNhMGM4YTlmMzRlMDhfMTAtMy0xLTEtOTIxNTA_a5353bbe-3628-443f-bec3-8596f17b7aae"
      unitRef="usd">49511000</us-gaap:InventoryGross>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90ZXh0cmVnaW9uOjU0ZjUwMjRkN2Y3ZjQ1ZjI4YWUyYmZhMmRlYWE2ZjI1XzIwMA_26db53c4-ba7c-4a5f-be02-e7185012994d">PROPERTY AND EQUIPMENT&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;up to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;up to 3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $20.9 million, $13.6 million and $9.1 million during the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90ZXh0cmVnaW9uOjU0ZjUwMjRkN2Y3ZjQ1ZjI4YWUyYmZhMmRlYWE2ZjI1XzIwMg_ed2bc7f3-01ae-4c9e-aeba-23de548d02c9">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;up to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;up to 3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i29abdea0de484029b656cfe3041033c3_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzItMS0xLTEtOTIxNTAvdGV4dHJlZ2lvbjo5Nzg0OTQxMGJlZTA0NTYyODZmMTEwYjJiNTM0ZTU0Nl8xMA_71088f02-2586-426f-ba79-ee27b246d25f">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ied09a4ba58274c3596cc89a3777f1174_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzItMy0xLTEtOTIxNTA_0be30cc8-5c82-4889-a8e9-6c537db423df"
      unitRef="usd">83334000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7215386183c44fd2aa5b09fe609d09a0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzItNS0xLTEtOTIxNTA_462d1e71-3376-4c83-8a5f-38179de31ec6"
      unitRef="usd">73589000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="idb968a7ec21c46bda8be17bee6c569df_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzMtMS0xLTEtOTIxNTAvdGV4dHJlZ2lvbjpkOTZkYjU5ZDJiODU0MzQ3YWRiYzkyMTUzNDU3MGFlZl8xNjQ5MjY3NDQxNjg4_c6cb34ad-85d4-4252-a1f9-0c004512f6ce">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i89d86279d8cf4c6688a69b3db5f0650e_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzMtMy0xLTEtOTIxNTA_a084d218-eaf7-461d-90e5-97a874f397db"
      unitRef="usd">19569000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i261b348dea0344bc94589101e7e53f5e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzMtNS0xLTEtOTIxNTA_4fed44ae-59f3-46d1-a56d-7e2a1bd6d67a"
      unitRef="usd">14877000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="icd4ba0df5aff4776bc4e4486814a14a1_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzUtMS0xLTEtOTIxNTA_d438460a-ca72-410e-9f25-7b38d51d3578">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3a48c86b35e6435ea5fd025596c4038e_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzUtMy0xLTEtOTIxNTA_c61d0bce-6f34-421d-80dd-600d33a8f43e"
      unitRef="usd">24054000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5e43db2475c746e19470fa095df95b14_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzUtNS0xLTEtOTIxNTA_e4176aca-7665-4bc9-a2bb-ad347c1e9c23"
      unitRef="usd">15780000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4e7aa72456ac4985a26e7ee7471b2167_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzYtMS0xLTEtOTIxNTA_54e93b1c-2cd5-45b4-ae0d-ce3ad3535932">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i44a51d0f954f47abb686f58842236e4b_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzYtMy0xLTEtOTIxNTA_c1b71be5-1c23-4a9c-9695-bf213697823e"
      unitRef="usd">39606000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0ebe5b3d3ea6429d897818f4d64c6c70_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzYtNS0xLTEtOTIxNTA_0993faa2-2dc8-45f2-af22-1435af95d319"
      unitRef="usd">23744000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5e2afee13177452697583dfe3fb2e778_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzctMy0xLTEtOTIxNTA_a1a61270-500e-43f5-a4a0-655298b4a9ef"
      unitRef="usd">4933000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib510a5b7f321419fafd9bcd1b30bce22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzctNS0xLTEtOTIxNTA_03a315b0-40ed-4b39-86b9-ef1f43e6a056"
      unitRef="usd">16872000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzgtMy0xLTEtOTIxNTA_9ce55344-f915-4a98-b6e4-59927a611d23"
      unitRef="usd">171496000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzgtNS0xLTEtOTIxNTA_b71fcad1-395d-4596-b15e-d6b2997e625d"
      unitRef="usd">144862000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzktMy0xLTEtOTIxNTA_45472229-f628-4721-a104-88e4a2b69ada"
      unitRef="usd">60872000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzktNS0xLTEtOTIxNTA_dd949083-9706-4ddf-ae12-c1ad003c30c2"
      unitRef="usd">40831000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzEwLTMtMS0xLTkyMTUw_da7eed05-071d-4eea-8db7-82cbe70728fa"
      unitRef="usd">110624000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90YWJsZTo0ODIxZWI2YjRlNzk0YjYxYTBhOGE2YmFiNTE2OWJhNS90YWJsZXJhbmdlOjQ4MjFlYjZiNGU3OTRiNjFhMGE4YTZiYWI1MTY5YmE1XzEwLTUtMS0xLTkyMTUw_637b63a0-37ab-4aaa-93d8-81206ed2bb53"
      unitRef="usd">104031000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90ZXh0cmVnaW9uOjU0ZjUwMjRkN2Y3ZjQ1ZjI4YWUyYmZhMmRlYWE2ZjI1XzEyOQ_8c22a4f5-e1ec-4646-9676-d02157ebba98"
      unitRef="usd">20900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90ZXh0cmVnaW9uOjU0ZjUwMjRkN2Y3ZjQ1ZjI4YWUyYmZhMmRlYWE2ZjI1XzEzMw_4f6bca01-8cc9-4c24-b14f-d05e9ed30e3b"
      unitRef="usd">13600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDAvZnJhZzo1NGY1MDI0ZDdmN2Y0NWYyOGFlMmJmYTJkZWFhNmYyNS90ZXh0cmVnaW9uOjU0ZjUwMjRkN2Y3ZjQ1ZjI4YWUyYmZhMmRlYWE2ZjI1XzE0MA_28154005-27b2-4b1e-b369-b6a1151dcd5f"
      unitRef="usd">9100000</us-gaap:Depreciation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkzMzQ_15808538-8f81-4278-8350-7784d19cd130">EMPLOYEE BENEFIT PLANS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Incentive Plans and ESPP&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have several equity incentive plans under which we granted stock options and RSUs, including PSUs, to employees and directors. On May 25, 2022, at the 2022 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The amendment and restatement increased the share reserve under the 2017 Plan by 28,500,000 shares. As of December&#160;31, 2022, 31,971,047 shares were available for grant under the 2017 Plan. The share reserve is reduced by 1 share for each share issued pursuant to a stock option and 2 shares for full value awards, including RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Board of Directors delegated responsibility for administration of our equity incentive plans to the Compensation Committee of our Board of Directors, including the authority to determine the term, exercise price and vesting requirements of each grant. Stock options granted to our employees and directors generally have a four-year vesting term and a one-year vesting term, respectively, an exercise price equal to the fair market value on the date of grant, and a seven-year life from the date of grant. RSUs granted to our employees and directors generally have a four-year vesting term and a one-year vesting term, respectively. PSUs granted pursuant to our equity incentive plans vest upon specified service conditions and the achievement of a performance target or market condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a Change in Control and Severance Benefit Plan for certain executive officers. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&#x2019;s employment is terminated without cause during a period commencing one month before and ending thirteen months following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all their outstanding equity awards accelerated and the exercise period for their stock options extended to no more than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of 85% of the closing price at the beginning of the offering period or 85% of the closing price at the end of each six-month purchase period. As of December&#160;31, 2022, we had &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,561,567&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares available for issuance under our ESPP. Pursuant to the ESPP, we issued 606,787, 536,226 and 534,419 shares of common stock at an average price per share of $16.63, $17.76 and $14.55 during the years ended December&#160;31, 2022, 2021 and 2020, respectively. Cash received &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from purchases under the ESPP for the years ended December 31, 2022, 2021 and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was $10.1 million, $9.5 million and $7.8 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We used a Black-Scholes Merton option pricing model to value stock options and ESPP purchases. The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We considered both implied and historical volatility in developing our estimate of expected volatility. The assumption for the expected life of stock options is based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#x2019; current expectations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of RSUs, including PSUs, was based on the closing price of the underlying common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for stock options during the year ended December&#160;31, 2022 was as follows (in thousands&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options exercisable at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there was $16.6 million of unrecognized compensation expense related to our unvested stock options. The compensation expense for the unvested stock options will be recognized over a weighted-average period of 2.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal year 2022 and the exercise prices, multiplied by the number of in-the-money stock options) that would have been received by the stock option holders had all stock option holders exercised their stock options on December&#160;31, 2022. The total intrinsic value of stock options exercised during the years ended December&#160;31, 2022, 2021 and 2020 was $36.5 million, $76.0 million and $106.5 million, respectively. Cash received from stock option exercises during the years ended December&#160;31, 2022, 2021 and 2020 was $13.9 million, $14.8 million and $26.9 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Activity for RSUs during the year ended December&#160;31, 2022 was as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there was $183.6 million of unrecognized compensation expense related to our unvested RSUs which will be recognized over a weighted-average period of 2.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for PSUs, during the year ended December&#160;31, 2022 was as follows (in thousands&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, in connection with our long-term incentive compensation program, we awarded to certain employees an aggregate of 1,003,482 (the 2022 target amount) RSUs that are subject to a total shareholder return (TSR) market condition (the 2022 TSR-based RSUs). The TSR market condition for the 2022 TSR-based RSUs is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 1, 2022 through January 3, 2025. Depending on the results relative to the TSR market condition, the holders of the 2022 TSR-based RSUs may earn up to 175% of the 2022 target amount of shares. 50% of the shares earned pursuant to the 2022 TSR-based RSU awards will vest at the end of the performance period, and the remainder will vest approximately one year later, subject to employee&#x2019;s continuous service. These TSR-based RSUs will be forfeited if the market condition at or above a threshold level is not achieved at the end of the performance period on January 3, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $33.17 per share for the 2022 TSR-based RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of Exelixis common stock on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Monte Carlo simulation model also assumed correlations of returns of the stock prices of Exelixis common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, in connection with our long-term incentive compensation program, we awarded certain employees 1,027,650 (the 2021 target amount) PSUs, subject to a performance and a market condition (the 2021 PSUs). Pursuant to the terms of 2021 PSUs, the holders of the awards may earn up to 200% of the 2021 target amount, or up to 2,055,300 total shares, depending on the level of achievement of the performance condition related to certain net product revenues and a TSR market condition. The TSR market condition for the 2021 PSUs is based on our relative TSR percentile rank compared to companies in the Nasdaq Biotechnology Index during the performance period, which is January 2, 2021 through December 29, 2023. 50% percent of the shares earned subject to the performance and market conditions will vest at the end of the performance period and the remainder will vest approximately one year later subject to an employee&#x2019;s continuous service. The 2021 PSUs will be forfeited if the performance condition at or above a threshold level is not achieved by December 29, 2023. The performance condition for target achievement of net product revenues relative to the 2021 PSUs was deemed probable of achievement in the fourth quarter of 2022 representing 100% of the 2021 PSUs target amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of Exelixis common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During the year ended December&#160;31, 2020, in connection with our long-term incentive compensation program, we awarded 2,327,840 PSUs (the 2020 target amount) that will vest upon the achievement of performance targets related to (i) clinical trial positive top-line results and (ii) product approvals by the FDA (the 2020 PSUs). Pursuant to the terms of the 2020 PSUs, employees may earn up to 200% of the 2020 target amount, or 4,655,680 total shares, depending on the volume and timing of achievement of the performance targets. The 2020 PSUs will be forfeited if the performance targets are not met by December 31, 2024. The performance condition for threshold achievement of a product approval by the FDA relative to the 2020 PSUs occurred in the third quarter of 2021, representing 25% of the 2020 target amount. The performance condition for threshold achievement of positive top-line results by the FDA relative to the 2020 PSUs occurred in the third quarter of 2022, representing 25% of the 2020 target amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense recognition for PSUs commences when it is determined that attainment of the performance target is probable. Of the outstanding PSUs as of December&#160;31, 2022, 869,502 relate to awards for which we achieved the performance target. As of December&#160;31, 2022, the remaining unrecognized compensation expense for the PSUs achieved or deemed probable of achievement related to the PSUs was $11.0 million, which will be recognized over a weighted-average period of 2.3 years. The total unrecognized compensation expense for the PSUs for which we have not yet determined that attainment of the performance target is probable was $79.5 million as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exelixis, Inc. 401(k) Plan (the 401(k) Plan)&lt;/span&gt;&lt;/div&gt;We sponsor the 401(k) Plan under which we make matching cash contributions to our employees&#x2019; 401(k) accounts. We recorded compensation expense of $11.7 million, $9.5 million and $6.7 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively, for matching contributions</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkyOTk_df3319b6-f2f0-48c6-9612-415e1c3dbc32">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5160dca23cbd4534bbd8f0c6583551eb_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzItMS0xLTEtOTIxNTA_68253b34-65f7-4ff6-b766-bbaf5f28b01d"
      unitRef="usd">45350000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i14b02cd880bf4d00b829d7485dae8233_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzItMy0xLTEtOTIxNTA_b5531be6-e398-4c49-8847-dbacb636c83b"
      unitRef="usd">46654000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iee5871015bd64ea0a1cea69d5451681c_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzItNS0xLTEtOTIxNTA_6a22da82-6364-45a1-a9ac-e699b77ffb3f"
      unitRef="usd">37198000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i37ff342a670f4b08a73196e2c605fefd_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzMtMS0xLTEtOTIxNTA_b2ccb865-289c-4d1d-8c73-ff4a545e3646"
      unitRef="usd">62224000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic2297486cdd248d085cac7850abaaf71_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzMtMy0xLTEtOTIxNTA_8e903f67-2ca9-4fb6-a8a2-6d9866580968"
      unitRef="usd">73166000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5491aa8fe4e24ba3ac8e4aaa781cce6a_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzMtNS0xLTEtOTIxNTA_96720bd9-20f6-4f2e-ad78-552b9732801e"
      unitRef="usd">67872000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzQtMS0xLTEtOTIxNTA_1251b7c2-c215-43bb-a97c-c3673a232d4f"
      unitRef="usd">107574000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzQtMy0xLTEtOTIxNTA_5a210a51-aeab-4da8-9283-d504bcd1bbe1"
      unitRef="usd">119820000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphNThlN2U3YzZlMzI0YjYzODkwOGFiOTIxNDUwY2U5Ny90YWJsZXJhbmdlOmE1OGU3ZTdjNmUzMjRiNjM4OTA4YWI5MjE0NTBjZTk3XzQtNS0xLTEtOTIxNTA_4308a136-4c49-4bc4-9683-9315220f28f9"
      unitRef="usd">105070000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzItMS0xLTEtOTIxNTA_933d53be-1ede-4637-8202-26c1cf58a1d9"
      unitRef="usd">12790000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzItMy0xLTEtOTIxNTA_f12c2f21-877b-46b5-9bdd-12a29bf6f9bc"
      unitRef="usd">19048000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzItNS0xLTEtOTIxNTA_c3d7f287-82e6-4eea-918f-324569c6ea15"
      unitRef="usd">19863000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzMtMS0xLTEtOTIxNTA_c74b8100-5c1e-4c2e-a58e-0260153829fc"
      unitRef="usd">69775000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i53d5d9f5ba5145de91b7ed6cafe85f4b_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzMtMy0xLTEtOTIxNTA_87ca9b87-7cf0-4b79-8b3e-fd2c6fd42ea7"
      unitRef="usd">53629000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i001bf94dda6a471d908297d31da5650a_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzMtNS0xLTEtOTIxNTA_815b8af7-6722-4852-8d73-ce5a28c536b9"
      unitRef="usd">35675000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzQtMS0xLTEtOTIxNTA_77bdb5c6-8f91-4d72-93f9-b8dc5bb6a7ce"
      unitRef="usd">21616000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8b2da2883e9244eb867ae85f79b46942_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzQtMy0xLTEtOTIxNTA_bc706b8d-9d6e-418d-9f36-eced58a3c0ea"
      unitRef="usd">43428000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i448f6fe1dd7842a5b8a72af4bafcacbe_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzQtNS0xLTEtOTIxNTA_b91059b8-70e3-4ada-8303-584273ad5a4d"
      unitRef="usd">47106000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzUtMS0xLTEtOTIxNTA_4fdd822c-047b-422a-a9d8-4acaf7ee3587"
      unitRef="usd">3393000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i265887804270466a84b8183ec8c715b9_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzUtMy0xLTEtOTIxNTA_6cf198dc-f691-4027-965a-6208b6b42169"
      unitRef="usd">3715000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzUtNS0xLTEtOTIxNTA_b5bb50b4-e4f6-48f5-8ced-f450644d6493"
      unitRef="usd">2426000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzYtMS0xLTEtOTIxNTA_2b2e75e2-e67d-4cd4-bc48-25d76abc940a"
      unitRef="usd">107574000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzYtMy0xLTEtOTIxNTA_b49dc969-ed5f-4671-bb3b-8af9522ad090"
      unitRef="usd">119820000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpkMTdjMjNlZmUzNDg0MTUyOTA1NDkwMTFiMjcxNTE2YS90YWJsZXJhbmdlOmQxN2MyM2VmZTM0ODQxNTI5MDU0OTAxMWIyNzE1MTZhXzYtNS0xLTEtOTIxNTA_c54633a8-382e-4fec-86b6-2cba2e644588"
      unitRef="usd">105070000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i078320950f3f4080b9cc748699315beb_D20220525-20220525"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTQyODY_676fa826-5f48-48dc-bd02-74fb732965be"
      unitRef="shares">28500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i3874dd04524f404cad068734350f1731_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTg4NDM_98ed262f-5f5a-4cce-a8ec-452004633476"
      unitRef="shares">31971047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward
      contextRef="i4fad33a89ad640298188cf7bb295b4ae_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTQyOTg_b600d181-69f2-4278-ba5b-cdc281cf264a"
      unitRef="shares">1</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards
      contextRef="i4fad33a89ad640298188cf7bb295b4ae_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTQzMDQ_d8f06f56-611e-42f3-a74a-4cf21edc05be"
      unitRef="shares">2</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i3a61f81952984a76817f7077b77e352c_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkzMjY_926bcf1e-d2d0-4e11-88f7-4d90bc746c70">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i94edb7e6d39c450a954861e65f48c315_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkzMzE_c20cd563-1f0d-4bfe-9c9f-ca25ecd0a281">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkzMzI_93350e35-6d04-4d1f-8849-4ff00d5a0da2">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie4196c2fa72f4675a1c7dc4470ac938f_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkzMTI_a4ecfc68-bc84-4bcb-8547-0c4cbd50cae0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1d192ee0ba8049e2a30c45ffc397e321_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkyODc_16c5340d-fd53-463b-846d-9f2f3888d8e1">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <exel:ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod
      contextRef="if0d9106c860342c6a5490820d5ac452c_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzIwNzY_e16d914c-d907-4be0-aacc-96fa86aa2908">P1M</exel:ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod>
    <exel:ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod
      contextRef="i4c2389c4c21e47d38ba918260c486bdd_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzIwOTc_200ea3e9-4ffc-45f6-8950-cf46bac792c3">P13M</exel:ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI1NDU_ad4ac048-b169-4d30-91c7-c77b3aea63e2"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI2MTI_04751227-d54f-4555-8240-ed17d7eac2af"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <exel:SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod
      contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkzMTk_155d69a1-7e08-477a-8557-db3f551133ee">P6M</exel:SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i8ab3ba9b700146e8a378297f9a6ef6c5_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI2OTg_6c98756d-10a2-47af-86a8-1bb52e5d6dc5"
      unitRef="shares">2561567</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI3Nzk_9aa1ffe6-7783-43c9-bfff-e348a112173d"
      unitRef="shares">606787</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i265887804270466a84b8183ec8c715b9_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI3ODM_89109f41-2a9e-4885-8ab9-981e85367768"
      unitRef="shares">536226</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI3OTA_547b038b-4667-44f9-beb2-86c80e87de91"
      unitRef="shares">534419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i8ab3ba9b700146e8a378297f9a6ef6c5_I20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI4NDk_a05eadb2-b30e-4970-bb4c-a6cd1b0828ee"
      unitRef="usdPerShare">16.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i2d394ecf14b74946a77659139d5f4878_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI4NTM_9e3560f9-4314-4236-918f-9f22ba6a2ba3"
      unitRef="usdPerShare">17.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="ia4d13e607a19484395fc6a707a9c2df9_I20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzI4NjA_7e5a7313-0180-4e5a-b585-78b974f2df5a"
      unitRef="usdPerShare">14.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzMwMTA_74d2a4df-a759-443b-921e-bee9ce1f9d93"
      unitRef="usd">10100000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i265887804270466a84b8183ec8c715b9_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzMwMTQ_e4aa8fb3-0144-449a-ba32-43d13c838f95"
      unitRef="usd">9500000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzMwMjE_fb6b0812-166f-4813-afb1-e8c9025c6cba"
      unitRef="usd">7800000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkyODk_1b730c02-d7c3-41cc-8db3-ce5a6b34acfd">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyYThhYzZiMjczYzE0ZWIwOTMwMjAzYjVjMzNlNDljYi90YWJsZXJhbmdlOjJhOGFjNmIyNzNjMTRlYjA5MzAyMDNiNWMzM2U0OWNiXzItMS0xLTEtOTIxNTA_827921e1-08ae-4104-8c16-2241c1b7b088"
      unitRef="usdPerShare">8.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyYThhYzZiMjczYzE0ZWIwOTMwMjAzYjVjMzNlNDljYi90YWJsZXJhbmdlOjJhOGFjNmIyNzNjMTRlYjA5MzAyMDNiNWMzM2U0OWNiXzItMy0xLTEtOTIxNTA_943dab6d-27e4-438d-b7a4-e4e0fa99089f"
      unitRef="usdPerShare">9.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyYThhYzZiMjczYzE0ZWIwOTMwMjAzYjVjMzNlNDljYi90YWJsZXJhbmdlOjJhOGFjNmIyNzNjMTRlYjA5MzAyMDNiNWMzM2U0OWNiXzItNS0xLTEtOTIxNTA_6ac8b975-88cb-4945-90ca-3b82bdbefe75"
      unitRef="usdPerShare">9.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyYThhYzZiMjczYzE0ZWIwOTMwMjAzYjVjMzNlNDljYi90YWJsZXJhbmdlOjJhOGFjNmIyNzNjMTRlYjA5MzAyMDNiNWMzM2U0OWNiXzMtMS0xLTEtOTIxNTA_3308dd1a-c331-41d5-b148-f1f17b2f6e1f"
      unitRef="usdPerShare">5.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i265887804270466a84b8183ec8c715b9_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyYThhYzZiMjczYzE0ZWIwOTMwMjAzYjVjMzNlNDljYi90YWJsZXJhbmdlOjJhOGFjNmIyNzNjMTRlYjA5MzAyMDNiNWMzM2U0OWNiXzMtMy0xLTEtOTIxNTA_cc3da367-37fa-4c53-8de4-e6d18d50c0b5"
      unitRef="usdPerShare">6.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyYThhYzZiMjczYzE0ZWIwOTMwMjAzYjVjMzNlNDljYi90YWJsZXJhbmdlOjJhOGFjNmIyNzNjMTRlYjA5MzAyMDNiNWMzM2U0OWNiXzMtNS0xLTEtOTIxNTA_b9c370a6-a5a7-44df-b9c4-860f0d8550a1"
      unitRef="usdPerShare">6.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkyNzM_df01e2f2-6d5a-4448-9d29-2312ee49b5c3">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkyOTA_cd92b29d-bc69-48b0-aca4-6d0e0e4b0dfb">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzMtMS0xLTEtOTIxNTA_a45c838f-9821-4fb0-aa25-c93a8cbcfaae"
      unitRef="number">0.0235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzMtMy0xLTEtOTIxNTA_5c12dc30-7dfe-4cf9-98a7-e3f3378ed9d1"
      unitRef="number">0.0074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzMtNS0xLTEtOTIxNTA_d8437c24-bea4-4f64-bd98-4dab60e5ffbd"
      unitRef="number">0.0030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzQtMS0xLTEtOTIxNTA_b6d0f837-de04-4b75-bca0-2ac4b5b3fd06"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzQtMy0xLTEtOTIxNTA_e19d1a3b-2e31-455b-8872-abf6d882e967"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzQtNS0xLTEtOTIxNTA_bddb7e16-a4a8-488a-a72d-a62a7b0728cd"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzUtMS0xLTEtOTIxNTA_7f4abb93-6711-4e40-90d1-069de5bf6f97"
      unitRef="number">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzUtMy0xLTEtOTIxNTA_fed02b98-9ee0-4b5b-8e84-4b8630a0ff04"
      unitRef="number">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzUtNS0xLTEtOTIxNTA_7c7dd5f1-d05a-4f33-904e-9f4282596e5f"
      unitRef="number">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzYtMS0xLTEtOTIxNTA_0cc5ae32-a7fb-4933-aaf3-71031b26207b">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzYtMy0xLTEtOTIxNTA_230823d8-710e-4689-aae9-40a7df02ba34">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzYtNS0xLTEtOTIxNTA_7c98f494-5682-4f5a-8c18-e7099b49ca74">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzgtMS0xLTEtOTIxNTA_f521ae06-a2d6-4507-9059-d9c2f02a8be4"
      unitRef="number">0.0149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i265887804270466a84b8183ec8c715b9_D20210102-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzgtMy0xLTEtOTIxNTA_9b49a30e-3b9e-4138-9277-e2ad9a9380d6"
      unitRef="number">0.0008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzgtNS0xLTEtOTIxNTA_af793066-2b8c-4b69-950d-f655e7676379"
      unitRef="number">0.0079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzktMS0xLTEtOTIxNTA_6950066a-5915-42c5-905f-cc678cde47c7"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i265887804270466a84b8183ec8c715b9_D20210102-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzktMy0xLTEtOTIxNTA_28a27305-8ad7-40d9-a983-1a08336c2206"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzktNS0xLTEtOTIxNTA_1e9dcc47-a0fd-46dc-b819-a49da5fd8fac"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzEwLTEtMS0xLTkyMTUw_6d0d39e2-e271-4f20-909f-4dbfdafce8a6"
      unitRef="number">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i265887804270466a84b8183ec8c715b9_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzEwLTMtMS0xLTkyMTUw_6732a39c-8f93-4191-a09e-cedafc045efb"
      unitRef="number">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzEwLTUtMS0xLTkyMTUw_8ebf2fae-48eb-4d05-9f89-955d5cbad100"
      unitRef="number">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia5a6dd262bde4dbe92bc17ac06d34e8e_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzExLTEtMS0xLTkyMTUw_e1a51c53-809c-4976-b579-0e41594f240f">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i265887804270466a84b8183ec8c715b9_D20210102-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzExLTMtMS0xLTkyMTUw_6a8647a2-ce64-416c-8eef-1bce69584351">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i69e5457ead5b46b2b5a5ce37053f1ae2_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpiNjVkMzgxMGYxYWQ0YTNlOTA5NTVmYmZiY2QyODE2Ni90YWJsZXJhbmdlOmI2NWQzODEwZjFhZDRhM2U5MDk1NWZiZmJjZDI4MTY2XzExLTUtMS0xLTkyMTUw_0bf9617c-f33e-4d12-b0c7-31412e71d52c">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkzMTM_5db6ddee-0b1a-4127-ac35-7cd82496d80b">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for stock options during the year ended December&#160;31, 2022 was as follows (in thousands&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options exercisable at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzEtMS0xLTEtOTIxNTA_29078ab3-00b2-42cb-8ccd-e906e326564b"
      unitRef="shares">13671000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzEtMy0xLTEtOTIxNTA_4467597b-8e93-4384-b6f6-580e90afaa11"
      unitRef="usdPerShare">16.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzItMS0xLTEtOTIxNTA_c8c9148b-f1a0-48d3-ad0c-4d36678674f4"
      unitRef="shares">589000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzItMy0xLTEtOTIxNTA_bb339330-8080-4fd4-ae50-91999e60508b"
      unitRef="usdPerShare">19.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzMtMS0xLTEtOTIxNTA_bf956b36-d557-4a78-9e07-97af34747a5e"
      unitRef="shares">2743000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzMtMy0xLTEtOTIxNTA_2fbc3448-e978-42d1-b2ef-cb15f71a1ae2"
      unitRef="usdPerShare">5.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzQtMS0xLTEtOTIxNTA_7733e8b0-e5e4-44a8-8d1a-7bd25ceecc4a"
      unitRef="shares">635000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzQtMy0xLTEtOTIxNTA_93d44f94-bfd0-40db-9073-8c3f864d482f"
      unitRef="usdPerShare">21.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzUtMS0xLTEtOTIxNTA_32fd5cf4-3fd2-4f13-99cf-766a9669b48c"
      unitRef="shares">10882000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzUtMy0xLTEtOTIxNTA_01cd21f2-615a-4ad3-96bb-154134687b9e"
      unitRef="usdPerShare">19.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzUtNS0xLTEtOTIxNTA_bfea4b42-49ee-402f-ad12-5a774acff8f4">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzUtNy0xLTEtOTIxNTA_22adee39-bc49-4316-802b-40ecf5e4ee00"
      unitRef="usd">9377000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzYtMS0xLTEtOTIxNTA_7d44b518-3134-4c1b-9d66-1a72ca982a9a"
      unitRef="shares">8743000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzYtMy0xLTEtOTIxNTA_71163992-5bd9-448c-bf3f-716d7ada1f49"
      unitRef="usdPerShare">19.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzYtNS0xLTEtOTIxNTA_b363e9c7-b177-4e23-b43c-8ab1a624aa2d">P2Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZToyZjQ1ODhjZDJiMGU0NmM0YTc5ZTA1NWE2ZDllMWFmOS90YWJsZXJhbmdlOjJmNDU4OGNkMmIwZTQ2YzRhNzllMDU1YTZkOWUxYWY5XzYtNy0xLTEtOTIxNTA_01fad71c-50c0-4617-822e-8550dea57450"
      unitRef="usd">9373000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i1665a438e56445b78cb7452df0643ba1_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQwNTU_bc347059-dd1b-44b0-b144-8602a55a7181"
      unitRef="usd">16600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQyNDM_c5f92ede-7d29-4e54-b0f0-7be122bde76d">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQ3MTc_e182095c-9ced-4685-8902-826e7dd99c77"
      unitRef="usd">36500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQ3MjE_d83ac057-c957-4905-ac4c-89d45da9664e"
      unitRef="usd">76000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQ3Mjg_b35574f3-1b0e-43ba-b155-655c433436fb"
      unitRef="usd">106500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQ4Mjk_100acd27-84aa-4104-8814-33b2460eb855"
      unitRef="usd">13900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if7cc4b3258d64f4088803c5568258cf4_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQ4MzM_2585be27-a213-4eb8-9215-d6b175a26a53"
      unitRef="usd">14800000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i7ae4a0f6f4b34266ae49f32b84e80321_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQ4NDA_1b355483-095e-4a16-8cff-bd4fc38ae726"
      unitRef="usd">26900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkyNzU_9efa44e1-faea-4874-80f5-efd171c7f10d">Activity for RSUs during the year ended December&#160;31, 2022 was as follows (in thousands, except per share amounts):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for PSUs, during the year ended December&#160;31, 2022 was as follows (in thousands&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4c54a7d88c1f429ba5559d7d2282d65c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzEtMS0xLTEtOTIxNTA_7a629dfa-6b0e-4bbf-b7b7-bebf7241af03"
      unitRef="shares">6828000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4c54a7d88c1f429ba5559d7d2282d65c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzEtMy0xLTEtOTIxNTA_ae84bbff-f82b-419a-89f7-a09811f311e8"
      unitRef="usdPerShare">21.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzItMS0xLTEtOTIxNTA_e2682de6-7446-4f35-89cf-e4324d2e2065"
      unitRef="shares">7933000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzItMy0xLTEtOTIxNTA_8ff497c4-0dd5-4c58-b827-badb1fae5c49"
      unitRef="usdPerShare">21.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased
      contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzMtMS0xLTEtOTIxNTA_cd05ecbf-6405-454d-8514-a92b821c79eb"
      unitRef="shares">2164000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzMtMy0xLTEtOTIxNTA_384a1273-4cfd-440d-8073-92225105a6cd"
      unitRef="usdPerShare">21.31</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzQtMS0xLTEtOTIxNTA_9dcab0dc-8860-458e-a5f6-a0c17fc1ebea"
      unitRef="shares">1303000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzQtMy0xLTEtOTIxNTA_f5e17ae1-e7af-4bbe-9e42-bda05cc220b0"
      unitRef="usdPerShare">21.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib5de3dc69b844f86ba1ee22cce4ea5c9_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzUtMS0xLTEtOTIxNTA_b9de6bea-b5ac-47aa-a153-fefe5d4056ce"
      unitRef="shares">11294000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib5de3dc69b844f86ba1ee22cce4ea5c9_I20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzUtMy0xLTEtOTIxNTA_d2c559b5-958f-4826-9886-49bcee3cecc0"
      unitRef="usdPerShare">21.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzUtNS0xLTEtOTIxNTA_76e7de3a-22c6-4409-bc4f-49fc9a743faf">P1Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="ib5de3dc69b844f86ba1ee22cce4ea5c9_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTphM2ZhZmE2ZTNlZTk0ZWI4YTM5YTgzY2M2NjBhYmQ3Zi90YWJsZXJhbmdlOmEzZmFmYTZlM2VlOTRlYjhhMzlhODNjYzY2MGFiZDdmXzUtNy0xLTEtOTIxNTA_0d5586ec-7097-4496-8502-d2c2278ab2a1"
      unitRef="usd">181156000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ib5de3dc69b844f86ba1ee22cce4ea5c9_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzQ5NzU_0865aa33-ed1b-4fe2-8b74-65f017b57879"
      unitRef="usd">183600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzUxMDM_09d924d9-a5ea-4176-9697-d609ac340bde">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie3d7d02ac4d34267a1d46e90f45bef37_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzEtMS0xLTEtOTIxNTA_cfff2090-4174-4547-a505-2bccfb0d5aca"
      unitRef="shares">6310000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie3d7d02ac4d34267a1d46e90f45bef37_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzEtMy0xLTEtOTIxNTA_e407d5fd-be97-4b0d-85f3-2631f9708148"
      unitRef="usdPerShare">23.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzItMS0xLTEtOTIxNTA_3d5ade14-0fe7-451b-a365-1fac59120489"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzItMy0xLTEtOTIxNTA_e1af4161-6590-4349-8887-4f7acebb13af"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased
      contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzMtMS0xLTEtOTIxNTA_4ee846d7-4897-4206-990d-21320e63e662"
      unitRef="shares">942000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzMtMy0xLTEtOTIxNTA_e4c47f62-9b9d-4d3f-941d-d345d0d8f3f9"
      unitRef="usdPerShare">21.32</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzQtMS0xLTEtOTIxNTA_dcd4f1fa-c94a-466b-a630-1ae39f3f5b7f"
      unitRef="shares">404000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzQtMy0xLTEtOTIxNTA_34fe6ef6-02b7-4e84-b080-8940086e32b7"
      unitRef="usdPerShare">24.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9aae7ba847d34422b359963bd9dc87f5_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzUtMS0xLTEtOTIxNTA_c51b3bde-0446-4c5a-86a9-cbf2bb259d12"
      unitRef="shares">4964000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9aae7ba847d34422b359963bd9dc87f5_I20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzUtMy0xLTEtOTIxNTA_5d16cef7-9d92-4fe9-a325-61545a01d9aa"
      unitRef="usdPerShare">23.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzUtNS0xLTEtOTIxNTA_1601b9b7-561c-4a49-b4ef-2263bc5e1ce5">P2Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i9aae7ba847d34422b359963bd9dc87f5_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTpjMjgyNjZlN2IwZjI0MTE5ODhiYmMyYWMzZmMxN2FjOS90YWJsZXJhbmdlOmMyODI2NmU3YjBmMjQxMTk4OGJiYzJhYzNmYzE3YWM5XzUtNy0xLTEtOTIxNTA_9b76a3e6-1bdf-4c88-93fe-31c1672aa920"
      unitRef="usd">79628000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i2fb2e18c946f487ea024e74f846cd36a_D20220301-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgyOTAyOA_45d5431c-1969-439f-8332-177a964bf6e9"
      unitRef="shares">1003482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i2fb2e18c946f487ea024e74f846cd36a_D20220301-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTQzMTI_a3b0af26-76bd-439c-a05d-b49fcbac8ef5"
      unitRef="number">1.75</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ia6d07a5ce0b943d9851f70f5a1bc4058_D20220301-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTQzMDc_e55c3e1a-705a-48e5-abaf-b538e6ef30b4"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia6d07a5ce0b943d9851f70f5a1bc4058_D20220301-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTQzMTc_6d5590bc-3aa8-4c2b-8817-7436a470b36a">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkzMzk_fdb84ae0-25ee-4704-8ccf-cc20d6711822">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $33.17 per share for the 2022 TSR-based RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of Exelixis common stock on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of Exelixis common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia1b5d625613f4f5d933afddd77da19b7_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgyOTAzOQ_1c217b5b-c1db-49fe-8fa6-089ba120d356"
      unitRef="usdPerShare">33.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharePrice
      contextRef="id8a52c2ef07a4489ad93e8b30e5e3368_I20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTplNDQwMTg3ZmQyNmI0ODRlOGIxNWNiZDBiYjg1ZmM0ZC90YWJsZXJhbmdlOmU0NDAxODdmZDI2YjQ4NGU4YjE1Y2JkMGJiODVmYzRkXzAtMS0xLTEtOTIxNTA_b1e4e346-834f-4f4b-9f20-c9c60ee4134f"
      unitRef="usdPerShare">20.70</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ia1b5d625613f4f5d933afddd77da19b7_D20220101-20221230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTplNDQwMTg3ZmQyNmI0ODRlOGIxNWNiZDBiYjg1ZmM0ZC90YWJsZXJhbmdlOmU0NDAxODdmZDI2YjQ4NGU4YjE1Y2JkMGJiODVmYzRkXzEtMS0xLTEtOTIxNTA_1b16fb64-bd36-4fc9-8906-b0ea6726da76"
      unitRef="number">0.4685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia1b5d625613f4f5d933afddd77da19b7_D20220101-20221230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTplNDQwMTg3ZmQyNmI0ODRlOGIxNWNiZDBiYjg1ZmM0ZC90YWJsZXJhbmdlOmU0NDAxODdmZDI2YjQ4NGU4YjE1Y2JkMGJiODVmYzRkXzItMS0xLTEtOTIxNTA_021ea156-b1be-449a-9c26-fd3f170f89b2"
      unitRef="number">0.0159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia1b5d625613f4f5d933afddd77da19b7_D20220101-20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTplNDQwMTg3ZmQyNmI0ODRlOGIxNWNiZDBiYjg1ZmM0ZC90YWJsZXJhbmdlOmU0NDAxODdmZDI2YjQ4NGU4YjE1Y2JkMGJiODVmYzRkXzMtMS0xLTEtOTIxNTA_f11477cd-601c-4b7e-9b6a-dde2f4f63840"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i63901f6ae4fb4bcbb543c24cd2c4216a_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgzNDUwMg_13e18e47-7740-4867-ac9e-841623304ef1"
      unitRef="shares">1027650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i63901f6ae4fb4bcbb543c24cd2c4216a_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgzNDM3NA_0d1461b3-8711-4d50-a484-9c6e2f487d87"
      unitRef="number">2</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest
      contextRef="i63901f6ae4fb4bcbb543c24cd2c4216a_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgzNDM4MA_16109201-ec6e-4c0f-b834-adc494eaebed"
      unitRef="shares">2055300</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ib652a5d9ce3a49709aea2941cebaac3b_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgzNTQwMw_bc31e3ae-1bdc-4d16-9b9a-abece591f645"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i63901f6ae4fb4bcbb543c24cd2c4216a_D20210301-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTgzNDk_2b859f2d-6f21-4f3e-b6d3-e329c7059015">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i04f2cc9dcfa7426e99f081418b205d0e_D20221001-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgzNTY0Mw_f38ab5fd-6988-4d90-b2a9-a32931d4816f"
      unitRef="number">1</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id33e4bb7f86d4f63bb3483974950eb21_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzM4NDgyOTA3MTgzNjU_a7e2a741-2b53-4978-be63-c412cd8f7b74"
      unitRef="usdPerShare">24.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharePrice
      contextRef="i9aae7ba847d34422b359963bd9dc87f5_I20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTplOGY2MGY4NmMzZWY0N2RiYTAwNWY2NWEyZWEwNmMyMi90YWJsZXJhbmdlOmU4ZjYwZjg2YzNlZjQ3ZGJhMDA1ZjY1YTJlYTA2YzIyXzAtMS0xLTEtOTg5NDM_b4086417-8313-4065-9615-5f8b9f70c730"
      unitRef="usdPerShare">21.31</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTplOGY2MGY4NmMzZWY0N2RiYTAwNWY2NWEyZWEwNmMyMi90YWJsZXJhbmdlOmU4ZjYwZjg2YzNlZjQ3ZGJhMDA1ZjY1YTJlYTA2YzIyXzEtMS0xLTEtOTg5NDM_dc7dd842-3819-4a76-8964-e1d4e7dd5b36"
      unitRef="number">0.4921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTplOGY2MGY4NmMzZWY0N2RiYTAwNWY2NWEyZWEwNmMyMi90YWJsZXJhbmdlOmU4ZjYwZjg2YzNlZjQ3ZGJhMDA1ZjY1YTJlYTA2YzIyXzItMS0xLTEtOTg5NDM_b7cd1348-f94f-4d5e-a406-b80b9bd7d708"
      unitRef="number">0.0029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90YWJsZTplOGY2MGY4NmMzZWY0N2RiYTAwNWY2NWEyZWEwNmMyMi90YWJsZXJhbmdlOmU4ZjYwZjg2YzNlZjQ3ZGJhMDA1ZjY1YTJlYTA2YzIyXzMtMS0xLTEtOTg5NDM_e94fb44e-092d-45d2-995b-dd6d5d77e854"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i053c349bf2894f5c9e19fc0cf85fe118_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgyNDg5OQ_01dec882-87eb-4120-b75a-99f5881d00b2"
      unitRef="shares">2327840</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i448f6fe1dd7842a5b8a72af4bafcacbe_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgzNDQxNw_c5f1d91e-111c-41d3-b963-e63a80cfb0bd"
      unitRef="number">2</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest
      contextRef="i448f6fe1dd7842a5b8a72af4bafcacbe_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgyNTE5Mw_8adedd9a-82ad-43bf-8e8b-f90416e87963"
      unitRef="shares">4655680</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i4a76d7c8a8dc41cfa3f976f8a86b8ac3_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgzNDY2OQ_0c9bef78-d9a6-46b1-a768-71d99eca322c"
      unitRef="number">0.25</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="ic5603f2e0fff4c849973ffaeafa13517_D20220702-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzU0OTc1NTgzNDg5NA_dcb8a2fd-f939-4235-9493-203921255e71"
      unitRef="number">0.25</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i425a3fc9ca83455daa4acf0026125185_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5Xzg0MDc_94360f42-5cd3-4256-abb2-7f0e1d026d64"
      unitRef="shares">869502</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="if2fc11d4d2754631a3733ccac92d04e3_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5Xzg2MTE_5e03bdf4-dfdf-490a-a5f3-fb3a3b11d295"
      unitRef="usd">11000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5Xzg2NzQ_ecf20f5f-3c8b-4778-8e70-a579185213f2">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ic4e6cc8bacaf4594895d5bbfc9c89791_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5Xzg4MzA_9005121b-bbb8-48e9-bac5-3631172a29e0"
      unitRef="usd">79500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkxNTA_9be71737-6697-482f-8fe8-b2cc36a599c4"
      unitRef="usd">11700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkxNTQ_da89d1ea-7037-4ed6-865f-d40c2ed787ac"
      unitRef="usd">9500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDYvZnJhZzoyYmMwNmRmYzhhNTc0ZWYxYTUyMWVlZTJkZGUxOTk5OS90ZXh0cmVnaW9uOjJiYzA2ZGZjOGE1NzRlZjFhNTIxZWVlMmRkZTE5OTk5XzkxNjE_76e14ca2-a44b-4d0d-8994-4e8f566ebfea"
      unitRef="usd">6700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzQzOTI_9d4d35df-f6e1-48df-9024-1df43e59f7fb">PROVISION FOR INCOME TAXES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income before income taxes is derived solely from within the U.S. Our provision for income taxes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes for &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the years ended December&#160;31, 2022, 2021, and 2020 primarily relates to the utilization of federal tax attributes and state taxes in jurisdictions outside of California, for which we do not have net operating loss carryforwards due to a limited operating history.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our historical net operating losses were sufficient to fully offset any federal taxable income for the year ended December 31, 2020 but were not sufficient to fully offset federal taxable income for the years ended December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the U.S. federal income tax provision at the statutory federal income tax rate of 21% for each of the years ended December 31, 2022, 2021 and 2020, respectively, to our provision for income taxes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal income tax provision at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax (benefit) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded prescription drug fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible warrant purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves not currently deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC Topic 740: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 740) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December&#160;31, 2022, based on the evaluation and weighting of both positive and negative evidence, including our achievement of a cumulative three-year income position as of December&#160;31, 2022 and forecasts of future operating results, as well as considering the utilization of net operating losses and tax credits prior to their expiration, management has continued to determine that there is sufficient positive evidence to conclude that it is more likely than not the deferred tax assets are realizable. As of December&#160;31, 2022 and 2021, we continue to carry a valuation allowance of $77.2 million and $70.1 million, respectively, against our California state deferred tax assets. The valuation allowance increased by $7.2 million and $2.9 million during the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, we had state net operating loss carryforwards of approximately $414&#160;million, which expire in the years 2023 through 2036, California research and development tax credits of approximately $52&#160;million, which do not expire, and California Competes Tax Credits of approximately $1&#160;million, which begin to expire in 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. We completed a Section 382 analysis through December&#160;31, 2022, and concluded that an ownership change, as defined under Section 382, had not occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change relating to prior year provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change relating to current year provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions based on the lapse of the applicable statutes of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify unrecognized tax benefits as a reduction of deferred tax assets or as other long-term liabilities in the accompanying consolidated balance sheets. We do not anticipate that the amount of unrecognized tax benefits existing as of December&#160;31, 2022 will significantly change over the next 12 months. As of December&#160;31, 2022, we had $87.7 million in unrecognized tax benefits, of which $55.4 million would reduce our income tax provision and effective tax rate, if recognized. Interest and penalties were nominal or zero for all periods presented. We have elected to record interest and penalties in the accompanying Consolidated Statements of Income as a component of income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 2001 through 2022 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzQ0MDE_ec4b14f7-b90c-40fd-8add-72aae6417dee">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income before income taxes is derived solely from within the U.S. Our provision for income taxes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzMtMS0xLTEtOTIxNTA_15f7d6f7-3cc3-4b15-a9ee-452a6d9bc6c6"
      unitRef="usd">100525000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzMtMy0xLTEtOTIxNTA_c443d1d1-5cb6-4ae1-b931-eecafc06e638"
      unitRef="usd">11338000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzMtNS0xLTEtOTIxNTA_ddf49ce2-1809-479f-9954-078b7562fcf4"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzQtMS0xLTEtOTIxNTA_3cf60b75-7b23-4e90-8d9d-7ad0b65f59d3"
      unitRef="usd">11903000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzQtMy0xLTEtOTIxNTA_4913e6db-5988-4ead-a7d2-9f05b9da5882"
      unitRef="usd">5224000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzQtNS0xLTEtOTIxNTA_6bb24f7c-099b-473a-8d50-18c94cbfaf71"
      unitRef="usd">3791000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzUtMS0xLTEtOTIxNTA_ab9b8cde-062d-48a0-9b9f-89f5938133ee"
      unitRef="usd">112428000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzUtMy0xLTEtOTIxNTA_97c1b44d-78d3-4cfe-8bc7-fe0db1887182"
      unitRef="usd">16562000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzUtNS0xLTEtOTIxNTA_d105d108-98f6-40cd-988a-84c8eaf9ed83"
      unitRef="usd">3791000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzctMS0xLTEtOTIxNTA_b7931b67-8287-4ae1-982e-200924c9ea9d"
      unitRef="usd">-54223000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzctMy0xLTEtOTIxNTA_04ff1b1e-6107-41ec-88dd-de83d41ee95d"
      unitRef="usd">46416000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzctNS0xLTEtOTIxNTA_ae68dff6-0be2-4a6a-9a95-e2371483478c"
      unitRef="usd">14886000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzgtMS0xLTEtOTIxNTA_151c5cbd-5fe3-4f96-850b-6e68d324a899"
      unitRef="usd">-6135000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzgtMy0xLTEtOTIxNTA_72d20819-bc1a-4043-86a3-f6ca2642f38d"
      unitRef="usd">113000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzgtNS0xLTEtOTIxNTA_c3837dbe-1735-4e88-ac9a-c9b6f3aa2846"
      unitRef="usd">379000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzktMS0xLTEtOTIxNTA_0e553243-0d5c-4879-84b6-b231ec0705c0"
      unitRef="usd">-60358000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzktMy0xLTEtOTIxNTA_f3c7c99b-fff4-4b42-9ae5-1c5a39f46307"
      unitRef="usd">46529000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzktNS0xLTEtOTIxNTA_20deb44e-a8da-4a55-8e9b-a67dca795db7"
      unitRef="usd">15265000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzEwLTEtMS0xLTkyMTUw_6ee7a608-fe49-4a41-a5f7-ddd11bc95b4d"
      unitRef="usd">52070000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzEwLTMtMS0xLTkyMTUw_7a7cdbc0-f9c6-4562-ab63-e74de5b9129d"
      unitRef="usd">63091000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZToxYjViMjU3NGY5ZGI0ZGFkYjJjYTA0ODNjNTQ3MGUyMy90YWJsZXJhbmdlOjFiNWIyNTc0ZjlkYjRkYWRiMmNhMDQ4M2M1NDcwZTIzXzEwLTUtMS0xLTkyMTUw_bd458919-9955-4097-81b2-ae218f29bb8c"
      unitRef="usd">19056000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzQ0MDg_a1f04820-d756-4f16-befb-938344d9b8fc">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the U.S. federal income tax provision at the statutory federal income tax rate of 21% for each of the years ended December 31, 2022, 2021 and 2020, respectively, to our provision for income taxes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal income tax provision at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax (benefit) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded prescription drug fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible warrant purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzItMS0xLTEtOTIxNTA_6b62c0e3-1870-4474-9c4d-2ea5e61009dd"
      unitRef="usd">49213000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzItMy0xLTEtOTIxNTA_be1ed11d-0ce0-4244-9297-2c260a3f6cc3"
      unitRef="usd">61772000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzItNS0xLTEtOTIxNTA_d64d84fb-fc17-436e-b10b-5b5cc5f8eb6c"
      unitRef="usd">27476000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzMtMS0xLTEtOTIxNTA_595c7f08-1f7c-4685-88f4-6d45ba75bd73"
      unitRef="usd">-2632000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzMtMy0xLTEtOTIxNTA_2d5add15-9d02-487c-8115-f02be1b4b3f5"
      unitRef="usd">1336000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzMtNS0xLTEtOTIxNTA_26c16e7d-f550-4205-ba91-dd04c20b3535"
      unitRef="usd">-2232000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzQtMS0xLTEtOTIxNTA_fbf4a009-83d2-4366-8539-bab5be2a906d"
      unitRef="usd">7162000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzQtMy0xLTEtOTIxNTA_840658dc-7a38-46e3-bae7-26b8679109e5"
      unitRef="usd">2883000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzQtNS0xLTEtOTIxNTA_08177094-52ef-4d20-b4ea-ef83319402a8"
      unitRef="usd">5525000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzUtMS0xLTEtOTIxNTA_c5908a60-a6a6-4347-9f69-ccad55b01a97"
      unitRef="usd">14130000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzUtMy0xLTEtOTIxNTA_493971b4-27db-474e-a006-75003351cabe"
      unitRef="usd">6263000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzUtNS0xLTEtOTIxNTA_4c502d2f-86b9-4b15-805d-59eb5fccd02a"
      unitRef="usd">11356000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzYtMS0xLTEtOTIxNTA_4d9421ff-71e3-4846-afcb-2101d24f037c"
      unitRef="usd">-2864000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzYtMy0xLTEtOTIxNTA_bd4f6492-62f3-4619-b9c4-98abb26f5530"
      unitRef="usd">-11831000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzYtNS0xLTEtOTIxNTA_b28f4c36-d3c0-407a-8e1f-74247dc61bb3"
      unitRef="usd">-20399000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzctMS0xLTEtOTIxNTA_3fa8b1d2-3a29-4d99-9952-e57d07d0a688"
      unitRef="usd">4549000</exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation>
    <exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzctMy0xLTEtOTIxNTA_aafecd9e-7710-48d1-8a99-aeec1b9721c2"
      unitRef="usd">11182000</exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation>
    <exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzctNS0xLTEtOTIxNTA_06532ee4-8ec8-4ccc-996d-65329e352d21"
      unitRef="usd">18067000</exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation>
    <exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzgtMS0xLTEtOTIxNTA_506e54ff-0abc-475d-b44c-3be5fdf99cf0"
      unitRef="usd">3855000</exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee>
    <exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzgtMy0xLTEtOTIxNTA_ced2edc7-1f59-485e-8acf-27ba2bba43a5"
      unitRef="usd">2897000</exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee>
    <exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzgtNS0xLTEtOTIxNTA_eefb6fd2-6412-4396-930a-98762aa34338"
      unitRef="usd">2537000</exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee>
    <exel:EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzktMS0xLTEtMTA0MDc2_5670c89a-e5c0-49bd-8190-f26f4b3b3e03"
      unitRef="usd">6300000</exel:EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase>
    <exel:EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzktMy0xLTEtMTA0MDg0_6431a6b1-7b02-458d-b647-5a8b3d783232"
      unitRef="usd">0</exel:EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase>
    <exel:EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzktNS0xLTEtMTA0MDkx_1d095352-8d49-4ccd-bbfd-2d9163dbab0b"
      unitRef="usd">0</exel:EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzktMS0xLTEtOTIxNTA_7cbf0d6e-c83c-453a-bb04-d1a87de44b02"
      unitRef="usd">617000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzktMy0xLTEtOTIxNTA_b77acc8c-af05-43db-99bc-fe6ac05a968d"
      unitRef="usd">1115000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzktNS0xLTEtOTIxNTA_f2764606-8b1e-41e7-98dc-b0d919f857f5"
      unitRef="usd">-562000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzEwLTEtMS0xLTkyMTUw_9aecbbc1-26ea-46da-ac0d-8d5efe5c9a12"
      unitRef="usd">52070000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzEwLTMtMS0xLTkyMTUw_cd96ce77-c4ec-44fe-a58b-e0e6974bfd89"
      unitRef="usd">63091000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo2MDU1YzQ5MzY4NGU0YzY1OWY1NDA4ZjllNGQyZjQwNy90YWJsZXJhbmdlOjYwNTVjNDkzNjg0ZTRjNjU5ZjU0MDhmOWU0ZDJmNDA3XzEwLTUtMS0xLTkyMTUw_5f00e6cf-6570-4554-aa8b-4555e3ff5b1c"
      unitRef="usd">19056000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzQ0MjI_4cf2b4c9-6c32-47a1-bc89-be7599573b86">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves not currently deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzMtMS0xLTEtOTIxNTA_e1c4b9b9-25db-450b-8707-edf628c20852"
      unitRef="usd">33635000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzMtMy0xLTEtOTIxNTA_be22dafc-673b-48af-8d24-8f1248204a1f"
      unitRef="usd">17993000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzQtMS0xLTEtOTIxNTA_70acec62-c6d7-448b-8cbb-6a56498855fb"
      unitRef="usd">40217000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzQtMy0xLTEtOTIxNTA_894d6e73-55d5-4c41-a499-77e3cc1a7206"
      unitRef="usd">101460000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzUtMS0xLTEtOTIxNTA_30dad60f-8d1c-4259-b30e-04012dd5bd9a"
      unitRef="usd">176208000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzUtMy0xLTEtOTIxNTA_0ca915f5-4664-492f-bd91-2f76c7844cae"
      unitRef="usd">7764000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzYtMS0xLTEtOTIxNTA_56e204e0-abae-4bb7-8e8f-06ba6175a27a"
      unitRef="usd">27531000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzYtMy0xLTEtOTIxNTA_720284b2-51d4-4251-a736-b3c4b78ad31d"
      unitRef="usd">23162000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <exel:DeferredTaxAssetsLeaseLiabilities
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzctMS0xLTEtOTIxNTA_9e808780-0647-4a02-9c72-1966b6b9581d"
      unitRef="usd">46759000</exel:DeferredTaxAssetsLeaseLiabilities>
    <exel:DeferredTaxAssetsLeaseLiabilities
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzctMy0xLTEtOTIxNTA_650a1ce1-039b-4f11-8a7e-07715e45210b"
      unitRef="usd">12385000</exel:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzgtMS0xLTEtOTIxNTA_20769311-0941-4e93-a5e3-d9394df9f44d"
      unitRef="usd">22418000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzgtMy0xLTEtOTIxNTA_4e9b4c6f-a34f-4485-b535-d57d1c18ae35"
      unitRef="usd">19531000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzktMS0xLTEtOTIxNTA_cb0b167b-897f-4612-b2bc-5b59d2788330"
      unitRef="usd">7656000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzktMy0xLTEtOTIxNTA_93bd88c2-f31e-4389-9caf-eaa028e50c8f"
      unitRef="usd">8040000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzEwLTEtMS0xLTkyMTUw_f1ab5972-c15a-4b80-bb57-cfc546ead1fd"
      unitRef="usd">6746000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzEwLTMtMS0xLTkyMTUw_c65a6b66-28e2-45bb-a021-5c10346df169"
      unitRef="usd">1303000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzExLTEtMS0xLTkyMTUw_97056809-ba2e-4003-958b-aa950f713014"
      unitRef="usd">361170000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzExLTMtMS0xLTkyMTUw_6960dab7-3402-49d2-829d-36b5a0ee8d49"
      unitRef="usd">191638000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzEyLTEtMS0xLTkyMTUw_458e7dc1-b319-46d3-ad2a-d66517aad227"
      unitRef="usd">77230000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzEyLTMtMS0xLTkyMTUw_a7b4d8e8-a298-4011-a509-50aec3876050"
      unitRef="usd">70068000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzEzLTEtMS0xLTkyMTUw_a4a963de-24c6-43df-a82b-b467a6b462b5"
      unitRef="usd">283940000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzEzLTMtMS0xLTkyMTUw_1dc96e0b-d212-4caf-8b31-08bf7b80fc4b"
      unitRef="usd">121570000</us-gaap:DeferredTaxAssetsNet>
    <exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzE1LTEtMS0xLTkyMTUw_23a8e536-0db4-4101-bd8b-ffce25ea6e4a"
      unitRef="usd">52830000</exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets>
    <exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzE1LTMtMS0xLTkyMTUw_9cd0fc24-17b8-455f-be05-24cf140d5a87"
      unitRef="usd">9907000</exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzE4LTEtMS0xLTkyMTUw_6b7b4a6f-bb9f-47b0-8b30-c5603039aa84"
      unitRef="usd">231110000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTpmYzkyNGQyZTlkMWU0OTEzODUxMTNjMjg5NGFmMjhlYS90YWJsZXJhbmdlOmZjOTI0ZDJlOWQxZTQ5MTM4NTExM2MyODk0YWYyOGVhXzE4LTMtMS0xLTkyMTUw_ff9b717f-c9a6-4a6b-84cd-3e81829be14d"
      unitRef="usd">111663000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzIzMDU_8ce57a3c-5126-4199-a56a-e379323f1a95"
      unitRef="usd">77200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzIzMTI_64d262d1-aa81-47f4-a936-b912c6f07352"
      unitRef="usd">70100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzI0MTA_ecfc79fc-2a59-418d-bf87-7acd888463b6"
      unitRef="usd">7200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzI0MTc_93a69d6f-811f-4226-b945-47ba2fe4f3d6"
      unitRef="usd">2900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i7f5be490ad62428386485550713032a7_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzI1MjI_6fba7154-5d48-48d8-9454-09345a32260d"
      unitRef="usd">414000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ic95667d6b2e54d3fa5b025ecb0ffea4b_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzEwOTk1MTE2MzI1NTE_58b3504b-317d-48d6-9e92-979704467d3e"
      unitRef="usd">52000000</us-gaap:TaxCreditCarryforwardAmount>
    <exel:TaxCreditCarryforwardAmountWithExpirationPeriod
      contextRef="ic95667d6b2e54d3fa5b025ecb0ffea4b_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzEwOTk1MTE2MzI3Mzk_38b70ef8-7041-4367-81d6-3a3d448c76a2"
      unitRef="usd">1000000</exel:TaxCreditCarryforwardAmountWithExpirationPeriod>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzQ0MTM_e7261226-a299-495a-926b-9df5329b5fd4">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change relating to prior year provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change relating to current year provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions based on the lapse of the applicable statutes of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzItMS0xLTEtOTIxNTA_80a3be9f-7700-48f8-8d64-4c164feec3b7"
      unitRef="usd">83583000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0958ab0a7b904c6abbc804e49a0e9544_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzItMy0xLTEtOTIxNTA_ed3028ab-7605-4e16-b434-c3e9ac5c7a2e"
      unitRef="usd">80941000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7a3670052766460e8f6681bfb2fe46da_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzItNS0xLTEtOTIxNTA_8fe3cd6d-9fdd-4587-a757-4cc24637e1c1"
      unitRef="usd">79078000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzMtMS0xLTEtOTIxNTA_249331cc-5a71-4af6-91b5-417f49c32c41"
      unitRef="usd">715000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzMtMy0xLTEtOTIxNTA_23862f30-1724-410d-bf7c-188417da89a0"
      unitRef="usd">728000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzMtNS0xLTEtOTIxNTA_3daa16d5-d396-494f-8f0d-4f1b1cb206e3"
      unitRef="usd">591000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzQtMS0xLTEtOTIxNTA_f1b43e2c-3a98-4557-a6cd-f8bbac1bd829"
      unitRef="usd">4129000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzQtMy0xLTEtOTIxNTA_9f5c0794-b367-4d98-abe1-3beb1990d9d7"
      unitRef="usd">2215000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzQtNS0xLTEtOTIxNTA_92ca1845-80cc-4c21-9633-b31976267f4d"
      unitRef="usd">3305000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzUtMS0xLTEtOTIxNTA_4d27f37c-d578-4ef0-8f86-5e14cb4096a2"
      unitRef="usd">721000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzUtMy0xLTEtOTIxNTA_f9f70a8a-0010-4bdd-901b-f6976b64e1f0"
      unitRef="usd">301000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzUtNS0xLTEtOTIxNTA_edbb08f3-c448-4dfc-b21f-6ad3d51bc4f5"
      unitRef="usd">2033000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzYtMS0xLTEtOTIxNTA_2a0fbbe3-c1b9-4b10-9ded-eab1a631e34e"
      unitRef="usd">87706000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzYtMy0xLTEtOTIxNTA_6b9e6664-8c0d-4dc4-8ad6-7b627c4a60f8"
      unitRef="usd">83583000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0958ab0a7b904c6abbc804e49a0e9544_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90YWJsZTo1MDQzYjMyNTdiNjM0MmU5YWZiODU1MjNkOGIxMGVjNS90YWJsZXJhbmdlOjUwNDNiMzI1N2I2MzQyZTlhZmI4NTUyM2Q4YjEwZWM1XzYtNS0xLTEtOTIxNTA_2a95d8dc-186c-4a91-8fe5-1e779dcb2e2c"
      unitRef="usd">80941000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzM2MjI_e54f1ffe-ed8d-4143-befd-1394d9d9f75e"
      unitRef="usd">87700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMDkvZnJhZzozNTQ4YmZmMmVlMTU0NDhkOGQ3YjdjODhlYzI3Njc5Mi90ZXh0cmVnaW9uOjM1NDhiZmYyZWUxNTQ0OGQ4ZDdiN2M4OGVjMjc2NzkyXzM2NjQ_ed81d23d-c59c-447c-80e2-7c1149fcf9ea"
      unitRef="usd">55400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90ZXh0cmVnaW9uOmZlYzNiZTliODFlMjQ5OGU5YzJiMmZkZThhYTFiYWFjXzgwMQ_5073bb17-812a-40d3-a5c3-61887da2aae9">NET INCOME PER SHARE&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive securities included outstanding stock options, unvested RSUs, unvested RSUs with market conditions, PSUs and ESPP contributions. Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. See &#x201c;Note 8. Employee Benefit Plans&#x201d; for a further description of our equity awards. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90ZXh0cmVnaW9uOmZlYzNiZTliODFlMjQ5OGU5YzJiMmZkZThhYTFiYWFjXzgyMA_3fbb9e1d-da9a-4ce2-9d8e-fd9154301ba1">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzMtNS0xLTEtOTIxNTA_380a7cc8-4a10-4538-9e88-0473245114c5"
      unitRef="usd">182282000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzMtNy0xLTEtOTIxNTA_0bf48d82-682a-442b-9271-3412a2b0049c"
      unitRef="usd">231063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzMtOS0xLTEtOTIxNTA_929e5dcb-449a-4b9d-8c0e-b85add7e1f46"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzUtNS0xLTEtOTIxNTA_0e1dd32b-3a4a-4496-a5b4-d980f96a2213"
      unitRef="shares">321526000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzUtNy0xLTEtOTIxNTA_6a626d3b-14f8-4338-ab54-35df5b40ddbe"
      unitRef="shares">314884000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzUtOS0xLTEtOTIxNTA_f8910795-c30a-4ec4-ae9d-81d50eb9a1e4"
      unitRef="shares">308271000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzYtNS0xLTEtOTIxNTA_3fe9610a-0502-4655-9af1-bb5babc27824"
      unitRef="shares">3030000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzYtNy0xLTEtOTIxNTA_71b7dd3d-d868-4877-91e2-0016e49387cb"
      unitRef="shares">7475000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzYtOS0xLTEtOTIxNTA_c42a45b6-971f-4128-83f3-0aaa3f8d7b83"
      unitRef="shares">9730000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzctNS0xLTEtOTIxNTA_32fce9ca-3716-41ce-9e11-cafeae60845e"
      unitRef="shares">324556000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzctNy0xLTEtOTIxNTA_e3974c29-3bab-4e43-9920-8ea9712d419d"
      unitRef="shares">322359000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzctOS0xLTEtOTIxNTA_c8d05297-45e0-4dcd-b474-3837a6b68681"
      unitRef="shares">318001000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzktNS0xLTEtOTIxNTA_e7576046-de8c-4e4b-8f1a-a2a5e8fbf66c"
      unitRef="usdPerShare">0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzktNy0xLTEtOTIxNTA_71c71f80-68d4-443f-91bf-679335779fe1"
      unitRef="usdPerShare">0.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzktOS0xLTEtOTIxNTA_c9a9ab81-b73b-438b-a8cd-3436aef265cf"
      unitRef="usdPerShare">0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzEwLTUtMS0xLTkyMTUw_49356d69-ed32-4c36-8acb-b820d315faf2"
      unitRef="usdPerShare">0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzEwLTctMS0xLTkyMTUw_e7e357d4-2b70-412a-af6d-d75deaa70b8f"
      unitRef="usdPerShare">0.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTozOTU3NzE2ZGQ3Y2Y0MTViYmY3NzljNjU0ZWRiZGQwOC90YWJsZXJhbmdlOjM5NTc3MTZkZDdjZjQxNWJiZjc3OWM2NTRlZGJkZDA4XzEwLTktMS0xLTkyMTUw_ad90da54-0329-4889-98f6-3a65995bf613"
      unitRef="usdPerShare">0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90ZXh0cmVnaW9uOmZlYzNiZTliODFlMjQ5OGU5YzJiMmZkZThhYTFiYWFjXzgyNQ_6aababa7-655e-44a9-9b4e-ff29860c9671">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i71c697b2f65940fa81b21b627eb077fb_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTpjMmRkNjJlNjU4ZmU0MmEwYTEwOGU3MDllNmY2ODhjZi90YWJsZXJhbmdlOmMyZGQ2MmU2NThmZTQyYTBhMTA4ZTcwOWU2ZjY4OGNmXzItNS0xLTEtOTIxNTA_30ac76d1-023f-4ea6-8b68-2136d094e7c8"
      unitRef="shares">17063000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i56ed82a42994483c92b32ba299673685_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTpjMmRkNjJlNjU4ZmU0MmEwYTEwOGU3MDllNmY2ODhjZi90YWJsZXJhbmdlOmMyZGQ2MmU2NThmZTQyYTBhMTA4ZTcwOWU2ZjY4OGNmXzItNy0xLTEtOTIxNTA_bfc49e54-a0df-47d6-a9ef-340e5a9ccde2"
      unitRef="shares">14305000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib28ac370d4ef4ca68b7bea32798fe004_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTIvZnJhZzpmZWMzYmU5YjgxZTI0OThlOWMyYjJmZGU4YWExYmFhYy90YWJsZTpjMmRkNjJlNjU4ZmU0MmEwYTEwOGU3MDllNmY2ODhjZi90YWJsZXJhbmdlOmMyZGQ2MmU2NThmZTQyYTBhMTA4ZTcwOWU2ZjY4OGNmXzItOS0xLTEtOTIxNTA_93d7a46a-98f3-4fe8-bbe6-27c5246ac05c"
      unitRef="shares">10959000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzEzMjY4_6eaf3868-8852-4c2f-8d34-0ab34968bfc8">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have noncancellable operating leases of corporate headquarters, office and laboratory space in California and Pennsylvania totaling 673,978 square feet with lease terms ending in 2024 through 2037. Certain of our leases include options to renew the lease or to early terminate the lease. As of December&#160;31, 2022, it is not probable we will exercise our options to renew these leases, nor is it probable that we will not exercise our option to terminate certain of our leases before the end of the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we have lease agreements for laboratory spaces located in Pennsylvania totaling 28,228 square feet for which the leases of the premises have not commenced. We expect these leases to commence upon substantial completion of leasehold improvements by the lessor and upon receiving access to those premises.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMC0xLTEtOTIxNTA_96cbace8-4798-438d-bd6a-d3ce92ddad69"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMC0xLTEtOTIxNTA_bf05f744-ae2c-4625-a413-f24a3f80b54d"&gt;Right-of-use assets included in other long-term assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMC0xLTEtOTIxNTA_3805e340-1810-45ae-9746-eaa8274e40f1"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMC0xLTEtOTIxNTA_4cf525be-b16c-489c-b6e4-ee90a9a764d7"&gt;Current portion included in other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of operating lease costs were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities for the years ended December&#160;31, 2022, 2021 and 2020 was $11.4 million, $5.0 million and $4.6&#160;million, respectively, and was included in net cash provided by operating activities in our Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the maturities of our operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future tenant improvement reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the weighted average discount rate used to determine the operating lease liability was 5.3% and the weighted average remaining lease term was 12.7 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease cost for leases with initial terms less than 1 year for the year ended December 31, 2022 was $0.4&#160;million, and immaterial for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MSN I ANDA Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (individually and collectively with certain of its affiliates, including MSN Laboratories Private Limited, referred to as MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#x2019;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#x2019;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#x2019;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the May 5, 2020 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#x2019;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#x2019;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. The two lawsuits comprising this litigation (collectively referred to as MSN I), numbered Civil Action Nos. 19-02017 and 20-00633, were consolidated in April 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#x2019;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#x2019;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#x2019;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#x2019;s counterclaims with respect to U.S. Patent No. 9,809,549. In our MSN I complaints, we sought, among other relief, an order that the effective date of any FDA approval of MSN&#x2019;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties narrowed their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the trial addressed two issues: (1) infringement of claim 1 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A bench trial for MSN I occurred in May 2022, and on January 19, 2023, the Delaware District Court issued a ruling rejecting MSN&#x2019;s invalidity challenge to U.S. Patent No. 7,759,473. The Delaware District Court also ruled that MSN&#x2019;s proposed ANDA product does not infringe U.S. Patent No. 8,877,776 and entered judgment that the effective date of any final FDA approval of MSN&#x2019;s ANDA shall not be a date earlier than August 14, 2026, the expiration date of U.S. Patent No. 7,759,473. This ruling in MSN I does not impact our separate and ongoing MSN II lawsuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MSN II ANDA Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. In particular, the January 11, 2022 amended ANDA requested approval to market a generic &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment). On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 arising from MSN&#x2019;s further amendment of its ANDA filing with the FDA. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 are invalid and not infringed. On June 7, 2022, we received notice from MSN that it had further amended its ANDA to assert an additional Paragraph IV certification. As currently amended, MSN&#x2019;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. 11,298,349 (pharmaceutical composition). On July 18, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 11,298,349 arising from MSN&#x2019;s further amendment of its ANDA filing with the FDA. On August 9, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 11,298,349 are invalid and not infringed and amended its challenges to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 to allege that these patents are not enforceable based on equitable grounds. The two lawsuits comprising this litigation (collectively referred to as MSN II), numbered Civil Action Nos. 22-00228 and 22-00945, were consolidated in October 2022 and involve Exelixis patents that are different from those asserted in the MSN I litigation described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 21, 2022, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#x2019;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015, if those claims are not found to be invalid, and (ii) upon approval, MSN&#x2019;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#x2019;s ANDA product prior to the expiration of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 would also infringe certain claims of each patent, if those claims are not found to be invalid. In our MSN II complaints, we are seeking, among other remedies, equitable relief enjoining MSN from infringing the asserted patents, as well as an order that the effective date of any FDA approval of MSN&#x2019;s ANDA would be a date no earlier than the expiration of all of U.S. Patents No. 11,091,439, 11,091,440, 11,098,015 and 11,298,349, the latest of which expires on February 10, 2032. A bench trial for MSN II has been scheduled for October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Teva ANDA Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, we received notice letters from Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#x2019;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book. Teva&#x2019;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#x2019;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed. On September 17, 2021, we filed an answer to Teva&#x2019;s counterclaims. On July 29, 2022, we received notice from Teva that it had amended its ANDA to assert an additional Paragraph IV certification. As amended, Teva&#x2019;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. 11,298,349 (pharmaceutical composition). On September 2, 2022, we filed a complaint in the Delaware District Court for patent infringement against Teva, asserting infringement of U.S. Patent No. 11,298,349 arising from Teva&#x2019;s amended ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#x2019;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873, 10,039,757 and 11,298,349, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva from infringing these patents. On September 30, 2022, the parties filed a stipulation to consolidate the two lawsuits, numbered Civil Action Nos. 21-00871 and 22-01168, and to stay all proceedings, which was granted by the Delaware District Court on October 3, 2022. Following a similar order granted by the Delaware District Court on February 9, 2022 to stay all proceedings with respect to Civil Action No. 21-00871, this case remained administratively closed, and Civil Action No. 22-01168 was administratively closed on October 3, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 6, 2023, we received a notice letter regarding an ANDA submitted to the FDA by Cipla Limited (Cipla), including a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,724,342 (formulations), 10,039,757 (methods of treatment), 11,098,015 (methods of treatment), 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,298,349 (pharmaceutical composition).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cipla&#x2019;s ANDA requests approval to market a generic version of CABOMETYX tablets prior to the expiration of the aforementioned patents. We have not yet responded to this Paragraph IV certification notice letter but are evaluating it.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i124df26053054aa2bdf51a23778af8d1_I20221230"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzU0OTc1NTgzNTkyNQ_5d41cfab-8171-467e-a721-1badbc17579b"
      unitRef="sqft">673978</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i4ca72b16cd354168a6373fa5107c1cb5_I20221230"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzU0OTc1NTgzMzY5Mw_0aff4959-e524-454c-99f7-e3dbc2869804"
      unitRef="sqft">28228</us-gaap:AreaOfRealEstateProperty>
    <exel:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzEzMjc2_217eb6ce-f6d1-4cdd-b062-57be858db131">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMC0xLTEtOTIxNTA_96cbace8-4798-438d-bd6a-d3ce92ddad69"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMC0xLTEtOTIxNTA_bf05f744-ae2c-4625-a413-f24a3f80b54d"&gt;Right-of-use assets included in other long-term assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMC0xLTEtOTIxNTA_3805e340-1810-45ae-9746-eaa8274e40f1"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMC0xLTEtOTIxNTA_4cf525be-b16c-489c-b6e4-ee90a9a764d7"&gt;Current portion included in other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMS0xLTEtOTIxNTA_317d47c1-86da-4f69-b383-cc80f1ed4fd9"
      unitRef="usd">234811000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzMtMy0xLTEtOTIxNTA_b0c7b7d5-085e-4673-b4ab-ef30f250b17d"
      unitRef="usd">45122000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMS0xLTEtOTIxNTA_5c34c9c5-9263-4d65-893d-d4bc0dc9e50e"
      unitRef="usd">17659000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzUtMy0xLTEtOTIxNTA_64a980b6-b3a1-4297-a9d3-fe91b22b3717"
      unitRef="usd">5137000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzYtMS0xLTEtOTIxNTA_3119f709-41c4-45e3-accd-bc50ce12fed3"
      unitRef="usd">190170000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzYtMy0xLTEtOTIxNTA_e37fc5c1-e00b-485c-84e7-1b9282d2e833"
      unitRef="usd">51272000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzctMS0xLTEtOTIxNTA_a00c16ad-63a1-4246-b5b8-ce3bf7216b08"
      unitRef="usd">207829000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i75acbf66dbac4a57be7f173a56d4d5b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTo3NDIzZDcyMTljMmU0YTkxOWY1OWZlYTcwYWM0OTQ0My90YWJsZXJhbmdlOjc0MjNkNzIxOWMyZTRhOTE5ZjU5ZmVhNzBhYzQ5NDQzXzctMy0xLTEtOTIxNTA_01739c93-a87c-4956-a5cd-d04a2ad25f46"
      unitRef="usd">56409000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzEzMjc3_973a2d7c-4476-47ef-8e7c-5ad8e2860cad">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of operating lease costs were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzItNS0xLTEtOTIxNTA_fe1081f8-8b7d-48c4-84de-21ea824f24ea"
      unitRef="usd">18315000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzItNy0xLTEtOTIxNTA_01531ec1-d817-4d8a-8984-5ba476f00ac9"
      unitRef="usd">5332000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzItOS0xLTEtOTIxNTA_518e1646-4b98-4a7c-b5bb-7e20e3052266"
      unitRef="usd">4825000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzMtNS0xLTEtOTIxNTA_a0335307-a86f-4de0-af7a-e2ef7b873ce8"
      unitRef="usd">3098000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzMtNy0xLTEtOTIxNTA_bc81892b-410e-4f8d-9780-96c5462e4067"
      unitRef="usd">2685000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzMtOS0xLTEtOTIxNTA_d77e5e8c-9a84-4406-a07b-79aa71d8f6e1"
      unitRef="usd">2830000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzUtNS0xLTEtOTIxNTA_ece6df93-7c87-48f0-bd8e-2e0064c884d6"
      unitRef="usd">21413000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzUtNy0xLTEtOTIxNTA_b2c5f329-89fa-4c26-8896-6084c28a122a"
      unitRef="usd">8017000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZTozYmMzNWI5YTQ0NTc0MDFiYmVjMTQ5MmEwZWI0MjFmZS90YWJsZXJhbmdlOjNiYzM1YjlhNDQ1NzQwMWJiZWMxNDkyYTBlYjQyMWZlXzUtOS0xLTEtOTIxNTA_debae5e0-a88b-4fae-bb05-dc7992008ae9"
      unitRef="usd">7655000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzE5NDE_d5e72191-7d8b-4d5e-a578-f5a8f7571b11"
      unitRef="usd">11400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzE5NDU_2452768e-5f1e-4522-b5a3-ab755fb0f3c1"
      unitRef="usd">5000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzE5NTI_ed67b691-38ea-4e20-8aca-e6dd25c468fd"
      unitRef="usd">4600000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzEzMjcz_ad8f25ff-dd26-48bf-9c93-2f2ded0dd701">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the maturities of our operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future tenant improvement reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzItMi0xLTEtOTIxNTA_74f5fcb7-7359-4885-86c0-18b75ac8544a"
      unitRef="usd">18057000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzMtMi0xLTEtOTIxNTA_c631624e-79b9-401c-965e-cbbec8562b5e"
      unitRef="usd">23682000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzQtMi0xLTEtOTIxNTA_8727c5e4-6af6-4ae6-8e68-426a6dcd9ea1"
      unitRef="usd">23111000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzUtMi0xLTEtOTIxNTA_904ed13e-99be-4f52-bcae-708ff021012a"
      unitRef="usd">23608000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzYtMi0xLTEtOTU1ODk_091c2702-c35b-469d-a428-ce473b9a924b"
      unitRef="usd">24313000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzYtMi0xLTEtOTIxNTA_5f7997cd-12dc-48bc-9499-90e70f1c5458"
      unitRef="usd">206605000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzctMi0xLTEtOTIxNTA_32c10125-a2c0-4bc9-be36-3a1246e8a8b6"
      unitRef="usd">319376000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzktMi0xLTEtOTIxNTA_8ab82643-58a1-4795-9d10-b03ef2181524"
      unitRef="usd">88310000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzEwLTItMS0xLTkyMTUw_6b320452-99d8-4ee4-9101-0e61dc531a42"
      unitRef="usd">23237000</exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements>
    <us-gaap:OperatingLeaseLiability
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90YWJsZToyODk3NGE3OGMyZDk0YzUwYTMxZTIwYzhjMTk3NTFkNy90YWJsZXJhbmdlOjI4OTc0YTc4YzJkOTRjNTBhMzFlMjBjOGMxOTc1MWQ3XzExLTItMS0xLTkyMTUw_f25983a9-a302-4d72-87d5-d77a098bd0c4"
      unitRef="usd">207829000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzIyNjk_34becf71-00c8-4368-9015-b6b026bc8532"
      unitRef="number">0.053</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if9edbc96fe6e479bbcc59afd221a28fc_I20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzIzMjI_caca8231-fe5c-4f37-a350-d78bd2b32e60">P12Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:ShortTermLeaseCost
      contextRef="i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzM4NDgyOTA3NzUwMzE_73f0e8d4-0681-401b-bd76-736d850e95b1"
      unitRef="usd">400000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i9bfa88d098aa479b8e75f965457a266b_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzU0OTc1NTg5MDk2Nw_a2a19350-99ac-44d8-9462-2c37d339dd4d"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i74cd2a761c304dd6a43fc2985d7e82d0_D20210102-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzU0OTc1NTg5MDk2Nw_c4028482-2ae0-4c97-8475-ecb9f8fb67aa"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <exel:LossContingencyNumberOfLawsuitsConsolidated
      contextRef="i46d4a2a715724209a705ccaf6ae07793_I20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzM4NDgyOTA3NzQxMTQ_e204a11e-d8c6-4a60-8150-8bf031cbbded"
      unitRef="lawsuit">2</exel:LossContingencyNumberOfLawsuitsConsolidated>
    <exel:LossContingencyNumberOfLawsuitsConsolidated
      contextRef="i787ca4c1857e40088e47d31bcee1d60b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4NTU3MDIxMzU5MDQwMDVhNDFkMjA4ZGViMjRlNjBhL3NlYzphODU1NzAyMTM1OTA0MDA1YTQxZDIwOGRlYjI0ZTYwYV8xMTUvZnJhZzo0OTk0ZWRlYjA5YTE0ZTVlODBlODU4NjI4ZWZhMGYwOS90ZXh0cmVnaW9uOjQ5OTRlZGViMDlhMTRlNWU4MGU4NTg2MjhlZmEwZjA5XzM4NDgyOTA3NzQxMTU_6ef6fc7c-3a74-4643-aa9d-5ecc5cbfb4a8"
      unitRef="lawsuit">2</exel:LossContingencyNumberOfLawsuitsConsolidated>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>90
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M <&R\O!L0]!M6C"]I$+0*/VZ(1B>)O( ^'U%J3ALR!/D1?JC_P!02P,$%
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M1C>BHHCEQXFN:9953+(=_[:DB^XWJ\#A]9G]MUJ\%/,8<[IFV;<T$?N;1;
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M;9S"WJ;A']B0PK/N2,W*%LW%-LY;[P/QC^Y*8=-V$T3845?P)B#T?:R.M\@
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M#YG%*9]F@I[6&SAPCH=*]K^U9&Z_7"YILDGKY<#K)ZB%7?Y;@_A,N?QO)OM
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M?X'VO-!%]%#IKD'NSL((FK0J?Y]R3NA,PY%ZCA]/HUT%T05M'SVDXM+T3\?
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M9<D?A(XPN,PSG:?)F+$3 4H^%$H#%OB'?!*\3K(HBY,H#6[A1\'=?U^,=%D
MP_U/&XH8@*-V % (?]"+*%;/#Q8X5W&O#E[\[;O^2>_IEN4=V>4=;1O]Q>7[
M-V\N7KZ_N;B[?O\NN/CQYNKJ[=6[N]O@XMVKX.4OM]?OKFYO@U=7OUZ]>?\!
MKP07EW?7OU[?75_=MJWEV\T6_*:"672O J7+:)0FP.+C8 ZREBQ2%<0^VVJ0
MF7(6I*"3DFP:C))\,8M 8F-5E4D,I(GS^0*HJG0 6BPH9_C\?*X*I)O0FH@[
MJ0JX6(!4.W8'&N=5$<0PVQ]15B99,@HF!=!\EFC5#2[&XP2?C])T%09+@7D>
MC7$.4%UC50#T*E@4.<@6B%(%C%_0D.I3HDL$&,D<%?&LOBJ"*,DZ:1*C#H3[
MH@+FG0J/E;D%5V4S@$?QH%&1KCJ LBG,F2P4DH1&4I\6^!_>$XV2-"E7.,0X
MT7%^KXK0K)GN];&C@@QN2!%K1;1 '!*R$8G3'' +^(&UW2>$^@RT< FVH634
M+9@ZB/08(2R"!2R-P,=I8(P$?IJM= )S9;H;_ 08R0NDF6 S2G4.ZRM5H1 9
M '%.2_Y<^B^J0E= 1ES[<I8 SI>(MU*P#).8\>>+'$C%@!+QHKD&" B!B[PH
M)Z 7\F[P"Y$3GM%-IF3X"T"3R@!UL")<2%*F, G,7JA8)<@J20H<G@N5BGP5
MI4":1;0B,H?,EXA 591@8]<F\88R#]'] /.XBDNPMHL%3(V*!):HPQISQ[DN
MX?%D/@*\*#?C$QY@DI0=#:A$K)K!N\&M4L'?OCL;#'I/W^6E"@;=X ;&S"JE
MZ>?^4P(@LI(!:&/O@70FVG*^&P'/IZ!M 2-.+!I"X"S2N") D/-6P.8:T DV
M!&Q3K.8C>'C89RM ?_N$./C0ZP:7ONQ>6MX.+NM,=+T S5[_$0;7<9$LC+;'
MN>LW7&?!:S4J*G!H8+;^"5&]QK!1BU@+M[G5,0<3!*%AS$@#\49:_:."&X"$
MT9P6''Z>$O,5F,>VF] -;*#=C(P:X3/4)7$*KL%]&P@%ND$B\U51X.PD0L I
M,#E@?5*5%4A%3:$FV1@$E<D THAJTZ#[E^YMET;X.0(9[EJS0)J!P"5Q<LM0
M'BZ1VW"0+;C8#:D'7#>XFZ&<%>C^(+/W3Y\&:@)#H$I#64=EFB%(LR*OIC.@
M_N\YL$&@2Z6(?1%C20G?:+)H 6*V*!($&XAM+^J:V8/U32O$"6EPF$'#XVO$
M$W@ @POE\1IZ(J6:)C$H^X)]X:>BLI&TLWRIR "4LZA$YBT4Z9E)@I([5G&"
M_G=G'GTD$U25,U#0H*$(R6"Y%C D$<##J8,DF^;XF(?_;O#*R;$&!0 @_@/$
MIT3QGY#H&GX#^V&%"&VA!E.TA#5W)J MS!!-=<:L=_G^]NWU96?8A\%(8\_
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M:UMO;85R#)T&QIPH><*+=_"X*CE9S*SXI\M+VW7 &6JJ3R*J2>7X[?;,G'P
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M3@6F+XN*I$>0-7T !<]DQ]2,-UXPO;,H<D#02JCM3M-J^[='&1WJ&1LI,$O
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MN(!2K69>H]F5=U3B)QG;PG<LX3F>=T2>W\[49WG^ 7FWRZB0YU=8P43<1 \
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MWS &3VG8EQH:31^T3T>P2EV</Q#/-6.24IIF19[)_6<6&U9REI8^P!FSW1E
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M\UW0?LT[C9^R;N=)+X&?=0=L;JCZT^Q*;<;-4;+14ZI+=4?*F(%FT&<^$;_
M!7Y8>U<A-2I4ZT]M@;\QA4<5AV&U!"IX"_=#!Y(Z5[9&("%]EGB)8*53#)X5
M>)JFZ#([(+I;ZVT+G!X0Z"U5IJI"0^*GX3;_JT%+^$SW.MIB>7P&W64'*@@O
M<&I1R?N1AK9V>NWKTZ"^^$C_6K"-?!S([BMIASG/HM:HI.VYU@#Y)N(W/\"4
MB@X&I+AM#XJ3.26$+!^==GW\C:0!\VIAJO"F@"4&YF>_,! CP0&!A6C8^0-&
M 6<2Q9_)N2<LO#E\+\W)RZ;R9^8PK_/>H@RE"NZ/88IN,&XJZD3N*O;#01OP
M-P?A-Q3&%<FQE"7#SZE YY?.:<R=AV@!:73*,#IE\VYH99E8=--6#2YQ^]DY
MPXB6Q7.18NX:V=.=RCW9A7DV7F!,C+$[0:]+0R^WSG1P=%#"2[EUJFL0D*BE
MSKT1>6!7G+_[0(-MLIBFW23DF3<($XS+,,T3K3$9A+,1]2F*2H"V7CT^8W]J
M#*%E*_"1'D48RY6?F_O25'<OJ'@>#!AM*LB<(E=6/!!2>3>E+C@2.HGYDX#C
M(&\1CN BUUL^BN@:XGW:'Q==/6CGQ\<C)70'Z -F82]*NN2IQL>^,/<MUE7H
M@C$KH(33]X%G>K&VMIS.LTG6US$H?52\@ AYS#U-TTE?6<2N13^87'%RC)_C
M((G]Z,X=67MVA2YN)?8,)QZKE:MY/;II6>Y'W\J@OP%VP7E_*FMXH$:Y;MMC
MQV<?B&<B\YORYY;\4<JGK1\=(-PH@S%WWPS=S4=+5/?8H.THQ,%&.TS5]IW#
MTP\68Z7+]K!O?R@[/,!30.IJY(26A@&T)?XD@A/JZWQJVP[O%-?@9TB2<!WE
M0J)'9MRE2;SXO7&U[VAJ/IHLT8:WM5PVP"W+T>^Q,0[#:- 7( !IF:\U?IPI
M^8!ZTQ;*W_FHABJQ)$=Q_BWWQY8DP,:X>G\R/63Y9(K[BZ+C^GFJ&#1? *,N
M%J@K72IZ/BR7Q( ^L_K8]$LG8Y^/+@8?^C;*WO'G3.JXD<3^FU__M/]B>NT_
M%.Z7^\^M/TL+:'>B5"ML#2=9>N*'].ZF-EO^;(BAIS8;OEPK"9O1 KQ?&5-W
M-\2@_XY\]3]02P,$%     @ O8)'5N9-9?)'!   \@D  !D   !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&ULG59M;]LV$/XK![4H-D"QWORB)+:!)'71?$AF
MQ.V*8=@'6CI91"12):DX_O<[4K;C=K:Q[8O$E[OGGGOAD>.U5,^Z1#3P6E="
M3[S2F.8J"'168LUT3S8H:*>0JF:&IFH5Z$8ARYU2705Q& Z#FG'A3<=N;:ZF
M8]F:B@N<*]!M73.UN<5*KB=>Y.T6GOBJ-'8AF(X;ML(%FJ_-7-$LV*/DO$:A
MN12@L)AX-]'5;=_*.X'?.:[UP1BL)TLIG^WD/I]XH26$%6;&(C#ZO> =5I4%
M(AK?MYC>WJ15/!SOT#\YW\F7)=-X)ZMO/#?EQ$L]R+%@;66>Y/HS;OT96+Q,
M5MI]8=W))J$'6:N-K+?*Q*#FHONSUVT<#A324PKQ5B%VO#M#CN5'9MATK.0:
ME)4F-#MPKCIM(L>%3<K"*-KEI&>FCY3W>Y')&F&."A8E4S@.#"';_2#;HMQV
M*/$)E"B&!RE,J6$F<LQ_! B(TIY7O.-U&Y]%_(A9#Y+0ASB,XS-XR=[/Q.$E
M)_!F3 DN5OK-2_CS9JF-HK+XZYC#'5S_.)P]*E>Z81E./#H+&M4+>M,/[Z)A
M>'V&;']/MG\.??HX^P+WCW>_/<Q@/GN"Q>>;I]DQCF=1CG,\!@VV"'A7! V%
M1[OP7-AJYQDPD4/.J]9@[L,::8<$&SL%IJ&0%9UK#;]P ::4K29Q[0.^9MB8
M S16RU88_>L5_(%,=64"E&2LER231%VB[2>RGQ >VQH5,U)='=)[#U$:^W$:
MTR@FK7"8V+4H\D=I1'A"TAGIM+ZY XGY!7LAH)6C75,?<'PT4(/2ALA24>Q=
M3>+('\1#HM/WT[1/]9?Z\8APK?O4/$!CUBIN..DG?IB$,/+[HP%<^B,:_R>#
MVXB2R;X_&)#)./:3P2693OTPC,ZGY#V$O<'(_4:)^R7#4QH[0TYGV.G$G<[@
MJ&.$4;4V.X>$J0]ESR ;VTDIO:UX06U1GQ9??YY2 S,EM2CU3(0R2?I;I;G=
MM-4T6\SG=L<HOFS=9@_N4!FZ0J"1!H7AK/HI>J[PJ*HZ:H62-?%3D+$J:ROF
M&KPL2.I_I&")&6LUH1-O"AQ]-G25M%4.)<'0APJ=K@]B=9'OXH5%0=<*$+0X
M%G:Y@[&L%1)!LF/DCH>C[\)A2F9VAXH,B!4Y7VV :]VR984N7(3TMIMM'"$A
M#?%&\HQ\UP6WA]$X220-BH0=*FRDLFJ6&9=Y#Q:(\.%=&L?A]2,%&M(>S.JF
MDAM:OT6!!3<PKYC03BBZIN.M@$'1*A>:''6F>+.+MDT ?F^YV0!;,Y53&K^0
MV7\DX51.SZ?31>54A_GW?>3FA[P=U+D-[?&@_TPO&KD^0TTA"0<0A?XE'=1C
M;3XXN(>I>ZW<:T.3%6I]W96\7]T_:&ZZ>_Q-O'L-/3"UXD)#A06ITID=>*"Z
M%T8W,;)QM_I2&GHCN&%)CS)45H#V"TE1WTZL@?TS;_HW4$L#!!0    ( +V"
M1U:! (RZW1$  +E    9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;.5<
M^V_;R+7^5P9N6M@ (XN49$G9)(#C)/>Z2.R@SNZVN.@/(W(D<<.'=H:TXO^^
MWSDS?.EE9=?I7;3 (I8HSIGS_,YCR'VYSO47LU2J$%_3)#.O3I9%L7IQ?F["
MI4JEZ>4KE>&7>:Y36>"K7IR;E58RXD5I<A[T^Q?GJ8RSD]<O^=HG_?IE7A9)
MG*E/6I@R3:5^>*.2?/WJQ#^I+OPM7BP+NG#^^N5*+M2=*GY<?=+X=EY3B>)4
M92;.,Z'5_-7)I?_BS9#NYQM^BM7:M#X+DF26YU_HRW7TZJ1/#*E$A051D/AS
MKZY4DA AL/&KHWE2;TD+VY\KZN]9=L@RDT9=Y<G/<50L7YU,3D2DYK),BK_E
MZ_]53IX1T0OSQ/"_8FWO'04G(BQ-D:=N,3A(X\S^E5^='EH+)OT]"P*W(&"^
M[4;,Y5M9R-<O=;X6FNX&-?K HO)J,!=G9)2[0N/7&.N*UU=YFL8%M%P8(;-(
M7.59$6<+E86Q,B_/"VQ!-YZ'CMP;2R[80\X/Q$=06!KQ+HM4U"5P#MYJ!H.*
MP3?!08IO5=@3@[XG@GX0'* WJ 4>,+W!;Q%8O(U-F.2FU$K\W^7,%!I>\\]=
M:K";#'=O0I'TPJQDJ%Z=(%2,TO?JY/5?_N1?]'\X(,*P%F%XB/KKJ]N/'Z\_
M?WQW\_E.7-Z\%5>W-Y^O;_[GW<W5];N[7<S^#G+B@X+/&_&S$DMYKT269Z',
M0D21G"5* !RT)/V)Q-Z7ST68ZU6.JU@!E/BUE+I0VGCX:1Z'BI6.Q71'KA\$
MJTG$F;B220R0R6+)MWQ2668>DGM)%XJ\P*_8Y6(\\*;C"8(79)68$VRMXV)I
MMQ?8*#5"91'="YKPF:$HECHO%TM\&8Q[XDKI EA%C.:EKMB.LS I(Y*'L,)@
M0R!.!DPIELK1SC5=55(G#[Q/G)&(]>\]<<G2PU]5.E-:#'SKLYZ("Q$;:*X0
M*YW/6&]K_!<GB5!?E0YCH@Y>=FUN''GH+P,'H!.WR!1+6=2T:(,=](A<PV^X
M4_R9@N:M,% >_=C(36L/"+=VCF%OE@NME TN4-RRLQ%)'H*-B(RSV\+!Q N"
MKH&)TGH9A\N&*U/QB/!*8_KNO+. ^Z5@(%11CYQ6?5T!_SN:)(54-XER!0V9
M$J$N@0,RH5]6B6+%80M>L<P3,)Q"Z_=.MMF#8\48\$;NRG0TU!/?DQ0RA+"\
M4[',3<-F3WS&NIE,*(:$3;MA(HV)$1NRVM4:KQ-9 O<H!UE)+&=Q$A<$6&NE
MZ3?H*$%^->(4BL66I<&-YNS%ML7H'Q_F)&HO!"?AY_G\>=ELX6*!;91#3)@Q
MSQ;/R0^J6YZ)8##T)KZ/3\.1YX/LAX:I%^*JU/!@.&JN6:9MDJ&[HRW+,^&/
MO8O1%!] <S 6'^I]*T*DG W%M"GXT[[GC_MBY'O!.!"?R:D.+H @_;$W"7C/
M"V_8G[*!R GRC$V]8\<P-\7CFO\'H,)FP7U&"/K^5-SN($Z:F'@#?\2:& P"
M4C.X'(F?I(XY\ELW#[S^="("[V(RPK^307^/W)9M2.Q[0W^ #Q.O[X_QEY0^
M OZ:I5C)..)XDVE>9AO.0"Z?@A2R(X5!'1\=C=)BNO$!XC,4[Y+?LPH@9\:'
MOEA#C\]\OS=$B9,D,+0GGHUZ_>H;W_ALV+MH?D96I<!&19<\>/P[T6ASFU%H
ML4R(VY@N(FH;G7 Y:%DFIT3$H1(P>1)'C$]W!?ZDE0>P;MZ3F0\@(:M'%J6V
M5/?$\;<$[SX7NF3CT+8#ZRK]T=CFNF  -V#W&M%GWR<O"R[X>G]"GW'C$*XU
M(#]'%3]'>.'R!7X>.;^Q?*[D@Q5_X$^]P?@"A8!!9%^GJ]+B-Q8J>-_IA#RU
M?R;>EP65387*@*1MN(2MXG16:N/T>0IF@L'X;,OU=P?F07VON>H&/T!_C29"
M1"C@6#E<@ #5(@+A2-D,:%/</I,\L ^->H,_LT/MI _71_ILUC(ZT3(_Z(VM
MT_=LS62#D[.@33M<IV MIQE;J22<))8R$SZO[43/ON"QT=)O!PNQ&Z.K E4B
M?DP,-M%'_"ZPZI/.0Z6H=#+BX]V-N*9J\!+ 7L0+FYJN,W&G5H6E0^C%Z=]F
M/=(1Y5\J\9 _R:TTR&HNQ2#@Y6RFU7W,P76#VN:M+A?B<K5*JKQW2KN=42Y&
M?5Y8NY$0[\$#(I<X^K24:,1"56(7F: DNL[0'"!J(H1R5,H$I1E)A:8HJ<#!
MJKU5]L2415&*)L0+:%C,("YIBP]5Q4).^$G']^1&'V*PI")"G;E"WF+>)&OI
MC"[^6B(26,X5>3V9-P<4Z"^ ("G06\ LH8 '&9?#KB[?W'Y\]_D??Q<%H3G:
M:J+UES]- G_\@ZF=I*O.&MRD^"3AC%JNEN+Z)Y:M*1]87(>.Q 9AT(^]NQ[6
M%!Q^-WD/R#\9C[TQHOK4R*1@I:WRY"%%Z8Y"BQPH-1!MZHT)+8:!.*5+9<)[
MT"]^W^M3"3 >B--4 ;0B6Y(!4KBY.F.:?!>( )YVW^6YPHYJO20V19-H+EF5
MY+CD*/#-J P+%T0$77+%;B#>_5K"2 D7<^_PH;0L(B82DV\:C C?:HEV3[S)
M\R\>1TIMC&.,$"$_NDJ>DLIA6\@%? X@L*7_L3<:3[TA*8]+#1-7U0UB&-N<
M4;<Q\8;3L1=,AGMUIR14AVM6A^@-NBIL2=H3MYFX#8N<(W?J-=&+0&"7XKH7
M[!;5ZA^SN$Z$W!@7<.("6;+418TP]66&Z$2NR9"G_$OUK;ORC)>N6!?8::ZI
M]^8L42F+HI#*3%W8)JYU"S9IJ7+#DU$9&5HQUWG:,22C&,4[?F3W<:C".KFA
M)&7AK%(*,6"U0E!!H01_4A4<U7HB#TO4@JAR&T8_6KZQ$C5]G)K'&*:^%RX+
MEZ)@(;>JQ(V8N8_R ?4?@W07:9U/5J):!M 8+B5(I1;PB7D6'8Q7[:V,(O8T
M0ON];@LP M"OT+;'(2)>VTS;XJ7>@LD[^",G^JWHAVB*77O]=17KN@\JUCEU
M3O<Q2B(@>9G5^FU(6%="97(@R$B[=335FO7]EFKWAL$>/WXZ-S[(['ZO[MA@
MIW??J)A;+5>(UI*Y7IF]E\'B$=;J)-!!_2Z\UTIUM7W_.X;18PI[/*HTT!)%
M*)=!FXR^CS6L=UEI-S,HTMV@L*2:U[%TROIGT];^ZZQ@3=72!9#:*/4%OWG4
M5^$6VP,72ZJU< WU*<BZ0<DO9;1@6[ Z-N%CZDWZ4V\TG![,W#PG:BEAG9>)
M5<5,-=JHRJK8%D5'1:IM6:K<[.8@[&[[.77#K\/)Z1(Z3&!59Y0Z),EUV\[3
MCH'C;.5!O=G#7NT_HN:6)FD,M5.1=JI#: 6L,"4ID_S;A2XVHLQ<5]&GG?)T
MNZ04UW"8K*2L1$B'TC81E_8,XR8'./O3YW J=.ZV@'_>[U\,!IZU3-CN8>-*
MJZ323@7@5VI>H2TKJ5^CW06*V)6K\2!?L58J0PO%^X O[R >*FX(R=V@IXCU
M"[V>QF<=BW%U;RKWJE,4L5W$15EP-][%HZIT=X&G56)[-W!\+"AXY.)V$.>H
MD !DQ3D<A54_JU'#=E.G,3CGH5Z5U;R.(#Q U"$5B*G,RKD,J?OUJ.-$M,N$
MY\7Y'+;E3,%7")ZKX@J<5VT;S;:D&Y,Y=+0_0_BM.F9E"^$F8_+,MI,UCX9*
MZ\Q<)U=*W]0VR'&1:3/=-^F1@P*]:=YRNV"/WZF5Y'[]21TPB@W[FNWL6I9K
MX_AFN[07"+@H(C"RK7&331FK#)TP%%V @:?&:NYM1 3;"W[!\2\H4$G),GO@
M1K<NH7;9?D;M!J_([$%$;(EF.YP 2?6P+WCMG,ENX>I2J^6$JOZB:2Z8.DVU
M&FM.R)AT,D?+403&G".<V##'+[D=E'!^I9SHG,QBHN(9$S/&JH444 M"@:Q@
MJ,M)DVI@$TJ**A[W4U4*-C*I=;Y6/*2)=55H<>U:YY))-2@B!LC.D59KQASV
M3YKWA$LJ/LCO=YB^UDB+IC]LG7OP88?-!@S>Q,,.*K66<1N/9VIW#G-M4QL5
M$CS'M!1!S?(K]_%K=C-<XYVD3 T7P%_GZ/YS:^>+Y^-=;4GM%SS@E!0295+8
M4Y:XTC?G4#*#DR."1@V/V)#Z$&HES?Y/_;-M#"<>A%\=VNS5] \6>X.S1N1Z
M]6C?ZC;KB)&,SHGJ,9B-UCSD\P9.B5R9L0EI+_CS7X'?$H67SVTQU86'8(;%
MI$Y!EUSM:?4+Q?(&R#@,?-3'(/7(\?[YP*9VEE$F[/"RZ&P%P%CEINH$JOP0
MY<IT:M]#C2C%KT//;O6Y'ZSF,361CT*6(>&K>LF!5P>Y+LM%"9QQ<>7 IP5E
MU9X'%0<'==8@^[+%&_G3E:3Y!)"[3C/6\(N\0J?KZZIPZU7?-T>?MRT_:9]]
M'M62SV%#R@B[6G,'&[^C,]_DZ]_7GB^!5JT&_?FA!MTJQ-8+Z_V]P(X^'G+U
MI[XW'*#G"?6#*>!2E!FX_ZDFE=5-P[XX777&Q*(U87-32;J7#K]&>R9K#/CO
MU4RS7EVG&/PAY@2-,CHR;XBU=VK0\<1JD]H=]PW)&E6,VCGU.W;WQXKY6*__
MUQ*.,OX>\9H=%[*<3MUA-YU.6(K>-E)25+A8-4\?JO+(,'5J,-\0I)6] AAE
M0'.) ^'G; )%^),_1%!M,O_$@>.RV_2[1\VV' <B@Z^T?7MO6?DMP4BQP2/%
MFN>FPJ_[1)7!=*'B1H$>IN0"K.D=%IKZ2//4\Y1'!BI!\+S?IX>.>*!"7Z;#
MT9Z!2GV&PHF6^O?L/D]0'+W[BK[G*SC;RG=13&, ,A)[E>V?:W,Z3[=52TNJ
M2)E0QS.RUBR_5PV:!77Y\1\VO#G*S?[+1SG'A>+W'NRT)R%;HQ!:N7/<34\-
M13$=N7_[L*")%Q=>G1;WR28L5G%/,6?9;2BO4[U8HSG(?G3L4A=A/I]4#H*]
M[>XUBAAZIA, 0 _Q1]PWTJ\M\**^2=W+78]XN ;9WUDOV6-P8VW$%+H/98!
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M%XN)\3X+D/F,QOOL$R SRV[JJH7=KB*@;AO?^JKC+P!:[XK*57GARNP.OO2
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M?4[P;EY7R/CQ3X0=P[*C@62<-ML;_-'S.%[(JEAE5=UE!< Y[_"E^Z+NV_(
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M;LW)P>46MY?(Z"X(WXNVPVT^%-T6%@$,P<Z*J]@W-0P.:%.?WD)&@+13S#(
M^:;T<P7Y.I!3$0^7P+;OFWU-!['._+TK>]X][(*> P#.\#D/Z$@_K/NN;SS^
M#MS!C N  -C#0@4V^&P$#@(-*(*^!4I![@CK[URS 3*9PMVO NY^-8EV/S-O
M?@N+W.'!C"'N] @H-X )[%T3D*S[[:)$^!.A@XL:"K [>'1? B@VO@(, >F!
MO_L]CE1401#,0+04^19 !V0-\!.T8[JI,\3%[-=^1:<*P/:Z7T;+%E39O?!9
M)#*W7H.N28,'IN9V0;XIETKX$_.366![-+)_!*6[E0^-+PD 2+-EW0(Z((FA
M#@(HOZEQOX3BL!>O..4)@5NCOX6E7V3 ,U"/I4?BCN ,@"*ZNBE0'.$*0, "
M[M :X,=[$+C L+,:MM< 9)J/OINW>R @F($?HE]@N; (9"9#\#R@_"P+CZA8
MPY_PJ&M!1B]+G_6@!#;,&(HF[W=M1V)X)L D9$<8\G&Q3-IZWC@1EA!P.*S,
M+<$&X1%=TQ ^(6R\.0I:M3D-.46@-Y14:.,4B#=[0%*B:A)$M$DA-% @\JZ/
MY CXV)<KXHT$(U L"L(]>I55FG@0$W3X=:##KR>IZ(-'XH8)KE<UX;95TYNZ
M@K]S(17<*S\^\=!?8=__">)5AALCZ]]M0< ! -(/GL!-$B:AX'3Q,MKR -P7
MN6W.Z+N&DT-)SLSCNJKP,#X0[2'.HMV675W._YU0!!]!S06T1; X,K 7_&X)
MY_39%=D,5\H,^!!)JW(I#3%]([="\? 4=[KXS?#^33 I@+Y0'?Y_ HP);/]S
MP/8_3R+7#>IHB,?TQUO@G$#1./@8GDX/!3P0)7B!7 <H%%C?9@M86Q8PZ$IT
M1 8S2.Q\"^QRQ6H#<MVFV!1H6@ 9]PUP;P9YXT$+9Y,6X%NB"L9LCE1+'U=[
MP>LWWP23")<QWS2@RX-.L86#FP,+V27K >D%L_B#L& T=5; )T$QZ5C=9@ZW
M@G-O"U;I^$GBLRN_[$ UR''=R/'XD)'E@5GU*TFO&MT,P*) C6I Y;-#9$W1
M?IPZR:O+Z':XG#R ]V9+.$'\G+T'!:!H\,]1M\+TN+_@'A%/40@Z,N]2V)V&
M!6BF[MX5)?XX!QJ9MW Z8HP"1:):-A/!#M "L-FA4<>&5;.,F3&N]!7($%"C
M 7<VKJA$WM1M2YIL7C<KUD: QOM=SU*>Y0LJ08W?HO/KWHNQ<X$4;-<+!+<2
MRXYT%49&%IEYW7:(!L/'05HN"9G%$ @"'"BAZH*]!LH^2*L5Z0J*FZ?WHF,A
MN&#. <1Y1VJPL?'VA*YG-#P8[[UL'VF6K<J#R%([DZH8JUJD-VETQ.MZ>C18
MK\9FX,.%%PEZGHFK0=<$T/G50ND9,*,$76N4&*=W\H;]"=D=.NC879&EIC'N
M$-2'#O0N?&'(+'!NPPF0L\25H &S1P8.N^KW<@SX.P!<Q$#CT36+ZZ)7#*+H
M$W$_F<B%P3MA),9072R9^Z-DF_U'[T#Y;<H#Z:2H; $S] Y(1APZ QB.D-TQ
MH\(#CR1&F(P^Y:P@O0O0G95!V.'*X[J!,63%<(O!:U'$U2(8>]))F>'-=:=K
MEX,^3.R\JJOQ'X$JY2F5)TS3N@:$XL/6$PT 3J73#H:TCC'_V(D1PBSZQ#92
M@+#00=Q-@8)6?EZ2[0Y+V_?+LFBWB&S,X-D$1X\+JA2-.K61KLDYYEM"#;&J
M0##LW4$L(B0@.S8N,UJI !(87QVF%:@;C+B@R2#C8?*FG='$@$YK(N%P?NX(
M1!%^_A',%;9Z'@I@]#NP)OJ&H2<;0_X4^9UCMP=H4TIG[._9U2M?@E ^-1.[
M%IY&492BR-9!1T(VB>*D(OO\@5@ <B*S+L1I4B@ 2L"7VCW""I#%K7[MA:+0
MQ_%[,4^RMX&-&%O;P))X(" 0<LXAQ(VLPBW!IU6?ZSBGQ55VAKL\YT6CR;7?
ME\#R4/!V[E'L4-(K*4)#_C\X4Z8 V%W3$T4(^I$!M:P[)@2#]2*>T<Z&S2'<
M#2]0I\+39Z<JL?7/B$@D"),.1 C&GPSP:",/,(Z?U^OU\=*/@19^$D@!?R!S
M7L@/M$TE04;<\+S2'?$KPFC9PJ1#\LK$@JZF?=$(U[\17']@:MJ=4J^?&(G4
ML#62L#VK5H^JCQ*;[ MR!N0>L&?%@DQU":0@M-6)_[B"D(3<\FA@NV"\'TB*
MH&J^0K%C/?<P=O> ;GM18<&8[PID8Z*UX8IV<;,9$E%V!LP%G=1%[L_A?/%\
M+$.'=S@.$S?'G\U C%,G' U1[18]915<(DIJW7 &XG3!:"%D#0P9'2"(]FZ%
MKA>W\>BID0T#9'@Z9)0$;85.(![QYC"G1!T_2S;"^TB=.6/0Y-%%VT+@":SB
M$8;SFK$&#1B!TZ'H0!6[HM6*6Q35&9]O*S#)R!&DIV[T#P:L2C$<:)(.%I$.
M%M-T #H@F!#9C<:./G@#D%%RF![P![#8.HRJGL 'X#2UQ)2BIDHQ5F:P)-.)
M\XT$MAB-9($(?P0[<%)X9^-1N+-H%H-=4-ZCPX[9HSB7K:^157Q2-DE2J6A3
MB^7W$DM3IQ7CM%>3<=+7UQI#_$ L!!G]Z!%-C_)3(Q$T&8(#33.DN,XA=Q&N
M!6=6,KFB(LL1>M\PM8->@VR>N)<H1R=>P_CCLA;?-Q)1I6.8> Q:FQNT"VO$
M'/3IX[A"IKL"_NXPXA.UL:8^N)(0:F"2@>1%A_)*5PC/PE]K$//MUK%(:QI$
M%QG(!H5(G@(][)9]TWJC]P5IE&R]!SE_R#!:79"'],<$2HA(P!F >Z!K=0^3
M[USN^XZ<SCCHLJB)ZNNRWAPR1J;$-<NAH($7GP-7HS =>_%MWX 12&_]FX,)
M2(0S?B.?2?$@*#"JR;4CJAPM8(L!EJ7+/PJ 2,=4G3. "=BH@H[F=00P%'0;
M/ BVO$D9$D_QV%0J!A"9C-N>%%X3<YJ).LF8)[Y$7KX8P[!I9#UYU-5E\<8Y
M3Z@'YPH:%GW6 !51LD2H1L:1> CY)"T21(4I0X7I&."6$TU"G10G^+CTR$TP
M%%TO:85J$Y ^"WBA81FF1C,9K$4UMS;QB[8#QRA+8_&.+FB)HS]=L?>VV*GW
M?Y+'Q62-J^DT"[2S*^0#HYQM^EV MEB(.H@* 0 M>PK87=00JK.?A\!(K]%Q
M19/,>I?B@"QTB.5T !O7K.;T$&.S.I,!U9OZ44-H'#I1=5UMM'71M-V\ -3E
MOS"*8[Q1#D3?X1\^>!%X^A+Y59O]7?T.=#Z,8JOZH3)/&C>G?]P7#6F.("S1
M<L:8[..>C1'1RX3=$6( T+:DS!L+(WD9C>XPP#@H.3TBKHPY(G,.)OI"+"J&
M\*:N5^*Z$^0,GCUDM$5DZ>H]8 4BX87*C&.0\9\T(C'J:( <PX[V5)1MA97A
M$N2 E,+6-9(UH<R#+^_]G!QMHHDHMJ !UZ/KI=G9%(XL/^2E5R85/(+QB#$,
M2J> \$1ME-RFY J6&=!U=*A%^:W\8R?+4'\?&%QJ>D=OFZANO]7E-T7^,4?H
M:CK+YQ;E5=,Q7F/@8W]2$7TR74CDW-X.Z75(Y R(8<%L7WFP[/-"LGLH;++;
M]XB]YH>$_!N'B9!SG%F%62#OB!MP+NL><W7N?;33)4 N,7G41UHP!_$8K[X0
MKLP.)YD:.!A(*;\ES_8.=G2O.'LO)A)ZQ((SM&A.+L Z/E?1>TK#DQ>4]TYT
MBC$ L,I:"8R@=5[1B2/@6N$LJ&ZA>0-4B9*6F1=C'TIJRGNZQZ35$^> E&(<
M-"CI/&X**9A-,M;O"2&3F#E\L:(X$+.L) (N\L\:UCMW(#$IQB?,(7+1AYRM
MX-3*,$5.!9M='@.&?;G5(34L0H;8=+[<5<R;NIK.>?H.>")*]U'T?S)=*I@Q
M&QDFJ.CBGHC\7$-_[ A@I-(X"3%UI!&UZ'*QXVUX)4&X:,F+NDG'?^)XPN(&
M>. HJJL"[I.18@HG6#>80 -)3B)FS/.+2Y]C!AH=D)?8'2-^_@CC0.0DU;.5
M"\^LX1_@_2)6V%.9CC\8&Y?*HP0U&%Z&GQRE.:G7/@D$J N>#YCRP'+/25@!
M= D1E9CA3DIS&$5\$N0J)6\IAHJ SWWTY6&.%OH< 1@ ;!Q?2&\2.42(]Q6_
M/W#7IUB0@)ZD+N:X\A8->"3"80%@?M6\%*3+\>6FFT-D6_-L8\.)AUA6A4SM
M)YY[=&EZ.FT"_3%>-(0-DJ '\"-8K ,LN+)RI,HTG"*\V;JK5=N0F98'$TOY
M5Y:!^;]B4N%0 <DE>9A.[HFL3*/CN+*M;?"('8&4OU67?KBF03@ZS(V1+T^&
MWI!CJ+\'SAGX6.M9%YMDQ3$-\&HZB^][U(Z^)[?M-?'!49[\=";@@!D)9R#=
MJZ314]5 5-WVA/"<90VI(/5ZWK<^\;F-J@LSQAKDQ\?P^YTD;]A8](>>8KEW
M6_;24B[0DO&<!];X05@=*=\=!4CJ9L@GE^(_:50W,\I/94)A8L&;B%@P8@ 7
MF85H!IMGA=IN0W/#CPDJ<?WR'YNF[O<4YSOU(T>UA6\K-?".,=,6U8LHH9\"
M\6!HEN!HI8U(964=2?C.( +Z'":I)B;M73V5)$=FV"BM3+XY7A+RBT\\.\'(
MBSF5FQYL$Q%XUW<_9S_5^R+/OKS\<I9]T*?I@,&0H6H5B4W>!+_=67CE_"+[
MF08V@P"@J +C$ $8C$UUTK3! 935RX[\R^A:;>J25"V8O6A%*VO98F.C=2:A
M'4$KHBS@?B6%C]D@9M8IXMD&S&511<M_B0.6;7;VCK.(P-2"HXE!N%D-0K<C
M.PP9W=9Q&IV-"#ZQ%('.]@1Y ["'*-I3<WB-,A38^+Y]D9U=G8<8I.Z43N>L
M/0^Q8X'IR^QL,7C:Y)0#Q,MB(SDOLBP=#-[\['S@W['A,])]X:'/ST,>_O@S
MR@@^>5YDR&=?G!OS(D&9,R+><X15"T.TL"UW8G"6N!4GZY8'T3/O_1PAR?%]
MJ691[!;'86%\AII 1.+4.@U3!$-O1^.?0*@1=").K3&L4$_#IW>1_15XU*TX
M<@))PJ;(;\$5/.RXCT$_W&?-"5RN!"P'CMXUQ;(GY9=<MN$G\;,?<)1[4LG(
MI26;!$!AI@ZE<48?+7NJ(@? LBN0L)S=B[QGN#!8S-;#=*B=D9=?II)805=P
M[N-[(.659(6@BJZKIBR13>.%DE+^P[GMJ,*P;R8A.GIT:NI#K7$ ^85.:8/2
MH,(AYCMT69*WN5H]YTR7>_@,>G+E-W572-[3$OV6,^OG9W=$\/#32C"70YQ/
MDE' 1J0H-0JOBP'K36)'PUP2PE<<[6:"AYK155&J\[QO*,P-I%,7'%\%T8>5
M4X>]."(HX XD4F!!D"[[)J"FHN4=+>S;L%G<^G7TSD?/4C.UKTY\;OH%LXZS
M(VYR?J3KF5*%-54C$-6FQ(GGJA4=)!T9DO"JTYRG&'VBY87#FZ7QFWC:]1PP
M"-6(@M4\_ T4)@D^LY?01"F""*BQ"$#2ALDEJ\Q'$Q)Z&<'2W6P<D6>*Q7%*
M5 D;Q+,87*.8"2E[=8C^M<=X]Y.4Z!D )3FAZ@_QKD$-C--+EY2W")@3'M,(
MC1PLQCJ;F-S(&E1(>^&J"PW4QOA+=B8&K(AW9,CNP/PX1<1S4N9"W"IF?DR.
MX"@0>+!A=!>'I-2.QG-< A #]D/IL[9,(^NP"(BX3HIKCCV4I+V :EC@C'7?
M<20J8 &+%UKI_(%*Q,7$"'4RZJ_0A(A!2"]6XLS"YA67>@F: F)V/?F^T[!%
MR.[]6&$41'(VQ)#A"E=/V>. 3  3>!_8H*-?-,8'JPT\9]F'7"@)8")?!Z9<
M89SWGNJL%'X!O417HVTMT5))Z-@<'(6A1E6YH<A-L!7UEH#D@<C$C11&/L$O
M-._-QD[&E1LTUI;\.GJX*[9%5F,O#YD;*2:"S9K6&9U(J?Z1UE@@)VU:*B,<
M0(JU!TH:1XUQH)R2R-#X)\D ]@ EU82A>,F4J*70 ;N/3HH$OF1G(1RDOHGK
MH6P1&1EV+BV)TJ10GOH>DV".7XQ9G!RO'A*A"@/.,)(Z.X2S2I>T? X8%R:T
MZMR2X$($1HA C)J#QDP:%]E-9/XO[ ?"O"CAZ9 8HB23%>$,F<22D8PYM(H:
M-ZZL702KRPX2ZF^8Y,L#GTW;&0&&Q?N8RYMG?V&A<<>Z)NP; -?U$LU_Y_%$
M2Z/PA'IY72J9SX4C:.GC=YS)<9>#U.PQX/8=V="W\0W;(4&R!D1ZV:A(G3X5
M"S(#F#B7C0^2:, X)XB$F)I'H4?F(8KC60A"X+EQZ(]&9FPE?Z]*7DF>(T@!
M''@UF%VX9-MA=*:0+3=<74Q,//FJC!N5*N).:6JPP3E;I:%A<O-S($82NC&J
M1F%A8CS&V+%(=6'4-YSSEK-1;IF9O^#"[8#&)L-&IS1G@Y,M_G@JJ44"L(EN
MPP2.Q)E=75[^,0;ETO<-M<'^9M;;2;GAA";,4D+P1L9J+:FRQXKJP5,=E @W
M,HQ$TT:MG!2_%U:W97F]E$PZ3E$.-D.<,3I<?L!:><2*;YM^(T,BM#>-V\U$
M&3'DN.=?-+='"_"M.),Q J]&3Z5;=S+?FNK18"48=S1%@+IQTH260'EK3&LM
M7643-XT&2*9 HEU$BXR*VC;$V:..P2;/GKE0ZW-"=ITG:J^JVRA<Q@@@ -@@
M?U1LZB995\#")I1C!Z<E\#WM7<#I9U'C4.M\[%F.-/$:$ITXZ#^B^&"%!*I)
M@0R#;_3(XBY\,!%3V]PH>'8)#4O1#V89D5\6U7T-["9P*5X*+ZK@0C*0%2[
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MN497TS0 TW?V?N)TTW73K7;4F[MA28\A&F] ^SNMW7'B"<;G=?494$L#!!0
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MG"V-W)S?8^99&<>>0!@Y0>12(W;B*,1&D#A>EL($TT)1+QQ88!A(5IJY+,>
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M;28?V/Y/VA3DE[R89:+Z!/LFUK% O!62Y4VR&D&>%O4W^=X(<9  @Q,)J$E
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MU#B#AG80<0:%=9!5RK@N90RHOD4<\T.NI/YRC5ERI \I<Y7LO67760,)1H#
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MU4JCF<[NPVH?/' #J("SMI.T_WYM("00!LVHS$NPS3V'>XYSB6\6>\9_B!1
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ME&4?-U15/=<&ZOL58_+U0C^@/'"=_P=02P,$%     @ O8)'5M/G^Y#@ P
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MV5Q6FH866UN^KX2&>L]^EG#!(](8P/^U$/JY80;HKHR+_P!02P,$%     @
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M^D3K#?JZP<FFVK)^)IR3HCI,,4HPE0'B^HH0_M*0-V@_D\S^ U!+ P04
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M-"\/5P0GA*D >7U!J7AIJ!LT7TFFWP!02P,$%     @ O8)'5G7N@_,: P
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M@SDNV(J;*[GYA&4\)Y8OEER[7]B4MH$'\4H;F95@\B!+1?%E=Z4..X!V[Q%
M6 +"AX#N(X!.">@\%= M 5VG3!&*TR%BAHT&2FY 66MBLP,GID-3^*FP:9\9
M1;LIX<R(].+L1BKFLC!>*D1*JM$P%G.8K#29:PT1KNF"Y'8'QC93J4E1PQOX
M./L"QQ$:EG+]BN;7LPB.CU[!$:0"+E/.B54/?$.>VO/\N/1J4G@5/N)5.X1+
M*4RBX;V8X[Q.X%.(59SA-LY)N)<QPK@%G> UA$$8-CAT_A1XV\';#?!H/_PS
M$RT(&N&U:#I5UCJ.K_/OK*T1QDHQL71Y T9IVYU_,PDJ, D34 ?]_$J<<&$P
MT[^:$E0XT&UVP!:C,YVS&(<>51N-:HW>Z.6+=B]XUR3N(<FB Y'5A.]6PG?W
ML3]X+FS[7"!'%=NO7("2]XR;>Z!]065;,XY-^A;GO'7GV-J\'@6MH#/PU[NZ
M[77FN;H=B*RFVTFEV\E3=:M?6$WUSB2NCMBK>U6*-TT8%?4FW?:>\]Q[>4BR
MZ$!D-7U[E;Z]_UT0>H<4_I!DT8'(:L+W*^'[>R_V]L+B'35BNO&E%P3M8.>I
MGYRVP@=/O<&JVVOUZE91@U4G;/4KJR(&?Z<?R% M75^E(98K88J_S&JU:MW&
MKF-YL#ZAEJ[HP/[2%/W@)5/+5&C@N"#*H-6GVZ^*'JN8&)F[KN-&&NIAW#"A
MMA25-:#]A91F.[$'5(WNZ ]02P,$%     @ O8)'5I1N%'[U!P  1D,  !D
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M,5Z]M*'Z(MFA?,G '9.2I>7'/25;RHL$ZO=[IL:7^DN10?/JC.4_4$L#!!0
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MCU+<RZ(64']?YGGU]4W]@,/# RWG_P-02P,$%     @ O8)'5LT&<7=C P
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MK0L*7!!D,#RC*Z[J<:S>&+EV \I<&AIWW')%$RPJJT#?%U*:EXT]H)V)D_\
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MGF. 9"DD*QJP4E 06O^CY^8@.@#;W0. #0"^%^ T *<R6BNK;)TCB>()9VO
M=;1BTX/J;"JT<D.H?HVWDJM5HG ROJ0K3"7C+^#P'$M$<G$$CL'][3DX/#@"
M!X!0<)>QI4 T%1-3JATUSDP:]K.:'>YA/\?)"7"L+P!:$/; 9^^!VQ7<WH2;
MRF=K%K9F8<7G_-/LKRNU!"XE+L3O/ELUC]O/HTOK5)0HP5-#U8[ ?(6-^/,G
MV[>^]ID<B6S#LM-:=H;8XQNT5NDB,2<H[WV!-=RKX+KF5W%H!<'$7'4=] 2%
M_EO0AC*W5>8.*GM0Y:W3J^0LP:)76TW@=[9U'<]WM\3M1L$@L/>H\UIUWJ"Z
M"T*)JJH4+!CKSWQO9UO;\AUO2UQ/%(S@'G%^*\X?%'?'),K[-/D[N_D0!OZ6
MIMTH-_)LNU]3T&H*!C7-EIRKX@(EX]7WF= D7Z;J (D>-W77IWF0]J.E-A+9
MQ@F$[0F$(WU=PC$MCT2V83EJ+4?_EXC13HHY#HRBK43<C8*!&SG]B6A;;U>:
M-:CJBM'%L?KD%;W)R&2&.<C;&"0$EOUWV^ V'WU/8[%M'DKGGK='RLZ&:"S;
M([%MVGZ[\>W!VW5_AC:X[IT&PVCGYNL+@Y8=;N6HV>G =/O[ _$%H0+D>*YP
MUDF@"'C=4=83R<JJ*7MD4K5XU3!373CF.D"MSQF3KQ/=Y[5]??P74$L#!!0
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M&U;X"P%E$W!](:793NP&_4\I^PM02P,$%     @ O8)'5MFJ4;V3 P  >PX
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M"N3G6TK%TX7Z@F;0M_@?4$L#!!0    ( +V"1U8B->8RQQ$  *?X   9
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;+W=87/:2+J&X;^B\MG:FJF:L9$
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MU$32 _NB(ZH!&D"CFH=J M5\5).HIE M0+60TO0V: +H@?GVU'./J,Q,Y[9
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M5?]H+G> 8^ Z0-W?,";/ [U ^2O#[!]02P,$%     @ O8)'5AUBR<,+!
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M4\-V2KK] 1F'VP;27D7:\Y+^*AG7F+X;HG<"T1N.FA'Z%4+?B_#E&662J0]
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M9^Z)HK>"_\W6>COWIAY:TPVIN?XB#K_3SJ'$V"L$5\TO.G2R@8>*6FE1=LI
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MR"ZDZ=CG\'BC&RXI=POIC"3GW0MCB]*6 ZDT'=83_^3D;JY-?Q#YP"J%.-V
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M$*$-8'W%N=H/] ;#7Y/%?U!+ P04    " "]@D=67OS3I?<"  !U"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6RM5FUOVC 0_BM6)DVMM)*0 %T[
M0(*FTSJM$RI[^3#M@TD.8M6Q,]N!]M_O[(04JH#Z@2^)7^YY?/?X<I?A1JI'
MG0$8\I1SH4=>9DQQ[?LZR2"GNB,+$+BSE"JG!J=JY>M" 4T=*.=^& 0#/Z=,
M>..A6YNI\5"6AC,!,T5TF>=4/4^!R\W(ZWK;A0>VRHQ=\,?#@JY@#N9G,5,X
M\QN6E.4@-)."*%B.O$GW.NY;>V?PB\%&[XR)C60AY:.=W*4C+[ . 8?$6 :*
MKS7< .>6"-WX5W-ZS9$6N#O>LG]VL6,L"ZKA1O+?+#79R/OHD126M.3F06Z^
M0!V/<S"17+LGV=2V@4>24AN9UV#T(&>B>M.G6H<=0'=P !#6@/ UH'< $-6
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M9OA? ,H:X/Y28HVO)_: YD]C_!]02P,$%     @ O8)'5BI6!7+9!   /QL
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MB=ZCSU1E@BDSX"OT)05!S3RZ YT[=,?HG$7%].4,%&61?*=5WQYGZ/+B';I
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MZ,B+@>)IWM3.N=(M<GZXT5\Q(,P"/;_B7#T/3)]<?1>%_P!02P,$%     @
MO8)'5D1D5HY> P  S!4   T   !X;"]S='EL97,N>&ULW5A=3]LP%/TK41@3
M2!-IFI$VHZVT54*:M$U(\+ WY#9.:\EQ,L=E+8_[/?M5^R7SM=/T U\H/(QV
MK2#V/3[G'MLWB:%7J06GUU-*E3?/N:CZ_E2I\D,05.,IS4EU5I14:"0K9$Z4
M[LI)4)62DK0"4LZ#=JL5!SEAPA_TQ"R_S%7EC8N94'V_VX0\>_F<]OTP?N][
M5FY8I+3OWYZ\_3$KU,4;SUZ/WAT=M6Y/+[;C)P8X]0.GZ/D.HF>M%BX,("8>
M[R;^F#8FW=F4-L./M9 E'F.T[DZ.'C&$"2<./T;H"6*GY7;TY]=OU-,*>TH\
M=+I:6RCH&')0U^"@EQ5B58J1;P-:G>34NR.\[P\)9R/)@)61G/&%#;<A,"YX
M(3VE[P&=+H1(=6_AT/;@]JAU<B8*:7+;#/;WJ!Z^!2Q[8)!QWAAL^S8PZ)5$
M*2K%I>Z8P2;X /+J]LVBU XGDBS"]KF_(IB+3C(J9$IEDR;TEZ%!C],,[$@V
MF<)5%64 H%)%KALI(Y-"$.-AR:@;6G9,.;^&9\?W;$-[GJWMFRD)T32UH;II
M96P']-?5K/:Z[/F+=+V2W17JTTQ/1Y@^%!J]DC1C<].?9XT!3#W$U4E9\L5'
MSB8BIW;R.R<<],B2YTT+R>YU-BB5L0Y0Z7MW5"HV7H_\E*2\H7.U+*=YAGMN
M'Z#G?[O.$RJH)'S=M*[]?5[E%SNN7[:OX=D\5K8=.TU&G?WW6!\P]MUD? @F
M#V*[NX=@,CD DYU7>VH^QV2X_R:C_=SMH#ZNK9T)-TZ$3=2#DW??_P;G>+Y*
MZHUFC"LFZMZ4I2D5#PZ&6EZ1D?Y3=4-?CT]I1F9<W31@WU^UO]*4S?*D&74%
M"U&/6K6_P/3"N#GVZUQ,I'1.TV'=E9.1:7JZH;/6'R!L(Y?FXT8PCL7<"&!8
M'LP!QK$L+,__-)\N.A^+8=ZZ3J2+<KHHQ[)<R-!\L3QN3J(_[IDF213%,;:B
MPZ'3P1!;MSB&'[<:Y@T86![(]+RUQG<;KY#'ZP#;T\<J!)LI7HG83/&U!L2]
M;L!($O=N8WF @>T"5CN0WYT':LK-B2+85<P;=@?C2))@"-2BNT;C&%F=&+[N
M_<'NDBA*$C<"F-M!%&$(W(TX@CD #Q@21>8]N/4^"I;OJ6#U_]O!7U!+ P04
M    " "]@D=6EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_
MQ=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+
MJ1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D
M5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@
M2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/
M['X 4$L#!!0    ( +V"1U;["+<=3@4  &XP   /    >&PO=V]R:V)O;VLN
M>&ULQ9I+;^,V$(#_"N%3>DAMZ^5L$ =P7FV ;M98+]+C@I9HFUB)=$G*6>?7
MEY+B[ B1!KU,=;+U_C04^9%#7KUH\V.M]0_VL\B5G8]VSNTOQV.;[D3![>]Z
M+Y0_LM&FX,YOFNW8[HW@F=T)X8I\'$PFR;C@4HVNKT[W6IHQW-!.I$YJY7=6
M.YZE>+&_CE>;[""M7,M<NN-\5/_/Q8@54LE"OHIL/IJ,F-WIES^UD:]:.9ZO
M4J/S?#Z:-@>>A7$R_;![54%^XVM;[W%\_95[D/DHF?@;;J2QKCZCOC_WC ?A
M3VZV2J<?9.Z$N>-._&%TN9=J6]W&O\48O$8=A]-O$\1+\U_"J#<;F8H[G9:%
M4*Z)HQ%Y!:CL3N[MB"E>B/GH5A^$84N^%=5+^:<\9LT+.D\&PF4NI3]@'K.:
MD8YG46;2L4?57.R/ JP P0IHL6[]MLYEYI^>L1N><Y4*5A>O!8 A A@.!LC.
MEAQ 1@AD]#]"KBJ(Z@++],:7>*H!9(Q QH-!WNIB#R 3!#(9$/)[ "!G".1L
M,,B5TRF O$ @+X:+)+<[ /D)@?Q$"_G%;+F2K_4!QI4'+8N"FV,=2KF%3?<$
M:[LGM)A?Q4&H4L F<8JZA%@FMU[7?*U-$[?%UHBWPEWX$-Z4$!-SRY1:+OX[
MJTOU41V$=34B9,.T,B7VR@.7ACWSO!3LL^"V-.(#'B:4*;%1JH@II\T1 F'R
MF!+;PW=(][Z[>*S+\_Z?4NZK"R =9HTIL3;NBWVNCT*P&Z'$QG>TEKZCT"I,
M3!=38E_XV%4/]57U09NZ1U (]HW_;#<HF"NFQ+)X$N[$M?3=YM6.FU:_&5/$
ME-@1OG-2R*;QJ#\^+S;G1Q5"I;(5P  S1$!L"%1DK7Y+@(DC(!;'263LS _9
M<F%_@V#H,(1\'((8K1T_S!H!]6BDPVB=L<3<$1"[HT=M)TZ(B1DE(#;*N^(Z
M XC9)""V2;?K.C$QK03$6NF67B<FYI: V"W]]JM1(2:FF8!8,UT*[(IEB&DF
M)-8,ZD)V!C$QS83$FL%M&$),3#HAL73>;7C.WO^NC^Q.6K[=MCI (9H!(Y8.
MP*P^4E^?LC)UK&-0&F+:"8FUTQ7-4RBW' X50DP[(;%V4,Q63R/$'!02.PA@
M+JH<NW15#:^%I#()L\<AYJ"0V$$ LVJ+#/<?YL):\=8^04S,02%Y,@SK7K8:
M),Q!(?E0!\.,8+(;LU!$;B$,,X:8F(6B(;-DWQ.(B5DH&G3H,X.8F(4B\HD8
M#/,"8J(S,=13,5TCM*JI3[7O).40$[-01#T9TXWYQ$T5X /$Q"P444_'=&.>
MMB F9J&(>D*F&_,T$(:8F(4B:@MAF*VN1X19*"*V4&_^X$XXWJI",6:AF-A"
M?9AOM0AB8A:*B2T$TAQ-_%JCR1@S3TQLGIX\QSE;^9MG<!HIQLP3$YNG%[-I
M+2$F9IZ8V#P]Z9BN:**K (C-@V*V&J$8,T\\R(Q.9Z%CYHF'R<&=L[^%W.Y:
MF)AY8F+SX(4.QS\Q9IZ8V#S]F'7^""Y1P<R3$)L'Q6Q5H00S3T)LGE[,>^MD
M 0698!9*Z"W4EQ^ND@H0$[-00F^A?LP57/238!9*B"V$8K:_3<Q""?UR@G[,
MI]:WB:Y&HY\)0J()V\T$LU!";*'.N8OS>EE?Z5JR3# +)0.L,O"82^W\=;)5
MZ)B%DB$7'+!SN 81L]!LR+F@]E))S$(S\BS<+\S%!TQ8A6:8A6;D63@LFC#U
M.L,L-*LM-*Y/MM=7F?>N$MF3?X3U^U.>ITO#JI]F<5X45TMK-F6>W_I]7]1?
MFF>GY?*GI?[7_P)02P,$%     @ O8)'5K?' S!" @  0BL  !H   !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W:2VZC0!2%X:U8+""X[JN25IQ13S*-
ML@'DE!^*;1#02K+[MIR!?5 />A)Q1JA 7/X!^H2 QY=R:,9]>QIV^VY8?!X/
MIV%5[<:Q^U77PWI7CLUPUW;E=#ZR:?MC,YZ7_;;NFO5[LRVU+)=1][<SJJ?'
MVYF+UZ^N_,_$=K/9K\OO=OWG6$[C/P;7'VW_/NQ*&:O%:]-OR[BJZL_#=?=0
M7S;I[CRY6CR_K:K^^2U5]=Q! D$R?Y!"D,X?9!!D\P<Y!/G\00%!,7]0AJ \
M?] ]!-W/'_0 00_S!Z4ERK@D2)I@3:!U0JX3@=<)P4X$8B<D.Q&8G1#M1*!V
M0K83@=L)X4X$<B>D.Q'8G1#O1*"WH-Y"H+>@WD*@MTP>M@GT%M1;"/06U%L(
M]!;46PCT%M1;"/06U%L(]!;46PCT%M1;"/16U%L)]%;46PGT5M1;"?36R<L2
M KT5]58"O17U5@*]%?56 KT5]58"O17U5@*]%?56 KT-]38"O0WU-@*]#?4V
M KT-]38"O6WRLIM ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U ;T>]
MG4!O1[V=0&]'O9U ;T>]G4!OGWRL)-#;46\GT-M1;R?0VU%O)]#;46\GT#M0
M[R#0.U#O(- [4.\@T#M0[R#0.U#O(- [4.\@T#LF/YL0Z!VH=Q#H':AW$.@=
MJ'<0Z)U1[TR@=T:],X'>&?7.!'IGU#O_I-[#^'4HP[7G>XW7_TFJQ_.YY7KY
MR_)[Y^16N>!<WU8,3W\!4$L#!!0    ( +V"1U;XPP(=!@(  $\J   3
M6T-O;G1E;G1?5'EP97-=+GAM;,W:S6[B,!0%X%=!V5;$^#?3$;"9F6V'15_
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "]@D=64(37)NX    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "]
M@D=6F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( +V"1U;T(/=UX@<  + O   8
M  " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "]
M@D=6_4=MI3L"  "]!0  &               @($E$   >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ O8)'5B&4S.'B!@  2AP  !@
M         ("!EA(  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( +V"1U;:V^\8RP(   @*   8              " @:X9  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "]@D=6&FEV 38&  "W'P
M&               @(&O'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ O8)'5NRH$)Y+ P  \0D  !@              ("!&R,  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( +V"1U;J1>RQK (
M .(&   8              " @9PF  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " "]@D=6:7Y2=S\'  "O-   &               @(%^
M*0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ O8)'5J/!
M=/UL"   YR<  !@              ("!\S   'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( +V"1U8*KSWZ%2L  +.%   9
M  " @94Y  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
MO8)'5DWW(095"P  <1\  !D              ("!X60  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " "]@D=6@//>,UTC  "PA0  &0
M            @(%M<   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( +V"1U:<%LML)0D  )(9   9              " @0&4  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ O8)'5N CURUR!P
M31(  !D              ("!79T  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " "]@D=6K/KLT]8"   -!@  &0              @($&
MI0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( +V"1U8E
M71#U;P,  #T'   9              " @1.H  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ O8)'5M!\N%2-$   G#4  !D
M     ("!N:L  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +V"1U:FLN/@5P<  /L3   9              "
M@0() 0!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ O8)'
M5C^L?<PM P  :@<  !D              ("!D! ! 'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " "]@D=6:PE\+44&  "/%0  &0
M        @('T$P$ >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( +V"1U;3I<R^S0,  %()   9              " @7 : 0!X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ O8)'5C\&6?S9 @  & 8
M !D              ("!=!X! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " "]@D=6@R_BRB4#  ##!@  &0              @(&$(0$
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( +V"1U;2=I4J
M(P<  ,<8   9              " @> D 0!X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ O8)'5O.EQM-^!@  :1   !D
M ("!.BP! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "]
M@D=6D'4')8\#  "W"   &0              @('O,@$ >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( +V"1U8(1O:/#P0  ',*   9
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M970S-2YX;6Q02P$"% ,4    " "]@D=6H X3'X<#  "6$   &0
M    @(&/3@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M +V"1U8"6>+OP04  'P=   9              " @4U2 0!X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ O8)'5M/G^Y#@ P  /@X  !D
M             ("!15@! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " "]@D=6]5^Q9JP&   9,P  &0              @(%<7 $ >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( +V"1U;3"8;F500
M #(9   9              " @3]C 0!X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ O8)'5FY6C<.9!@  4#4  !D              ("!
MRV<! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "]@D=6
MUN?TJU@$   Q&0  &0              @(&;;@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( +V"1U9U[H/S&@,  /0*   9
M      " @2IS 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ O8)'5I1N%'[U!P  1D,  !D              ("!>W8! 'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " "]@D=6'^Z%SRH#   V"@
M&0              @(&G?@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( +V"1U;C&ZR1[P,  %T1   9              " @0B" 0!X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ O8)'5H)JD-"S
M!@  I2H  !D              ("!+H8! 'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    " "]@D=6*F*BM@8$  "8$P  &0
M@($8C0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( +V"
M1U9,Y,HXP (  .$&   9              " @561 0!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ O8)'5@WA@JI]"   W%(  !D
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M=#4T+GAM;%!+ 0(4 Q0    ( +V"1U;9JE&]DP,  'L.   9
M  " @6>K 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
MO8)'5AKTGOGC P  ]!,  !D              ("!,:\! 'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"% ,4    " "]@D=6(C7F,L<1  "G^   &0
M            @(%+LP$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4
M Q0    ( +V"1U:*S+^(]0(  % +   9              " @4G% 0!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ O8)'5F_36.[* P
M<1   !D              ("!=<@! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6Q02P$"% ,4    " "]@D=6'6+)PPL$  !]#P  &0              @(%V
MS $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( +V"1U8>
MT2VP:@4  )P?   9              " @;C0 0!X;"]W;W)K<VAE971S+W-H
M965T-C$N>&UL4$L! A0#%     @ O8)'5HO1;J*? P  S@T  !D
M     ("!6=8! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +V"1U8!:6!=B0,  '4*   9              "
M@5OK 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ O8)'
M5I)'.S2< P  I@P  !D              ("!&^\! 'AL+W=O<FMS:&5E=',O
M<VAE970V."YX;6Q02P$"% ,4    " "]@D=67OS3I?<"  !U"   &0
M        @('N\@$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0
M   ( +V"1U8J5@5RV00  #\;   9              " @1SV 0!X;"]W;W)K
M<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ O8)'5@0FPDU0 P  _ H
M !D              ("!+/L! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q0
M2P$"% ,4    " "]@D=62,-YR>8"  !7"   &0              @(&S_@$
M>&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( +V"1U:@4-YJ
M;P,  ",-   9              " @= ! @!X;"]W;W)K<VAE971S+W-H965T
M-S,N>&UL4$L! A0#%     @ O8)'5D1D5HY> P  S!4   T
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;72YX;6Q02P4&     %$ 40 N%@  %!0"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>297</ContextCount>
  <ElementCount>381</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>83</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>15</UnitCount>
  <MyReports>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Collaboration Agreements And Business Development Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities</Role>
      <ShortName>Collaboration Agreements And Business Development Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Provision For Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxes</Role>
      <ShortName>Provision For Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Revenues</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables</Role>
      <ShortName>Collaboration Agreements And Business Development Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashandInvestments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyandEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Employee Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansTables</Role>
      <ShortName>Employee Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Provision For Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxesTables</Role>
      <ShortName>Provision For Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ProvisionForIncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsandContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails</Role>
      <ShortName>Revenues - Revenues by Disaggregated Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails</Role>
      <ShortName>Revenues - Net Product Revenues Disaggregated by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Significant Customer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails</Role>
      <ShortName>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Revenues - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Collaboration Agreements And Business Development Activities - GSK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - GSK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Collaboration Agreements And Business Development Activities - Other Collaborations Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Other Collaborations Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Cash and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Cash and Investments - Investments by Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails</Role>
      <ShortName>Cash and Investments - Investments by Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails</Role>
      <ShortName>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails</Role>
      <ShortName>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Fair Value Measurements - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails</Role>
      <ShortName>Fair Value Measurements - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Employee Benefit Plans - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Employee Benefit Plans - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Employee Benefit Plans - Schedule of Employee Service Share - Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails</Role>
      <ShortName>Employee Benefit Plans - Schedule of Employee Service Share - Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Employee Benefit Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails</Role>
      <ShortName>Employee Benefit Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Employee Benefit Plans - Weighted Average Grant Date Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails</Role>
      <ShortName>Employee Benefit Plans - Weighted Average Grant Date Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Employee Benefit Plans - Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails</Role>
      <ShortName>Employee Benefit Plans - Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Employee Benefit Plans - Summary of All Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails</Role>
      <ShortName>Employee Benefit Plans - Summary of All Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Employee Benefit Plans - Summary of All RSU &amp; PSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails</Role>
      <ShortName>Employee Benefit Plans - Summary of All RSU &amp; PSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Employee Benefit Plans - Estimate Grant-Date Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails</Role>
      <ShortName>Employee Benefit Plans - Estimate Grant-Date Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Provision For Income Taxes - Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Provision For Income Taxes - Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Provision For Income Taxes - Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails</Role>
      <ShortName>Provision For Income Taxes - Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Provision For Income Taxes - Schedule of Deferred Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails</Role>
      <ShortName>Provision For Income Taxes - Schedule of Deferred Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Provision For Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails</Role>
      <ShortName>Provision For Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Provision For Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Provision For Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Net Income Per Share - Potentially Dilutive Shares of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails</Role>
      <ShortName>Net Income Per Share - Potentially Dilutive Shares of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Commitments and Contingencies - Balance Sheet Classification of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Balance Sheet Classification of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Commitments And Contingencies - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Commitments And Contingencies - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="exel-20221230.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0540-CurrentFiscalYearEndDate-Registrant-Value] In submission type 10-K, CurrentFiscalYearEndDate value "--12-30", should match the Entity Registrant Fiscal Year End Date "12/31" on record within EDGAR. exel-20221230.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="exel-20221230.htm">exel-20221230.htm</File>
    <File>exel-20221230.xsd</File>
    <File>exel-20221230_cal.xml</File>
    <File>exel-20221230_def.xml</File>
    <File>exel-20221230_lab.xml</File>
    <File>exel-20221230_pre.xml</File>
    <File>exel20221230exhibit1020.htm</File>
    <File>exel20221230exhibit1040.htm</File>
    <File>exel20221230exhibit211.htm</File>
    <File>exel20221230exhibit231.htm</File>
    <File>exel20221230exhibit311.htm</File>
    <File>exel20221230exhibit312.htm</File>
    <File>exel20221230exhibit321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20221230_g1.jpg</File>
    <File>exel-20221230_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="933">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>96
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exel-20221230.htm": {
   "axisCustom": 3,
   "axisStandard": 24,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 933,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 297,
   "dts": {
    "calculationLink": {
     "local": [
      "exel-20221230_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exel-20221230_def.xml"
     ]
    },
    "inline": {
     "local": [
      "exel-20221230.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20221230_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20221230_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "exel-20221230.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 604,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 4,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 8
   },
   "keyCustom": 64,
   "keyStandard": 317,
   "memberCustom": 41,
   "memberStandard": 42,
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20221230",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.exelixis.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Revenues",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.exelixis.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Collaboration Agreements And Business Development Activities",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities",
     "shortName": "Collaboration Agreements And Business Development Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Cash and Investments",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.exelixis.com/role/CashandInvestments",
     "shortName": "Cash and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.exelixis.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Inventory",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.exelixis.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.exelixis.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Provision For Income Taxes",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxes",
     "shortName": "Provision For Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Net Income Per Share",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.exelixis.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.exelixis.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.exelixis.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Revenues (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.exelixis.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables",
     "shortName": "Collaboration Agreements And Business Development Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Cash and Investments (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.exelixis.com/role/CashandInvestmentsTables",
     "shortName": "Cash and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Inventory (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.exelixis.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.exelixis.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Employee Benefit Plans (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansTables",
     "shortName": "Employee Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Provision For Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxesTables",
     "shortName": "Provision For Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.exelixis.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Net Income Per Share (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.exelixis.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.exelixis.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exel:NumberOfCountriesWithDrugApprovalExcludingTheUS",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exel:NumberOfCountriesWithDrugApprovalExcludingTheUS",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails",
     "shortName": "Revenues - Revenues by Disaggregated Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i89478d8e53974982878b9f548166f990_D20220101-20221230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
     "shortName": "Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if237b256b8c34d6f87bec83d450b03ab_D20220101-20221230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "ide7ae702d2f94f168ad5eb6d613db43b_D20220101-20221230",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails",
     "shortName": "Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "ide7ae702d2f94f168ad5eb6d613db43b_D20220101-20221230",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
     "shortName": "Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "ia505016291bc4b92966a63cb457f79cf_D20220101-20221230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i75acbf66dbac4a57be7f173a56d4d5b3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails",
     "shortName": "Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i0958ab0a7b904c6abbc804e49a0e9544_I20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Revenues - Contract Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
     "shortName": "Revenues - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:MilestonePaymentsEarnedToDate",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "id4f5961955974e53a8d6b5ad85acfe4d_D20220101-20221230",
      "decimals": null,
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "id4f5961955974e53a8d6b5ad85acfe4d_D20220101-20221230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:MilestonePaymentsEarnedToDate",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "ifaedfc761d77477d83685f07ca670fc4_D20170101-20171231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "exel:UpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i5e5a7fdf85fc4fc7bfa8e4d51f47e59b_D20220101-20221230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborationAgreementPercentOfRoyaltyOnNetSale",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Collaboration Agreements And Business Development Activities - GSK (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - GSK (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i41fe2331cabe4050a30129ee051c2799_D20220101-20221230",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Collaboration Agreements And Business Development Activities - Other Collaborations Narrative (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Other Collaborations Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "exel:IncreaseInBasicEarningsPerShare",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "2",
      "lang": "en-US",
      "name": "exel:IncreaseInDilutedEarningsPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Cash and Investments - Narrative (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
     "shortName": "Cash and Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Cash and Investments - Investments by Security Type (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
     "shortName": "Cash and Investments - Investments by Security Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
     "shortName": "Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
     "shortName": "Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Income",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Fair Value Measurements (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "ia82be6e971604c2da30b378bdf9985c9_I20221230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i12667066e7cc4662b0936e2e393953fd_I20221230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "derivative_instrument",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Fair Value Measurements - Narratives (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails",
     "shortName": "Fair Value Measurements - Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i12667066e7cc4662b0936e2e393953fd_I20221230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "derivative_instrument",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Inventory (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.exelixis.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Property and Equipment - Narrative (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails",
     "shortName": "Property and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Employee Benefit Plans - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails",
     "shortName": "Employee Benefit Plans - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i5160dca23cbd4534bbd8f0c6583551eb_D20220101-20221230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Employee Benefit Plans - Schedule of Employee Service Share - Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
     "shortName": "Employee Benefit Plans - Schedule of Employee Service Share - Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "ic5603f2e0fff4c849973ffaeafa13517_D20220702-20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Employee Benefit Plans - Narrative (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
     "shortName": "Employee Benefit Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "ic5603f2e0fff4c849973ffaeafa13517_D20220702-20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Employee Benefit Plans - Weighted Average Grant Date Fair Value (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails",
     "shortName": "Employee Benefit Plans - Weighted Average Grant Date Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Employee Benefit Plans - Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
     "shortName": "Employee Benefit Plans - Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "iae5b26c4932a47cb916d8fd6f8e5fdbf_D20220101-20221230",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Income",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i75acbf66dbac4a57be7f173a56d4d5b3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Employee Benefit Plans - Summary of All Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails",
     "shortName": "Employee Benefit Plans - Summary of All Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i75acbf66dbac4a57be7f173a56d4d5b3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i4c54a7d88c1f429ba5559d7d2282d65c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Employee Benefit Plans - Summary of All RSU & PSU Activity (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails",
     "shortName": "Employee Benefit Plans - Summary of All RSU & PSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i3b58587e7b964211aa0b8c59b478758c_D20220101-20221230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i5d0769f83041428ebd89a4c71d6f91d1_D20220101-20221230",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Employee Benefit Plans - Estimate Grant-Date Fair Value (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
     "shortName": "Employee Benefit Plans - Estimate Grant-Date Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i9aae7ba847d34422b359963bd9dc87f5_I20221230",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Provision For Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
     "shortName": "Provision For Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Provision For Income Taxes - Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails",
     "shortName": "Provision For Income Taxes - Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Provision For Income Taxes - Schedule of Deferred Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails",
     "shortName": "Provision For Income Taxes - Schedule of Deferred Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Provision For Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails",
     "shortName": "Provision For Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i75acbf66dbac4a57be7f173a56d4d5b3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Provision For Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails",
     "shortName": "Provision For Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i71c697b2f65940fa81b21b627eb077fb_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Net Income Per Share - Potentially Dilutive Shares of Common Stock (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails",
     "shortName": "Net Income Per Share - Potentially Dilutive Shares of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i71c697b2f65940fa81b21b627eb077fb_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Commitments and Contingencies - Balance Sheet Classification of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Balance Sheet Classification of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Commitments And Contingencies - Components of Lease Expense (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails",
     "shortName": "Commitments And Contingencies - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "if9edbc96fe6e479bbcc59afd221a28fc_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "iee90ac3decac457ea10ccb1f57c3be9f_I20200103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "iee90ac3decac457ea10ccb1f57c3be9f_I20200103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20221230.htm",
      "contextRef": "i16334905d5a74c5cb7e8f66057c4bc80_D20220101-20221230",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 83,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exel_A2021AwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Awards",
        "label": "2021 Awards [Member]",
        "terseLabel": "2021 Awards"
       }
      }
     },
     "localname": "A2021AwardsMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AccountsReceivableForUnsettledInvestmentSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable For Unsettled Investment Sales",
        "label": "Accounts Receivable For Unsettled Investment Sales",
        "terseLabel": "Accounts receivable for unsettled investment sales"
       }
      }
     },
     "localname": "AccountsReceivableForUnsettledInvestmentSales",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccredoHealthIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accredo Health, Incorporated",
        "label": "Accredo Health, Incorporated [Member]",
        "terseLabel": "Accredo Health, Incorporated"
       }
      }
     },
     "localname": "AccredoHealthIncorporatedMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AccruedClinicalLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Liabilities, Current",
        "label": "Accrued Clinical Liabilities, Current",
        "terseLabel": "Accrued clinical trial liabilities"
       }
      }
     },
     "localname": "AccruedClinicalLiabilitiesCurrent",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccruedCollaborationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Collaboration Liability, Current",
        "label": "Accrued Collaboration Liability, Current",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "AccruedCollaborationLiabilityCurrent",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AchievedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achieved [Member]",
        "label": "Achieved [Member]",
        "terseLabel": "Achieved"
       }
      }
     },
     "localname": "AchievedMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesOfAmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "label": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "terseLabel": "Affiliates of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AffiliatesOfAmerisourceBergenCorporationMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofCVSHealthCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of CVS Health Corporation [Member]",
        "label": "Affiliates of CVS Health Corporation [Member]",
        "terseLabel": "Affiliates of CVS Health Corporation"
       }
      }
     },
     "localname": "AffiliatesofCVSHealthCorporationMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofMcKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of McKesson Corporation [Member]",
        "label": "Affiliates of McKesson Corporation [Member]",
        "terseLabel": "Affiliates of McKesson Corporation"
       }
      }
     },
     "localname": "AffiliatesofMcKessonCorporationMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofOptumSpecialtyPharmacyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliatesof Optum Specialty Pharmacy",
        "label": "Affiliatesof Optum Specialty Pharmacy [Member]",
        "terseLabel": "Affiliates of Optum Specialty Pharmacy"
       }
      }
     },
     "localname": "AffiliatesofOptumSpecialtyPharmacyMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "label": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "terseLabel": "Other Customer Credits/Fees and Co-pay Assistance"
       }
      }
     },
     "localname": "AllowanceForCustomerCreditsFeesandCoPayAssistanceMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForProductRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Product Rebates [Member]",
        "label": "Allowance For Product Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "AllowanceForProductRebatesMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AmendedAndRestated2017EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended And Restated 2017 Equity Incentive Plan",
        "label": "Amended And Restated 2017 Equity Incentive Plan [Member]",
        "terseLabel": "Amended and Restated 2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "AmendedAndRestated2017EquityIncentivePlanMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Balance Sheet Classification of Lease Liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.exelixis.com/20221230",
     "xbrltype": "stringItemType"
    },
    "exel_BioInventInternationalABBioInventMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioInvent International AB (BioInvent)",
        "label": "BioInvent International AB (BioInvent) [Member]",
        "terseLabel": "BioInvent International AB (BioInvent)"
       }
      }
     },
     "localname": "BioInventInternationalABBioInventMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CabometyxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cabometyx [Member]",
        "label": "Cabometyx [Member]",
        "terseLabel": "CABOMETYX"
       }
      }
     },
     "localname": "CabometyxMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health, Inc.",
        "label": "Cardinal Health, Inc. [Member]",
        "terseLabel": "Cardinal Health, Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "totalLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "totalLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTotalLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CatalentIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Catalent, Inc.",
        "label": "Catalent, Inc. [Member]",
        "terseLabel": "Catalent, Inc."
       }
      }
     },
     "localname": "CatalentIncMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ChargebacksAndDiscountsForPromptPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chargebacks And Discounts For Prompt Payment [Member]",
        "label": "Chargebacks And Discounts For Prompt Payment [Member]",
        "terseLabel": "Chargebacks, Discounts for Prompt Payment and Other"
       }
      }
     },
     "localname": "ChargebacksAndDiscountsForPromptPaymentMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementPercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "label": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "terseLabel": "Collaboration agreement percent of royalty on net sale",
        "verboseLabel": "Cost of goods sold is related to product"
       }
      }
     },
     "localname": "CollaborationAgreementPercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration [Member]",
        "label": "Collaboration [Member]",
        "verboseLabel": "Total collaboration revenues"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Achievement Levels of Commercial Performance, Period",
        "label": "Collaborative Arrangement, Achievement Levels of Commercial Performance, Period",
        "terseLabel": "Collaboration period to achieve specified levels of commercial performance"
       }
      }
     },
     "localname": "CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_CollaborativeArrangementMaximumAmountOfWarrantExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Amount Of Warrant Exercise",
        "label": "Collaborative Arrangement, Maximum Amount Of Warrant Exercise",
        "terseLabel": "Maximum amount of warrant to be exercised"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumAmountOfWarrantExercise",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsExerciseAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Exercise Amount",
        "label": "Collaborative Arrangement, Rights And Obligations, Exercise Amount",
        "terseLabel": "Option to exercise, amount"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsExerciseAmount",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments",
        "terseLabel": "Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments",
        "terseLabel": "Potential future development milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development, Regulatory And Commercial Milestones Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development, Regulatory And Commercial Milestones Payments",
        "terseLabel": "Additional development regulatory and commercial milestones payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "terseLabel": "Potential regulatory milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Upfront Payment",
        "label": "Collaborative Arrangement, Rights And Obligations, Upfront Payment",
        "terseLabel": "Collaborative arrangement, upfront payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements with GSK And Royalty Pharma",
        "label": "Collaborative Arrangements with GSK And Royalty Pharma [Member]",
        "terseLabel": "Collaborative Arrangements with GSK and Royalty Pharma"
       }
      }
     },
     "localname": "CollaborativeArrangementsWithGSKAndRoyaltyPharmaMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Genentech [Member]",
        "label": "Collaborative Arrangement with Genentech [Member]",
        "terseLabel": "Collaborative Arrangement with Genentech"
       }
      }
     },
     "localname": "CollaborativeArrangementwithGenentechMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithIpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Ipsen [Member]",
        "label": "Collaborative Arrangement with Ipsen [Member]",
        "terseLabel": "Collaborative Arrangement with Ipsen",
        "verboseLabel": "Collaborative arrangement with Ipsen"
       }
      }
     },
     "localname": "CollaborativeArrangementwithIpsenMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Takeda [Member]",
        "label": "Collaborative Arrangement with Takeda [Member]",
        "terseLabel": "Collaborative arrangement with Takeda"
       }
      }
     },
     "localname": "CollaborativeArrangementwithTakedaMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CometriqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cometriq [Member]",
        "label": "Cometriq [Member]",
        "terseLabel": "COMETRIQ"
       }
      }
     },
     "localname": "CometriqMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment And Software [Member].",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "label": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "terseLabel": "Contract revenue recognized, including revenue from deferred revenue beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CotellicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cotellic [Member]",
        "label": "Cotellic [Member]",
        "terseLabel": "Cotellic"
       }
      }
     },
     "localname": "CotellicMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CybrexaTherapeuticsLLCCybrexaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cybrexa Therapeutics, LLC (Cybrexa)",
        "label": "Cybrexa Therapeutics, LLC (Cybrexa) [Member]",
        "terseLabel": "Cybrexa Therapeutics, LLC (Cybrexa)"
       }
      }
     },
     "localname": "CybrexaTherapeuticsLLCCybrexaMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liabilities",
        "label": "Deferred Tax Assets, Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Lease Right-Of-Use Assets",
        "label": "Deferred Tax Liabilities, Lease Right-Of-Use Assets",
        "negatedTerseLabel": "Lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeaseRightOfUseAssets",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Branded Prescription Drug Fee",
        "label": "Effective Income Tax Rate Reconciliation, Branded Prescription Drug Fee",
        "terseLabel": "Branded prescription drug fee"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation",
        "terseLabel": "Non-deductible executive compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible, Warrant Purchase",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible, Warrant Purchase",
        "terseLabel": "Non-deductible warrant purchase"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleWarrantPurchase",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eligible Payment From Collaboration For Development And Regulatory, Milestone Achievement Under Collaborations Agreement",
        "label": "Eligible Payment From Collaboration For Development And Regulatory, Milestone Achievement Under Collaborations Agreement",
        "terseLabel": "Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement"
       }
      }
     },
     "localname": "EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_FinalTierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final Tier[Member]",
        "label": "Final Tier [Member]",
        "terseLabel": "Final tier"
       }
      }
     },
     "localname": "FinalTierMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_HeadquartersLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Headquarters Lease [Member]",
        "label": "Headquarters Lease [Member]",
        "terseLabel": "Headquarters Lease"
       }
      }
     },
     "localname": "HeadquartersLeaseMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_IncreaseDecreaseInResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Research And Development Expense",
        "label": "Increase (Decrease) In Research And Development Expense",
        "negatedLabel": "Decrease in research and development"
       }
      }
     },
     "localname": "IncreaseDecreaseInResearchAndDevelopmentExpense",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IncreaseInBasicEarningsPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase In Basic Earnings Per Share",
        "label": "Increase In Basic Earnings Per Share",
        "terseLabel": "Increase in basic earnings per share (in dollars per share)"
       }
      }
     },
     "localname": "IncreaseInBasicEarningsPerShare",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "exel_IncreaseInDilutedEarningsPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase In Diluted Earnings Per Share",
        "label": "Increase In Diluted Earnings Per Share",
        "terseLabel": "Increase in diluted earnings per share (in dollars per share)"
       }
      }
     },
     "localname": "IncreaseInDilutedEarningsPerShare",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "exel_InitialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial [Member]",
        "label": "Initial [Member]",
        "terseLabel": "Initial"
       }
      }
     },
     "localname": "InitialMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_IpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ipsen [Member]",
        "label": "Ipsen [Member]",
        "terseLabel": "Ipsen Pharma SAS"
       }
      }
     },
     "localname": "IpsenMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Agreements For Laboratory Spaces In Pennsylvania",
        "label": "Lease Agreements For Laboratory Spaces In Pennsylvania [Member]",
        "terseLabel": "Lease Agreements for Laboratory Spaces in Pennsylvania"
       }
      }
     },
     "localname": "LeaseAgreementsForLaboratorySpacesInPennsylvaniaMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LeaseArrangementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangements [Axis]",
        "label": "Lease Arrangements [Axis]",
        "terseLabel": "Lease Arrangements [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementsAxis",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_LeaseArrangementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Lease Arrangements [Axis]",
        "label": "Lease Arrangements [Domain]",
        "terseLabel": "Lease Arrangements [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementsDomain",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements",
        "label": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements",
        "negatedTerseLabel": "Future tenant improvement reimbursements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementReimbursements",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Reduction Of Payments Due [Abstract]",
        "label": "Lessee, Operating Lease, Reduction Of Payments Due [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseReductionOfPaymentsDueAbstract",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_LossContingencyNumberOfLawsuitsConsolidated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency Number Of Lawsuits Consolidated",
        "label": "Loss Contingency Number Of Lawsuits Consolidated",
        "terseLabel": "Number of lawsuits"
       }
      }
     },
     "localname": "LossContingencyNumberOfLawsuitsConsolidated",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount eligible for commercial milestones under collaborations agreement.",
        "label": "Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "terseLabel": "Maximum amount eligible for commercial milestones under collaborations agreement"
       }
      }
     },
     "localname": "MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_MedicarePartDFundingMandate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Part D Funding Mandate",
        "label": "Medicare Part D Funding Mandate",
        "terseLabel": "Medicare Part D funding mandate"
       }
      }
     },
     "localname": "MedicarePartDFundingMandate",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_MilestonePaymentsEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Earned",
        "label": "Milestone Payments Earned",
        "terseLabel": "Milestone payments earned"
       }
      }
     },
     "localname": "MilestonePaymentsEarned",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_MilestonePaymentsEarnedToDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Earned To Date",
        "label": "Milestone Payments Earned To Date",
        "terseLabel": "Milestone payments earned to date"
       }
      }
     },
     "localname": "MilestonePaymentsEarnedToDate",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Lease Expense",
        "label": "Noncash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NotProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not Probable [Member]",
        "label": "Not Probable [Member]",
        "terseLabel": "Not Probable"
       }
      }
     },
     "localname": "NotProbableMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_NumberOfBondSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Bond Securities",
        "label": "Number Of Bond Securities",
        "terseLabel": "Number of bond securities"
       }
      }
     },
     "localname": "NumberOfBondSecurities",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_NumberOfCountriesWithDrugApprovalExcludingTheUS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Countries With Drug Approval, Excluding The U.S.",
        "label": "Number Of Countries With Drug Approval, Excluding The U.S.",
        "terseLabel": "Number of countries with FDA approval, excluding the U.S."
       }
      }
     },
     "localname": "NumberOfCountriesWithDrugApprovalExcludingTheUS",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_NumberOfSponsoredEnterprises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Sponsored Enterprises",
        "label": "Number Of Sponsored Enterprises",
        "terseLabel": "Number of sponsored enterprises"
       }
      }
     },
     "localname": "NumberOfSponsoredEnterprises",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_NumberofProductsinCommercialMarket": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Products in Commercial Market",
        "label": "Number of Products in Commercial Market",
        "terseLabel": "Number of products that entered in the commercial marketplace"
       }
      }
     },
     "localname": "NumberofProductsinCommercialMarket",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_OperatingLeaseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Assets [Abstract]",
        "label": "Operating Lease Assets [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "OperatingLeaseAssetsAbstract",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OperatingLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liabilities [Abstract]",
        "label": "Operating Lease Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesAbstract",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OperatingLeaseRightOfUseAssetAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Right-Of-Use Asset And Other Assets",
        "label": "Operating Lease, Right-Of-Use Asset And Other Assets",
        "verboseLabel": "Right-of-use assets and other"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAndOtherAssets",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Line Items]",
        "label": "Organization And Summary Of Significant Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesLineItems",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Table]",
        "label": "Organization And Summary Of Significant Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesTable",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OtherLongtermAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long-term Assets [Member]",
        "label": "Other Long-term Assets [Member]",
        "terseLabel": "Long-term portion included in other long-term assets"
       }
      }
     },
     "localname": "OtherLongtermAssetsMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of royalty on net sale.",
        "label": "Percent of royalty on net sale",
        "terseLabel": "Percent of royalty on net sale"
       }
      }
     },
     "localname": "PercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_PerformanceSharesClinicalTrialResultsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Shares, Clinical Trial Results [Member]",
        "label": "Performance Shares, Clinical Trial Results [Member]",
        "terseLabel": "Performance Shares, Clinical Trial Results"
       }
      }
     },
     "localname": "PerformanceSharesClinicalTrialResultsMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probable [Member]",
        "label": "Probable [Member]",
        "terseLabel": "Probable"
       }
      }
     },
     "localname": "ProbableMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Gross [Member]",
        "label": "Product, Gross [Member]",
        "terseLabel": "Gross product revenues"
       }
      }
     },
     "localname": "ProductGrossMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductSalesDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Sales Discounts And Allowances [Member]",
        "label": "Product, Sales Discounts And Allowances [Member]",
        "terseLabel": "Discounts and allowances"
       }
      }
     },
     "localname": "ProductSalesDiscountsAndAllowancesMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromOtherCompoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products Derived From Other Compounds [Member]",
        "label": "Products Derived From Other Compounds [Member]",
        "terseLabel": "Products Derived From Other Compounds"
       }
      }
     },
     "localname": "ProductsDerivedFromOtherCompoundsMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "label": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "terseLabel": "Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances"
       }
      }
     },
     "localname": "ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities",
        "label": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities [Member]",
        "terseLabel": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities"
       }
      }
     },
     "localname": "ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent",
        "label": "Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent",
        "terseLabel": "Research and development arrangement performed for others, reimbursement for costs incurred, percent"
       }
      }
     },
     "localname": "ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_ResultingFromDiscoveryEffortsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Resulting From Discovery Efforts [Member]",
        "label": "Resulting From Discovery Efforts [Member]",
        "terseLabel": "Resulting From Discovery Efforts"
       }
      }
     },
     "localname": "ResultingFromDiscoveryEffortsMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_RevenueFromContractWithCustomerCommercialSalesMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer, Commercial Sales Milestone",
        "label": "Revenue From Contract With Customer, Commercial Sales Milestone",
        "terseLabel": "Commercial sales milestone"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerCommercialSalesMilestone",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RevenueFromContractWithCustomerRegulatoryMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer, Regulatory Milestone",
        "label": "Revenue From Contract With Customer, Regulatory Milestone",
        "terseLabel": "Regulatory milestone"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerRegulatoryMilestone",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RoyaltyTier": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Tier",
        "label": "Royalty Tier",
        "terseLabel": "Royalty tier"
       }
      }
     },
     "localname": "RoyaltyTier",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RoyaltyTierAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "royalty tier [Axis]",
        "label": "Royalty Tier [Axis]",
        "terseLabel": "Royalty Tier [Axis]"
       }
      }
     },
     "localname": "RoyaltyTierAxis",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_RoyaltyTierDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for royalty tier [Axis]",
        "label": "Royalty Tier [Domain]",
        "terseLabel": "Royalty Tier [Domain]"
       }
      }
     },
     "localname": "RoyaltyTierDomain",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_SairopaBVSairopaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sairopa, B.V. (Sairopa)",
        "label": "Sairopa, B.V. (Sairopa) [Member]",
        "terseLabel": "Sairopa, B.V. (Sairopa)"
       }
      }
     },
     "localname": "SairopaBVSairopaMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_SalesRevenueDiscountExpectedtobeEarnedPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Revenue, Discount Expected to be Earned, Percent",
        "label": "Sales Revenue, Discount Expected to be Earned, Percent",
        "terseLabel": "Discount expected to be earned"
       }
      }
     },
     "localname": "SalesRevenueDiscountExpectedtobeEarnedPercent",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_SalesRevenuePercentDiscountForPromptPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Revenue, Percent Discount for Prompt Payment",
        "label": "Sales Revenue, Percent Discount for Prompt Payment",
        "terseLabel": "Percent discount for prompt payment"
       }
      }
     },
     "localname": "SalesRevenuePercentDiscountForPromptPayment",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions",
        "label": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released",
        "negatedLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released In Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and released (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest",
        "terseLabel": "Additional shares to be earned (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards",
        "terseLabel": "Reduction in share reserve after all other awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award",
        "terseLabel": "Reduction in share reserve after stock option or stock appreciation award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement By Share-Based Payment Award, Termination Of Employment Following Change In Control, Period",
        "label": "Share-Based Payment Arrangement By Share-Based Payment Award, Termination Of Employment Following Change In Control, Period",
        "terseLabel": "Number of months following change in control in which an employee was terminated"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementByShareBasedPaymentAwardTerminationOfEmploymentFollowingChangeInControlPeriod",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "terseLabel": "Maximum potential to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_StatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status [Axis]",
        "label": "Status [Axis]",
        "terseLabel": "Status [Axis]"
       }
      }
     },
     "localname": "StatusAxis",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_StatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Status [Axis]",
        "label": "Status [Domain]",
        "terseLabel": "Status [Domain]"
       }
      }
     },
     "localname": "StatusDomain",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TSRBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TSR-Based Restricted Stock Units",
        "label": "TSR-Based Restricted Stock Units [Member]",
        "terseLabel": "TSR-Based Restricted Stock Units"
       }
      }
     },
     "localname": "TSRBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TaxCreditCarryforwardAmountWithExpirationPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Amount With Expiration Period",
        "label": "Tax Credit Carryforward, Amount With Expiration Period",
        "terseLabel": "Tax credit carryforward amount with expiration dates"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmountWithExpirationPeriod",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_UpfrontPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment(s)",
        "label": "Upfront Payment(s)",
        "terseLabel": "Upfront payments"
       }
      }
     },
     "localname": "UpfrontPayments",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "label": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "terseLabel": "Provision related to sales made in:"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsToProvisionAbstract",
     "nsuri": "http://www.exelixis.com/20221230",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r236",
      "r545",
      "r609",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r336",
      "r488",
      "r504",
      "r528",
      "r529",
      "r542",
      "r553",
      "r561",
      "r607",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r336",
      "r488",
      "r504",
      "r528",
      "r529",
      "r542",
      "r553",
      "r561",
      "r607",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r236",
      "r545",
      "r609",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r233",
      "r491",
      "r543",
      "r559",
      "r602",
      "r603",
      "r609",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r233",
      "r491",
      "r543",
      "r559",
      "r602",
      "r603",
      "r609",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r328",
      "r336",
      "r366",
      "r367",
      "r368",
      "r464",
      "r488",
      "r504",
      "r528",
      "r529",
      "r542",
      "r553",
      "r561",
      "r601",
      "r607",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r328",
      "r336",
      "r366",
      "r367",
      "r368",
      "r464",
      "r488",
      "r504",
      "r528",
      "r529",
      "r542",
      "r553",
      "r561",
      "r601",
      "r607",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r234",
      "r235",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r544",
      "r560",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r234",
      "r235",
      "r512",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r544",
      "r560",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r558"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r66",
      "r152"
     ],
     "calculation": {
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r22",
      "r23",
      "r155",
      "r500",
      "r509",
      "r510"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r19",
      "r23",
      "r101",
      "r457",
      "r505",
      "r506",
      "r580",
      "r581",
      "r582",
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Operating Activities [Abstract]",
        "terseLabel": "Non-cash operating activities:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r4",
      "r558"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r587",
      "r588",
      "r589",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Stock transactions associated with taxes withheld on equity awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r85",
      "r86",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r381"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities and contingently issuable shares excluded (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of leased property (in sqft)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r123",
      "r131",
      "r154",
      "r175",
      "r218",
      "r227",
      "r231",
      "r254",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r419",
      "r421",
      "r434",
      "r558",
      "r605",
      "r606",
      "r653"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r146",
      "r158",
      "r175",
      "r254",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r419",
      "r421",
      "r434",
      "r558",
      "r605",
      "r606",
      "r653"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets carried at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r241",
      "r261"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Debt securities available-for-sale:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r62",
      "r244",
      "r498"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r62",
      "r243",
      "r497"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r59",
      "r240",
      "r261",
      "r493"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total debt securities available-for-sale",
        "verboseLabel": "Total debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]",
        "terseLabel": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r108",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r42",
      "r149",
      "r530"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r37",
      "r42",
      "r45"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash equivalents at beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r37",
      "r121"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r17",
      "r127",
      "r137"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r281",
      "r282",
      "r515",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r587",
      "r588",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r3",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r3",
      "r558"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 323,951 and 318,842 at December\u00a031, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r24",
      "r164",
      "r166",
      "r171",
      "r494",
      "r501"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r50",
      "r51",
      "r118",
      "r119",
      "r236",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r50",
      "r51",
      "r118",
      "r119",
      "r236",
      "r511",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r50",
      "r51",
      "r118",
      "r119",
      "r236",
      "r514",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r50",
      "r51",
      "r118",
      "r119",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r48",
      "r50",
      "r51",
      "r52",
      "r118",
      "r120",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r50",
      "r51",
      "r118",
      "r119",
      "r236",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r102",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Other Assets and Other Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "auth_ref": [
      "r301",
      "r303",
      "r324"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Contract other long-term assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r301",
      "r302",
      "r324"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Total contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability [Abstract]",
        "terseLabel": "Contract liabilities:"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r301",
      "r302",
      "r324"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r301",
      "r302",
      "r324"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term portion of deferred revenue",
        "verboseLabel": "Long-term portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "verboseLabel": "Cumulative catch-up revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "verboseLabel": "Revenues recognized for performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds",
        "verboseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r27",
      "r491"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r586",
      "r642",
      "r644"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r402",
      "r410",
      "r586"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r586",
      "r642",
      "r644"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r49",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Rebates and fees due to customers"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r242",
      "r261",
      "r268",
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r251",
      "r266",
      "r538"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r251",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "terseLabel": "Accumulated loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r248",
      "r262",
      "r538"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r249",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r247",
      "r538",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r250",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r586",
      "r643",
      "r644"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r385",
      "r386"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r40",
      "r96",
      "r403",
      "r409",
      "r410",
      "r586"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r586",
      "r643",
      "r644"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r94",
      "r641"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r640"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r640"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r94",
      "r641"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r94",
      "r641"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r92",
      "r94",
      "r641"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r94",
      "r641"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": {
     "auth_ref": [
      "r94",
      "r641"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves",
        "terseLabel": "Accruals and reserves not currently deductible"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails",
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expenses relating to stock match"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r40",
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r40",
      "r216"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r648"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Net gain (loss) on maturity of forward contracts"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r109",
      "r110",
      "r112",
      "r113",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r646",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Forward contract outstanding, amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNumberOfInstrumentsHeld": {
     "auth_ref": [
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of derivative instruments of a particular group held by the entity.",
        "label": "Derivative, Number of Instruments Held",
        "terseLabel": "Number of forward contract outstanding"
       }
      }
     },
     "localname": "DerivativeNumberOfInstrumentsHeld",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Forward contract maturity (in months)"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r323",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r340",
      "r371",
      "r372",
      "r374",
      "r379",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r172",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r196",
      "r198",
      "r200",
      "r201",
      "r202",
      "r206",
      "r425",
      "r426",
      "r495",
      "r502",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "netLabel": "Basic (in dollars per share)",
        "terseLabel": "Net income per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r172",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r198",
      "r200",
      "r201",
      "r202",
      "r206",
      "r425",
      "r426",
      "r495",
      "r502",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "netLabel": "Diluted (in dollars per share)",
        "terseLabel": "Net income per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET INCOME PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "verboseLabel": "Total unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Unrecognized compensation expense weighted-average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP",
        "verboseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r72",
      "r144",
      "r168",
      "r169",
      "r170",
      "r183",
      "r184",
      "r185",
      "r187",
      "r193",
      "r195",
      "r209",
      "r255",
      "r300",
      "r375",
      "r376",
      "r377",
      "r405",
      "r406",
      "r424",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r457",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r427",
      "r428",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Assets Measured on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r296",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r428",
      "r461",
      "r462",
      "r463",
      "r540",
      "r541",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r430",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r296",
      "r329",
      "r334",
      "r428",
      "r461",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r296",
      "r329",
      "r334",
      "r428",
      "r462",
      "r540",
      "r541",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r296",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r461",
      "r462",
      "r463",
      "r540",
      "r541",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r431",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r116",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r245",
      "r246",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r265",
      "r267",
      "r270",
      "r297",
      "r299",
      "r423",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r538",
      "r594",
      "r595",
      "r596",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiscalPeriod": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "terseLabel": "Fiscal Period"
       }
      }
     },
     "localname": "FiscalPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Remeasurement"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign Exchange Forward"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r153",
      "r274",
      "r492",
      "r539",
      "r558",
      "r599",
      "r600"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r277",
      "r278",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r40",
      "r275",
      "r276",
      "r277",
      "r539"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment charge on goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r337",
      "r339",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r337",
      "r339",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r28",
      "r170"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r176",
      "r389",
      "r395",
      "r401",
      "r407",
      "r411",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "PROVISION FOR INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r177",
      "r194",
      "r195",
      "r217",
      "r387",
      "r408",
      "r412",
      "r503"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r167",
      "r383",
      "r384",
      "r395",
      "r396",
      "r400",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Provision for Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r638"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "U.S. federal income tax provision at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r638"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r638"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r638"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r638"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedTerseLabel": "Research credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r489",
      "r583"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r573"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Current portion included in inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r577"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r157",
      "r531",
      "r558"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r148",
      "r156",
      "r208",
      "r271",
      "r272",
      "r273",
      "r490",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r576"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r575"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r253",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments and Investment Impairment"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.",
        "label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]",
        "terseLabel": "CASH AND INVESTMENTS"
       }
      }
     },
     "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r455",
      "r557"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r175",
      "r254",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r420",
      "r421",
      "r422",
      "r434",
      "r536",
      "r605",
      "r653",
      "r654"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r124",
      "r134",
      "r558",
      "r585",
      "r597",
      "r650"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r147",
      "r175",
      "r254",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r420",
      "r421",
      "r422",
      "r434",
      "r558",
      "r605",
      "r653",
      "r654"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds",
        "verboseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r37",
      "r38",
      "r41"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r25",
      "r41",
      "r128",
      "r138",
      "r145",
      "r162",
      "r165",
      "r170",
      "r175",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r194",
      "r195",
      "r199",
      "r218",
      "r226",
      "r230",
      "r232",
      "r254",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r426",
      "r434",
      "r537",
      "r605"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r218",
      "r226",
      "r230",
      "r232",
      "r537"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r448",
      "r557"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails",
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion included in other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails",
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r445",
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets included in other long-term assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r454",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average operating discount rate used to determine the operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r453",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term for operating lease"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r46",
      "r56",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r163",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r159",
      "r161"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $3,886, $1,481, and $(394), respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r21",
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Tax impact of available-for-sale, unrealized holding gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r14",
      "r558"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r173"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "negatedTerseLabel": "Acquired in-process research and development technology"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property, equipment and other"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance stock units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r2",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r2",
      "r558"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r36",
      "r83"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Cash received from option exercises and purchases under the ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenues",
        "verboseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r69",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r65",
      "r151"
     ],
     "calculation": {
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r67",
      "r136",
      "r499",
      "r558"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r135",
      "r139",
      "r558"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r87",
      "r140",
      "r661"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development technology"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r513",
      "r572",
      "r584"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash equivalents included in other long-term assets"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r5",
      "r73",
      "r133",
      "r508",
      "r510",
      "r558"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r144",
      "r183",
      "r184",
      "r185",
      "r187",
      "r193",
      "r195",
      "r255",
      "r375",
      "r376",
      "r377",
      "r405",
      "r406",
      "r424",
      "r505",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r214",
      "r215",
      "r225",
      "r228",
      "r229",
      "r233",
      "r234",
      "r236",
      "r322",
      "r323",
      "r491"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Net product revenues",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r236",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Sales revenue, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r327",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r312",
      "r313",
      "r326",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenues Disaggregated by Geographic Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation",
        "verboseLabel": "Transaction price allocated to our performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r452",
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Shares of Common Stock Not Included In Computation of Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Revenues Under Collaboration Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Basic and Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Income Taxes At The Statutory Federal Income Tax Rate to Net Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r81",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Allocated Employee Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r9",
      "r10",
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "verboseLabel": "Schedule of All RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r45",
      "r122",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r337",
      "r339",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r74",
      "r76",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Schedule of All Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r556",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r48",
      "r50",
      "r51",
      "r52",
      "r118",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration Risks"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Collaboration services revenues"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date",
        "terseLabel": "Discount rate from market value on offering date (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Discount rate from market value on purchase date (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of awards granted (in shares)",
        "verboseLabel": "Awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, awarded (in dollars per share)",
        "verboseLabel": "Awarded (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Awards outstanding at end of period (in shares)",
        "periodStartLabel": "Awards outstanding at beginning of period (in shares)",
        "terseLabel": "Number of awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Awards outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Awards outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted\u00a0 Average Grant\u00a0Date Fair\u00a0Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted\u00a0 Average Remaining Contractual\u00a0 Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in share reserve under 2017 plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable at end of the year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable at end of the year (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding at ending of the year (in shares)",
        "periodStartLabel": "Options outstanding at beginning of the year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding at ending of the year (in dollars per share)",
        "periodStartLabel": "Options outstanding at beginning of the year (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted\u00a0 Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased",
        "terseLabel": "Average price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r344",
      "r363",
      "r364",
      "r365",
      "r366",
      "r369",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r339",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "terseLabel": "Share-based Payment Arrangement, Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r337",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "Share-based Payment Arrangement, Nonemployee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair value of Exelixis common stock on grant date (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting award percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic value, exercisable at end of the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted average remaining contractual term, exercisable at end of the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r125",
      "r126",
      "r130",
      "r578"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r449",
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r18",
      "r72",
      "r144",
      "r168",
      "r169",
      "r170",
      "r183",
      "r184",
      "r185",
      "r187",
      "r193",
      "r195",
      "r209",
      "r255",
      "r300",
      "r375",
      "r376",
      "r377",
      "r405",
      "r406",
      "r424",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r457",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r209",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Share-based Payment Arrangement"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r2",
      "r3",
      "r72",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r2",
      "r3",
      "r72",
      "r73",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r2",
      "r3",
      "r73",
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r3",
      "r6",
      "r7",
      "r58",
      "r558",
      "r585",
      "r597",
      "r650"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r237",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r245",
      "r246",
      "r297",
      "r299",
      "r423",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r594",
      "r595",
      "r596",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r496",
      "r550",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Treasury and government-sponsored enterprises",
        "verboseLabel": "U.S. Treasury and government-sponsored enterprises"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of Investments by Security Type"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r382",
      "r390"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails",
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Change relating to current year provision"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r391"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Change relating to prior year provision"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Reductions based on the lapse of the applicable statutes of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would reduce income tax provision and effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r210",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "verboseLabel": "Valuation allowance increase (decrease)"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r178",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and customer credits issued"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r450",
      "r557"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r590"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r197",
      "r202"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r196",
      "r202"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:",
        "verboseLabel": "Weighted-average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 15
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL108322424-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r563": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r564": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r565": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r566": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r567": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r568": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r569": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r571": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5291-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>97
<FILENAME>0000939767-23-000019-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-23-000019-xbrl.zip
M4$L#!!0    ( +V"1U8"'V:IYW0$ ) ;*@ 1    97AE;"TR,#(R,3(S,"YH
M=&WLO7M76SGR+OS_^11^,^?]G>ZUVHGNEW1/SB) ,O3$D ;2&?@GJR25P,07
MQC;A\NE/:=LF(2$)20![.^Z9IFWOF[:>TE-/227IC_][UNTTWN%@V.[W_OF
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M28 U/$JF4C*@9([".YTL.I'8#-I?+>S>APS.)>8=0.GQ<VAU]D8K;8&(*\S
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M[<%D@N<&%"3R>RI*4CG.\\04.B#U[A:G!<TZ!KX]R$+V3+G(*X]F+0]*>B5
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M.O5VEH)(3C%#\8?V00D"E2!6I%I2<I)S-9XK31YF*EAX/;%=/0\#/(/=0QS
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MIQ.@$U+6*)=D[@&>248)HG:6 -2!% L" QY)R?BD%;5MQ\=Y8(P 5LT)TDN
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MR,]'_H#MI0>$:9<G2&.V&8'C#[NW]+#_%29%B,E+E.;"([)+ =3Z:P6F;8+
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MS1>I58GF8M.,.LEK/H:UI8#/N<Y+PSJ'!94@Q*Q14N"9@>;S?$:-J[8Z_!U
MYWUNMK+=H*WVOCY)8*86PP]-?7X?@6V9AF7+@9B6"67#YV0YP^>'!Y#4-:.
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M7$.^%?KI)!IDJ4JN(]!8.'IR:I)0^0F=BNJ5"^B+F>EZTKW@4%EY-$@9]&;
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MP O*ZO5B&*C*)"4?-%KYP>7OQY(13>ZBO-1LN^&TX3XYXG*!K*SK)MO1A%L
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MD?.$(FBW.X>UM>_[@B_"*$NG82-XT_I7*]B1?^[BZX79!=VWGYKMEWN'#8-
M9)1J7[G.7T3O>_U?+H[/S_[C'Z\.#E^SNE#GC9!7KJ4WXF[%X(=%:^QOT1I;
MM,:FH#6>7E_Q:J%JYD_Z2U82+#:7V(J5LB* #51\/8"[DL(OHB'7)H@F#$0P
MB<7"EQE9@7G6V!9+:U 8!AF!)9U2S5J305%&$AIM1C>9JDX]=F6C P@A%2?A
M86!FCOH$JK?VI*/)C<<4C>94O%.+DR(7BR3*O#!BM30\35#XA>B^TR4S%HQ[
M?+DV[4M2\4V48C@ _GG,E17$SNV^"7;,=[L-*KV917T.()& &V+_,*PS"F+<
M =>/TD&A:U1@6)Y7*%DBW&S!-RVL(BO$X&2.1Y-)D:1-FYOND@;'7G&OS$0K
MPZ])LY>^5>?_\8_VBX/7-JD>B9WM-Q.$:J* R8""WK6.6^>MB];E@[H\GK<.
MEV$@B\(5[W9SGWY=ZH[:!RV+F?/ER=/VI5ASOJ3KMA,^RYJY=%W80)&>059Q
M%=V)8L2@A;OY?!JTW)_+W=;<A6N.R//8H00^Z\8A<"@*?@ZE7JW@@GTE7J<:
M(B\PYNH11@6E%(NT*\1K]1O9#%EP-H[B<*CBZ3@*D=>%^B9*L5..*;O130$=
M4*8+\**!CNDYC$GFLX1-MF#ED64B)C>R9_X;UB$>ZG,*0R-S $5Y$K3WFK\;
M-NWFBUU+C^D)1V*!3MI[SMN,+2B)<F*=Z;(R03&E-2,+Q-UT.8XC.2BL[SF"
MG>><Y$TR.;14H^E2X%53$6,YKK",%9Q.I9S0S2BOE0,_06N;[5-$GYB*^JZ(
MM"F_UNS6K%](*%=BEL&0B3EFVZ7Q;^4R77QJXG!.HG^GE8&[&T0555L#IDT&
M9)D5 X8TK@\+J(U95GN)WI0H7"*6^?HLZ%:>=H(-[.2RUMO\+)"Q;8.GC7%Q
M6WW/C)93VA%27XRGPJI+V&P402NJ+@\CQ[EA76Q;[\6*^(8M"</Z4I2 %L"A
M$^.J1%Z"3Y''%(4>)>5)! <,]"*)_EV@BH,<!4O[<0B RZ#S=,Q0C> *QDY$
MJ3*LCA2T5 .PO*7HG'#<U]QZ?DQ2"<L)OC 19Y=3+2U$]4SX;K'O!O=]3%7$
M0'V)\KQ0N;BB_+VVGBE33OP:B&1(+FV0,\;791(6Y_R3ZS#.G78,.I(1Y"%;
M/WH3Z0!1FN14KRH.L+)Y3DT5;*DO<4A1"UK3>5!S6^LJ=EF&,[%*=](B5UOP
M*)%9KW%6=[N7Q'5GL'S6*5HR*;"FF+(1Z5"C>F9(3]3>+!(P>9&KA63I*GW;
M>/$4*-PIZ?!2$DQ5%0@C^\6O>F2GZ(D57;-2-/:APE/U,(Q48%'[L'*\>G+U
M0\:5U6T_=>0K76LC/W6.?^DW^.)?EN+K^^@-8M!U,U8C8%6')<;87*,< G)R
M/7^]1D'ITN:U]CJX6]UA2)G27+=0_K5;;66QN2C/& /HHOON",V<QUGJ$U@V
M3P<B\%&\6K%B,W82YI_A6/357Y!NY8M(-]SO%\OMMDT5!!8.>)>^+ 4.VU[(
M;W$AC8?!N8.N>>5X>#P'D_8V-/ND+3AU-C1\4Q#DR_DP5O1>!#FH*8I@QEJ"
MZ?G/4M!F*'>)7#D6!LMA&4Z!PN@@$+4$O3@E1S>4TZKF<E"">U'EEOB8^'KA
MC(I:<!E:0Q_5]6N1N,[5\"9-ATA3.79'&2C^:2,X;YVU@HL!'#P<_:5F9*22
M?Q# L7Y;<$;(!\Q[+R0NR.+(XIQC<1W /!C<#A]D:J2R3&@I-Z/5""_I,J2M
MED7OH-$NB:6RK--C5MZ4BY/N^65X)=X^K$+>="M.ZNJ8I'(91O[M..L3TO!3
MD"JQL"PT%9?YG_<]?):IHL575! M.8VI +)!NABDW6OZY?:$'^:$/ZX1NP2Y
M?-1T*WT'W=^"G8]OCAZ&VX#5+;6=D>O L(;AB.^!6A4 />H,8LN%K,'(]6_M
M:]UL$'=(X%N]IN'(<_C\X&7G=; 3EGA8-0/CAO)\7W2QWT5L%A_:K__9SW[^
MM?8^K(VC'FXR*!J3$,Q35$\HB)3,'"<O59UB%X5U)=W?"Z&!.57^W2'";W4?
M/'I:F@F($P5A'Q*%:P3]N^M[<_TE+N^W5A?J'E6WW;+[Y8)*LNT:FHD7T-:E
MK(%E1DZ!WJ?IEWD[YE>.;1&Q8X(V%5DP&IRCX8>5SYAR0T@R>C3=AOD=$YSD
M(5P*GK1GPAGR@MIV$ ;ATXWSM,'(U&&$S0<%8VT=?N[5,.$9ZRR>C1$I5S9E
MJX,LO^!VM?>H@G^;.S_^^>9YYV5+?XXT1GA=8I,F75/7^8\1D&L0=+K! 0K^
M*Y4$AY<'Q$_3;(H7G>PJ:Z/D,/; ](5@580-KY!Z+W ( QZH42M%E;Q=B=2<
M?HT2Q>]JM^&> P,DJE2JUW)D7#& @))G;YL?VH'MQ(&-==AK&O3>'KPH?8,Q
M FQ$C@AH+"M)53\#L#T&G\GQ^MJ9A3YB?@/)LA#('2[?9V#%.EO"5!) UC@-
M.ET0]K__UNF"N-<X T5A5<P0GZCLBMWP$^0F]KWLP\5B'1,UI$J<&?:UF'%<
M- T(Y<?)%_8WDE1%0-(W&/HM[^.-(D-:%_75\)&:! &AQKO2"_@ZFL.Y3;9M
M<7MEW-[!%K>WQ>UM"F[OD2]'O2:L.U1+YD!=Y&A]$,OK(W=71!]<$);F1&-I
M-@Q\<!&AN,0T8RNQR#[:VZO,0F"1C;%MH^-U#DWF<J[CG\<?W^J:*U+'')<X
M5;1.JMW$ M27J0@02"C22TB8= C"_0;%,05I*V9C+7=T4_*$[@*:SM(;; _-
M6!N6[C7@(:I D2N#+$,=*^8P/IM4V.%0<8U'ZEX-VH=7)D*'=SDM#?ZVCU&3
MZUAL*0>ZIM<&,^ZG?X?<**\!^]2/)HJ[YE&H/0_!O%-)BLF)U+(07F/#X]@9
MS2O0/<02D%&?4BMH0R3M1]*$BBMVG12+,-TJ+(K>M_L9Z94 6T9>$2RU;@;.
MSOZR#:$]513CXO+T_,3KRQ=\N'P;[-#G]W78F3+?N?47GW_L8D)8-)I3>:3D
M[_G$KUK??=L]7S(%=DL*WP3>8-*COR(LX-]VK'+CA%?1O?8HWO_M6=]U[6=J
M<C$'X7PUKVS*Z7S_=6$B@Y"U.@6GAA"NF]B$>(\$WX;5D(S#HA?F"D3([U'"
M/DFJV1;L]'YO<V;?KDFJ_IC.,'TTG(W!4%S*Z[/_Z,K9,EZ%^\G@DGE0DZ.[
MM0Y6/+#N)$VN\DI%RNXI@[OA*>[.@/J:UQ;9M'((<W-A.#5*^Y)9/Y9JKC7/
MFE(1P?]Z/9?92:NAF@0V)=67M?[V*RE)IDKN?O[9["85=_^^:?*<SPH*W=[6
MY9ES+>RDZU[?:2_G2BN%&FZCUZ?UYAMO?3GUP(U*3<+/RL;#8)$Z?MEP-X)Z
MM6#P9J*KFQCX)Q<8=%6HD*#@BK- ZE+7IS'85VY,+DMCR4UQ&*PA"#1&!M&4
MX<68J&>M&TRUF4G[8)[2("UB3$U'TZ0RI(#PW1D50UR^ L6W=+!4&_>K<[L-
MX51_W 8!KX 1$_GA#>A'J=12(04@C!TC;A&^KDF50ZV<U%(2^YS"9(W=8 3L
M?S".L+YRUY _!I T;)UBR1CXB8;<$J(<3&;K'$Q>J2]T#P%9D6M%HSK-[DW%
M#-/F2QH&V\10S9(;!E]:KE.D1.VQ.N]"8I&M>DOII189,[7(<)/N(#5I1,O!
MU-/Q/(=K"Z0B]:-TEA7Q8,;J6R[3@ <X8N=N%\'2N:IG/HZFZ FA.G5NVI(#
M0F/VP+7HC%^AG-E2EY5D,M ^F:-TLB'*)2XDJ(E.E5G,^@Q&EW#&<%F N--$
M4)I9.@]C\EY@M4Q)I!B$7 _4<:\TG"<IXH@)&)B0.T-RHU]]:EVT&$89Y&-\
M/1_2"+UH.W 8<8J5.G?YYXMW0=Y-H]A%WHM,S0:D<(=-L^@IQL3J5B\:G\X4
MTBZW#4[_ZKG,HV=IQ>?=&["\FE3\::X2?S'KLY:[B@B\4_U,JDRUGW.%%S=)
M*"S7_:[/<.=MN)>$<:6+OG(\2&7-\8:\2QC)T*M27GZM=%\G'LR)KPPBL[D
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M*'DGY"'GE\8ZO0 J,>DVSX%IH&JI<[RCB?S(SI\N=X;VXBS (\<+ 9L E#X
M?00E+#K,7<C$8S)TLM;RF?'=H ]B#!^D&5>D\CT[,&_CQ\R4G+.X,<-@W[GE
M:9E6[CY&FU52/DE7&[$_UW=X4_) _M#[)DT48JX(/RJXF)V[X*8V"[UX7)H;
M^J4RUQA0)4N7 BB(;M2MPX@.RQZ\6WB:X_YY'5S%:;_DZ;>O=JOU\/MQ3>1;
MQWR^V8U2NO 1.7P:KF<I4]&D7V2YM 7$\?8/?Z*.-P6YTPF4J?TL\J/!.$US
M\89/9[P4>IS?SS5]Z"I1Z,?$9.YP&2(N%L8S[DWD/RCVF^8\X,*B4\</8+M^
MN5^"'J:KG,!)-5\=G3>"WNG%R7&O2:Q2_MYONW]W\.^/E]W>97./DV[,/SMK
MA"MZ]NL&W:E,3?"8RM=JL><(MJR-YY6^3)1'99VUPF]M8;7%79[I5G#.5UBB
MH25?NLRETG%.]$U?C[ ?_%@Q AK>HN(2)IA;R&O L!.Q@I=EB#"(5*7;VBJ&
MUJ1R1&$=EW#TXS#X=Q%R>SKSM5LJ+-=^3M0C]*->_Q@W"AW"'S0&O$_IDVH%
M[U@EQI*4C?NRMH;+C<1P\<]"]QNY!G,F)A[B_)CE^E"-*"&/%%:)PQF';>6J
MN+6)-(&DML?D!:]_%4]-A*IN;8"434R(@LS,EV5DS&G&M&>)*;MADTOXH5(<
MRY5H(Y=R\WV,XI9VS\%,EWBR?9$TMUR>J"@:2\F@N3AYJ:0H@:UPLU+<?UE0
M96Q9,UMRKN.M37@B4OE$[H3IL0E+*S9/(_B4Q.BG0:1"A%M$+4J1:31NO8:4
MTL$75L+W#%""[4JI4R<SAV9_WM1\@AE:D<RR.7XL?V+>/$+4X!\1X1J R<Q0
MFX53W6GOBN-^&F6F11-"BJC-4QA-/&BBKZ[M=*I^[!"?#@<@5S %,CVV#!2Y
MLP^C $.DC'_1LRW K:+PHC\)A^YZZ$XZ/_YOW:AT@?FZQ0=0H2(32/;%780]
MI&4,Q=LB@9@-VU?.F<M%QKJ(_3G;O9*/@PQG;FL<%,F@P.LSP7K$N/Q^IM-*
MY >W$8_<](4]$)=<:M^(9162SUDQG7$G]M+7.)+'Z<(\%>0*KLTL[-;91".C
MY6'EJ^1*<16WZ91T/C(/A.0$+RGSK-US'FZE&>#7[]YV\<5')_@?*GZ39I8;
M8\AV%NKF)-0>UJ75DHK(M5J=H]6S(A8_9MB\[86]W#SI9F/_>#!HX0;S7WR!
M5[T:U"-/.T;/>SVM-'#%5AZY%7R:4KT32^U8>CMRR2.D=GH4S<N#JRQ,I' J
MRRY>,ETM$#4IXD+9)VO62U9O@WKJD6+/+.-:NW7++[>P A0C)>IGCEDU&Z-4
MP;3R,?>KPSZ82JP(YR6D)=(C_HRE\.Y-FL783@<F3L D3;N4B.X=9)K$TA[/
MK:3+.]N0NM&.WB4,0._\NQ0KPI'KW=\!L9GHK4;]6-B($I,R6X J)HAMX3%8
MHU3QGR!C29^](I3'6/<"0H:8I>2L#^7*.ZE?W">:H?P")=6F541)J[IGHX96
MR;.DZ,I"0NR>'*5#XBZ@UZV1W%X1^7,9?L:"\QL*_;']Y=HOO@KYP]O@HN+K
MP"Y<T<2@7>#Z #= 2+X1V]AMKR%I96PD3%!K846"_0@Z2U'9^ ,U 4=G1=G_
MSL ]<5E5Z.'6MJ.J9Q:3IW&+B]$.+V @$S5>@Q3K/L-K2)EVE'!'9Z+:/*@O
MVU(GBTZ7\CIJ_0=+P:6$3E$&?5.H%%84PI4U3!*/ML 8B%2)01+@4:4]4"'"
M'+C5%B!1!D@\WP(DM@")+4"B\G+<B?73UDX)M.ASU2BO1RYR;T3-6Y> +JZ1
MYG.7LO (^+X;)T 9)F6@'L5ZO0 \J9@BVABR]V+90#)#8C5XKP3!<P60HQ'(
M]$OP! _NLA2LSP7JR.SO$X[^HU9!<:,URRS-0!T:QEC ILMP(J70SZUXWPTA
M9=DVDSI4L7W.6=GC=X.1%6 602:8,'.=06[<=&"PC9@Z_]ENO[(TQ ?+3N$*
M1 @.7H]OL.K1:K@/GDC[\"?^8Y;R?SL'\H'N,2==L?^YO^?>0\P,MQ 1#J0;
M4W9,!=R7^)THW&0E+PU7V2O->'_/SKB,7J$,+D4:CP&J[!%0!7[U&$"53ML!
M"MV%4[D_9]B0B]C;: @"'\_&(/2/V-E&4*TZ2]*8B9$3W)*P*EX40W95]NE"
MCJ@K:;#AGG%<N9:EB!$=]3$0 )E(.IWE"Y%_YC!HA["W:N79>&62PAGS2:W'
MQ!9MVE>)&D6D=PA3715RX)C=MV(.2G@"ZTP84[8,F@4>Q*#.%; AQ+B$P^*F
M&C2#OUGO"+_Q8BQ$6DR\RXG#E*<,0PC-K!"?;WRG 7HW$ WWDQW47Q&CG]=&
MZ#&6LD$!^:<.MHOLVQAN\UC1]H6PNGZGCJO?I%Y0FXT$:F07#9#ZL\5<01)\
M5D^1L\<HN<3:XU!'[KOWCMS3.>^\^>K@O>^=?;P0^(,%L;&R#6P59FUJZ6UX
MR2B,XH(C?N(XT/6B84;8OD*R$!Q#7V54&8?: O$B*(&!E<CK-"ZHK2>E)& '
M@U3,;,Z2;>C\&FM/YM$7(:!*B:#Q##D83\5,43GP!:S 73Z%Q1"Z%S07\?1@
M<?NNB6$[&Q>'<-+C6NO6*%;+A_MIWV<@)+'L!-SDL?'N3;,(2YUFZ)!+"!<_
M4)[]B@-'5(XTP>:E.4;,9!^7#KO+K?C:V+HL^\[@>FU07 9XT*CX&LF!KRE+
MX=8**M44VH %UC3M.;G8U-BT6Y:B.CCM%QB[%>&.^Z!5JVF1(;,BV-27*:S#
MWG+;!=(Z.BLN,_=I<'H,P/!&2ASWCD$% $Z!W#WL:_8>34$#G> G#0H!8R)C
MJ038?*H=05@HB!Q-NFG] F>S975L23=.D,3J4#-OB@L .6]RSLS8?"A7+Z*-
M<]!"!M2^SSLOY>"PM>$ WNXZJ,J/WK?X6^T]E>=,W4.[Z LI>:?/Y\XJA3]L
MQ/C%-F*\C1AO2L3XJ073G9XKPW :UB$Q-QJ8;CU.&E](28K&\=BP&E6P@Z-4
M1DLU%G^.S)I='W?%59G+SW+VWM!'KGL]WVW01*C[^XBK]>D*:_/F".%:.K1+
M:J,JVU+6L6O* 9L))62VHJBE2(HGLN]?(,A'2^E ^T-4 6H%1Z%V-+./EE:
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MC"OO8U<V-Q;'>V2"=^Y2 Q(@R%[&6.*X%;PIHIAB7N21@9N9%M+VU1R$1&/
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M7)[31.B!.^,*SD2ABQ0L+A6&Q+:-8[C8P5\F^6(VGY:SE 64J\OY%%P[A.>
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M1ARS)!W5N^TT>,6#SLNX KA*/Z1DITC\FGT[\9ZTBPX+U8F[IA,/(SS8VQO
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M?]R#M5]XQ*[N(->88']!_XTP>EB )LNCA4F5?I_='US'20#7:B<&CZKH&Z)
M*<8M9BW!5 SM#BON9XZH1]'$\AB=M#21FH(K2>=PU 0@5>U'0H (GVG#Q!9W
M)^!6)F8V TTCZA0TEAI.0=^)PT*S(#7*MD&:QX&<)44,QRC@;D3;&_0R )/9
M],D1;A5XL_U,Z"A4IQYVEQ;]5U4L8)^RX"BZ1^AGC8 K:Z]<0Z^.-4K1W*@
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MKAC9J!'1Q-,*9=-G2=-E(Q"&@I#]8),]JCJ\'@LJDPNPPX1KSR%-=SX9Y6C
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M%(YY1?X1XP\8R\Q#8[<*.R%Z$')6<$,MK4"($9VFU1[6NTSAQP[M*K#B O,
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M,T+!"HUDT1)3! * "C8+D8]TAW %2Q (&E-6&Q-E($ 5ZN- 27]&Y)@"(%N
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M%/\;-1?)YF@7O7X6C7Q9EN/'XIB\#DIFGH+ZGN#V+N#TB.[VDVS:JL"8 87
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MFK"_U4*X#*2'X,A;.M=MI=>)9'S00(!%_1<@Z#>O(!D5LA]0)D@EIIO03R"
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M'\0OT;;Z9QBXWG_.T.E!)?A&-DQOG[O9)\F!D)%[L4+O:X!+S2D38Z9E\;%
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M=%$IM3 S/JBGJEE(6 U1QEL44Y8?A9."# @,31M]P#6FXT'B;QE:0%K$:6\
MD*&X!EQC,DZB7B?[!"ZY+,H<W7@6;-:<\V3>C;%[TSD0HVS),'G)5)*J7?)
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MK+JJF.:E!9=*-+3C(J9;=M';O-W!6@LO[\FK]85]J:. ]<-P$!F2'X')4%=
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M<'=Q\*7H+@:/J"6.7":,*9A^Q&4.F:0V51-^^^8M_OSM]V\?2HCVTW(CCMW
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MR:FI3W.O,@DIY/',@[!1[T#%/XAC$ (!43BZHN-5W.Q"2-W(84Q9B9)' /M
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M7[51+2 YS0&D7+N.%4GWRZ4VH*E'>Z*)X5T0*+@&$C?.0'(:G/K#E#+R?=W
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M Z;%= F_N1;W,3]T_#?<AY*N8<TZIY7J<<.#?V#\1*<E1/DW41Q$=ZS;( 9
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M+D[JL(BK\;RW]B>_O[^!\.3G+W]__L_>4IP^>4IS1S(BKBQ17&HVXANF 53
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M:HBA #KA.(E;G=1K<FU\I-_$;?](XV#HU8<OE_.XAG7<5=D4.Y)"^6["X\_
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M%NYD W=;QD"?F\A3PU!"-'GU(TVVA+5,H30&D<!'E=7$%7+O,U5,)L-(C5X
M#"NFLL9_MABN7(@]HFX2\OI(#^'J9MFXE$Z7TK%VM(3R @R%VU#<.;O#]%=U
M;$)NB5UC8Y\=9)+G #;%R2W?,XX^;%$G+KY3;.KO(RN4_9TG0U6GCN7.<)V9
MJDO'(G>@-CD9 MD#MKW"4O=K.>A0-H.>A+I@!1$O2(LQX7@" )WA3''@.<F4
MN_#R.^4 A_ O]>8,ONB+S/0%X&D+U @?EN268MC_J]R(3<YD*$UA)-R/O#&V
MCW F"6!E$6&')ZMA%[<32/"7@GI<"6;_^%4]Y@$0=91$8<),,_7&:G%3HH.R
MYPLV^PHE75+G4@"C7^EA@36D@#N"^D+#5SP:(.MPZV0DCF*"55:SJ;P65:*#
M,HRZ\)%  13 4]N</B3F.PVG@IK=8;>-"1:AJG/#N\_>#FR)-0SIO]Z48 CT
MOR?8SMT%4MG0!WOXVAW8/)^Z>NMBM8GW1Y+*:;0(NQ3Y4B'@N(-2XS8:1A'&
M-^$0NW_@TQ/@BN$4E/=\EB:H,SC [*@FWJ#8AW?7 -?__.HZ_W[WTWMJS#@E
M)DSZT+MK^J\>ZL"]\4R'7FK?3)?L'/7DK=#N4](MLE?S7?)<!PQ@D$]1$@OU
M79MT"4?>?+B22H5S\>GM^;\O"!I><(ND"_L:#+B8S[3\Y@:*\-G/@P$NZUK]
M,"J;?;?PRZYS>7;>0E9!DFCFO+T><*M?/,/E^?_"34TSQ$4#"5XI&:-N 6:_
M"UPI]U"> .5\N!Y@NV-XX 943V 3<<:O,AV@F5 T5RH3MP0\]:M#I47^(MMC
MRJ$O@"J*$4JU(<1QLY&LYD8]1+?>9G+9H!?,4Y,*E@DR6F%?:\4CI<37#<R)
M52LN+4=YD_X-^'=Q_>[77\\'[AQU?'CWBVNNT<N(SY7(IE:B(/_#*W2PERCJ
M<MR1D_10A9\3(.TXF7A2P9$,GPT6[/\>17#)J87O/X%0BS$ZQ$.H/YQ__/CN
MS>6%[*..8X/B)&YA X\D#/!7>;]PI<,H\3]SJZ,/EVX9+WE<MFPL2LV09LCB
MX1@\*,CY'V_JL9$ IAC\F=G16R\,07-VKKSX\RS9%U0!.:@ZWFAY6!%W1F6D
M7CBC*+G+N"_BE'14ZM$H9S.S:%3J(Q%HJ4TFRF^@WSZ/P,D(WC'.>+?DG3()
M)&+H4EAGF"8X<R%-/6+K %.!_2 K HWE<$D(,JOQ)EG]_4K5!L0RP!I/H7%Y
MD@#>A-KDFPAL(!%F$VU X?R&"S:RE71ND5I,#2[5[#-2:. @*<Z4,[174I.D
MZ2K4,LH^"ZF.N8"MJS&F/&$/9YM$.$( 54" \%^P40:SB_V!*TH?DH-S_<LY
M]\'\SYM.AZ:IHVX@APV0=I(YU^_UJ +N!)J I<+&./;,1P59(8*T0QA1R$SF
MT>]R_R,OC-#^&*IF.8A.;+'3F S_SR),%9\JX0U\F6#CHY84D%TOC;XP#71G
M?ST!2T(Z$!,<;$;CP@553/NBM"&P\'SJ&7H18Z-9;S*-C&%"' !+O^'GP9O_
MM+H(G]*=@J+V":"%.U7M]@>S80H+,00!^4"?A8W)OY;&O8-DS[&%J1<! 43B
MBV,%M5']C&_(^B9["30Y0@B405_@-  &W,L-4&TTD[/%D9?!?03V'0-'2<(,
MI%Z*)'9N^#:KGZ1A^F"'[I(86^C4JK?02KK;>]">@>%F^]/OAK6I49AFN1$Y
M1M?#AB[ <F+)SF:+E+4IW#<9V20%;?T..2QW9^QUND>N8J5Q=274-==92Q=E
M8N$AS9%3,Y1YV [BJ]D_R&<14:L%MG!8+BHW"AV[159*]35SFBRKK_;D#&Y
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MSP?G!'$,X$J'JO;-RG  G0I @J.\,G1<LHO;1,!K[P >\],DRS2+F PN/PW
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M%%GX%42($HAJ T8:;N1GF%"<0;1H?%,"8@?CP*0]$F",@9=,^4;*.*.A0C>
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M7-PZCXD*5^KJ!NZ0K_+MO%L/C'@>(9I[.K:@LG-DSCBBAE;V+4N#WL]U&RH
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M,FX1&:-%053#X!9PM<O9;3'?S*ZFM[7A4?@5T\KC^OSC3U9[J>9B'^%BYQP
MBIUHF[^O;/XP-@,29#9R7N(E1)!V;>VB^</(4LAMJ.?>R<EKKI6]7LUPL[T+
MZ$]Z?Z7< Y2JFA3#FOTLW(%4FM0&E+>C[9RAJPT5+ YRJT8WX<1X1)3I;HV0
MLP91XN3)11 *PH <!%:./F6.6[EQ(@9&F;O*%@2M726?,V.?2US%C[!%:<EC
M@YO@K%KE8VQLOFV2T]R0\J_UXU^#P';OY? N>^MQ'<U1:]WT.,,V'(?4N4EN
M6B<THV/*N):[58\^5=/Q4-.2-YTWK[W-)2>X7AM(C6W5VAB -3BX*[.HT0E"
MR:%5_SR;UEBNL8%W7J\.)(Y3N8V3FMWMH%9@X]]I 2Q%:AWPYB0-.(EFV1V&
MY6$KZ[K4$6J-0_UYT+_)LD?[G+#1$J"$8-)HYU9>V(\#KTSGEB)KUP%7Y_S\
MO#PXY^K#!<[8(56Y4LRPW.4 ?R / _H5S#Q!\I%CDPL_P;%]-'TE]<,XF7@;
M>A_*TU7,&:5C<V@!Q(RG[UK*1-DZ*16OV>WO34JZ:GZ?P4<X;I!$(  K&<(5
MWRJ.,P<5Z6C5<U7T2)72%"@VAV+J,S[ER4#<G1\9!G*JAHBV1T1+)E21O:'*
M\V2Q0<4I7YG_004"TRG6'E6<+1^NN(R>.Z(C:A>9;AXS"K^(H$7E?$M51\HX
M VQD ]F@LBQ)!M),R$.BT'YQ!&&U.:[)367UU4XL:\RCQT'%^PY+8RN@@A@U
M 24U+VJ-(77N)@/8FHS*:D;E09-1V614[F]&Y6/WKWM> QP;8;DU83D_"JY<
M;5,_BLV>YY,YTFVW8!(;AC<J,^ ^O1WP$G(Z1J86KIUDX$6 2)'X4IFS(N(;
M:F0HQXE3U0(L 0]Y/*F'FS$ QC;%+(^',&N&3A=6L]=THEXQB&_9N+WFWA_G
MWBDI=T$H2;5YEZYVY.-RXHSN&\'\'CM!Z7 V(,B/\#QVJ3<](IK[W-Y];K'U
M$9O-BZTBU?EG4ZOHT=HH.2M5F@;S'@?SEH0P98%W#8)MEH>\+.U8Y0#+G*Y2
ME+0N]C<1"X*?'+=#;.(D;!V3;/#H4?!H6<+-P783;HQO$3&K+J-\ =_#S!H?
MI!XKJ>C:EY/I*[C$+;6Y#T'@7%Q>.E,X].6[P?G5M7/;=KKMK@XQU\6QP>"Z
MN&H0[T$13[<B>0N4[ERWG;,1F+*N\^EF=2.2MZ6>LM<X-Y7E+87^N >IW8/D
MBMNC8]&^:D/27.[VDFNLS'IW>:@XRPI2?M,B8I>RJ:Y2>3:IH&Y/\*E=>N??
MX.1%C%F!35/-!CAVCP]/W8/COJK,$5^F8$UGSEDQ+D#/Z0+_@LT=,;-8F(N
M(;RTB)3"8[\>C>L$L_0PA4#W=PH2D<F*%TY7F-O9B7MR#+L[/JKN3'G<3W!G
M_8[KV-.!_R@"[F7/1AJWA>066+HI'3;08$&)60LJG1X_L?=-V\T0=K3/(>;;
MT I (E%(+4U1+2R#B>^0=BIEMWSG0KC+3 ESJWRC&CZ .-36CM03+]4=@X]?
MXV"F<)*5,.%<Y4=L5)WWJ+D$3?#I86J"^R0;=,&(A]B#O#\2>*%80.*E 7<:
ME+A-%6:R5XS*X1G.G &8(Y[=SL7#6P8[VYO>..?_!OTA)7E@:26<]*:;Y,P5
M#VM:=K[/O(@=,M,DF@%V3H&VN;SA!]<Y=8][!V[_H.=\CW\J6#+A)]V.V^G#
MQX?'SO<3D=\D ?=.4F5./[AV&?+21ZB(V?G>3V<9*&'4.I0VI39A53=_+YW*
ME")/D>.)"F+]H$J?53+5LF=?3@=I0IXR#TVQ>AO'JVA.2UT#T\\X!IB[$@(*
M8$:FY$NF:(D<]&SP)*E"4XN[2B;F8:8C7C'\C35@Q#SJ&4RIXLA'9X)F(4X3
M-669^-02Q"Z3S[#(JZVQ0\9C2JN\#<=)RIIX($9"-C.LF(J8^ Y4@HP1A2*\
M;48-./,F-^3A>.(&S3+H)H?B?A54_>TUQ-C)7I/W[9S:8.T:0W_9/4V*L6G'
MJCJ84@[@MR"0.MUVSX&M1)2]1U-.)Z 2,CN#!SK'Q^V^>D!]O]OPEBW=TC7Y
M;!;?SU&WV^XNNY^#_F&[T]S/0]V/GJ!2'9:#Y0QQ-G]E)Z?=]LGB"SLZ[;>/
MF^MZL E(6 88CU5?ZD@F&4] 4',5SZU8>','AZ?MT\4WAYRRN;D'N[E/F(J1
M*=!BJ]()1EF_E.X)[N3;P]XRAGC4-Y\VE_00.H6\FO*E=$]Z1DO DA[GVTX;
MS&IT\V=@P@K7&7H9-G1%@L3/CNS/@A S-X/YZ^SU2^*/USWN+U[WN%>[[D:8
ML -]^:^$>"A+>Z&*O@0#.SA)3+66OM#=_*7+[BE< F!2878=M2ZN\4!JYR0Y
M3&*RS4@46$6)9.1/DH(^&R:WNSIXXJ+(HR3Y[#H#Y7/GLUR&V>=]F3/Q>\V(
MDY'G"^P++=#'80(*?+@4#\?^]HDWPVI;S^=9LK*Z?[T!%52<1!YNOXB\U-7%
MLNC<R82@7,T1#>LA3Z<<_5)YCQQR@0;\2+4-\+T,+'W$01K.))TS399[-<O]
ML,ER;[+<]R++_?&U.\.PR@-RY%15XI@\3-TIIHENZ2E[JUF3<++"]VD=R\^M
MYBM&(/Y6S%2TYBA21R_3YTVQ2QJ"P_-@1<YSW+!WG"\WC8_)>;.4K,%.>5+H
M*"@#LGD8<7>P1 V)K_ERV:V:60.\A@*=XVHR'YU%3_^!CR,/U(&6GBM4&4?N
M.N$(U%2<X)GS=(%<I=4ISA[8LS[5$/.?DSLP^%,>C(2).12P18>^1^%1Z:>M
MO(VS>*2OOG;JO9HYB*ZYD'K2TCU;/1@"\2=-()3%GA2+5H,(0S6-MC0KSX 3
MQ)&,U]7U=U.!W8GW!\WYTRC$L1,<5X_&L(F66+?9=M[=BAB!2;GR@E+D%W21
M,]$8L]2H.N#/;!HAXODWH2"D60U!U E4 !WY%(V14F?!N5'FK3I4'\UD62;1
MRJB(HI7 K-0VFT7IRI*82,)H-$-A[0(^,Z]"H$W3\);'2H9IT,*C\(;&F#D3
M\Q1#;X:GL]>4)0H.Y==@Y0&7?X:389%F%)]J.V<TDI9P$7/!",X1'B2&RR!B
MK801+8)/AHC-:EC<!'Y6OR]^8Z4+8(B-%N#@G&O@8RXK_(A1JQ"1%NP&R8OD
M9!#<*$5S)5="70P4%(6"%:#?4/]!;*V$T=W0GTV\SPBDTD+4HLEZ,^AQF. @
MQY< R8*&"*>Q%_.3+)=U/B!M9!0/OQ")<9BQ8J9BRB'1G1FY1Z:$'K;,\4#J
M-1%Y18S-C>6\;"^WML6,M+P!T%G3 *=P HH#FP;65+FIB1<7H"BC@IJ6IZWP
M?#.Z.&;^>>+*J^(T&O5*P#M?E 0+9?G1'Y.16WGC>OF=.V!2G#&[4/U$%A@
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MH+FL<0A[H(]2,?009E,O)!JT%_1F(I7;]*(L,8NVG:J(6H@'VQ!38Q$#\XR
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M!&@C6N4H!Z2,">&%:%TBE9(30UG,I9 *;&L2TD\&WD!W:)/P<0& @H!:/2"
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M)!&<9P&8D2%9[.@?>%=-R'[R0RY%6'VDL74DKWPDHVFCJ\]#;TX4)7>9\WV
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MISD0ZB%&^1@6F""<Y0(XZZ0 8@?YZ4V #P'  A2K0-2@@-PBM:.PQ3TP=@2
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M+8!I,)%RCC5H(6%,M):K#TX[3N#-B*PBD654&;K0HN:,/Y,86LT<]<:IL!+
MD? 8_S@;T*I/Q_112L7/F67)<Z_._.2C<OZ9.=[R$OOW6(QN\IK#>)2D$U7:
M/O922BVD+.IMM +(A'#^_K>37J_S^F,"T#IH.QH3SJT'Z9GN:\4_K:\0WR_Q
M4YG5#IN_RN$/M(#Z/M8!<$HOK/3)2W/G_-QUSN$IYX399Y@Y9W%<4$,'*LF
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M#D^.[J?=[)'VW6#8D_+E[@'HT-WU^?(6$6R_\XHNM-OD;)Z[/OEA5@=X5KF
MG!#[9Z;A+3_B!7\4K.2K=!K9BQ?#83A.@02162C,Q<1NQ#D2:<I),Q@IHVD(
M+>Y\51ZY$(AI*OQ0_J87YM :A=MP" ;%&:FXF[-GS/Y-ADW3OK/:OK/?M.]L
MVG?N2_O.1R8.*Q_/]#$?1=02D[/AY!B<V*?>\#S?A)MX^2*<<O: RF90R4C
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MS6,77\V__C%,?_S70M3;.5Q#+:(RW.^)V2OAD<WJ%,.MFT.(FODTP?A'2-.
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M12@"A""DE=.,<K.U34@[F#!K9*=D#\.::0E98.](8.>5 R59 3T1 #M=1.5
M 4,+&=1\QJ&P%DH?]7K1IFJ=7(*/+;7TT7A"_ASZ<]V-C,'GOC^JJF93G?N$
M1;7,CLK.D;M2=JHEV"M78*?O#N/T[Z19S_;6BB'UH(33I <=QOL>[?S-"X0*
M1R$0@MOH*Z$!4X,F9)B%M"#8JVAP<=P.)^$:V5O95;)F2E 6Y/L6Y,M907:.
M>H@X!H6)5<6.<J"$PL *1I0RNF 8;VTST6;DL3I.,'LFUE77.!J,8[>=VZL5
MU?M?N\3B\4#5JG2.#$IW!$K["]J%$@5A A= &H( E0&>#*$$8%08@BUT2MFM
M;=3F2+8%QRLRVFY2?K0I+I@G*.^K4DVRO-^=O,\I(5!!KB0J %:& 0IUD'PA
M@DZB!+%(!936*,J[)+0MJ-@4>7\<Q7_+!?+EH/]A-8FDC]I.6I7R$:<[9Z/=
M&20=+*@@F$),!)9 V9A(RJP&"AH+>($A\Q+:PLJM;<%X6Y#LX7B$DKLJ-2)+
M[EU+[IPR01A%VKL"<(H$H(460!5!?#GVTI&@4G@?))<(U ZKMT:2^YBKQO\<
M1G;KJB]W+#(^+WL3_F@&Z:,.,*\N2%).^I\]W1_O]-U>/>\YX+Q2"'JUH#P8
MJSW!D #'I0:4L@(H;"APCGFO& VK9X(]@V";XUMGDN8<D?43X=6%1[((WY,(
MSVD14FI*#,1 4 VC"Y(!HXP&7D@+)>80P2*(,*1M>'O]?_W*4=92B]CU=1<V
M_:6*A>0BE#M5(>H9W^_;P9D_TE]*IVA&GY6BS]L%!<)R;0QR"(3%*P U$@'#
M>0$(E"*L)/)0NJWM<'P$&V:=PK+9^[!F"D06X'L2X#GUP>I""60-X,;SH#X4
M%FA?0&"%0]K8(BPFCA8 :G-^ZZ33[(2XEOB]& S<YVZOEST.=Z4NU#.<L65U
MV'*\&)HP#F&*8DL((J)RH(#16@%5.,\-HQ13L[7-29O?ODPU.Q?63UI7I1MD
M:;T3:9W3!+SSB'DG0%@="ZAB#BBK")"&<FX*JS&4:RBMC]F/\#K^# 8%N!CY
MRH\PK>'(SH15:P?^B^_]>EAW-WWI]<BG%3@LWHY\LD=F\[XS'JT.C^QB;J7!
M1EBO0?1A NJL!2:L*\""0D6M\(3KK6VL8)L)N4:6278MK(GZD,7Y0<7Y<KX0
M2RKN49!D+PF@!4% 4:8!\5Z[H'88C8(X(X+:$#[";(<-*>!87KAQM\G;&\AN
M?./WWG@P7FUQ2H;:U4'MAP7-"2EO&!46%-@Q0*D60.,B;%[M%<7$.6;5UC9I
M0X':5*Z*^V-3JE(RF#UY,%MMY4T&LY6"V7R6K"TH8M%KS+P"5&L/).(2\ ):
M5&#.A1/!#&QSQ-N8; R8/0ZWU?)^6R_W=W[??[E_M+_WIK73V6V].3I\_K__
M.GRYN_?Z3=4^O+7WZNW^T?&*>G*1L AN<!%;;:YQ4Z[KCO(QAS;KKER]KC;=
M7G?<];DUU\;S#.U8&]YB/&J=Z\M()IH[<CW2_C<K,P*K#?-GN5]RZ?*J]:C3
M12(DHF70:8,I*+B/#2>@!;*0$'!F<2&1,JR(;)!!D>*WKEM>/V]ZAJ!' D$K
M,]TR!-T]!,V9<N'8((I:#ACG'%"B'-"08X U,M!PQP4)J@NF;<S6*:#W5+BO
M@T@,+WQ\Q[-(<J:3*,9T ^/[ONCF]EMWJA#%J=\[.^\-+KW_O9KPC$HK1Z5%
M#B>A/3$0>N"XM;& 2@'MHY<),XB$8L(YN[4M1!O='I5REN+ZR? *-8HLP_<E
MPW.:!2/8B((J((,* 2A&!"@B*"!%80EBRG!)MK8Y:JO;=_-<O]S%S=$LPD=Q
M+*WQL!O^;#@!<S+CG20S5A/_O)KWE],)S["T<EA:Y&92!9+0!EN'RQB()Q("
M*3D$6"#O4(&(]3C $FM#L4XI3SF#<4U4BRS##R##<ZH%(@9Q$ME1<&RVIQT!
M4A<66,2E%87P6I-D'C"Z3KWVGHK3XK4W>ERUMBA\^,%=^-9XT+(7HS ;?IB=
M%G?FM'A>37&X:YBZ&I<N,RJM')46B9N@<DIC8D!!,004$@>,) 0()# NN(NG
MRM8V@VUR^S:"V6FQ?C*\*J=%EN%[E.$YS8(B)+0V%%"D@G5@/ *J$ 7 R&,E
M?"&<P:D_GX#K),-/SFDQZ/6T&0S+>$CV6=R7SZ(Y[1F8[@Z8%DF="*>0T<(#
M)YD,P(0D,#B8/,9Z$Q"*,V5BRBUL([E.<=KLME@3Y2*+\<.(\7S%I5*$%YH
MK"P!5$@&9)!=(*#VG$I4.!_$6/*V8!O$[/0(VHG>WM7R( AR.-,Y]+:*T*,V
MSU;E8DE3GCV^=XF;B\03S%%!+5& :Q2)<*0&FO* H,QKB[WA"!5;VT*V5>;$
M?HS"NRK?2A;>^Q#>^7 -@E9IZ '#6@ :Y58+:@ R4!30"4,@W]IFI$TX7R/A
M7:539?U9)E:E0RS6V#V5WH$K:]>5X>D.X6F1FD$CX[5G$&A52$"Q]T S@P$O
M+,14<NY)I&; M$W8K3/5;BH>&^1X>8(BO[(^7UGD[U;DYW-3M4:%*P1PF#E
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MU,9K5>CVF)GVRFR-WD33R/D:#Y"OD?'G+O!G";E9."T\1AQX132@7#H@G2^
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MI0Y&[XS'PZZY&&O3\T>#/_70]\?9J[,Z-'V[8*=H:!"6U +$1>Q9J@H@$4&
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MVO#V?$49#S)<Y^7)R[/FR[,FYG(^3=?^-%VPJ2&U"F)+ ,$, JJD!^$ -4!
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M1,2HQ&.>^U'(HD0$.#R(ANDH3H*!Z1\]T]\FQ<\2GG*=A6$,7!_2E/,LS/.
MZ5R(0$?YS5Q_BUDB X??CL.7%#K+(Q8*)@E+L1Y;1(IPE8<D"7BH\CQ381;N
M[*;Q:@QA&!7R1-E:!LS75*5IJ!5-E&1A+%)*8YFR+)()WPA;#UI]<SR_/"(H
MS62:J"PFDFN?T,@/P9P'2SZ(HBSU4QY+ 3P?!LDH]E>K6 :^?T1\?YL,1,PE
M3OI4L"F4QZG0:1ZD$8\3154LHL&&WPYN7TD5Q'X2YRS)"(_C'(SX5!.1^3YA
MBN5^EH.2SU(TXL/ 'R4_WG;E9W']8\;H#8."AD3U<#S#\0S',QS/<#S;8P.'
M*@O](%.!E)Q&7 LE?3],HC3/.-,^-RB<$"=E(@H'#CWRAUDC]V(''RP-"CH\
MEQ$<O_1SD@LM",8C"0>_A80R8$+R6,B<[NP&# QA]L,)Z8%YMX]Y@R2*:.;'
M*N8IE;$4J6;@S_IQ*BE.O!V8=WN8M^/$?CEZ?W1]+N)41UG(2)3A6&OA,W!G
M%2>)%I'0*O"ERK>1>Q]SYY5A4-!0C#P<SW \P_$\ON.Y34*0!Q$3H>\S%G,J
MTB0+*>6@CS.MN0A#]1V&U3"78MMMLL.E04&'Y[XO=)**"!&^&8$C9T103DFN
M?95D04Y9KL$DBT;IFM&-0^^;K6/Y02)O]?'<1B)OP-4=)/+V2^05+SF201Y0
M/R6)RE-"LSPGR-/@+TL=!WD*_T^W2R0_YBSN,"KH#BO$A$JIKY/(9X&F?I@Q
MEL5Q!O0=95SK]'N,SF%4T!9)LZ.E44&'YRJ.="2CE*2FQ#7G*6$Z$D13G<="
M)#'-&(X]"_P?KC89PO7WS>.K-LS/8O!A5- &67C)1<QEG"L=YB1C&2-41P$1
M><:)9G$L E\P%B7 P@/[/C[VC1,JA(II3)FB09X  82YYEE&8YG$0?93V'=0
MSYOC[>,E]9SD02:E4(12%F(IJ" \YXSXC/$XSR(:^U@;%HVR-!D8_($P^ !5
M&HYG.)Z'"$89U.,]F[[+L3@:BU D 0>M*%)P7X.<B#CA)(CS@*5PLKZ,K'YD
M/UPX/0!6AE%!]Z]GAE30<#S#\=PN4[=Q-WD8@[ 5!L'O*_ZR'T=*^RPEL41_
MF4I&>)IRPB+N,RIIFD>QL0<B2K<C-S=P^2"$A^,9CN>^=>3&?>5!1VZ)CEPM
M\Q"I2J1(B*\2AKT*(L+\) )-F<@H2[*8RF2[E.1C!K ,HX*&:.MP/,/Q/+A<
M\3#<X.%8 >]6/.60,T;#+"$,.)M0#>8 RW).?.E'*H=?\Y#O[ 8^&R7QD%I^
M*/)@$-?#\0S'\Q!3RX,V?4C:=,6G#B(>^HGPB0XIQ<!S2E@D0\+S5(C,#\#H
MRK91G3[%44'A!D8%V5U\&<&VJW(AQMJT7;RY(>.C$(-K:T1D$J4AYZ'.N4]3
M%;& Y@$#P1A+'BB>F9:EWR$ ARE"/T=X_;E2 R+S+(A"K4@J_(S0A#'"I<I(
MHA,:^5&<YDFXLQLABB;>\/B!'V*C>TX:W)NDV)K0Y?^YCU._Q6EOA=!<T]M]
M0Q)SF-3PXZ)PJ98F%%3S (MYI9;P#^=$""5(E&29$B+.PC!'4;B:%QG$X" &
M!S%XJSZ?7(>93(*<2I]*I7B<)SJ,XR20/@NU^!$Q.)B+FY.1RY'C( \SA<@J
M'()+*(L988SEA/MXHHS*R&"N1W&4C!C=\)"Z05(.DO)Q2,K;@'-2I>/0IRJA
M"@R4P,^HEBH63.221XD*;A:5PS2@^Y&92W:E2E*EXBPA/LO KF0\(5F<I"3S
M Y\&OH*C5#N[ 1W%X:J'_7>' 0VR<I"53T]6ADQ*FDC@J""F@8A$(".?!R)&
M-LMB-<C*+9.5RSWDXP#''T<)B7RE"-6Y("S0BO"$1:E*TU2H%'QP.@K#U:86
M@ZP<9.73EI6W$)5YII6069+K1-,T$T+*...Y O'(0Y;+P0/?#@FYDFU6F4^U
M4#'!3H2$BHP1.#Q% AK[<: "_,R,C&8,QT8_ A?<Y*G_8=I<PO]5\7'WO^&?
M>LE7O+HH)N;965]$8=L_7?T\%@R1!<\NM<<E@KGYY!K>W)N4<SWS>(7M![T"
M5G11\;$WY=4<VQ;.+_5,>_OEQ.R9*9-^74SX1!9PT>D<_F!@(2^:\UI^???P
MF,+JIN7,@#Y>5EAT47S4OWPJU/RR%@Z=;[ES]-NO< $K6,QO_LJ6[3.+^EO2
M_1=7;80+9W&<^F$0Q< TOA]S&JC09TJ+D.K$Y^=ILE-_Z;*JES[E%YJ(2O,/
MA.?P9B_Y^!._GNW\H[\?L!G=S?^^?;MYE_+\-KO$OF.3[!F!X"TK Q9Z:=IB
MXE6P"G[?2_ N*U1$__4=AP1<A<R/_+)?_O<_^$-;/; '\+!9^!J:[=#*SV.J
M="U3'?SOP6^'_WMX.O(.C_=OECGWO<S]D^/3D]\.7^V=';SR3L_@?T<'QV>G
MWLEK;W_O]'^\U[^=_'&ZM:M_5DQ [)<+N(>:/;]QF=\A;XU*;$6ZT<&P^C&?
MSO3+^H=?5#&;COGURV)BUF*^](N[N],#\705M87/LQ^WHNV%;\6; XVY)[N/
M7YB/E@P*^UGBOV ^O?%C_T5PXV=?NVWP]V_[]<^R[.:'/IW%LN^Z[3=0A+<$
M"UX52HUU7X.Z6Q"\_F7R(HV_ID9OQ[+9MSC60;=[)K.5W<M.?!!_SSM;WKU;
M9_&;+V7$T)^:5]X!*#35 TGV'(.[.]OM.[].$.86D[6W\VR_"G2]Y8O>B/]_
M9!L6#!MVNPWS;R,J'G1;LYNGQ7]GV.3;!_TX8ZS?\=X//I Z3#UET7%1!U/_
M71Q_^?W+R:OCXNC+O^":WZ^/7ZGB*#R\_NO]AT_'9WOQ\2OI__7^]\]-,/7J
MK_%?5P<^_/?YK[-_%G]^>7OUUQ]_%? [K.L=_?/JST\G9Q?^R=F_/RP'4_\R
M =NW\-_K\=&O_WI__"O>ZU_P^^6'O\XNB[_>[\4GKWZ/C_]XFQ\5-M5T=.K'
M1^\/@J.]\T@$L0("($)D(:$JY83[44ATP'S!(^XK&FQLYNEM.>-A))8&R?9X
M)1N(,Q7R-,$D.E4JX33*99BQ6(&("Y65;"#7_! E6P"2+1@DV_U(MB]+DDUK
M07W*$R)C;" ?RHQD"C20CF--&6<Y#T)L\Q.,_#6#J@;)-DBV1RW9,I%SQI2?
M,<XQ^<UT&N=9$M,XY6&2""/9?,3G$2?B!LEV3Y(M6))LL1)!("4C6>8S0J.0
M$BXT(P&/PXCJT(\"1%,&P2C]\;;?/TNR;:C'F95'X8LPWE*9U&ETX,U+K]+
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MQ E+"8T#GV21!FJ&'Z,DBZ(D3W=VLU% -^7H;ILON\T>PQ/OW7VOH_@>\.2
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M2G.,%.#A%I.%5GMH2F=^*$7$DRR&SV4L>)3[/!$ZH;GF:9KO>!HLZRDR:+4
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MF**&M"T=&N.QYM6.F&E':7A6U]5*FZ_W*EXT 9_N39I!.E9DCJ\M,<_F'5,
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ML-$-]ZM!%@\WQORFG_[H*J3[\7+>->;;4C>7M8 (:\_^"@IJ@GD !P,30(/
MV(48K6LWR#&;:6G28,)M!LAUUR]1C[7X'=N[:6)9JS6>6U7:J=WH/+=&J37M
M5,$3F/43O097">QG>,K<N)-3AF\;-$$WCN[:*QH)@SN =VEMW79'>N.C5DM6
MC77G!@?W!<G79,)-QNDZSV+-?G9M\AO.\::.DM_; &>U^4VO972_^\W#Y=>W
M)AMI@Q2GG:3HFB#%O5@,K]>V=*V-A#:7^NVD[LA]RU09K+K:KC=98QV[V9"M
MB>LP=KSM.KB4X%%(>G6"RA*N5B6.143^G.NKMNM47T%8A\T"@=8FHFJ[&BU>
M7$/CL_8[IMD&.-_V:?M->2M' 8W;WKKCS9]:9W<[6Z ; Q<VYE<#BSDMQVI[
M&/(;J+99,ZK553(4O2*E3K>]?ONI!L+?:SS$[[.A20\WN5>+8M>FXB1WHN9D
M<JSG*&J><OG,17S\_O \Y@EE4@4DCKDF-,DHX8QF1&:IH(Q&0:#TSFZTIGJF
M9EJGP!VPPU ,8I5+P\5]= F&AFI* DE85M/2@1$E'-H7'+]J+!RK52U9MM58
M!A[<M(DTQUR#*CY5(-R(*C]->I0+MFQ1U8W]W!B'8H)- DL,-"$H;UI_7#=3
M+"I%;'O%<7F!SI1<*INQ :P:R-=ACF^G+;=6!JQ/GWP['?)':SRMB_-V .%P
MPG!RRO:=-.JIB>;6WIZYK%-\IUPQCID*LGKOSCP3([06$S.'>-VE(,]L^UX3
M*K4-*2V5]:BK<ZQK5MTXIU]=51/7YE-C +G9'@W5>4!!-4K6(JU,B/P&9\PL
M:,T4D"T=?/^V^Q[=Z,^!<RI_[H 0NYB]B>HLQ:WDJ4Z<CV!-YQE5<>[KC$2!
M$(2"O"<L9RF1FJI$R2@*LVPE!9O#MNL0)RD%-!0)J(=,\%@F,LAC7_*',Q7D
M[;<B'TT_19!>.'#!*1P3S:VU3Q/$:D6&B0 :=!^V];;3%Q;3/BJT$]=R#09M
MFV>-T9OZ(AMG=O NU$SV=[!OP UPT-*1*3DT\)G.VZSQ*1JI986:J"%=R\64
M%OM&[!J64:,.?W5CS-#5O+N5-)V)BLE*F/1KLM.-?S"C)Y8C@\M.N5E+'8N=
MFQB\V]?E<81V'^M&C'5#3:^A@EZK2N_9_MN3Y[7/@MOPJ:P^H"UC^_M>\G&^
M18[VUXO8;MXB&XDQ;A50E5PTVXI)E+)J@L>M+03;8C:VF7^ SJ&-))F@HC.B
M3+49_G(Q!E(;+SU_UJUT;+C-Q+?ZZ^R4IKBC:*L1<27=SE,F[=G,UVJ#)^;@
M<"#96,]MX-9D1<T#+-QPZ:'U@JQAT(W0U'VL%S,;/G./P_<<FE3=FBXS?X"I
M#3"U!P%3^Q;L;-E&"A.612D#2XE1QE*!UT=,)X+Y29C&6]0\ZH87_I:1MUOW
M*VBTJ[.'0"K7OK@!7IM CW'_ZG)Z/:EP^HU:OL!5%S;"&*2:GM5%B^YJM5B9
MAV&;-=6E^H6MY*J?T2*<"E=#X2[%,09VK('$>0'6O4*E=%6"-88FDKO.WLD.
M8D1CI"Y<M*&%CG[J][QOQB74"4O<%VP38+JTVYA9A?-J2C0+</!!8TC:2<?U
M<_!GUZ>^Z<]EDD=FM<*,M^DU%G&:T(P@*"9VJKU)1WSDQ=@PKHO@8C*SDZ^L
M1P.9_$/[-3L*P/2-;^]@2Z/L_N,%IM>8::9=PN\?#"*BM-GBA4D--YE?.(]>
M7_Z9:V&$8]@^UN4/;OQ -Y#D4C==2(^=$?H-"W[E>6T\VFVF.=6&_LS\4FT'
M7)A7<*$)$RU0IMV+,*-+*UO@*<#&'S49_,;8ON*JWJ6F]?\-%K-[V6:F_=](
MT3Z8Z:"_X7SO'RE>O]M P6]Z-M/:+G(8&WK\Y>!<9BJ5F8B(+UA,:*(4R7PM
M")>@X(72>>Z+%8?_)Y>7MJ4Z1;Y2<ER#A;F=+5_+OI7ZHR99:ST"XR'48^[M
M%Y<+&VN)M&:8/<(L+3N;?DEPCP869@NH;,YX;$?-F&_4J3[[,(-L,1!*]X>V
M%\S*K?NI-"-][7=J8?3".VE*_>TGJRMV">VB+3Y<&H-69_W,]TTF$G;0-J=&
ML=Z;5&.[%5GT23,;N;\F!Z?IO;#1!/5AUG#I7I&D];NPC)B/Y6)<XU6_XWFV
M1LSI2CA\6Q&.?9] "]OIFM7*>WQ5>]ZP$[;-E_FP#R&K,8,F&3$W\-S*L^]:
MOX>]I=6JN/W+,.T.;700!4U)^76CAGK3*IMH$:]QL0VTT4BZ6HDTP9^R3RVS
MI?G4!CQK0+M(1,B1%C:[_DAKL(>I6]<6ISXO.XT'N@7[O6Y). ]A*YI]X#A@
MT!L)\</[0!V,MF,7++'<ZX!A1L/GADIGEV4U)X81+(FVD;CEN,M6F3]["EAD
M7F!4]8&$#CLK;FWJ3]CFXO_<F-M?S-1F$_LD7C;4.LMR:9P=S\IJ>-KG^4MP
M*HDJ3;  []$D]Y,G9L8=G_T>'W]Y%\ :KX_>'T3G*O1YF@E!<@J;3:.4$D'C
MA&0A4T&4R2C1Z<XN#5XD*WE^S"F,#9[W-D</YZU"GB:!C'P,E7 :Y3+,6*R
M!D)ECQZ[GH:F_2D<?3 <_<:/_NSB^CP/1!S)5! 6ACGF^E+",\9)*A+A,Q8$
M28CXCN %N_'HC9%XF]/_P>:WP^EOX/2_'+TZ^G3NIP&-LR0G"?45G#X7!$^=
MR-0/XHSZ<2#]G=TP?A'<?/JUCW)M6KIJDW5\I<'X%=AO%5LQ1<$(VT^'YM_
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MJ^)-;'T8>Q-WS@\^_]UI[8?/>_L!_OO^<^O[2?OP]/V7O5=_=':_O[W8/3W
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M#"4"0!>M2LHG@R@#&XDGK9'15B 2<0I2Q)S'L Q#Z88V\NL =$_@9'ZV^)!
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M!WP(QB%-E4.&)VDT$:#-@FA^<$69&AYJ>!A7RV92,,JBP-IP*<$<=PX,)4%
M2H$154?7K8JA1%KOCKS%AD:PC*2W G%A,9A,\$D%' D+@C'JEU''8<WQX8I2
MV2M;7'F[L'C&)4?+?6*DV<BZ>L-V0_X OPX7:S#W;8B-/GRQ_37/]#YEF!L$
M_ZLQ7WQYX7GS]9<;/T4!9L4V#:YK&FLL[_K8*V3QPWK:_4QU=LUZE4F^MC9R
M30=UO>6ZWO*/K;?\0[EI)5N;/O8BK'>,T8\IY'5;4;=Y+GM6YG$,@C,FG(R$
M<A^5MBY@A75TS(LD;>U=7VP,%;X<?MX1AZ=_=PY?>7KX^?UI:__PI/7]^/R
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M"=82Q;0F)AO#/_GQ17V\N3Q\4-1&90/6CEJN;33.)4ISR]/(,/5UF/A*:%F
M#W3WW5%2)/<1("@E2W(:B4$&D!Q PGBC"-CB&1\>WM/W6>)#[1=[XGYESQ9#
M Y/:<^59$H%K$ARFT5D:-,; EY+7.M9386CKY8R.Q5OOCK2+T9$8$6Q60MQK
MCYRV11,AG&S$5%"[Q*9DSPM#ZUR;?U2K!-1WY51@%'O.@W J$B5$8(EBDZ2I
M=:PGQ(=I'8OL;1_10&#I@T?,"95U+, 'SCB*T0MOF=/&JB6V GI>^% ?P-8>
MNZ<H$?[<K70<9(J*$H4UYU(8I[$PD3,#JHR,S-<:YI-)D%DO'L\Y"IIPRG5
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M+EF PFHNXK&?R3*0*,]W))92I>9C+^^+P90=S$>-7W;U"?X&Q[&=$B.P":F
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M4?VS'>//7__Z:*/7W^ SI6Y_Z%W??%Z#E?>Z[9I^%'=TX2OD;0F5GI;C5"U
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MII5GRD["K#&6<$R]T-&"CI*HE<1(,LXDQ=R$=9S=#<QN%\Q>+YG4S <9,!%
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M'"A&I!2.04+"W@%1;8$?.4#2(&R#L W"/IC*OD'8+4/81<\*X09;;17@UGA
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M806Y+/$JG5!&42*5=-SZ(#3R$ >K?.-UV%&<BM<DC,J>ASB^+T<G+TZU8S9
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M*Z'U$[.YJ!70>Q,\X '=4]OQ^?T? .6MP:P4IM:/&- YF/557^Y\.,\[?,N
MYALEG!1,(ZL!O[BV!AD:!6+>R<29],R%>^TA_J)5G'*6[S7+.G)OO48QYYB"
M;TIS.6V!C+-,4!*=8FIMH],=S(#+K /5BT"71D9K,@<%(?;%+$Q !S[H J;T
M*JWC$_"1LG=5\4W;.\C?=2K=(7QSL1)TQ1=?K[RS?<"?X<GX5_\=VAZX8NVS
MJV?JQ>^M>#H"H0C?'K<Z< P0]D$!9+,86"Q)PO-5[&#0:[EA7A<8="?W#&[>
M4;4"GXY^!V[?L>VUX)*VW^_Z5K9D(]\/GJ"3GZ"55Q'@NG#_E<P;1Q0"#CJ*
M, *M_PY;<-JSR;/ D^2[ZOMF#,-VS#\<3*@'(//UL>C/?2JXR5/ \6/P3>'\
M1Q'NK5B>R(]4_ "..04+4&EVV_F0V(]7SUE,D*V<Q%ZK&_(U!ZUCN*%A2L"(
M\H".OL]3"[[PV>2N?!>>S]E^"Z;E>MC)2"B JL 9_=1BAV2,&RR"L(I[X9V*
M&E ?"^6Y\QKO;V8 P 03=(D$UU5_^_+._VC#'+12*X9W9]D1R6(XM.W:: 3/
M-F'P&QD6&G#]=^VN/WIU"NY/\VHM\!UKI$5&BX"X(@K9H!1*00BPN<9@Z]8J
M$5#P!,9YT!O&M>7>1IAB5G=84W1GA1R.!62B8V>%WMBL 1FM^I5_MK(V@C,+
M&MO_UYOK8EV6+2[+%M^YJ.KS97W<K7;G5-C._%R/%2X)?)]JP"]JSEY2T=[L
M JQ N=ZE&K![U<%>Z0($(S>O<Y =[FYGM$)1&>_/E55C7T?UQ&=H6#.]V'"Y
M#)$7)6H7[.T;<,)69Z<3=T$N<_GQHOKX*PBO._[<JF_N'>W O=6/=VF]\?EH
M[]O7)MSC>?W#)UP_W.;UXR]T[WB73(?7[7W8QO7C3[QVN 77VR5UN*^];UNG
M]<T:WMO\1&N'!W2OL7>\=_@UU68S^;BPG%B"D:1"(,Z, *(3!%#)1%BB0<F0
M>]54">%5K6=W <L*LB4&OF@,7%2<<8F!2X.!TR'&U%++I(R(>Z\0ESHBXZ-!
M3D?*O9#<*UU@H-15*F[:@5PZ#/S551B>Q9&U"7C$I2\[:,(3'30KJ?5]O/_V
MH ):JY>]O<1>W=L\10!HC='<O(>IR=C6+\%M\> VFZK&B'0.,XU8I!)Q2@#7
MI&!(B<2M]%9+B=<VE&!5Q6[:"U^>3.^R6,/2.S"ENO]*=9_V93@FS&,1D=>@
MZ9P0#[Z,<RBIX&)@VA /O@R3HLK)HZOH+5#=%[3J5ER;BJ*8P%(Z+D7)@3ML
MOSUC;NB+I*HO-VEVZ3R_JT'V)=(O!NGG5KPG'*03N"K--0B<P,@H95'02BBI
M.$ZQ8*T:6*LDCZ[#M>09LF45@A)07ZIO70+JDP#J3"4T+:1BE",93 37&3MD
MHA:(:T&C%2XDF3*@"L:J4NH7 Z@WI,A?QB/>/67^PNN>C77;^+?K_;8Q&QY6
M2*K50BC0%"8,!J7,>U*!8@UN,N518KN?TS]NBRE[,IB8'SA0WVEL5<1ZY8EC
M-R]H\V:K[]O=_K 7^\L2G%G_8Z+H1V*WT6S7/FR=U38/Z.[AYV-0-@Z?'=</
M_8^]QL%9[7";P']X.CASI]%N[GSX<KK;@/-O[K7J'W;/=C:;\!DH__G[-@ !
M'/L%_ON<:HTOI':PCY6*R2N.DDXY.#-G+":ND'> O4):JY4< 37(:PQO,UPZ
MA1TEP6HJ.&>"6H*I2_"/L"1&$*^I8,[W;[<_5[Z^_>O+5J6V]?;O+Y^W:EOU
MQM^56=68"N.]JB:CV;G]TM=OE0,N4"9I$(KP%+A-1%)'J"<L.&G",D>:OK^,
M,NW%U(Y^T"]BM>TQ0%_Q.L=6=X?M4''Y)SZVOD^BTXNHTVXJ(N'[_3C(@2DG
MME4$E@]Z<%,IYJ#J=LNZ5CM'HHX2SPMXS/';^2=CD^WBX#2GIH\CR$]LAK\6
MC /<PCBF_;C(6(Q%^'NP@[A>F8J2;;9BS_9\\ZS2M*.'&(6\CK)[>C%6VO%[
M;/?O%/(*N#[!ZE'!0SX-E>@I$6S^9/V_?VA*Y87%^G67GAJ*=4SSL_^5A[-"
M*FAD2/\[[.8\@1/0LMBO_'/8L>%PV(>/_E5,?%&G8#S!HWC\5A[';.5&XC/*
M(9A("SA/OY<3M<B)HI.):G5.AC#:H_24(HNB/9[)0MMM#[3:P>6_%^'=L57\
M+K1 ^0>@MGGB.I-WU4I_Z)LYO/SZ[,^?\'X+'M3FX_L VJ/$C)PGDY-) HA*
M[ZQRW V@HI5A/VLMJ+FMC.[V\D)S\D[&%RWNWMN,)E=NMWB2G(22TSEZO:XK
M"AV$V5O\/9]K*O+T9V[4>-@%SQ(X3@5]TXMMFT]Z&;/^O]?A?^PWXLM#K ,7
M<3BX^9 [1.+_2N$FF$^-TI6_S=YEQ/$!F/E>M$>HV/-]8]NG]JR_]MOU9X,'
MNSJ0=QN#FY\XI?L\L;Z+2A7C'7+25R$#;X 2@/UJ%26K['/?0@4,&SBN_[C=
M(U=K&T6B4+;8?W3__9M=M;L'40? *&Y\COC-]>0>[)F55N6N5H5-K,JP<\5H
MC$W,A3WI#T].NKT,N^X,3/Q@D.6P5^ET)QY? <791[P\! "NE< ] '\O.Y37
MG;TKWN#ZK\S,NV!W;PN7I3:ZC;#3^9S7?'*$R[N<+OB*"1_>^;0?C$LN5X9@
M$5/$-;%(1T)R.2+&',-"Q+A:V7A^G(;I"W3I%]FPK<ZT5%Y2D'$":6IU;*?H
M\CQV<<>YJKT+"0Z%!S/**<YO!M<2_SJCI-219(TR44='O_*$/OGPS+N7E="W
M4C>K%YE]>&/@$!&KF])7F4D'>^QH/#[UZZ[](9Z,E]PM<W"\&K'8U,%R6(MA
M'7EXM!S;Q8[M3>U,7G)&XQ_=8_#,"Y?H!+R_7IG%6&;P3&W2Q^@<!\9.M7!<
M2>QHD"G!(QIM<^;'TT8]+6'1I >RN/'^_!>R=_SU:/=X2^PTPN%.WE<_WFOM
MGF^?U\ZWS^J'6S]VX1QYKWUF?[[Q]7COV^?6;N-(U&F-US=WS_:._SRL'=;.
MX1JTUGC?VMD\ #:X-R]5,3B#.5$:"" 3B+L@D9.1(:#@01$<9?!JM*I!Z.^K
MDJ3SW(F*KQ+C7AC 2:63]33$1'.S;*(#9EY36S1A9H2^SK#.%4&YZ2@D%JV.
M#FOD0S*(,T^0"U@@AV.41 CC#5G;4)168:*?&N5>!,2]5I1[>4 'SAI7*6$"
M,,<C4Q8[8:1B&#OC&+ZA[G\)=$L!=&2FAY[0-!B%%",$W+F4D(:I0XICIS$7
MDN<>>K\(Z!:%=2\YY_J/:UT=RL3J67@25"3AA'>1<4FQ5CJ*:*),V!-/8DDT
MEQ&99E.F'6-)YKJ?TBN'<H4<9)F52 ECH^!24*<71C3+E.GE4V3N Z548X:C
MX8Q9AVE0&A,C3&0Q/?&*4>EG/$J;IPE5(%Y1(2WBFF<_PRGDE&0H<A$=D_!2
M9S_#J*KFC_8S2FU>0FW&T?%$9$PQMXYB)GFEB>-.6T>"":4V+[$V3[,&*8--
MP1M$+)>(>\R1UCIKL[9>2VP-74IM?LE[</=O ?4@[C!G1%X.2'ELC+5 'BP3
M/ 7LO%")A^1)TC2)5'*')<2G.5GYG@2A Z&(64\13SHB:S%&PN3<-$&B$F+1
MFU1+M$A;*K),"3.BH\4B<!:\3H)K<$ <MBXW,B^]C276YIEJ2LII$X5&V-B\
M&0-Z[8)SB!/&"4!SL,JO;3!&JT*K4IM?GC9;'[E,5AB30)M-M#))2RP-01FK
MB"FU>8FU>9H[L-R8306)M'0*<<P\TC88))(40@EL>,#+J,TO>5.A=JV)<+FI
M,(M @N:6\<FK:('C)AND%P%8 =.1$6-+8K",X//W##$PP4<G4D0>T]Q-'0ND
M%?RQSDL>#94ZL7)3X04K,O@-B>&8I$N8VQ!=\I(8BGW0EA/ZQ(I<NA*/TN9I
M8A"I%#X%BK1G0 QR:T"=V8%RS#DFN"2.KFT0625RF:JLELJ\(&4FQGB:@O/8
M"$Z<T<EBS2,7F"MO3,D+EEF9IWF!$UX+*A@B@D0PS<Z 6BN"I.52<0OSJL02
M*O,B2R83NDY?6LGD^ZQ>/"YX="4A+ II0@#9IA;^)F 71F*7DM?46V7*:*6E
M1*_9M!B5!!@C(E%P$="+XIP6XQD*,+DJ1*-<[N#U.M-B2@CXN1=CN9 R2,.H
MX]I:;3 -#$MOM$E)E(DCRXP#TY3$A$B<U!0%HW-5S""0%90@X8!S!D(C9?;)
MZH&_#B1XH3!@-751@J4  >">!LNP8TJ[D(S1PI=D9IEA8)K,@*('9KA FAN%
MN-<8:9L+)GF&%7@$U/GX"V&@W "Y;0.DVXEGD[)E:5CN@<SK6\*2YXP$ZY/F
M/+&\:R>E"AY'K92_LY_RA^TWWW9"_F?KO\/6=\"9SJ _I\)VB5 +0ZC9] HN
MN#:&.91#VQ"75B(;64YS]8D3F%W*Y-J&X57&']UON%P[73YM]D9:@@.05JXX
MUA2XAK!!,Q8DH=C=.8OS@=I<KCP\5)&G&8>E/!G-/>()PY](<^]P;X& *)L2
MX5&Y5&YIOF!-5B):XCVXE5IQYK66C%H&1AI[%]C=HZ-*N_P<ZCS-'$(2T=G$
MD-,*(V /%KF<FHT===1;+@PG2VB77W)FQ1_Y'HHJL;&?:\"&6)1Y+],GY@17
M!)RC=66B/)?Z9HD2'I3P@C >[YP^4?H4OQ*$=F;S)Y3E4EA.47+!YORN@)QW
M"BF"54PQNA@77N1K19<I7Z8F"Y(<430*&AUG,F<_&24,U0X'R57I4RRU.L]0
M!*98PB:A( UP?282 @_#(^&3PH1AS&G(+4!85>I'=Y\OU7GYU-E2'%EP.<8Q
M<!&TYI:"658&/$HAI"K5>9G5>2:#PIDD38XP2%8BSJU"1GN"K%#:>Q.L"'89
MU7E!&P@K$BHUTR7"VUZO-=T-XKY<K6R(_/0#L_)PO["@LD)P2WA_2GB?S5%Q
MF'KGJ$5,19QW9CS .^6(B4 E3%KBSBQX!>CYVQ\O:#7XZ1ZTQ,Y74,-Y8:%X
M)7#^ N"<IKG).VZ(L<@0;W*-,8ZLH1C\8LTUMDFQO*5-JD;1*C7RV;'S=0!G
MB9VOQN]<6 AC"9^_ #YG=AZ]32'&B)+##G&5%QAX<H@HRIP*5@FBUS9H%4M9
ME1P_.WPN-*[QMZ+A8=E@\77T+%RIFRT;+-ZEP2*Y!CQE@\6RP>*S#VO98/%)
MQK9LL%@V6"S;\LP6V%8D,F9YKG_!K18F!J*B"5PJP:,>+?H3(%^DS"2_G88=
MOH?K'9WM?/@"UP%*=?@)K@.4Z@,<V_ATNMOXVJIO;I&=S?;Q- VK??MZN-/8
MYGN-+Z+^X4_XW==F[?P [WW8_5'??->L?]O&M<87OO-M;H-%EW@2TGLD(K.(
M<VR1,80C['PB0HJ0&'^MF>0ES+UZF',I8*T YZR1N<"3I4I+FIC'.#CC]=/"
MW(M<<OIU6#>]8N^DTS9GK&@2!,H):<CX%)&FUE"A'$\XYJU.4=5\49$L)=:5
M6+<B6*<33H((K;VGX-=)YS'E7G)J*9/!/+%+5V+=H[!NIF<*-<YS<.2<,#FF
M/CFDF0B(:&6X#=B$2%<.ZUYR38"RT^)MB8=41FI!SG3DG'&;,P4T-P0'*1,8
M\))Q+B,RS98"P %X930)$1-S*0#LD4D>G#(398P8)Y^[.949Q"]6D0FVB45F
MB0^2$ZJL(6 _C(=/- -Q*/V,)=;F:4ZE 7X#:#+",3+$*; KPSA'*1$M/9>
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MB>221P$FGD<3 T]*&ZQ*KK_4ZCP3+468A%FTB @,ZLRH1LY9BYQU%!MJC4E
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M.60#X\J3:#QE.:*CJC1>(AU^R7L.?UG7[=F<7GBYZ_!$&PTKXG7SJ"QX;ER
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M+<H":R7"3R/\[@P3HXY&)2)%4:J N \<.<\UHB(H:9TW'-NRP%I9&Z@$T;+
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M50/(J586AK-@G0R(JL@19SH@IVQN !=QLL9@;5+>%<4+;@9T)Q>[Q,@2(Y<
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M52FWI0,4M#8QI AF!,2 8N7 Q]N4D[0W%<?K0N/6KT'9'N7PU,JV(LHVX>$
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M["3__QZ@Q41*83G344C.A5,:+ 4N:$A8<N8LN4&+Q:06?S@Y;77.8_P[=G^
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M!+,7.6$]XLI:9(E@*,441>!82)\Y<$F#FB>?Z<U1)>L0<1TBGJ=!_3A4K+.
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M.L.UN1:(GEF\4:?%KU]:_&IDQ->Y\.N6"S_/=J[KD N_^^<^W?YSG^^<;%_
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M- 2>00U6.>-EE4-5!9QEO"H .XM7]0:SI7>S>'NK9%X5WF11'K2'NG01P_6
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M5X[Y T'P&AH?@=B53O0Y& Y/M38>#)">1^GA_:VWB0O#M1%!.)=-"6U@'FJ
M7%89YML7;P\,QH)0XI!S3F>F-X-@*05BL-<112TUL:02WIRVYD< >:L=>E^[
M?L*,O_$$<W[VO;K!OJ^J QK%Q[;?+#@FOWS_M?BK98=]5<;^\.L#R+:6RXFY
M@6WH3O:@K['HG8(E/H2B\<D95$74(TPZL=_S/WVPQL#$\[9W5*)&M^D&EWPL
M^5#S\G1E6$$[NJ?U/GN%@)%?JQVW:L8T"QCOJE6;P*M'L1S=!ESO8\IP^V[L
M]?*,9"BJ0>A.?J,AGWE41#&%I#0*0(@FI%/4R%'OF;3"&,]+*VT&L<JEE?80
M(5"Y1M\J23P87R%(R\'WI4:+ -( AOTP!DNJ6!0!(2"U$"Q4"#X=!*M-(#%S
MCH(D\!@DTA*,J\"QIS$HK:S?V+I](VJ'!XF!<<EJ';#1UG)E'%AO(ADIN%"6
M2NGN.$*KQ6#>8G#\X4#)2+BW%&7*.\0##D@;PT$@=!)21I>BW=B2MT#!I:E<
M6MFW)=N,&MADN:ER;[JQEW/@FC]BZ[Q1WNAJ$QO?OZ9W^YL-G5=+M$GPS42;
M>=BE?-])G4BPV:CI.5> X'*=Z3D?(2L+<4]V=O<^%&;SUKC2$W@\1_L8^#Z=
MD[AG?[YO]GRKTQMTEXB#\_MH7\I-J/C^R;>3[1/82_9RW^FC[[M_?F+[Q^%X
M]_T1W/LCVSGV(J?N7M^7M@E\M_GM9/_\V]<OV?S <!W_]CXT=^@VW_WSG^/M
M8T]W+KZ?_^?BT\7NWL<#$WA@(B248(,"&Q5^,IAR1$+B+ J35'*3')S61:.Y
MD\)IQ2.1!NQ(Z7$(7@9'99SDX/SK\^X_'__^N+M3_+'[N?BX\VYW^T.Q]_8_
M'_Z>ZNM\=SN3NQ]^?; A,J.BBLD;>",3-+/2)FD$]2HR;19&'GMY<G3)'YM#
M.IUV>0:4+D5Q>/+VK]@&(ZN_9+RPSRZ3,)X/!Q'FEO"DD#/8(XX3V$HV!*2H
MM3%75X<X)6/+&Y78'71S:C.L=N$BF%YQ]%O?_HR]ZBBUV\Q'/V 'Y=9LJ=LY
M*?.CASD+7S;_WBSR72[;69<6W+6[Y/"F[0W[C/2*7\I+.P,8=^C]^CH:C4B\
MJ3&?>Z,1\OC;WOZ9,?/OBK)Z@]7SZ.'RP!*RR\J/^7&GF+O,G%*F)ZI;9E.F
M$'&?]ZKT<[$U+7>^5(EO^[GTX\,U;S3G.3ZD-G"MUF^LY+%"RXRNN2H)X+T9
MBCRXVVH>EV=ALT%S8[7C0]X2YW?<6/.I(O54W7>J\$LT5GB1<K]W.?D4S,[[
MR,9-[WGC>C]4;NZ:R*?<8TT'.:>:]JK4FVY2L:1R^D>$B;&MI]3=WKM!W(N\
MX/U[Q,UZM14KT9__Z3";#&H,@6TH-U-AC/N=!;$5C6]4)?:=G_O'^?E?V,Z?
M^^+;GW#?/__XOG_\[^-]>.[N^YUCN"?;_O/+^?;Y1(G]\1_-G:\?S\LSI^,6
M7//Y^_[7S\WMDYTC>$>^37/,Q)]]V_MX,8M+CHBD@DP*,>\9XHX(9$V,B MJ
M93#.2R_+?L(-,2-;?4$E]K?KQ8/@>N*1DY!?H]*:H-)3TQ5J5'I15#J_CDJ>
M<Q9(( BV%XFXC00YPPB*T=ODL8R2Z7QZVF!,UZ!4@]*2@M)3DV>>!DHS.A'5
M>'0_/-J9L))"2-SX2!'1V"!8RI0;$7&$E79*2)I\>OY&1/< I#G%0Y;>Y_R[
M7W>9?$97K9SNM^WPOQU?FT8+A:)/4PX;\TEB !VD' 6'+1J,=# !*1NPDR()
M$UAI&AG,7K0M^.-,H_N&Z%ZM3B_*T:EU^AEU>L+=X8:P*(-#HB1UBC8@JW*S
MPX2%,\$*K>G&EFA0.DT74ZOTRJOTHMR$6J6?3Z4G/0;I'.5)>82-R86OS,(V
M+3 X$-YP#PN><@,0UE#F9<D[GN@OW.*K4+&IEM5?**MB"U^I24Y[&Y7*/=1)
MN]\!^IH%:>[YTBN/RXMRGV[(UZT!>7Z _&7*;[(.-E8?(L(R]Y+6%F<:YH2T
M 9>):<)8C-EOH@U.YQ53OG=ZS3)'FVN(6V.(6Y0W64/<<T#<A!MIE">.\X"4
MS@VM?(I(.Z]0BC@XHK4BV8TDLB'D=#^K&N%JA%M'A%N4<UTCW#,@W-0Y' %K
MG&"-#!CBB&,?X"<-KC7W.MID8M!L3E[ULP#<.N<KOX\IYG:YBTE87OY$X%4=
M89VG7"??+.W&_\OSAF]Z\*+PTXP>-B6T#46H-@46;@KXJ7B.4X81)Q725*LJ
M1=!H&F$IL:'<FVA-V-@2O$'I]#GXKW5VX!(H\SH"U$O&7FI8>@%8FHC!8)X2
M<20B23# $HD>@?<98'XU"_!K- )@B<L&)W*)$@5K;*JQ::%1DQJ;GA^;)J,G
M-DH=4I((NTC!9)(6&6L$BI0IPC7C2ON-+<(;6B\3-M5)S.N7';5<?MRU1*D:
MFA8.38<SRE!)7MF 1(H,<=AJD!;8(9DABU%NM3$;6[)!V'01ZOV=N3KY<?DL
MC85Y0?=3ZEIO'Z:W$^Z.HKE+*#'(>6(1QYPA+2U#27JP$SE-3(><55.7(JRA
MZB[,2:A5=P&J.^D->*:9"BXBHIC(O<,ULMY8Y(V3B5E+-9<;6TR9)5+=UY6?
M'(;J<%N"\KU0Z.EY+LN#3\OE.=3.PL*1Z_N4LX"C$. 3,(2#\(AK95#NXHP<
MV(;18X6%Q^ LX 83TYF\#S[Z68D4MU<' \O@8=3*_QS*/^%Q).:5SS55(,H<
M<<<I,C8*1+RPS"0N&5;E 8N@3[9<:@18#P18F*-2(\ S(,"DXT)QB([SB*P.
M%G$K!-(1 ,%*%;Q51@0'"$!$@\IY=:Q;B2S0\ME,+:E+\]>-A ,/=22'BS&D
M F#PXJ$SR,0"Y8*\KF3^>4[)RL/\W.LU:WA?.+Q_.,O07GEXW^&]OIP=R!B5
ME5BC%+D!?.<D$Y(K%$(@Q'DC',^9?;0!GMZ<8E/ST)\7#D?7J%FCYG*XQS5J
M/@MJ;E]'3665#\YCE(R7B M)D762H:AXB,(90G,^M&0-/+>.(S5JUJCY6E%S
M[B&%&C6?!36_7$=-%[C0AIC<SE4@CHU"FCB SDB)3M0X5Z9$F@863TZ)7 +4
M+",-OY6,>I><4Q.LF4O+?;AW%&]C+<Q_&"W%^+!NC.DL>KP/H==N7/)KPRN"
M9G=A&$7)?PUOUN^4U(V#?K/5O*C82SNI2%4B=7DV;/L5[39\.=^GE],G1I20
M[>)XT&WV0K.4V5[1&?1[S5"1$,-KPK2UF[;B\3X[:OJCXBR"0!;M3K\XLC]B
MT8[]HG,:,W-P^[!H=7J]PMMN]QPN.+/=T"O"(.8AVJ+5/&GVX46OOGW4[/4[
MW?/-6>NRZ.DO62ZK 61UF/$>F>HR=F/1&Z34],VR$UBG2(,6S'TGI1Y<8-OG
MXQ-=TE<.I6Z<07UBA8OAXN("UJ1Z1I[.6YYSCV?<+D8C^2$3'.O/14?[(:6*
M$_YR&_L,,O@YPA,]B&TIM34?[?O# TL2YIIB%)0 ,ST1B5Q,#AFF&><!#(GD
M5X>/-F-R]]HB9URY))H=B?454(\AN.V77\Q@-<@H,>O;W0QD<$=*_KM4AF@!
MH(9/F*44Q758O435!HRR=UI):.N\D?6O4Y/@UB2X:SC8F@2W)L%=K_5;)[K2
MF@2W)L&=_U2]'A+<>YF55R9E=T9%Y=/;):UO4'?MP[:+2Q&X[NO>$,U].Z+N
M^GLDHM?\Y5<1[*7;\*S]BT]B^V*?[_SY!>]?[)/=K_O@2L/8CENMG3\_G7\[
M_G2V,Q7LW3_;V?OG>.?]]XN=XT,8S^?CG>,OXMOQ%QCOT<GNUR_XV_M_G\!]
MV'\N/DZEC4LGJ<>1(:(51IPKCHSG =%H190@2B;DUARF0>=6KK9.9V U(*XC
M("[N]+\&Q*4#Q(E4>A=)#(0$A'T$0*0< )$:A:BG$EN6I/=L8TN2AE)/[A==
M V(-B"L!B(L[V*\!<=D <:J]M.1!\^10\D0ASF1$CF"'A!/>BZ2CDQX<;M7@
M:L[9 ,M263"[7GHI$>SOT2EW\8NK=.?749%T\90JZ14J@5J.6N@; &YV$X?8
MJR%L?A"V/>7D"B.\2E@CDLGGN-0":9TXDH$+9Y5P08%-1QN239MTJ]P5=TTU
M? D]N5JOGT6O)WPU"K@= A'(!%A KD&Y-8%?$Z;@QCGN6!(;6Z3!V#*U;JR5
M>U[;]QS<DGK[7CXUGZIMEI[(J )*0N20#!;(64-0")A[BAT33.3MFR[+]KW.
MAXWOCFS[,"=C%C]L:U"EM]F<#V;;_K4T:EW"L[5J63ZV1TT8X MO>[W8[_TS
M6J6WHT6JP6I^8/5IRM=(+G&+L4&:!9K#);EI*S. 6$ZX2*W!,FQLJ09Y.MU@
MW?YQ^?3]N1R.6M]?2M\G?!#-L10Z>*0LTXC+R$#5HT)4.BV5(=C$TCC1NF[W
MNH;Z_EPG([6^OY"^3SHC6!.EL.%(T)@0#Q0CQZ-%,6G&B.&86KVQ)1J"/KG/
MTO+UB%U*C^1S[$7;]4>%![UH]J=:)]6!DF?S0N /[ZI%&"U*#4;S Z,O4\Z&
M%P9K*S&RTDIP-KA")DF#O+=!"(>)-:HDKR%LNBM0?;*QTCK]7)Y&K=,+UND)
MAX(;9A1Q8"^JX!!7N:<CQA(I@3%C@GCK8F9]H7*]*#QKE7XV9Z)6Z<6J]*3/
M "87IH$FI*4SB#LBD 9C# D3G4C>!W :,B%,@\UHJ%*?8,P]1ZKCOR-G>S&_
MVTE.CBJUXI4<7BQU?M1.)Y?X#F!@KA6'2:!_']EN_%=>KG=CJ_6NTWL=?:">
M";7VIYP+'@RG)"6D2*:?TUPBF[Q#>>,)E"?,E"\CFY+7]'/KI?=S\"UJO5\9
MO9^L@ D\26XHDC2!WLM,9&<\1V"5.D=E$@)0/ELKFDTWS:P5?Z45_]DSJFK%
M?SG%GW13'-6)>R918!XCCI5%.A+8_SGE*GA)G,MITKC!S#2+S(LH_CH?:X!F
MH"O5*.+/Z >Y5=?3?9;5"Z*\Q%$'3'CKS7U:^,V"L-$Q[3B U> U/_#R4]X*
M@XW+@5^"F*4&@>]2MJ^E* H5,/S?2JTWMGA#\'DQ8-6QTR52^[F=AM1JO]QJ
M/^&L6 LK%4Q$2A&P670@2%O0?1NC)\XH2CPMG16BGYQO6>O]\NG]W(Y,:KU?
M:KV?2L.2@M$8.7@H7B/NO8?M7@:4_VPB$S10 GJO&UBJ)=+[=3Y7^5?7EOTY
M3[NQY[O-TU)U0W=P6*185X8L@:,R7*"_QM;G/2S/'[%.&9TC5AU.EY]C&05/
M"6'K/.)*!.0X]XBY*%)(QOB$-[980XME2AFM@ZHKZYK4BOY,BC[AC/@8: Q>
M(9*$ 6=$1'!&?$)4.4N=@X6W52V(>;)-4BOZ\BGZ\_LBM:(_CZ)/>A\@Q$ZF
M0)'D)!=Y&HD,PQ89K22UEG'&=%9TP99)T5_1:<F9[8)J](O30=<?V=[CW(^U
M#IR\\#G)UVJ!_AJN3PU7\X.K[Y<.R';Y/IX>"*FPU\:B*/+)KG$!:6(P2E0F
M[IAC$>>FI@V&GTP>70=)ET_77_APY%9=3\V?,:"+V.W4:OY0-3\?5_-#?" Y
M(U8Z@I3+_;"$#LA)KI"PVK&@-*.,9GX9#7#^>ZWHZZ?H+WP:4BOZ8A1]Y]I^
M_OWG 8$E%DQ0I ,W^?0#%-VE@&@P8-<%9QUVRZCHZWS\L=L_BMWZF..E2L_+
MZ7\;C@>]_DEL]WLUR#S2:1C%.)1W"0<9D=?,@S'!+& ,;!R!6*U"Y!QLC$R$
ML$P1CCJ4N6P>PX.UMHX#S-]!N$SP5LIZKSVR"0O$P5! QCB/4I368V&-U"'W
MRR6D/HA<%:5>ZNJ.>E.>D^5_V5V2*LDEED@[$A$G42&3F\\Y#):_25JHW/%:
MS.@MN<KU&94&FB4U_/^ZD3#]H2[6D/=D2&7.X,5#9Y"/,TKND]?%L#3/*5E.
MY%X*)^HZT5)M?LT/O#^<E2&;$L"_PWM].3LP-GKG/"R2C!9Q&2P"NRL@'41,
M47AC";A4@C:PFM<YS#STYX7#NC5JUJBY9$YLC9J+1,WMZZCI@Y$^*H4\CQYQ
MGB*R0CL4<91&<9>"-AM;DC6PF>Y'4*-FC9HU:BY'1^L:-1>)FE^NHZ9(&/#1
M)R1%)G87@B-K 37A)Q%92L(1O[%%3 //Z#FW>JA91AI^ZUMX'/PW-']LC5YJ
M9W ".N.W_@?^.'J%$]L];+;+L5Q&%9KM$-O]-TR6,/I,RDFS<HZJ!TO>3EMV
M=2]L.Q2MIG7-5K/?C+VB&U,K^G[1/XI%._;+K\;R?+Y7=%+YI\YI[-H^3&31
MZO2J.^1O55VQ"V^[W7/0N#/;#<,/X\EIIVN[YT5HPIVZL>WA02[VSV)LEP\J
MK\DWM">PW-63;AA?#GVD9MNV?=.V8+1PYW(HY8/@5J,[#'+7O>MQDIRD>=KI
MQ=[FI<!=KE]&IF:[:G!_;06'$R@XS#!<W,Q?>-.-+9OS%7X_:X;^T0CZQJX:
MBB:^NL0Z$,1!_^9+9HE*)8 >Q"5VGUE6""$3LS3V[U%W-(Q3>QB1ZT;['=D$
MHWQC6V?VO+?QV_5W@Q<;G\C[S<'-;YS20]Y8W^.%J_F&3:'3+67@#:!.[.9O
MP2CL2P^A..KF+?._FE8+0%E*F# 8[B$L)X%B':*C/$IL#]3&UE[&IJQ![SK_
M\YM=M=&#J+=S:WT8^ SQF]#4X98=F5%1Q>1-XLP$S:RT21I!O8H,;/9B>$T,
M;[,5X', "QYK.,V4T\%9S#F63KK@N7#TTHH9(OH<0F37#96__5$,@U;<35,L
M&YGS[PKMRJ7<@T?_J]7QWU?40OGVGR/L3_YIVZ]FL'N\#1;)4?/;R?[YMZ]?
M?L)],%S'O[T/S1VZS7?__.=X^]C3G8OOY_^Y^(2WCS\><)^HX]X@Z1E%7%F"
M8)X-<F O&B,4<UIN%!'LN%.8XWYW$.\&UI?;@W<'73!B[]Z'SV"?A,]@"\MT
M*[WBEV;>*CL#>';H_?KFNG(\;!LIC9>KG:JTEN"U6_:T%]^,?O@]-'NG+7O^
MIMDN7Z*\Z/?AW8?;FSB=,I;*YU4?7Z'\)JZ0?GA ,WSR\./-\J,)TZ_Z3+%-
M@V_^&&^2&S^[[;8$;VK,'W7;VS\S9D&#E?>Z[1V'8(_-;2LE;"XJ8B8T1,UT
M(2=\@@K])P,69AZO-;K%PFRM^[WP^^CCB8O=ZL49:<QX]]>TMF/!J)M<N1G>
MW#34+38@<N<+EW"?38 ;<S4?^*(W)IJLV821:Q.VSJF\,QSR-_>1EIO>>6YB
M].B<IX4,<J[9'723BB45AYWIX,JU:,I3,NG7+(2^7J'P9&)PWL@49<RA<.>]
M,#8%<!\MU<D??+Q?ML64.[D[DJ;_!6%Z-RY+KR$J?GJR#WYD&?G>:WW?_OH%
M[^Y]N(#G_]S>VP$_\U#L_/G'R?8Q7/OW1%3\Y-OQ[M[''/EN[7Z%L>U]$C!>
M>-<//[?I]OGN^^_P_?US\%>/,I/\9$Y[))X[XPRB(G,K">R05EBA&)*DVE.L
M!=W88JPAV9,S8)>O/J[&I37!)26L=TG* ._+K5 NJD04LT(&'H1C)2[=(Y^A
MQJ67PJ7)Q/Q(:;#)(ZD8X)*V">E .=*)4*XIYI:DC2VB&L8\F45Z^<KYEMX
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M1)1[B3@+"5E-'7)<*BOA7^K$QA;5K&'F=I1;ASU67-\79I/4^CYW?9\P0D@
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MGB2$VW6+  /Q:9_YU]*&=-;UF]AE$" 6!7W2;C\Q1 8XM(NNG5Q?\FF2$6S
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M<[)TZ0C!4.W^S@NR"L.9]S+%G&E69E9VOJH^<U*C*^Z+](O ?V/T@XH]AYZ
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MUM7<6F-Q\Y\A.;,'$D'T,!02H;X6ILTL3'<PJ'>H]9 UCXEYU+_OIYFDNLS
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MNED*].'2*+LHC0HG"/0_29=/P62E49JRJ$3_#)>2,(&]2Z<GU]S.GBG*IZL
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M1B&0]U4@:R&:UJ2PK+-XEL%=IJ=I2B%\P2C.6CA74@AP(<"% !?><B' -R#
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MN4XHMBH1MLT.W%ICVML]7F+L&1\YCG]@V)/<3W'$[UO\ K/:2(8]8DDZ%%;
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M'%%W1WHOS(O8=HG8HM/(3K3EV.=.(_7J]C.9;=^>_7YY=/?IYO1V2_AQM;0
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M5.N=_/*-I(=@X&$#@&:QCGW57@8QX;^!ITU78<HF]D,L4!(ZC-!AZJ3#'+=
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M+(J>YRMZMJ<7/1]Z<? $_[2R3OO]_P=02P,$%     @ O8)'5@=_@(@_&
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M@PC\WULR!N[P^\>[JV9?1I+- 116A3=GZ,N!_.?0Z>4N<\^1D Z"_KJ_"+"
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M!^VL92%$Y7WKA<E[ ?7)6S:E13LUM"O8PA%]]/DW')-)'A&PY_EX.![.YM5
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M3LIQPUMO.-@6ZV-8+6].U7WHM=WN<1J1&P?ADJ><3X>)L)\?E'O]C2O?7.Z
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MZ;'/"0)/&6*DA)<568QIO3E@(X!]F@KMDFLW36IW6FSF\%="O&LPOM=D#KS
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M/'TQRA]P\GF8</IA?)H'!M$3 2,D)<@W8\F#LTE6]TLG5YQ(FC<FP&HTNV=
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M^Y* ^>=5:_/E>#0?-%/S]%Z>3V?C,YQ<YNB]F$Z1_I=_#U\&(IH4JXFK>&W
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M. ],RV("()>FSEZJZ6[TQ\1)C)+[I&[?Y;9BV#44S_QJIZ0>2ET>QOX*:\/
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MGHNQNH$YIZ>6K#T8AS6,27ME](8#?2,P"^>"-)UX=JRMY#<F3AN9MQY%<:U
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MU9?X$/1]3[A]?_'V>Z(!EXNB?<M%I1T$VKE V;H>:S58,H94T>2UR?8W/VL
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MHB:_2J=Z AC.P25M@<S9I) CY[+TS\U[D#TS=)>J;3X0L.%BYFE_QAI7Q]-
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M_WO^\Y6+&7B)5EEIP*9$Z["F)M!)"4(7YSUGG(?6\=56V(^.<GM1:@\A_)7
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M^=G9F_FB_"-T%KG(AC#01I)R8@2PRI8+V:56W&A%[.#F9%4.1[CSUT5^M;1
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M^J\CV07@)US1^'^P9? " %K@G5(;,9OG9HEEO<C6YLI%5A+@@B9(L^$?G_X
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MY)KFQ\RZ.69X FZEVHD++3D0XFIN%^(,I#.U2LN2#^0S];C+Y@KH7-TNXTH
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M 7<\4VM(/I<9Y+VE-@A@!<XBX 6+&^<D0\2K/-T0@Y&B'\-1MAX/V (EL\M
M6:[@4,16,V#V@52Z#;3;JF6Y?*MM$T6H:>MX)'N",:.N<+&92X5@PZ4#?1,B
MMH0-#L?;JIY6VS&[)T0K).EP4+8&YV':_FHF84X$7;44QG,V,D)ZW+"B81H"
M@^K#GDZ6$ %G[:Q%(!E5C0I4)M*"6AZ;N>G/*Z42W$:R0H+WIZQ*'+&C5CK6
MJK%F+%B&Z&(DFZSXK1(MD+82!.)IHV1)V L*J(5K4A/FC91$QN1&AA,+.9CP
M1L/>8J@24J&LI82VBIBFDW;%Q].VN%_,R$RH$$,= ASPX6:]T(Z##!\J6ARJ
MC8?=WFR<,XBB4W42$$4J9126&3%',(K'K[>!E34;^4K$QB@U:R->5!2Z$A#\
M;(@NILQ6)T1G0BZ0U5!L6!<]4<E"9BJ.#,@-0-V?EMM^5PMR4K8,">*3D +>
M,<R(,.$JA$M@',S!;;_H(CTRC+D9FQBH0!67(P9R2\13+Q%Q9\R/0Y: *^E&
M"S85R\)8U@XLGG(%H&(T)NO^0#PCM= 84W;7;48^ZJ"MUHH>-Q@+22JD+1!P
M^[58"N1(^60JF6<DR2$'DV(0QHH"H\'^>A4D30W-@\80U<]#$:X9%#'5+E!0
MB2:JL:*G"7'A6EN()<TDWC#+HH6L:[T]7$-F4:+LM$)EL:HVW)9PB*ZY834+
MI?%2L9 4]9 U[Y71.&$)\)&D6*&2D09DCII];2_M)R"E; 4-*102-+ LR566
M98GP&@1ASWH4* NW9=APTP50MQ$A+PPG AY%:@90$#L"%;/9"=/>0BWB9FO!
M',>A2BI8C2<<K%P'#@ID^(X87@4I?2"2!<6+!XX3:C #QQTA,:;9^(AD-5O-
MCDJF O%BNPEC<30-%WUY.,$II,?6AN(-6*F'*-@6!JL!'^)7#:#@$4+%2L .
M, +(S.]%0:T3!7MTQ4&.3@&O!0JF")0H(L %NP!OM;P_;X]BDCEL1MJQ0"&>
M*XMU$)V1LFZN)+A<Q099PQE(= 6K;M*1#IA3NJKAY584*]A%&K>FD[6*(+$H
M'E ,-J_A1MGF*#)(4M41)THYJE8H 2C-:$A+)1L5(2Q$$M:<%Z?S=JS<*!5B
MNJ55#(GUK$<JY%.JK9300$QGW(T6[?-AA7#%L*%D-2W[V+K8$$..) IL 13Q
M)8.26Z*&-RVP+@193 _K@$M!<ZRL8?$Z%7 A.AYD20<,T6$+'L3:H6*IPC4:
M*"'@YJ+:9-WQ(B35HR!3!;SB"0=N]D7U=)2G:K50+0_9:V:76L_SA7J[9,G6
M<)ONS'O#A!PN8 T]!/)-5574MB(:/M4"AZ,^"!?R<$<*WI@5MA9\JL$EZH#K
M' ^>"I%T! JJ#;!25 &.A ;Y1XD*IGT070L'DI#N;?DTR!=!TAB<;QKY6!VF
M+>T&D$+$[#+7 _%D$JJD<;Q!\XS?8X  X\RT6GE@L4S<K(&$HRSH,0.* O[4
M$SF;6FDYV'(K0C6@5@(JEZQ9#ZBD!Z)SC< ;*5SQ%E VI7 :%E,\I:P<+M&6
M0)#E:W@RZ</KK(<6Q;2EFDG5(9#+:(E<O1%MA?,9OJBE/8EF)^4"V *1#A41
M$.^CI3B@J!B",362=[GPE#G7<NBI6JP599/95EI1_'G-4R#H9(PEBO484[3
M_BH<*<&$)QLHV?,=W^MDS8X,3,=;:;TH,;:"P-:(7-+>-BN2E)$:S0)&5@UG
MR*_6\I*?<80-.N.!.+3&>H!'UG1?@FIRZ:0##^4[OQD5 H!Z>\61]Z5M0HFS
M@JROY*8I,>[#8C:DG"H+B4#*8JZ'<FRLF8BF53VE!_Q\FXI;R'P%$<OV+*FY
M0T%7N@T\$L2E8:7I2,,V$&7<%8_<8C*JW^YK>;!FPP[\7M5!ETJU+()%8Q5G
M,RN2.2M:H0MPP-T&@:<<\I2<&;,S)Y<AH+VJY"RP9D@1_9#:MB4QSFR)9]&D
M9H^AA;R:#2&8O^S4TK4T52U)%LP*-,@OM&#<P".V N!&(R6V@%JI3<T'M#?:
MA!%/S.HJ9TL@)VQW=$X"DE'=N0A<*S=%O$A7*29%=[QYA^,N!2T#C$$/W [%
M@;.VE"A-\ $IMD'MC!;3OB(+O 8CINPIDA;:;H=6P&.4R'LB:8N&MHL"@C7#
MJ7R;L(A,(RMZE(+6ROK,+9"464I6N%!L:F( +CK%WAY_M:CGT^FHI11-Q30B
MJSJ3V5@C+KLL/M5:"D:,8"G/@7TY16N@%M>#3H1JBE@Z#Q-P/,:):J0B%%%?
M$0W8;%)O#Y;VAYRY>$GS^3$/H%!J5.%X,8JFE8(O8*O7#<Z'RF8H3FL%0S2*
MK3 N5K&&R-DT'!4 _ ]F:KB!)]]IID!;[7#)!_9@*2!MN$#GP%LR&XR50?A"
M<,66QJKF9BZ,TW(Q3PM(72$"S6J4L?LJ&LRF&U(MT R F-5HQ7$[*]B]2+Z
M^(DDI=0L!%MJ^&B#;51KG,KZ,[S \GJX8(GI0@II9M*@_!;*A68DP2,T$3$7
M7'F;!8K#P.J+K":R2DFUI+0"[\VF0@6^SK8X)5'-6'*.2D522#L<KD>IF,NA
M&/1 .=D)UY@3QLMMS0*#4$T$6R4C[\QTM#<.I%LW@\2VDBK';8V@.<@W77+4
MDV!CNM-6LE-ALN*KB+#?UF@Y8"RG1: H:8%#89=:\[(1B!65=BH4D\R@7C#J
M%J5N5]2,$@S*DN)/A>U^I]D+@FHD$O0V6+$<5BS>2MJ.!P1@TCZTE(&S4:<E
M6S ;?BC#\T@IU0A'B@E+H-S;8T8POD[I,23.4366]I9:.@)E6W&/K<F)BIAU
MMV*U$IF,%*,1!Q6RI.2&/]IP)F"[CI;=5KNC%?1H&I;$DGC+UMM3P\)XTV6+
M>I/65# $9R-)@27,0BB/9LB<K\KY?6:XC%93WJHM"]QD)B: @MB/*[EZN)G,
MH]EX-:JDXE@;#@> 1R*"Q4@%6(HY!SN8:BKF)AO1".W#="%6\^.:+:LA=B'B
MXU-F*I9UNOV&.TG;\C&W1,59H1-[?^!F)RXHT1#<CH.LKN5NM3$@C7; &8IH
M9#L>1>U.D$>&?%'97[ S7F? :..X""4<*BA1K2+BHYW.+ ^E?5@)5/,D#NI3
MEM>$LB773*L-FZ52K@8+$H=AOK15313L 3?!U*HJ\ 1)1%3M(.K4S*#HDG-P
ML02*+G^DC94*);S \A&2;;9 )8X'RH*:9"U%JNE291#0@*/PQ]D"W':*>#MA
MJ(Q#!D:4R40"4#X=UF()-NHT:M8V9/&CK0!,0@C7Y),E;\#;^38/][2A=HWD
MX\4",$T=<^M0V&&M812NI1M%.$WG*HYL(:-169ZIQZMIOM!RA.)PT +"J3G;
M%@KF:BT:QL0XJ-H"E@9K81,A3Y[,B.EDU,=CL-N>KN/U8HJL%VN:;@0<439@
M=A/.:-07+S0)7SP7UL)ANF @-B&.(;Y(,!LAG0X>4"H60?X3$E74AM=M]HB&
M:W32W:YI]1* Q]UBI"J*X0B2*H6]65F4((TOL2C(0N0,1-D+".SC'#H<$-M<
M) AR\KR?MNB59"D&8@$/*AP%1ADOW$B'%3L(YK)A@<H<C#0(1YTOPFK5HL%U
M+%=P4)#/ HIAK$7!EH(91%"J!7RO#R8S.$KP5!I4]7;8WK1A<%.IP1#5RJA,
MJ8'EQ2*6$Y*.:#IFCYD]#M%?:7!XR4I[O98D+\52?CN$6M*D,P<\DLT-"6G5
M!><3K)(-^>LBJBA)+6/K9(*T5XO 3G^039EK<%#'VQ$*+0M)NQ[/Q1A6XX%-
M9#RID%&-)U$U4*\ ._4[ZF'8G)'\,=P!^]UQ77;@,,ME),&CM^NT)>U0249*
M.D -T3!;8U)$*X'HU?D&+T7!Q21&UQLA5$W5U!R@U)_24SBL>S BY?0Y5:T&
MZQDF*?"BPX7;VC#"Z\!_T9Y&ON8)@_WF!3X+V^I(#6BR;&G6V"R-N6%:@=(U
M3@:9J@PWD+J6RX0<Z;S,5!JTZL>+V4*#(>T)@]1C(> /<5!@EHHVA^QB2^X<
MF\X17A?BK\>RKHBL"*!^K$8(,6@%&7[% J4C6"(%JZR]B+@<I9@#(0OY7+BB
M)F6F8)7]<"UDUJUBA%190;*2C4BD3<!^?QMOIPTDW*I',ZQDN"P>4-=CT9;9
M0[03%,46$=Y1I?S^9*-EQ?-0!O8'S3@):8Q%4"T$*+S]>EY1?5&S7JN'BKA8
M;M))NA&&L9"MA,FX&?"M7C5L!;?3PPMJ4^9] ;?9FBB$8J%:2^68I 8RGA]9
MU0J(;M9LAPF_!T-*<,6.PB#V!T0O CP7E.[X-]I7@_U>)99BT\ZZ+EL51\I:
M\N-$'"292;;&$.XFK$ET#.001J150'SM"":+R4P \EH*K#\<,6-DII9TQFK1
MWA[9)8,$$">81K@*8F@2K36@:,Z:2RG1#+@/1T(6!UL(.2JXB"1(;S230;%J
MV.K,2*Y& 62/ 1 LVG:\&:&#%A !@4=@;?%LNXF6$-8:RZ8XCVJ--AN^IB?B
M$$F/WPVHL8#>*N#E"&=)(!8'U]#5J*\%:DW:ZVY1!$W3 ;<.-"0F%X,0G[7;
MVSK6DH'AIY!<(-Z*1D)(-&T#KC<.Q>TN"&ZW00[G3VEMM\^G^G"RP3E4)E\.
M^3DH;L/P/(+G\=X>(0MG'(PY$LVYHWPP;[8UXWFG*ZQ!9KO/'J\*6 :KXV%O
M.$P5?(I/":4K&IC;BH<QV$/!@;0WT\:L> $5BT4SX%M4$RL(EE.*+LR%.PH.
MS>M)5C1(0#.IFIEI2[PK##2B)2 :&XZ&N$26:T)JH:&Z\6H-1)E L=9D\YX*
M%VB"C"M3+Q-Z :&*M@)6J$3$8"3&E[+!8).*^8KV>"U0L[LK55K*Q!IEOB87
MTU@18@+M=MZIX7R-;Z):%56R!4H/M1R]/8S?&2_ %:PN 4\B-UIV7#*@N"-<
MIR)ZM&ZOV/ET2;7B'H(A_14]65?CC32I^FG< C&10*-8(=T)P 2^*2NAWAZ[
MBZE6"@9-45DQF\<K&51OP8D(Q DU-L; 97LRQ[+AA@&G/$H^%!$ENAHJ:]F=
MVB,6G1@3 /5"V)R7]3KP2(129$LM/A.%PB$]CJ1;.<QKCK>T;,BIV50,JWBQ
M.N;WQIA".527"]5R*Z1EW;_Z17QOSS_[HC[F;FLZW];J"J1JMB*H,9B<3=?,
M,9@-%@H\K,BP)V$7PIEBM>TE_87>'@=7D^R!:B/6;&&Y4DW.VS1?R]XHM%)0
MK.'WU+"<N<H@9 V.1.TH9E,MP.8:S73- 8N^J"V1R2 P*63CJ Z\;V]/,AO
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M$_KF^9V6LSX__!*L*4DZ_^'L-S7?O2?\.H(9_AD$"$62@\85 '_U9 RA0Q1
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M*HV=MC__^%&*?Z6'X/(PG_/,%VX)P1@0D<7I90_HZ30?>N"G8>T$EHX'4!N
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M4"#[6J;=(-&'^QBLW>O8G7-O;76N.Z*0$U]TFRK-23]XU7R1)#SNQSLFL+1
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MBZ&:1*%P!;;(-#S "G!<A"6!_-17\4/,G>FO!@QMA[',=[E;XO,1C92R.>7
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ME27WBV^V1<1.*S*!!,.[))HTO^<.,^P^)-QA'3+@38XF<2PFDN)T27&!HDQ
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M+UMP<&Q7-4>:ZNVR@XD?_#8U?30U>>AM45,*9UL/J.V!$'R+,,]H0V7(1TQ
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M2FA^0KK=^[R:O+SJ.^?R)O7]C?0_@/3%A'.?13GA 88@+G/A[VF6N;D)R"Q
MN%N7X$8 98VG,$":)3X QEAB@!4 G,>HKV0 ,ZWD-NBA]BN FE6F%GS^/H#]
M.[GDD+<PLN@R-8Z]'DTY<@:Y=GG@O4DXL$H0Y-1'!!=RL, *\#&,:YY6L$Z^
M!\#RP-_=X]B:K5S9K_=AEP8(H82L@V%PP!X0/B,4HB;8G]WW)',WFH#G/ D9
MK2F6YT6=F$>?JT<F1A>^87U,U=KV 6*)[..D<.*-#UL9SZEJ5FP9*0ORBPY>
MCJ<VK34WYO?BGOZ@!@HYR(HX2!]#%3@54#BH#N5?G*H7.MGG^?+=571BOU67
M=8[>.;=J]=%$L/S6SL+^WF^^![X)9KSX'LJS7O]>GD$?'O,>O1B>AVB"\>7!
M=:QF+&;+$AP]:N1N!%/N3^$$=[UH%W+UBTC,_4#^R?W2=8&DH9YC#ZW!@FN9
MNJOUQD?('A+<YF4W$G1?AQ\^OBZ@SA1]VL7H"?.N0S>BR4, > 8#&QP 'HIM
M"<8ACV"Y"-PO)$%!/JBI+LD1D&[4QFT$$\D@8)(5-21W:R'BHPI[GEN;O'Q(
M_D\\F8NXG:H73F<YC"FT:7#^T6]#$=Y70YW@SS5W%SM813ND0&I=VGD@C;P5
M0T^[J][?AP.(O3M]^Z$,D#-L#,Y'L-[88DWU)VK@V>FU1N<IA]_3N<Y)6^6
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M%F]!1V?+PA[MV+C]<J4F^H7E#K4;!K&:-J?65?F^.X3(,?CA'^N+FS.')8N
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M+QISU)*=Z)F* W/-#8]%>9R,R4K[>K(OEXB*%SOD)T9MN?K,9'$&'TS1L6.
M2J ?1D6;C!$W%2*EAM:5-,Y3!(9W3(M2,HZ_VC"QW.0B6UG&$3A(A404?N2M
M=PZ4D)]R/X5H_;(D$1,T5#?A'4YHXZQ\OHA1,=*F<3?4GH-#@N/1/OKQ&Y'8
M."D/M&IX*S8%(DCT:^!J*F=Q9NEUE8W_%M5UKO15RG!_ZZ-V7Z/8QLX<R'9M
M6AF&*KPQ@&*A@KVQ0_V%/HCCM?[DRFBH?) 608S)AR["]U!LE*!R+K%%=%JB
MM\=AVCLVL,!L3-44;] W&ZO=DF:2,;&TA7*L@X.?C.=F)YD\,=<RT\V=VHA:
M]>6^%&E^#)")#ZJY_].PD $B"V7\6 ^M/M&(/5CBX+L%]K/>?T< <2/Q0D@6
M>+U)&WG/MM,*)@R'$$32B4K-6R8![@Z>E7UR"6G%I8%(CHH/G2EA:6L@CF&,
M&\0&^F38!O^-8*5.0+S*_C(G/W[OC23KU\5579E'19&N@[?80.A^^,EQZ.*9
MSH6^OKEK12MN%/%O1,BEI!D< D*<(4GJT&+]HW,FHL(2FE$CB)M8EO4H\\8E
MX&WI19#'OYEJ]9^78F4R#:5R"Y%X7]Y$UL\2.MY-N0J@7^!"$7,\VLYGYT(+
M,.^$SGT+I,EGQT^_L)EP/+*LURMQN^8]QG]QR7'Z K&3[VEN"/NN@]K'MOHT
MC;TX3"#QL!_)16WV=F\W9-VY$L@@MN7!PD.!FJ:-AM![;J3]N7%\5R(J*&=:
M2L\/MBR?FC>5@^< ;WO1:_#/'NG_,V[Z9E%,2 ?H"W"1XTH'#L/C</2,_4A\
MU\G5^U,J"%NP^Q7?MIGX5<R/'Q.#0\32.V $V(!Q64^MN+>%F;=Z[JSZ+G?>
MR*'."3/^1Z+V% H.N7@<YSRLWJ";319M'+Z'<2CF/;Q/_NL-F^+WI<(A%,4@
MNGNML_T 031\O?.YX*F2?JI2COU1D;R[(V^K"A.3XR&P..US*GMGM9CEWF3E
M^V<5;5U-P?R M(*0)4?[7L54LC??@)2H-]I-Z"F""D55G!Q[;P=0]$$7P*XO
MA!&OO/E:XJ4:L2QF"TF"?6<\$L'7PC^5516_UN7,P6NY?O'[>.SI#JXW*?W3
M03KQO?H:VG^8#O@?T;CLWW)#RP!D5;"^BUX7[R!=F!O?M"HFM,R*N_MP92]5
MG&@%4&HLE"R"K3>K94$TPMC=E3*'^69ZD,5.^L\%A"LCEBZ742Z?W+]8QA6M
M%YQ1L22KKW'G#UDJ5]1DY\XY" ><-]L;:5D0<+UK/=BKI*KTE?6]T.=[UYG+
MA78=W%L'ZB_Q85\LH%C.(@L"ZOB6.>V3+/K3)1V+?140 [U.@2=->D_09IS:
ME JN78!P(YVA0]+.@SVD%[W50J39=0%Y[7X&2!?UR4#&7-OT6+36:,3EPB20
M8]7C'8_11[>CY>0\HNY-\@"1PYAH\D(JK;<DSQ[W]>8G>L;C;(B_T04C_?KL
MQXHF$$ [K__,F7[WNPS*8-%Q>&7ZG('3INF)I5LYD2[25T&"4X_%?NKA"4(L
M AP1,'ZW:V1($F2Q ]*^,1O-@L<N5?:O[WW?=H/WAG="M?X4C@'B..(D#=HZ
MC5%D@'#!6((^.UG//0'F1Y>M_5R0T5368%($47A_JK7X#O);FOT^=:HV"^&:
M$XTSW\YR*T'+$1#.K%._FQG__U [:M4>0(39MIT^"\ 9+ ((8:KC NDRY@RP
M=&-8?YE1JAIQ(TPX)"_O.>I(P*YGKN(=Q^(OJ/2J'4$NI&S%TZ[D/TQ(4+^5
M\C=%'/_M(_T/]Y'^M>D);1B"4>>0)G:RY8-#.(=IVEERU >"KB]_R$7:NR^L
M/?57'^T>JUA*.^ L@A%R6.NA[S]/,4+M(1_I' \+=RV[3CP<7&,146M[IJ]6
M.SPY>D#TS6+(T[T/J>WH*22/.,[>9O$V-X8G73_O326\]W["IE,B _1%*K66
M6S:U/B)&A;YD$)66-"^ N'KS\^D1!\_X @U.DV\V2[_91'G[E6>YJ8?$2:Y%
M?<XEF!?#?C=NWK0K+(U(ORA@EI=VUSC^GH!1D&+*VOC4Y*ZCM*/H9H"HB: 7
M'V(+.UM.)?=)*F/V>K]-C\GFH<:$OM'P8(#NMQ['#-K@7I90!/B?&AD;'\B5
MWKL,&Q!DGR3(%?*,$W)BW$=F+&XF95N&VE:9C[*O;LRQ1D][(T['2/%O9O4%
MD: I(=>O"A9X.6.D8][T"P!?,!\P?ORWO@ FO3V[%_.-'WD(L\3' &4H7=ZR
M_Q42IC^Z@VSWG14ST?G\N^=D?Q,G%'_]*U*BS3Z[M1V+??NW=J>5V/FD&/FB
M]F"O+"L26M)7[&A^!$#J<KVN3P&90@7\![6./5;;Q;3="E4?2A9&!T*L*578
M(]XB?)V'X*IWNMLX>:5DC[]9?,5F>5#QLB+(:_'#/=KKY%>*N!5V_04C7MGM
M"0[Q/T4DUC=(H\#7BGF;3-[?2#I!=CZ)>DK5$YFS[FD[E(;%P"I3Y?&^US@G
MEW;JFGSK;($-88 M+((&\VD0RP(\6-F615M]##QJ!@7,Q4S$3E"RSLVZ>.>E
M"G_Z:GXN_#L-ROW=JIU_[DW.(& R&*"1J!9( 3*D%CN>L%QLIR#)EIHR>M9!
M?'U=G'IX1[=&G<"&I"%YYB]]"-XZ#RZ3>@E>BQF$#8I-@P*K<Z;9HIZ!=OEM
M4IZ\^IL] KQ\S/>#&T /?[ 6Q, ^:WW A"6)T-X@1.S&SA"24D42<NWRZBA=
M7S41:]?16J&/ZPSPFGMW(6;H#:C2\  &R!'I1UC8@L5:YYDN^IEW!R]%0=^$
M$$=3X8?#O][EEW[/\_F(?$C^(PU.?;-7?T0-_LR%A$ (UR";*IU!&)(,##G;
MCSX&K,P 8.W?(E<>H;B0^'NU@!#F6:H!PFSH^7> ][_\QJ1P>U#;^[)PR/UE
M[G34<_S1 8VG%RJ?5WB&E!J+-VLN;]J)L!]"BQY+S(EA(3&E N)[#]&B "G9
M6#R>,3QJ7IQTB("/F%=<RX5X$L6M)59I<W&>D_E?\*J+B*7L9S?90+,JXAT,
MD#5JR*T>6RA5[P#91S8>S#T$5EQ9NL;:G.IR@54VHXH?!!J_ '(1[Q9/NE[U
M_<3+W[YD=MU, LW[GF)BGX UAG*/,S\N<>8@!VT)*%SJ<AR>7YJ^&NCW7L#L
M17UV2,P=T*Z7X@1GTC=:P3IZQ&#2<>"%5/6"RM$!^6')^,[H]Z6=O"U[M#[8
MW.[%^?9=4RFBLRP -H65 7H>3USU!M=[C5!WCU=%34/W6\M5E;3%/5!=$_MX
MM:-]-;JEZ:=1HWUQETV^?$]E>Q__ PJU\W- WIBWC7EQKSLE*W<9+Z(;_"CP
M9MI+[6?2E1$? 4.TSD4!L'379UH-P"4<H7YM\2$O;Y!7&S+?+QC[[2<]Z9*<
MA"VIJMY2G9QR/W6#  A:_@S)A9:LK$&1@EMVPZW'$\)%K_7 #E]LW%1X_\;G
MI3:SX6WRTQT\QPX=_FD ;&$0#GD/-JS4@"F!U=6(-B/X$CR2WE:)EGGN<50=
M=YU6.R4@H"/X*=W4VI0#^P>YOO_"W(A_UXT%H>6Y!_M1[[ 6[>[[,[UR*I?=
M2TM*_;UTE/,O9F>N"P<5X6 ['& <U48VR60OW=K^$E^U1D]2C$N<]4O*CD$/
M80*S*.@>QA*)>XTB7*Y"#NFV$LM"Z>U9\ OES_)JJKTCL1>,>:PUIY0;73Z?
MNW8Y7^U,EYAI9O-,):(>7+@&*>3&=[XE0\ZV9I].6+3TWC1;MJY[Z3=JN#L4
MZA'J,)CY*\5P_RUV^R<5N_U5C)6()A.6L02W\>:2B5![9U'=+XN6\P]45T'G
M--;OW>'2>O#!1 .6L%V #QW.H5B9%Y"-4BWNC5P5RW1X)S\^+?3#!U=:GZH5
M4[.EZ@),JIE?"RK<-F^53G3</0:UGBU#Z*!<Q[',1A/W26$F^S,5.O311;N)
M$!,">ED6#B-B)N@YQ(6)VHJ)1;L-V(*7WOD+33&CBL*7H824W?KXE K%4^@)
M?HV'T=F72TQ\=$I'YL?RJ)UKD_O]TY^G'I#;FUF_3U/L?J2QCL_VN(<[_W-\
MZHLD(.G[U">D C&%J@63CU(]'"9RRHT9H(;*"S=]LT?5[JWNX,4"I"V'B:<^
M\BH#% ,CG\3@#S% ^U>;#I%GFCP=&:"]]X(A6R>KLU86%$XCEO9N)E]4=?K4
MX Q1A1C5^P/F'_V5JD#XG&3U/,8J06-%3T[O_KKQS*9OTK)%'O+;,B_\?E[4
MY.VH*>FK>>?%C&+FS#+PM4BG$2G/#2=LITRJYC>SRX5O  [6XX"'DL4S\'X,
M$(O-1#UY8;L@4&&2=RC?6&[SC/-GLX$AZ\TT\.(^9M .F,# 5!Q=-[#-=?T'
M'E00.R+4W:$U#\G:B25#7[Q_HQ:MW_'>>30S?\"TU>X4YEP56J4_%%@0R_-K
M?X4<6 Z8H-TYO$'G5JCWPUDX+2!?*//MS"O2QJJL/_=,WK M#]DN"52.=%A)
MJF2 GH!YU\.'5B>:@R<6V?3*AI4GU'GOG_QD\^($DF2A8S#W)NP"^CT.<2HK
MXEY$$[*];*G#*WAAO@SFV8%*)*,^%)?G"&4]Z3(.K[D*31O0)45NP/(VM&F+
M*14HX'NYBL/#P ?6G+EF#7Q3=?OS&HD<&ZDJ@O)K=V^U:67'S^50[H3:&F<<
M+4Z<%(YWN)>4A3:@=C6.SX\O7/;W+O\L\2XI5!;?LPJ] *BB^L%?+2/ZQ?&"
MK]ROD/7,I<=4V>]/V-)F?M<A_ILQ']&??B7I)XUYS1=P&\2^_&I8)GAR.<"<
MO0FZ_ZMMK7#7VJB73B5/3/?6J,V+&K9^Y@-*ASXJAQCW<>[8G*'H :_+1)6;
M*"OOK3VRT$V^0VSUZ):[.""_BP'R.,D;?WQ@V:>"A'Z"M(4,*DQ@\$UG.B?0
M>^WUYUY&,4 <-^0HEDD-;SAD?0P_[VM8O,\636/ZRR2*/"[-%RY7Z/=^"CG0
M9L@ -]C53!:G7/#IL4_:7]!=(E9X-36% 6JLG72=QPLU/E"H#NQ;86Y&DA4J
M5[CC)\>7PQV7.%"2+8U'FN7UEUWW'@<L<[[X%C$E,W#*9AKS(RVVW" "RAA,
M;,<5:6_%/I8+O?Q9.<(K=7=OBO52XT6S+\C:G!XB>E^O[$*H"$G7(5.DI-R_
MM)4S4__+UD&?/5E*>#7N?^D\/[0A#6 >]HM>)$7R^#MRF9:=2(GQD:V\Y[2"
M>>,037+GK:].QG1N(^40OV\_Y1I(?*!'JAZ%:W71I>"0+BITG-)4VU72;EA5
MG.C]-43F*<0_X%C6U$&UJ:.CZ$]0\K&,Q7O]6V$%!*1IY2>O'>M(=I_0C9MN
M;DX8H\:W;'N&PA_2E/+MQ&7<EY[^ YTC_KV)V!<P-LODXR94*=@3.A<QEBHA
MA<>0=8H_RH$+&*!ZN1E:PJ<+(PJT+"^K<Y^[4&H6X53U# ;(*)@!DH#2\>AB
MS"_J!V]2\4,:IE2 .@4"[NY\ ?);%@,T^@K9J(A<-\6L]#) 2VTTZ9189;]H
M<!R&R(:B&4M12R"4PG!R )2>PTTW1]&&8.\,]3N/?=.:=O[9\U+IQWL8H.PF
MP, #?_4TF8OF=/MX7G\30+2#<PQ0WQT&J-V  :HZ]?.'1V]9:_"OL!DB[@&B
M_]UK0"8$(%NYL$U[Y(8U(DY?ZQ>OA+)C@/8L7(K=/T.UC-3&O+ BE&M"+CI]
MA@C!TM=^?,%F[&XD+@"Y!\$#4_?)EZR8#"X?_"'<L/R0N3C32WCFQ27!Y*'>
M+9,!2UY";0*N9L_ Y:XUBH2H;@%4<JS[\^ZG>[GS^S1 IQ:^>.6L77_@_"!O
MNYO!'R9RF,R@J$?<Z"Q" ,90-"K)ZKBJQ<KIK+VP0Y8?&" Y_ZH06K2VLLX)
M5 (E<W"> 9*J 6S.98SS?JG!#-R"7$C,AN YXDYEQ9.IC^M/G'/(XJ9$3-T"
M5S>R)012Y0?6*<M<#K'Q[](]7'TSYV5J.OH^+=V-F3"Y\QG?$MGT0C@IK?_5
MI*_9X=B+WR=1WHC[Y^9X@ %V5B</<5I8'LR8/%J#C^56W4MD2CLZ&O^M.OF-
M1*\# Z0BU(KS_=:V/JRU9!)00@$?L957?!?GX>S[;O[:R;Z\3VR"2H&)ZD)9
M_%RGU9B_#*SJ 91J%DH]%$QG 0,KMW"CA*PQ*;Y8R9:EBF4;NX*51#U8C+K?
M4OR@H V0+LT6K;9OUU7TA"1#:#<!1.+XS::3O^8G;*G]R+-<V:DO4/N1"ZOZ
M#- 7B?G4"NE!:N7/D.GW,\^W;.C[ )'?!4CW<QH#]*R%+BY%OK2=Z43AIM8C
ML"1TL6\J/4&CR#F"WN]%:H'( -"U!;#%/7-K9$!/7&"TCX8Z0UP"#3]7'?V_
MT1CQM;:@EB3--YE_J+AA/LRG(3+([U0'_)W&8*YDIB:IM85_PGZGS5H_-QH]
MIT_-O'R0NJKPQZ]T?HK_'WDC3S! #G!8Z(Y9KWVB07#'">>#^+J57,>)'BO$
M&WEX?XME"#L&/<O%Z?;^FQ8308ATDXRDR-BBK7#(_7/Q+%>2[R4)2UO<!(RN
MBLB#NZ[8 XUL@_E;WPU*_&^P^U\1[&9&(7K!8&"KAU"XYQ43-/7VB&*RY]"(
MC"/%NMV54QTC$1+1I2[81W:<!'/;"ZH2+=/S[0>D?++F!Z0M1J_2K*,'B\!J
MK<ILS)>WVNG[F2A&X& 4KQ5!,MJE\ZVWB*9N8NC*S?E=CB\CL&V\(5X'K/$.
MDY5T':)5$*9X%9KU!5F9[%YUWC=CA6R2ZN!& Q'V/P9>?47N]825/3E'!^O=
M0SFT4K.)RH:. RN)$8-X_W51-]@'H22%7N1]<+#.+3@%LG_NI&@_^HL;_UWJ
M^V1EG\);3Y(>R]Q:K,/1=\#W#V!LEX,>VCRC*C''^6:JWHU^LI)W'(RPVSL;
M!)%Y+*W-3"HB.=.2UL!#X>.JB>,J.R%?S=FEI[^]W.>\M)=O&H[DN.4Z=#$3
MQT)3;[#<'>,5M-4OABSJ><@ ^2ZW55>VKID[+6'8B:E-IUR:F>;/\<)XS1YA
MUI:4SF-47T*]\K-DM\*9R>IZ!&;_8AJW5I$?M'NM_/!P_QA7O<;1$!"D<04J
M&M^;$D2OS+CZ0] SKLBNDU\8(-5LPT2=RF@^QZK2=<>:$=^A%JHG^6PJ_0N,
M10Z]=R%BJ:#_V-D7H/81[?-AA@R0'<\>P?(Z7#SU/+F!D&%"!A,5S CO*IBC
MLFW+]HQ=4\7[96O79L\;/5GB,5DN@4-_JN,-;UP.B*!J?UF$=[C5O^3LG0Q%
M.%2!=+DW;'4DZ).JT+84C!#1X1FD^#UXV-263@KJ'VGC*UD0&(B5'DW=VC_+
M $UPD^0=:*$AT>_),7F^R0:VF),2)ZB;EB]D5I:"3J&_<5 ^?1]4I]R@[]V@
M6 )<IX#\0K3!]\'"/?^)K(:Y2&VL1/HF:!?)[/%^^M8[U=6C-$WT3-+PM*Y2
MX/1SK2#;U\H/A+CNWOYX+.R9"7Z[VH)4'$[*)[,[>_A((^N-QFFEBI_@3$+^
MFY(@.CYH'UZ!F>FQ^)9N7:T4J3A)*RBVAJ_2<3WLIU)>(7+GG,#X<M]"_JD/
M+5\3]+.W2WFW=,>18SKS4YUP 'LV4C>O_,=G./_J]8 !.JRZSUMIDC5VB&HR
M#F,GATE4&=HKPDU.0D8ET[(V=AVRT.#<L0)I@I!/>'U !3[5D:6)FA/\VZG-
M>N#KONF8A3<3ADQ#%XES_;6NY&0 V=8<CJ3HP+F)''JU\]='S L>W:E]W'XH
M"@([8S(OQW7S4Y(AXC#<!"#-^E1OLLZTCBONQN*#S\H3D^H1<B &2'M21)_\
M%KUC@'H^T]O ,++%L*"ZQ_GVA.ZCS*.\!O.Y.\#12%VY@$G4\R0!<N([WX#&
M^#W!$_M5D:Y99EH>8 C^8YK1Z? LU<X"ZLA/$4"*#3& OK>*(#/QZD'K[91Y
M2];:*-'.+BDS Z_[35)Q/()M.1%?7;1:D8!WBGML>8Y0V>F!@W#.TD^7W2P<
MPB;W++.G9+4WMHS&,7<7&QU2#B'_M"7Y Y-2^,E)S-"",04<JBR>Y^UI_""B
MU</I$D?$0/NK>^<5!?4#\\6G2=F7 OX!EXH-C8,UU:CC%)HAK.06W7O<M0*]
M)ZJ-6,L^&SDG22,KYRK8BX[2@ZK%)AY!^+QOZ/47#_DW)^8,-SUR.#5WYOHQ
M=^<F4W S)AZ=,(QQ ;XL#'N$;R(#SS=N& ]57*U?Z4R^.C1[W+>+_;Z:L!"A
M\V%;RKP=M&"=BU/?-/X/Y>8/+G!GYZ_DB:P#/.P4F)HTTP2C\*(Q:PXF+X'M
MZ1,(^UF+Y=_I^;$]6N@7;?2J 7<7<+I$U DY]*9@,.UP"9[KH[/ =C3S]A\,
MOO_-ZZ;HXDG*1?(CD@49DN/=WE@F:!&6('C"WW2?<\:Q31=-=I,'9_$[1$&'
M%6F/+ H)M2]\LNQ-KIG.;<&EW-Q<E9Z%[?URQ.:>\F[089U9<<(,G<6"XCU&
M'T;RQ+EOBI01I +N>LO>T-R$TSL]CM&IKWF8ET2XL^[T\8Q&B9FNH(9AI" B
M^Z(^,<J8F/%"!/LH2W70L2\\ZK93Q0HNQ/,2\WQC$7_186^IOZ+_ ?4_?1)T
MO97CXHB9&=N702'^0R^1!]6H#O,0\DDLGLF#8@TWH7?W'X\'!]!YX\"&";N1
MQ2?'8S[+K]]^.N7;JQ(L@F@!]+8&62>?5RM*!L'5"6Q1K)C :O&[[[%SI:Z[
MCD8_N[SS=9?WZG&U#TP2/,/21IPMBE>;'E3=I+[Z;HO_8(R"OV.&T-/SNSS_
M$BH>8B<+0ZB<LHCNL9VPG>1"BE>XLL)]Y;AI9]2-8LM=<72QE[<@GCR(!V2*
M,28!^AQ[J 3]S%+YQ];DF\4=#AKE/[8F[^ +:W0_K:DN]M%:F/^I!H)(K\>6
M7@VFV%,/EQ"YPJ/L\LP62_K7^ISN2[I&/?8YBSD3^EE3TTO\+P/>AD]]/^#M
MW^1@T&08(#_W+3C NLNEZ%/BJS+3)'0/A*P S6B6HCP%*/;%E(QZ0R_(E<R4
MH!GY/V27_R7'_PIR;"E&>83H/8MHPQ;UI^?6R3I,L.HJ(H)Y&S@>S"-]BM=-
M>[E5"KF@8UR+'F0L -4RM&S,^#ND[8W7Q0OA"O5CG-@,NT=\9[_*+V-OLF_-
MMH%4NCAJ'7!PS0DT_LH[@S0&Z)'!:( [P)I'S;=&*K9:_. LY(3 XU>KG0-2
M[7KQW0@\9'$C'1.MLZ;J55D9LS6O\RY2YUU<<*M0P;V(%ZW"23JB-5H:7-0[
MH^LV6Q=RHU]^UT&;#'" 9L%CA=WN53K+)1(_G4OIZBB'7<S.7-(YD3DP#Z$>
MSB$Q,T#^"F_KB!Q-_?:UXGW)G^/LI.'#&E5H[#':4-IUM:5,U[[7[-DX.E?C
MS.#ZL]2T(T6QVBW4L58/A$X1CJH^^0G,8GV]94)E/ORRR\)Y1,2-UC5+1]$%
MR'M1O,EMRC&XQ*&O/MQ)4OW1(OU2AG>/\P=[=\(DI'WH(NVN]>A:?0VDG;7/
M/;!4?0/SL_ SQW)CYRFEZ\XYD(XWJXK-]\CS<6&J\'5[I;)-X4KA8MT4G>U
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M+1XV%6^24T+!G&5AZ@/1I$,F%-9MB[T]OV@2=UN6 HRUAM\HH,9D2"LMS5-
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M_]-H+_M(=,0@.UP\%A7@I^][=.L*E*,_S]UF(I#7OK#6A2<O-^;0Y(EG,8?
MMF00;3("E6AP[WL\%K$[0Q-U5/\4_"?9ZTPF3U^0+MP9I,G@D!]MICZ*-T.V
MVFFB/4V;XJ-[9/S7(5&HU40(11X2\Z.I4-R2!H_SX?@35O6@G9,D=RK ;XBF
M"D,T#4,'PS8$B(N4;5JPARW9%OJ+%DMN%OWR<31Q<.+0E.>HT[#Q*RB2!XJ?
M\F>96T)+80W7X$=I(M?$]Y/7[:B 9NO?_PB: G]#]Z&)H9(3</)AJ!P54.,
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M8S5YFCG')^PXNU<E6F2^97:GF6U#6WIWW SNQZO\.';MW2^/7:-K]7,@7OH
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M$/$->-!+\CXQ''M,\EJG_4R/M,.C:=&EY12@5%?EP3ORQ\'WOO"\U]]@W16
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M9O&\EF[&\OGB;N.,$BV.28F-Q:XW7)TZ$;%:BO? -Q.6.G>_[LK[N='B>*;
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M,8G/'U_ _!AX8F3625G+-,RP8K\LW,4:L>WJ_N3!#0
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M]1N@PVM3-GS^X%*#5U:>^\2><?(]OOS\CXI\I:55%\Y@$\Y;7;0"3CX!@$=
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MG.8B32FA7< ZQJJN?_9)_7K@_5O>3/KCE3V+18KY XEX=""L2WZX>LT+.1\
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M$1O,WC>841')I#M,:_-&NO=_MRO^6S(+DZ 0]T*T&1P>('G0X+"IQNB9FPE
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MW_[D#!*UA^1\I%Q7*QEX-NP9 _!ANL4P!C#0C4IS;W _I]Z_\%D=C)U-4V8
M[GN!V_JW:&DHS(L&Y;02E2[4C)B#O@I1;FS./>/BX\+,<3G=]/JT%H_"(<MV
MUR.[3WZVH$>W*'S'NZ54+I='H=&S<HFSL[-'DCN?W#U9A#TO"9P1T10AGF4
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M!@"B:=^<C&0 /^ZI$%!?Y(<U+(W@<HC@OQO["PJ+.@*L*6X?03$,@(^J2(S
MDI $5(_6J$7>2HV*:W&;MS^AZ1/JP-.O4;?CF6:*[==Y:4M"'HE.UB3VD!HG
M4<QP+E)(N58^JDGI>$E)<&;_FL.PE^!/SD,CNJP_TWZ-5<7.&+"'',%YHP=(
M@_!I1#>,F^R.189G[B1!S?#(M?TC518'A@2OE$_W2*8TAKQU>O@:M*Z='\+1
MAHA$'&CA82K_7668)/4$P3,J(H?)^RLO>K@7+'WBQ%]9>6XFO=JY^;FS4M!4
M]NVD$>4*[#.H>J<+//.F WP(QL4T+!W9 E^K^*-W#MV6EANOVE@[]^9<W[I$
M0?"I@6.550[7]P>BA4W;SAD!H=JK"Y2K4 ?R.%YQB ]J0$O2=25LCLQ<\2BJ
M3A+X-M.DWBN;P,8M([MQ=+H>+Y");3)D#IA#1*U2'+_P($47UCNK0D[%@EF7
MU6\%YW7MZ>>[>XNA[TEDGU.X[ZU&[OFZ&]RW],(J4;X#@CY,^D"6HY@N@\LG
MUPSP?#+=&79#X2JZA@0&T!-J'-O@7WL5@&M-_!SG2A!_>)\]E%U""?5CBCGD
M5&]-VS&;0[M%^@X:^[Z9/E[7^.IM5:56<:#$JQU=]B'*L2=Z>$Q2-QR ?9WC
M]K>(9P \VTZ/<U9(CKA^UZME36G!W^&1P^/)T6=<9.1+ ZPV(50!3#6R%0(*
M#IW"6XSH:P8G#EU*@*T&ME]Z>W)/>0&67=!2]9MG=59;H#/P2E&%?O<\*:+D
MV>4S\L'X^MB?,P_[Q9_@E;X^3=[^-_;/B'6BQ(([2-/$GN<!<Q%[7R("M,.W
MME(OC\G&#QPTO60M9WYZ6A;>X+&X038-@.\)J\ W\M_QQ2J"Z()W(/1(GCG*
M$C-L?Y9APP!R+NS0]^Q^+V0SW9O<. -8O-;, %K2D_XL^6?)/TO^>THF,$=K
M-Y*/>I)0/930(M/=H)SJ5I_]^VVNK]+]:K#[>OOB4X*!3#(<#Z&*B#'-M0HN
MD'R8P@;5&Q?U>-=WO$6I=K8WBZ>[\$=5$F*[0JKC"'TU=@\FA95<B"F4CXI-
M4* &W-]U;POP3:6FS:4EGKI_+ZI-[LN&?)5UZ9[,<A*ZD;1)YJ'(+B&]\5>#
M*&:=*J(4,,^2%S+@N$G_2.!3_AV$A 1:/-ZFF\N5$LHT?G::R9K?$(1(Z&FQ
MLY;19L<^?(_F+[JL.H;3O L?7Q!9@E2@J()YEP@%92@F"7Y T_K5/2N;[5W5
MDG:*[O+2-S5EM#)KTCO;?/6X+R>,+RS?]>.L^T3R+7<Z>UTXI\PM;-3!V.1W
MXMSO'@&2@.**0T@[5; YVT@DIJN4*")6S\$ S.\R "YPAEK@&?V2A,_57?J7
MX;VU<!R\\$?(T&HIA1?*3DOQ3]-G(>S,!$P?FP[#A5E:F_55Z+O<B+\037D.
M'.'K>C[X6,J) ;2;E3" KSF/F3&;$HB0LLP MA0<&,"<&>3M?8E$L%;7@$A\
MT?+-],W41@;PI%$N=_&QL-M(SM4+;Q]F7/S+/HX_%C*ARC:@:-QBJ)V128&<
M<J._]X"_;&OX:_YA9HV4D0S@0N0&;:N*Y1]:UI<!B+;(+TL?)KS\JARGES^^
M^<K3.7EROG?WE5,V"[6W[$J@6B(DHCCF VWJ^-QN:'/&:Y&3QFG:9Q\FYK4[
M: _KNI(V5D-JP\*)I3\6-ISRDD@69_2[:Q1_)CU#'9S!SL5<I;7KI@<)B*_C
M#/NDK*+KP#F:RS*D5X2S*^[^^L40E1<^49"DUA/XD]U9%]'N5<V'4&:P$V^#
M'X:=K$):OA\RSFU:A8VTL.O=JP/=!&/-(6C#UOA';'.QIQG M,=W6Y(QJ>L&
M VC%TUU-)A[-?6G9"A41:559$\$$2; S@]^D)0L(FJ?MX2,0\F._HE&6\^:,
MT._I@*3=M.U8$#-[T$N; RAIJN1WN21B@P'-?8 XVGY*[7@TL>4YW*XZTR7I
M =/OM^;1G4AC\-=A"YY&/B5$9/O'1\I*<"ES9GQ4>6,4#XJ6E3#UO!6:<)WI
M82NMXT!/'ULET=E0GV$CB%\J32N+958P1;?U\Y<<SRXE7)"&$Y>3]>6F3>E(
M"[[$NN;G#&!U/+?K7G[5Y&STT(&%JT9^)426V_NO2O3J<38D41]8$;-&LXJQ
MC>%A;'UTS=P2<WO3,'S#_361V&R%<5D)"ZX[G[8/%.Z-HOYH2#[^WF'Q-YT/
M_V._ W]/0?^R^^#OEKV]7HT?R&*]C+ =:U(*DA0E9B1/C_'?([_E[ZX#1X#%
M-1-LK,8T/*U'S/K6UZ67QV5\7@[-&F2WWGVZZM'7M7!&5]3)A-V2LNWMK>@)
MM\G]I9H5ZK_<_>9[=O/?56Z'\O+_,B/GOT992<3:/0(__1 <LQ]%4*<+#JV"
MUX8J&$#GZ"K(?5/W39$7>'PW>7THK7:#UVOH3!NYARXIQ0!L[C" =!4&$&0S
M!_FWK-3$#]V KMNJ$>EBISH?Z_BFIMY^D=$T<G76,A6M:#9C&"&2?M>G6GCE
MPIJBUP3B>"-BW]^NFE'.D2S(3(/,VT9@/4^68-;*E;1  J%1.'<2?V4(/6!L
M$K1,[=/"#\[L) 8NQ&,"$/\&DF&$SZ2(C_Z!,[>'!-9.=%\V];V@OWE5/KA;
MQ5U/Q=.0)_WN(RO)Q?;!$J]9A!;E[[1F]:9)R/]O_3A>JFC5/";KWS L7\U=
MSW="W-M+8=_VOWRAB[^0/C0GX(G"Y&<P@&K>F@D$(?8V5,*"S^1T@S1\IKN@
M5@[:TJC[">;MH*B"7^A(FCG<"JK*0JZI4]1F#?!7I7]US$WK'R?;XD#"9DY>
MMK=U'*8OM6&C;CQ!IDD -!P#4!E^>8WC,P/8!W9%HEEQH#5+[;5"BNWBWO&G
M14LMA\(X6NGL7ZMEH U638D.C^/BLIY7?-EU/KS_>^G0$:<XLB<AFD2CQ5#/
M(NE#H$J3=A0'>;(MPZYY?J&# 1STD#Y!8<N62%PV?MD6]-#)R3^Y=[6C_ZZ]
M;.JOAY!*A7?\"K18^'VFA7-&3>.-R>  9 +$*M%TH\GP(_M)E6J>F$.V/X!?
M5>H/;V/6C(;.(FW^J\]R*SZEO0.[H\+G*D&1_''Z*N0O?'I2]JO6 O3-]>UH
M0L?!7<0G^<C;"9\Y-(>?M3N63SW_VF'PQ3?0,M:S]D>RR,D++R5_KF98!XUO
MUJY%,$-4:[(21><-DAUZ[C1YH(OX4]W5!;PG$I\%AJLM^+%.R XX'^S2F1S2
M5Z<5HSR1Y!.(&*\64?H 7:B14!A^,=L\OX@G0M1);WU]#/H.J7_15E:0_]5^
MCR7OWROQ881SI'NB+<I$855R;;? O>[RHIFD8WT,8 DM].*9=(K6 OY(T3F/
MK0]0E0[J479(3.&:XH:DDC8RHSISA*?/P_-&:%YW\#>'N[N/+@_3 ZL80*W-
MC07^Z+GRH+5D)G8AXAUD-VA&K#LT.HJJTOAYM"J//^WL\__!WGM'-?6UZZ)1
M5%10E"XH40%1B@A(A^2G"(@(B"(@+2K2A5"EA41%0&E1$5 I49 F)2(@G0"A
MB B1+D4"07I+*&&1LG+CM_>X9]^SOWWNV>>>O?>Y8WQ_S#$8(>^::\[WG>_S
M/%GKG7/]RV _Z\N"L=3]A[60/,$@?#V,%TU"[(6[0??F/08/A<@/F50T:JJ=
M7,E<;F2N7R&?3Q@J:.R&\,0NG\:G4<ZJ=55%'R;67B<:3&2;^??%SF<!N+3%
M<-OE9I?^<PDD2MJXA34'\I4;)MM"=?_/QR-O @*\W7@<?HW)6+[K[)".NBGU
M>^/#2&SMC@T;(0J""VD'6? :!<<+FT=B6&6ECIVXK6XQZ$6O%TE3 JUDZ%?O
M!FC(M=&+[5)AQC.'-U\T7MBVZ:8 A:>:^^G7T@KAT[G5Y,D\BC])\J) LFY#
MYXTA? 7?@;/#>'6%G]Z3B'K%M5V60*;"4YKFLM#$ 8% G?MEG@$''P^<>[/U
MH'UF1XE_.SV"AHLML;D.8*?D%$/77AJH/9JO;KC)4E6HI XUX6(RQ49E<Q^G
M"BFSZA#HS;+%R+7(C9W5Z,K66ZG,>O')2=8 ]'R#I9W<M#0,Y8V,EE<@V6P=
M/0*DT6HI*BHATD37MF% J%TJ9"OEJO+O'7@5VH'!PH#";O4,Q]6\Q(M8W[[R
M1Y_\B%)9#7E#&Z-=-PRJ>\N[+MTRU=NCM7+)GE5$O7SDZ)36;*035Z#P9W,@
M-U;!ZQP(TQN%%_2M/'2W_FV.-D6JQ.R;2NQ2]IZ!VGI&:'I(G=2I!V7^$4$F
MJ!=3F\N(/76RU,[V<8'$"(/FP66,Z[C9I*!."KP9.#"&?C>  %R@#!QFC9OK
M1KT^ "[4NUN37RI/Y?'&HP?XJ:]G*S0D>;9NX,Y-1"[_>#%>'>(5K59'.!]?
M^MI0_GJO3>"T3Y="/<[;V__<:SU#^:$"OKR&[S^0CW#[TU^B9*&PU!L"OS>%
M4#L!<R)/\W1$ZP8',K!8FD6X&BIJHD3EAB]U+P?R8I%M+\"*6S'FRH^RV>8V
M;0G^PB5E%[#8LG)ID=KTB,>\VH'AI G-"#YOC8SQ%^- SOVSY?.&PFC0<.NH
M$-C%@1RP7R&&$4P)-!%)=!?TH.U+V?[4GX[*T+=#[WJN 6XQ9!;18.42^P8?
MZ^EZ"OLU&GJNL;_"94OL, =BNZ#)3D7MM^@H]FP,[^)^,!(T;V6-C-(*XD"^
MG\= U\7Z/Q&^8E60P\AFF6.9)_IC<E%E',CG?B13,<1WJI-F2-W\?MFK/[^(
MO-=WE -Y[;)%X-KXXKZ&FJ*_C:C(N<65/%Q.<X$/9B&'KW_%)K5]CER]+0"2
MG"H-70&U: 2+B&?M1[">$\JHN$Z L*[WB -QD9'[31OF(5\E@0,?.)!HA_[L
M&>C3H]A:\+$QV(^_G97-OCR9^4J) T&2.)"78G2TP#9&#'3CKBFB>DBF\B;T
M$"V34.W'G50N:/*O3GT%;='2OCJH7NRB4Y,A=,%&H/B][!]K%I&K((?92UQE
M"UPCBTAOOP>2US%#8Q0L<!TC(;U]&TA[1 9/!4OCOM4_CH7W?W]S?X:PO(UY
M'6$@,+M5UL[5RY:H".PK(",]$#IJ@Q@XS8%$N3 -6K=@QU=(;,-<>)?73WG<
M4_5:Y0-SJ7;T+"!Z4$B:D1[(,Y:^8\53WC?EIM%!G^++'TK(Y6&R_1:[C>19
M72A2!BCCR#+ZL6(1R;I#F5=6C5-\+CMZ.;MFY>O1K?8?#!O=;"\);,SF9?7B
MD[^) <A3P ?(4>C[B<2?>2&1]O6T4Y5!>$_E-R6YJO!WI+_T'S9*-1<,4<3'
M[ L3D^VN)R=M.:3YF^BKKP[U;R\DS11TB;)J,TMS6=Y UX$G=AFDR.OTWIMC
MJ29WS@Y"5T^,,FXN*H^D[,+(V5,=>E394[M_R(';+N*L!>AP4AL'0J--F,[7
M^RAJ0IG+O& 4=JMP$!GX2_>ZA;)EWT2&WY;K4RVV(;KBQ?7N,KW/XD5G;V_V
MM/G&+\O6-(!>'=FC1./#=K'I\NQYM:=]! ]H]%:5V'6$G5M!YM!Q#'EW8; Y
M@*=.6;4/HUSN[IN32_T&3Z*DY;.D :^/;LM.!SX[;#)UQ D;.Q7X+-EOP:/C
M]T8DF0:C'=7\<!IU8)$#:?.(X4!PZC;L>C'0B+MTWD.G,6&ZA?H7B=>P79_J
MHP/!#=4]T-<%A5]7N'%'.&E1[NZD^5(.&FCJ16)O%,&3+Z%%4:@?VCUZ#WP.
MHY><+9,XD O/O=GNX!C)'5/GTKOY9 I.-(+:MK13/H!F:C_=\5(<R),8>CIU
MBX5QC]ZV 3/NIDJ#/Y^[0\O=$LJM1RGXF$=[F3\%N8ME[DX^!^+@_PVS>GZ!
MF]N.:1 48H;FVJ?,8?ET"87OY:LC<<U"DT'ZO-<JY0JP]QZBWX')M7FH8, Q
M?Q(S*;,FSEWZ7;6Y\*/.F_B+,8*_Q7&10@)ITQQ(;Y''42>)<+-C42)I>2&=
MS3H->]Y0(F#^88HV[A;3Z8//C\='.K7J]!<:OTU_E9I4_2/GB$*NL*6A^[]9
M&/WO?1+2S/I7O^_^/1KUOU;F^[_4BA!2*&,J;_.OG1;"+&-:[IOW'CT1BUW6
MF\<O8FKX7E37"]_+;"Y)EJ_X*!](F9;+,G$D7(HZ8R2_/ Q-)U"O88'3\.4_
M)*:!%MR\&D46PWS>4%)>@MXI!1O[9M?JNF C;MLSCS(^KVE/)ZH]>@C!<[T3
M@P?)A TN(5\;["5LBU:3@=,6K<B=*&_V)Y0S37,RLY*=D^6I:EN<3'TT);BM
MH4'5YCM9N*-!$_)<=8_QGKJ[A,HJM\@0)-NA*0)Y-F<Y(AF&]CPW,_/;86PH
M81L?3K9?07LE?/?#.10L+9JFOAGI?5"Q\:46:@%(@OMQ7%8D,*AWPRM[CGS8
MXNFJLN;HB/OBI*28QW2@R\5"Y,ZOWXL,\GEW/_?AK[ZQP;O$X;IG5SZ002MK
M=9["+[.G(HQ !BWEQF0IVHER<T&0XJ(5Q7N!7W\'C__M8E0?]\OO.) D-E6
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M*ZRMX?&1E#O/B$R4%.)I@<4V.RD!GC[MCG^M-[I_MH.O@XX8('U *X _H'O
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MH_>+C>KWWI!VFS(#(<<\V(8\XAE8AS:4VH5EUK5:4<6<ND2U^@B Q?<OX\R
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MH.NY5STE,[]&>DZ8VX2$M@S,%YJ100(@$$CV(V^ ((T70;>:HMTQ#\"[>8;
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MX]6 V+8&=&HY3DR?KU'#BQ*1=/-3#QTM@C2?W=B.6MFKTBAE=11U.4Y-FX]
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M%9;PG;C<FG^,&8\-I#5[3UVZ7'W^@?*G-@O2JMLA.U>K5D_#(S8Z\J]XG[9
M\@0?,'"@OWN)4(@\/MP41O-WMFT>KB /%]G5?&@8#3AP-=*X;I_B^($,Q2^I
MW;T*Q *M//81) )89!]"M%.P2_O8#ASPR*D4$VA[TFM M"L?/)'/(FY2!V8N
M3+D(FYWXV"N@ -K6^V)/Z*'M6Z O!E3A%+YN6$[.KN!(0VGE==HS<PG^SI<
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M"W$%YX78F2EQV\P2F 3:(PK?OVF;$#U0&->3 &+G]KRF4VGKS %9+G%,OSJ
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ME3UY^@R]"! ZV2?$VJ(NYV'F!G>S7CRK-\CQ+NYN6UHN##:@/J_E(FW2XZI
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MZ-8ENKQJS\HG'/:_,(*^7W;B_FT15'9%K%WJH5#.IY6:U@ ;TW'7LYH&>M<
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M^/EV;UCH$_E2PM\;_@GZP6_N;=\/%.SV"3Z'E]G]H3!D7E;[+K?]91G*/:7
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M/(CF/7H>BA$BZ3$0(#! /\X8LL*E_QT[@>N06!,3L$AA^BBE_5O,Y(=J1O(
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MH)K\FTA&\2BF!J[_?Q, 4$L#!!0    ( +V"1U9/1BKDZR,! .%0#  5
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M[$5$>I->S]\]7M;J10WVTDXO7SW,7/LHU[7U]T$WT(J25&2IVK#EH4P@BGD
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M8F9=>TRMVU_4!*N%NOTU>%-5M:IG7&L/%""@001H2!S2O^MY<;4$.)-KW&7
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M%\G:>'N5J8!Y3(7:XY ((DDS2).(P$2';TDJHYA:[7'V'S\U(NA$<0[RG1^
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M$AAS'B8XE32,C>H(7!IH:M11RPH:89N8#U!W9ZP$-F..B_CVLX9+U#PSQG#
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MQW]DN@1-)C&,8L3C6-((<ZNHVN&B3(WD&DTL0SVNF HSQAL'8-_>K\:TK+4
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M+!0,$H*XY!ASG@F[+;31N-/;4U<Y@]IW?%@DRLZ0-4/=S#1UCJ3O\ZYS$-Z
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MCPZK;:<!"_KS/)T&J]-T)LGS8J9%OSE1H6JG7/W+EFR[/^O<4/U^%\#Y;AO
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MP7+[9<SUWH1WY;6M\F ^"6;,X@E:SUS32EVU'&Z#BW8$5!49?VT$\X#"$-:
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M:W9^F5%#6.^EWHKDEO&D9]"T.Z&['*.>S:)&0+!N+^K_@*X=!$\'="<&&?2
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MR59@(^<$K'6 :K&$YJ &_&&D!Z7XG7MRVTR,'1?V!G?/3'@&Z:_62%\0A^:
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MD>!VQ;"'%MWJ<QFT6'8E8NE27-9"NK<3&/P-L.#NL<WJ@+6=P)G:3K_6M9W
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MF0+-92QB*=.<QWZY;,<[&IL!J>2,"D&C6M+H#RNK)PO$26S=C$<(Q'HV&]W
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M37=I+#NUT-7CLS5?O]F2KY^?;7MWNB1N^L*J&AYS65BZ;<+8ML1@CF(,%52
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MX<?I#&MXQAQ_4=Z*0Z<S:"VL.MW;]#/+4DTGU\]R:KZ03_9#L1<SB$J4HYP
MJ:  Q@/3@&<\!R+C,,&)2G/JY) =:7ML1K,2+ZKE<S-YQT!KMV 70M'W/LL5
M!6?3TJ+O$4NQ4N(OWQ<O_\>\51H)\\/6-AQK:Y"IWJ)$/7/;'ND0S/'>1N;Q
M14D-V @^^>=T_7#/_E225728*H\AU@P!2K&M(48PX! 10!C)J)F_B:3N96%<
M>QW;Y-V1.V*-@#8K>52*[G$%[HQ^^USO#=.>K< NG-?'X>Q2),P95X_X@#[P
M'>B2/Q#.?O?UOGBU7KH[-S;<S;FO?CO7W]XO^_M8-_.U<=L^3F=J^=[X;M\7
MR]>)(%"F9D,++-$7P 9FP!&*@1;8^%^)1HET*A1[HOVQF>M2Q*B0,:J%='>X
MCB%XWNFZ$)>>3:X?)%[>5XOBG3RP8^T-YH6U*-/TQ-H>ZW9:M1>U^_G9FH$J
M2F9U][Q>K=E<5DF&8A(GC"B4IH#I1-J3;#.AL89 0FTS6!!GPBLUVZOWL4WW
M0J@BWZ3(,5EY)IEX(B^81@)F(&&,F2UK#@$33  2*VU#@Z"*D1\33&_8#\/E
M4HL/6)6$(1:/CXMZ+*+%5H$(1'S(H7([ZNL-_IXM^D'R2RGY)O)[%36$OXH*
M\<.=Y'5"+=#1G5_?@Y[5=8)E_W"N6R/=EIWJOO6CDK9HP#W[494)>*?F2D_7
M$X$3SHWW""1)C;FC. 9$(@4T4A@IA:C.O%C^SO0WMJ6EDM//2IW#U,TN!42J
M[^U\*6E4B5I<H5;"1K]4XIXV]-ZFQQ&80,;F7&^#FA='U?<-BNMK?B:DB-LP
M6Z._?IO G"?&("B0"AN F0@!*-09D)QKK%.DL]3ID'#;Y-@,P5__\NTO;E:@
M 4O[1.^F;,]S^:^?;^]O+(GI]?W-M\OG[*&.+5O"ZN%R5E;_V$[(1E.#S+E#
MT>MI=>0O'<,39P5R2A[/":UFZ41)37*[T<@%3P".%0,L3F/ A33[0*F8CJ7?
MEL.MX_'M->XM=TRT*LHB\B)?230SS54IMV=@H]L@Y%!+F9I]'U&I&00D)2 8
M64:TC$,>TT0)ZA4S&GP(AC"#;S@ ;EY3>%A[-KAGJE!>U9Y4P$!4+XA"!::Z
M=3ILH*H7$ >!JWYO=ULA/AM-V.JA#-<H&<<^3N=L+LS/MVOUN*WHE0HN(<\9
MB#-* "9" JIC#3A!+*,2(J&\-FK./8_-1!G!@94\FM:B1T;*Z4M!9>29&N,.
MOYMUZ@74G@U4)7-TNX5S+J.-V%$A=R\9--YH!;)5[OT.:JZ\X=BW6/X-=#Q3
M6CP^3LO@,M-%6<[BNS+=J-6$8&VKI6&@&!:VTJT"A&,",A8G"C*1<^B5JM?2
MU]@,4T/48@J)IK#1+Y\7:Q4EB>>)>!O6CN=,81#L^XQI#[P=.0.>+9T'(]2Y
M4DM/PYXIG5?YX#S)X17_P(6*</#UYH=XL.[O9_,Y6$(@B!+,0))KL^UB, 6,
M9@((C74<9P1AZ>36G.I@;$:BEC&JA8RLE.ZQ"T=!;#<$(:#I>Y/DAXI7^$*;
MZIWB%XXV.%@ 0YLZS0B&UN?>AM:S<;75RLO(=0R%4!PD,%4 9YP#+A/+&88A
MT1A!+./)4\&%]FW-EFLW3V(@Z7UFU;X._4VP2H>=VWJVCKCZ/IW/[3\6.EH_
MJ.A5L>4HF#U=OQ7*8Y8J*FV01@ZP$!H0+2" B48(4YAP"*MOY68N?_(OI=9@
M\.]$E3_]K!^)FZ,\PF$?\&SR4DK7G6"4GX:XU7/,1D+1ZBKU3T7&ZCD4H6E7
M?;OO6GU3V%/C*DL!09U+D>8@35D&,.04$)Q#H.,\I4F&D21>49X[K8]MYU,)
M%RW5BYH_MVSJ'8!S,^B=X>C9[-9(A$O,:-4X6"W+9ML#%ZP\HM9A5<IC#W5(
MG;N=BZ4R5N)V7@3@W;"E]9!77]2R," 3"1/)8)X"RHVWB34F@""2 8THUPG6
M.F%.1Q8NG8UM$M?B6I;V,M9751)OG<"+7$.G$6B?_J%Q[=D:;""]G9=!O%$M
MK.7!+WVO@-AY9,8%Q'"@A+B+L/1+@W,$IS7[[5P;PR6].6JSD^OF^DY70LCE
M]*5(H_N\L!\-FUT_VKBLB<QRFE"4 ,1B!G!,-6"YV?'+-,.*HCB-8Z=<MW,=
MC<WT?EPLK;M:7"O92[SF'OTJ8H7,OL20)R!V<Z]" ->S;=V*>!750D;7[5!U
M(()LQR$8">2);@8F@&Q7]I#\\<SSW:S#EV5%*EE4'R_XB2:YC=2CN3#;)^.-
M8<T8X#E2QC! "F.6Z"3V8GT\TL?8;,)&Q#)D[RKZ]_@O<9Q$3VP9O93U,)/X
M*H[C.EN+E?Q;MHR;O66=+^H_3%>K9R7][,>Q07 S'1="V[/5V*+ZK42U*BUZ
MVXZ1M^%H02&0S3C6PZ#FHD7%?4O1]FA7([$PVX_UZQ<SNFM;2^=_GZ=/U@O]
M-)VK(B!FP@2!2$ -<F*V<3BE"%![%I-G&<>::R$SIWHT[EV.SX24$E]%A<QE
M.:Y:ZN@/*W<9 N9))ND OJNM" EI[Z;C8C0[F!%7@()9E;,=#FQD7 $XM#G.
M;W8S05_+P\Z/1N::>^WOT_7#^V>S7C^JY<T/,7NV#KPEQC;_9SFR)P*QG&0$
M TUB>_U-(>!:4?,?03,1<\$9\4L'Z2"%SYP:,C>DV^EQEV'@L>+$,F%16Z4,
M8ZX!3W(&4*PSAE.(<1)/YLHQ^J"O(:#E$-1R] >_I=%_6B[DL]EY#C<(;DM$
MS]]WSVM&)7UD#=N&M[-D<*HUL%DBE0Y1K81-PPVWB%P 8:!5I8L$@RXS%T"T
MO^Y<TE37F.WEDZ6E4N\6<[DM_5S=I^E88RI2#'*1V2@:8_!(3(VMTUC ."$,
M(Z?\7J?>QN8!;X2-N)'6TZBUXYHH#"F4"4AC+0'F# *24@Q8+%(.698G0ODM
MY<&0'6;1[A%;MZ4A&%X]+P);H*R@T5;2'FZ)G3 )%@;?UM? @? .:A^&PKN\
MU)7%[^]J-ON?^>*?\V^*K19S)8LCIN4$*Y[%24X!XCP%&&'+/Y5(H+3&F,4Q
M2=SN.,[V-#9;7-'866G!GU;<J):W/'U;^K+\G4*XW7H$Q:UGR]$=L@XL@&?@
MN( /\%3+ S,#GE'PD"/PW O^IN']PJS-F\33G&N9X42!F.0:8*@18!H*D"4"
M$L(Y-+; U13LM#RVJ5\(YY)G>@:P\S.[,PR]^P"."'A-W*/:=IJHNRT--C&/
M*M"<B,<?Z!B@:?=;ZI.-:UA]6<RFXK51=)H;7Y[K&$!LEF:,<P9H+%,@6*S-
M'BG-)/**/&CI:VR3LQ32,V2S!4HWYST00#U/VU+*JZB4,_JCE+2? BL.B(0*
M]VSI:=C@S_,J'X2".KS2U67_VV+V/%^S94D.O)IHGA.&1 R4H-"LSQ@#:H^)
M-2$2JY@AG#D=G9SL86RFH/(W-U*6G-..MN$TCJX.^07H#..(.P/3P?T^H?P%
M;O=^BP.[VR<4.G2S3SW8;97_;;&0_YS.9K>/3VRZ+"[\%JO5)(=<)2Q-+0>8
M6>!C@@')8@5XEO&<IBG+<^&SP!_O9FP3>BM=)![8\KN*%O/H>R6ZWY)_ E>W
MU?YRM'J>X+6 5U$#,BMCN/6]'8- 2_N)3@9=U=L5W5_0SSS=,<)XNA*SQ>IY
MJ>YT,V?LJYI9VJ_WB]5Z=9 RMMKZL#I/,P73'* X%\"FI0.F$@X$32@A,:-)
M[,7(=:$\8S,K-[]_^73WCYN;Z-W-YYN/M_?1ET_7GT]3CO8R1&Z&9T#@>[90
M9\@&HS]ZV90$PB]4G/2%T@P;3AT&NH.HZT#-=J[.722&?%!U@LB'*K1S4P=8
MK290R)@11$">2QOF1#C@*)6 9@+3F) \Q?EDKKY;@>^]:G:?[]POM&9/A/ZF
M;RUIM+9">A?O=@#=S2"&PW#@%+I?:HE_M0F*&SBWI;]#<HEYH12N]+=#GT-7
M G>'X4AA<(^7>XG!;#AT/,<YL0DDDMM2F"H#+$L%D%ABI$6FN%\"B6O'8_/<
MOM[\[>;S7UOHX2^#V<T&]0%>SV;((9"O)P_,%ZQA0O;>R*?R!<,S."^4EU0;
M.F/B;)C?>K5K^2RSE80QPB#+$PQP(@F@&": ,RDI%I)DF/OEN;;V-S8CM%F\
MJV!CW]36=G =-X;A(.O9]&S0LK5Y2EFO]OV?D!FO3K@$2WQM[VW@_%<GU0_3
M8-U>Z^CA+%[9S%(]EI448)+J/%4QB'-A+ >ERNRLXA@(*JGY?!C,D1>MT&[S
M8S,4E73=:E/L(>?HFG3&HV\'I((B>$F)XQJ'\B)V&Q_65SBJV(%'</RI#MQ"
MQ:$+/\]2QO=9RFQFVOKU=KY:+PLBE=7=^L'X(@]L7O&7_<Y^3!^?'[\LUN:O
M4S:[7_Q-K=83Q'2B,\9!CBU9$9(*4+.; 2EEB124BQQI9[*BH:4?FZFII(R>
M:C&C]2*R9/L>_#R#?P'M-FWTXSK(B3EOI\!\5U-@\F,4F"4(40.%J( ALCAL
M"3+KCV>#172_B/XV\H_'@RUJS!_10/138_Z8_-BMWFHP6^FR!A=J./ZMM\)[
MA]#KS808F([^(YLN"WX1LQ5[?BPE_#I=_?EQJ=3MW#@21K:O;*TF.A4TCR6S
MP?89P'%BG"<44X!BK"1.,$E%YI>^U[O,/E9QF!1 *R701LQH6LD9V7RJ@9C"
MG<<:LS1/TC0! IIAQIAAXRA##5!B&>5B*7CL%?LUJI$>9!_^<XRSVQ9_5*,W
M8-!(1Q9XJW7)DA4U]+Z*K.:153VJ=8^^MGT3P_&_^X[36S._.\O[<W"^^\(?
MC.W=NV/_/($/U69C9<]VJ^QA^>[UJSWQ50;6[4UH#!.:210#EB@,["TS8#(1
M0.:8&Q>#<98XYPXX]SJV=6,C>-24W!J<C>SNN07NV+>O [TAVO<]T'DP U]!
M=T*J4\*">R^#)3%X*]Y,;/!_N6,5>FOW/IC&KW],5Y-42 [S5 ))H+$YC!N;
M0RD%.HY)RA$UNQSI5>>\V?K8;$LA7&2EB_ZP\GER&.XBY^8Y=L:C9\O@#H5_
MP?%C*H>J*[[3]K#EPX^I=5 E_.A#'?E*JSC<*DKW?G'/?MC(DX?%S))!?5PL
MC[L]$YH:V!C+0(*(!-A2F7**<[-W352*,@UAKCJ$TG:5Q^FK'SZZMH@EC)[8
MU,:4%!K9ZYNY6E=E*U9JO9Z5NYV%CE1Y$,OL^'J&XG8>1S<+T^NP#$236JIP
M582K-&2_.K[)W+KU 5E3+T0Q%)=J5S&&95B]$*P#WM5+V^M:?8OQZ:P@<+J>
MESS3MD=C>\H3[ DD]M,E&I#8.D<TD8!!E (H*$1<Z0S2;+*V1*1N%O1<AU[^
MTJ;;'DUDP;$ZVTI=$!BO&G+_Q[\1F.3_69E'WQI>9^!WLW\A0>W9SGW:0_*F
M';4.];[<H A6 NQ,=P-7!7-3_K!0F.-[7>)[UFS]O"JV"S'->*K3###-$,"0
M0$"S. =0\90D$B'$E'ODS:;=L6VQ2LF\ME?[2+E$J'32O^^#\\M5]XFOZ 3!
M4)$/3E!XQB <*-P>';!]?,![^P,9=V_4#__<\:Y;/"CY/%-W^B"2V-BPAD6[
M9WS6..4D<8XAEP@PQB' BC% 30. ,)2G6#,!H5<H<$<Y1F>T*C7L1F\3)5^J
M4:S3#44\[R\[CI/CK63_Z/=M,H\!O\U9V <_^J/0I!\NK0O1#'4CV%&*8>_Y
M+H/JX/;NPN:ZV=![\]J=;APF%"LP%KG$ G) E-0 9PD&S#AH("9(2L03):47
M]?G17L9F_][;ZJS<WCA,7]3./;^=@,U_E\&':QM\N/M2E_/TXR/@9OLNQK5G
MR]8_I-X&KA6R0.;K>!^#&J=6-?=-3_O#7?DNJK@!)=3TQ9JL2:8T5T@@P#%.
MS>8O)X!SR(!B"34V1B093'VLRF$78S,IFP"?Y49$7P*+ Q3=+,-EV/1L%K9Q
M3^=AZ<! <4KS8'03!QT,S"UQ2L%#(HF33W:;U#9(J PJFLT6_V1&7.N;?%4K
MM7PQCHEIM%B\2)9+B&D.XB2-;94H:*_>-& R4RFF1$+I%3;JUNW8)O^WF_=1
M[=1=10D$,2VK9E:!A!M=BL6PUB:RZG1R)!P'Q\U^A(>\[TU4?VA[FR _\ *9
M)<=.!S55?D#LFR_/M[N9M+OE=S:?_JOHY_UBOEK,IK+L="Z_F ^T/B:\TQ^G
M<R/#E,WL 5;A)JTV_/I8,4DT4B#%& -L4\PI4V;_E%.5)[%*L]2I($%0J<9F
M$)M*744[:A63LJF8/0O9J!9M=?.NA1!VG-V,Y^"CU[-M'6K@O UM4* #V>$P
M,@UJIH/"N&_%PS;>X?K1LN):SJ*IV=S.Q>OG9UNEZDY_8O]</4_7JZU,2DZ0
M1BFB60X@)AP85U4!EI$$,(+RG-C;R\3I:L"WX[&9ZE)6.Y=GE;0>5WD^@#M<
M<_8$8\\VTTH=-<2.*DCO=%1+'C5%[PE?C[O4GG >Z+(U&-Y^][$=0&N]L/5I
M;[@;W0Y:[ESY=GD_$('<;TM+MH\0$U+A%$"(*<"00< @%4 C(5.98BXT]HEA
M.]Z-EQ4?+')--@AT(U9(>R%O7(FIFR]\.5(]&^JC+'&%D#URP^V T!<E7-G)
MVS+![2AZE@!N]^D.OM[=D[+W1O/O19VCK]/O#^L[_=>5*IHW#F=QS53V-=$,
M*BTE!D3!&&"><< %$2"+I?D'1BA!J1N1@6_7/E__4'P$1ERPT.!YI2H;4>SL
M%E9H#]?$!W\'UZ\G3/O>+M=2E]7/;,:W1?=. R-Z:6(B(WQUYWGM89&],?9P
M_WK">B#W+RCF?BY@!^!:74"?]H9S 3MHN>,"=GF_PP+PGJT>[/^W4<LO;%;F
M4ZS6RZFP)1[,'\H3Y,8O&D^:OUV_L.G,WI39= OSVP^*K[<5KJ^%^9B?B_2,
M8JGZZWRIV&SZ+R6MA_M.Z<72LK-/>,)RDL8:<!UG !.6 )+$"4!Y9CY?C 7$
M9)-[=M[K'(]F3C-_+XMM $>W$#G:REP4H'(-4QP/NBY+XB@$'=%B:S6\BNQ_
MHX:B5]$6@_*/U^6MW\[O&B\4?]]@$QEP(HN.Y8OFZV@+T%74@"@Z^MU=125.
M=D/QTWV!'@[#* 0>H2ORDWZ1?D[/J :_U9T:AZ3#.6KCT/>8"S@NR;J=+]X\
M/LT6KTI]4\N7J5 G*)=FQ>PI+K6^*K'X/K=B?%'+Z:(L,_9I.E>W:_6XF@A,
M-4]3!CBRE9(M_0C56(&8, [-7Z1"B4_@0&#YQG8O5:L75?KML,8V5;R*MDK:
M:ZRMFE&I9U0H&OUA58T*73T#"D)_"6['J6\XOCT[<F=(#JYJ G]9'$R]9T_3
M=3F]S5 _+IYM(4>7L?0^N^T)\4"'OJ&E&_2TN"=H]X^9^^JFVPJR(=N[G3\]
MFV;5BYK!WY6]$9M )'&>ISG@*M?E:D $@8"+F(DDCT6<89_5H*6OL5GV0K;_
M^+<DB_\3^AGB-D#=C&H@F'HVD%L^T:NH%/0J*D2-8/1'*6U L^> 22 3UM;3
MH.;(0>5]T^+RRF6\5_>+:V&\X*7IP1;5*'XWT0F$/,<<T!@F ,<9 @QK!G(B
M::J@SAC%%W!;'>NSR\G? &;CBVGHP=CRE77RIEMQNY%3'07;S89<C-V@)%,K
MR_)5"1K=.L#6F4JJ#8_ =%%'NWH32J@VI4_1/K6^XT^X^_YYN31-?)RN!)O]
M0['ES;R@Y)O$.,F$5A#D&10 8Y( 0E$.D@0F,(.**.+,KWNJD[$Y%Y6<42EH
M9"6-C*@%\Z,[C^Y)2-LM1"B@^CY([X*1%R/N.1 Z$>">;'0POMMS:C7I;<\^
MVY'#3:U62NU>L=:, :]_G4O3G=TA*WGS0YA'R_WR)*<Q%EPR("EA=K>A 6-0
M@3214$+"=9ZC#EY$)V%&ZE[</AJW3LE-]09/;K=.P^+F;_2'\D#QT87\5]%!
MX,9&B:NHJ494ZE&=]01DB[L$QU 4<IUD&)97[A*8#LCF+FJL8^JRF;VFKR(%
M5FN4:Z0A8 A!FZVG >$D!R(3G"FA8D&\B @:;8_-\ZE$ZY90W(#,S2AU!*)G
M4^.(@7^:[Z&VH7)Y&RT/F[![J-)!5NZ11SK>I;'EW+2T^J)*9ML/TYE=;"=9
MS#G$20H05@3@U)9JAA(!SC13.<F2G-GHJ;7CC=CQ7OP<CG7/T[02*OIE.H^D
MY;]9KB)C'DL2[E\]+Z9.P*K3C&8I$D 3C@#660XXSBG0+$^QV0Q2P;U8&2X!
M=LA4-K4V[ILM*+Y%- *1' !QQRN]RW'LV8#6$MJKT_+&]2JJI QXS]8.0ZC[
MLA.]#'OOU:[JP?W5F<>[$C2]F)WH8OFZN=B:Q,;[D3+G(*.IV1!2@0#5.@$J
M0XKQ3 L9,S^"IOTNQF8<-A)>$ AP!$BWB7\9/#W/>4]D.M TG5(^&$W300<#
MTS2=4O"0INGDDX&2(,T/]>^J*(J:1<6&50FQ?&:S5?VKB90\3>-4@!AQ#C"6
M,:!4I4 JS)#4$ADGS,<,7";.V$Q&+5\1AK*L>83FBW4DRL.]V6LDE7P6ZZDW
MW=N% ^=F=H8;CIY-U-',3?OSY@^5.E=;OJ>"=[)2:?OK'C,].X';5T:HGS!O
MFSG:";BS&:;=6AVX%G?QGVJ?748@)1-L'#.9\!1@(>QA?:(!@X("&:<D2>*4
MH9P/4HKYB'"C,]%%6;>7ZMCGJ1!RH)++QX;.S2R_U8#T;*0#%%(NA[,^Q?O2
M/IS#54MNP?VM"R,?$^WGJ('< FJP<L=M?72L)BK_O^<J9.-^<2WEU$K"9E_8
M5-[.JU#E0A:^+^Y76S-J-5W7P:FE/%4 JGV@B"Z;,)G*7-M".683#C WWCB%
M&0>,0"%$GC,LG>KF#"7PV%:$HJ!1E28@&MIXEC[M>YC=5HHQ#5[/J\?UE]OW
M9^L?VG!8L;27B)%>+(O$CJBA4\":K@,!'ZI,;-_B#EMY=B#P#XK9#M5OMZ7G
MO45OOEZ6/4Y7?[Y[W5 ]RQ1F*4D54!E& "/+PQVG&*1YGE(4RYQSKU6CI:^Q
M&?P=42,K:W=B[3:(W2QV(.!Z-K8=,?,VHPYH!+* ;3T-:KP<5-ZW.RZO7%SQ
MM8I'G,A$0ZRQ!M+2]N-$,$!H3 '%22P1YR1/6,<:KU477@9B,&Z\ZLBV6=VU
M<_G6&DLWDW 90CU;@H9P5U$E7B\%6O=4#U^2M>[@K8JP[BG84G9U_\D>(H'K
M5(,/S\K&'M__<S'12A(DDLSL*>VQHH@3P 3-0"9YHI32<<:]\L\]^Q^;VV ^
M)1PPQO<(X([6H3\8^S8=#G&]ZT7$560]Z*LRS\"H,%!$[VGLAHCE/=+[>*)X
M3T/C%;_;TLR%@2J5A2SJ'TXXTQ#%9ENC$I8:CR6'@$@5 ZT0U8K1E,=>]R%'
M>QF;>=H(N5F5JV*@74-6=B#UC%KI"M10@2ON&'4/7CF&0>CXE9T^WB:$Y9B:
M)Z-8CC[<\7#C>;5>/*KEP5ZH2N_7E#!.(0&"VV-Q#8T1$ @"J8B@N4R5Y%Z1
M*F?Z&YLYJ,6-Q,[.?6D$]CSA.(.SXRE'./3Z/NFH@3MRY!&>2L$1EU!G'F=Z
M&_;<PTWU@[,/Q]>Z617+#%83O-RS'^_47.GI>C5!A&<\2Q%(.;5%O) $5.<(
M$)RK#"O()48^UN1$/V.S(DTQBQH!O!+4SX:<0A7+!+(82@ 12VSIA10PF0B0
M,99K;2!/4S0I8S2^K=G2,:LC +;[??:'\#OU?3JW(=P19S-;QRX,LD(EBE.F
M ")* 2QQ!CC*4Q CLVOGDD*<RPK9F[D<&->ZQ_Y0-3T$A]1MH0L 4L\+W,Z<
MMB&1[\[-:>]5[0P(@5:S4[T,NHJ=475_]3KW>*"@[L]J/<%0TQ02X_'FRCK
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M?E#?HBLX^ZY&YW:Z6<./;+HLJI%\F*[$;+%Z-I_O=G.C.$-:)0!"ALSF1FM
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MN :KSM%=DH'+>%P,V6&]C\N;O)0-Y^PRLSJUSA2,#Q,2"YPC+@#+;)T_E2E
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MT3H/O<UZOJ6BD=>NX^W22@QN "(?X1M,KS;C0!FO0(-.FS&,KQZ)T?C*)$4
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M1XW3,473JS-;:1_#OEN?&<6# Z&!P_ *<.4X[D2,?YY )^MI>G%9GK;^:Q7
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M-H/)DN6DA7'W)X=/,'YB+QVE^X'&]M3M !J/CR>+G@F5-%E^*=!KJQ6"9]9
MG:_O0^2%?FT,D>W'"Q[3J*1MS)AVK.H ;V-'F6D5LV$%(3*90$FI@#P1!UKQ
MR)T6TJ-MC,03&"\X"A0[CA<<PZ&IDR]#Y]MEH4*H+<5,FT!W<K6Q*"-P'D-2
ML>3(=^NQ.>KQ@J,XOLUXP3'D[T"G-4T *&,2>3 ,LBF,1)=L$J<4.3.!%\:4
M\D:V7]9WX [=8QHLM<N+/1DP.A"*%Y*F/_]]M3>G+N&D_\U_AK_/A$_1:7*K
MK*FCVTI=>1T- ZZX(A.<3.C0>AGT%L<\H5[=49AZ/-NX-P:?W!*//\._,(=>
MMG@,.<V4V</1U.HJ.Y@U"EM3Z[S$4 5+0N#T?FAMA#>YCDANO>GY5+.#7O <
MT=*SZXL%Y7(DN[/:AH9Q(H)17@T:</@].WA 3!\@.S@&%QW80X\[ZO3B\6A3
M@1QS(9HF ='; "BC3KQXRT7KP23?QAZ/4>@8%&@;PZH.\#9Z9T"(,9@@07-7
M9VR1XQT5V8,9I48656"\=1'&"03:1H%BUST>(SC4<Z#MTK*[NE2P-C@, HJK
M [!\T!!LW2/H6.;HM?%^V.BZH=]X7*&V43P?&FK;F@$3UT+<V"2_XN+],GSZ
M,$OA?".&W*%%S3.D+%C=:%\@UG$$B%8E<G$-^A;;/)X\P,GEJ;9Y/MNQ:&J<
MX?O[5[A*$]N".OBD(?%J K/DB2P1(8L<2B':,#?(7'L)9T\=8+JJBD:,7;2F
M\H102;5-?OGE['^]/1,A)OI?"P99'4(?#,1,MH#AD?.(66?[7+Y\A>E_O%]\
M_H^K3[R$QM4?OB+CZ_=-"(,V3%OL1,&IC9O[4XB%Y=FC2Z!K+%,Y18\T*S6J
M*6(J0;JBAV4+MQG-?4RYE&U>E9TIWA%:KD1%J$PJLR;FE22G(3I-&K.BWN52
M1-1!YV$V;\^CN4>QZ/G1W&/H-36W7\]GZSHHY6KA@.6!D5<(9&+'NM4H@9,E
M0"E)VY(Q2L$'<?K.Q_;!Y6V8LVA"J:EY?'^@N%)5BTE>A]S4C5.*@<NV *>_
M-3'1XV6'39[;9OQZ<Z^B-9]WH58/>Y8N][4R40SYQ:!+G46#]$N0T8,7=3JB
M246D065H3?=S'=-6CFT=RNU8T -NKNN!N1<I<4E(CX;DQALZ=J[O8""[5BEO
M^0GNYQK%K"?V<XVAW-1KFN[LEV)T<I>= ;IE'1C$&80BZQ^-#T'EZ.^_!Z>R
MGVL4RY[<SS6&?E,S_LY^*:U9L2XK*%PB*)TU.'KB(45C;+%2ZC*HL^+X]G-M
MS?BMZ==!BJUI*18&DZ.+#M H 61LD0%LA 0B@LX\!E3R^V:6S@V6R8$QM6>T
MKPED*NML!.=@ZO8^5:(D2Z(@D/=$:H%HXN,P/WK2\7-'41(Z"FZ'F#XWAO=3
MX[_1(I <0\PF("14] Y*X<!I9D!@X4(S*[/:+2G^S:YXV1K=$W!V:C#?7SLB
MH@LNY03:14TO(A/@0C9@"'=*HT0OALU#/MT5+UO#:Q=:3XV3YU>+2(E9)Y\@
MQBSJYEX%/AM3;7IR&#0OF'9:RW%R*UZVQE [/G2*J#.1R+M4B@'&6&N5LB0O
M4T<P&'-!YHP3 [<&G/R*E]8H&D7[R?'3:I%!XDPKSAC(Q#?3& ,$G1"L584G
MP9.R':ZI.([E+-LC= KN3@WII\?3<SIER=J#<5A[_4FG1V\XT&\$9N%<D&80
M1G=;&G <NU&V!ET;^D^-HEMIW;.<DB_"F>I(DU^=:H%&+@J<XH*C4-RZ8;KM
MUH>>T$*3[>,@6])X:FR,78O!-;WX2G/(W),K6P= ^%*UIQ$VB)2#R&40?K[=
M%28MHA'->=5!8F78(.N4T*L@/'@9:S-YBN0CQP#<U31A\%:HUD.J&HXC/XY=
M)-L@=']<_#Z._&O[SM',([][W",<2/X,O;N:.1!,C,F0L>%C-39LJ:L#3 :;
M%//1<R?]]XGDPY*_21FEG24CGGX%A>%JF*SVWO.4-6>V]=2Y[S,'=L7T 68.
MC,%%'X.C[PY)UDH'(Q,C7[46V"AEP>7 (467&5.,6SEH+,GWB>0CL?#21/(Q
MC.D#6*N'0W2#"ZIP04<W@8Q%$LXJK @,BXO%&<[O][6<]$3R43P=-)%\#($[
M<./NSLQFY&I&(3-@)"*H$"Q$A8[DA9P,A=$IT]H\Z7XB^2B&/CN1? QU.X#&
MW9G9J+6RQF=(PB4ZO'!URH&"*(4/4151]#<WD7P7:&Q/W0Z@\?B@%1^+*MYJ
M\":*6F7,(.:<(/FDF0FN&-W/H*1CFO2PC1G3CE4=X&WL2!9O@A4E:; A15#U
M17>!Z)=RB89G3M=,C9%X H.21H%BQT%)8SC44=;E^3D]TF@>O=$@37W@,UW/
MNUH5:VK9H(^6*+A33>AQ#TH:Q?.M!B6-84 ':JUI&D K0;:E,E"8KCM#N:*[
M^P \%$D&)D]2L\8Z[_M0\CT]VI,!HP.AV&9FM4[,%Q45""\RO5P\@R>O"B2Y
M\=I:>M>2;(S];WLH^2A,-1A*/H;!)S>4_-<__O_#9Q)O?>F4^<"G[MY75H]K
M'97WD%,MW5!1@S-207%"Z)"]=,-ZBK]G]<YB+E+%Z.F9%!(4T[SVE7M0QI'U
M%NO:ON][A@^2U1N!Z4/L&1Z!BPZ,F,<=;"*B])K5;(-G9!)JA,!E :3S;YXW
M95KO3ODV)HF/0L>@ -D85G6 M[&NN%69*TZF5"ZY3G$0M2#:(D3-Z]]KET3K
MW1<G$" ;!8H= V1C.-1K@&Q5[7JRX.B^5^6N;S^$Y<?K:(T0+!<O!!B3Z@JY
MI"'45LJZ^S &%,KQ8=7MVWW_<07/1N%A2/"L(7,Z4(!MO=M8LJVK@4O2A6P?
M5E='6PF(**21=6 .-M:.!P^E'5/^:Y?G?3)@=*24!_4?2%25J!&\$W5C*/T2
MI/+@<HS(><S.#)O?LH]>D2.)BHV!QRZ](F-XU8%ROCK_SW]_JM4P9RXD1<^9
M!I;(H23!-N M4R S2R:C4?E^FFSW:.V=$YS0L)1M(-> +2?6Y;$9=72W!7G"
MM8]#3C-E3'8TM?H*UAI4.3H!3+,Z*=E:"*I(LBVB]-*DJ,KW%HQA=AD75D>I
M"IA0LS(^"(A9.)#,YY"="\6U+K/Y'JS=%=,'"-:.P44'YLGCP1ZNO7::DZ^=
M!;D:'".XI!+(H+(7FNLD6N>4OXU@[2AT# K6CF%5!W@;&_K)(B7'M0*1R+)3
MOAB((G@HVEKM?$RE^:+B$PC6C@+%CL':,1SJ*"[PH)CN5YS3[S!]N+J7L3YR
M@22EF!R0S\D@:DG/3-:*J9@?5G1O4=!X[TN/*RP[BO-#:QIW8</4\/IAMG@]
M_TS'?TTW6,XWC OGKWZX^?OKC@>1,P;O0*-EH))-X)0($# P9X1"%8=!:^ 7
M3NOS'PQ6^R#_U)#Z\4M<XM_A3_(ZPR>\6,_2ZK???KSZV^O[8"1)2!$X3Z3M
MB\H0C+*@8[+(,9?L7G37AW[9M*6JA]-0C<D^-8S^"+/EXE/XX9]7O[G>=<20
M2U=B+6\A2:@.5.1,@]"!(5W">B\&(>?QSY]VZNG!P-* N%/CX\>P#N<;S9FN
M]RZ;4B3G%EQ=I:5X07!!D@E)WK90=3^>C,.4ROV/GG:*Z>%4R$XDG1H0U]/R
M[X8Z7\\ONWIKA?)=.F[BHL]&3J]SZ\$10@J''.HZEB@1O#35 ]9*"9Y2EN-6
M);0^X;0C3 \&SRX8W,>HB+MC$;Q0RC'2V,R66FQB&'CNL&[ZT=)DSLRP#-V^
M9I <4_'"-N&N)HSI UBKAVWSQ21N--F+0?NZB(K3[VPR8*,N@BP&INY;7"<]
M@V043P?-(!E#X*D?V1\7:SP_GUW;!QX5EV0&U!D(='0=%3D4:("GR)WR"=7]
M)9Y/1IQN?^[D+-^52XLV).L@^MVT_(&;;%(T&1RK.RR9+.!T=% L5^BT92[X
M(:JDYTJ]8VIZW26W,QDP.A"*;7HBO2KH W? !2LU-(P05$C@,5COHF FMZY2
M_;:;7D=AJD'3ZQ@&-VQZ;9Q7>C=[_^'2>[H9*+RZNTJ)+LJMEYRTAJD.7)()
MHC,&,G?<2FN+4;LU KQ\AA,J"=P&IH?DX/06Y_!K7N\Q>?]^B?17>,OI?["$
MYXP5<NT+65XY57GE.8'C9-4EH[.LZW*S2LUA/.:$)[3%[2 @WQOW>Q6!.VM[
MWI3_W,3=UC__75?VK,BZ<THPM 9,5"3EV7F(IB2Z(JH81;:R[ ;PY[__A!;(
M-8=O0\[U"LZ1$OH.WU^<U^_Y0O_)8WNG;B17<:5XLK6H0@1ZO(J#4,N%?)TB
ME4R48GSGRT%.?D*[\*;6Y_M!RS&)TK6NN%0A9Y[K8+17D"TW4#>I@T^^0++*
MBYS0*=9>*.Z>X806Z1T$WCMPL(L0R&4R[M6=W>37S4E,,UU,-"1K=2FS<@YB
M8!&RC)BLXYI.U#S8\<R!3FC?WFYAC59,FUI5OIZG)885O0F7___U_/F[D:HO
MVB6$% L] P89N,(98"Z83-9TXV&U(2._^(36]VVM%/?)J_$X])<XG&],BMP.
MB:_G/X35+-7=OK/Y^]5;7/[Q@9AT5IC31J@(6C)/4B49A*PC",5*SL4HE,,*
MUE[XHA-:XK<STEKPHA<-]WK^T^S\@J#ZX#;61:G11#)M'<F)]X+D1"GPPH6<
M9(H:V4AD/?%5I[1_KP&X6C!D:GCM+;"6L2C#2;QBT@H4MP:\R@YXD61"<"N0
MA>:>R/9AU0.2[:O3^I!J&!RSMA0P*B6B&OFJGGD#+ELT1G*-N/^@QC,''*8!
MOF=<]L[\8]8;CP1J;FA .M)%I1T$TI*@;+V^M1HLV7RJ:'**9?NDXH@##A.
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MSFL'Q0UR:8/(UNT?Y8^<;%J7\)A1OBN;CUJ3T[^-CLMG6QC/T8/(69(*V(S
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M>H!34R<LD3WBM=;@1-UILIGR+^I&PIR+UI9(JUL/L3E\&+SKR,SN;^]TB.A
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M"^,6<#N>)L>MR7.W#>TL&\2 1D.,I%65,:K6P LP%HU2+'JKNYG#-/)NG3M
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M#0HNA6(]M]PT'R?]%"T]>L%[*GP[*]1"^AV@Z+9Y=173Y_!C98DGB:?L/%I
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ML$ZH8>1W. >9:_(_K/*ZM+XL>4#$*>4^#L'/8=+O #ZWA NEE2_94L#C JA
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M2)!]S]EBL#+A,C=#T;>H_RWR:#960R#M70) :QD$5D0LM*T.<"N?QZB?PJC
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M)0#1EDO'.5U9?H[#H<R0=;Y.F#$"DZ'B _5#K!,![M:QJ63K;S:8A!L-)+#
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M7N\\9^8\9^8\X<R<K9X*IO#/,!F%K_\'4$L#!!0    ( +V"1U:Z/96='0,
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M>>8Z*LZN*B2*&&GT(RXP$;JJAJ$L)V[ST,<TSQC:N#0M<RN-^K7WB$O)YV6
M)1&2QHC50<IXE;@FE6.J"5,E%X$5W!(WD6O.&94,2KPMM'M'1M=Y6/ZH\>.>
M3<NPG^H9EHF+1J-NDVU516&@,,LSE!YK;:W1R1#&:NQ=.UL#ZWX?&$FV8*L0
M>RZ&]?81K)SS4S0G@"<@7$0YQ12)S0]2U8C\6ET5O_Z%RD*I#E[ !3B3,R+
MYX6@.:9Q<;P7!0=IS$7&!:H^*#4Q12F]+=_O8;"[\9;S2.,C%-],!5^D6*^K
MC&-"DJ1?#UHQF HXD'-&,6@@^*MTV3J0.CM1':T)HVN:@W.%K@KK\[FJ?=,"
MX['_!.8\.S OP;<G0C,D#*V0(,]/GJ2\7AD_&%)1PYB2-"9YJY@WX[<(LK_X
M_X(#]9R\*@Y<&J'QQR?#:V\\+)>F'4O:SZMWQJL?#U<H/Y(NR=8R?K>JE5N7
M>6>"(G5:+N2VR9[]O;Y7OQ+E3\W@.U!+ P04    " "]@D=6R;U!T8P#   .
M"@  &@   &5X96PR,#(R,3(S,&5X:&EB:70R,S$N:'1MS5;?;]LV$'[?7\$J
M6+H EB61DBC9KH'.=K!B66>D'H(^#?I!V41ETJ"H.-Y?OR,EI2V<;-U#A^B!
M^"C>=_SN>$=P]FKY^V+S<;U".[VOT?J/GV_>+9#C>MX=67C><K-$OVQ^NT'A
MV _01F6BX9I+D=6>MWKO(&>G]6'B><?C<7PD8ZFVWN;6,ZY"KY:R8>-2E\Y\
M9O[ R+)R_L/LE>NBI2S:/1,:%8IEFI6H;;C8HKN2-9^0Z_96"WDX*;[=:81]
M3-"=5)_X?=:M:ZYK-A_\S+QN/O/L)K-<EJ?YK.3WB)=O'%X4:9X5/J4EJ\(
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M;-4-KRFNS2?BRDDB4O <!F'IJ<!QNX)AO3(NT@2 3K''@^^QS!G(A&BLN"6
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M\+57 I8YX$I$;;F$1I (N=V\9!/%;GR_H/CTKSJXERY._@%02P,$%     @
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M87OH< $80>_5_F,8\_0>6!<3:)@G.,.U" =[L-(BT)6_E%134Q]YDL\HRU8
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M96PM,C R,C$R,S N:'1M4$L! A0#%     @ O8)'5@=_@(@_&   1Q(! !$
M             ( !%G4$ &5X96PM,C R,C$R,S N>'-D4$L! A0#%     @
MO8)'5L+_2?:>)   +W0! !4              ( !A(T$ &5X96PM,C R,C$R
M,S!?8V%L+GAM;%!+ 0(4 Q0    ( +V"1U:YC>X8-VL  '#@!  5
M      "  56R! !E>&5L+3(P,C(Q,C,P7V1E9BYX;6Q02P$"% ,4    " "]
M@D=68=$JD5D1 0#"Q@$ %               @ &_'04 97AE;"TR,#(R,3(S
M,%]G,2YJ<&=02P$"% ,4    " "]@D=6TR50:[H+ 0 (;@$ %
M    @ %*+P8 97AE;"TR,#(R,3(S,%]G,BYJ<&=02P$"% ,4    " "]@D=6
M3T8JY.LC 0#A4 P %0              @ $V.P< 97AE;"TR,#(R,3(S,%]L
M86(N>&UL4$L! A0#%     @ O8)'5E3Q7C1_L0  8U<( !4
M ( !5%\( &5X96PM,C R,C$R,S!?<')E+GAM;%!+ 0(4 Q0    ( +V"1U;M
M4#M7#P0   (.   ;              "  081"0!E>&5L,C R,C$R,S!E>&AI
M8FET,3 R,"YH=&U02P$"% ,4    " "]@D=6(E>OLUX4  !YC   &P
M        @ %.%0D 97AE;#(P,C(Q,C,P97AH:6)I=#$P-# N:'1M4$L! A0#
M%     @ O8)'5KH]E9T= P  +PT  !H              ( !Y2D) &5X96PR
M,#(R,3(S,&5X:&EB:70R,3$N:'1M4$L! A0#%     @ O8)'5LF]0=&, P
M#@H  !H              ( !.BT) &5X96PR,#(R,3(S,&5X:&EB:70R,S$N
M:'1M4$L! A0#%     @ O8)'5F/Y9J4R"   SR$  !H              ( !
M_C ) &5X96PR,#(R,3(S,&5X:&EB:70S,3$N:'1M4$L! A0#%     @ O8)'
M5N"-Q88W"    B(  !H              ( !:#D) &5X96PR,#(R,3(S,&5X
M:&EB:70S,3(N:'1M4$L! A0#%     @ O8)'5G)7'_G*!0  C!T  !H
M         ( !UT$) &5X96PR,#(R,3(S,&5X:&EB:70S,C$N:'1M4$L%!@
0   /  \ " 0  -E'"0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
